<SEC-DOCUMENT>0000950170-24-026205.txt : 20240305
<SEC-HEADER>0000950170-24-026205.hdr.sgml : 20240305
<ACCEPTANCE-DATETIME>20240305170035
ACCESSION NUMBER:		0000950170-24-026205
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240305
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tracon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001394319
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				342037594
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36818
		FILM NUMBER:		24721915

	BUSINESS ADDRESS:	
		STREET 1:		4350 LA JOLLA VILLAGE DRIVE
		STREET 2:		SUITE 800
		CITY:			San Diego
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-550-0780

	MAIL ADDRESS:	
		STREET 1:		4350 LA JOLLA VILLAGE DRIVE
		STREET 2:		SUITE 800
		CITY:			San Diego
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tracon Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tcon-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:tcon="http://www.traconpharma.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_75a04f3f-e55a-48ac-a534-b51065901239" name="dei:DocumentFiscalPeriodFocus" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366">FY</ix:nonNumeric><ix:nonNumeric id="F_23731db1-5ab4-4335-832e-f836b7524b00" name="dei:EntityCentralIndexKey" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366">0001394319</ix:nonNumeric><ix:nonNumeric id="F_aecfc7e0-50cc-46a2-b567-6219d44176a8" name="dei:AmendmentFlag" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_edd6578b-51b9-4d94-9c92-e08d58d290ce" name="us-gaap:CommitmentsAndContingencies" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_af0f1790-87f7-4d5a-bc14-b2897ded686a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f35279c3-d90a-4876-9a14-4f57ff1df69e" name="us-gaap:PreferredStockValue" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3fcf7105-039a-49a1-b08a-a181e9c9b3ad" name="us-gaap:PreferredStockValue" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_bed86c5b-265c-474e-b396-4938148d8b03" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366">http://fasb.org/us-gaap/2023#CollaborativeArrangementMember</ix:nonNumeric><ix:nonNumeric id="F_dea40108-736c-4212-9bb9-d449f9499fd0" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680">http://fasb.org/us-gaap/2023#CollaborativeArrangementMember</ix:nonNumeric><ix:nonNumeric id="F_7148ed3a-8abb-4a16-af47-75112a2b7341" name="us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366">http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric id="F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2">http://fasb.org/us-gaap/2023#OtherAssets</ix:nonNumeric><ix:nonNumeric id="F_b539fbc4-b194-4f51-b5a6-68a58edce5fb" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6">http://fasb.org/us-gaap/2023#OtherAssets</ix:nonNumeric><ix:nonNumeric id="F_0423c714-cd31-4fc4-8227-88bbd1c67cbd" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861">http://fasb.org/us-gaap/2023#RetirementPlanNameOtherMember</ix:nonNumeric><ix:nonNumeric id="F_46bdfe8e-ae21-43ca-ba32-3a33adf3437b" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680">http://fasb.org/us-gaap/2023#RetirementPlanNameOtherMember</ix:nonNumeric><ix:nonNumeric id="F_b40b095e-6fd8-4db7-9688-34b629bf1179" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366">http://fasb.org/us-gaap/2023#RetirementPlanNameOtherMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tcon-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_88b652d5-3be6-4a6b-aa98-270cb604d499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d0aab07-6eea-4e52-afb9-65f4dc53f96e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb79e9b9-01cb-43a2-8165-d3fd9d65c898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46f8a63c-b29e-40ea-8d58-941155df4da0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ada76ad5-45b1-47ad-8d9b-60845220bcd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49078ec3-8121-4069-a2aa-dbede8ef99ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9016afcd-3dde-4d11-9f4f-8fa39038db47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:WarrantsExpirationJuneFourTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74db5b1f-1c60-43e0-86e8-20cdd644d6d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23ef9799-fd43-4275-9cd7-31fdf18c3424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f092d4a-d7e5-494a-a9df-840fef3b8d29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b16315b6-4843-44d0-9eb8-3298bc62f493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0247f2f4-3917-4a82-af24-9a5bf778c6da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecaa62df-706a-45f3-889a-732b21b200f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecdebc03-6503-4399-b16e-c105c0c28931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tcon:OrphanDrugTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_739f0e0d-35e3-4a1e-a0c0-95af5f5ab2ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_475df304-3dbb-4958-a84d-d4bcdf488834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_079f3f02-0a8c-4168-a44f-3fb63206aa35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f618c112-b46d-4d38-bbca-dce456ac7680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a70ce266-0b0f-498a-b880-2e0cec4cebe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d44d79c-a241-471f-bb27-6c48118f0d44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8c5c302-7618-485c-9ff6-32bd1855c0cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcon:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55363737-381a-4453-8820-38a565d61aac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_076a27be-5a0e-4964-acbe-3687b701e0a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c28515c-df0f-44e6-bbaa-f389e653f073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0094047e-e7f2-42e3-a4eb-0ed27b0d1e40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-04</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf3c9e40-b8ea-4aaf-989b-00a5b9696dd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa5025a8-1fb4-4cdf-bae0-549dd0c077ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40c3a24d-66cc-419c-a6ce-68d4a1b37552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afe12a9f-a1ba-4eb0-8945-f294141cf382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a421996-059e-47aa-914f-9c7cd5e3b7d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_753dbf14-c0c8-4d2d-b958-384acd243082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c22bb402-0325-47cc-ae07-b1647b8287b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e41e9c0b-0129-486b-9356-bb65e6d7e6e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseTwoClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbc58ab3-c43d-4ba1-8648-0ac74912cc07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeOnePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ae2be0d-9dfa-467f-9bce-05b3c0ba56fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4750715-b498-4b30-8b83-398f57734854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e2ed30c-2d9e-4355-9b3f-cda6cfbdfac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eafe3fa1-222e-4c1b-81f5-552231208588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fe7dfff-ab8a-41ec-b669-52df31405891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8c41e95-942f-4e44-ae98-385347e4f1c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48cb3f8c-97ab-41bf-b369-556c94253861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c9cb59b-f528-4f05-be7c-a82ef8ff9fa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9e0def7-4f33-4329-8019-2a7db36180ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_849890bd-5478-410b-adc7-afb456b7c75e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeOnePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_871edb40-17b4-426d-9503-2ecbf34f60e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bdfeab3-03b0-41d5-bcd4-2f2f5ac6bc5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cdaff81-414c-42cf-8429-30f12793a1a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f785d70c-45d9-4158-b4cc-5971017cd60b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0592da9d-0e35-4ada-8b6a-801b2b01bdcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ab8712e-6090-44da-8908-64f2c34aef15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce9c7c28-c3e5-426c-8989-80f05562dd11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e3c61d-6eef-4e6d-be34-c3497437219f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38834898-65ec-45e0-a908-a6b01f5f5240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2b07739-4905-4cff-bd81-929c2939c81e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8341fd7b-20e9-4123-b191-98d68cf29a63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f396fb6-a65f-482a-85ae-a6132f8551fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-31</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19d1e4ec-58ad-4668-bed8-1390374bb8c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6b50908-851a-401b-87d4-7d20d639276e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfb0c8e3-22a8-49de-b419-5303ff8938e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tcon:ResearchAndDevelopmentTaxCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4946e13-3da8-4743-9ee6-bc34ada03788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0dbc715-f6a8-4d77-87d7-e3f962470a0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_577ee070-e073-4976-81d8-6e2937b0617e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd3ca734-457b-4506-8892-6849fbff690f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3632bdcc-d356-4f7e-83a3-f74f7f3535fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cad07f2-1244-4aba-b9a0-b522e10e9007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2122e3b2-efd5-46f7-9ea2-4421118c4fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c775d2e-ff5c-46f6-b93f-e69459dc4932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e8ae800-d235-4098-a3fa-dc1794018749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2872028b-ba94-482c-8437-c4832c35599a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bcf6ae1-6f62-4022-a841-9cb5606b41f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96edd94d-e38a-4eb9-8c60-62d39af94ba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:InhibrxLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:InhibrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65bae7f1-a046-426a-b301-55274f90e5e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tcon:ResearchAndDevelopmentTaxCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5feec96-d065-4192-b005-a1dbce905bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3f43995-11fa-4df2-a9ec-f4edd6b8a5b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fba94f6-47dd-4e8a-9960-b690725bb795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fa826a9-e422-4f13-8418-0d37f204106d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_639cfa51-d355-4e4e-883d-a0c36228443f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ae2450d-d4e4-40a6-b829-f38b64d59da3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a62feee6-1322-4bcf-9874-c9bc8fbcda7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ff50e62-5e4c-4461-884d-ca0bbc261a94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25f6f616-38af-477d-9616-f204a98ff0ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">tcon:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63121456-f0cf-46ef-b24c-282d6b4d3d1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbe644e9-34fa-49cf-aac0-7fe06affdd7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64263ac1-80a3-46bd-b083-27c74a051284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0cfd32a-d85b-4d8a-9619-e9e603c0063b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c23779b-d204-40a0-a57c-ba7a3fd5104a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3707c748-2523-40f2-89ed-37a5e0f02667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f40826a-5d90-43c5-8575-ad4a021189c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36e936e9-4748-422c-af13-03094cd386a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8336abd2-bdbf-4da8-8873-f9e6e654f71b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e523f290-ecdf-4b86-9681-520bb864b996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cb97554-1115-4af1-8cfc-e45b449853ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeEightPerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dadec75d-3635-4b34-97db-e4a9d80be690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:TwoThousandEighteenLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_948e03ad-dcda-4e45-bb27-1fb7cf42583e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be1af667-5078-4781-80f6-a273e57ebc33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c670a0a-691a-4b51-b9b6-9c1738acbd91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dee76b1c-3511-482e-af8c-baca4374550b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f47e236-54b6-4d53-9564-adba4ece78af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa5fbb77-e965-4baf-b389-6c9224794641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ac1269c-37c7-4ba8-ad75-d74191163fc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a40186b-dfa3-4450-9805-28d0eb65430b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c65da7a-8508-4963-9ecf-2e2bffdab2b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18ad7425-f5b0-4ca5-b02f-4051b623fbc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62d20795-8235-49dc-84d8-78968b279332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70a6deb7-5ef8-433d-a7ac-fd7f122fe2e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a381d93-758c-43f0-bafa-d1d2c3addbf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbf3b97c-e0f0-4dfe-8eea-e3775ccab160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e8d066a-2058-4cb0-bb65-2e20e51ef896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89504bb5-ef30-4956-bf15-4942d09489d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationMayThreeTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af8d7bab-03a5-4ea5-b757-607eeb29fa0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_318cdc34-f5fd-4dd9-b958-8376a005bba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb97f606-1fe3-428b-be6a-b8b232235366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d67d2e6-6d0a-4e23-93d1-f44a73a8c83e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12cbadd1-c66c-4148-a655-212d5c0bb0a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:WarrantsExpirationMayThreeTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f964d2c-14b2-4bc3-b709-922d50a40833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:BispecificAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce6896ec-3d61-4ba8-b0f3-65531cd77796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_901ce9d0-b622-4dc1-9cc3-0c5fd70773be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42ea9fad-5f3b-4079-b265-ececb47bd4b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dde0b8e-4306-4c73-b564-93d2dc9f8a26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:EnvafolimabCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0b548c4-d2f9-43e6-8243-8c33b7859be8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3383f0ff-32ac-4e6c-9cf5-2ccf590edc61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d853f01-db0c-4afc-ac37-748d6a24b52f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tcon:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0c31950-7a73-4c3c-b339-8d2b3ea2f977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b34aed6-5a9c-4e22-8703-226017dd6deb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa0eef6d-4f4f-4aa3-86c1-d8232518e2b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16e27699-d842-4a09-9bc5-311bdb55cc7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationJuneFourTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2497856b-e351-4137-a3e8-c281dd005061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:InhibrxLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:InhibrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4da012b8-a385-42a2-9bf0-9a586e2e0ba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-31</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef2536be-eee0-447c-816b-aa4f24348c47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeEightPerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f06370c-a07e-49f3-9851-fcdb008745c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7eb1035b-caa0-4638-9b3d-88715a101c8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_050dae8e-e369-4b11-afe6-d1549da44936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44f937fc-97bc-42b8-97d8-361c9c6f366c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_814ee833-9257-47ee-8583-cde42cd6e260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6105ad8-44d1-4f33-bd31-6a2890669839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:InhibrxLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:InhibrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af96e684-e605-4756-a75e-d1a500792e14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3b2c60e-9c95-477b-af58-492387fc1056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f632fdf6-d5bb-47f5-b665-011709762d71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac868d35-ee5d-4979-85bb-00dafa76357d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">tcon:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c703b19c-a29e-4412-99b9-5310a244f3a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_114c5392-d3f7-41e4-b75e-3aac9f0e4167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa2d3186-d82c-44fe-9ee7-07c5a15c9315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001394319</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcon:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>tcon:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Antibody"><xbrli:measure>tcon:Antibody</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Tranche"><xbrli:measure>tcon:Tranche</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:14pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35a31844-f312-4f4c-bf4f-8db536ecee34" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b75c1b3-31c2-449b-8bbc-55d81f32fd07" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc8184ef-9c4d-4e72-b4bf-5421e2e6098c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12aa6682-1487-48fd-a7e8-2086da8fd05c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b33970ce-6c5c-4904-a0e2-6be57f406adf" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6734b61-caee-4040-b9ee-96fc8aeb7eaf" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6da27319-e55e-4926-98d6-510f024ec9e6" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">001-36818</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7635860d-fd5e-4a0a-b57a-5570ca1851fd" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:1%;"/>
    <td style="width:49%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0c718e5a-e9df-4e15-9e17-041fd5b6dee2" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_958e2a48-2ac8-4563-9167-7a9ec9eca666" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">34-2037594</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2e2cbf53-e7c8-4d85-b7cc-bc32caf84aec" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4350 La Jolla Village Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_24ebe13f-8f66-466f-9190-834861a79e50" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 800</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">,</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_73737e9a-2b78-4e9e-9ac7-ed0190b68e5a" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_4d8a0e7d-57d3-4a7c-942c-c21bcb6a6200" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b4086bf4-3863-4404-a4b9-414c6c29153a" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92122</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f427da8-e6f1-4a76-a9cb-57b1c4aab3e9" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3509074-fe71-4ba0-886c-be4c04eb86f7" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">550-0780</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:1%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:36.44%;"/>
    <td style="width:21.86%;"/>
    <td style="width:41.7%;"/>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="font-size:9pt;"><ix:nonNumeric id="F_c9d7a163-2460-4cd6-a09d-5a404ff17ebc" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="font-size:9pt;"><ix:nonNumeric id="F_9c014604-f6dc-49f9-85cd-6bd0a34734fd" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TCON</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="font-size:9pt;"><ix:nonNumeric id="F_f669e562-8146-46bd-9fbd-fa0a679a2d39" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes &#9744;    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bbfa8af-17c4-4d38-a60b-7dfc3782c566" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes &#9744;   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eecfd880-c634-4f07-8a90-41da8b62311c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54366c30-7996-4246-aacd-61c1fea003ef" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30760647-6abf-4169-a843-7f0fe3505f9c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;    No &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.113%;"/>
    <td style="width:1.589%;"/>
    <td style="width:14.347%;"/>
    <td style="width:1.598%;"/>
    <td style="width:40.156%;"/>
    <td style="width:14.678%;"/>
    <td style="width:6.257%;"/>
    <td style="width:2.261%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="text-indent:59.05pt;vertical-align:top;"><p style="margin-left:59.05pt;text-indent:0;font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Large accelerated filer</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="text-indent:58.7pt;vertical-align:top;"><p style="margin-left:58.7pt;text-indent:0;font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="text-indent:58.7pt;vertical-align:top;"><p style="margin-left:58.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">     </span><span style="font-size:8pt;"><ix:nonNumeric id="F_54ad6f75-2e5c-4efa-a503-0e3df74e4f0d" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e54d0c3d-e9bd-4d81-a44c-6fa1c3301feb" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="text-indent:58.7pt;vertical-align:top;"><p style="margin-left:58.7pt;text-indent:0;font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="text-indent:59.05pt;vertical-align:top;"><p style="margin-left:59.05pt;text-indent:0;font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b675d5d5-f227-4b44-abf6-09cac0569a85" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bf70893-46dd-4f31-976a-d9131b4d7df1" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_710aaf73-d86c-400e-ad9d-d833cd7c029c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act).      Yes &#9744;    No </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8276067-af37-46da-9fa6-885b78f75af4" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.44in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s voting and non-voting common stock held by non-affiliates of the registrant was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b7ca7e2-1b41-4356-80ff-b79bcf59e971" contextRef="C_3383f0ff-32ac-4e6c-9cf5-2ccf590edc61" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Capital Market on June 30, 2023 of $0.291 per share.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The number of outstanding shares of the registrant&#8217;s common stock as of March 1, 2024 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1acd673c-6d20-4ae8-8f07-3a86f9d66870" contextRef="C_e0c31950-7a73-4c3c-b339-8d2b3ea2f977" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">45,504,501</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.44in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM 10-K &#8212; ANNUAL REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Fiscal Year Ended December 31, 2023</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.94%;"/>
    <td style="width:1.14%;"/>
    <td style="width:84.58%;"/>
    <td style="width:1.96%;"/>
    <td style="width:3.38%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#forward_looking_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forward-Looking Statements</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#summary_of_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Summary of Risk Factors</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factor"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of <br/>Equity Securities</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:4.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.44in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="forward_looking_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K (Annual Report), including the sections entitled &#8220;Summary of Risk Factors,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; contains forward-looking statements within the meaning of the safe harbor provisions for the U.S. Private Securities Litigation Reform Act of 1955. We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success, cost and timing of results of our and our collaborators&#8217; ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our and our collaborators&#8217; plans to develop and commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential benefits of our collaboration arrangements and our ability to enter into additional collaboration arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our regulatory strategy and potential benefits associated therewith;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of unfavorable U.S. and global economic conditions on our business, financial condition and results of operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of any approved product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competing products that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential effects of macroeconomic and geopolitical developments, such as the ongoing military conflict between Ukraine and Russia, the war between Israel and Hamas and the related risk of a larger regional conflict, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, actual and anticipated changes in interest rates, and economic inflation and the responses by central banking authorities to control such inflation, on our operations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to remain listed on a national securities exchange;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources, and our need for additional financing; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to realize the anticipated benefits associated with our capital efficiency focused initiatives.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under the section entitled &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We qualify all of the forward-looking statements in this Annual Report by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.44in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="summary_of_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to numerous risks, as more fully described immediately below. You should read these risks before you invest in our common stock. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, risks associated with our business include:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses from operations since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or sustain profitability.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and failure to obtain additional financing when needed could force us to delay, limit, reduce or terminate our drug development efforts. There is substantial doubt as to our ability to continue as a going concern.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our ENVASARC Phase 2 pivotal trial does not achieve its primary endpoint, we may not continue development of envafolimab as a single agent in UPS/MFS or obtain regulatory approval of envafolimab in UPS/MFS.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to continue to meet all applicable listing requirements, our common stock may be delisted from the Nasdaq Capital Market, which could have an adverse impact on the liquidity and market price of our common stock.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are heavily dependent on the success of our lead clinical stage product candidate envafolimab. We cannot give any assurance that envafolimab will successfully complete clinical development or receive regulatory approval, which is necessary before it can be commercialized.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration (FDA), and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend in part on NCI and other third-party sponsors to advance clinical development of TRC102. If these third-party sponsors ceased their support for our product candidates, our ability to advance clinical development of product candidates could be limited and we may not be able to pursue the number of different indications for our product candidates that are currently being pursued.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on our corporate partners for the advancement of our product candidates. Specifically, we are dependent on 3D Medicines Co., Ltd. (3D Medicines) and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) with respect to certain aspects of our development of envafolimab for sarcoma in North America. Similarly, we are dependent on Eucure (Beijing) Biopharma Co., Ltd. (Eucure) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) with respect to certain aspects of our development of YH001 in North America. The failure to maintain these collaboration agreements, the failure of our corporate partners to perform their obligations under the agreements, or the actions of our corporate partners or their other partners with respect to envafolimab and YH001 in other indications or outside North America could negatively impact our business. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unfavorable U.S. and global economic conditions could adversely affect our business, financial condition or results of operations.</span></div></div>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.	B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing our cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, we entered into a collaboration and clinical trial agreement (the Envafolimab Collaboration Agreement) with 3D Medicines Co., Ltd. (3D Medicines) and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) for the development of envafolimab, also known as KN035, an investigational PD-L1 single-domain antibody (sdAb) administered by rapid subcutaneous injection for the treatment of sarcoma in North America. The ENVASARC Phase 2 pivotal trial (the ENVASARC trial) is enrolling 80 patients at 600mg of envafolimab every three weeks in cohort C, in the sarcoma subtypes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). Nine of 80 responses (11.25%) by blinded independent central review (BICR) are needed to satisfy the primary endpoint of the trial which is to statistically exceed the known 4% objective response rate (ORR) of Votrient&#174; (pazopanib), the only U.S. Food and Drug Administration (FDA)-approved treatment for patients with refractory UPS or MFS. Achieving the primary endpoint of exceeding the known 4% ORR could be the basis for accelerated approval of envafolimab by the FDA. The trial will provide at least 86% power to demonstrate the lower bound of the 95% confidence interval is greater than 5% in each cohort, which would be greater than the 4% ORR of Votrient reported in soft tissue sarcoma in its package insert. We presented a poster on the design and endpoints of the ENVASARC trial at the Connective Tissue Oncology Society meeting in November 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, we announced that the ENVASARC trial had enrolled more than 70 of the 80 planned patients in cohort C of single agent envafolimab treatment. Safety and efficacy data were re-reviewed for 46 patients enrolled into cohort C. Since September 2023, an additional patient has achieved an objective response by investigator review, which increased the ORR by investigator review to 15%. The most recent objective response has not yet been confirmed by BICR. The primary endpoint of the study is achievement of an ORR in nine of 80 patients (11.25%) treated with envafolimab by BICR and median duration of response of greater than six months is a key secondary endpoint. Median duration of response by BICR remained greater than six months in December 2023. In addition, envafolimab remained generally well tolerated.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses out of 46 by BICR and based on the results of the second and final mandated IDMC efficacy review, the trial would continue as planned. The IDMC reviewed interim safety and efficacy data from 46 patients enrolled into cohort C of treatment with single agent envafolimab who completed two on-treatment scans, which are a minimum of 12 weeks of efficacy evaluations. The ORR in the initial 46 patients treated with single agent envafolimab was 13% by investigator review and 8.7% by BICR. Envafolimab monotherapy was generally well tolerated and median duration of response by BICR was greater than six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, an independent data monitoring committee (IDMC) performed an ad hoc review of interim safety and efficacy data from more than 80 patients equally randomized into cohort C of single agent envafolimab or cohort D of envafolimab given in combination with Yervoy. The combination of envafolimab with Yervoy did not demonstrate synergy when compared to single agent envafolimab and we terminated enrollment in cohort D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the trial has enrolled more than 75 of the planned 80 patients and full accrual of the ENVASARC trial is expected to be completed by the end of the first quarter of 2024. We expect to report a review of safety and efficacy data in the first quarter of 2024 following a review of a data package that is being prepared for an ad hoc IDMC meeting, including in the more than 20 patients enrolled following the September IDMC review who will have had a minimum of 12 weeks of efficacy evaluations (e.g., two CT scans) at that time. We expect to have final response assessment data including duration of response in all patients from the ENVASARC trial in the second half of 2024. Assuming positive data, we plan to submit a biologics license application (BLA) to the FDA seeking accelerated approval in 2024. At any time that we reach nine responses in cohort C by BICR and meet the primary endpoint, we expect to discuss the submission process with the FDA.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UPS has an incidence of 0.8 to 1.0 cases per 100,000 patients in the western world and accounts for approximately 17% of new cases of soft tissue sarcoma in the United States, with prevalence rates estimated at approximately 1.5 to 2.0 times incidence, and MFS accounts for half as many cases as UPS in the United States. We estimate that marketing envafolimab in refractory UPS and MFS could generate peak annual sales of up to $200 million in the United States without considering a price premium to the reference PD-1 inhibitors Opdivo (nivolumab) or Keytruda (pembrolizumab) that are administered intravenously. We estimate that marketing envafolimab in rarer sarcoma subtypes where the activity of checkpoint inhibition has been demonstrated could generate annual sales of up to $100 million in the United States.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other clinical stage oncology product candidates include TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, that we licensed from Eucure (Beijing) Biopharma Co., Ltd. (Eucure) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) in October 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). In initial clinical trials of more than 100 patients, TRC102 has shown good tolerability and we believe promising anti-tumor activity in combination with alkylating and antimetabolite chemotherapy for the treatment of cancer patients. TRC102 has been studied in Phase 1 or Phase 2 trials in mesothelioma patients in combination with the approved chemotherapeutic Alimta&#174; (pemetrexed), in glioblastoma, ovarian cancer, lung and colorectal cancer patients in combination with the approved chemotherapeutic Temodar&#174; (temozolomide) and in lung cancer patients in combination with the approved chemotherapeutics Alimta and cisplatin as well as external beam radiation (i.e., chemoradiation). A poster on the Phase 2 trial of TRC102 with temozolomide (TMZ) in patients with granulosa cell ovarian cancer was presented by investigators at the National Cancer Institute (NCI) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting held in June 2023. The authors concluded that TRC102 combined with TMZ was well tolerated in patients with granulosa cell ovarian cancer (GCOC). Durable disease control was observed in four of eight patients, which the authors considered as promising activity in this heavily pretreated GCOC cohort.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All current TRC102 trials are sponsored and funded by the NCI. We retain global rights to develop and commercialize TRC102 in all indications. In October 2020, we received orphan drug designation (ODD) from the FDA for TRC102 for the treatment of patients with malignant glioma, including glioblastoma. O6-methylguanine DNA methyltransferase (MGMT) deficiency is observed in about one-third of glioblastoma patients, and a prior study of TMZ and TRC102 reported at the Society for Neuro-Oncology in 2018 demonstrated that two MGMT deficient glioblastoma patients had prolonged survival when treated with TMZ and TRC102 after progressing previously on TMZ and radiation therapy. A December 2020 publication in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cancer Cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> also demonstrated TMZ and TRC102 were active in MGMT deficient patients with colorectal cancer. Based on these data, we believe a trial in first line glioblastoma patients of TMZ, radiation therapy and TRC102 is warranted and are discussing further development with investigators at this time. In addition, based on data presented at the ASCO 2020 virtual meeting that the combination of chemoradiation and TRC102 produced objective responses in all 15 evaluable patients with advanced localized lung cancer treated in a Phase 1 trial, in January 2022, the NCI initiated a randomized Phase 2 trial of chemoradiation with or without TRC102, followed by consolidative durvalumab treatment. The primary objective is to improve the 56% one-year progression free survival (PFS) rate with current standard of care to 75% with current standard of care plus TRC102. The trial began enrollment in June 2022 and is expected to be complete in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other product candidate, YH001, is an investigational humanized CTLA-4 IgG1 monoclonal antibody that completed dosing in two Phase 1 trials sponsored by Eucure for the treatment of various cancer types. CTLA-4 is a protein expressed on T-cells and expressed at high levels specifically on regulatory T-cells that act as a checkpoint to inhibit effector T-cell immune responses to cancer cells. The CTLA-4 inhibitor Yervoy (ipilimumab) marketed by BMS has been approved as a single agent in melanoma and approved in combination with other therapies in multiple indications including non-small cell lung cancer, renal cell carcinoma (RCC) and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer. Data from the Phase 1 dose escalation trial in Australia of YH001 in combination with the PD-1 antibody, toripalimab, were presented at the American Society of Clinical Oncology 2022 Annual Meeting. YH001 was well tolerated up to 4 mg/kg when combined with toripalimab in the 24 patients as of the December 31, 2021 data cut-off date. The Phase 1 dose escalation trial in China of YH001 as a single agent, completed enrollment and determined a recommended Phase 2 dose. No CTLA-4 therapy is approved by the FDA for the treatment of soft tissue sarcoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we announced that the FDA had cleared the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial of YH001 dosed in combination with envafolimab and doxorubicin, an approved treatment for soft tissue sarcoma. In December 2022, we initiated dosing in the Phase 1/2 clinical trial to assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma and of the doublet combination of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma. Given the recommendation of the IDMC to terminate enrollment in cohort D of the ENVASARC trial of dosing envafolimab with the CTLA-4 antibody Yervoy, we reviewed safety and efficacy data from more than ten patients who received envafolimab with the CTLA-4 antibody YH001. Following the data review and discussions with principal investigators, we discontinued enrollment in the Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin. We presented data from the 15 patients enrolled into the Phase 1/2 clinical trial in a poster in November 2023 at the Connective Tissue Oncology Society meeting. We plan to continue the development of envafolimab with doxorubicin in soft tissue sarcoma in a separate trial and may initiate trials of YH001 as a single agent or in combination with immunotherapies in other tumor types.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes key information regarding ongoing development of our clinical stage product candidates:</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.24%;"/>
    <td style="width:19.36%;"/>
    <td style="width:34.4%;"/>
   </tr>
   <tr style="height:12.95pt;background-color:#425e5f;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Data Expected</span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#1f497d;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Envafolimab</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.35pt;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:7.85pt;text-indent:-4.5pt;padding-left:4.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soft Tissue Sarcoma (UPS and MFS)</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pivotal Phase 2</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Updated Interim Data &#8211; Q1 of 2024</span></p><p style="text-indent:0.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Final Data &#8211; second half of 2024</span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#28a16f;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRC102</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Lung Cancer</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Randomized Phase 2</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize a product development platform (PDP) that emphasizes capital efficiency. Our experienced clinical operations, data management, quality assurance, product development and regulatory affairs groups manage significant aspects of our clinical trials with internal resources. We use these internal resources to reduce the costs associated with utilizing CROs to conduct clinical trials. In our experience, this model has resulted in capital efficiencies and improved communication with clinical trial sites, which can expedite patient enrollment and improve the quality of patient data as compared to a CRO-managed model. We have leveraged this platform in all of our sponsored clinical trials, in addition to recently monetizing our platform independently by licensing our PDP to Inhibrx, Inc. (Inhibrx) in November 2023 for a $3.0 million upfront fee. We have also leveraged our PDP to diversify our product pipeline without payment of upfront license fees through license agreements with Eucure, a division of Biocytogen, 3D Medicines and Alphamab, and Janssen. We continue to evaluate life science companies that would benefit from a rapid and capital-efficient U.S. drug development solution that includes U.S. and European Union (EU) clinical development expertise, or that wish to license our PDP to enable them to run CRO-independent clinical trials. We believe we will continue to be recognized as a preferred U.S. clinical development partner through a cost- and risk-sharing partnership structure, which may include U.S. commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to be a leader in the development of targeted therapies for patients with cancer and other diseases of high unmet medical need.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Lead Clinical Stage Product Candidate &#8211; Envafolimab</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of PD-L1</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PD-L1 is an immune-inhibitory checkpoint molecule expressed on epithelial and vascular endothelial cells, as well as by a number of immune cells, that is utilized by tumor cells as an immune escape mechanism. Numerous preclinical and clinical studies of PD-1/PD-L1 products have demonstrated that antibodies that block the interaction of PD-1 with its ligands, PD-L1 and PD-L2, or those that block only the interaction of PD-L1 with PD-1, can augment anti-tumor T-cell responses and lead to complete and durable tumor eradication in a certain proportion of patients.  Potent therapeutic anti-tumor responses due to blocking of the PD-1/PD-L1 non-small cell lung cancer (NSCLC), small cell lung cancer, gastric cancer, melanoma, RCC, head and neck cancer, cutaneous squamous cell carcinoma (cSCC) and urothelial carcinoma.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">About Envafolimab and Preclinical Studies</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Envafolimab is a sdAb that binds selectively to PD-L1 and is administered by rapid subcutaneous injection without an adjuvant.  In November 2021 we announced that our partners 3D Medicines and Alphamab had received marketing authorization for envafolimab from the Chinese National Medical Products Association (NMPA) in the indication of MSI-H/dMMR cancer, and is being further developed by 3D Medicines for the treatment of various cancer indications, including an ongoing first line biliary tract cancer (BTC) pivotal trial in China, and by us in the United States for the treatment of sarcoma in the pivotal ENVASARC trial.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Single-domain antibodies are a novel class of therapeutic protein that contain the unique structural and functional properties of naturally-occurring antibodies from camels and llamas that contain heavy chains and lack light chains. On February 6, 2019, the FDA approved the first sdAb, Cablivi&#174; (caplacizumab), for adults with acquired thrombotic thrombocytopenic purpura.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Envafolimab is a camelid IgG1 sdAb with single digit nanomolar affinity to PD-L1. Benefitting from the sdAb format, envafolimab has approximately half the molecular weight compared to a typical monoclonal antibody with better stability and high solubility, which enables the development of a high concentration formulation suitable for rapid subcutaneous injection. In addition, the effector functions are muted in envafolimab to help limit side effects and limit its exposure to the immune system to avoid unwanted adverse immune responses. As a result, compared with approved PD-(L)1 inhibitors, envafolimab potentially has the following advantages:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Better patient compliance with increased convenience</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Subcutaneous injection enables more rapid administration and the potential for self-injection, which enables better patient compliance with the treatment regimen; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Relatively stable plasma-drug concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The plasma-drug concentration of envafolimab is relatively stable without significant fluctuations due to the nature of subcutaneous administration. This unique PK profile compared with intravenous formulations may result in lower risks to patients; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential for improved tumor penetration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Envafolimab is approximately half the size of a typical monoclonal antibody, which may provide for improved tumor penetration in cancer patients as was observed in pre-clinical experiments. This unique tumor penetration compared with typical monoclonal antibodies may improve efficacy.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In pre-clinical studies in human cell models and a humanized mouse model, envafolimab was compared with 2.41H90P, an antibody with a sequence that is identical to durvalumab, an approved PD-L1 inhibitor marketed by AstraZeneca, and envafolimab showed the following potential advantages:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stronger T-cell activation effect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The level of T-cell activation can be measured by the secretion levels of IFN- and IL-2. Higher secretion levels are generally associated with stronger T-cell activation. In pre-clinical studies, envafolimab (referred to as KN035) demonstrated higher potency and a higher maximal stimulatory effect on IFN- and IL-2 secretion compared to 2.41H90P, as illustrated in the following figure.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:3.571%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_0.jpg" alt="img19885085_0.jpg" style="width:474px;height:240px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Higher anti-tumor efficacy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Envafolimab and 2.41H90P were each injected intraperitoneally in mice at 0.1mg/kg, 0.3mg/kg and 1.0mg/kg dose levels. As illustrated in the following graph, envafolimab showed more potent tumor growth inhibition effects with maximum inhibition demonstrated at a ten-fold lower dose.</span></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_1.jpg" alt="img19885085_1.jpg" style="width:502px;height:283px;"/>&#160;</p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">More rapid tumor penetration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. After injection of envafolimab and 2.4H90P in tumor bearing nude mice, the tumor radioactivity signal was consistently higher in the envafolimab group up to 52 hours post injection. The tumor radioactivity signal in the envafolimab group between 1 hour to 2.5 hours was statistically significantly higher, which suggests potentially better distribution of envafolimab into the tumor.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials of Envafolimab</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, envafolimab had been dosed in more than 1,000 patients in a total of more than 7 ongoing or completed clinical trials in the United States, China or Japan, including our ENVASARC trial, a pivotal Phase 2 trial in MSI-H/dMMR cancer patients in China, a Phase 2 trial of envafolimab plus chemotherapy in gastric cancer, a Phase 3 randomized trial of envafolimab plus chemotherapy versus chemotherapy alone in BTC in China, a Phase 1 dose escalation and dose exploration trial in the United States, a Phase 1 dose escalation and dose exploration trial in China, and a Phase 1 dose escalation and dose exploration trial in Japan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1 Dose Escalation Clinical Trial in China</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An open-label, single-arm Phase 1 dose escalation and exploration clinical trial of envafolimab has completed enrollment in China. The safety and efficacy data from this trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2019. Based on the data presented at the 2019 ASCO Annual Meeting (the ASCO Presentation), 17 subjects were enrolled in the dose escalation phase in this trial as of May 1, 2019. A total of 287 subjects were enrolled in this Phase 1 trial at dose levels shown to be tolerable during dose escalation.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial purpose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The primary objectives of the Phase 1 dose escalation were to assess the safety and tolerability profile and MTD of single agent envafolimab administered subcutaneously in subjects with advanced solid tumors. The secondary objectives were to evaluate the PK profile, immunogenicity and anti-tumor activity.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design of the dose escalation phase. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This trial adopted a modified &#8220;3+3&#8221; design with a dose-limiting toxicity (DLT) evaluation period of 28 days. Subjects received envafolimab in six cohorts at 0.1mg/kg, 0.3mg/kg, 1.0mg/kg, 2.5mg/kg, 5.0mg/kg and 10.0mg/kg once every week (QW) subcutaneously. Starting from the 1.0mg/kg cohort, a traditional &#8220;3+3&#8221; design was followed. Safety and tolerability were assessed by monitoring treatment emergent adverse events (TEAEs). Tumor assessments were performed based on RECIST version 1.1.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Safety of dose escalation phase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The majority of the subjects received two or more prior systemic oncology treatments. According to the ASCO Presentation, 16 of the subjects discontinued treatment due to disease progression (n=15) or consent withdrawal (n=1). All of the enrolled subjects experienced TEAEs. 13 (76.5%) subjects experienced treatment-related TEAEs. Three (17.6%) subjects experienced serious TEAEs, although none were determined to be treatment-related. A TEAE led to treatment discontinuation in one subject and was also determined to be not treatment-related. No DLT was reported and the MTD was not reached. Details of the TEAEs observed from the 17 subjects enrolled in the Phase 1 dose escalation trial are summarized in the following table.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_2.jpg" alt="img19885085_2.jpg" style="width:530px;height:483px;"/>&#160;</p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> According to the ASCO Presentation, 15 out of 17 subjects were evaluable for the efficacy analysis. Three subjects had confirmed PR, including one RCC subject in the 2.5mg/kg cohort, one intrahepatic cholangiocarcinoma subject from the 5.0mg/kg cohort and one BTC subject from the 10.0mg/kg cohort. In addition, five subjects achieved stable disease. All 15 subjects completed at least one post-baseline tumor assessment, according to the ASCO Presentation. Two enrolled subjects who had not reached the first post-baseline tumor assessment were excluded. The table below summarizes the best overall response in the efficacy analysis of this trial, according to the ASCO Presentation.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_3.jpg" alt="img19885085_3.jpg" style="width:530px;height:341px;"/>&#160;</p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following waterfall plot shows the best overall response of the 15 evaluable subjects receiving envafolimab as measured by percentage of change of target lesions from baseline, according to the ASCO Presentation.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_4.jpg" alt="img19885085_4.jpg" style="width:560px;height:312px;"/>&#160;</p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conclusion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. According to the ASCO Presentation, envafolimab exhibited a tolerable safety profile and preliminary efficacy in patients with advanced malignancies in the Phase 1 dose escalation trial in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1 Dose Escalation Clinical Trial in the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An open-label Phase 1 dose escalation and dose exploration clinical trial of envafolimab was conducted in the United States. Safety and efficacy data from the dose escalation phase of the trial were presented at the 2018 Annual Congress of the European Society for Medical Oncology (ESMO) in October 2018. Based on the data presented at ESMO (the ESMO Presentation), 18 subjects were enrolled in the dose escalation phase of this trial as of July 5, 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial purpose of the dose escalation phase. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary objectives of the Phase 1 dose escalation clinical trial were to evaluate and characterize the tolerability and safety profile of single agent envafolimab in subjects with locally advanced or metastatic solid tumors. The secondary objectives were to characterize the PK profile, determine MTD and to evaluate anti-tumor activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design of the dose escalation phase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This trial adopted a modified &#8220;3+3&#8221; design with a DLT evaluation period of 28 days. Subjects received envafolimab across eight cohorts at 0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.3mg/kg, 1.0mg/kg, 2.5mg/kg, 5.0mg/kg and 10.0mg/kg QW subcutaneously. Starting from the 0.3mg/kg cohort, a traditional &#8220;3+3&#8221; design was followed. Safety and tolerability were assessed by monitoring TEAEs. Tumor assessments were performed based on RECIST version 1.1.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Safety of dose escalation phase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The median duration of exposure to envafolimab was 9 weeks with a range of 6 to 32 weeks. As of July 5, 2018, two of the subjects (11.1%) remained in the trial, 11 subjects had discontinued treatment due to disease progression, three subjects had discontinued treatment due to TEAEs, and two subjects had discontinued treatment due to the opinion of the investigator that no more clinical benefit could be obtained or for other reasons. All of the 18 enrolled subjects experienced TEAEs. Treatment-related TEAEs at grade 3 or above included increased aspartate aminotransferase (10.5%), increased alanine aminotransferase (10.5%) and lymphopenia (10.5%). No DLT was observed and the planned maximum dose of 10.0mg/kg was reached.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Efficacy of dose escalation phase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. According to the ESMO Presentation, 17 out of 18 subjects were evaluable for the efficacy analysis. Two subjects had confirmed PR, including one NSCLC subject from the 0.3mg/kg QW cohort (response duration of 9 months) and one MSI-H prostate cancer subject from the 2.5mg/kg QW cohort. In addition, five subjects achieved SD. All 17 evaluable subjects completed at least one post-baseline tumor assessment according to the ESMO Presentation. One enrolled subject who had not reached the first post-baseline tumor assessment was excluded. The table below summarizes the best overall response in the efficacy analysis of this trial according to the ESMO Presentation.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_5.jpg" alt="img19885085_5.jpg" style="width:554px;height:356px;"/>&#160;</p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PK profile of dose escalation phase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This trial showed that the exposure to envafolimab was dose-dependent and increased proportionally across all eight dose levels. Mean half-life of envafolimab was approximately 200 hours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conclusion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. According to the ESMO Presentation, envafolimab exhibited a favorable safety profile in subjects with advanced solid tumors and preliminary efficacy results demonstrated encouraging anti-tumor activity. Based on the PK profile, patients in the trial were treated with envafolimab at 300mg every 4 weeks by subcutaneous injection.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1 Clinical Trial in Japan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An open-label Phase 1 dose escalation and dose exploration clinical trial of envafolimab was conducted in Japan. The safety, efficacy and PK data of this trial as of May 5, 2019 were presented at the ASCO Annual Meeting in June 2019. Based on the data presented in the ASCO Annual Meeting (the Japan Trial ASCO Presentation), 26 subjects were enrolled in this trial as of May 5, 2019.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial purpose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The primary objectives of the Phase 1 clinical trial were to assess the safety and tolerability profile of single agent envafolimab in Japanese subjects with previously treated advanced solid tumors. The secondary objectives were to characterize the PK profile, determine MTD and evaluate the anti-tumor activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This Phase 1 trial consisted of a multi-dose escalation phase followed by a dose exploration phase. Subjects received envafolimab across five cohorts at 1.0mg/kg, 2.5mg/kg and 5.0mg/kg QW subcutaneously, and 2.5mg/kg and 5.0mg/kg Q2W subcutaneously. The QW schedule adopted a traditional &#8220;3+3&#8221; design. For the Q2W schedule, six patients were planned for each cohort. Safety and tolerability were assessed by monitoring TEAEs under common terminology criteria for adverse events (CTCAE) version 4.0. Tumor assessments were performed based on RECIST version 1.1. Full PK sampling was performed after the first dose of cycle 1 (28 days) and sparse PK samples were collected at pre-dose and around Cmax during the subsequent cycles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Safety</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. According to the Japan Trial ASCO Presentation, as of May 5, 2019, no MTD had been reached. As of the same date, three subjects had remained in the trial. 21 subjects had discontinued treatment due to disease progression and two subjects had discontinued treatment due to TEAEs. All of the enrolled subjects experienced TEAEs, 17 subjects (65.4%) experienced treatment-related TEAEs, and only one grade 3 treatment-related TEAE (cerebral infraction) was reported. There were no grade 4/5 treatment-related TEAEs. There were a total of four serious adverse events, two of which were treatment-related. No DLT was reported.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Efficacy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. According to the Japan Trial ASCO Presentation, nine out of 26 patients were evaluable for the efficacy analysis as of May 5, 2019. Two subjects had confirmed PR and two subjects had unconfirmed PR. The other five evaluable subjects had achieved SD. 17 enrolled subjects who did not reach the first post-baseline tumor assessment were excluded.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PK profile</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In the dose escalation phase, the exposure to envafolimab was dose-dependent and increased proportionally. Tmax varied from 96 to 168 hours after a single dose as shown in Figure 1 below. In the dose exploration phase, the exposure to envafolimab was dose-dependent and increased proportionally. Preliminary PK suggested a prolonged half-life that may support a less frequent dosing schedule than once every 2 weeks.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_6.jpg" alt="img19885085_6.jpg" style="width:520px;height:291px;"/>&#160;</p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conclusion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Envafolimab exhibited a favorable safety profile in patients with advanced malignancies and preliminary efficacy results demonstrated promising anti-tumor activity in the Phase 1 clinical trial in Japan. Based on the PK profile, patients in the trial were treated with envafolimab at 300mg every 4 weeks by subcutaneous injection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pivotal Clinical Trial in China in MSI-H/dMMR tumors</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A pivotal clinical trial of envafolimab dosed as a single agent for the treatment of MSI-H/dMMR tumors was initiated in August 2018.  The trial was a non-randomized trial enrolling approximately 110 patients in China, including CRC patients who are required to have been previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin or irinotecan, and other solid tumor patients, who are required to have been previously treated with at least one line of systemic standard of care therapy. Patients received 150mg of envafolimab subcutaneously dosed weekly and ORR was the primary endpoint defined by RECIST version 1.1.  In a presentation at the CSCO 2020 Virtual Scientific Program entitled, &#8220;Subcutaneous Injection of PD-L1 Antibody Envafolimab (KN035) in Advanced Tumors with Mismatch-Repair Deficiency,&#8221; single agent envafolimab was shown to have a 32% confirmed ORR by central radiographic review in 41 patients with MSI-H/dMMR CRC who failed a fluoropyrimidine, oxaliplatin and irinotecan, and had at least two on-study tumor assessments. The 32% ORR is nearly identical to the 28% ORR reported for Opdivo and 33% ORR reported for Keytruda in separate trials of MSI-H/dMMR CRC patients who failed a fluoropyrimidine, oxaliplatin and irinotecan. DOR was greater than or equal to 12 months in 75% of patients and OS was greater than or equal to 12 months in 65% of patients. The ORR in the overall population (n=103) of MSI-H/dMMR cancer patients, including tumor types other than CRC, was 43%, DOR was greater than or equal to 12 months in 92% of patients and OS was greater than or equal to 12 months in 75% of patients. In November 2021, envafolimab received marketing authorization from the Chinese NMPA and was approved for adult patients with MSI-H/dMMR advanced solid tumors, including those patients with advanced colorectal cancer who have experienced disease progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as well as patients with other advanced solid tumors who have experienced disease progression following prior systemic treatment and have no satisfactory alternative treatment options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Ongoing Clinical Trials</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Phase 3 randomized clinical trial in BTC was initiated by 3D Medicines in April 2018.  This trial is an open-label trial to assess the safety and efficacy of envafolimab plus standard of care gemcitabine-based chemotherapy compared to gemcitabine-based chemotherapy alone with OS as the primary endpoint. In the envafolimab arm, envafolimab will be dosed at 2.5mg/kg subcutaneously QW, along with gemcitabine and oxaliplatin at recommended doses. The trial is expected to enroll over 390 patients in China and data are expected in 2024.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Phase 2 clinical trial of envafolimab in combination with folinic acid, fluorouracil and oxaliplatin chemotherapy (FOLFOX) in the first line treatment of advanced gastric cancer was fully enrolled (n=15) as of January 15, 2019. In an abstract at the ASCO 2020 Virtual Scientific Program entitled &#8220;Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer&#8221; data were reported in 15 patients who were evaluable for response. The Eastern Cooperative Oncology Group (ECOG) performance status was 1 in 80% of subjects and the majority had gastric cancer (86.7%). At the time of data cutoff, the minimum follow-up was 6 months. The occurrence of TEAEs was 100% (all grades) and 73.3% (grades 3-4). The most frequent grade 3-4 TEAEs included neutrophil count decreased 46.7%, anemia 20.0%, and platelet disorder 20% (3/15). Confirmed ORR was 60% (unconfirmed ORR: 73.3%). Median DOR was not reached. Median PFS was 6.8 months.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Stage Product Candidate &#8211; TRC102</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of Base Excision Repair and the Mechanism of Action of TRC102</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Base-excision repair (BER) is a complex and fundamental cellular process used by cancer cells to repair the DNA damage caused by chemotherapeutics, especially the classes of chemotherapeutics known as alkylating agents, including Temodar, dacarbazine and bis-dichloroethyl-nitrosourea (BCNU), and anti-metabolite agents, including Fludara and Alimta. The process of BER removes DNA bases damaged by chemotherapy, resulting in the formation of gaps in the DNA strand called apurinic and apyrimidinic (AP) sites. The appropriate base is then inserted in this gap to restore the proper tumor DNA sequence. By this process, cancer cells can circumvent the anti-tumor effects of chemotherapy.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inhibition of BER has been proposed as a way to improve the efficacy of chemotherapeutics; however, to our knowledge, no inhibitors of BER have been tested in clinical trials. We are developing TRC102 (methoxyamine hydrochloride) to reverse resistance to specific chemotherapeutics by inhibiting BER. TRC102 interrupts BER by rapidly and covalently binding within AP sites, converting the AP site to a substrate for the enzyme topoisomerase II, which cleaves TRC102-bound DNA, resulting in an accumulation of DNA strand breaks that trigger cellular apoptosis, or programmed cell death, as illustrated in the figure below:</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TRC102 binding results in apoptosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img19885085_7.jpg" alt="img19885085_7.jpg" style="width:520px;height:321px;"/>&#160;</p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The induction of apoptosis by TRC102 is relatively selective for cancer cells, which typically overexpress topoisomerase II. In nonmalignant cells with low topoisomerase II expression, TRC102-bound DNA is excised and replaced by a separate DNA repair system.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, we announced the publication of clinical data in the journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cancer Cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that provides molecular insight into TRC102&#8217;s mechanism of action and patient populations most likely to respond to treatment. The article, entitled, &#8220;Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment,&#8221; highlighted the clinical features and tumor biology of an exceptional responder patient treated with TRC102 at the NCI. The patient was diagnosed with metastatic and highly refractory CRC and received Temodar and TRC102. Following treatment, the patient was considered an exceptional responder through the achievement of a near complete response lasting 45 months at the most recent follow-up. Detailed molecular analyses of the patient&#8217;s tumor showed silencing of DNA repair pathways that may have resulted in sensitivity to the inhibition of DNA BER pathway by TRC102. Specifically, MGMT expression was silenced by promoter methylation, and RAD50, a mediator of DNA double strand break repair, was silenced by genetic mutation and loss of heterozygosity. The publication authors hypothesized that the combination of Temodar and TRC102 was effective because all necessary DNA repair pathways were compromised genetically or through the activity of TRC102. MGMT expression was also assessed in biopsies from 11 colorectal patients who subsequently enrolled in an expansion cohort, one of whom demonstrated a PR. The tumor associated with the PR did not express MGMT, whereas each of the 10 tumors that did not respond to therapy expressed this enzyme robustly. MGMT deficiency is observed in about one third of glioblastoma patients, and a prior study of Temodar and TRC102 reported at the Society for Neuro-Oncology in 2018 demonstrated that two MGMT deficient glioblastoma patients had prolonged survival when treated with Temodar and TRC102 after progressing previously on Temodar and radiation therapy. Based on these data, we believe a trial in first line glioblastoma patients of Temodar, radiation therapy and TRC102 is warranted and are discussing further development with investigators at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TRC102 Development in Oncology</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRC102 is being developed to reverse resistance to Temodar, an alkylating chemotherapeutic, as well as to Alimta and Fludara, two antimetabolite chemotherapeutics. We consider it advantageous to combine TRC102 with Alimta because Alimta is approved in one large market indication (lung cancer) and one orphan drug indication (mesothelioma). Temodar is an approved chemotherapeutic used as a standard of care agent to treat glioblastoma, and Fludara is an approved chemotherapeutic used as a standard of care agent to treat lymphoma and leukemia. In initial clinical trials of more than 100 patients, TRC102 has shown good tolerability and promising anti-tumor activity in combination with alkylating and antimetabolite chemotherapy.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We filed an IND application for TRC102 in March 2008, Case Western filed an IND application for TRC102 in March 2006, and NCI filed an IND for TRC102 in March 2013, all for the treatment of patients with advanced solid tumors. The IND application filed by NCI cross references our IND application.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2020, positive data from multiple TRC102 clinical trials were presented at the 2020 ASCO Virtual Scientific Program.  Dr. Koczywas of City of Hope Medical Center presented Phase 1 data for TRC102 in combination with cisplatin and Alimta in patients with advanced solid tumors, and Phase 2 data for TRC102 in combination with Alimta in patients with mesothelioma refractory to Alimta and platinum therapy. Notably two of 14 mesothelioma patients who progressed previously on Alimta had objective responses following treatment with Alimta and TRC102.  Multiple responses were also noted in the Phase 1 trial of Alimta, cisplatin and TRC102, with particular activity noted in parotid salivary gland tumors. Dr. Biswas of Case Comprehensive Cancer Center presented Phase 1 data of TRC102 in combination with chemoradiation for locally advanced non-squamous non-small cell lung cancer.  All 15 patients demonstrated an objective response, including three patients with a complete response to treatment.  The 100% ORR compares favorably to historical data of the same combination of chemoradiation without TRC102 in locally advanced lung cancer.  For example, the PROCLAIM clinical trial reported an ORR of 36% and the PACIFIC clinical trial reported an ORR of 51% in locally advanced non-squamous non-small cell lung cancer patients treated with Alimta, cisplatin and thoracic radiation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 ascending dose clinical trials evaluating the safety, tolerability, PK, PD and anti-tumor activity of TRC102 were completed with Alimta in patients with advanced solid tumors, with Fludara in patients with hematologic malignancy and with Temodar in patients with solid tumors. In each trial, TRC102 was tolerable with the companion chemotherapeutic, and demonstrated signs of activity.  One patient treated with TRC102 and Alimta had a PR as assessed by RECIST 1.1 and remained in our clinical trial without cancer progression for 14 months. In addition, 14 patients had SD including patients with squamous cell lung cancer (three patients), epithelial ovarian cancer (three patients), CRC (two patients), non-squamous non-small cell lung cancer (one patient), pancreatic cancer (one patient), prostate cancer (one patient), endometrial cancer (one patient), head and neck cancer (one patient) and breast cancer (one patient). These data were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investigational New Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2012. Case Western reported data from a trial of intravenous TRC102 given in combination with Fludara in a Phase 1 clinical trial that were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Oncotarget</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2017. Anti-tumor activity, including PR, was noted in patients with lymphoma and chronic lymphocytic leukemia, including patients treated previously with Fludara. TRC102 combined with Fludara was safe and well tolerated. Hematologic toxicity was comparable to single agent Fludara and activity appeared to correlate with increased levels of DNA damage. Case Western reported data from a trial of TRC102 given intravenously in combination with Temodar in a Phase 1 clinical trial at the ASCO annual meeting in June 2015. Anti-tumor activity was noted in patients with ovarian cancer and neuroendocrine tumors.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NCI reported data from the Phase 1 trial of TRC102 in combination with Temodar in relapsed solid tumors and lymphoma patients at ASCO in 2017. There were no pharmacologic interactions between the two drugs and TRC102 target concentrations were achieved. Based on PRs in patients with ovarian cancer, non-small cell lung cancer, and KRAS-positive CRC, the NCI decided to enroll expansion cohorts in each of these tumor types at the recommended Phase 2 oral dose of TRC102.  The authors concluded that the combination of Temodar and TRC102 is active, and DNA damage response markers (Rad51, &#978;-H2AX and/or pNbs1) were induced in four of five paired colonic biopsies, indicating DNA damage following treatment.  Updated data in the cohort of patients with CRC reported by the NCI at AACR in 2019 indicated a low response rate in patients with CRC treated with Temodar and TRC102. A December 2020 publication in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cancer Cell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstrated TMZ and TRC102 were active in the subgroup of MGMT deficient patients with colorectal cancer. A poster on an expansion cohort of TRC102 with TMZ in patients with granulosa cell ovarian cancer was presented by investigators at the NCI at the ASCO 2023 annual meeting held in June 2023. The authors concluded that TRC102 combined with TMZ was well tolerated in patients with GCOC. Durable disease control was observed in four of eight patients, which the authors considered as promising activity in this heavily pretreated GCOC cohort.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The combination of TRC102 and Temodar was assessed in a Phase 2 trial of patients with recurrent glioblastoma that was reported at the Society for Neuro-Oncology annual meeting in November 2018.  The combination of Temodar and TRC102 was tolerable, but did not meet the primary efficacy endpoint of demonstrating objective responses by Response Assessment in Neuro-Oncology criteria in the 19 enrolled patients, most of whom were treated at Cleveland Clinic.  Two patients (10.5%) demonstrated evidence of clinical benefit and met the secondary endpoint of PFS beyond six months.  Both patients who demonstrated PFS for more than 11 months were alive over 30 months following treatment initiation with TRC102 and Temodar for recurrent glioblastoma.  PFS of greater than 11 months was associated with N-methylpurine DNA glycosylase expression, a biomarker that initiates the BER pathway of resistance that is inhibited by TRC102. Efforts to identify whether DNA glycosylase expression or other biomarkers can be used as a predictive biomarker of TRC102 activity are expected to continue in ongoing TRC102 trials.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on data presented at the ASCO 2020 virtual meeting that the combination of chemoradiation and TRC102 produced objective responses in all 15 evaluable patients with advanced localized lung cancer treated in a Phase 1 trial, in January 2022, the NCI initiated a randomized trial of chemoradiation with or without TRC102, followed by consolidative durvalumab treatment. The primary objective is to improve the 56% PFS rate with current standard of care to 75% with current standard of care plus TRC102. The trial began enrollment in June 2022 and is expected to be complete in 2025.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Stage Product Candidate &#8211; YH001</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">YH001 is an investigational humanized CTLA-4 IgG1 monoclonal antibody.  YH001 is being developed by Eucure for the treatment of various cancer indications. In October 2021, we entered into a collaborative development and commercialization agreement with Eucure and Biocytogen pursuant to which we obtained an exclusive license to develop and commercialize YH001 in North America for the treatment of multiple specified indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTLA-4 is a protein expressed on all T-cells but which is expressed at the highest level on Tregs and contributes to the suppressor function of Tregs and acts as a checkpoint that prevents T-cell immune responses to cancer cells. A CTLA-4 inhibitor has been approved as a single agent in melanoma and approved in combination with other therapies in multiple indications, including NSCLC, RCC and MSI-H colorectal cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development of YH001</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021, YH001 had been dosed to more than 41 patients in China and Australia in two completed Phase 1 clinical trials.  YH001 is also being studied in additional ongoing Phase 1 clinical trials in combination with investigational and approved immunotherapies China sponsored by Eucure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase I Dose Escalation Clinical Trial in Australia</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An open-label, single-arm Phase 1 dose escalation clinical trial of YH001 in combination with the PD-1 antibody, toripalimab, was completed in Australia. The safety and efficacy data from this trial were presented at the 2022 ASCO Annual Meeting in June 2022. Based on the data presented in the ASCO presentation, 24 subjects were enrolled in this trial as of December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Study purpose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The primary objectives of the Phase 1 dose escalation clinical trial were to assess the safety and tolerability profile and MTD of YH001 in combination with the PD-1 inhibitor toripalimab in subjects with advanced solid tumors. The secondary objectives were to evaluate the PK profile and anti-tumor activity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Study design. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This trial adopted a modified &#8220;3+3&#8221; design. Subjects receive YH001 in six cohorts at 0.05mg/kg, 0.1mg/kg, 0.3mg/kg, 1.0mg/kg, 2.0mg/kg, 4.0mg/kg, and 6.0mg/kg by IV administration during a three week run-in period, after which subjects receive YH001 in combination with 240mg of the PD-1 antibody toripalimab every three weeks for four doses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Safety</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. At the December 31, 2021 data cutoff, the maximum tolerated and recommended Phase 2 dose of YH001 when given with toripalimab was 4 mg/kg i.v. every three weeks for up to one year of dosing.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Among 23 patients that had tumor imaging assessments available at the December 31, 2021 data cut-off, four achieved PR by RECIST, including in one patient with urothelial cancer who had failed prior treatment with a PD-1 antibody, and nine had stable disease.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_8.jpg" alt="img19885085_8.jpg" style="width:624px;height:335px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conclusion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The authors concluded that YH001 was well tolerated up to 4 mg/kg when combined with toripalimab and demonstrated activity in patients with advanced solid tumors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase I Dose Escalation Clinical Trial in China</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An open-label, single-arm Phase 1 dose escalation clinical trial of YH001 was completed in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In pre-clinical studies in mice, YH001 was compared with ipilimumab, an approved CTLA-4 inhibitor marketed by BMS, and YH001 showed the following potential advantages:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Superior in vivo activity compared to ipilimumab as a single agent and when combined with pembrolizumab, a PD-1 antibody marketed by Merck</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The following graphs illustrate the tumor size growth and body weight changes in mice. </span></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_9.jpg" alt="img19885085_9.jpg" style="width:259px;height:171px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img19885085_10.jpg" alt="img19885085_10.jpg" style="width:265px;height:182px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">More potent and active than ipilimumab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. YH001 was more potent and active than ipilimumab in blocking hCTLA-4 inhibition of CD80/86 activity. The following graph illustrates an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reporter assay demonstrating the ability of YH001 or ipilimumab to induce T-cell proliferation by inhibiting the interaction of hCTLA-4 with CD80/86.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img19885085_11.jpg" alt="img19885085_11.jpg" style="width:311px;height:192px;"/>&#160;</p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development in North America</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we announced that the FDA had approved the IND application for the initiation of a Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin, an approved treatment for soft tissue sarcoma, for the treatment of sarcoma patients. In December 2022, we initiated dosing in the Phase 1/2 clinical trial to assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma and of the doublet combination of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma. Given the recommendation of the IDMC to terminate enrollment in cohort D of the ENVASARC trial of dosing envafolimab with the CTLA-4 antibody Yervoy, we reviewed safety and efficacy data from more than ten patients who received envafolimab with the CTLA-4 antibody YH001. Following the data review and discussions with principal investigators, we discontinued enrollment in the Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin. We presented data from the 15 patients enrolled into the Phase 1/2 clinical trial in a poster in November 2023 at the Connective Tissue Oncology Society meeting. We plan to continue the development of envafolimab with doxorubicin in soft tissue sarcoma in a separate trial and may initiate trials of YH001 as a single agent or in combination with immunotherapies in other tumor types.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration and License Agreements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inhibrx License Agreement</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, we granted a non-exclusive and non-transferable license of our CRO-independent PDP to Inhibrx for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals (the PDP License), for a nonrefundable upfront fee of $3.0 million. The PDP License allows Inhibrx to use our configuration documentation with a widely used software package in addition to our validation and qualification of the software package, and our standard operation procedure documents, policies, work instructions, and clinical operation templates (the Licensed Technology). We are also able to earn an additional $0.2 million upon the completion of up to 500 hours of training to Inhibrx by us or six months following our delivery of the Licensed Technology, whichever is earlier.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with 3D Medicines and Alphamab</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, we, 3D Medicines, and Alphamab entered into the Envafolimab Collaboration Agreement for the development of envafolimab, an investigational PD-L1 sdAb, or nanobody, administered by rapid subcutaneous injection, for the treatment of sarcoma in North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Envafolimab Collaboration Agreement, we were granted an exclusive license to develop and commercialize envafolimab for the treatment of sarcoma in North America.  We are responsible for conducting and will bear the costs of any Phase 1, Phase 2, and Phase 3 or post-approval clinical trial in North America for envafolimab in the indications of refractory and first line treatment of sarcoma. 3D Medicines and Alphamab are responsible for conducting and will bear the costs of IND-enabling studies (other than those specific to the sarcoma indication) and the preparation of the chemistry, manufacturing and controls (CMC) activities sections of an IND application for envafolimab. 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third-party manufacturer to manufacture and supply, envafolimab to us at pre-negotiated prices that vary based on clinical or commercial use. 3D Medicines and Alphamab retained the right to develop envafolimab in all territories outside of North America as well as within North America for all indications other than sarcoma.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue, unless (a) envafolimab is first approved in North America for an indication other than sarcoma and launched in North America, or (b) envafolimab is first approved in North America for sarcoma and subsequently approved in North America for an additional non-orphan indication and sold commercially by 3D Medicines and/or Alphamab, or licensee, in which case 3D Medicines and Alphamab will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue. If 3D Medicines and Alphamab become responsible for commercialization under the Envafolimab Collaboration Agreement, we have the option to co-market envafolimab for sarcoma in North America. In the event that envafolimab is first approved in North America for sarcoma and within three years of the commercial launch of envafolimab in North America for sarcoma 3D Medicines and Alphamab replace us as the party responsible for commercialization, and we elect and 3D Medicines and Alphamab agree for us to not co-market envafolimab for sarcoma in North America, then 3D Medicines and Alphamab will be required to compensate us for our costs associated with preparing for and conducting commercial activities.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we have the responsibility for commercialization under the Envafolimab Collaboration Agreement, we will owe 3D Medicines and Alphamab tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits.  If 3D Medicines and Alphamab have responsibility for commercialization under the Envafolimab Collaboration Agreement, we will be entitled to (a) tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits if we have elected to not co-market envafolimab in sarcoma or (b) a 50% royalty on net sales of envafolimab for sarcoma in North America if we have chosen to co-market envafolimab in sarcoma.  Payment obligations under the Envafolimab Collaboration Agreement continue on a country-by-country basis until the last to expire licensed patent covering envafolimab expires.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3D Medicines and Alphamab retain the right to reacquire the rights to envafolimab for sarcoma in North America in connection with an arm&#8217;s length sale to a third party of the rights to develop and commercialize envafolimab in North America for all indications, provided that the sale may not occur prior to completion of a pivotal trial of envafolimab in sarcoma without our written consent and the parties must negotiate in good faith and agree to fair compensation be paid to us for the value of and opportunity represented by the reacquired rights.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party agreed that during the term of the Envafolimab Collaboration Agreement, it would not develop or license from any third party a monospecific inhibitor to PD-L1 or PD-1 in sarcoma.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Envafolimab Collaboration Agreement continues until the later of the date the parties cease further development and commercialization of envafolimab for sarcoma in North America or the expiration of all payment obligations.  The Envafolimab Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to envafolimab.  In the event we elect, or a joint steering committee (JSC) determines, to cease further development or commercialization of envafolimab, or if we fail to use commercially reasonable efforts to develop (including progress in clinical trials) and commercialize envafolimab and do not cure such failure within a specified time period, then our rights and obligations under the Envafolimab Collaboration Agreement will revert to 3D Medicines and Alphamab.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with Case Western</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2006, we entered into a license agreement with Case Western, under which we obtained an exclusive, worldwide license to certain patents, know-how and other intellectual property controlled by Case Western related to methoxyamine, which we refer to as the TRC102 Technology. Under the agreement, as amended, we have the right to use, manufacture and commercialize products utilizing the TRC102 Technology for all mammalian therapeutic uses, and to sublicense these rights.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the agreement, we are generally obligated to use our best efforts to commercialize the TRC102 Technology as soon as possible. We are also required to meet specified diligence milestones, and if we fail to do so and do not cure such failure, Case Western may convert our license into a non-exclusive license or terminate the agreement.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the rights granted to us under the agreement, we paid a one-time upfront fee to Case Western. In addition, we may be required to pay up to an aggregate of approximately $9.8 million in milestone payments, of which $0.7 million relates to the initiation of certain development activities and approximately $9.1 million relates to the submission of certain regulatory filings and receipt of certain regulatory approvals. If products utilizing the TRC102 Technology are successfully commercialized, we will be required to pay Case Western a single-digit royalty on net sales, subject to adjustments in certain circumstances. Beginning on the earlier of a specified number of years from the effective date of the agreement and the anniversary of the effective date following the occurrence of a specified event, we will be required to make a minimum annual royalty payment of $75,000, adjusted annually based on the Consumer Price Index, which will be credited against our royalty obligations. In the event we sublicense any of our rights under the agreement relating to the TRC102 Technology, we will be obligated to pay Case Western a portion of certain fees we may receive under the sublicense. Our royalty obligations will continue through the later of (i) the expiration of any orphan drug marketing exclusivity for a product utilizing the TRC102 Technology, (ii) August 2026, or (iii) on a country-by-country basis upon the expiration of the last valid claim under the TRC102 Technology or any patent we receive that is a derivative of the TRC102 Technology.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may unilaterally terminate this agreement in its entirety, for any reason or for no reason, upon at least 30 days&#8217; notice to Case Western. If we do so, we will be required to pay Case Western a termination fee. If we fail to pay any amount required under the agreement and do not cure the default within 90 days of receiving notice, Case Western will have the right to convert our exclusive license to a non-exclusive license or to terminate the agreement entirely. Either party may terminate the agreement in the event of the other party&#8217;s material breach of the agreement that remains uncured 60 days after receiving notice of the breach.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreements with NCI</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Health and Human Services, as represented by NCI, for the development of TRC102 for the treatment of cancer. We entered into the CRADA governing the development of TRC102 (TRC102 CRADA) in August 2012 with NCI&#8217;s Center for Cancer Research.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the CRADA, as amended, NCI conducts clinical trials and non-clinical studies of TRC102. Pursuant the TRC102 CRADA, we are required to pay NCI $20,000 per year per Phase 1 clinical trial and $25,000 per year per Phase 2 clinical trial, as well as expenses incurred by NCI in connection with carrying out its responsibilities under the TRC102 CRADA, up to an aggregate maximum per year of $200,000. We may also provide funding to support assays and other studies, and if NCI supplies TRC102 for additional mutually approved clinical trials beyond the planned trials, we will reimburse NCI for costs associated with manufacturing TRC102. In addition, we made a one-time payment of $20,000 for the initial IND filing and may be required to make additional one-time payments of $10,000 each for additional IND filings. Funding for clinical trials beyond those contemplated by the TRC102 CRADA will be determined in an amendment to the applicable CRADA.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the CRADA, each party individually owns all inventions, data and materials produced solely by its employees in the course of performing research activities pursuant to the CRADA. The parties jointly own any inventions and materials that are jointly produced by employees of both parties. Subject to certain conditions, we have the option under the CRADA to negotiate commercialization licenses from the government to intellectual property conceived or first reduced to practice in performance of the CRADA research plan that was developed solely by NCI employees or jointly by us and NCI employees.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The TRC102 CRADA had an original five-year term and was subsequently amended to extend the term to August 7, 2023. The CRADA may be terminated at any time by mutual written consent, and we or NCI may unilaterally terminate the CRADA for any reason or no reason by providing written notice at least 60 days before the desired termination date.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Eucure and Biocytogen</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, we, Eucure and Biocytogen entered into a collaborative development and commercialization agreement (the YH001 Collaboration Agreement) for the development of YH001, a monospecific investigational CTLA-4 antibody. Pursuant to the YH001 Collaboration Agreement, we were granted an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including sarcoma, microsatellite stable colorectal cancer, RCC, and K-ras positive non-small cell lung cancer (collectively, the Initial Indications) or one or more of bladder cancer, endometrial cancer, and melanoma as substitute indications, which may be substituted for Initial Indications at our discretion (each upon such substitution, a Substitute Indication). We are responsible for, and will bear the costs of, preparing and filing all regulatory submissions and conducting any Phase 1, Phase 2, Phase 3, or post-approval clinical trials in North America for YH001 in the Initial Indications and potentially the Substitute Indications, while Eucure is responsible for conducting, and will bear the costs of, the preparation of CMC activities for YH001. Eucure has agreed to manufacture and supply, or to arrange for a third-party manufacturer to manufacture and supply, YH001 to us for clinical trials pursuant to the terms of a clinical supply and quality agreement that will be separately negotiated and agreed in good faith between the parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eucure may pursue clinical trials for YH001 in North America outside of the Initial Indications or Substitute Indications, and also within the Initial Indications or Substitute Indications as part of a combination therapy of YH001 and an additional Eucure product. During a specified period, we have the option, subject to Eucure&#8217;s prior written approval, to expand the license to include the development and commercialization of YH001 for the treatment, through administration by intravenous or subcutaneous means, of all human and veterinary therapeutic indications in North America for a payment to Eucure in the low single digit millions (the Company Option).</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the YH001 Collaboration Agreement, we granted Eucure an irrevocable, perpetual, royalty-free, exclusive license, with the right to grant sublicenses to develop, register, sell, offer to sell, have sold, market and distribute YH001 in all territories outside of North America as well as within North America for all indications other than the Initial Indications and the Substitute Indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be responsible for commercializing YH001 in North America, including booking of sales revenue in the Initial and Substitute Indications. We will owe Eucure escalating double digit royalties on net sales of YH001 in North America ranging from the mid-twenties to mid-double digits; provided that until the end of the first full calendar year following the first commercial sale of YH001, royalties will range from the lower double digits to the mid-double digits. If sales of YH001 exceed a pre-determined sales threshold in the first full year of sales following first commercial sale, we will owe a milestone to Eucure in the high single digit millions. Payment obligations under the YH001 Collaboration Agreement continue on a country-by-country basis until the latest of (i) expiration of the last to expire licensed patent covering YH001, (ii) expiration of marketing or regulatory exclusivity covering YH001 and (iii) 10 years from the first commercial sale of YH001 in such country in North America. Eucure has agreed to manufacture and supply, or to arrange for a third-party manufacturer to manufacture and supply, YH001 to us at cost plus a low double-digit markup for commercial sales pursuant to the terms of a commercial supply and quality agreement that will be separately negotiated and agreed in good faith between the parties within 180 days prior to the anticipated first commercial sale in North America.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the YH001 Collaboration Agreement, each party agreed that during the term of the YH001 Collaboration Agreement, it would not develop, manufacture, commercialize or license from any third party a monospecific inhibitor to CTLA-4.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the YH001 Collaboration Agreement continues until the earlier of (i) the date that the parties cease further development and commercialization of YH001 in North America or (ii) on a country-by-county basis, the expiration of the royalty obligations in such country.  The YH001 Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to YH001. In the event of a termination of the YH001 Collaboration Agreement, other than by us as a result of Eucure&#8217;s material uncured breach or bankruptcy, (i) our license shall terminate and (ii) we would be obligated to grant Eucure an irrevocable, perpetual, royalty-free, non-exclusive license with the right to grant sublicenses under its rights in all development data and intellectual property to develop, register, sell, offer to sell, have sold, market and distribute YH001 in North America. In the event of a termination of the YH001 Collaboration Agreement by us as a result of Eucure&#8217;s material uncured breach or bankruptcy, the license shall continue in the Initial Indications in North America, provided that (i) such license shall remain exclusive during the royalty term and non-exclusive thereafter; (ii) we shall have the right to have YH001 manufactured for its development and commercialization requirements in the Initial Indications in North America; and (iii) the license shall terminate in the event of an uncured material breach by us of any provision (including payment obligations) that survives termination of the YH001 Collaboration Agreement.  In the event the YH001 Collaboration Agreement terminates for safety reasons related to YH001, by mutual agreement of the parties or by Eucure in the event of an uncured material breach or bankruptcy by us, then our rights and obligations under the YH001 Collaboration Agreement will revert to Eucure.  In the event Eucure does not approve the Company Option, we may terminate the YH001 Collaboration Agreement for convenience with a 30-day notice to Eucure, provided that such termination is given within 12 months of the effective date of the YH001 Collaboration Agreement (the Company Option Termination).  In the event of a Company Option Termination, Eucure would be obligated to reimburse us for all costs and expenses that we incurred in performing the development activities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate, nor do we expect to own or operate, facilities for product manufacturing, storage, distribution or testing. We contract with third parties or our collaboration partners for the manufacture of our product candidates and we intend to continue to do so in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Envafolimab is manufactured by AlphaMab in China. Pursuant to the Envafolimab Collaboration Agreement, 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, envafolimab to us at pre-negotiated prices that vary based on clinical or commercial use.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">YH001 is manufactured by an experienced contract manufacturer in China. Pursuant to the YH001 Collaboration Agreement, Eucure and Biocytogen have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to us at pre-negotiated prices that vary based on clinical or commercial use pursuant to the terms of a clinical supply and quality agreement to be separately negotiated.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRC102 drug substance is manufactured through a standard chemical synthesis and may be obtained from multiple manufacturers.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drugs is highly competitive, and we and our collaborators face competition with respect to each of our product candidates in their target indications. Many of the entities developing and marketing potentially competing products have significantly greater financial, technical and human resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any products that we may develop.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are approved, they will compete with currently marketed drugs and therapies used for treatment of the following indications, and potentially with drug candidates currently in development for the same indications.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key competitive factors affecting the success of any approved product will include its efficacy, safety profile, price, method of administration and level of promotional activity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Oncology Therapies</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no PD-1 or PD-L1 therapy approved by the FDA for the treatment of sarcoma. Keytruda (marketed by Merck) has a compendia listing for the treatment of UPS, and is used off-label for the treatment of patients with UPS. If envafolimab is approved, it may nevertheless compete with currently marketed PD-1 and PD-L1 inhibitors, including Opdivo (marketed by BMS), Keytruda (marketed by Merck), Imfinzi (marketed by AstraZeneca), and Tecentriq (marketed by Roche) which are approved by the FDA in multiple indications other than soft tissue sarcoma. The global PD-1 and PD-L1 inhibitors market had an approximate value of over $30 billion in 2022.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no CTLA-4 therapy approved by the FDA for the treatment of soft tissue sarcoma.  If YH001 is approved, it may nevertheless compete with the currently marketed CTLA-4 inhibitor ipilimumab (Yervoy, marketed by BMS), which is approved by the FDA in multiple indications other than soft tissue sarcoma. Other antibodies to CTLA-4 are being studied in clinical trials of cancer patients.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing TRC102 to be used in combination with alkylating chemotherapeutics (including Temodar) and antimetabolite chemotherapeutics (including Alimta and Fludara) for the treatment of cancer. If TRC102 is approved, it could compete with other inhibitors of DNA repair. Tesaro, Inc. (now GSK), Clovis Oncology and Astra Zeneca each market inhibitors of DNA repair that work by a mechanism of action that is distinct from that of TRC102. In addition to the therapies mentioned above, there are many generic chemotherapeutics and other regimens commonly used to treat various types of cancer, including soft tissue sarcoma and glioblastoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold North America commercialization rights in the field of sarcoma for envafolimab (subject to certain rights held by 3D Medicines and Alphamab), North America commercialization rights of multiple human indications, including the Initial Indications or one or more of the Substitute Indications, which may be substituted for Initial Indications at our discretion, for YH001, and worldwide commercialization rights for TRC102. If any of our product candidates are approved in oncology indications, our plan is to build an oncology-focused specialty sales force in the United States to support their commercialization and seek a partner(s) to support commercialization outside the United States to the extent we have commercial rights in other territories. We believe that a specialty sales force will be sufficient to target key prescribing physicians in oncology. We currently do not have any sales or marketing capabilities or experience as a company. We plan to establish the required capabilities within an appropriate time frame ahead of any product approval and commercialization to support a product launch.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our protein therapeutics, novel biological discoveries, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. Additionally, we expect to benefit from a variety of statutory frameworks in the United States, Europe, Japan and other countries that relate to the regulation of biosimilar molecules and orphan drug status. These statutory frameworks provide periods of non-patent-based exclusivity for qualifying molecules. See &#8220;Government Regulation.&#8221;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patenting strategy is focused on our protein and small molecule therapeutics. We seek composition of matter and method of treatment patents for each such protein or small molecule in key therapeutic areas. We also seek patent protection with respect to companion diagnostic methods and compositions and treatments for targeted patient populations. We have sought patent protection alone or jointly with our collaborators, as dictated by our collaboration agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual patents extend for varying periods of time depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued from applications filed in the United States are effective for twenty years from the earliest non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period; however, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also twenty years from the earliest international filing date. Our issued patents and pending applications with respect to our protein therapeutic candidates (excluding licensed rights) will expire on dates ranging from 2027 to 2030, exclusive of possible patent term extensions. However, the actual protection afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of extensions of patent term, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">National and international patent laws concerning protein therapeutics remain highly unsettled. No consistent policy regarding the patent-eligibility or the breadth of claims allowed in such patents has emerged to date in the United States, Europe or other countries. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries can diminish our ability to protect our inventions and enforce our intellectual property rights. Accordingly, we cannot predict the breadth or enforceability of claims that may be granted in our patents or in third-party patents. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our ability to maintain and solidify our proprietary position for our drugs and technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether any of the patent applications that we may file or license from third parties will result in the issuance of any patents. The issued patents that we own or may receive in the future, may be challenged, invalidated or circumvented, and the rights granted under any issued patents may not provide us with sufficient protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may be able to independently develop and commercialize similar drugs or duplicate our technology, business model or strategy without infringing our patents. Because of the extensive time required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. The patent positions for our most advanced programs are summarized below:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Envafolimab Patent Coverage</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specific to the development of envafolimab for the treatment of sarcoma in North America, we hold an exclusive license from 3D Medicines and Alphamab to any and all intellectual property rights, including patents, copyrights, trademarks and know-how, claiming or covering envafolimab. We also hold a non-exclusive license for the conduct of clinical trials in the EU in support of the development of envafolimab for the treatment of sarcoma in North America. 3D Medicines and Alphamab retain ownership of any and all intellectual property rights, including patents, copyrights, trademarks and know-how, claiming or covering any pharmaceutical composition or preparation comprising envafolimab.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">YH001 Patent Coverage</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eucure has an issued patent on the composition of matter and a pending application on the methods of use of YH001 in the United States. The terms of the patent would expire in 2037, exclusive of any patent term extension. We hold an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including the Initial Indications or one or more of the Substitute Indications, which may be substituted for Initial Indications at our discretion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TRC102 Patent Coverage</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold issued patents directed to combination of TRC102 and pemetrexed in the United States, Australia, Canada, Europe, Japan, Mexico, Norway, Russia, Singapore, South Africa, South Korea, Ukraine, and the United Kingdom. We also have pending applications in other jurisdictions, including Brazil, China, Hong Kong, and India. The expected expiration date for these patents is 2027, exclusive of possible patent term extensions.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold an issued patent on further combinations of TRC102 in Europe. The expected expiration date for these patents is 2031, exclusive of possible patent term extensions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Secrets, Trademarks and Know-How</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patents, we rely upon unpatented trade secrets, trademarks and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements with our employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. In addition, we seek trademark protection in the United States and internationally where available and when we deem appropriate. Furthermore, we are a party to a number of license agreements under which we are granted intellectual property rights to know-how that are important to our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Government Regulation</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, marketing and sales, among other things, of our product candidates and future products, are subject to extensive regulation by governmental authorities in the United States and other countries. In the United States, pharmaceutical products are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (FFDCA), and other laws, including, in the case of biologics, the Public Health Service Act (PHSA), in addition to the FDA&#8217;s implementing regulations. We expect envafolimab to be regulated by the FDA as a biologic, which requires the submission of a BLA and approval by the FDA prior to being marketed in the United States. We expect our small molecule product candidate TRC102 to be regulated as a drug and subject to New Drug Application (NDA) requirements, which are substantially similar to the BLA requirements discussed below. Manufacturers of our product candidates may also be subject to state regulation. Failure to comply with FDA requirements, both before and after product approval, may subject us or our partners, contract manufacturers and suppliers to administrative or judicial sanctions, including FDA refusal to approve applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, fines and/or criminal prosecution.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The steps required before a biologic may be approved for marketing of an indication in the United States generally include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices (GLPs) and other applicable regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may commence;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of adequate and well-controlled human clinical trials in accordance with Good Clinical Practices (GCPs) to establish that the biological product is &#8220;safe, pure and potent,&#8221; which is analogous to the safety and efficacy approval standard for a chemical drug product for its intended use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of a marketing application;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with applicable current Good Manufacturing Practice requirements (cGMPs); and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review of the marketing application and issuance of a biologics license which is the approval necessary to market a biologic therapeutic product.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation as well as animal studies to assess the potential safety and efficacy of the biologic candidate. Preclinical studies must be conducted in compliance with FDA regulations regarding GLPs. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. Nonclinical testing may continue after the IND is submitted. In addition to including the results of the preclinical testing, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase or phases of the clinical trial lends themselves to an efficacy determination. The IND will automatically become effective 30 days after receipt by the FDA, unless the FDA within the 30-day time period places the IND on clinical hold because of its concerns about the drug candidate or the conduct of the trial described in the clinical protocol included in the IND. The FDA can also place the IND on clinical hold at any time during drug development for safety concerns related to the investigational drug or to the class of products to which it belongs. The IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can proceed.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All clinical trials must be conducted under the supervision of one or more qualified principal investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the applicable phase of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must timely report to the FDA serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure, or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the drug. An institutional review board, or IRB, at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution, approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#8217;s legal representative, and monitor the trial until completed.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials are typically conducted in three sequential phases, but the phases may overlap and different trials may be initiated with the same drug candidate within the same phase of development in similar or differing patient populations. Phase 1 clinical trials may be conducted in a limited number of patients, but are usually conducted in healthy volunteer subjects for indications other than oncology. The drug candidate is initially tested for safety and, as appropriate, for absorption, metabolism, distribution, excretion, PD and PK.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 usually involves trials in a larger, but still limited, patient population to evaluate preliminarily the efficacy of the drug candidate for specific, targeted indications to determine dosage tolerance and optimal dosage and to identify possible short-term adverse effects and safety risks.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 trials are undertaken to further evaluate clinical efficacy of a specific endpoint and to test further for safety within an expanded patient population at geographically dispersed clinical trial sites. Phase 1, Phase 2, or Phase 3 testing might not be completed successfully within any specific time period, if at all, with respect to any of our product candidates. Results from one trial are not necessarily predictive of results from later trials. Furthermore, the FDA or the sponsor may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug candidate has been associated with unexpected serious harm to patients.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of the preclinical studies and clinical trials, together with other detailed information, including information on the manufacture and composition of the product, are submitted to the FDA as part of a marketing application requesting approval to market the drug candidate for a proposed indication. Under the PDUFA, the fees payable to the FDA for reviewing a marketing application, as well as annual program fees for approved products, can be substantial. The fees typically increase each year. Each marketing application submitted to the FDA for approval is reviewed for administrative completeness and reviewability within 60 days following receipt by the FDA of the application. If the application is found complete, the FDA will file the marketing application, triggering a full review of the application. The FDA may refuse to file any marketing application that it deems incomplete or not properly reviewable at the time of submission. The FDA&#8217;s established goal is to review 90% of priority marketing applications within six months after the application is accepted for filing and 90% of standard marketing applications within 10 months of the acceptance date, whereupon a review decision is to be made. The FDA, however, may not approve a drug candidate within these established goals and its review goals are subject to change from time to time. Further, the outcome of the review, even if generally favorable, may not be an actual approval but a &#8220;complete response letter&#8221; that describes additional work that must be done before the application can be approved. Before approving a marketing application, the FDA may inspect the facility or facilities at which the product is manufactured and will not approve the product unless the facility complies with cGMPs. The FDA may deny approval of a marketing application if applicable statutory or regulatory criteria are not satisfied, or may require additional testing or information, which can extend the review process. FDA approval of any application may include many delays or never be granted. If a product is approved, the approval may impose limitations on the uses for which the product may be marketed, may require that warning statements be included in the product labeling, may require that additional studies be conducted following approval as a condition of the approval, and may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a Risk Evaluation and Mitigation Strategy (REMS) or otherwise limit the scope of any approval. The FDA must approve a marketing application supplement or a new marketing application before a product may be marketed for other uses or before certain manufacturing or other changes may be made. Further post-marketing testing and surveillance to monitor the safety or efficacy of a product is required. Also, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur following initial marketing. In addition, new government requirements may be established that could delay or prevent regulatory approval of our product candidates under development.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 (the BPCIA) created a pathway for licensure, or approval, of biological products that are biosimilar to, and possibly interchangeable with, earlier biological products licensed under the PHSA. Also under the BPCIA, innovator manufacturers of original reference biological products are granted 12 years of exclusivity before biosimilars can be approved for marketing in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both before and after the FDA approves a product, the manufacturer and the holder or holders of the marketing application for the product are subject to comprehensive regulatory oversight. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to spend time, money and effort to maintain cGMP compliance.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the FDA strictly regulates marketing, labeling, advertising and promotion of products. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we currently do not have any products on the market in the United States, we may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal, fraud and abuse, including anti-kickback and false claims, privacy and security and physician sunshine laws and regulations, many of which may become more applicable if our product candidates are approved and we begin commercialization. For additional details regarding the federal, state and foreign healthcare laws that may affect our ability to operate, see &#8220;Risk Factors&#8212;Risks Related to Our Business and Industry&#8212; &#8220;We are subject to extensive federal, state, and foreign regulation, and our failure to comply with these laws could harm our business.&#8221; If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, significant civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Act</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States Orphan Drug Act provides incentives to manufacturers to develop and market drugs for rare diseases and conditions affecting fewer than 200,000 persons in the United States at the time of application for orphan drug designation (ODD). ODD must be requested before submitting a BLA. ODD does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. If a product that has ODD subsequently receives the first FDA approval for the disease for which it has such designation, the holder of the approval is entitled to a seven-year exclusive marketing period in the United States for that product except in very limited circumstances. For example, a drug that the FDA considers to be clinically superior to, or different from, another approved orphan drug, even though for the same indication, may also obtain approval in the United States during the seven-year exclusive marketing period. In addition, holders of exclusivity for orphan drugs are expected to assure the availability of sufficient quantities of their orphan drugs to meet the needs of patients. Failure to do so could result in the withdrawal of marketing exclusivity for the drug.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislation similar to the Orphan Drug Act has been enacted outside the United States, including in the EU and Japan. The orphan legislation in the EU is available for therapies addressing chronic debilitating or life-threatening conditions that affect five or fewer out of 10,000 persons or are financially not viable to develop. The market exclusivity period is for ten years, although that period can be reduced to six years if, at the end of the fifth year, available evidence establishes that the product is sufficiently profitable not to justify maintenance of market exclusivity. The market exclusivity may be extended to 12 years if sponsors complete a pediatric investigation plan agreed upon with the relevant committee of the European Medicines Agency. Orphan legislation in Japan similarly provides for ten years of marketing exclusivity for drugs that are approved for the treatment of rare diseases and conditions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New biological products will benefit, if approved, from the data exclusivity provisions legislated in the United States, the EU and Japan. All three regions effectively provide a period of data exclusivity to innovator biologic products. U.S. legislation provides a 12-year period of data exclusivity from the date of first licensure of a reference biologic product. EU legislation provides a period of 10 to 11 years and Japan legislation provides a period of 8 years during which companies cannot be granted approval as generic drugs to approved biologic therapies. Protection from generic competition is also available for new chemical entities, including potentially the small molecule TRC102, in the United States for 5 years, in the EU for 10 to 11 years and in Japan for 8 years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity in the European Union</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU has led the way among the International Council for Harmonisation regions in establishing a regulatory framework for biosimilar products. The marketing authorization of generic medicinal products and similar biological medicinal products are governed in the EU by Article 10(1) of Directive 2001/83/EC (2001). Unlike generic medicinal products, which only need to demonstrate bioequivalence to an authorized reference product, similar biological medicinal products are required to submit preclinical and clinical data, the type and quantity of which is dictated by class and product specific guidelines. In order to submit a marketing authorization for a similar biological medicinal product, the reference product must have been authorized for marketing in the EU for at least 8 years. Biosimilars can only be authorized for use once the period of data exclusivity on the biological reference medicine has expired. In general, this means that the biological reference medicine must have been authorized for at least 10 years before a similar biological medicine can be made available by another company. The 10-year period can be extended to a maximum of 11 if, during the first 8 years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization are held to bring a significant clinical benefit in comparison to existing therapies.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many EU countries have banned interchangeability of biosimilars with their reference products to ensure adequate characterization of the safety profile of the biosimilar and to enable comparison to that of reference product.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity in Japan</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2009, Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Device Agency (PMDA) issued the first Japanese guidance on biosimilars. The guideline (currently available only in Japanese), which shares common key features to EU guidelines, outlines the nonclinical, clinical and CMC requirements for biosimilar applications and describes the review process, naming conventions and application fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Japan does not grant exclusivity to pharmaceutical products; however, the country does have a Post Marketing Surveillance (PMS) system that affects the timing of generic entry and, in effect, provides a period of market exclusivity to innovator products. This system allows safety data to be acquired for each product. A PMS period is set for most of new drug approvals, and until this period is over, generic companies cannot submit their applications for drug approvals as generic drugs. Recently, this period was extended to 8 years for all new drug approvals. Japan&#8217;s regulations do not allow currently for interchangeability of biosimilars with their reference products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Review and Approval</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has various programs, including Fast Track, priority review, and accelerated approval, which are intended to expedite or simplify the process for reviewing drugs and biologics, and/or provide for the approval of a drug or biologic on the basis of a surrogate endpoint. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs. Breakthrough therapy designation is for products that are intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Priority review is designed to give drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months as compared to a standard review time of ten months. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the application for a drug designated for priority review. Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a drug candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity and Pediatric Use</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Best Pharmaceuticals for Children Act, certain drugs may obtain an additional six months of exclusivity, if the sponsor submits information requested in writing by the FDA, or a Written Request, relating to the use of the active moiety of the drug in children. The FDA may decline to issue a Written Request for studies on unapproved or approved indications or where it determines that information relating to the use of a drug in a pediatric population, or part of the pediatric population, may not produce health benefits in that population.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not received a Written Request for such pediatric studies, although we may ask the FDA to issue a Written Request for such studies in the future. To receive the six-month pediatric market exclusivity, we would have to receive a Written Request from the FDA, conduct the requested studies in accordance with a written agreement with the FDA or, if there is no written agreement, in accordance with commonly accepted scientific principles, and submit reports of the studies. A Written Request may include studies for indications that are not currently in the labeling if the FDA determines that such information will benefit the public health. The FDA will accept the reports upon its determination that the studies were conducted in accordance with and are responsive to the original Written Request or commonly accepted scientific principles, as appropriate, and that the reports comply with the FDA&#8217;s filing requirements.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Pediatric Research Equity Act (PREA) requires a sponsor to conduct pediatric studies for most drugs and biologicals, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must include the evaluation of the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In both domestic and foreign markets, sales and reimbursement of any approved products will depend, in part, on the extent to which third-party payors, such as government health programs, commercial insurance and managed healthcare organizations provide coverage, and establish adequate reimbursement levels, for such products. Third-party payors are increasingly challenging the prices charged for medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Additionally, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. If third-party payors do not consider our products to be cost-effective compared to other therapies, the payors may not cover our products after approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The containment of healthcare costs also has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, ensuring adequate coverage and payment for our products will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. Third-party payors are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly-approved health care products. Recent budgetary pressures in many EU countries are also causing governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates. If budget pressures continue, governments may implement additional cost-containment measures. Cost-control initiatives could decrease the price we might establish for products that we may develop or sell, which would result in lower product revenues or royalties payable to us. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biological products, government control and other changes to the healthcare system of the United States. It is uncertain what legislative proposals will be adopted or what actions federal, state or private payors for medical goods and services may take in response to any healthcare reform proposals or legislation. Adoption of new legislation at the federal or state level could further limit reimbursement for pharmaceuticals, including our product candidates if approved. We cannot predict the effect medical or healthcare reforms may have on our business, and no assurance can be given that any such reforms will not have a material adverse effect. For additional details regarding health reform activity, see &#8220;Risk Factors&#8212;Risks Related to Commercialization of Product Candidates &#8212; &#8220;Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we and our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates. Whether or not we or our collaborators obtain FDA approval for a product candidate, we or our collaborators must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the EU, before we or our collaborators may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain countries outside of the United States have a process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application (CTA), must be approved by the competent national health authority and by independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCPs and other applicable regulatory requirements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under EU regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing application is submitted to the European Medicines Agency where it will be evaluated by the Committee for Medicinal Products for Human Use. A favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is valid for all EU member states within 67 days of receipt of the opinion. The initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. The decentralized procedure provides for approval by one or more &#8220;concerned&#8221; member states based on an assessment of an application performed by one member state, known as the &#8220;reference&#8221; member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#8217;s assessment report, each concerned member state must decide whether to approve the assessment report and related materials. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In China, the NMPA monitors and supervises the administration of pharmaceutical products, as well as medical devices and equipment.  In order to conduct clinical trials in China a clinical trial application must be submitted and approved by the NMPA.  When clinical trials have been completed, an applicant must apply to the NMPA for approval of a new drug application. The NMPA, the Center for Drug Evaluation (CDE), and the Drug Inspection Institution will then conduct reviews and on-site inspections. The NMPA determines whether to approve the application according to the comprehensive evaluation opinions produced by the reviews and on-site inspections. We or our collaborators must obtain approval of new drug applications before our product candidates can be manufactured and sold in the Chinese market.  In addition, all facilities and techniques used in the manufacture of products for clinical use or for sale in China must be operated in conformity with good manufacturing practice guidelines as established by the NMPA. Failure to comply with applicable requirements could result in the termination of manufacturing and significant fines.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Regulation</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations. These and other laws govern our use, handling and disposal of various biological and chemical substances used in, and waste generated by our operations. Our research and development involves the controlled use of hazardous materials, chemicals and viruses. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had a total of 17 full-time employees, 11 of whom are involved in research, development or manufacturing, and three of whom have Ph.D., Pharm.D. or M.D. degrees. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relations with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate and Other Information</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in the state of Delaware on October 28, 2004. Our principal executive offices are located at 4350 La Jolla Village Dr., Suite 800, San Diego, California 92122, and our telephone number is (858) 550-0780. Our corporate website address is www.traconpharma.com and we regularly post copies of our press releases as well as additional information about us on our website. Information contained on or accessible through our website is not a part of this Annual Report, and the inclusion of our website address in this Annual Report is an inactive textual reference only.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Access to our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to these reports filed with or furnished to the Securities and Exchange Commission (SEC) may be obtained through the investor section of our website at https://ir.traconpharma.com/. We do not charge for access to and viewing of these reports. Information in the investor section and on our website is not part of this Annual Report on Form 10-K or any of our other securities filings. Our filings with the SEC may be accessed through the SEC&#8217;s website at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included unless otherwise specified, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="risk_factor"><span id="risk_factors"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A.	Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Annual Report as well as our other public filings with the Securities and Exchange Commission.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Financial Position and Need for Additional Capital</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred losses from operations since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or sustain profitability.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biopharmaceutical company with limited operating history. All the product candidates we are developing will require substantial additional development time and resources before we or our partners would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We have incurred losses from operations in each year since our inception, including net losses of $3.6 million and $29.1 million for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023, we had an accumulated deficit of $240.5 million.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur substantial expenses as we expand our development activities and advance our clinical programs. To become and remain profitable, we or our partners must succeed in developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we or our partners may obtain regulatory approval. We or they may not succeed in these activities, and we may never generate revenue from product sales that is significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical and biological product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA or comparable foreign regulatory authorities to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any product candidates. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates or continue our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and failure to obtain additional financing when needed could force us to delay, limit, reduce or terminate our drug development efforts. There is substantial doubt as to our ability to continue as a going concern.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our current level of research and development expenses to decrease in 2024 with the completion of enrollment of the ENVASARC trial in Q1 2024, however this is based on our current expectations which are subject to change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, we had cash and cash equivalents totaling $8.6 million, of which $0.1 million is pledged as collateral for our obligations under our corporate headquarters facility lease. Based upon our current operating plan, we believe that our cash and cash equivalents as of December 31, 2023 will be sufficient to fund the current requirements of working capital and other financial commitments, including our operating lease obligations, into mid-2024. We will need additional funding to complete the development and commercialization of product candidates, including envafolimab and YH001. In addition, in December 2019, we entered into a collaboration and clinical trial agreement with 3D Medicines and Alphamab, and in October 2021, we entered into a collaborative development and commercialization agreement with Eucure and Biocytogen. Under these agreements, we are responsible for various portions of the costs to conduct clinical trials, among other development obligations. We will need additional funds to advance the development of these programs and meet our cost-sharing obligations, and these requirements may be substantial depending on how many programs are selected for development and the stage of development each program reaches. As more fully discussed in Note 1 to the audited consolidated financial statements included in this Annual Report, the uncertainties around our ability to obtain additional funding raise substantial doubt regarding our ability to continue as a going concern for a period of 12 months following the date these accompanying consolidated financial statements were issued.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regardless of our expectations, circumstances beyond our control, including the effects of adverse macroeconomic and geopolitical developments may cause us to consume capital more rapidly than we currently anticipate. For example, our clinical trials may encounter technical, enrollment or other difficulties or we could encounter difficulties obtaining clinical trial material or other supplies that could increase our development costs more than we expect. We will require additional capital prior to completing clinical development, filing for regulatory approval, or commercializing any product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, as amended in March 2022, we entered into the Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sales Agreement (as amended, the Sales Agreement) with JonesTrading Institutional Services LLC (JonesTrading) pursuant to which we could sell from time to time, at our option, up to an aggregate of $50.0 million of shares of our common stock through JonesTrading, as sales agent or principal, $41.5 million of which remains available for sale as of December 31, 2023. In May 2023, we and Lincoln Park Capital Fund, LLC (Lincoln Park) entered into the LPC Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Lincoln Park is committed to purchase up to an aggregate of $26.0 million of shares of our common stock from time to time and at our sole discretion over the term of the LPC Purchase Agreement, $25.0 million of which remains available for sale as of December 31, 2023. While the Sales Agreement and LPC Purchase Agreement provide us with an additional option to raise capital through issuances and sales of our common stock, there can be no guarantee that we will be able to sell shares under the Sales Agreement and LPC Purchase Agreement in the future, or that any sales will generate sufficient proceeds to meet our capital requirements. In particular, sales of our common stock made pursuant to the Sales Agreement, if any, will be made on the Nasdaq Capital Market under our effective registration statement on Form S-3, subject to limitations on the amount of securities we may sell within any 12 month period, by means of ordinary brokers&#8217; transactions at market prices. Moreover, JonesTrading is under no obligation to sell any shares of our common stock that we may request to be sold under the Sales Agreement from time to time. If sales are made under the Sales Agreement and LPC Purchase Agreement, our existing stockholders may experience dilution and such sales, or the perception that such sales are or will be occurring, may cause the trading price of our common stock to decline, and may make it tougher for us to raise additional financing.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. For example, if we do not achieve the primary endpoint of our ENVARSAC Phase 2 pivotal trial, we  may not continue development of envafolimab as a single agent in UPS/MFS, which would likely adversely our ability to raise additional financing and could significantly impact our ability to continue as a going concern and negatively impact our stock price and operations. As a result of adverse macroeconomic and geopolitical developments, such as recent and potential future bank failures, health epidemics, ongoing military conflict between Ukraine and Russia, the recent state of war between Israel and Hamas and the related risk of a larger regional conflict, actual or anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate further, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, scale back or discontinue the development of product candidates or otherwise significantly curtail, or cease, operations. If we are unable to pursue or are forced to delay our planned drug development efforts due to lack of financing, it would have a material adverse effect on our business, financial condition, operating results and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to product candidates on unfavorable terms to us.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek additional capital through a variety of means, including through equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to product candidates, or grant licenses on terms that are not favorable to us.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently authorized to issue 60.0 million shares of our common stock. We may be required to increase our authorized shares in order to raise additional capital. Issuances of our shares of common stock following an increase in authorized shares would result in further dilution to our existing stockholders. For instance, our cash and cash equivalents are sufficient to fund the current requirements of working capital and other financial commitments, including our operating lease obligations, into mid-2024. In the absence of additional capital, we do not anticipate being able to provide final response assessment data including duration of response in all patients from the ENVASARC trial in the second half of 2024 or complete the Phase 2 trial of TRC102 in 2025, and therefore may not be able to complete our trials on the current timelines or at all. If we are not able to raise additional funds on a timely basis, we may be forced to delay, reduce the scope of, or eliminate one or more of our planned operating activities or otherwise significantly curtail or cease operations. Any delay or inability to pursue our planned activities likely will adversely affect our business, financial condition, and stock price. The continued low trading price of our common stock (with a closing price of $0.181 per share on February 29, 2024) presents a significant challenge to our ability to raise additional funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Clinical Development and Regulatory Approval of Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our ENVASARC Phase 2 pivotal trial does not achieve its primary endpoint, we may not continue development of envafolimab as a single agent in UPS/MFS or obtain regulatory approval of envafolimab in UPS/MFS.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are initially developing envafolimab in refractory UPS/MFS, where the PD-(L)1 inhibitors given as single agents demonstrated response rates which were significantly higher than the response rate demonstrated by the FDA-approved treatment Votrient or chemotherapy in UPS/MFS. Nine of 80 responses (11.25%) by blinded independent central review (BICR) are needed to satisfy the primary endpoint of the trial which is to statistically exceed the known 4% ORR of Votrient for patients with refractory UPS or MFS. In December 2023, we announced that the ENVASARC trial had enrolled more than 70 of the 80 planned patients in cohort C of single agent envafolimab treatment. Additional safety and efficacy data were reviewed for 46 patients enrolled into cohort C who were the subject of the September IDMC review. For patients that completed a minimum of 12 weeks of efficacy evaluations and the ORR was 15% by investigator review and 8.7% by BICR. Median duration of response by BICR remains greater than six months. If the response rate of envafolimab as a single agent in UPS/MFS by BICR does not exceed 11.25%, we will not achieve the primary endpoint for our Phase 2 pivotal trial and may not continue development of envafolimab as a single agent in UPS/MFS or obtain regulatory approval of envafolimab in UPS/MFS. Any discontinuation by us of our development of envafolimab as a single agent in UPS/MFS would likely adversely impact our ability to raise additional financing and could significantly impact our ability to continue as a going concern, cause a decline in our stock price and adversely affect our operations. Even if we demonstrate sufficient responses in the ENVARSAC trial, the FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions, including that we conduct more than one pivotal trial in order to gain approval. Any such additional trials would significantly delay our clinical development, result in additional costs to us, may significantly impact our ability to continue as a going concern and could adversely impact our stock price and operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Even if product candidates demonstrate favorable results in ongoing or planned Phase 1 and 2 clinical trials, many product candidates fail to show desired safety and efficacy traits in late-stage clinical trials despite having progressed through earlier trials. In addition to the potential lack of safety or efficacy of product candidates, clinical trial failures may result from a multitude of factors including flaws in trial design, manufacture of clinical trial material, dose selection and patient enrollment criteria, or differences in determination of progression events by investigators compared to central radiographic reviewers. With respect to envafolimab and YH001, while results of trials conducted by others outside of the United States have been promising, they may not be predictive of results in U.S. trials due to differences in trial design, target indications, patient populations, availability of alternative treatments and other factors. Based upon the recommendation of the IDMC following an interim analysis of data from the ENVASARC trial, we have proceeded in the trial using a dose of envafolimab that is twice the dose administered to the first patients in the trial. While dosing at higher levels has shown promising results in other trials outside of the United States, we cannot be certain that we will observe similar results in the ENVASARC trial, including whether the higher dose will result in tolerability issues that were not encountered with the lower dose. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we or our partners may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. If patients drop out of our trials, miss scheduled doses or follow-up visits or otherwise fail to follow trial protocols, or if our trials are otherwise disrupted due to adverse macroeconomic and geopolitical developments, such as recent and potential future bank failures, the ongoing military conflict between Ukraine and Russia or the recent state of war between Israel and Hamas and the related risk of a larger regional conflict, the integrity of data from our trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our stock price would be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, topline and preliminary data from preclinical studies and clinical trials may change as more data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our collaboration partners publicly disclose from time to time, interim, topline or preliminary data from preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as more data become available. We and our collaboration partners may also announce topline data following the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We and our collaboration partners also make assumptions, estimations, calculations and conclusions as part of the analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. In addition, the manner in which clinical data and results are reported may differ depending on the jurisdiction in which a trial is conducted or between us and our collaboration partners. As a result, the interim, topline or preliminary results that we or our collaboration partners report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the previously published preliminary data. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available. Adverse differences between previous preliminary or interim data and future interim or final data could significantly harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we or our collaboration partners may also disclose interim data from clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us, our collaboration partners, or by our competitors could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, our company in general and our common stock. In addition, the information we or our collaboration partners choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we or our collaboration partners determine to be material or otherwise appropriate information to include in such disclosure, and any information we or our collaboration partners determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that is reported for our product candidates differ from future or more comprehensive data, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in clinical trials of product candidates. Our ongoing and planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to raise funding necessary to initiate or continue a trial;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining regulatory approval to commence a trial;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement with the FDA on final trial design;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse findings in toxicology studies, including chronic toxicology studies;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a clinical hold for safety reasons or following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective clinical trial sites;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining required institutional review board approval at each site;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in recruiting suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrollment caused by the availability of alternative treatments;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites dropping out of a trial to the detriment of enrollment;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">time required to add new clinical sites; or</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in our ability to acquire sufficient supply of clinical trial materials.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the FDA may require additional or different data in order to move forward with a BLA submission for envafolimab for patients with local advanced, unresectable or metastatic UPS and MFS, which could ultimately delay regulatory approval and could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, adverse macroeconomic and geopolitical developments have impacted clinical trials broadly, including our own with some sites pausing enrollment or not completing all assessments specified in the protocol, and some patients choosing not to enroll or continue participating in ongoing trials. We and our collaborators may continue to experience delays in site initiation and patient enrollment, failures to comply with trial protocols, delays in the manufacture of product candidates for clinical testing, supply chain disruptions and other difficulties in starting or competing our clinical trials due to macroeconomic and geopolitical developments.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If initiation or completion of our ongoing or planned clinical trials are delayed for any of the above reasons or other reasons, our development costs may increase, our approval process could be delayed and our ability to commercialize product candidates could be materially harmed, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates or those of our partners may cause adverse events or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse events (AEs) caused by product candidates or other potentially harmful characteristics of product candidates could cause us, our partners, including Eucure, Biocytogen, 3D Medicines, Alphamab or the NCI, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Envafolimab has produced AEs consistent with other inhibitors of the PD-L1 and PD-1 pathways, including rare fatal immune related toxicities. Based on the August 9, 2021 data cutoff from the YH001 Phase 1 dose escalation clinical trial being conducted in Australia, no dose limiting toxicities had occurred and a single related serious adverse event of grade 3 colitis was reported, which led to treatment discontinuation. Phase 1 or Phase 2 clinical trials of TRC102 conducted to date have generated AEs related to the trial drug, some of which have been serious. The most common AE identified in our clinical trials of TRC102 has been anemia. There can be no assurance that AEs associated with product candidates will not be observed. As is typical in drug development, we have a program of ongoing toxicology studies in animals for clinical stage product candidates and cannot provide assurance that the findings from such studies or any ongoing or future clinical trials will not adversely affect our clinical development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if any approved products cause serious or unexpected side effects after receiving market approval, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way the product is administered or conduct additional clinical trials;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; or</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for product candidates, our business will be substantially harmed.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, for certain oncology indications where the FDA has traditionally granted approval to therapies that can demonstrate progression-free survival, the agency may later require us to demonstrate overall survival, which would greatly extend the time and increase the capital required to complete clinical development. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design, scope or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of product candidates may not be sufficient to support the submission of a BLA or a New Drug Application (NDA), or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may change significantly in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market product candidates, which would harm our business, results of operations and prospects significantly.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could harm the commercial prospects for our product candidates or those of our partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not previously submitted a marketing application, or any similar drug approval filing to the FDA or any comparable foreign authority for any product candidate, and we cannot be certain that any product candidates will be successful in clinical trials or receive regulatory approval. Further, product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more product candidates, our revenue will be dependent, to a significant extent, upon the size of the markets in the territories for which we gain regulatory approval. If the markets for patients or indications that we are targeting are not as significant as we estimate, we may not generate significant revenue from sales of such product candidates, if approved.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could negatively impact our business.</span></p>
  <p style="text-indent:4.199%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.602%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve proposed clinical trials or new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. More recently, in response to the global COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most foreign and domestic inspections of manufacturing facilities and such delays continued for several months.</span></p>
  <p style="text-indent:4.199%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.602%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may attempt to secure approval from the FDA through the use of accelerated approval pathways. If we are unable to obtain such approval, </span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">we</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></p>
  <p style="text-indent:4.199%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.602%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future seek accelerated approval for one or more of our product candidates, including envafolimab in UPS/MFS. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug. In addition, the FDA currently requires pre-approval of promotional materials for accelerated approval products, once approved.</span></p>
  <p style="text-indent:4.199%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.602%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we decide to submit an application for accelerated approval for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. In the event we do not receive accelerated approval, the related development costs associated with our product candidates will increase and the related timelines will be delayed. The FDA could require us to conduct further studies prior to considering our application or granting approval of any type and may require us to have a confirmatory trial to verify the clinical benefit of the product candidate underway and partially or fully enrolled before granting approval. Even if we receive accelerated approval from the FDA, it will be subject to rigorous post marketing requirements, including the completion of confirmatory post market clinical trials, submission to the FDA of periodic progress reports on confirmatory trials, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required post market study with due diligence; a post market study does not confirm the predicted clinical benefit; other evidence shows that the product is not safe or effective under the conditions of use; or we disseminate promotional materials that are found by the FDA to be false and misleading. Under the Consolidated Appropriations Act for 2023, the FDA may use expedited procedures to withdraw any product for which we receive accelerated approval if our confirmatory trials fail to verify the purported clinical benefits. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not receive fast track designation for our product candidates from the FDA, or fast track designation may not actually lead to a faster development or regulatory review or approval process.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. A new drug or biologic is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for the disease or condition. While the FDA did grant us fast track designation for the development of envafolimab for patients with locally advanced, unresectable or metastatic UPS and MFS who have progressed on one or two prior lines of chemotherapy, it has broad discretion whether or not to grant this designation for our other product candidates. Even if we believe another particular product candidate is eligible for this designation, we cannot assure you that the FDA will grant it. Further, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unsuccessful in our efforts to obtain orphan drug designations (ODDs) from the FDA for product candidates, and even if these designations are obtained, we may not ultimately realize the potential benefits of ODD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 people in the United States, or a patient population of greater than 200,000 people in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drugs do not require prescription drug user fees with a marketing application, may qualify the drug development sponsor for certain tax credits, and may be eligible for a market exclusivity period of seven years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the FDA granted ODD for TRC102 for the treatment of patients with malignant glioma, including glioblastoma and in June 2021, we received ODD for envafolimab for the treatment of soft tissue sarcoma subtypes. Generally, if a drug with an ODD subsequently receives the first marketing approval for the indication for which it has such designation, the drug may be entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same orphan designated indication for that time period. The applicable period is seven years in the United States, which may be extended by six months, in the case of product candidates that have complied with the respective regulatory agency&#8217;s agreed upon pediatric investigation plan. Orphan drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, even after a drug is granted orphan exclusivity and approved, the FDA can subsequently approve another drug for the same condition before the expiration of the seven-year exclusivity period if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, if an orphan designated product receives marketing approval for an indication broader than or different from what is designated, such product may not be entitled to orphan exclusivity. Even though the FDA has granted ODD, if we receive approval for a modified or different indication, our current orphan designations may not provide us with exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ODD does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Also, regulatory approval for any product candidate may be withdrawn, and other product candidates may obtain approval before us and receive orphan drug exclusivity, which could block us from entering the market. For example, 3D Medicines has U.S. ODD for envafolimab for the treatment of BTC, an indication that is outside the scope of our current license agreement with 3D Medicines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug exclusivity also may not effectively protect us from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions before the expiration of any orphan drug exclusivity period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If orphan drug exclusivity is lost and we were unable to successfully enforce any remaining patents covering our eligible product candidates, we could be subject to generic competition earlier than we anticipate. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as any product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although we intend to seek breakthrough therapy designation for envafolimab for the treatment of soft tissue sarcoma subtypes, such designation may not be granted, and even if granted this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that envafolimab will receive marketing approval in the United States.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Although we intend to seek breakthrough therapy designation for envafolimab for the treatment of soft tissue sarcoma, we may not be granted such designation and even if designated this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that envafolimab will receive marketing approval in the United States. In addition, if granted breakthrough therapy designation, the FDA may later decide that envafolimab no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of product candidates in other jurisdictions.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as studies or trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we would intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates or those of our partners will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates for which we receive regulatory approvals will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy (REMS) in order to approve product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves product candidates, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing, as well as continued compliance with regulatory requirements for current good manufacturing practices (cGMPs), and current good clinical practices (cGCPs), for any clinical trials that we conduct post-approval. Although physicians, in the practice of medicine, may prescribe an approved drug for unapproved indications, pharmaceutical companies are prohibited from promoting uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses of approved pharmaceutical products, and a company that is found to have improperly promoted off-label may be subject to significant liability. Later discovery of previously unknown problems with product candidates, including AEs of unanticipated severity or frequency, or with our third party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of existing approvals;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of product candidates; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our partners rely on third party manufacturers to make product candidates, and any failure by a third party manufacturer may delay or impair our ability to complete clinical trials or commercialize our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing drugs and biologics is complicated and is tightly regulated by regulatory authorities, including the FDA and foreign equivalents. We currently rely on third party manufacturers to supply us with drug substance for preclinical and clinical trials. Moreover, the market for contract manufacturing services for drug products is highly cyclical, with periods of relatively abundant capacity alternating with periods in which there is little available capacity. If our need for contract manufacturing services increases during a period of industry-wide tight capacity, we may not be able to access the required capacity on a timely basis or on commercially viable terms, which could result in delays in initiating or completing clinical trials or our ability to apply for or receive regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on other third parties for drug substance and to perform additional steps in the manufacturing process, including filling into vials, shipping and storage.  For our clinical stage pipeline programs, there can be no guarantee that lack of clinical supplies will not force us or our partners to delay or terminate any ongoing or planned clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to rely on third party manufacturers for any drug required for commercial supply and do not intend to build our own manufacturing capability. Successfully transferring complicated manufacturing techniques to contract manufacturing organizations and scaling up these techniques for commercial quantities is costly, time consuming and subject to potential difficulties and delays. With respect to envafolimab, pursuant to the Envafolimab Collaboration Agreement, 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, envafolimab to us at pre-negotiated prices that vary based on clinical or commercial use. With respect to YH001, Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to us for clinical trials pursuant to the terms of a clinical supply and quality agreement to be separately negotiated, but we cannot guarantee that we will successfully negotiate and enter into the contemplated clinical supply and quality agreement or do so on commercially favorable terms.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any long-term supply agreements for the manufacture of product candidates and cannot guarantee that any third party manufacturer would be willing to continue supplying drug product for clinical trials or commercial sale at a reasonable cost or at all.  In addition, manufacturing agreements are often subject to early termination by the third party manufacturer under certain circumstances.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The facilities used by our current or future third party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit a BLA or an NDA to the FDA. While we work closely with our third party manufacturers on the manufacturing process for product candidates, we generally do not control the implementation of the manufacturing process of, and are completely dependent on, our third party manufacturers for compliance with cGMP regulatory requirements and for manufacture of both drug substances and finished drug products. If our third party manufacturers or those of our collaborators cannot successfully manufacture material that conforms to applicable specifications and the strict regulatory requirements of the FDA or other regulatory authorities, we may experience delays in initiating planned clinical trials and we may not be able to secure or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers or other third party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or commercialize product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend in part on NCI and other third party sponsors to advance clinical development of TRC102. If these third party sponsors ceased their support for our product candidates, our ability to advance clinical development of product candidates could be limited and we may not be able to pursue the number of different indications for our product candidates that are currently being pursued.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NCI is currently sponsoring and funding multiple clinical trials involving TRC102. In addition, Case Western has sponsored and funded two separate clinical trials involving TRC102. The advancement of TRC102 depends in part on the continued sponsorship and funding of clinical trials by these organizations, as our resources and capital would not be sufficient to conduct these trials on our own. None of these third party sponsors are obligated to continue sponsorship or funding of any clinical trials involving our product candidates and could stop their support at any time. If these third party sponsors ceased their support for our product candidates, our ability to advance clinical development of product candidates could be limited and we may not be able to pursue the number of different indications for our product candidates that are currently being pursued.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if these third party sponsors continue to sponsor and fund clinical trials of our product candidates, our reliance on their support subjects us to numerous risks. For example, we have limited control over the design, execution or timing of their clinical trials and limited visibility into their day-to-day activities, including with respect to how they are providing and administering our product candidates. If a clinical trial sponsored by a third party has a failure due to poor design of the trial, errors in the way the clinical trial is executed or for any other reason, or if the sponsor fails to comply with applicable regulatory requirements or if there are errors in the reported data, it could represent a major set-back for the development and approval of our product candidates, even if we were not directly involved in the trial and even if the clinical trial failure was not related to the underlying safety or efficacy of the product candidate. In addition, these third party sponsors could decide to de-prioritize clinical development of our product candidates in relation to other projects, which could adversely affect the timing of further clinical development. We are also subject to various confidentiality obligations with respect to the clinical trials sponsored by third party sponsors, which could prevent us from disclosing current information about the progress or results from these trials until the applicable sponsor publicly discloses such information or permits us to do so. This may make it more difficult to evaluate our business and prospects at any given point in time and could also impair our ability to raise capital on our desired timelines.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on 3D Medicines and Alphamab with respect to certain aspects of our development of envafolimab for the treatment of sarcoma in North America and on Eucure and Biocytogen with respect to certain aspects of our development of YH001 for the treatment of certain sarcoma subtypes in North America. The failure to maintain these collaboration and clinical trial agreements, the failure of 3D Medicines, Alphamab, Eucure or Biocytogen to perform their obligations under the agreements, or the actions of 3D Medicines, Alphamab, Eucure or Biocytogen or their other partners with respect to envafolimab and YH001 in other indications or outside North America could negatively impact our business.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of our collaboration and clinical trial agreement with 3D Medicines and Alphamab, we were granted an exclusive license to develop and commercialize envafolimab for sarcoma in North America. Pursuant to the terms of our collaborative development and commercialization agreement with Eucure and Biocytogen, we were granted an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment of multiple human indications, including the Initial Indications or one or more of the Substitute Indications, which may be substituted for Initial Indications at our discretion. While we are generally responsible for clinical development, 3D Medicines and Alphamab are responsible for certain critical activities associated with envafolimab and Eucure and Biocytogen are responsible for certain critical activities associated with YH001, including, as applicable, the manufacture and supply of envafolimab and YH001, CMC activities and prosecution and enforcement of intellectual property rights. We have limited control over the amount and timing of resources that 3D Medicines, Alphamab, Eucure and Biocytogen will dedicate to their respective efforts, and their failure to perform their obligations would impair our ability to develop envafolimab for sarcoma in North America and YH001 for certain sarcoma subtypes in North America.  In addition, we have very limited influence or control over 3D Medicines&#8217;, Alphamab&#8217;s, Eucure&#8217;s or Biocytogen&#8217;s (or their respective other partners&#8217;) activities with respect to the development and commercialization of envafolimab and YH001 in non-licensed indications or indications outside of North America, even though these activities could have a significant impact on the development and commercialization of envafolimab for sarcoma in North America and YH001 for certain sarcoma subtypes in North America. For example, Eucure may pursue clinical trials for YH001 in North America outside of the Initial Indications or Substitute Indications, and also within the Initial Indications or Substitute Indications as part of a combination therapy of YH001 and an additional Eucure product, any of which could have a significant impact on the development and commercialization of YH001 for sarcoma in North America. Additionally, adverse events in clinical trials outside of the United States could cause the FDA to put clinical trials of envafolimab or YH001 in the United States on hold, and negative results of clinical trials of envafolimab in other indications may cast doubt as to the likelihood of positive results of clinical trials in UPS/MFS or other sarcoma indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a number of other risks associated with these collaboration and clinical trial agreements, including:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we and our corporate partners could disagree as to future development plans which could delay initiation of clinical trials or stop a future clinical trial;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be disputes between us and our corporate partners, including disagreements regarding the terms of the collaboration and clinical trial agreement, that may result in the delay of or failure to achieve development, regulatory and commercial objectives and/or costly litigation or arbitration that diverts our management&#8217;s attention and resources; </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our corporate partners may not provide us with timely and accurate information regarding development progress and activities outside of sarcoma and North America, which could adversely impact our ability to report progress to our investors and may cause us to make ill-informed decisions with respect to our own development efforts; </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our corporate partners may not properly maintain or defend the intellectual property rights licensed to us in North America or may undertake activities that invite litigation that could jeopardize or invalidate the intellectual property rights licensed to us or expose us to potential litigation; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our corporate partners are responsible for conducting CMC activities for envafolimab and YH001 and may not conduct such activities at the quality level required to seek FDA approval. </span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we have disagreements with our corporate partners, if they do not perform their obligations under the collaboration and clinical trial agreements or there are negative events with respect to envafolimab or YH001 outside of the licensed indications or North America, there could be material adverse consequences to our ability to successfully develop and commercialize envafolimab and YH001 in North America or to the value of envafolimab and YH001 to us. Any such consequences would likely adversely impact our ability to raise additional financing and could significantly impact our ability to continue as a going concern and our stock price and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in establishing and maintaining additional collaborations, which could adversely affect our ability to develop and commercialize our existing product candidates or to leverage our clinical development capabilities.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A part of our strategy is to strategically evaluate and, as deemed appropriate, enter into additional licensing and collaboration agreements, including potentially with major biotechnology or pharmaceutical companies. In particular, we are actively seeking additional corporate partnerships in which we would share in the cost and risk of clinical development and commercialization of innovative product candidates of third parties. We face significant competition in seeking appropriate partners, and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view these product candidates as having the requisite potential to demonstrate safety and efficacy and as being economically valuable in light of the terms that we are seeking and other available products for licensing by other companies. With respect to additional partnerships whereby we would develop third party product candidates, we will need to identify promising product candidates where the owner of the development and commercial rights could benefit from our clinical development capabilities. Even if we are successful in our efforts to establish new collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any inability or delay in entering into new collaboration agreements related to our product candidates, in particular in foreign countries where we do not have and do not intend to establish significant capabilities, could delay the development and commercialization of our product candidates and reduce their market potential.  If we are unable to enter into additional collaborations that leverage our clinical development capabilities, we may be forced to reduce these capabilities, which could lower the value of our company and make it less likely that third parties will seek to collaborate with us to develop their product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct preclinical studies and clinical trials of product candidates, and if they do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have our own capabilities to perform preclinical testing of product candidates, and therefore rely entirely on third party contractors and laboratories to conduct these studies for us. In addition, while we intend to continue designing, monitoring and managing our clinical trials of product candidates using our clinical operations and regulatory team, we still depend upon independent investigators and collaborators, such as universities and medical institutions, to conduct our clinical trials at their sites under agreements with us. We will compete with many other companies for the resources of these third-party contractors, laboratories, investigators and collaborators, and the initiation and completion of our preclinical studies and clinical trials may be delayed if we encounter difficulties in engaging these third parties or need to change service providers during a preclinical study or clinical trial.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We control only certain aspects of the activities conducted for us by the third parties on which we currently rely and on which we will rely in the future for our preclinical studies and clinical trials. Nevertheless, we are responsible for ensuring that each of our clinical trials and certain of our preclinical studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. With respect to clinical trials, we and these third parties are required to comply with cGCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the cGCP regulations. In addition, our clinical trials must be conducted with product candidates produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state health care laws, including, among others, fraud and abuse, false claims, privacy and security, and physician payment transparency laws. Any third parties conducting our preclinical studies and clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical development programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our preclinical studies and clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize product candidates. As a result, our financial results and the commercial prospects for our product candidates or those of our partners would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Switching or adding third parties to conduct our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete effectively.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies which could do harm to our business and affect our ability to be profitable. In particular, our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. Additionally, we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Any disclosure or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in our market.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology companies is generally uncertain because it involves complex legal and factual considerations in a legal framework that is constantly evolving. The standards applied by the United States Patent and Trademark Office (USPTO), and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents. There is a substantial amount of prior art in the biotechnology and pharmaceutical fields, including scientific publications, patents and patent applications. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. We may be unaware of prior art that could be used to invalidate an issued patent or prevent our pending patent applications from issuing as patents. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If patent applications we hold or have in-licensed with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidate that we may develop. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For applications filed before March 16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the claims of our applications and patents. As of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to &#8220;first-to-file&#8221; from &#8220;first-to-invent&#8221; is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act (the Leahy-Smith Act) signed into law on September 16, 2011. Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. It is not yet clear, what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. Furthermore, due to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all our product candidates or methods involving these product candidates in the parent patent application.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent and the protection it affords is limited. If we encounter delays in obtaining regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic and biosimilar products.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any loss of patent protection could have a material adverse impact on our business. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on our licensors to prosecute and maintain patents and patent applications that are material to our business. Any failure by our licensors to effectively protect these intellectual property rights could adversely impact our business and operations.*</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specific to the development of YH001 in North America, we hold an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including the Initial Indications or one or more of the Substitute Indications, which may be substituted for Initial Indications at our discretion. As it relates to the development of envafolimab for the treatment of sarcoma in North America, we hold an exclusive license from 3D Medicines and Alphamab to any and all intellectual property rights, including patents, copyrights, trademarks and know-how, claiming or covering envafolimab. We also hold a non-exclusive license for the conduct of clinical trials in the EU in support of the development of envafolimab for the treatment of sarcoma in North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a licensee of third parties, we rely on these third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third party claims of intellectual property infringement or misappropriation may prevent or delay our development and commercialization efforts.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on us and our partners not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination and review proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we and our partners are developing and may develop our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, that we failed to identify. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until issued as patents. Except for the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18 months after the earliest filing. Therefore, patent applications covering our product candidates or methods of use of our product candidates could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use or manufacture of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Also, in proceedings before courts in Europe, the burden of proving invalidity of the patent usually rests on the party alleging invalidity. Third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any third party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, the holders of any such patents would be able to block our ability to develop and commercialize the applicable product candidate until such patent expired or unless we or our partner obtain a license. These licenses may not be available on acceptable terms, if at all. Even if we or our partner were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we or our partner could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we or our partner are unable to enter into licenses on acceptable terms.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us or our partner may obtain injunctive or other equitable relief, which could effectively block our or our partner&#8217;s ability to further develop and commercialize one or more of our product candidates. Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may submit applications for patent term extensions in the United States and/or supplementary protection certificates in the EU member states seeking to extend certain patent protection which, if approved, may interfere with or delay the launch of one or more of our products.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may face a claim of misappropriation if a third party believes that we inappropriately obtained and used trade secrets of such third party. If we are found to have misappropriated a third party&#8217;s trade secrets, we may be prevented from further using such trade secrets, limiting our ability to develop our product candidates, and we may be required to pay damages.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our product candidates or intellectual property could be diminished. Accordingly, the market price of our common stock may decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our inventions, patents or other intellectual property or the patent of our licensors, which could be expensive and time consuming.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our intellectual property, including our patents or the patents of our licensors. In addition, one or more of our third party collaborators may have submitted, or may in the future submit, a patent application to the USPTO without naming a lawful inventor that developed the subject matter in whole or in part while under an obligation to execute an assignment of rights to us. As a result, we may be required to file infringement or inventorship claims to stop third party infringement, unauthorized use, or to correct inventorship. This can be expensive, particularly for a company of our size, and time-consuming. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference, derivation or other proceedings brought at the USPTO or any foreign patent authority may be necessary to determine the priority or patentability of inventions with respect to our patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us may fail. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party, or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors or collaborators, to prevent misappropriation of our trade secrets, confidential information or proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have in-licensed a portion of our intellectual property, and, if we fail to comply with our obligations under these arrangements, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to a number of license agreements that are important to our business, and we may enter into additional license agreements in the future. Envafolimab and associated intellectual property have been licensed from 3D Medicines and Alphamab and YH001 and associated intellectual property have been licensed from Eucure and Biocytogen. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If there is any conflict, dispute, disagreement or issue of non-performance between us and our licensing partners regarding our rights or obligations under the license agreements, including any such conflict, dispute or disagreement arising from our failure to satisfy payment or diligence obligations under any such agreement, we may owe damages, our licensor may have a right to terminate the affected license, and our and our partners&#8217; ability to utilize the affected intellectual property in our drug development efforts, and our ability to enter into collaboration or marketing agreements for a product candidate, may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The failure of our partners to meet their contractual obligations to us could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us to our standards, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration. Litigation, arbitration or adversarial proceedings may be prolonged and might result in substantial costs and may divert management&#8217;s attention and resources, which might seriously harm our business, reputation, overall financial condition and operating results.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate; and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our technologies and this circumstance would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Commercialization of Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval of product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third party payors and others in the medical community.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that will influence whether product candidates are accepted in the market include:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which product candidates are approved, if any;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">physicians, hospitals, cancer treatment centers and patients considering product candidates as a safe and effective treatment;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of product candidates over alternative treatments;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of product candidates as well as competitive products;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement by governmental and commercial third party payors;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage by governmental and commercial third party payors;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If, for any of these or other reasons, product candidates fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers, third party payors or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Off-label use of approved drugs could adversely impact peak sales of our product candidates if approved, including Keytruda&#8217;s off-label use in UPS/MFS.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While no PD-(L)1 treatments are currently FDA approved in UPS/MFS or any other sarcoma subtype, Keytruda (pembrolizumab, marketed by Merck &amp; Co.) has a compendia listing in UPS and is reimbursed for off-label use in UPS. The off-label use of Keytruda in UPS/MFS may adversely affect the peak net sales of envafolimab in UPS/MFS and other sarcoma subtypes, if envafolimab is approved by the FDA and commercialized in the United States. Similarly, while no CTLA-4 therapy is approved by the FDA for the treatment of soft tissue sarcoma, if YH001 is approved, it may nevertheless compete with the currently marketed CTLA-4 inhibitor ipilimumab (Yervoy, marketed by Bristol Myers Squibb), which is approved by the FDA in multiple indications other than soft tissue sarcoma.	</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face competition both in the United States and internationally, including from major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions.	</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing product candidates against competitors.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of our license agreement with Case Western, we obtained an exclusive, worldwide license to certain patents, know-how and other intellectual property controlled by Case Western related to TRC102. Despite our exclusive license, Case Western retained the right to grant non-exclusive licenses to third parties in the same field of use as our exclusive license as a means to settle any intellectual property disputes Case Western may have in the future with such third parties. While Case Western has not made us aware of any present intent to exercise this right, there can be no guarantee that Case Western will not do so in the future or that it would not grant such a non-exclusive license to a competitor of ours seeking to develop and commercialize a product that is identical to TRC102 in the same field of use that we are pursuing. If this were to occur, and we did not have other intellectual property outside of the Case Western license agreement to prevent competitive products for the same indications, we may face competition much earlier than we currently anticipate and the value of TRC102 may decline substantially.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, we may face competition from &#8220;biosimilars&#8221; due to the changing regulatory environment. In the United States, the Biologics Price Competition and Innovation Act created an abbreviated approval pathway for biological products that are demonstrated to be &#8220;highly similar,&#8221; or &#8220;biosimilar,&#8221; to or &#8220;interchangeable&#8221; with an FDA-approved biological product. This pathway could allow competitors to reference data from biological products already approved after 12 years from the time of approval. Future FDA standards or criteria for determining biosimilarity and interchangeability, and FDA discretion to determine the nature and extent of product characterization, non-clinical testing and clinical testing on a product-by-product basis, may further facilitate the approval of biosimilar products and their ability to compete with our product candidates or those of our partners. In addition, companies may be developing biosimilars in other countries that could compete with our products. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. Any such event or further changes in the law could decrease the period for which we have exclusivity and consequently negatively impact our business and competitive position. Expiration or successful challenge of our applicable patent rights could also trigger competition from other products, assuming any relevant exclusivity period has expired.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, as a result of the expiration or successful challenge of our patent rights, we could face litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for product candidates, which could make it difficult for us to sell product candidates profitably.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third party payors. In addition, because our product candidates and those of our partners represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from these product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients who are provided medical treatment for their conditions generally rely on third party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities and other third party payors, such as commercial health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third party payor may depend upon a number of factors, including, but not limited to, the third party payor&#8217;s determination that use of a product is:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for products exists among third party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Obtaining coverage and reimbursement approval of a product from a government or other third party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data to each payor separately for the use of our products, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Patients are unlikely to use product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of product candidates. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to seek approval to market product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of product candidates will depend significantly on the availability of coverage and adequate reimbursement from third party payors for product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third party payors, whether domestic or foreign, or governmental or commercial, and governments are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, was enacted in the United States. Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA.  For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017 (Tax Act) includes a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA), into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative changes to the statute will remain in effect until 2032 unless additional Congressional action is taken. In January 2013, former U.S. President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been heightened governmental scrutiny over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In addition, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.  Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.  For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for product candidates, if we obtain regulatory approval;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our products;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain market acceptance in the medical community;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business in the future, or the effect any future legislation or regulation will have on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any product candidates are approved for commercialization, we expect that we or our partners will be subject to additional risks related to entering into international business relationships, including:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different regulatory requirements for drug approvals in foreign countries;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements, including the significant sanctions and export controls imposed against Russia, Russian banks and certain Russian individuals by the United States, United Kingdom and EU, along with others;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our partners outside of the United States are unable to successfully manage these risks associated with international operations, the market potential for our product candidates or those of our partners outside the United States will be limited and our results of operations may be harmed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business and Industry</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to develop, acquire or in-license other product candidates or products, our business and prospects will be limited.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have internal new drug discovery capabilities or a technology platform with which to develop novel product candidates. Unless we develop or acquire these capabilities or a technology platform, our only means of expanding our product pipeline will be to acquire or in-license product candidates that complement or augment our current targets, or that otherwise fit into our development or strategic plans on terms that are acceptable to us. In addition, part of our corporate strategy is to leverage our existing internal clinical development and regulatory capabilities by entering into collaborations where we conduct development activities related to third party product candidates in exchange for commercialization and payment rights, such as our collaborations with Eucure and Biocytogen with respect to YH001 and 3D Medicines and Alphamab with respect to envafolimab. Identifying, selecting and acquiring or licensing promising product candidates requires substantial technical, financial and human resources. Efforts to do so may not result in the actual development, acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. With respect to envafolimab, 3D Medicines and Alphamab retain certain rights to reacquire the rights for sarcoma in North America in connection with an arm&#8217;s length sale to a third party of the rights to develop and commercialize envafolimab in North America for all indications.  While we and 3D Medicines and Alphamab must negotiate in good faith and agree to fair compensation be paid to us for the value of and opportunity represented by the reacquired rights, we cannot guarantee that any compensation paid to us would adequately cover our investments in the program, the present value of the rights to us or our opportunity costs as a result of having advanced the program prior to reacquisition.  Also, in the event that envafolimab is first approved in North America for sarcoma and within three years of the commercial launch of envafolimab in North America for sarcoma 3D Medicines and Alphamab replace us as the party responsible for commercialization, and we do not co-market envafolimab for sarcoma in North America, then 3D Medicine and Alphamab will be required to compensate us for our costs associated with preparing for and conducting commercial activities. However, we may not be able to agree with 3D Medicines and Alphamab on adequate compensation and cannot guarantee that any agreed-upon compensation would adequately cover our investments in commercializing envafolimab in North America or our lost opportunity costs in pursuing commercialization. If we are unable to retain existing product candidates and add additional product candidates to our pipeline, we may not be able to execute on an important part of our business strategy and our long-term business and prospects will be limited.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to successfully out-license our CRO-independent PDP, our business could materially suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed and out-licensed our CRO-independent PDP for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals. Currently, we have only granted a non-exclusive and non-transferable license of our CRO-independent PDP to one licensee. However, we may not be able to identify additional suitable partners. If we are unable to identify suitable partners for our CRO-independent PDP or if we are required to enter into agreements with such partners on unfavorable terms, our business and prospects could materially suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our partners are subject to extensive federal, state, and foreign regulation, and our failure to comply with healthcare laws could harm our business.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we do not currently have any products on the market, we and our partners are subject to healthcare regulation and enforcement by the federal government and the states and foreign jurisdictions in which we conduct our business. The healthcare laws that may affect our ability to operate include:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. Federal Anti-Kickback Statute, which applies to our business activities, including our research, marketing practices, educational programs, pricing policies and relationships with healthcare providers, by prohibiting, among other things, knowingly and willfully soliciting, receiving, offering or providing any remuneration (including any bribe, kickback or rebate) directly or indirectly, overtly or covertly, in cash or in kind, intended to induce or in return for the purchase or recommendation of any good, facility item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare or Medicaid programs;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal civil and criminal false claims laws, including the federal False Claims Act, and federal civil monetary penalty law that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other governmental healthcare programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, imposes certain regulatory and contractual requirements on covered entities, and their business associates and subcontractors that create, receive, maintain or transmit individually identifiable health information for or on their behalf, as well as their covered subcontractors, regarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal &#8220;sunshine&#8221; requirements imposed by the ACA on certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services information regarding any payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as nurse practitioners and physicians assistants), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state or foreign law equivalents of each of the above federal laws that may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information relating to drug and biologic pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened certain of these laws. For example, the ACA, among other things, amended the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them to have committed a violation. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to laws and regulations governing data privacy and the protection of health-related and other personal information. These laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and disposal of personal data. There are foreign and state law versions of these laws and regulations to which we are currently and/or may in the future, be subject. For example, the collection and use of personal health data in the EU is governed by the General Data Protection Regulation (the EU GDPR). The EU GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The EU GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States, provides an enforcement authority and imposes large monetary penalties for noncompliance. The EU GDPR requirements apply not only to third party transactions, but also to transfers of information within our company, including employee information. The EU GDPR and similar data privacy laws of other jurisdictions place significant responsibilities on us and create potential liability in relation to personal data that we or our third party vendors process, including in clinical trials conducted in the United States and EU. In addition, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, significant administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, imprisonment, exclusion from governmental health care programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates or those of our partners. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment of our business reputation;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs due to related litigation;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distraction of management&#8217;s attention from our primary business;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize product candidates; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for product candidates, if approved for commercial sale.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently carry product liability insurance covering our clinical trials with limits we believe are customary for other companies in our field and stage of development. Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss (NOL) carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal and California NOL carryforwards of $190.2 million and $146.9 million, respectively. Certain of the federal and California NOL carryforwards will begin to expire in 2030 and 2033, respectively, if not utilized. The federal NOL generated after 2017 of $106.9 million will carryforward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. As of December 31, 2023, we also had federal research and development and Orphan Drug tax credit carryforwards of $15.1 million and California research and development tax credit carryforwards of $3.3 million. The federal research and development and Orphan Drug tax credit carryforwards will begin expiring in 2031 and 2036, respectively, if not utilized. The California research credit will carry forward indefinitely under current law. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (Code), if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event we experience one or more ownership changes as a result of future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results in the event that we attain profitability. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:6%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New or future changes to tax laws could materially adversely affect us.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), modified certain provisions of the Tax Act and the recently enacted IRA, includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, the IRA or any newly enacted federal tax legislation. The impact of such legislation and any future changes in tax laws on holders of our common stock is also uncertain and could be adverse.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to attract and keep senior management and key clinical operations and regulatory personnel, we may be unable to successfully develop product candidates and execute our business strategy.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on members of our senior management, including Charles Theuer, M.D., Ph.D., our President and Chief Executive Officer. Our clinical development strategy and ability to directly manage or oversee our on-going and planned clinical trials are also dependent on the members of our clinical operations and regulatory team. The loss of the services of any of these persons could impede the development of product candidates and our ability to execute our business strategy. We may be particularly impacted by the unexpected loss of employees due to our small employee base and limited ability to quickly shift responsibilities to other employees in our organization. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recruiting and retaining other qualified employees for our business, including scientific, quality assurance and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue, making recruitment and retention competitive. Competition for skilled personnel is intense, particularly in the San Diego, California area, and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. The inability to recruit or loss of the services of any executive or key employee could impede the progress of our development and strategic objectives. In response to competition, rising inflation rates and labor shortages, we may need to adjust employee cash compensation, which would affect our operating costs and our margins, or equity compensation, which would affect our outstanding share count and cause dilution to existing stockholders.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:6%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable U.S. and global economic conditions could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the U.S. and global economies, the U.S. and global financial markets and adverse macroeconomic and geopolitical developments. U.S. and global market and economic conditions have been, and continue to be, disrupted and volatile due to many factors, including the recent COVID-19 pandemic, material shortages and related supply chain challenges, recent and potential future bank failures, geopolitical developments such as the conflict between Ukraine and Russia or the recent state of war between Israel and Hamas and the related risk of a larger regional conflict, and higher inflation rates and the responses by central banking authorities to control such inflation, among others. General business and economic conditions that could affect </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, financial condition or results of operations include fluctuations in economic growth, debt and equity capital markets, liquidity of the global financial markets, the availability and cost of credit, investor and consumer confidence, and the strength of the economies in which we, our collaborators, our manufacturers and our suppliers operate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A severe or prolonged global economic downturn could result in a variety of risks to our business. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise raise capital on acceptable </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if at all. In addition, the U.S. Federal Reserve has raised, and may again raise, interest rates in</span><span style="color:#0000ff;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">response to concerns about inflation, which coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks. Risks of a prolonged global economic downturn are particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers and manufacturers, possibly resulting in supply and clinical trial disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, financial markets around the world experienced volatility following the invasion of Ukraine by Russia in February 2022. In response to the invasion, the United States, United Kingdom and EU, along with others, imposed significant new sanctions and export controls against Russia, Russian banks and certain Russian individuals and may implement additional sanctions or take further punitive actions in the future. The full economic and social impact of the sanctions imposed on Russia (as well as possible future punitive measures that may be implemented), as well as the counter measures imposed by Russia, in addition to the ongoing military conflict between Ukraine and Russia, which could conceivably expand into the surrounding region, remains uncertain; however, both the conflict and related sanctions have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability and/or supply chain continuity in both Europe and globally, and has introduced significant uncertainty into global markets. In particular, the Russia-Ukraine conflict has contributed to rapidly rising costs of living (driven largely by higher energy prices) in Europe and other advanced economies. Further, rising tensions between China and Taiwan, the ongoing conflict in Israel and surrounding areas, the attacks on marine vessels traversing the Red Sea and the ongoing military conflict between Russia and Ukraine have created volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain which could strain our suppliers, manufacturers and collaborators, possibly resulting in additional supply disruption for our product candidates and delays to our clinical trials. As a result, our business and results of operations may be adversely affected by the ongoing conflict between Ukraine and Russia, particularly to the extent it escalates to involve additional countries, further economic sanctions or wider military conflict. If economic conditions in Europe and other key markets for our business and the business of our suppliers, manufacturers and collaborators remain uncertain or deteriorate further, we could experience adverse effects on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our common stock may be highly volatile, and our stockholders may not be able to resell their shares at a desired market price and could lose all or part of their investment.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even though our common stock trades on the Nasdaq Capital Market, we cannot assure you that an active, liquid trading market for our shares will develop or persist. Our stockholders may not be able to sell their shares quickly or at a recently reported market price if trading in our common stock is not active.  The trading price of our common stock has been, and is likely to continue to be, volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse results or delays in clinical trials;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to obtain additional funding;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delay in submitting a BLA or an NDA for any product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that marketing application;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to successfully develop and commercialize product candidates;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations applicable to product candidates;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to obtain adequate product supply for product candidates, or the inability to do so at acceptable prices;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory decisions;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">introduction of new products or technologies by our competitors;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed product development or financial projections we provide to the public;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed the estimates and projections of the investment community;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, collaborations, joint ventures or capital commitments by us or our competitors;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to enter into new, or maintain our existing, collaboration and clinical trial agreements;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of 3D Medicines or Alphamab to perform their obligations under our collaboration and clinical trial agreements, or the actions of 3D Medicines or Alphamab or their other partners with respect to envafolimab in other indications or outside North America;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of Eucure and Biocytogen to perform their obligations under our collaborative development and commercialization agreement, or the actions of Eucure or Biocytogen or their other partners with respect to YH001 in other indications or outside North America, or within North America in combination with other Eucure product candidates;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key scientific or management personnel;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of macroeconomic and geopolitical events, such as general political, health and economic conditions, including recent and potential future bank failures, economic slowdowns, recessions, inflation, rising interest rates and tightening of credit markets on our business;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us or our stockholders in the future, in particular any sales by significant stockholders or our affiliates; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general, and the Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations, and we have in the past experienced volatility that has been unrelated or disproportionate to our operating performance. From January 1, 2023 through February 29, 2024, the closing price of our common stock has ranged between $0.1322 and $2.06 per share. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to continue to meet all applicable listing requirements, our common stock may be delisted from the Nasdaq Capital Market, which could have an adverse impact on the liquidity and market price of our common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is currently listed on the Nasdaq Capital Market, which has qualitative and quantitative listing criteria. If we are unable to meet all of the Nasdaq Stock Market LLC (Nasdaq) continued listing requirements and at least one of the Nasdaq continued listing standards in the future, including if the closing bid price for our common stock falls below $1.00 per share for 30 consecutive trading days (the Minimum Bid Price Requirement), or if we are unable to maintain at least $2.5 million in stockholders&#8217; equity or a market capitalization of at least $35.0 million, Nasdaq could determine to delist our common stock. For example, on June 8, 2023, we received letters (the Notices) from the Listing Qualifications staff (the Staff) of the Nasdaq notifying us that (i) for 30 consecutive business days preceding the date of the Notices, the market value of our common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the Market Value Rule), and (ii) we failed to satisfy the Minimum Bid Price Requirement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Nasdaq Listing Rule 5810(c)(3)(C) and Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq had provided us with 180 calendar days, or until December 5, 2023, to regain compliance with the Market Value Rule and the Minimum Bid Price Requirement. On December 6, 2023, we received written notice (the Delisting Notice) from Nasdaq notifying us that we had not regained compliance with the Market Value Rule (and we did not satisfy any of the other applicable financial and liquidity standards) or the Minimum Bid Price Requirement. Consequently, Nasdaq had determined that our common stock would be scheduled for delisting and suspended at the opening of business on December 15, 2023 unless we requested an appeal of this determination on or before December 13, 2023. On December 12, 2023, we submitted a request for an oral appeal hearing before a Hearings Panel (the Panel). The hearing is scheduled to occur on March 7, 2024. Accordingly, the delisting and suspension of trading of our common stock will be stayed pending the issuance of the Panel&#8217;s final written decision. There can be no assurance that a favorable decision will be obtained from the Panel or that we will be successful in maintaining the listing of our common stock on the Nasdaq Capital Market.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we regain compliance with the Market Value Rule and the Minimum Bid Price Requirement, Nasdaq will provide us with written confirmation and close the matter. If we fail to satisfy the Nasdaq requirements for continued listing, our common stock may become subject to delisting. If that were to happen, we may not be able to regain compliance. If we cannot regain compliance after any such notice and if our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that our appeal of the delisting determination will be successful or that we will be successful in maintaining the listing of its common stock on the Nasdaq Capital Market.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limiting the removal of directors by the stockholders;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">creating a staggered board of directors;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminating the ability of stockholders to call a special meeting of stockholders; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors (Board), which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our Board. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our development processes that involve proprietary know-how or information that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, and outside scientific advisors, contractors and collaborators. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.  Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations, reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). In the past few years, numerous U.S. states, including California, Virginia, Colorado, Connecticut, and Utah, have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018 as amended by the California Privacy Rights Act of 2020 (collectively, the CCPA), applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for fines for noncompliance (up to $7,500 per intentional violation) and allows private litigants affected by certain data breaches to recover significant statutory damages.  Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels and we expect more states to pass similar laws in the future. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties upon whom we rely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR) and the United Kingdom&#8217;s GDPR (UK GDPR) impose strict requirements for processing personal data.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, Euros or 4% of annual global revenue, whichever is greater; or  private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.  In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate.  Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA's standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.  Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obligations related to data privacy and security are quickly changing becoming increasingly stringent, and creating regulatory uncertainty Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations. If we or the third parties upon which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to interruptions to our operations such as our clinical trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we and the third parties upon which we rely, process sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats, including, but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third party sites that take part in clinical trials we sponsor or third parties that are also sponsoring clinical trials involving our product candidates or those of our partners, such as NCI and Case Western, face similar threats and any security breach of their systems could adversely affect us. Security breaches could be particularly harmful to our business due to our reliance on internal clinical development functions and systems to conduct our clinical trials. For example, for clinical trials that we conduct, we rely on third party hosted software to manage the resulting clinical data. While the third party vendor is obligated to back up our clinical data on its servers, we do not independently back up our clinical data, and a loss of our clinical data by the third party vendor could result in delays in our development programs, cause us to breach our obligations to our third party collaborators, and significantly increase our costs to recover or reproduce the data. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party sites or other service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party sites or service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely), but we may not be able to detect and remediate all vulnerabilities in a timely manner because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred. Unremediated vulnerabilities pose material risks to our business.  Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon which we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon which we rely) to provide our clinical development activities. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents.  Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon which we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our contractors, consultants and collaborators, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. To the extent our collaborators are unable to comply with their obligations under our agreements with them or they are otherwise unable to complete or are delayed in completing development activities due to business disruptions, our ability to advance development in the United States may become impaired.  In addition, NCI may be affected by government shutdowns in the United States or withdrawn funding, which may lead to suspension or termination of ongoing NCI-sponsored clinical development of our product candidates. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. In addition, our ability and the ability of our partners to obtain clinical supplies of product candidates could be disrupted if the operations of our third party manufacturers are affected by a man-made or natural disaster or other business interruption. Our corporate headquarters are located in San Diego, California near major earthquake faults and fire zones. The ultimate impact on us and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are regularly subject to general litigation and other claims, which could have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are regularly subject to general litigation and other claims that arise in the ordinary course of our business. The outcome and impact of such litigation cannot be predicted with certainty, but regardless of the outcome, these proceedings can have an adverse impact on us because of legal costs, diversion of management resources and other factors. While the results of these claims have not historically had a material effect on us, we may not be able to defend ourselves adequately against these claims in the future, and these proceedings may have a material adverse impact on our financial condition or results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to intellectual property claims, which are extremely costly to defend, could require us to pay significant damages, and could limit our ability to use certain technologies in the future. Companies in the biopharmaceutical industry are frequently subject to litigation based on allegations of infringement or other violations of intellectual property rights.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party intellectual property rights may cover significant aspects of our technologies or business methods or block us from expanding our offerings. Any intellectual property claim against us, with or without merit, could be time consuming and expensive to settle or litigate and could divert the attention of our management. Litigation regarding intellectual property rights is inherently uncertain due to the complex issues involved, and we may not be successful in defending ourselves in such matters.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many potential litigants, including some patent-holding companies, have the ability to dedicate substantial resources to enforcing their intellectual property rights. Any claims successfully brought against us could subject us to significant liability for damages, and we may be required to stop using technology or other intellectual property alleged to be in violation of a third party&#8217;s rights. We also might be required to seek a license for third-party intellectual property. Such a license may be unavailable or may require us to pay significant royalties or submit to unreasonable terms, which would increase our operating expenses. We may also be required to develop alternative non-infringing technology, which could require significant time and expense. If we cannot license or develop technology for any allegedly infringing aspect of our business, we would be forced to limit our service and may be unable to compete effectively. Any of these results could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are at risk of securities class action litigation.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, principal investigators, consultants, vendors and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors and commercial partners may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate:</span></p>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA regulations, including those laws that require the reporting of true, complete and accurate information to the FDA;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing standards;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal and state fraud and abuse laws and other healthcare laws;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laws governing the conduct of business abroad; or</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.708690330477356%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laws that require the reporting of true and accurate financial information or data.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, these parties may fail to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, contractual damages, integrity oversight and reporting obligations, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we seek to advance product candidates through clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with additional third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with partners, consultants, suppliers and other third parties. Future growth will impose significant added responsibilities on members of our management, including having to divert a disproportionate amount of its attention away from day-to-day operating activities to implement and manage future growth. Our future financial performance and our ability to commercialize product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and, if necessary, sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our third party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States and abroad governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability, including through obligations to indemnify our third party manufacturers, or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our development and production efforts or those of our third party manufacturers, which could harm our business, prospects, financial condition or results of operations.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b"><span id="item_1b_unresolved_staff_comments"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B.	Unresolved Staff Comments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C.	Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk management and strategy</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, and confidential information that is proprietary, strategic or competitive in nature (Information Systems and Data).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our IT personnel, third-party service providers, and Board help identify, assess and manage the Company&#8217;s cybersecurity threats and risks. In doing so, they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s and industry&#8217;s risk profile using various methods including, for example, manual and automated tools, subscribing to reports and services that identify cybersecurity threats, conducting scans of potential threat environments, and evaluating threats reported to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: maintaining disaster recovery and business continuity plans, conducting risk assessments, implementing security standards and certifications, encrypting data, maintaining network security controls, access controls, physical security measures, and system monitoring tools, conducting employee training, and maintaining cybersecurity insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, cybersecurity risk is addressed as a component of the Company&#8217;s enterprise risk management program with our Board maintaining oversight of cybersecurity risk management, and, to that end, the Board typically meets regularly with business personnel responsible for cybersecurity risk management and receives periodic reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, third-party cybersecurity software providers. Additionally, we use third-party service providers to perform a variety of functions throughout our business, such as application providers and hosting companies. We have a vendor management program to manage cybersecurity risks associated with our use of these providers, including the performance of audits. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider. For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including the &#8220;If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to interruptions to our operations such as our clinical trials; regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences&#8221; risk factor.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The Board is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology who has over twenty years of experience in IT and Systems Administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Director of Information Technology and Chief Financial Officer (CFO) are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our CFO is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our CFO and CEO. The CFO and CEO work with the Director of Information Technology to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s incident response processes include reporting to the Board certain cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board receives regular reports from the CFO concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The Board also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.	Properties.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located at 4350 La Jolla Village Drive, Suite 800, San Diego, California 92122 in a facility we lease encompassing 6,724 square feet of office space pursuant to our August 2021 lease amendment. Our lease expires in April 2027.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span id="item_3"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3.	Legal Proceedings.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings. From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. For a description of our dispute and related proceedings with I-Mab, see the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Item 7 of this Annual Report.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span id="item_4"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4.	Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Capital Market under the ticker symbol &#8220;TCON&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, there were approximately 101 holders of record of our common stock. Certain shares of our common stock are held in &#8220;street&#8221; name and thus the actual number of beneficial owners of such shares is not known or included in the foregoing number.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our Board and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about our equity compensation plans is incorporated herein by reference to Item 11 of Part III of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Reserved.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, timing of future events and future financial performance, includes forward-looking statements that are based upon current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should review the sections tilted &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements&#8221; of this Annual Report for a discussion of important factors that could cause our actual results and the timing of selected events to differ materially from those described in or implied by the forward-looking statements contained in the following discussion and analysis. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Annual Report or to reflect actual outcomes.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing our cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, we entered into a collaboration and clinical trial agreement (the Envafolimab Collaboration Agreement) with 3D Medicines Co., Ltd. (3D Medicines) and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) for the development of envafolimab, also known as KN035, an investigational PD-L1 single-domain antibody (sdAb) administered by rapid subcutaneous injection for the treatment of sarcoma in North America. The ENVASARC Phase 2 pivotal trial (the ENVASARC trial) is enrolling 80 patients at 600mg of envafolimab every three weeks in cohort C, in the sarcoma subtypes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). Nine of 80 responses (11.25%) by blinded independent central review (BICR) are needed to satisfy the primary endpoint of the trial which is to statistically exceed the known 4% objective response rate (ORR) of Votrient&#174; (pazopanib), the only U.S. Food and Drug Administration (FDA)-approved treatment for patients with refractory UPS or MFS. Achieving the primary endpoint of exceeding the known 4% ORR could be the basis for accelerated approval of envafolimab by the FDA. The trial will provide at least 86% power to demonstrate the lower bound of the 95% confidence interval is greater than 5% in each cohort, which would be greater than the 4% ORR of Votrient reported in soft tissue sarcoma in its package insert. We presented a poster on the design and endpoints of the ENVASARC trial at the Connective Tissue Oncology Society meeting in November 2023.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, we announced that the ENVASARC trial had enrolled more than 70 of the 80 planned patients in cohort C of single agent envafolimab treatment. Safety and efficacy data were re-reviewed for 46 patients enrolled into cohort C. Since September 2023, an additional patient has achieved an objective response by investigator review, which increased the ORR by investigator review to 15%. The most recent objective response has not yet been confirmed by BICR. The primary endpoint of the study is achievement of an ORR in nine of 80 patients (11.25%) treated with envafolimab by BICR and median duration of response of greater than six months is a key secondary endpoint. Median duration of response by BICR remained greater than six months in December 2023. In addition, envafolimab remained generally well tolerated.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses out of 46 by BICR and based on the results of the second and final mandated IDMC efficacy review, the trial would continue as planned. The IDMC reviewed interim safety and efficacy data from 46 patients enrolled into cohort C of treatment with single agent envafolimab who completed two on-treatment scans, which are a minimum of 12 weeks of efficacy evaluations. The ORR in the initial 46 patients treated with single agent envafolimab was 13% by investigator review and 8.7% by BICR. Envafolimab monotherapy was generally well tolerated and median duration of response by BICR was greater than six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, an independent data monitoring committee (IDMC) performed an ad hoc review of interim safety and efficacy data from more than 80 patients equally randomized into cohort C of single agent envafolimab or cohort D of envafolimab given in combination with Yervoy. The combination of envafolimab with Yervoy did not demonstrate synergy when compared to single agent envafolimab and we terminated enrollment in cohort D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the trial has enrolled more than 75 of the planned 80 patients and full accrual of the ENVASARC trial is expected to be completed by the end of the first quarter of 2024. We expect to report a review of safety and efficacy data in the first quarter of 2024 following a review of a data package that is being prepared for an ad hoc IDMC meeting, including in the more than 20 patients enrolled following the September IDMC review who will have had a minimum of 12 weeks of efficacy evaluations (e.g., two CT scans) at that time. We expect to have final response assessment data including duration of response in all patients from the ENVASARC trial in the second half of 2024. Assuming positive data, we plan to submit a biologics license application (BLA) to the FDA seeking accelerated approval in 2024. At any time that we reach nine responses in cohort C by BICR and meet the primary endpoint, we expect to discuss the submission process with the FDA.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UPS has an incidence of 0.8 to 1.0 cases per 100,000 patients in the western world and accounts for approximately 17% of new cases of soft tissue sarcoma in the United States, with prevalence rates estimated at approximately 1.5 to 2.0 times incidence, and MFS accounts for half as many cases as UPS in the United States. We estimate that marketing envafolimab in refractory UPS and MFS could generate peak annual sales of up to $200 million in the United States without considering a price premium to the reference PD-1 inhibitors Opdivo (nivolumab) or Keytruda (pembrolizumab) that are administered intravenously. We estimate that sales of envafolimab in rarer sarcoma subtypes where the activity of checkpoint inhibition has been demonstrated could generate annual sales of up to $100 million in the United States.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other clinical stage oncology product candidates include TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, that we licensed from Eucure (Beijing) Biopharma Co., Ltd. (Eucure) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) in October 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). In initial clinical trials of more than 100 patients, TRC102 has shown good tolerability and we believe promising anti-tumor activity in combination with alkylating and antimetabolite chemotherapy for the treatment of cancer patients. TRC102 has been studied in Phase 1 or Phase 2 trials in mesothelioma patients in combination with the approved chemotherapeutic Alimta&#174; (pemetrexed), in glioblastoma, ovarian cancer, lung and colorectal cancer patients in combination with the approved chemotherapeutic Temodar&#174; (temozolomide) and in lung cancer patients in combination with the approved chemotherapeutics Alimta and cisplatin as well as external beam radiation (i.e., chemoradiation). A poster on the Phase 2 trial of TRC102 with temozolomide (TMZ) in patients with granulosa cell ovarian cancer was presented by investigators at the National Cancer Institute (NCI) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting held in June 2023. The authors concluded that TRC102 combined with TMZ was well tolerated in patients with granulosa cell ovarian cancer (GCOC). Durable disease control was observed in four of eight patients, which the authors considered as promising activity in this heavily pretreated GCOC cohort.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All current TRC102 trials are sponsored and funded by the NCI. We retain global rights to develop and commercialize TRC102 in all indications. In October 2020, we received orphan drug designation (ODD) from the FDA for TRC102 for the treatment of patients with malignant glioma, including glioblastoma. O6-methylguanine DNA methyltransferase (MGMT) deficiency is observed in about one-third of glioblastoma patients, and a prior study of TMZ and TRC102 reported at the Society for Neuro-Oncology in 2018 demonstrated that two MGMT deficient glioblastoma patients had prolonged survival when treated with TMZ and TRC102 after progressing previously on TMZ and radiation therapy. A December 2020 publication in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cancer Cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> also demonstrated TMZ and TRC102 were active in MGMT deficient patients with colorectal cancer. Based on these data, we believe a trial in first line glioblastoma patients of TMZ, radiation therapy and TRC102 is warranted and are discussing further development with investigators at this time. In addition, based on data presented at the ASCO 2020 virtual meeting that the combination of chemoradiation and TRC102 produced objective responses in all 15 evaluable patients with advanced localized lung cancer treated in a Phase 1 trial, in January 2022, the NCI initiated a randomized Phase 2 trial of chemoradiation with or without TRC102, followed by consolidative durvalumab treatment. The primary objective is to improve the 56% one-year progression free survival (PFS) rate with current standard of care to 75% with current standard of care plus TRC102. The trial began enrollment in June 2022 and is expected to be complete in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other product candidate, YH001, is an investigational humanized CTLA-4 IgG1 monoclonal antibody that completed dosing in two Phase 1 trials sponsored by Eucure for the treatment of various cancer types. CTLA-4 is a protein expressed on T-cells and expressed at high levels specifically on regulatory T-cells that act as a checkpoint to inhibit effector T-cell immune responses to cancer cells. The CTLA-4 inhibitor Yervoy (ipilimumab) marketed by BMS has been approved as a single agent in melanoma and approved in combination with other therapies in multiple indications including non-small cell lung cancer, renal cell carcinoma (RCC) and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer. Data from the Phase 1 dose escalation trial in Australia of YH001 in combination with the PD-1 antibody, toripalimab, were presented at the American Society of Clinical Oncology 2022 Annual Meeting. YH001 was well tolerated up to 4 mg/kg when combined with toripalimab in the 24 patients as of the December 31, 2021 data cut-off date. The Phase 1 dose escalation trial in China of YH001 as a single agent, completed enrollment and determined a recommended Phase 2 dose. No CTLA-4 therapy is approved by the FDA for the treatment of soft tissue sarcoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we announced that the FDA had cleared the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial of YH001 dosed in combination with envafolimab and doxorubicin, an approved treatment for soft tissue sarcoma. In December 2022, we initiated dosing in the Phase 1/2 clinical trial to assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma and of the doublet combination of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma. Given the recommendation of the IDMC to terminate enrollment in cohort D of the ENVASARC trial of dosing envafolimab with the CTLA-4 antibody Yervoy, we reviewed safety and efficacy data from more than ten patients who received envafolimab with the CTLA-4 antibody YH001. Following the data review and discussions with principal investigators, we discontinued enrollment in the Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin. We presented data from the 15 patients enrolled into the Phase 1/2 clinical trial in a poster in November 2023 at the Connective Tissue Oncology Society meeting. We plan to continue the development of envafolimab with doxorubicin in soft tissue sarcoma in a separate trial and may initiate trials of YH001 as a single agent or in combination with immunotherapies in other tumor types.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes key information regarding ongoing development of our clinical stage product candidates:</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.24%;"/>
    <td style="width:19.36%;"/>
    <td style="width:34.4%;"/>
   </tr>
   <tr style="height:12.95pt;background-color:#425e5f;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Data Expected</span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#1f497d;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Envafolimab</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.35pt;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:7.85pt;text-indent:-4.5pt;padding-left:4.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soft Tissue Sarcoma (UPS and MFS)</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pivotal Phase 2</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Updated Interim Data &#8211; Q1 of 2024</span></p><p style="text-indent:0.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Final Data &#8211; second half of 2024</span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#28a16f;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRC102</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Lung Cancer</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Randomized Phase 2</span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize a product development platform (PDP) that emphasizes capital efficiency. Our experienced clinical operations, data management, quality assurance, product development and regulatory affairs groups manage significant aspects of our clinical trials with internal resources. We use these internal resources to reduce the costs associated with utilizing CROs to conduct clinical trials. In our experience, this model has resulted in capital efficiencies and improved communication with clinical trial sites, which can expedite patient enrollment and improve the quality of patient data as compared to a CRO-managed model. We have leveraged this platform in all of our sponsored clinical trials, in addition to recently monetizing our platform independently by licensing our PDP to Inhibrx, Inc. (Inhibrx) in November 2023 for a $3.0 million upfront fee. We have also leveraged our PDP to diversify our product pipeline without payment of upfront license fees through license agreements with Eucure, a division of Biocytogen, 3D Medicines and Alphamab, and Janssen. We continue to evaluate life science companies that would benefit from a rapid and capital-efficient U.S. drug development solution that includes U.S. and European Union (EU) clinical development expertise, or that wish to license our PDP to enable them to run CRO-independent clinical trials. We believe we will continue to be recognized as a preferred U.S. clinical development partner through a cost- and risk-sharing partnership structure, which may include U.S. commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to be a leader in the development of targeted therapies for patients with cancer and other diseases of high unmet medical need.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception in 2004, we have devoted substantially all of our resources to research and development efforts relating to our product candidates, including conducting clinical trials, in-licensing related intellectual property, providing general and administrative support for these operations, and protecting our intellectual property. To date, we have not generated any revenue from product sales and instead, have funded our operations from the sales of equity securities, payments received in connection with our collaboration agreements, and commercial bank debt. At December 31, 2023, we had cash and cash equivalents totaling $8.6 million, of which $0.1 million is pledged as collateral for our obligations under our corporate headquarters facility lease.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate, nor do we expect to own or operate, facilities for product manufacturing, storage, distribution or testing. We contract with third parties or our collaboration partners for the manufacture of our product candidates and we intend to continue to do so in the future.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses from operations in each year since our inception. Our net losses were $3.6 million and $29.1 million for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023, we had an accumulated deficit of $240.5 million.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant expenses and operating losses for at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect our current level of research and development expenses to decrease in 2024 with the completion of enrollment of the ENVASARC trial in Q1 2024, partially offset as we:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in-license additional product candidates for development and commercialization, and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for product candidates that successfully complete clinical trials.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to generate any revenues from product sales until we successfully complete development and obtain regulatory approval for one or more product candidates, which we expect will take a number of years. If we obtain regulatory approval for any product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, and distribution. Accordingly, we will need to raise substantial additional capital. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our preclinical and clinical development efforts, developments under our collaboration agreements, including whether and when we receive milestone and other potential payments, and the timing and nature of the regulatory approval process for product candidates. We anticipate that we will seek to fund our operations through public or private equity or debt financings or other sources. Debt financing, if available, may involve covenants further restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Further, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. As a result of adverse macroeconomic and geopolitical developments, such as the ongoing military conflict between Ukraine and Russia or the recent state of war between Israel and Hamas and the related risk of a larger regional conflict, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, actual and anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and ability to develop product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License and Collaboration Agreements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inhibrx License Agreement</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, we granted a non-exclusive and non-transferable license of our CRO-independent PDP to Inhibrx for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals (the PDP License), for a nonrefundable upfront fee of $3.0 million. The PDP License allows Inhibrx to use our configuration documentation with a widely used software package in addition to use our validation and qualification of the software package, and our standard operation procedure documents, policies, work instructions, and clinical operation templates (the Licensed Technology). We are also able to earn an additional $0.2 million upon the completion of up to 500 hours of training to Inhibrx by us or six months following our delivery of the Licensed Technology, whichever is earlier.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with 3D Medicines and Alphamab</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, we, 3D Medicines, and Alphamab entered into the Envafolimab Collaboration Agreement for the development of envafolimab, an investigational PD-L1 sdAb, or nanobody, administered by rapid subcutaneous injection, for the treatment of sarcoma in North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Envafolimab Collaboration Agreement, we were granted an exclusive license to develop and commercialize envafolimab for the treatment of sarcoma in North America.  We are responsible for conducting and will bear the costs of any Phase 1, Phase 2, and Phase 3 or post-approval clinical trial in North America for envafolimab in the indications of refractory and first line treatment of sarcoma. 3D Medicines and Alphamab are responsible for conducting and will bear the costs of IND-enabling studies (other than those specific to the sarcoma indication) and the preparation of the chemistry, manufacturing and controls (CMC) activities sections of an IND application for envafolimab. 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third-party manufacturer to manufacture and supply, envafolimab to us at pre-negotiated prices that vary based on clinical or commercial use. 3D Medicines and Alphamab retained the right to develop envafolimab in all territories outside of North America as well as within North America for all indications other than sarcoma.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue, unless (a) envafolimab is first approved in North America for an indication other than sarcoma and launched in North America, or (b) envafolimab is first approved in North America for sarcoma and subsequently approved in North America for an additional non-orphan indication and sold commercially by 3D Medicines and/or Alphamab, or licensee, in which case 3D Medicines and Alphamab will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue. If 3D Medicines and Alphamab become responsible for commercialization under the Envafolimab Collaboration Agreement, we have the option to co-market envafolimab for sarcoma in North America. In the event that envafolimab is first approved in North America for sarcoma and within three years of the commercial launch of envafolimab in North America for sarcoma 3D Medicines and Alphamab replace us as the party responsible for commercialization, and we elect and 3D Medicines and Alphamab agree for us to not co-market envafolimab for sarcoma in North America, then 3D Medicines and Alphamab will be required to compensate us for our costs associated with preparing for and conducting commercial activities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we have the responsibility for commercialization under the Envafolimab Collaboration Agreement, we will owe 3D Medicines and Alphamab tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits.  If 3D Medicines and Alphamab have responsibility for commercialization under the Envafolimab Collaboration Agreement, we will be entitled to (a) tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits if we have elected to not co-market envafolimab in sarcoma or (b) a 50% royalty on net sales of envafolimab for sarcoma in North America if we have chosen to co-market envafolimab in sarcoma.  Payment obligations under the Envafolimab Collaboration Agreement continue on a country-by-country basis until the last to expire licensed patent covering envafolimab expires.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3D Medicines and Alphamab retain the right to reacquire the rights to envafolimab for sarcoma in North America in connection with an arm&#8217;s length sale to a third party of the rights to develop and commercialize envafolimab in North America for all indications, provided that the sale may not occur prior to completion of a pivotal trial of envafolimab in sarcoma without our written consent and the parties must negotiate in good faith and agree to fair compensation be paid to us for the value of and opportunity represented by the reacquired rights.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party agreed that during the term of the Envafolimab Collaboration Agreement, it would not develop or license from any third party a monospecific inhibitor to PD-L1 or PD-1 in sarcoma.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Envafolimab Collaboration Agreement continues until the later of the date the parties cease further development and commercialization of envafolimab for sarcoma in North America or the expiration of all payment obligations.  The Envafolimab Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to envafolimab.  In the event we elect, or a joint steering committee (JSC) determines, to cease further development or commercialization of envafolimab, or if we fail to use commercially reasonable efforts to develop (including progress in clinical trials) and commercialize envafolimab and do not cure such failure within a specified time period, then our rights and obligations under the Envafolimab Collaboration Agreement will revert to 3D Medicines and Alphamab.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Eucure and Biocytogen</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, we, Eucure and Biocytogen entered into a collaborative development and commercialization agreement (the YH001 Collaboration Agreement) for the development of YH001, a monospecific investigational CTLA-4 antibody. Pursuant to the YH001 Collaboration Agreement, we were granted an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including sarcoma, microsatellite stable colorectal cancer, RCC, and K-ras positive non-small cell lung cancer (collectively, the Initial Indications) or one or more of bladder cancer, endometrial cancer, and melanoma as substitute indications, which may be substituted for Initial Indications at our discretion (each upon such substitution, a Substitute Indication). We are responsible for, and will bear the costs of, preparing and filing all regulatory submissions and conducting any Phase 1, Phase 2, Phase 3, or post-approval clinical trials in North America for YH001 in the Initial Indications and potentially the Substitute Indications, while Eucure is responsible for conducting, and will bear the costs of, the preparation of CMC activities for YH001. Eucure has agreed to manufacture and supply, or to arrange for a third-party manufacturer to manufacture and supply, YH001 to us for clinical trials pursuant to the terms of a clinical supply and quality agreement that will be separately negotiated and agreed in good faith between the parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eucure may pursue clinical trials for YH001 in North America outside of the Initial Indications or Substitute Indications, and also within the Initial Indications or Substitute Indications as part of a combination therapy of YH001 and an additional Eucure product. During a specified period, we have the option, subject to Eucure&#8217;s prior written approval, to expand the license to include the development and commercialization of YH001 for the treatment, through administration by intravenous or subcutaneous means, of all human and veterinary therapeutic indications in North America for a payment to Eucure in the low single digit millions (the Company Option).</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the YH001 Collaboration Agreement, we granted Eucure an irrevocable, perpetual, royalty-free, exclusive license, with the right to grant sublicenses to develop, register, sell, offer to sell, have sold, market and distribute YH001 in all territories outside of North America as well as within North America for all indications other than the Initial Indications and the Substitute Indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be responsible for commercializing YH001 in North America, including booking of sales revenue in the Initial and Substitute Indications. We will owe Eucure escalating double digit royalties on net sales of YH001 in North America ranging from the mid-twenties to mid-double digits; provided that until the end of the first full calendar year following the first commercial sale of YH001, royalties will range from the lower double digits to the mid-double digits. If sales of YH001 exceed a pre-determined sales threshold in the first full year of sales following first commercial sale, we will owe a milestone to Eucure in the high single digit millions. Payment obligations under the YH001 Collaboration Agreement continue on a country-by-country basis until the latest of (i) expiration of the last to expire licensed patent covering YH001, (ii) expiration of marketing or regulatory exclusivity covering YH001 and (iii) 10 years from the first commercial sale of YH001 in such country in North America. Eucure has agreed to manufacture and supply, or to arrange for a third-party manufacturer to manufacture and supply, YH001 to us at cost plus a low double-digit markup for commercial sales pursuant to the terms of a commercial supply and quality agreement that will be separately negotiated and agreed in good faith between the parties within 180 days prior to the anticipated first commercial sale in North America.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the YH001 Collaboration Agreement, each party agreed that during the term of the YH001 Collaboration Agreement, it would not develop, manufacture, commercialize or license from any third party a monospecific inhibitor to CTLA-4.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the YH001 Collaboration Agreement continues until the earlier of (i) the date that the parties cease further development and commercialization of YH001 in North America or (ii) on a country-by-county basis, the expiration of the royalty obligations in such country.  The YH001 Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to YH001. In the event of a termination of the YH001 Collaboration Agreement, other than by us as a result of Eucure&#8217;s material uncured breach or bankruptcy, (i) our license shall terminate and (ii) we would be obligated to grant Eucure an irrevocable, perpetual, royalty-free, non-exclusive license with the right to grant sublicenses under its rights in all development data and intellectual property to develop, register, sell, offer to sell, have sold, market and distribute YH001 in North America. In the event of a termination of the YH001 Collaboration Agreement by us as a result of Eucure&#8217;s material uncured breach or bankruptcy, the license shall continue in the Initial Indications in North America, provided that (i) such license shall remain exclusive during the royalty term and non-exclusive thereafter; (ii) we shall have the right to have YH001 manufactured for its development and commercialization requirements in the Initial Indications in North America; and (iii) the license shall terminate in the event of an uncured material breach by us of any provision (including payment obligations) that survives termination of the YH001 Collaboration Agreement.  In the event the YH001 Collaboration Agreement terminates for safety reasons related to YH001, by mutual agreement of the parties or by Eucure in the event of an uncured material breach or bankruptcy by us, then our rights and obligations under the YH001 Collaboration Agreement will revert to Eucure.  In the event Eucure does not approve the Company Option, we may terminate the YH001 Collaboration Agreement for convenience with a 30-day notice to Eucure, provided that such termination is given within 12 months of the effective date of the YH001 Collaboration Agreement (the Company Option Termination).  In the event of a Company Option Termination, Eucure would be obligated to reimburse us for all costs and expenses that we incurred in performing the development activities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with Case Western</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2006, we entered into a license agreement with Case Western, under which we obtained an exclusive, worldwide license to certain patents, know-how and other intellectual property controlled by Case Western related to methoxyamine, which we refer to as the TRC102 Technology. Under the agreement, as amended, we have the right to use, manufacture and commercialize products utilizing the TRC102 Technology for all mammalian therapeutic uses, and to sublicense these rights.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the agreement, we are generally obligated to use our best efforts to commercialize the TRC102 Technology as soon as possible. We are also required to meet specified diligence milestones, and if we fail to do so and do not cure such failure, Case Western may convert our license into a non-exclusive license or terminate the agreement.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the rights granted to us under the agreement, we paid a one-time upfront fee to Case Western. In addition, we may be required to pay up to an aggregate of approximately $9.8 million in milestone payments, of which $0.7 million relates to the initiation of certain development activities and approximately $9.1 million relates to the submission of certain regulatory filings and receipt of certain regulatory approvals. If products utilizing the TRC102 Technology are successfully commercialized, we will be required to pay Case Western a single-digit royalty on net sales, subject to adjustments in certain circumstances. Beginning on the earlier of a specified number of years from the effective date of the agreement and the anniversary of the effective date following the occurrence of a specified event, we will be required to make a minimum annual royalty payment of $75,000, adjusted annually based on the Consumer Price Index, which will be credited against our royalty obligations. In the event we sublicense any of our rights under the agreement relating to the TRC102 Technology, we will be obligated to pay Case Western a portion of certain fees we may receive under the sublicense. Our royalty obligations will continue through the later of (i) the expiration of any orphan drug marketing exclusivity for a product utilizing the TRC102 Technology, (ii) August 2026, or (iii) on a country-by-country basis upon the expiration of the last valid claim under the TRC102 Technology or any patent we receive that is a derivative of the TRC102 Technology.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may unilaterally terminate this agreement in its entirety, for any reason or for no reason, upon at least 30 days&#8217; notice to Case Western. If we do so, we will be required to pay Case Western a termination fee. If we fail to pay any amount required under the agreement and do not cure the default within 90 days of receiving notice, Case Western will have the right to convert our exclusive license to a non-exclusive license or to terminate the agreement entirely. Either party may terminate the agreement in the event of the other party&#8217;s material breach of the agreement that remains uncured 60 days after receiving notice of the breach.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreements with NCI</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Health and Human Services, as represented by NCI, for the development of TRC102 for the treatment of cancer. We entered into the CRADA governing the development of TRC102 (TRC102 CRADA) in August 2012 with NCI&#8217;s Center for Cancer Research.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the CRADA, as amended, NCI conducts clinical trials and non-clinical studies of TRC102. Pursuant the TRC102 CRADA, we are required to pay NCI $20,000 per year per Phase 1 clinical trial and $25,000 per year per Phase 2 clinical trial, as well as expenses incurred by NCI in connection with carrying out its responsibilities under the TRC102 CRADA, up to an aggregate maximum per year of $200,000. We may also provide funding to support assays and other studies, and if NCI supplies TRC102 for additional mutually approved clinical trials beyond the planned trials, we will reimburse NCI for costs associated with manufacturing TRC102. In addition, we made a one-time payment of $20,000 for the initial IND filing and may be required to make additional one-time payments of $10,000 each for additional IND filings. Funding for clinical trials beyond those contemplated by the TRC102 CRADA will be determined in an amendment to the applicable CRADA.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the CRADA, each party individually owns all inventions, data and materials produced solely by its employees in the course of performing research activities pursuant to the CRADA. The parties jointly own any inventions and materials that are jointly produced by employees of both parties. Subject to certain conditions, we have the option under the CRADA to negotiate commercialization licenses from the government to intellectual property conceived or first reduced to practice in performance of the CRADA research plan that was developed solely by NCI employees or jointly by us and NCI employees.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The TRC102 CRADA had an original five-year term and was subsequently amended to extend the term to August 7, 2023. The CRADA may be terminated at any time by mutual written consent, and we or NCI may unilaterally terminate the CRADA for any reason or no reason by providing written notice at least 60 days before the desired termination date.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that any revenue we generate will fluctuate from period to period as a result of the timing of entering into any additional license and collaboration agreements and recognition of associated upfront and milestone payments, and the extent to which any of our products are approved and successfully commercialized by us or our partners. If we or our partners fail to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues, our results of operations and our financial position could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of costs associated with the preclinical and clinical development of product candidates. These costs consist primarily of:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">salaries and employee-related expenses, including stock-based compensation and benefits for personnel in research and development functions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs incurred under clinical trial agreements with investigative sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to acquire preclinical study and clinical trial materials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs associated with conducting our preclinical, development and regulatory activities, including fees paid to third party professional consultants, service providers and our scientific advisory board;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments related to licensed products and technologies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facilities, depreciation and other expenses, including allocated expenses for rent and maintenance of facilities.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs, including third party costs reimbursed in connection with our collaboration agreements, are expensed as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses by product candidate for the periods indicated:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.749%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:10.618%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:10.618%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:10.618%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third-party research and development expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Envafolimab</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,628</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,570</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,704</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">YH001</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,248</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">390</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRC102</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">379</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total third-party research and development expenses</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,989</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,339</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,849</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unallocated expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,288</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,549</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,297</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,277</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,888</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,146</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unallocated expenses consist primarily of our internal personnel and facility related costs.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our current level of research and development expenses to decrease in 2024 with the completion of enrollment of the ENVASARC trial in Q1 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The costs of clinical trials to us and the timing of such costs may vary significantly based on factors such as:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which costs for comparator drugs are borne by third parties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per patient trial costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of sites included in the trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of time required to enroll eligible patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients that participate in the trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of doses that patients receive;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the drop-out or discontinuation rates of patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration of patient participation in the trials and follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of macroeconomic and geopolitical developments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the phase of development of the product candidate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of the product candidate; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which costs are borne by third parties such as the NCI.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration, corporate development and administrative support functions, including stock-based compensation expenses and benefits. Other significant general and administrative expenses include legal services, insurance, occupancy costs, accounting services, and the cost of various consultants.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our general and administrative expenses will remain relatively consistent in 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, other income primarily consists of the arbitration award collected in July 2023, partially offset by interest related to our arbitration financing agreement, which was paid off in full in July 2023. In 2022, other expense primarily consists of interest related to our loan agreements with SVB, which was terminated in June 2022, and Runway Growth Finance Corp., which was terminated in April 2023, offset in part by interest income from our cash equivalents and investing activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the reported revenues and expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on our historical experience and on various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are more fully described in the notes to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policy related to clinical trial expense accruals is the most critical to understanding and evaluating our reported financial results.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Expense Accruals</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate expenses resulting from our obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our objective is to reflect the appropriate trial expenses in our consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates taking into account discussion with applicable personnel and outside service providers as to the progress or state of consummation of trials. During the course of a clinical trial, we adjust the clinical expense recognition if actual results differ from our estimates. We make estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. Our clinical accruals are dependent upon accurate reporting by third-party vendors. Although we do not expect our estimates to differ materially from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three years ended December 31, 2023, there were no material adjustments to our prior period estimates of accrued expenses for clinical trials.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Company Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Operating Loss and Research and Development Tax Credit Carryforwards</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal and California NOL carryforwards of $190.2 million and $146.9 million, respectively. The federal and California NOL carryforwards will begin to expire in 2030 and 2033, respectively, if not utilized. The federal NOL generated after 2017 of $106.9 million will carryforward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. As of December 31, 2023, we also had federal research and development and Orphan Drug tax credit carryforwards of $15.1 million and California research and development tax credit carryforwards of $3.3 million. The federal research and development and Orphan Drug tax credit carryforwards will begin expiring in 2031 and 2036, respectively, if not utilized. The California research credit will carry forward indefinitely under current law.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Sections 382 and 383 of the Code, our annual use of our NOL and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. We completed a Section 382/383 analysis regarding the limitation of our NOL and research and development credit carryforwards as of December 31, 2018 and did not identify a cumulative change in ownership of more than 50% within the proceeding three-year period. Future ownership changes, including changes during the year ended December 31, 2023, may limit our ability to utilize our remaining NOL and research and development tax credit carryforwards. As of December 31, 2023, we had a full valuation allowance against our deferred tax assets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This section discusses our results of operations for the year ended December 31, 2023 as compared to the year ended December 31, 2022. For a discussion and analysis of the year ended December 31, 2022 compared to the year ended December 31, 2021 please refer to the section titled Management's Discussion and Analysis of Financial Condition and Results of Operations included in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 8, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,045</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,045</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,277</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,888</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,611</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,666</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,006</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,340</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Arbitration success fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,375</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,375</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,685</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,241</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,926</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Revenue was $12.0 million for the year ended December 31, 2023, $9.0 million of which was from the termination of the TJ004309 Agreement and $3.0 million of which was from the license of our CRO-independent PDP in November 2023.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Research and development expenses were $12.3 million and $13.9 million for the years ended December 31, 2023 and 2022, respectively. The decrease of $1.6 million was primarily due to the termination of enrollment in cohort D of the ENVASARC trial, partially offset by envafolimab drug product purchased in 2023 for clinical trials. We expect our current level of research and development expenses to decrease in 2024 with the completion of enrollment of the ENVASARC trial in Q1 2024.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> General and administrative expenses were $6.7 million and $14.0 million for the years ended December 31, 2023 and 2022, respectively. The decrease of $7.3 million was primarily due to lower legal expenses. We expect general and administrative expenses to remain relatively consistent in 2024.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Arbitration success fees.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arbitration success fees were $2.4 million for the year ended December 31, 2023 and were related to our legal fee arrangement with our attorneys from the I-Mab arbitration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Total other income (expense).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Total other income was $5.7 million for the year ended December 31, 2023 and primarily related to the $13.0 million gain associated with the collection of the arbitration award in July 2023, which consisted of the $22.0 million amount collected less the $9.0 million TJ004309 termination fee recognized as collaboration revenue, partially offset by $7.2 million of interest related to our arbitration financing agreement. Total other expense was $1.2 million for the year ended December 31, 2022 and primarily consisted of interest expense incurred associated with the RGC Loan Agreement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our sources of liquidity include our cash and cash equivalents. We believe that our cash and cash equivalents as of December 31, 2023 will be sufficient to fund the current requirements of working capital and other financial commitments, including our operating lease obligations, into mid-2024. Based on our current business plan, we believe that there is substantial doubt as to whether our existing cash and cash equivalents will be sufficient to meet our obligations as they become due within one year from the date the audited consolidated financial statements are issued.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may fund our future liquidity needs by selling shares of our common stock under our existing Sales Agreement with JonesTrading and our common stock purchase agreement (the LPC Purchase Agreement) with Lincoln Park. In addition, we periodically consider various other financing alternatives, including debt financings, or potentially other capital sources, such as collaboration or licensing arrangements with third parties or other strategic transactions, in order to meet our liquidity needs and may, from time to time, seek to take advantage of favorable interest rate environments, if any, or other market conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses and negative cash flows from operations since our inception. As of December 31, 2023, we had an accumulated deficit of $240.5 million, and we expect to continue to incur net losses for the foreseeable future. We expect our current level of research and development expenses to decrease in 2024 with the completion of enrollment of the ENVASARC trial. Given we do not anticipate any revenues from product sales in the foreseeable future, we will need additional capital to fund our operations, which we may seek to obtain through one or more equity offerings, debt financings, government or other third-party funding, and licensing or collaboration arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lincoln Park Capital Fund, LLC (Lincoln Park) Common Stock Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we and Lincoln Park entered into the LPC Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Lincoln Park is committed to purchase up to an aggregate of $26.0 million of shares of our common stock from time to time and at our sole discretion over the term of the LPC Purchase Agreement, $25.0 million of which remains available for sale as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At our special meeting of stockholders held in September 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the potential future sale and issuance of shares of our common stock to Lincoln Park in accordance with the pricing terms set forth in the LPC Purchase Agreement that could result in Lincoln Park owning in excess of 19.99% of the shares of our common stock outstanding immediately after giving effect to such sale.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock and Pre-Funded Warrants Offerings</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, we issued and sold 174,508 shares of our common stock at a purchase price of $1.38 per share and pre-funded warrants to purchase 2,013,999 shares of our common stock at a purchase price of $1.37 per share of underlying common stock with an exercise price of $0.01 per share of underlying common stock (the 2023 Pre-Funded Warrants) for net proceeds of approximately $3.0 million in a private placement (the Private Placement) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2023 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of our common stock would exceed 19.99% of the shares of our common stock outstanding immediately after giving effect to such exercise, unless approval by our stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, we issued and sold 841,989 shares of our common stock at a purchase price of $1.32 per share and pre-funded warrants to purchase 2,205,018 shares of our common stock at a purchase price of $1.31 per share of underlying common stock with an exercise price of $0.01 per share of underlying common stock (the 2022 Pre-Funded Warrants) for net proceeds of approximately $3.9 million in a registered direct offering (the Offering) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2022 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of our common stock would exceed 19.99% of the shares of our common stock outstanding immediately after giving effect to such exercise. In connection with the Offering, we amended two existing pre-funded warrants to purchase shares of our common stock held by the same institutional healthcare-focused fund to extend the exercise periods and to permit exercise in excess of a similar 19.99% limit following approval of our stockholders of such exercise, unless approval by our stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d).</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At our 2023 Annual Meeting held on April 19, 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the issuance of shares of common stock upon the potential future exercise of certain outstanding warrants held by such accredited institutional healthcare-focused fund that would result in it and its affiliates owning in excess of 19.99% of the shares of common stock outstanding immediately after giving effect to such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Facility</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, as amended in March 2022, we entered into the Sales Agreement with JonesTrading pursuant to which we could sell from time to time, at our option, up to an aggregate of $50.0 million of shares of our common stock through JonesTrading, as sales agent or principal, $41.5 million of which remains available for sale as of December 31, 2023. Sales of our common stock made pursuant to the Sales Agreement, if any, will be made on the Nasdaq Capital Market under our effective registration statement on Form S-3, subject to limitations on the amount of securities we may sell pursuant to its effective registration statement on Form S-3 within any 12 month period, by means of ordinary brokers&#8217; transactions at market prices. Additionally, under the terms of the Sales Agreement, we may also sell shares of our common stock through JonesTrading, on the Nasdaq Capital Market or otherwise, at negotiated prices or at prices related to the prevailing market price. JonesTrading will use its commercially reasonable efforts to sell our common stock from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions we may impose). We are required to pay JonesTrading 2.5% of gross proceeds from the common stock sold through the Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Lease Obligations</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating lease obligations relate to our corporate headquarters in San Diego, California, which expires in April 2027. As of December 31, 2023, future minimum lease payments under this lease were $0.3 million and $0.7 million for each of the next 12 and 24 months, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Obligations</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with vendors for preclinical safety and research studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our net cash flow activity for each of the periods set forth below:</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,676</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26,239</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(17</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,539</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,684</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,863</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,572</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Net cash provided by operating activities was $3.7 million for the year ended December 31, 2023 and was primarily due to collection of the $22.0 million arbitration award and changes in our working capital, partially offset by non-cash charges including stock-based compensation. Net cash used in operating activities was $26.2 million for the year ended December 31, 2022 and was primarily due to our net loss and changes in our working capital, partially offset by non-cash charges including stock-based compensation.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Net cash used in investing activities was $17,000 for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Net cash used in financing activities was $12.5 million for the year ended December 31, 2023 and primarily resulted from our repayment of $10.5 million and $10.0 million under the terms of our arbitration financing agreement and RGC loan agreement, respectively, partially offset by $3.0 million in net proceeds from the March 2023 Private Placement and $5.1 million in periodic issuances and sales of our common stock under the LPC Purchase Agreement and Sales Agreement with JonesTrading. Net cash provided by financing activities was $19.7 million for the year ended December 31, 2022 and primarily resulted from our $10.0 million debt financing with RGC, $3.4 million in net proceeds from our arbitration financing arrangement, and $7.9 million in net proceeds received from the Offering and periodic issuances and sales of our common stock under the Sales Agreement with JonesTrading, partially offset by $1.7 million in SVB loan repayments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, we had cash and cash equivalents totaling $8.6 million, of which $0.1 million is pledged as collateral for our obligations under our corporate headquarters facility lease. We believe that our cash and cash equivalents as of December 31, 2023 will be sufficient to fund the current requirements of working capital and other financial commitments, including our operating lease obligations, into mid-2024. We will need additional funding to complete the development and commercialization of our product candidates or those of our partners. In addition, we may evaluate in-licensing and acquisition opportunities to gain access to new product candidates that fit with our strategy. Any such transaction will likely increase our future funding requirements. These uncertainties raise substantial doubt about our ability to meet our obligations as they become due and continue as a going concern for a period of 12 months following the date that the accompanying audited consolidated financial statements were issued.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Our future capital requirements are difficult to forecast and will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to initiate, and the progress and results of, our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability and willingness of our collaboration partners and licensees to continue clinical development of product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into and maintain our collaborations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve, and our obligations to make, milestone payments under our collaboration and license agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of procuring supplies of product candidates for clinical trials and regulatory submissions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of preclinical development, and clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which adverse macroeconomic and geopolitical developments, including as a result of recent and potential future bank failures, delay our clinical development activities or those of our collaborators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we or any of our partners, including Eucure and Biocytogen or 3D Medicines and Alphamab, may receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidates for which we receive marketing approval and do not partner for commercialization; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other products and technologies.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until we can generate substantial product revenues, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, and licensing arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Any discontinuation by us of our development of envafolimab as a single agent in UPS/MFS would likely adversely impact our ability to raise additional financing and could significantly impact our ability to continue as a going concern. As a result of adverse macroeconomic and geopolitical developments, such as the ongoing military conflict between Ukraine and Russia or the recent state of war between Israel and Hamas and the related risk of a larger regional conflict, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, actual or anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans or programs which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. Any of these actions could materially harm our business, results of operations and future prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Financial Statements and Supplementary Data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of TRACON Pharmaceuticals, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.36%;"/>
    <td style="width:2.56%;"/>
    <td style="width:82.08%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Clinical Trial Expense Accruals</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">During 2023, the Company incurred $12.3 million for research and development expense and as of December 31, 2023, the Company accrued $6.7 million for clinical trial expenses. As described in Note 1 of the</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.36%;"/>
    <td style="width:2.56%;"/>
    <td style="width:82.08%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">consolidated financial statements, the Company records accruals for estimated research and development costs relating to clinical trials comprising payments for work performed by third party vendors and consultants, participating clinical trial sites, and others. The Company accounts for the expenses based upon the progress of the clinical trial as measured by patient progression through the trial.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditing the Company&#8217;s accounting for clinical trial expense accruals was especially challenging as evaluating the progress or patient progression through the clinical trials is dependent upon a high volume of data which is tracked in spreadsheets.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">To test the completeness of the Company&#8217;s accrued clinical trial expenses, among other procedures, we obtained supporting evidence of the research and development activities performed for significant clinical trials. We inquired of internal clinical trial project managers to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial costs, our audit procedures included, among others, obtaining and inspecting significant agreements and agreement amendments, evaluating the Company&#8217;s documentation of key milestones and completion terms, activities, timing, and costs of clinical trials, and testing a sample of transactions by comparing the costs against related invoices and contracts. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5d11b77-f58a-448c-9493-6b5ae706bff1" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2011.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_487940d7-17ae-4c0b-a571-f3725d40a063" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 5, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bs"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.013%;"/>
    <td style="width:1.6%;"/>
    <td style="width:1%;"/>
    <td style="width:12.663%;"/>
    <td style="width:1%;"/>
    <td style="width:1.6%;"/>
    <td style="width:1%;"/>
    <td style="width:12.663%;"/>
    <td style="width:1%;"/>
    <td style="width:1.46%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98bdf829-2a4b-41c1-bfaf-fb4857760740" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,564</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90184ef3-f597-4ef4-9c84-9dc8c2d67af7" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,433</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da61ebd9-0de3-43ee-b85e-5ec077f5dddd" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">526</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_935d8092-5816-4cde-9432-2eff2bff27fc" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">795</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b01632d-3a0f-43cb-9fcb-6a8153496b7a" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,090</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55c88196-aa11-416a-8d38-8ed2221391b0" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,228</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f27af587-759e-4d9b-8283-a1951b52541f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c9ae591-a51c-474f-b3f7-30f8516fd1a6" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19afcd54-61c2-440c-94fc-429d6e06b8f8" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58adc410-4a91-4493-9aff-2809fe4defaa" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe95e0e3-b48a-44ec-8900-2ac5fcdaa706" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8b44f66-7a3e-4da3-8f87-1f02129f2ea5" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3626bec3-b712-4f95-94af-28bfa4035fa5" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,105</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea4d4b6-3496-4c1a-9d6e-77955e1662da" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,469</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Deficit</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc9cf45-103b-4dee-8d5c-52e86abf0747" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,544</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b058743e-7298-4176-891d-e5a15f74953a" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,923</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c882de5e-8439-4736-bdb4-13d9a1b8921f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,211</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d81376b-cfa6-4795-a8ec-7133d56f8496" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,184</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_180c5af8-bc15-4223-bb5a-d68e172a1fa6" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c26a30e5-7a5a-4c31-b1bd-ea5379e847f2" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,457</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, current portion</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e50b30e-e886-419f-ac59-75fcb985cc47" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,807</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e122c03e-5d5a-482f-b615-eab3aee81f92" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,182</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8ea527e-b6e5-4185-accc-b1ff1fac84af" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4374ee6d-e1cd-49f4-a6f3-6148e5445131" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_355a8cb7-16bc-4784-9c22-f35c750542d9" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">969</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Arbitration financing payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a4a8e62-acae-482f-9fc2-d7b6d59608e3" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:ArbitrationFinancingPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_edd6578b-51b9-4d94-9c92-e08d58d290ce;"><span style="-sec-ix-hidden:F_af0f1790-87f7-4d5a-bc14-b2897ded686a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(Note 5)</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; deficit:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3fe3fd4-652c-45f2-906f-3888eff68058" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9ce93b42-1f90-44ef-af77-695e14a1b414" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, authorized shares &#8212; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c6ccf55-74bf-483a-be5a-f4e0e8f5b5cd" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9a01ac39-bfc2-4d8d-afb8-cbe6dfbbfa51" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at<br/>&#160;&#160;&#160;&#160;December 31, 2023 and December 31, 2022; issued and outstanding<br/>&#160;&#160;&#160;shares &#8212; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f485436b-b3b3-4aef-ac32-7e27211d8cb0" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b52581be-4699-4138-9c6a-bacafcae5764" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_438f78a4-bfc9-4a1f-99bd-8b45d26d627f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cb776419-0525-4980-a40e-05d121d50120" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_f35279c3-d90a-4876-9a14-4f57ff1df69e;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_3fcf7105-039a-49a1-b08a-a181e9c9b3ad;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b61db3e4-9d07-4451-a451-41403970914e" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_17779db0-1ae2-4c70-9259-bf8c502f6f62" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; authorized shares &#8212; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_768186fb-e974-49c3-a8cb-090ae480a195" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b95f825-a114-45a3-84b6-97dc1a0b10dc" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at<br/>&#160;&#160;&#160;&#160;December 31, 2023 and December 31, 2022, respectively; issued and outstanding <br/>&#160;&#160;&#160;shares &#8212; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5326080-1267-4be6-b1cc-14008dd8be7c" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c4f66fcc-cc3b-4c1b-aab2-f47b7c73d092" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,269,976</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e09adac0-faf8-4051-b8fb-00d907445b71" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4c792344-82bb-45b4-b559-03ff3dee32d9" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,125,250</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at December 31, 2023 and December 31, 2022,<br/>&#160;&#160;&#160;respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14bab557-736e-4edc-a635-be879fff0267" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b1bd68-c52b-4c82-87a5-1e728a83cf91" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cb1312e-a900-4302-a026-c160ff926570" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,646</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_759bb0ed-5c1f-4fb5-8823-468b88b542d6" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,737</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc2bcb7c-2685-434f-9949-6efb30679e86" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ad7c9af-3ce6-497a-bbc8-d519cc5c8527" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">236,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; deficit</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_489465de-0503-4782-9d97-c22b1e4adc57" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">809</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b001e6c7-cd2a-4b28-9453-8adaa6b98cb9" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,151</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6bfe39a-9130-49c0-9140-f5ccfddb8473" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f60f443-1c8d-44f1-8a53-d25c5742036f" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="pl"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.929%;"/>
    <td style="width:1.2%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.198%;"/>
    <td style="width:1%;"/>
    <td style="width:1.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.198%;"/>
    <td style="width:1%;"/>
    <td style="width:1.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.558%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="13" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_651b4d42-19f0-4f8c-94ff-e9d3cb162937" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,045</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_316399da-ba28-4be5-a8e1-f58cee827883" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_bed86c5b-265c-474e-b396-4938148d8b03;"><span style="-sec-ix-hidden:F_dea40108-736c-4212-9bb9-d449f9499fd0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></span></span></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5da84af-45f0-4c4e-953c-cad85a1eed8c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,277</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd986e62-8284-4fa5-9573-acad0ddc14e6" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,888</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f9dcd66-4a87-457c-bbe5-023a1cca8636" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4005ed30-6664-459b-a108-697890dfac8f" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f2846d5-c240-4753-b701-c6bc04e71f42" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23e46a52-781a-42b1-adde-a675b1cfb5d0" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,547</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Arbitration success fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3db47e11-ebbc-45e7-9f06-106c2de36918" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ArbitrationSuccessFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a73e09-ff03-4e5a-9114-77555436f2c8" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dfc8ecf-90a5-45e0-85f1-aa84e0271c86" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,894</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dea56bd9-8592-45c1-a626-f4aa4954d811" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,693</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0399574e-158d-437e-b179-bbac64faf0f4" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,273</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c962dcac-8ae5-462a-b2d6-c80d71908a8f" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,894</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0cf1b89-5f36-45d5-93b5-6508f814dfa2" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ab6592a-e2df-4ff0-8f26-35f7e76a9201" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbfc5b15-fa99-42bd-abd2-3f5e236886ff" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">994</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37dbfb01-9728-4727-a5b2-d80a9ac46a21" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b2e44b1-60eb-4b90-93f4-bd2b74a9bc60" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5ddd61d-a9e7-4ed5-ae90-dff73712f9f4" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af377011-999e-44d8-9b99-810debc0f5b1" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d3d4490-bf59-47b5-9a6b-97efbf46fb30" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7313d02e-a36f-4b48-9e3c-32efbae8b109" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,241</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4c44370-51fd-4a84-8601-cd96dd85ece7" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43afa32d-9805-466a-adbf-9b0474155b6b" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63375cd5-6f55-4389-bf48-69a06a11c3ac" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20b14af3-4b38-4c0b-a23b-56b61946d62c" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aea65718-bc00-49c3-b3f9-a447bdd4e3ce" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f5284f79-c3a1-4080-bc29-edc74390aa64" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47b038c3-2fbe-4ae7-b6ff-4fd34f55bcb9" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_63355943-ff38-4241-999a-794bb163344f" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.39</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fe7f604-0405-4a99-8d0a-0ce208d78741" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c8c128b-8ade-4797-9949-1e42bd8c6041" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.66</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_516f522d-e9a8-4d50-a799-3d01a910c66a" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_411df331-7c61-4657-a0da-d62dba103e17" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">32,745,708</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ccd0023-10b6-4771-afc7-7d42a100e20b" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7f3df95d-c199-4b68-93a2-2a956c1ad900" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,919,118</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_184dbb4b-f856-4312-88dc-4c8b5340049c" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_66199b1b-4575-4fc4-a1ae-bd0e6ba2b9cf" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,252,637</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="equity_stmt"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.391%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.099%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:3.979%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:7.577999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:9.498000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:9.498000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.2%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity (Deficit)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bf797ae-2b9b-47a8-ac54-590290659ed2" contextRef="C_55363737-381a-4453-8820-38a565d61aac" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,478,787</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_385058f2-2888-4097-8fd3-0a50133f75fa" contextRef="C_55363737-381a-4453-8820-38a565d61aac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec67289e-2430-4429-bb4b-7528c808e2dc" contextRef="C_9fba94f6-47dd-4e8a-9960-b690725bb795" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,166</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a73d82cd-cb8b-47a7-8326-a1bb68e5c7ca" contextRef="C_70a6deb7-5ef8-433d-a7ac-fd7f122fe2e8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">179,109</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33a89216-ac9a-4d94-92af-1d6b90625a1b" contextRef="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1078b15e-14e2-44b0-9dc8-4b581d400a60" contextRef="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,414</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1e3b2de-5556-434e-ae36-0c6d24a31b3f" contextRef="C_b3b2c60e-9c95-477b-af58-492387fc1056" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bdb8c73-2776-458b-8c87-2c0f899b13fb" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3f11916-6ac8-4351-bbad-c6d1b60f4342" contextRef="C_b3b2c60e-9c95-477b-af58-492387fc1056" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ade47460-4943-460f-a25f-c269c1da2d88" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee5605c4-60af-49cb-9300-bef6c93871bf" contextRef="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1" name="tcon:IssuancesOfCommonStockNetOfOfferingCostsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,926,702</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a4c1a7d-3d36-4d53-8d5d-9228d7a2c5cd" contextRef="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1" name="tcon:IssuancesOfCommonStockNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c458734c-b021-46e7-95a9-bad59bb76011" contextRef="C_b3b2c60e-9c95-477b-af58-492387fc1056" name="tcon:IssuancesOfCommonStockNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a55b348e-5b18-4116-89c5-27052e01810b" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:IssuancesOfCommonStockNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8522c302-d95e-4fb6-a910-7e5c94d22a12" contextRef="C_f785d70c-45d9-4158-b4cc-5971017cd60b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,667</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_645735e2-93fd-4712-ad62-19ab967df636" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,667</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c67a7a7-3f16-49c6-afb9-21a74da04d45" contextRef="C_475df304-3dbb-4958-a84d-d4bcdf488834" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">19,445,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9595163e-da59-4a7c-bd01-8e62ab416d0f" contextRef="C_475df304-3dbb-4958-a84d-d4bcdf488834" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d09faa4b-44ed-4a52-99e1-aa736f960c42" contextRef="C_74db5b1f-1c60-43e0-86e8-20cdd644d6d0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a6519a2-e298-4a15-acfe-dee9076920d5" contextRef="C_050dae8e-e369-4b11-afe6-d1549da44936" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,776</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b7907af-9669-40a6-9648-da0a4c1a5d3a" contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,714</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under equity plans</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_545e9483-87fa-461a-9af5-54dc6531d19f" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,261</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f1cd178-f3a6-472a-8931-8eb63c8a8fcb" contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba7588b5-4a78-4214-b7c6-286b22198b59" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe23c254-4daf-47c0-abfd-b896d307cf61" contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed6d856e-9729-4d0f-bdc8-78dcdceda621" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock and warrants, net of offering costs</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a912b4a8-1656-4c85-8ed3-6001f719dc2f" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,232,418</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee10c2aa-99b6-45a7-b678-93f5111c8bb9" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59fa3880-ece0-469d-9ae8-3bad6604d041" contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,871</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62c5a3aa-14b8-4155-b150-2495aa2a5a70" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon cashless exercise of pre-funded warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a51492cc-828d-4574-b0ff-5e78be70d9c1" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">390,668</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d2473e8-0404-4803-b53d-99035326e265" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b454bb3-ef73-473b-a73c-de708b6f6cf7" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock warrants in connection with debt financing</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a69c6573-a9fb-46eb-9b23-0f88dda370c5" contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3175c419-1b77-4c89-b0d2-150c5b48c38d" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f04fb4b-aefd-4bc8-b10a-57ae23511aad" contextRef="C_af96e684-e605-4756-a75e-d1a500792e14" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90b0c5d1-6c22-4f16-baf9-de16738d1f0d" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9973d71e-0279-474e-829e-2fb117131637" contextRef="C_0a421996-059e-47aa-914f-9c7cd5e3b7d5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,125,250</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fd2f930-c16b-42c7-93d8-0dcf057aad09" contextRef="C_0a421996-059e-47aa-914f-9c7cd5e3b7d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1ae1733-2695-47fd-8361-de143ca0604f" contextRef="C_38834898-65ec-45e0-a908-a6b01f5f5240" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,737</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79768a71-6cf3-4e23-b649-e3e1b91917a2" contextRef="C_42ea9fad-5f3b-4079-b265-ececb47bd4b6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">236,911</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80c763ad-26df-4bc0-a275-6d90d99fe7b2" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,151</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b2a8d24-0f20-4ed8-8fc9-49b3b99a1478" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">45,569</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3938729a-fda6-460a-adbc-42d23f9dc682" contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e700193b-0aa4-4fbb-b026-3c792d71f4f6" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f65a4f39-c6fe-48e9-8dfe-34b3893f015b" contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,969</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61275293-c071-4814-89dc-ac84e67418f7" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,969</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock and warrants, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a137a5fd-f5ce-432b-b406-95c895b32d03" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,231,653</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cfea3cc-af42-40cb-be33-8877df559a1f" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6570aebe-b2e6-4d3b-b6a6-db2a9ab09bf3" contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,902</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d6fc045-bcaa-493f-80c6-3b19e9b86f31" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,916</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon cashless exercise of pre-funded warrants</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30dd7cfc-30a9-463e-815b-4ffdb4fb1038" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,867,504</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5f6f452-daeb-46aa-81ba-11f717022cfb" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16619424-73b7-45d5-90a7-7039f848e7c2" contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58dd05b8-6954-4cac-9ff0-03b11072a426" contextRef="C_40c3a24d-66cc-419c-a6ce-68d4a1b37552" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d1651a0-3738-4ed9-a8e5-cd12770999ba" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe073bf8-0a7d-4000-9fb1-9ed0ebbd1427" contextRef="C_0c28515c-df0f-44e6-bbaa-f389e653f073" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">44,269,976</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76b572c0-ede3-4ccf-8d33-906d69c02ad1" contextRef="C_0c28515c-df0f-44e6-bbaa-f389e653f073" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b7fed4b-1fe3-43df-b28e-81afaeaea877" contextRef="C_af8d7bab-03a5-4ea5-b757-607eeb29fa0c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,646</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bc238aa-3462-423e-88a7-4e2ac192e7ef" contextRef="C_948e03ad-dcda-4e45-bb27-1fb7cf42583e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,499</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44a50f06-a1f3-4344-abf2-d966eaf0f9a8" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">809</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cashflow"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.992%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:10.622%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:10.622%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:10.622%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_602f8af8-252b-4c63-b762-4eea019b00ba" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95d02305-ae02-4fae-80d7-256de5497c67" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_125da621-a44d-443e-b77d-5a6c489465fb" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f16c4011-420d-4abc-9f39-0432e7811921" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_854a6634-60b9-4dc3-82ad-bb49976d24e0" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfe69fae-b4b4-4d34-a627-b02560deedb7" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ed3b137-4890-4db4-b206-17399f3538d3" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_384aad4a-6a32-43d4-bee8-2567b48e8d04" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_488f76cc-420e-41ba-8170-64e2c6bfba5d" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncash interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50d09403-f958-4313-b5c0-9df0b24e2090" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:InterestExpenseNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e8ffe48-83fc-4c01-99a6-38e8b95df899" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:InterestExpenseNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81e1dce6-0f52-4b0f-8146-7ca2856b1b73" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:InterestExpenseNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec2155b1-00ba-4bd6-a6f1-5080a5044410" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ca069cf-ff92-4de1-a2c4-10cc4a13c06d" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41b65217-f23a-46ec-a3b3-59c0dc58abc2" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premium/discount on short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a51238bf-1b0b-4feb-a52a-82bd7d44e195" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease asset amortization and liability accretion, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95a9dfde-3027-4799-9a74-27410af87723" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:LeaseAssetAmortizationAndLiabilityAccretionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b726622d-c423-423e-a62b-6d23cb4efd8d" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:LeaseAssetAmortizationAndLiabilityAccretionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb8e477b-b4a3-4bf9-8b2a-e10656373959" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:LeaseAssetAmortizationAndLiabilityAccretionNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity ownership license revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb0234bd-6101-4ab8-82a7-d5b905d9f802" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:EquityOwnershipLicenseRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of private company equity ownership</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_958a8f39-9c5f-42a8-a6bb-8fb3868d6ee7" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:ImpairmentOfPrivateCompanyEquityOwnership" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31adb16f-2dfb-4f84-b4dc-1cc5ea93c3b0" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6debfd1-7567-4e51-9172-1d3f93a809c7" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94ce549c-8cf4-4499-9a34-1a961872e86d" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7b094a8-309b-41a4-875e-8f2f35d44045" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08027018-e9dd-49c4-b252-0a608cb927e4" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ae9ec37-cf94-450b-a947-cc06a2fe5b74" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_963ff0dd-46c7-4162-97fe-a8f9753404d3" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4a4efbe-bdbd-47a0-99a4-cd42190e67e5" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f85a76e7-9f73-4b7d-a976-d536e17f51a1" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_518aa0a4-31e9-4422-9e9e-cd94a873224a" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,676</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abdaf322-91ea-42b4-b7e7-095589224dbc" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9fb6e6f-f3e7-4e77-b73a-857ab1866ce3" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,571</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e39de1a-540e-48b3-920a-b3278eebb90f" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f893d9-f694-4545-a5ee-9850bce2246b" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the maturity of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_402e4169-fcd7-4a85-942d-9172bdacafa5" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:ProceedsFromMaturityOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_190e73f1-c115-4788-be82-8f2a6424c9ed" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be73806a-d503-4026-bfd4-bb227cecf209" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from long-term debt and arbitration financing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a069bd0-db5e-4a63-9935-cd8ffe74ff84" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:ProceedsFromLongTermDebtAndArbitrationFinancing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,390</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of long-term debt and arbitration financing payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca265712-a4b3-482a-b29a-bad7ba2dc358" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a936a05-3fb2-4900-b685-f16086eeccf2" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,680</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_543596be-8aa2-4e9d-b844-2cce22e9a930" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of common stock and warrants, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59e51efa-33c6-442c-a1c6-cf54b6aeed03" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,916</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b199c85-9396-47ad-a8ad-120403875ee0" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a84fe79-738e-419e-8f80-07a8b75d4416" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock under equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e4080ff-3a52-47ea-9689-d0d979417153" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c92d0c96-6cd3-4f91-bb4d-0a1c3ff3ef3d" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3611cd2-558a-4840-8df5-c317d721686d" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d9cbb9f-e784-4d34-9417-36cd0cb9f9a7" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e02356b-b567-4c66-9967-65a79c0b1de9" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_682572c8-bb70-4d9a-b731-824d86f22c64" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,560</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332f250a-a340-4314-a026-3d6de931d78d" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,863</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52d50e0b-0026-47ff-8b98-4c9e8a9bce4f" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_579c9ee3-14a2-41cd-a5d5-f73a6b5cfc86" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_062f1301-1bf9-4716-8fe8-b98dfd35fa7d" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff5c546-2e27-4ddd-a678-d50234406e79" contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18141452-b1b1-4c6d-8927-932274060fb5" contextRef="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69717792-f7ba-40d2-8866-99ad2e74ae0e" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,637</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9540037c-32ff-46c1-bd79-230f0663783c" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d3a5fce-60b5-47d2-9e4d-508a7c66161a" contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06a4e669-b12a-4fd1-9847-277e5fd0f0a9" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,491</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64bd2c9b-8c5e-41a6-a3b6-f97ffcd83e91" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecb372b7-0323-4242-ab5e-1298c0f90ad6" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental schedule of noncash investing and financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock warrants in connection with long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f448d33-e679-4999-b648-aa0cc12ef924" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_453d1100-6637-4d26-92fb-fb281bcccc92" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization and Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ebd5d09-c9e0-4fb5-bb52-7092146e5a38" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Business</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc. (TRACON or the Company) was incorporated in the state of Delaware on October 28, 2004. TRACON is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and utilizes its cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, TRACON Pharma Limited and TRACON Pharma International Limited, which were formed in September 2015 and January 2019, respectively, and are currently inactive. All significant intercompany accounts and transactions have been eliminated.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e7849d5-49ea-4ebe-bcad-97df0feb76e2" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has devoted substantially all its efforts to product development, raising capital, and building infrastructure and has not realized revenues from its planned principal operations. The Company has incurred operating losses since inception. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_317a524e-8a7e-48ef-8527-6e6c92d722bb" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">240.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its product candidates and works to develop additional product candidates through research and development programs. At December 31, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93503cee-2923-4a29-8c1f-60a0f47bda96" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d260d85-081e-426e-aa1d-c3285174c94a" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is classified as restricted cash as it is pledged as collateral for the Company&#8217;s obligations under its corporate headquarters facility lease. The Company&#8217;s ability to execute its operating plan through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financings, or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company&#8217;s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, management believes that there is substantial doubt about its ability to continue as a going concern for a period of 12 months following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company plans to continue to fund its losses from operations through its existing cash and cash equivalents, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. In addition, the Company may fund its losses from operations through the Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sales Agreement (the Sales Agreement) the Company entered into with JonesTrading in December 2020, as amended in March 2022, pursuant to which the Company may sell, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed27b498-e2c7-4e1f-bf3b-75d22a4f088f" contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007" name="tcon:MaximumAggregateValueOfStockToBeSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e07e4d29-ea55-4823-8022-a7aaf7fe9402" contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007" name="tcon:RemainingAmountAvailableUnderTheSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the common stock purchase agreement (the LPC Purchase Agreement) the Company entered into with Lincoln Park Capital Fund, LLC (Lincoln Park) in May 2023, pursuant to which the Company may sell, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc0ff916-84ce-4219-bc93-8792c9e935d0" contextRef="C_8c775d2e-ff5c-46f6-b93f-e69459dc4932" name="tcon:MaximumAggregateValueOfStockToBeSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_037b4983-21a2-4c05-a5b6-bba5d4b49d1d" contextRef="C_8c775d2e-ff5c-46f6-b93f-e69459dc4932" name="tcon:RemainingAmountAvailableUnderTheSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a88de92-2989-4ef0-9c63-0f06fa850658" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global economic and business activities continue to face widespread macroeconomic uncertainties, including labor shortages, inflation and monetary supply shifts, recession risks and potential disruptions from the Russia-Ukraine conflict. The Company continues to actively monitor the impact of these macroeconomic factors on its financial condition, liquidity, operations, and workforce. The extent of the impact of these factors on the Company&#8217;s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company&#8217;s business</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b31ae96-86da-4da9-adff-d3d7c39e4c42" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company&#8217;s consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5aeafb44-b912-4f61-a9a6-5065975d58bb" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these investments. Cash and cash equivalents include cash in readily available checking and money market funds.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f77be179-151c-43ec-8f98-b5a50db7dbc2" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of money market funds held by the Company&#8217;s financial institution as collateral for the Company&#8217;s obligations under its facility lease for the Company&#8217;s corporate headquarters in San Diego, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f4e0964-09c7-4aac-8e1b-d2dcda519d92" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7470ac2-ad67-44cd-bef7-5e54ee0705a8" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets, which is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1067d166-b835-46a1-aa90-bef94380caed" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or estimated useful life of the related assets. Repairs and maintenance costs are charged to expense as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a19bda86-6496-4846-b64f-5e79dd7c7657" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are recorded as other assets, accounts payable and accrued expenses, and other long-term liabilities within the consolidated balance sheet. The Company currently does not have any finance leases.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#8217;s leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db03bc94-a9ea-4250-a128-7282210e3378" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company&#8217;s revenue has been derived from license and collaboration agreements. The terms of these arrangements included payments to the Company for the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. In accordance with Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 606), the Company performs the following five steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.  The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. Once a contract is determined to be within the scope of ASC 606, at contract inception the Company assesses the goods or services promised within the contract to determine those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of intellectual property:  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method.  Performance milestone payments represent a form of variable consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Achievement of milestones that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis and the Company recognizes revenue as or when the performance obligations under the contract are satisfied.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing Supply Services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its out-licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company receives payments from its collaborators based on billing schedules established in each contract. Up-front and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its collaboration arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eea23f10-dab4-4e99-b3db-9a7fdbc3573c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ClinicalTrialExpenseAccrualsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Expense Accruals</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the Company&#8217;s consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s objective is to reflect the appropriate trial expenses in its consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with the clinical sites and applicable personnel and outside service providers as to the progress or state of consummation of trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s clinical trial accruals are dependent upon accurate reporting by clinical sites and other third-party vendors. Although the Company does not expect its estimates to differ materially from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were no material adjustments to the Company&#8217;s prior period estimates of accrued expenses for clinical trials.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccf9b642-d4be-495b-bbc6-d40710d15086" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs, including license fees, are expensed as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f5f7599-cdb8-4989-8fe9-df5eef8ef874" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:PatentCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b806a6c-d2a7-4dcf-86c6-68baa6e46844" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the grant date fair value of employee stock option grants, employee restricted stock unit grants (RSUs), and employee stock purchase plan (ESPP) rights recognized as expense over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and ESPP rights using the Black-Scholes option pricing model. The fair value of RSUs is based on the closing sales price for such stock on the date of grant. Equity award forfeitures are recorded as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f54a350-86d5-455f-b4bb-f0bfe0c1c830" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than&#8209;not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_165a1fa2-373e-4003-8229-03c8f2e7c495" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and comprehensive loss were the same for all periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c7cf2d8-dd85-462a-8c31-8cededb79d0d" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted average number of shares of common stock outstanding that are subject to repurchase. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3618f84-2319-45fa-a0a5-aee55e071eaf" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.62%;"/>
          <td style="width:1%;"/>
          <td style="width:13.6%;"/>
          <td style="width:1%;"/>
          <td style="width:1.18%;"/>
          <td style="width:1%;"/>
          <td style="width:13.6%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a814dcd8-c6ba-4b5f-9066-5305ff8cf620" contextRef="C_c3f43995-11fa-4df2-a9ec-f4edd6b8a5b2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,533,293</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed3e3185-91d1-4e0d-a529-0afae35febbf" contextRef="C_a62feee6-1322-4bcf-9874-c9bc8fbcda7d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,766,246</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_948949bc-e666-45de-8142-3108f3910bde" contextRef="C_e8c5c302-7618-485c-9ff6-32bd1855c0cd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,121,152</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d8425c-5211-414e-adcd-398b16d18dc5" contextRef="C_fa2d3186-d82c-44fe-9ee7-07c5a15c9315" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,246,310</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP shares</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bee2a68-8c2f-453f-9751-d17fea3d63b9" contextRef="C_3d0aab07-6eea-4e52-afb9-65f4dc53f96e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,444</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1086ceb6-44b3-4fb7-9cc1-b17b2427d257" contextRef="C_5ae2450d-d4e4-40a6-b829-f38b64d59da3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,387</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d7d070b-6f20-49a7-90d3-9cee9d8835d7" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,664,889</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5a611a0-5a8d-47e7-9c9a-20d2cbe00137" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,015,943</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b24b8b3-26ac-4e88-b974-0de74d07e0cf" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b028cd23-0f0d-4668-b234-0c6ae352c73e" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95c37d5a-4acd-4dd5-b9dc-f1ceef1a78fa" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Financial Instruments and Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc5f99e8-adfc-4430-9f08-d3f8447a2142" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, which are classified as equity securities, and restricted cash consisted of the following (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.367%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:4.941000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:4.941000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:4.941000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:5.981%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:4.941000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:4.941000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:4.941000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:6.0009999999999994%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized (Loss)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized (Loss)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fbf51c7-84b8-4cbf-8874-b1d777bc6f64" contextRef="C_2872028b-ba94-482c-8437-c4832c35599a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91154500-a32a-4b62-aa39-54fed72e833f" contextRef="C_2872028b-ba94-482c-8437-c4832c35599a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b620f6a-aa14-4bd9-bd11-b4631b39f3f8" contextRef="C_9d44d79c-a241-471f-bb27-6c48118f0d44" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_151637e6-131d-4c7e-bd89-75ecdeb90f8e" contextRef="C_9d44d79c-a241-471f-bb27-6c48118f0d44" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0be0b736-8c7d-4b4f-b7d7-41f49377bdc8" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,616</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bbfb9bf-3787-479a-b264-4e4008857c9c" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,083</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f18d95ef-aacc-4f2e-a70d-cdf77e1f07a3" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="tcon:RestrictedCashFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7434d50-59a0-4fc8-9ed4-939e1b015df6" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:RestrictedCashFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77fb99fd-1cbd-4ab8-b4ef-58eba35285df" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="tcon:CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7441b99-8cd7-498f-81d8-7016cf6d0c39" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,150</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f87e7ebe-a985-47e3-8eae-dac7166f05d1" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash and cash equivalents, prepaid and other assets, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1:	Observable inputs such as quoted prices in active markets.</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2:	Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d7ad7ee-07a6-4a2e-8d13-14cfd239f527" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="tcon:FairValueTransfersBetweenLevelsAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between levels have occurred during the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bb5d043-196e-467b-b380-ace7707983e1" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the Company&#8217;s assets and liabilities, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.09%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:8.798%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:8.798%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:8.798%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:8.798%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Active Markets</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">for Identical</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_697e4c5e-3efa-46c6-8c71-4fd75d47efdc" contextRef="C_aa5025a8-1fb4-4cdf-bae0-549dd0c077ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb48eb2f-eb16-4fa4-afbb-abeb07f0866c" contextRef="C_f632fdf6-d5bb-47f5-b665-011709762d71" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3385f62-d85b-46e3-a245-2d0a5895e371" contextRef="C_7ac1269c-37c7-4ba8-ad75-d74191163fc4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adfa59ff-70ce-4eb7-9c43-d3a056f92975" contextRef="C_4da012b8-a385-42a2-9bf0-9a586e2e0ba2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5da60362-22af-4f79-a4b0-314dd20546da" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:BalanceSheetRelatedDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Balance Sheet Details</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b13a3fa2-3ed9-410c-8538-424764912891" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ScheduleOfPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b69b83b-8e82-4e91-9021-565d3c4bbfa0" contextRef="C_25f6f616-38af-477d-9616-f204a98ff0ba" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cdbd4cb-f7a0-4ab7-9a93-9199b49ef5f6" contextRef="C_ac868d35-ee5d-4979-85bb-00dafa76357d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9722eca0-e1ef-415a-b040-1c4aac617bb8" contextRef="C_afe12a9f-a1ba-4eb0-8945-f294141cf382" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fb17be6-2851-4356-884b-88df6637b3d0" contextRef="C_18ad7425-f5b0-4ca5-b02f-4051b623fbc5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd07181d-69cc-4074-97cf-89a8f1ca4624" contextRef="C_e8c41e95-942f-4e44-ae98-385347e4f1c0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be628cf5-5de0-4c22-87e5-73f7a2a69bb1" contextRef="C_88b652d5-3be6-4a6b-aa98-270cb604d499" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f47a13e-45a5-4dc1-81e1-2ffcd1b48dc0" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_422a6ff3-2c17-416f-b590-e28486d529ac" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3bb68b0-bb2a-4a6a-b491-44608a9b4615" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22924ae0-9210-44c3-9b4c-40c8b2ff5fa7" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd80bdd7-71cb-4060-be56-27aed5a7be56" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6940a508-38e4-4d2c-b9e9-e2d42074a18d" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense related to property and equipment totaled approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64b3657f-659d-456b-b63b-68946759d4e7" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f7b1f7-8782-4554-9c73-252f10c08a44" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba70183-52aa-4155-85dd-bf6af6d11b1d" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts payable and accrued expenses</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7bae144-282b-4e02-b52a-b71e372477b5" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff87433a-12b8-4a16-8558-a71bf72427bd" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,544</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdeab0a3-67c9-45e4-a3b0-82e8c2ad04d1" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53f3e68c-020b-450f-add3-af9da523304f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,736</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f400bcb-d963-4b0a-b60e-8bc60e5fc230" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal and accounting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38ab88c7-14ff-4d96-8d9b-49df9547ebaa" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_118c3c09-aa0f-4f52-b325-77527541aea1" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">299</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued long-term debt terminal interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba0693a-f736-42de-8c72-162219b0befd" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:AccruedLongTermDebtTerminalInterestCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4313ae60-5a9e-4c2b-a0b2-5c716736f08a" contextRef="C_2fe7dfff-ab8a-41ec-b669-52df31405891" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b9df6df-7ede-41ac-b04d-345ab586ec01" contextRef="C_753dbf14-c0c8-4d2d-b958-384acd243082" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8661689-cca7-41de-b27b-e7368873276a" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4f8a5e0-78fc-4273-9b04-e396d7a166d0" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e4eb5d3-8ebc-447a-a186-76b074133079" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,755</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5fc3d7a-c113-43ed-b366-ec52d89ec6f2" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,107</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74d0207f-b124-47a7-84a4-cbe75332170b" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Long-Term Debt</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Arbitration Financing Investment Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the Company entered into a non-recourse financing agreement (the Investment Agreement) with certain investors (collectively, the Investors) pursuant to which the Investors agreed to pay the Company a maximum aggregate amount (Maximum Capital) equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19a90205-1b72-4250-8325-ad596e1d5fa9" contextRef="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9" name="tcon:MaximumCapitalContribution" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or a lesser amount based on the amount awarded (Arbitration Award), if any, to the Company in connection with its arbitration proceeding (the Arbitration) with I-Mab Biopharma (I-Mab). Of the Maximum Capital, (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_529e66e9-157c-452c-a692-5fdf969d4257" contextRef="C_dee76b1c-3511-482e-af8c-baca4374550b" name="tcon:InitialCapitalContributionFromInvestors" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (Initial Capital) was paid to the Company shortly after execution, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02885daf-8205-45bd-81aa-37cee8043cc1" contextRef="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9" name="tcon:PercentageOfInitialCapitalContributionFromInvestors" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% was to be paid to the Company within 15 business days of issuance of an Arbitration Award, subject to the Arbitration Award size exceeding a prespecified threshold and satisfaction of other conditions set forth in the Investment Agreement, and (iii) the remainder was to be paid to the Company in tranches over a multi-year period, subject to the issuance of an Arbitration Award and the Arbitration Award size exceeding a prespecified threshold and satisfaction of other conditions set forth in the Investment Agreement. In connection with the execution of the Investment Agreement and funding of the Initial Capital amount, the Company paid a closing fee in the amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0839c8fa-6fcd-4b2f-9661-28d67cb4d596" contextRef="C_dee76b1c-3511-482e-af8c-baca4374550b" name="tcon:PercentageOfClosingFeeAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. In April 2023, the Company received notification of the Arbitration Award resulting from the Arbitration. As the Arbitration Award did not exceed the prespecified thresholds under the Investment Agreement, the Company will not receive any additional funds under the Investment Agreement such that, as of date of the Arbitration Award, the Maximum Capital is equal to the Initial Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to and contingent on the Company&#8217;s actual recovery of proceeds from an Arbitration Award or any contemporaneously resolved settlements with I-Mab and following the payment of applicable attorney&#8217;s fees (the Proceeds), the Company was required to pay the Investors an amount (Repayment Amount) equal to the sum of (i) all amounts paid by the Investors to or on behalf of the Company pursuant to the Investment Agreement, plus (ii) a low sub-single digit to low single digit multiple calculated on each tranche of Maximum Capital actually paid by the Investors to or on behalf of the Company with the applicable multiple being based on the timing of payment from the Company and whether certain events relating to the Arbitration occurred, plus (iii) a mid-teen percentage annual rate of return on the amounts set forth in clauses (i) and (ii) that begins to accrue if the amounts are not paid by the Company to the Investors within a multi-month period specified in the Investment Agreement. If the amount of Proceeds are less than the Repayment Amount, then the Company was only required to pay to the Investors the Proceeds recovered (other than in circumstances in which the Company accepts a settlement offer that resolves the Arbitration for an amount less than the Repayment Amount without the prior written consent of the Investors), and in the circumstance in which there are no Proceeds then the Company was not required to pay the Investors any Repayment Amounts and the Investors have no right of recourse or right of action against the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the Investors funded the Initial Capital amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03aaac48-7808-4b92-9df8-f19fee9c6592" contextRef="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9" name="tcon:ArbitrationFinancingPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which was recorded as arbitration financing payable on the consolidated balance sheets, net of debt discount, including the Initial Capital closing fee, and amortized over the estimated term of the agreement using the effective interest method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company agreed to and collected a settlement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15c76efc-631b-40fe-94e7-c43583a63e8b" contextRef="C_f6b50908-851a-401b-87d4-7d20d639276e" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in full satisfaction of the Arbitration Award. The Company determined an effective interest rate and term over which the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related debt discount was amortized based on the known timing of collection of the proceeds from the Arbitration Award resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c17ef000-8ed0-4bbf-915e-22cea87d6a62" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ArbitrationAwardInterestExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f interest being recognized during the year ended December 31, 2023. At December 31, 2023, the arbitration financing investment agreement was paid in full and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa00f297-8a32-404b-85c2-aa98c844939c" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="tcon:ArbitrationFinancingPayable" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> future amounts were owed.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Runway Growth Finance Corp. Loan and Security Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company entered into a loan and security agreement (the RGC Loan Agreement) with Runway Growth Finance Corp. (RGC). The RGC Loan Agreement was a long-term debt facility that provided a term loan commitment in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32c0a6a3-e117-44c7-8661-1bb39d83ab11" contextRef="C_6bcf6ae1-6f62-4022-a841-9cb5606b41f4" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_080504ff-2ce9-466e-bcb8-b161ace2c5be" contextRef="C_a0cfd32a-d85b-4d8a-9619-e9e603c0063b" name="tcon:NumberOfTranche" unitRef="U_Tranche" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tranches: (i) a Term A loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bc09844-2715-47d6-a8c0-051a3d2309eb" contextRef="C_b0b548c4-d2f9-43e6-8243-8c33b7859be8" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with the full amount funded in a single disbursement on closing of the RGC Loan Agreement and repaid in January 2023 in connection with the Investment Agreement; (ii) a Term B loan in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_781bcfa5-c7f3-401e-aacd-e68bc520a355" contextRef="C_7c23779b-d204-40a0-a57c-ba7a3fd5104a" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to be funded in one or more disbursements at the request of the Company on or prior to June 30, 2024, subject to certain conditions being met; and (iii) a Term C loan in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c70aa2b1-886a-4135-b74a-9639efc8fb19" contextRef="C_871edb40-17b4-426d-9503-2ecbf34f60e9" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that may be disbursed in a single disbursement in the lender&#8217;s sole discretion upon the Company&#8217;s request at any time from closing of the RGC Loan Agreement through and including December 31, 2024. In December 2022, the Company and RGC amended the RGC Loan Agreement (the RGC Loan Amendment) under which: (i) the Company repaid all amounts of principal and accrued but unpaid interest in respect of the Term A Loan (as defined in the RGC Loan Agreement) on January 3, 2023 without the obligation for the Company to pay the final payment fee or the prepayment fee described in the RGC Loan Agreement; (ii) on or before March 31, 2023, at the Company&#8217;s request, if the Company has raised at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c000889-67e2-45fd-86d4-1585e0a6e878" contextRef="C_c4946e13-3da8-4743-9ee6-bc34ada03788" name="us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net cash proceeds from certain equity or debt transactions (including amounts raised in connection with the Investment Agreement) prior to making such request, RGC will loan to the Company an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc735f88-8afd-46bc-a1dd-780d6fcc6013" contextRef="C_36e936e9-4748-422c-af13-03094cd386a4" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with the full amount funded in a single disbursement; (iii) the Company will not issue an additional warrant to RGC in connection with the loan, if any, described in clause (ii) above; and (iv) RGC&#8217;s security interest in Specific Collateral was subordinated to the arbitration financing Investors&#8217; security interest in the Specific Collateral. If the loan described in clause (ii) above is not made by March 31, 2023, the RGC Loan Agreement will terminate on that date, and the Company will not be obligated to pay the prepayment fee described in the RGC Loan Agreement but the final payment fee of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f82bd807-b127-415f-b90c-4f7bfddaf80f" contextRef="C_ce6896ec-3d61-4ba8-b0f3-65531cd77796" name="tcon:PercentageOfFinalPaymentFee" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the funded term loans as described in the RCG Loan Agreement will become immediately due and payable. All other material terms and conditions of the RGC Loan Agreement remained unchanged and the transaction was accounted for as a debt modification. On April 5, 2023, the Company and RGC amended the RGC Loan Agreement effective March 31, 2023 such that the Company would have until April 15, 2023 to raise at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe55f2d8-c290-4813-92f5-4a1f88709236" contextRef="C_0094047e-e7f2-42e3-a4eb-0ed27b0d1e40" name="us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net cash proceeds from certain equity or debt transactions prior to making a request of RGC to redraw an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7af7516-d344-4d9b-8c67-427525c4df51" contextRef="C_aa5fbb77-e965-4baf-b389-6c9224794641" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the RGC Loan Agreement, which RGC may, in its sole and absolute discretion, allow or deny. On April 20, 2023, the Company and RGC amended the RGC Loan Agreement effective April 15, 2023 to extend the time period described in the foregoing sentence from April 15, 2023 to April 28, 2023. The Company did not redraw the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a2a6db4-96d0-4282-8fbd-8f3e9281466b" contextRef="C_2f47e236-54b6-4d53-9564-adba4ece78af" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the RGC Loan Agreement, as amended, by April 28, 2023, resulting in the RGC Loan Agreement terminating and the final payment fee becoming immediately due and payable on that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the funding of the Term A loan, the Company issued RGC warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ccd0705-ee3c-4342-aafd-fe129cb9bc3c" contextRef="C_3b34aed6-5a9c-4e22-8703-226017dd6deb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,753</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock (the RGC Term A Warrants) at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a6aad33-9de1-46e7-9425-5327b6c74691" contextRef="C_3b34aed6-5a9c-4e22-8703-226017dd6deb" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per underlying share of the Company&#8217;s common stock. The RGC Term A Warrants are fully exercisable in whole or in part at the option of the holder, payable in cash or on a cashless basis according to the formula set forth in the RGC Term A Warrants, and expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_676bc16b-3010-4365-adae-5ac7e34b8cd4" contextRef="C_3b34aed6-5a9c-4e22-8703-226017dd6deb" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2, 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The fair value of the warrant at the grant date was determined utilizing a Black-Scholes pricing model, recorded as a component of the total debt discount and stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets, and was amortized to interest expense using the effective interest method over the term of the debt.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fa19861-1e14-4eb4-aa3d-5db0fbf3d45e" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, long-term debt and unamortized debt discount balances associated with the RGC Loan Agreement were as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c879cf24-918a-46ea-b197-48c7ea031e02" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less debt discount, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f918502e-7ae1-4797-b028-e4a496f29ebe" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:LongTermDebtNetOfUnamortizedLongTermAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69d2fe68-6214-45a0-9989-94a600f1581b" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:LongTermDebtCurrentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_085667db-92b2-46b5-a0dc-f4dd32f9903a" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:LongTermDebtCurrentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b15a852-edd5-450a-b188-6f5b5ce7516a" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e405e43d-1545-4682-82fd-306eba14f1a0" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the RGC Loan Agreement was paid in full and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50308951-f3d4-4752-81c8-6e40e66501ed" contextRef="C_e523f290-ecdf-4b86-9681-520bb864b996" name="tcon:InterestAndFinalPayment" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> future amounts were owed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Silicon Valley Bank Loan and Security Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2018, the Company entered into a third amendment to its Amended and Restated Loan and Security Agreement with Silicon Valley Bank (the 2018 Amended SVB Loan) under which the Company borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a15a65f-052b-4a61-979f-7585ab66e536" contextRef="C_dadec75d-3635-4b34-97db-e4a9d80be690" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, all of which was immediately used to repay the Company&#8217;s then existing loan with SVB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2018 Amended SVB Loan matured in June 2022 and in accordance with its terms, the Company paid a final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74df8b79-a200-49e0-a6d5-db50db5f2318" contextRef="C_dadec75d-3635-4b34-97db-e4a9d80be690" name="tcon:FinalPaymentOnPayoff" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the payoff of the 2018 Amended SVB Loan. In August 2022, the Company terminated the 2018 Amended SVB Loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbfa3f1b-4a04-4d54-bd2d-0bbbba072286" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" continuedAt="F_bbfa3f1b-4a04-4d54-bd2d-0bbbba072286_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company&#8217;s loan agreements with SVB:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"/>
        <td style="width:2.1%;"/>
        <td style="width:1%;"/>
        <td style="width:23.94%;"/>
        <td style="width:1%;"/>
        <td style="width:2.58%;"/>
        <td style="width:1%;"/>
        <td style="width:23.459999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d73313f0-cca7-42ca-8e55-1188d18c615b" contextRef="C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,669</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b3b708a-1578-4cbe-991c-251e31570595" contextRef="C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">51.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94a9807c-66ae-4eef-9501-ecb369d68c58" contextRef="C_9016afcd-3dde-4d11-9f4f-8fa39038db47" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,906</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5110a429-ac66-4a27-bf88-f3cf6c2a47af" contextRef="C_9016afcd-3dde-4d11-9f4f-8fa39038db47" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">77.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dab5ea98-26ae-4491-87de-1026a2688a65" contextRef="C_12cbadd1-c66c-4148-a655-212d5c0bb0a1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,363</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bb5bf1a-f927-4f81-bba1-a31b868055e6" contextRef="C_12cbadd1-c66c-4148-a655-212d5c0bb0a1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">26.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cdddef6-036a-4fd0-9b93-7936a678e709" contextRef="C_9c65da7a-8508-4963-9ecf-2e2bffdab2b5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,938</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ea94d46-5862-4372-a105-c50610d21531" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various license agreements pursuant to which the Company acquired licenses to certain intellectual property. The agreements generally required an upfront license fee and, in some cases, reimbursement of patent costs. Additionally, under each agreement, the Company may be required to pay annual maintenance fees, royalties, milestone payments and sublicensing fees. Each license agreement is generally cancelable by the Company, given appropriate prior written notice. At December 31, 2023, potential future milestone payments under these agreements totaled an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03ffe534-ea5d-4cf5-80bf-70a09b991c6b" contextRef="C_3bdfeab3-03b0-41d5-bcd4-2f2f5ac6bc5f" name="tcon:CollaborativeArrangementsMilestonePaymentsPotential" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dadd8b55-ea52-4f76-9e5b-1fbdd5c6f7c4" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lincoln Park Common Stock Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company and Lincoln Park entered into the LPC Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Lincoln Park is committed to purchase up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1557bc3b-ab21-4372-bd44-a05097508b83" contextRef="C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702" name="tcon:MaximumAggregateValueOfStockToBePurchased" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company's shares of common stock from time to time and at the Company&#8217;s sole discretion over the term of the LPC Purchase Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84d64a69-aaf2-4cc2-a3e5-5c369f94571e" contextRef="C_c703b19c-a29e-4412-99b9-5310a244f3a2" name="tcon:RemainingAmountAvailableUnderTheSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of December 31, 2023. In consideration for entering into the LPC Purchase Agreement, concurrently with the execution of the LPC Purchase Agreement, the Company issued to Lincoln Park </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e3a4233-f0f3-472f-967a-25d51ddbd8e3" contextRef="C_0a40186b-dfa3-4450-9805-28d0eb65430b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">599,216</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock as a commitment fee, which was recorded as a component of stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets. Concurrently with entering into the LPC Purchase Agreement, the Company also entered into a Registration Rights Agreement in which the Company agreed to file one or more registration statements as permissible and necessary to register under the Securities Act for resale of the shares of its common stock that may be issued to Lincoln Park under the LPC Purchase Agreement, which occurred in May 2023. In May 2023, the Company also issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba909ff-d18b-475f-8613-26ea487d595a" contextRef="C_1f396fb6-a65f-482a-85ae-a6132f8551fb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,735,207</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the Initial Purchase Shares) of the Company&#8217;s common stock to Lincoln Park pursuant to the LPC Purchase Agreement at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4698f726-dcef-428d-8820-b485ecd35c83" contextRef="C_114c5392-d3f7-41e4-b75e-3aac9f0e4167" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.5763</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Initial Purchase Share resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a97dac-53e9-432b-bf78-8f4b907ed4f1" contextRef="C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company's special meeting of stockholders held in September 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the potential future sale and issuance of shares of the Company&#8217;s common stock to Lincoln Park in accordance with the pricing terms set forth in the LPC Purchase Agreement that could result in Lincoln Park owning in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da4d330b-82eb-4d77-8025-fb38981f2240" contextRef="C_3632bdcc-d356-4f7e-83a3-f74f7f3535fb" name="tcon:PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of the Company&#8217;s common stock outstanding immediately after giving effect to such sale.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sale of Common Stock and Pre-Funded Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55f381b3-c9b8-450f-b67c-5cca884f4ef0" contextRef="C_6cb97554-1115-4af1-8cfc-e45b449853ca" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">174,508</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_320a3e2d-8e64-4b1d-acda-7175829dfce9" contextRef="C_ef2536be-eee0-447c-816b-aa4f24348c47" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.38</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7b7a4ee-af33-4195-a7d4-ce13490783a5" contextRef="C_2e8d066a-2058-4cb0-bb65-2e20e51ef896" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,013,999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7251269c-5e6d-40be-9f04-fae4c65345da" contextRef="C_fa0eef6d-4f4f-4aa3-86c1-d8232518e2b4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e3d7e3c-f84f-46c3-b6a4-a76bbeb0bd4d" contextRef="C_3cdaff81-414c-42cf-8429-30f12793a1a2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock (the 2023 Pre-Funded Warrants) for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaf7f97d-edeb-4fad-adfa-8261b92f6e97" contextRef="C_8c670a0a-691a-4b51-b9b6-9c1738acbd91" name="tcon:NetProceedsReceivedFromIssuanceDirectOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in a private placement (the Private Placement) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2023 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c86e9fa6-d689-4e00-900f-99f53cd68d19" contextRef="C_63121456-f0cf-46ef-b24c-282d6b4d3d1d" name="tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise, unless approval by the Company's stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). The 2023 Pre-Funded Warrants were recorded as a component of stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_754c8b77-091c-4ac9-8474-3e09ceb43fdb" contextRef="C_b0dbc715-f6a8-4d77-87d7-e3f962470a0c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">841,989</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2787c2a6-b13d-42f6-be4c-2f843a9cac01" contextRef="C_8336abd2-bdbf-4da8-8873-f9e6e654f71b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_807e879c-4d3b-46fb-b97c-a76a269c6aad" contextRef="C_fbc58ab3-c43d-4ba1-8648-0ac74912cc07" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,205,018</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c576cbf6-0077-4586-9b7c-7bb30cabc1b0" contextRef="C_849890bd-5478-410b-adc7-afb456b7c75e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bbc1870-4bc1-4a73-aa32-7c9519f9bd81" contextRef="C_1e2ed30c-2d9e-4355-9b3f-cda6cfbdfac8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock (the 2022 Pre-Funded Warrants) for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ce15d2f-4631-4ca1-8326-5b1ba23febad" contextRef="C_ada76ad5-45b1-47ad-8d9b-60845220bcd2" name="tcon:NetProceedsReceivedFromIssuanceDirectOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in a registered direct offering (the Offering) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2022 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c720945b-f672-4906-bd97-1a3dddec42d8" contextRef="C_9ab8712e-6090-44da-8908-64f2c34aef15" name="tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise, unless approval by the Company's stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). The 2022 Pre-Funded Warrants were recorded as a component of stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets. In connection with the Offering, the Company amended two existing pre-funded warrants to purchase shares of the Company&#8217;s common stock held by the same institutional healthcare-focused fund to extend the exercise periods and to permit exercise in excess of a similar </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_023abfbc-8866-4eba-bda7-d91bda6dd264" contextRef="C_9ab8712e-6090-44da-8908-64f2c34aef15" name="tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% limit following approval of the Company&#8217;s stockholders of such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the Company's 2023 Annual Meeting held in April 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the issuance of shares of common stock upon the potential future exercise of certain outstanding warrants held by this accredited institutional healthcare-focused fund, including the 2023 Pre-Funded Warrants and the 2022 Pre-Funded Warrants, that would result in it and its affiliates owning in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf73041-4ac8-44ae-b7fc-59ef85187ac5" contextRef="C_63121456-f0cf-46ef-b24c-282d6b4d3d1d" name="tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of common stock outstanding immediately after giving effect to such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-The-Market Issuance Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, as amended in March 2022, the Company entered into a Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sales Agreement (the Sales Agreement) with JonesTrading, pursuant to which it may sell from time to time, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8946c5cb-efaf-41e7-b152-0afad61adf34" contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007" name="tcon:MaximumAggregateValueOfStockToBeSold" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock through JonesTrading, as sales agent or principal, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b436204d-cf1d-4305-b1f1-0cf5e27013f8" contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007" name="tcon:RemainingAmountAvailableUnderTheSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of December 31, 2023. Sales of the Company&#8217;s common stock made pursuant to the Sales Agreement with JonesTrading, if any, will be made on the Nasdaq Capital Market under the Company&#8217;s effective registration statement on Form S-3, subject to limitations on the amount of securities the Company may sell pursuant to its effective registration statement on Form S-3 within any 12-month period, by means of ordinary brokers&#8217; transactions at market prices. Additionally, under the terms of the Sales Agreement, the Company may also sell shares of its common stock through JonesTrading, on the Nasdaq Capital Market or otherwise, at negotiated prices or at prices related to the prevailing market price. JonesTrading will use its commercially reasonable efforts to sell the Company&#8217;s common stock from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay JonesTrading </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2adde181-27af-4c68-af39-1993df1246df" contextRef="C_bf3c9e40-b8ea-4aaf-989b-00a5b9696dd3" name="tcon:PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of gross proceeds for the common stock sold through the Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:continuation id="F_bbfa3f1b-4a04-4d54-bd2d-0bbbba072286_1"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had the following outstanding warrants for the purchase of common stock:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"/>
        <td style="width:2.1%;"/>
        <td style="width:1%;"/>
        <td style="width:23.94%;"/>
        <td style="width:1%;"/>
        <td style="width:2.58%;"/>
        <td style="width:1%;"/>
        <td style="width:23.459999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_533a7a68-bd9a-4ab3-83fc-e84dcd6f416c" contextRef="C_076a27be-5a0e-4964-acbe-3687b701e0a6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,669</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afc24f57-88b9-4a85-81a2-92eb97033adf" contextRef="C_076a27be-5a0e-4964-acbe-3687b701e0a6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">51.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f07f0aa-313b-4f02-b1fb-744899fab3e7" contextRef="C_3707c748-2523-40f2-89ed-37a5e0f02667" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,369,602</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fdc4c2c-f73e-46c2-b201-9c8276395205" contextRef="C_3707c748-2523-40f2-89ed-37a5e0f02667" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">27.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42aed9e4-512b-469d-a0d0-b5df85b1864b" contextRef="C_16e27699-d842-4a09-9bc5-311bdb55cc7f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,906</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49713795-4f9d-4d11-9254-bf6034317e9c" contextRef="C_16e27699-d842-4a09-9bc5-311bdb55cc7f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">77.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4af26c33-1402-4602-b6c4-dd34015f4cdd" contextRef="C_89504bb5-ef30-4956-bf15-4942d09489d7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,363</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_080e1054-4ab1-456a-aa93-4c2d3f3bb5db" contextRef="C_89504bb5-ef30-4956-bf15-4942d09489d7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">26.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2, 2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ac71f78-15c8-45df-ac01-4d6156242bec" contextRef="C_2122e3b2-efd5-46f7-9ea2-4421118c4fa8" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,753</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fc4b108-508e-4e8c-8dfc-6aae566a35b9" contextRef="C_2122e3b2-efd5-46f7-9ea2-4421118c4fa8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.99</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ada29e34-7695-4d74-967b-51e16c597e6b" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,533,293</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:continuation></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4453c47b-8f97-4bbd-82bd-f120159e65a6" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,867,504</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock upon the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37ca99de-22e2-4927-9110-48c4de58f707" contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144" name="tcon:CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,245,984</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants. During the year ended December 31, 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e24214c3-5944-4a47-8a98-067b98b7e24e" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">390,668</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock upon the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_419ac5e7-d869-4659-896a-69c3aa537966" contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b" name="tcon:CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">398,093</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Compensation Plans</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2015, the Company&#8217;s Board adopted the 2015 Equity Incentive Plan (2015 Plan). Under the 2015 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. Initially, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21962738-e7ff-45c4-9413-2b7edfb950db" contextRef="C_b16315b6-4843-44d0-9eb8-3298bc62f493" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,103</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were reserved for issuance under the 2015 Plan. In addition, pursuant to the June 10, 2021 amendment, the number of shares of common stock available for issuance under the 2015 Plan will be annually increased on the first day of each fiscal year during the term of the 2015 Plan, as amended, beginning with the 2022 fiscal year until (and including) January 1, 2031, by an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d535c88-5aae-4df9-9e99-7cfecf574f43" contextRef="C_6f092d4a-d7e5-494a-a9df-840fef3b8d29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year or such lesser amount as the Company&#8217;s Board may determine. The maximum term of the options granted under the 2015 Plan is no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b41a2d45-7729-4da7-b71e-b5297cd41e53" contextRef="C_318cdc34-f5fd-4dd9-b958-8376a005bba1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Grants generally vest at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bebf2c36-df59-49ff-8420-31183ab151fb" contextRef="C_814ee833-9257-47ee-8583-cde42cd6e260" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_117c1059-a034-4797-917a-40f661bd3027" contextRef="C_814ee833-9257-47ee-8583-cde42cd6e260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the vesting commencement date and ratably each month thereafter for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4f04151-d1a4-47c4-8a5d-69bb76153aa2" contextRef="C_0a381d93-758c-43f0-bafa-d1d2c3addbf9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, subject to continuous service. In addition, pursuant to a June 2021 amendment, the 2015 Plan was amended to allow an additional aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbe1924d-9a7b-41f7-abcb-40775f8f9262" contextRef="C_6f092d4a-d7e5-494a-a9df-840fef3b8d29" name="tcon:AdditionalCommonSharesToBeUsedForSpecificAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to be used exclusively for the grant of equity awards as a material inducement for individuals to commence employment at the Company in compliance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0def9fea-8f12-405b-967f-798ba5c38e83" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under all Plans is summarized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f0f3407-d829-42ec-a64b-11459a67f3cd" contextRef="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,246,310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f737813-efa4-4a1a-9475-a1a03acfd1d6" contextRef="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba55af1a-8cdb-4641-873c-fcb8ac0d3792" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,089,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af54f67b-2624-4e75-90a9-32c1e5cdd0f7" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31f96f6d-dd78-40c5-93bb-75aa1dab695d" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">214,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6751dcff-ade5-4fba-b3ae-1379516b2344" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7edf46e7-2c34-49d2-9b54-e64c0daa16f8" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,121,152</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e815994-c74c-4290-8fef-40daf4b8be27" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2abdf6c9-db12-4b2f-b183-614ec8c51e67" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about the Company&#8217;s outstanding stock options as of December 31, 2023 is as follows:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3be1aa63-e0da-4a7e-a0b3-82d79386c8bd" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,121,152</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14e6d5fe-dec7-4792-97a1-f044031f6860" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0bf2371f-2658-47bc-9096-3472e4bbf264" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cad6c732-3621-450d-943e-d0fbee3812a6" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,121,152</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fe702dd-5a1b-4dfb-a991-76f59176f21f" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_074083c2-7fc6-49de-9568-e85eeaad0cf6" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0ffae82-5c43-4d2c-aff5-49b02b9d1dcb" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,446,873</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f91778b-90de-4d37-b6c1-d621588a8c44" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6f746c86-da9a-4f38-9770-c7491dfe43e9" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.47</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of employee option grants during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9000e9cb-17cb-486e-9f09-2d46e579a8a1" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09afae0a-b2cd-4d4a-b511-1c14244dbd87" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5101e14e-7931-4e50-af5c-6bc668b5a3a3" contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The aggregate intrinsic value used in the above table of options at December 31, 2023 is based on the Company&#8217;s closing market price per common share on December 29, 2023, the last business day of the 2023 fiscal year, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e1f714-0429-4b8b-927e-05fa7df50c7c" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.1751</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd0e6043-db7a-4c44-93d8-2e5781110e5f" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_87db1cc5-826b-4ced-8e69-d3c2e7a528c8" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options were exercised during the years ended December 31, 2023 and 2022. The total grant-date fair value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28abab7b-2044-4c2d-92f7-e9183979e094" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc7a3b80-1520-4b63-85f6-76e3fa9efa01" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70c11f46-fe2c-4773-9cb6-3ac74c80af4a" contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchase</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan (ESPP)</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2015, the Company&#8217;s Board adopted the ESPP, which became effective upon the pricing of the Company&#8217;s initial public offering on January 29, 2015. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a949e53-024c-4033-a7dc-aa1a903047ba" contextRef="C_901ce9d0-b622-4dc1-9cc3-0c5fd70773be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible compensation. Initially, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e97544-733b-47a6-87aa-323603349dd2" contextRef="C_577ee070-e073-4976-81d8-6e2937b0617e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,346</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock was reserved for issuance under the ESPP. In addition, pursuant to the June 10, 2021 amendment, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2022 fiscal year, by an amount equal to the lesser of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d005411d-30d8-4545-89e9-c3fb6576994b" contextRef="C_cd3ca734-457b-4506-8892-6849fbff690f" name="tcon:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f40255-c210-4999-b0ea-dc01f17125e4" contextRef="C_cd3ca734-457b-4506-8892-6849fbff690f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (iii) such other amount as the Company&#8217;s Board may determine. Stock compensation expense for the years ended December 31, 2023, 2022 and 2021 related to the ESPP was immaterial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2916e36-6cdf-408e-83f8-e6a1623ae333" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.265%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.564%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.325%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84b75e7f-976d-420f-8909-69cce1dad1a4" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faf2879d-208f-44cb-b6f6-099fffc7eae2" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a0fd96e-4190-4d6a-a776-1ff04b973f5a" contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94d34471-1173-4de9-a553-deac8505bd14" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">90.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d324b4-746e-4f11-9545-7883f078cbb7" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">89.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a2be0d-8a44-42f3-b647-a571cd10f035" contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">90.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_31845c6e-a158-431c-b4f6-92557f1f0e32" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_20575880-788d-401e-8835-0f874afcdc72" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_89d13d26-408f-42c7-a985-5e7d36b76f1f" contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64304e4c-d6fb-4105-b45f-295683b6e271" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f16c6894-d6ad-413e-a9bf-52148d91beea" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b8c5b5f-5144-48f5-b7d4-bc2b440981f7" contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The Company bases the risk&#8209;free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The Company considers its historical volatility when determining the expected volatility.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b0e4bdf-6b26-4e07-b772-501b12325608" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The allocation of stock-based compensation expense was as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.992%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:15.437000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:15.437000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:15.437000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_854412ef-855b-486a-9dc8-0819754b9f54" contextRef="C_3ff50e62-5e4c-4461-884d-ca0bbc261a94" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08213838-eccc-408b-82d0-7eec8796ac7e" contextRef="C_d2b07739-4905-4cff-bd81-929c2939c81e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dba361a8-7109-4d0f-8fe8-47faef45de70" contextRef="C_6c9cb59b-f528-4f05-be7c-a82ef8ff9fa6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a8178f4-e0ce-46d0-817e-f8a20937142f" contextRef="C_44f937fc-97bc-42b8-97d8-361c9c6f366c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,034</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e503db6-e37c-486d-813b-73c21a066872" contextRef="C_7eb1035b-caa0-4638-9b3d-88715a101c8a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbba9155-3dd8-41e7-90f0-db5c82457924" contextRef="C_a70ce266-0b0f-498a-b880-2e0cec4cebe4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce10fa0b-f449-43d0-a174-64babc4ccd07" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce449ec-b694-4498-9066-8053ceacf061" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94975c0b-4c15-4d4b-9cce-08f63a6fd85f" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the unrecognized compensation cost related to outstanding time-based options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d754e9b7-14f4-4ad0-9694-edac2c51aedc" contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b3d5c61-27b7-4e5f-a674-274375e7b668" contextRef="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and is expected to be recognized as expense over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f4b184a-8caa-44aa-9cd5-4dbe4db503e6" contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_845f544f-c2e4-422d-8b4c-7c0f6f4afa7b" contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7b978e6-3dbe-446c-bf97-a4c70a587996" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance was as follows:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d12b374f-009f-45f8-b2f1-4574f3a027c9" contextRef="C_639cfa51-d355-4e4e-883d-a0c36228443f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,533,293</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26e7b2d1-385c-467c-97b7-a988788fa1d7" contextRef="C_62d20795-8235-49dc-84d8-78968b279332" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,766,246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_251cb4e5-a3de-4da6-a4ce-58e5b9c4f697" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,121,152</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db0a1db6-8540-4f03-b0a4-0d7e8e3fddfa" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,246,310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Awards available under the 2015 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfd11edc-3dd9-4086-bcec-c64e9ea58af3" contextRef="C_61e3c61d-6eef-4e6d-be34-c3497437219f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">431,755</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b5c4115-eee5-4d92-9e95-dc823ca99b62" contextRef="C_eafe3fa1-222e-4c1b-81f5-552231208588" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">150,335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available under the Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fd5bde8-8fd7-4aa5-a9d0-2528d814bffc" contextRef="C_a4750715-b498-4b30-8b83-398f57734854" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">429,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb4f80dc-aaac-4333-adde-ae74bbbf7159" contextRef="C_49078ec3-8121-4069-a2aa-dbede8ef99ef" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">243,817</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0ee9742-d028-4adc-808f-7c3cc17efabc" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,515,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_158a651a-65f0-4396-851e-54ae8528c412" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,406,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_005139f5-0d57-4ed6-85d7-9edfb694e87c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Collaboration and License Agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inhibrx, Inc.(Inhibrx) License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Company granted a non-exclusive, non-sublicensable, non-transferable (except in the event of the transfer or sale of all or substantially all of the business or assets of Inhibrx) worldwide perpetual license of its&#8217; CRO-independent product development platform (PDP) to Inhibrx for a nonrefundable upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d726d7d8-e894-478e-8e19-6376f696bbc5" contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839" name="tcon:NonrefundableUpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million plus an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bde662a6-321d-48ac-b443-e3e4bf8fd564" contextRef="C_2497856b-e351-4137-a3e8-c281dd005061" name="tcon:AdditionalPaymentOnPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the completion of certain training. The Company is obligated to be available over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d280e4a4-430a-4b6a-98d9-0c72493b547d" contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839" name="tcon:TrainingPeriodDuration" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period beginning on the date of license transfer to provide up to 500 hours of training to Inhibrx. The PDP license allows Inhibrx to use the Company&#8217;s configuration documentation with a widely used software package in addition to use the Company&#8217;s validation and qualification of the software package and the Company&#8217;s standard operation procedure documents, policies, work instructions, and clinical operation templates in the administration of clinical trials and related research and development activities.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, Inhibrx has sole responsibility for funding and conducting any such clinical trials and related research and development activities. The Company is not obligated to tailor any of the related documentation and is not involved in conducting any of the related clinical trials or research and development activities.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3970eb95-7193-4700-be0b-5d53383db2e8" contextRef="C_96edd94d-e38a-4eb9-8c60-62d39af94ba2" name="tcon:LicenseAgreementTerm"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this agreement and identified multiple promised goods and services, which included at contract inception: (1) the PDP license and (2) up to 500 hours of training over a six-month period. Management evaluated these promised goods and services and determined each was a separate performance obligation. The transaction price at contract inception included fixed consideration of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42db2ae8-9df0-4f87-89c7-4ffc5506d67e" contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839" name="tcon:NonrefundableUpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_250f1e95-33ca-4106-b223-5b18a599cc86" contextRef="C_2497856b-e351-4137-a3e8-c281dd005061" name="tcon:AdditionalPaymentOnPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment due upon the earlier of the completion of 500 hours of training or six months. The total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f7bb44b-6851-4217-8cb0-ab52fbe2e250" contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839" name="tcon:TransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million transaction price was allocated to each performance obligation based on relative standalone selling price. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb67852-70d3-4d0d-9986-3a0668c08a3f" contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839" name="tcon:NonrefundableUpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million amount allocated to the PDP license performance obligation was recognized at the point in time Inhibrx could first use and benefit from the license, which occurred in the fourth quarter of 2023. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca6e20a-17aa-495a-8029-61de2036e5b9" contextRef="C_2497856b-e351-4137-a3e8-c281dd005061" name="tcon:AdditionalPaymentOnPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million amount allocated to the training performance obligation will be recognized over the six-month period in which the Company is obligated to be available to provide training.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eucure and Biocytogen Collaborative Development and Commercialization Agreement</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Company, Eucure (Beijing) Biopharma Co., Ltd. (Eucure) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen), Eucure&#8217;s controlling affiliate, entered into a collaborative development and commercialization agreement (the YH001 Collaboration Agreement) for the development of YH001, a monospecific investigational CTLA-4 antibody.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the YH001 Collaboration Agreement, the Company was granted an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including sarcoma, microsatellite stable colorectal cancer, renal cell carcinoma (RCC), and K-ras positive non-small cell lung cancer (collectively, the Initial Indications) or one or more of bladder cancer, endometrial cancer, and melanoma as substitute indications, which may be substituted for Initial Indications at the Company&#8217;s discretion (each upon such substitution, a Substitute Indication).  The Company is responsible for, and will bear the costs of, preparing and filing all regulatory submissions and conducting any Phase 1, Phase 2, Phase 3, or post-approval clinical trials in North America for YH001 in the Initial Indications and potentially the Substitute Indications, while Eucure is responsible for conducting, and will bear the costs of, the preparation of chemistry, manufacturing and controls activities for YH001. Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to the Company for clinical trials pursuant to the terms of a clinical supply and quality agreement to be separately negotiated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During a specified period, the Company has the option, subject to Eucure&#8217;s prior written approval, to expand the license to include the development and commercialization of YH001 for the treatment, through administration by intravenous or subcutaneous means, of all human and veterinary therapeutic indications in North America for a payment to Eucure in the low single digit millions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will be responsible for commercializing YH001 in North America, including booking of sales revenue in the Initial and Substitute Indications. The Company will owe Eucure escalating double digit royalties on net sales of YH001 in North America ranging from the mid-twenties to mid-double digits; provided that until the end of the first full calendar year following the first commercial sale of YH001, royalties will range from the lower double digits to the mid-double digits. If sales of YH001 exceed a pre-determined sales threshold in the first full year of sales following first commercial sale, the Company will owe a milestone to Eucure in the high single digit millions.  Payment obligations under the YH001 Collaboration Agreement continue on a country-by-country basis until the latest of (i) expiration of the last to expire licensed patent covering YH001, (ii) expiration of marketing or regulatory exclusivity covering YH001 and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52ca0786-18ad-4ea2-8446-deb6673037ff" contextRef="C_3d853f01-db0c-4afc-ac37-748d6a24b52f" name="tcon:CommercialSale" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the first commercial sale of YH001 in such country in North America. Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to the Company at cost plus a low double digit markup for commercial sales pursuant to the terms of a commercial supply and quality agreement to be separately negotiated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">3D Medicines and Alphamab Collaboration and Clinical Trial Agreement</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the Company, 3D Medicines Co., Ltd. (3D Medicines), and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) entered into a collaboration and clinical trial agreement (the Envafolimab Collaboration Agreement) for the development of envafolimab, also known as KN035, an investigational PD-L1 single-domain antibody (sdAb), or nanobody, administered by subcutaneous injection, for the treatment of sarcoma in North America. No consideration was exchanged in the Envafolimab Collaboration Agreement. Given no consideration was exchanged, no value was assigned to the Envafolimab Collaboration Agreement in the accompanying consolidated balance sheets.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Envafolimab Collaboration Agreement, the Company was granted an exclusive license to develop and commercialize envafolimab for the treatment of sarcoma in North America.  The Company is responsible for conducting, and will bear the costs of Phase 1, Phase 2, and Phase 3 or post-approval clinical trials in North America for envafolimab in the indications of refractory and first line treatment of sarcoma. 3D Medicines and Alphamab are responsible for conducting, and will bear the costs of, investigational new drug (IND)-enabling studies (other than those specific to the sarcoma indication) and the preparation of chemistry, manufacturing and controls (CMC) activities sections of an IND application for envafolimab. 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, envafolimab to the Company at pre-negotiated prices that vary based on clinical or commercial use. 3D Medicines and Alphamab retained the right to develop envafolimab in all territories outside of North America as well as within North America for all indications other than sarcoma.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue, unless (a) envafolimab is first approved in North America for an indication other than sarcoma and launched in North America, or (b) envafolimab is first approved in North America for sarcoma and subsequently approved in North America for an additional non-orphan indication and sold commercially by 3D Medicines and/or Alphamab, or a licensee, in which case 3D Medicines and Alphamab will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue. If 3D Medicines and Alphamab become responsible for commercialization under the Envafolimab Collaboration Agreement, the Company has the option to co-market envafolimab for sarcoma in North America. In the event that envafolimab is first approved in North America for sarcoma and within three years of the commercial launch of envafolimab in North America for sarcoma 3D Medicines and Alphamab replace the Company as the party responsible for commercialization, and the Company elects and 3D Medicines and Alphamab agree for the Company to not co-market envafolimab for sarcoma in North America, then 3D Medicine and Alphamab will be required to compensate the Company for its costs associated with preparing for and conducting commercial activities.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company has the responsibility for commercialization under the Envafolimab Collaboration Agreement, the Company will owe 3D Medicines and Alphamab tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits.  If 3D Medicines and Alphamab have responsibility for commercialization under the Envafolimab Collaboration Agreement, the Company will be entitled to (a) escalating double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits if the Company has chosen to not co-market envafolimab in sarcoma or (b) a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cefdca20-9289-40d3-a7b6-42292909e730" contextRef="C_0dde0b8e-4306-4c73-b564-93d2dc9f8a26" name="tcon:RoyaltyPercentageOfNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net sales of envafolimab for sarcoma in North America if the Company has chosen to co-market envafolimab in sarcoma.  Payment obligations under the Envafolimab Collaboration Agreement continue on a country-by-country basis until the last to expire licensed patent covering envafolimab expires.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3D Medicines and Alphamab retain the right to reacquire the rights to envafolimab for sarcoma in North America in connection with an arm&#8217;s length sale to a third party, provided that the sale may not occur prior to completion of a pivotal trial of envafolimab in sarcoma without the Company&#8217;s written consent and the parties must negotiate in good faith and agree to fair compensation to be paid to the Company for the value of and opportunity represented by the required rights.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party agreed that during the term of the Envafolimab Collaboration Agreement, it would not develop or license from any third party a monospecific inhibitor to PD-L1 or PD-1 in sarcoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Envafolimab Collaboration Agreement continues until the later of the date the parties cease further development and commercialization of envafolimab for sarcoma in North America or the expiration of all payment obligations.  The Envafolimab Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to envafolimab.  In the event the Company elects, or a joint steering committee determines, to cease further development or commercialization of envafolimab, or if the Company fails to use commercially reasonable efforts to develop (including progress in clinical trials) and commercialize envafolimab and does not cure such failure within a specified time period, then the Company&#8217;s rights and obligations under the Envafolimab Collaboration Agreement will revert to 3D Medicines and Alphamab.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">I-Mab Collaboration Agreements</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2018, the Company and I-Mab entered into separate strategic collaboration and clinical trial agreements (the I-Mab Collaboration Agreements) for the development of programs for multiple immuno-oncology product candidates, including I-Mab&#8217;s proprietary CD73 antibody TJ004309 (the TJ004309 Agreement) as well as up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a23f8c0a-34bd-4a5e-a244-855436c5eeda" contextRef="C_8f964d2c-14b2-4bc3-b709-922d50a40833" name="tcon:MaximumNumberOfProprietaryAntibodiesUnderDevelopment" unitRef="U_Antibody" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> proprietary bispecific antibodies currently under development by I-Mab (the Bispecific Agreement).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the TJ004309 Agreement, the Company and I-Mab were collaborating on developing the TJ004309 antibody, with the Company bearing the costs of filing an IND and for Phase 1 clinical trials, with the parties sharing costs equally for Phase 2 clinical trials, and with the Company and I-Mab bearing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43b1d06d-bda2-4512-a76b-109e0a2bd55b" contextRef="C_0247f2f4-3917-4a82-af24-9a5bf778c6da" name="tcon:CollaborationAgreementPercentageOfCostBearing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4312ab63-9bc7-4dd1-918a-f9cd2df55466" contextRef="C_0592da9d-0e35-4ada-8b6a-801b2b01bdcf" name="tcon:CollaborationAgreementPercentageOfCostBearing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of the costs for pivotal clinical trials. I-Mab was responsible for the cost of certain non-clinical activities, the drug supply of TJ004309, and any reference drugs used in the clinical trials.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company would be entitled to receive escalating portions of royalty and non-royalty consideration and a royalty based on net sales if I-Mab licenses TJ004309 in certain territories or commercializes TJ004309, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The TJ004309 Agreement was terminatable by either party in the event of an uncured material breach by the other party or bankruptcy of the other party, for safety reasons related to TJ004309 or by I-Mab if the Company causes certain delays in completing a Phase 1 clinical trial. In addition, the TJ004309 Agreement was terminatable by I-Mab for any reason within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88fe0b68-9ec4-4d7e-84bf-6da4c1f05c4d" contextRef="C_dbf3b97c-e0f0-4dfe-8eea-e3775ccab160" name="tcon:TerminationOfAgreementUponCompletionOfClinicalTrial" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days following the completion of the first Phase 1 clinical trial, in which case the Company would be entitled to a minimum termination fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1541b28c-b2db-4b35-94b1-338b9ffbe7cd" contextRef="C_19d1e4ec-58ad-4668-bed8-1390374bb8c1" name="tcon:TerminationFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or following the completion of the first Phase 2 clinical trial, in which case the Company would be entitled to a pre-specified termination fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_689b524d-aa26-46fd-9a4e-119f153ed6a8" contextRef="C_e41e9c0b-0129-486b-9356-bb65e6d7e6e8" name="tcon:TerminationFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and either a percentage of non-royalty consideration I-Mab may receive as part of a license to a third party or an additional payment if TJ004309 is approved for marketing outside Greater China before a third-party license is executed, in addition to a double digit percentage of royalty consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed, in June 2020, I-Mab commenced an arbitration proceeding under the Rules of Arbitration of the International Chamber of Commerce before an arbitration tribunal seated in New York City (the Tribunal) after the Company invoked contractual dispute resolution provisions asserting that I-Mab had breached its contractual obligations under the TJ004309 Agreement and the Bispecific Agreement. In April 2023, the Company received notification from the Tribunal of the Arbitration Award. The Tribunal found in favor of the Company for certain claims and declared the Phase 1 clinical trial of TJ004309 Agreement &#8220;Complete,&#8221; as that term is defined in the TJ004309 Agreement as of January 2022. The Arbitration Award included the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62f567a3-96e1-459a-a44d-f86e0826765f" contextRef="C_1ae2be0d-9dfa-467f-9bce-05b3c0ba56fb" name="tcon:TerminationFeePayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million prespecified termination fee payable by I-Mab under the TJ004309 Agreement, which was collected in July 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company re-evaluated the transaction price as of the end of the reporting period and concluded the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_075f98e0-0ed1-4fb6-ba25-8514fa76346b" contextRef="C_8341fd7b-20e9-4123-b191-98d68cf29a63" name="tcon:TerminationFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million variable consideration associated with the prespecified termination fee was no longer fully constrained as it was determined to be probable that a significant reversal would not occur if the Company recognized the variable consideration as revenue in the current period. Accordingly, the Company recognized the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63bca51e-dee9-43e9-9c2a-e2aeadd03140" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7148ed3a-8abb-4a16-af47-75112a2b7341;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration revenue</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> within the accompanying consolidated statements of operations for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the resolution of the arbitration, the TJ004309 Agreement and the Bispecific Agreement have been terminated and no further revenue will be recognized associated with these agreements.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8b3b212-e28d-401b-816f-1d18c03f547e" contextRef="C_f6b50908-851a-401b-87d4-7d20d639276e" name="tcon:LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million gain associated with the collection of the Arbitration Award in July 2023 consisted of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a665f03e-3540-4349-913b-a559047a0287" contextRef="C_f6b50908-851a-401b-87d4-7d20d639276e" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million collected amount less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f04935f-6460-4853-a0ed-ff87a99b72f3" contextRef="C_c22bb402-0325-47cc-ae07-b1647b8287b1" name="us-gaap:LossContingencyDamagesAwardedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million TJ004309 termination fee recognized as collaboration revenue. The gain has been included within other income, net within the accompanying consolidated statements of operations. Additionally, in connection with the Arbitration, the Company entered into a contingency fee arrangement with its legal counsels whereby counsels agreed to defer a portion of their legal fees (Success Fees) and would receive payment of the Success Fees in full or at a low single digit multiple depending on the amount awarded and contingent upon recovery of proceeds from an Arbitration Award. Success Fees in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9efbff4-56ce-4a72-a517-8ba192f36ff6" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ArbitrationSuccessFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were paid in 2023 and have been included within arbitration success fees within the accompanying consolidated statements of operations. In connection with the settlement, legal counsels also forgave approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab833990-f43f-473d-9ac7-a08c73b37f40" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:LossContingencyPaymentWriteOffAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in related legal invoices.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_731bba8f-1aa0-4a26-8e1c-52a987692537" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Leases</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operating lease obligations relate to its corporate headquarters as the Company leases its office space under a non-cancelable operating lease. The Company amended its lease in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccbce6e9-9636-474c-848d-1ff85fdbc783" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:NonCancelableOperatingLeaseExpirationTerm" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> extending the lease term to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82ee6a93-c200-4608-b7a1-4bd7f8b94ffd" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:NonCancelableOperatingLeaseTermToBeExtended" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease is subject to base lease payments and additional charges for common area maintenance and other costs and includes certain lease incentives and tenant improvement allowances. Operating lease expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91dee6ff-9443-464f-9d49-0f9b667f3fe3" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4ec2f867-3503-4820-857f-395c6ac5fdff" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dec1b580-3d93-4203-a241-8406889e83cf" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the three years ended December 31, 2023, 2022 and 2021. As of December 31, 2023, the Company did not have any finance leases, nor any other operating leases.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3822da41-601c-4a8c-a98f-0591f4274d73" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.7%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.700000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.700000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.700000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid within operating cash flows</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6274e52a-5836-4b9c-a602-7249a1bece68" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:CashPaidWithinOperatingCashFlows" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad11af25-f537-48c5-b06a-164792b8b7ea" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:CashPaidWithinOperatingCashFlows" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_747fa5e6-88aa-4126-a9d1-0d51df92f7dd" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:CashPaidWithinOperatingCashFlows" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU assets recognized in exchange for new lease obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed9c20dc-9ea3-41a0-8654-f0f2c4570e55" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,117</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d27fc73-e4cb-45cb-b82d-09a27621039c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.187%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1%;"/>
        <td style="width:12.786%;"/>
        <td style="width:1%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1%;"/>
        <td style="width:12.786%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reported as:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span><span><span style="-sec-ix-hidden:F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17;"><span style="-sec-ix-hidden:F_b539fbc4-b194-4f51-b5a6-68a58edce5fb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(ROU asset)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e8620eb-0fcb-4d60-8cab-e5f288839fe4" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a31a5b47-4143-47b1-9345-4e086907e0f3" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Accounts payable and accrued expenses (lease liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc1bd56f-446b-48fb-bf7d-4999b19e1f66" contextRef="C_f5feec96-d065-4192-b005-a1dbce905bcf" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55735a2a-ef04-44b1-b9e7-895d7f684461" contextRef="C_e9e0def7-4f33-4329-8019-2a7db36180ce" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Other long-term liabilities (lease liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e95484e2-d7ab-49ca-93b2-963800225754" contextRef="C_46f8a63c-b29e-40ea-8d58-941155df4da0" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07bacb2c-7986-4b58-a70f-019345a9a43a" contextRef="C_ce9c7c28-c3e5-426c-8989-80f05562dd11" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6adabc86-514d-41e7-9ecb-1d943241eae8" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdeaad83-aac8-430c-bc1b-e46165350a31" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_14c76450-f8e1-442a-b4fa-9d00cf26eac1" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d09f7c39-902b-4766-b938-4ad8a979ff3a" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff6588c-8a85-4b5e-b10b-e5bf11d14224" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_820fe716-ca34-45fe-bf38-7da9a1f6a433" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_254f4671-24c9-40de-84b2-dd78a1ad3a9c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="tcon:ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.36%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.700000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f36820a2-8e72-4eef-a278-d7dfa34be2b2" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62ddbf51-844e-4df5-8411-6fdc9afc454f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a98dbec3-1ed5-4594-9f2b-8aacd7375878" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_301401e7-7530-43a8-898d-620938beb9d7" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77d51688-2e3c-461b-8ef5-44eb5b197851" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,171</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e218c22-9c09-4377-a015-d701473493f9" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d824c9d0-b201-4bba-b5da-878e6cba4d26" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Und</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">er the terms of the lease agreement, the Company provided the lessor with an irrevocable letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bb9e27a-0ba7-4c86-b53c-b28956b8e33e" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">73,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e lessor is entitled to draw on the letter of credit in the event of any default by the Company under the terms of the lease.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59603721-fcf9-4cf7-869a-cb7ad852999d" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c81546f6-2a10-4027-a19d-8799a6d4c9dd" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_750b7671-8a5d-458d-baad-1813ae5935b0" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">754</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a0e3ece-05ca-4c37-9c83-969209a0fbe5" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22c55c2b-0320-4cfe-bf90-af1a98c971d8" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,020</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a68fd256-58de-4d03-b1e6-0552eb554723" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb567db6-9add-4aea-8173-7e42096b7c2d" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,962</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_068f8974-d04c-4455-bbc1-f362f8fa93fe" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,889</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b9d9dfe-cdc3-42a1-96b3-e564af10970c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79a817ec-df3f-4313-9349-b41a7a91cfee" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3986f461-af2e-4aa4-b652-d0fdcb40def0" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05ae5f24-c991-497d-88fd-5f43697076fe" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fad3cea-d4b2-4cdd-a621-00c5709d01f6" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e8bb53c-8ea2-4f9f-9ac5-868f5e6bf4b0" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70d1cf8f-b002-40fd-8017-62d0303c9b51" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4258bfe-571c-4670-816a-5d87709dffd9" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1302eb7f-662b-4ca9-9a6e-342991e59569" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,661</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05787da9-d9a9-4916-82ac-f20456f3497d" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa4e77d0-4cbe-47b2-bc94-90c6ab4078cb" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc6fd198-d46a-4e24-bf54-33c996e47dec" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b30bccd-3b38-4793-bedf-edd0215d6d37" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f32295b-7c2b-4934-9936-1dfff3f04ded" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfae0153-759c-468f-9fff-6af0b575ac1e" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_004e2b8e-98a5-446d-8211-0fc806a46c69" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa117f8e-ba06-46d4-bd84-9f6d20ffaa94" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,438</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3c6a06d-df8c-494f-899a-bb11f3f96514" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f1b891b-d7f6-459b-a302-baa5287c802a" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c478aa8-ac62-493e-8aa5-8c7a340e29ce" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60a00216-0fff-4ede-be4a-1631f3841759" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa4f20ea-b4fe-4c85-b078-ade8fec6015e" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a72ddbf2-a72e-41b7-9952-4240d0d84397" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7f28d34-3c0f-4b37-b687-72039c94c0ca" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,779</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits and Orphan Drug Credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cc1e7f2-fbdc-4f75-bc12-ddb860ffad5b" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3f7d921-bec8-43fb-88fe-1364e7041eb4" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21eb3473-db5b-4dc0-a5d6-06d1e77d383c" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33583017-d994-4505-8388-6ad18e6f5ab3" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b363ded7-c3cc-4026-880c-f0ecb0b7ac24" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="tcon:DeferredTaxAssetsRightOfUseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06541643-728a-4ec6-bbae-717e8ba41bcf" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="tcon:DeferredTaxAssetsRightOfUseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 capitalized research expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3822d03b-226b-4c8a-aa10-95bf9f600c64" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,253</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b17a8513-14dc-46d1-8bfe-5de67ce927f3" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,503</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc8fafb8-89aa-430e-9a81-b909bf106e7f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,720</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3113084-f48c-42a1-bdfd-f80cacf2559a" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,906</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94a86926-9857-4b9a-aa2f-0e94ac793640" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ed2c482-7450-48bd-b922-3f06490a7d40" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80a1b34a-0a43-4628-89ec-e0147eceec2b" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_325d4da9-7c0d-41de-ad06-8619e427b532" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b61cf8c2-c2c2-4b6b-a11f-88b91dc18e0c" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa031f2c-c173-4c78-ba4a-c24850437918" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_532f9cad-e734-4a4e-8c32-faea4fca32f6" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0992d496-b793-4b13-b2fb-d0653728b6f3" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,361</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23ca090e-91dc-43d8-a3ff-09e7d4e2d6aa" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad8f5a96-f9e9-412d-b349-caafa589c044" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,361</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbc331ee-57c7-4aa8-b341-77e91d13125d" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ccc4417-4dbe-4276-81a3-f16352393435" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has net deferred tax assets relating primarily to net operating loss (NOL) carryforwards and research and development and Orphan Drug credit carryforwards. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 requires taxpayers to capitalize and amortize research and development expenditures over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b41926ce-c331-4342-8802-97e8522dae82" contextRef="C_739f0e0d-35e3-4a1e-a0c0-95af5f5ab2ff" name="tcon:ResearchAndDevelopmentExpenditureAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for domestic research and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_225d70f5-bcab-4b37-a239-01535d92e947" contextRef="C_0f40826a-5d90-43c5-8575-ad4a021189c6" name="tcon:ResearchAndDevelopmentExpenditureAmortizationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years for foreign research pursuant to Section 174 of the Internal Revenue Code (Code). Subject to certain limitations, the Company may use these deferred tax assets to offset taxable income in future periods. Due to the Company&#8217;s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company&#8217;s deferred tax assets, as it is more likely than not that such assets will not be realized. The net change in the total valuation allowance for the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f62c498d-0548-48c9-8ae9-117b92109bff" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8b475d2-8d65-41e7-9425-d2fd86d4bbcf" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a65d0f5-f44d-4328-9234-20e0d48c8911" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had federal and California NOL carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_750dae08-377b-4b81-9288-38208a9ee153" contextRef="C_9fa826a9-e422-4f13-8418-0d37f204106d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">190.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa298b7f-fe3a-4db3-b13b-eb963b9315db" contextRef="C_3d67d2e6-6d0a-4e23-93d1-f44a73a8c83e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">146.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal and California NOL carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_364fd51b-746a-4dd4-86dc-10acf4e3045f" contextRef="C_23ef9799-fd43-4275-9cd7-31fdf18c3424" name="tcon:OperatingLossCarryforwardsExpirationBeginYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bda5449d-f639-48ba-8469-136d3f84852d" contextRef="C_dbe644e9-34fa-49cf-aac0-7fe06affdd7e" name="tcon:OperatingLossCarryforwardsExpirationBeginYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, if not utilized. The federal NOL generated after 2017 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2624c9aa-2d08-4111-ae8b-d38404274bfe" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will carryforward indefinitely, but the deductibility of such federal NOLs is limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2758cdc6-3193-462c-a4f5-0f3cf1fc45f9" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="tcon:PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income. As of December 31, 2023, the Company also had federal research and development and Orphan Drug tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0541e288-9202-4b90-87fa-32f6f3ee8295" contextRef="C_cb79e9b9-01cb-43a2-8165-d3fd9d65c898" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and California research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2ec5b2d-4eee-4ba5-8795-d7d6e32aa683" contextRef="C_65bae7f1-a046-426a-b301-55274f90e5e5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The federal research and development and Orphan Drug tax credit carryforwards will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41adbd27-c5af-4427-ab9e-067b9ef94ee1" contextRef="C_cfb0c8e3-22a8-49de-b419-5303ff8938e6" name="tcon:TaxCreditCarryforwardExpirationBeginYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16fe8f94-acb1-49b4-88a6-e4a7808fbd43" contextRef="C_ecdebc03-6503-4399-b16e-c105c0c28931" name="tcon:TaxCreditCarryforwardExpirationBeginYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, if not utilized. The California research credit will carry forward indefinitely under current law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Sections 382 and 383 of the Code, the annual use of the Company&#8217;s NOL and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aebd6677-5c77-4079-802b-8d7ceb57b5f6" contextRef="C_be1af667-5078-4781-80f6-a273e57ebc33" name="tcon:PercentOfOwnership" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% occurs within a three-year period. The Company previously completed a Section 382/383 analysis regarding the limitation of NOL and research and development credit carryforwards as of December 31, 2018 and did not identify any change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26247d9c-f12f-4656-97bf-cd26ff1d45d0" contextRef="C_079f3f02-0a8c-4168-a44f-3fb63206aa35" name="tcon:PercentOfOwnership" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% within the preceding three-year period since an ownership change was determined to have occurred at the time of the Company&#8217;s initial public offering in January 2015. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since December 31, 2018. If the Company has experienced an ownership change at any time since December 31, 2018, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation under Section 382 of the Code. Any limitation may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act of 2022, which incorporates a Corporate Alternative Minimum Tax (CAMT), was signed on August 16, 2022 and changes became effective for tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The act is not expected to have a significant impact on the Company's financial position, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d7e0ce2-9265-459c-9768-847ab80ef315" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in the Company&#8217;s unrecognized tax benefits are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73ca2ece-9f93-4789-816c-b832bb2e8812" contextRef="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,610</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae3da179-0e64-4c68-9ad0-49c4f0516ab7" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="tcon:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e89a993-e7a3-400a-95d8-1a8c84ea8141" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6afe1993-e07f-4ee0-b950-ca93c506c6dd" contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,117</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9e308e2-d2ed-40de-baff-6ebba3c3439b" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="tcon:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c268336-20ea-438b-8b38-245291870d01" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,984</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_131f0e08-f8ef-404d-8566-663aef7971b6" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,096</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1ce012e-e2af-4264-870d-5e292581e14c" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f02b10cc-9c0f-460d-863b-50be72cdb80f" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3fb0463-a040-4d1c-b7e5-43ccc0401f7b" contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8f188335-a399-4617-ac38-5441c68cb030" contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accruals for interest or penalties in the accompanying consolidated balance sheets as of December 31, 2023 and 2022 and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e51e5b7-7980-4b08-aec4-9f3466a75d94" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized interest or penalties in the accompanying consolidated statements of operations for the three years in the period ended December 31, 2023.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the valuation allowance recorded against the Company&#8217;s deferred tax assets, future changes in unrecognized tax benefits will not impact the Company&#8217;s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the United States and California. Due to the net operating loss carryforwards, the U.S. federal and California returns are open to examination for all years since inception. The Company has not been, nor is it currently, under examination by the federal or any state tax authority.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb3c4b29-6783-4c12-90dc-8b8e4ff7d3cd" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. 401(k) Plan</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains a defined contribution </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0423c714-cd31-4fc4-8227-88bbd1c67cbd;"><span style="-sec-ix-hidden:F_46bdfe8e-ae21-43ca-ba32-3a33adf3437b;"><span style="-sec-ix-hidden:F_b40b095e-6fd8-4db7-9688-34b629bf1179;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">401(k) plan</span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain matching contributions to the 401(k) plan. Matching contributions for the years ended December 31, 2023, 2022 and 2021 totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13de92e1-14b0-49a7-b190-f3197ac9cc21" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be651047-daa9-40a8-a37a-b34c31b6dfc2" contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd2b8154-78b7-4ce4-99f3-31617e8e2521" contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified and pursuant to the requirements of the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (who are our principal executive officer and principal financial officer, respectively), to allow for timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required by Rule 13a-15(b) promulgated under the Exchange Act, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of December 31, 2023, the end of the period covered by this report. Based upon the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s Board, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.</span></div></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control &#8212; Integrated Framework.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our assessment, our management has concluded that, as of December 31, 2023, our internal control over financial reporting was effective based on those criteria.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Regulation S-K Item 308(b), this Annual Report on Form 10-K does not include an attestation report of our company&#8217;s registered public accounting firm regarding internal control over financial reporting.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes. During the quarter ended December 31, 2023, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Other Information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Executive Officers and Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth certain information regarding our current executive officers, including their ages, as of February 29, 2024:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.92%;"/>
    <td style="width:2%;"/>
    <td style="width:1%;"/>
    <td style="width:10.52%;"/>
    <td style="width:1%;"/>
    <td style="width:2%;"/>
    <td style="width:47.56%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Position(s)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.25pt solid #000000;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA, M.S.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The name, age and certain other information of each member of our Board, as of February 29, 2024, is set forth below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.36%;"/>
    <td style="width:1.42%;"/>
    <td style="width:1%;"/>
    <td style="width:9.44%;"/>
    <td style="width:1%;"/>
    <td style="width:1.42%;"/>
    <td style="width:7.62%;"/>
    <td style="width:1.42%;"/>
    <td style="width:13.14%;"/>
    <td style="width:1.42%;"/>
    <td style="width:13.58%;"/>
    <td style="width:1.42%;"/>
    <td style="width:13.74%;"/>
    <td style="width:1.42%;"/>
    <td style="width:7.6%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Committee Memberships</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Audit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Compensation</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nominating &amp;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Corporate</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Governance</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term Expires on</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Annual Meeting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">held in the Year</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Director Class</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen T. Worland, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.25pt solid #000000;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">I</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Saundra Pelletier</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">C</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">I</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carol Lam, J.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">II</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin A. Mattingly, Pharm.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">C</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">II</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">J. Rainer Twiford, J.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">II</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William R. LaRue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">C</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">III</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lisa Johnson-Pratt, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">III</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">III</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a brief biography of each of our current executive officers and non-employee directors:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Executive Officers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Theuer has served as our President, Chief Executive Officer and a member of our Board since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016, and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Dr. Theuer&#8217;s experience in the biotechnology industry, his medical training and his experience with our company provide him with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scott B. Brown, CPA, M.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Brown joined us as Director, Finance and Controller in August 2015, was promoted to Sr. Director, Finance and Controller in January 2017, Vice President, Finance in January 2019, Chief Accounting Officer in September 2019, and Chief Financial Officer in January 2021. Prior to joining us, Mr. Brown was Associate Director, Finance at Ardea Biosciences (acquired by AstraZeneca) where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015. Before that, from 2011 to 2013 Mr. Brown was Finance Manager at SciClone Pharmaceuticals, Inc., and Finance Manager at Exelixis, Inc. from 2009 to 2011. Prior to Exelixis, Mr. Brown held accounting positions of increasing responsibility at AcelRx, Inc., Spinal Elements, Inc., Stewart Title, and as an audit associate for KPMG, LLP. Mr. Brown received a B.S. from the University of California, Santa Barbara, a M.S. in Accountancy from San Diego State University, and is a Certified Public Accountant licensed in the state of California.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-Employee Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stephen T. Worland, Ph.D.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Worland has served as a member of our Board since February 2015. Since May 2012, Dr. Worland has served as the President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a company focused on new treatments for cancer. Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for Hepatitis C and cancer, from August 2007 until the company&#8217;s acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named Chief Executive Officer, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career in 1988 at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. Dr. Worland currently serves on the board of directors of Blacksmith Medicines Inc., a biotechnology company discovering first-in-class medicines using a breakthrough drug discovery platform, a position he has held since April 2017.  Dr. Worland received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Dr. Worland&#8217;s experience as an executive officer and director of publicly traded biotechnology and pharmaceutical companies and his educational background, including research expertise in oncology, provide him with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Saundra Pelletier</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. Pelletier has served as a member of our Board since March 2020. Since February 2013, Ms. Pelletier has served as Chief Executive Officer of Evofem Biosciences, Inc. (OTCMKTS: EVFM), a clinical-stage biopharmaceutical company focused on women&#8217;s sexual and reproductive health. From 2009 to 2016, Ms. Pelletier was the founding Chief Executive Officer of WomanCare Global International, an international non-profit organization focused on empowering, educating and enabling women and girls to make informed choices about their health and creating sustainable supply chains that delivered products to women in more than 100 developing countries. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a business unit focused on women&#8217;s healthcare, and Vice President of Pharmaceuticals for Women First Healthcare. Among her many honors, Ms. Pelletier was named a &#8220;New Champion for Reproductive Health&#8221; by the United Nations Foundation, awarded the Athena San Diego Pinnacle Award for Life Sciences, and named San Diego Business Journal&#8217;s 2019 Businesswoman of the Year. Ms. Pelletier received her B.S. in Business Administration and Communications and her Honorary Doctor of Business Administration from Husson University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Ms. Pelletier&#8217;s experience as an executive officer and director of a public biotechnology company provides her with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Carol Lam, J.D.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. Lam has served as a member of our Board since October 2021. Since July 2018, Ms. Lam has served as a consultant to Qualcomm Incorporated, complementing her experience from February 2007 until July 2018 as Senior Vice President and deputy General Counsel of Qualcomm Incorporated, a multinational corporation specializing in wireless telecommunications systems and a leader in 5G technology, where she dealt with complex tax, antitrust and intellectual property issues in China, as well as global matters involving intellectual property, privacy, employment, and antitrust laws. Ms. Lam worked closely with the company&#8217;s government affairs team in building relationships in other countries to create positive business environments for the company&#8217;s products. From September 2002 until February 2007, Ms. Lam served in an executive role in the government as the presidentially-appointed, Senate-confirmed United States Attorney for the Southern District of California, leading an office of more than 120 attorneys charged with enforcing federal criminal and civil laws. From December 2000 until September 2002, Ms. Lam was a Superior Court Judge and, prior to that, an Assistant U.S. Attorney in the Southern District of California. Past honors include the Health and Human Services Inspector General&#8217;s Award for Exceptional Achievement; the U.S. Attorney General&#8217;s Award for Distinguished Service and the U.S. Department of Justice award for Superior Performance as an Assistant United States Attorney; California&#8217;s Top 100 Attorneys and California&#8217;s Top 75 Women Litigators (Los Angeles Daily Journal); Outstanding Attorney of the Year by the San Diego County Bar Association; the National Asian Pacific American Bar Association&#8217;s Trailblazer Award; and Legal Momentum&#8217;s Women of Achievement Award. Ms. Lam serves on the boards of Stanford University (Audit Committee Chair), the La Jolla Symphony &amp; Chorus (Audit Committee Chair), the National Association of Former U.S. Attorneys, and Stanford Women on Boards. Ms. Lam received her B.A. in Philosophy from Yale University and her J.D. from Stanford Law School.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Ms. Lam&#8217;s extensive experience as a public company executive and her global perspective on technology development acquired through her service as deputy General Counsel for Qualcomm and as United States Attorney for the Southern District of California provides her with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Martin A. Mattingly, Pharm.D.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Mattingly has served as a member of our Board since December 2014. Since February 2012, Dr. Mattingly provides consulting services through his company, Mattingly Biotech Consulting. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until January 2012 following its merger with Synageva BioPharma Corp in November 2011. He also served on the board of directors of Trimeris, Inc. from November 2007 until November 2011. He has been a director of OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, since June 2010 and currently serves on the board of directors of Achieve Life Sciences, Inc. From 2005 to 2007, Dr. Mattingly served as President and Chief Executive Officer of Ambrx, Inc., a biopharmaceutical company. From 2003 to 2005, Dr. Mattingly served as Executive Vice President of CancerVax, Inc., a pharmaceutical company, and as Chief Operating Officer from June 2005 to September 2005. From 1996 to 2003, Dr. Mattingly provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., a pharmaceutical company. From 1983 to 1996, Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company, a biopharmaceutical company. Dr. Mattingly received a Doctor of Pharmacy degree from the University of Kentucky.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Dr. Mattingly&#8217;s extensive experience in growing and operating biotechnology and pharmaceuticals companies, his educational background and his experience as a public company director provide him with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">J. Rainer Twiford, J.D., Ph.D.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Twiford has served as a member of our Board since September 2008. Dr. Twiford has been President of Brookline Investments, Inc. (formerly Capital Strategies Advisors, Inc.), an investment advisory company he founded in 1994, since 1999. Dr. Twiford has been a member of the board of directors of Integrated Photonics, Inc., an optical device company, since November 1999. Prior to founding Brookline Partners, Dr. Twiford was a partner of Trammell Crow Company, a real estate development and investment company, from 1987 to 1991. From June 2007 to July 2013, Dr. Twiford was a member of the board of directors of Care Investment Trust Inc. (now Tiptree Financial Inc.), a real estate investment company. He also served as the Chairman of the Compensation, Nominating and Governance Committee of Care Investment Trust Inc. from September 2011 to July 2013. In addition, Dr. Twiford previously served on the board of a children&#8217;s behavioral health company. Dr. Twiford received a B.A. and a Ph.D. from the University of Mississippi, an M.A. from the University of Akron and a J.D. from the University of Virginia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Dr. Twiford&#8217;s extensive experience in finance, his experience as a public company director and his educational background provide him with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">William R. LaRue</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. LaRue has served as a member of our Board since July 2014. He served as the Chief Financial Officer, Senior Vice President and Treasurer at Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from June 2006 until its acquisition by Mallinckrodt plc in March 2014, and from April 2007 to March 2014, he served as the Assistant Secretary at Cadence. Prior to joining Cadence Pharmaceuticals, Inc., Mr. LaRue was the Senior Vice President and Chief Financial Officer of Micromet, Inc. (formerly CancerVax Corporation), a biotechnology company, from 2001 to 2006. From 2000 to 2001, Mr. LaRue served as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Previously, he was the Vice President and Treasurer of Safeskin Corporation, a medical device company, from 1997 to 2000 and the Treasurer of GDE Systems, Inc., a high technology electronic systems company, from 1993 to 1997. Mr. LaRue served on the board of directors of Conatus Pharmaceuticals, Inc. from February 2017 to May 2020, and served on the board of directors of Alastin Skincare, Inc., a private innovative skincare company, from October 2018 to December 2021. In addition, since December 2017, Mr. LaRue has served on the board of directors of Oncternal Therapeutics, Inc., a cancer therapeutics company that entered into a reverse merger agreement with GTx, Inc. in March 2019. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Mr. LaRue&#8217;s extensive experience in finance, his experience serving as an executive officer and director of private and public companies in our industry and his educational background provide him with the qualifications and skills to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lisa Johnson-Pratt, M.D.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Johnson-Pratt has served as a member of our Board since March 2021. Dr. Johnson-Pratt currently serves as Founder/President of Ananias Ventures where she provides commercial consultancy with companies in the Cell and Gene Therapy space. Prior to full time consultancy, Dr. Johnson-Pratt was SVP, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) which is focused on discovering, developing and commercializing RNA-targeted therapeutics for a broad range of diseases. Prior to joining Ionis in 2020, Dr. Johnson Pratt was Head of Global Pharma Commercial Operations at GSK. During her time at GSK, she also served as Head of Early Pipeline Commercial Strategy supporting assets in early- stage development across multiple therapeutic areas, including oncology. From 1996 to 2013, Dr. Johnson Pratt held clinical development and commercial leadership roles at Merck&amp;Co., Inc. During this time she led global marketing strategy, country operations and global band management teams. Earlier in her career she worked in Medical Affairs at Glaxo Wellcome. Her career has spanned globally, including time in China and Vietnam, supporting products that have contributed strongly to improving patient health for vulnerable patients. Dr. Johnson Pratt received her medical degree and completed her residency in Internal Medicine, from Howard University. She completed a Fellowship in Clinical Pharmacology and Pharmaceutical Medicine at Howard University and holds a Diploma of Pharmaceutical Medicine from the Royal College of Physicians. Dr. Johnson Pratt is the Founder of Ananias Ventures which supports projects focused on issues related to vulnerable women and children, and is on the board of Young People in Recovery (YPR) a national non-profit that support young people to thrive after recovering from substance abuse.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board and our Nominating and Governance Committee believe that Dr. Johnson-Pratt&#8217;s broad business and commercialization experience as a senior member of management of a public company in the biotechnology and pharmaceuticals industries provides her with the qualifications and skills to serve on our Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board Composition &#8212; Independence of the Board of Directors</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business and affairs are organized under the direction of our Board, which currently consists of eight members. The primary responsibilities of our Board are to provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and additionally as required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required under the pertinent listing standards of Nasdaq, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by its board of directors. Our Board consults with the Company&#8217;s counsel to ensure that the board of directors&#8217; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time. Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent auditors, our Board has affirmatively determined that all of our directors, with the exception of Dr. Theuer, are independent directors within the meaning of the applicable listing standards of Nasdaq.  In making this determination, the Board found that none of these directors had a material or other disqualifying relationship with the Company.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board is divided into three classes, as follows:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class I, which consists of Ms. Pelletier and Dr. Worland, whose terms will expire at our annual meeting of stockholders to be held in 2025;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class II, which consists of Ms. Lam, Dr. Mattingly and Dr. Twiford, whose terms will expire at our annual meeting of stockholders to be held in 2026; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class III, which consists of Mr. LaRue, Dr. Johnson-Pratt and Dr. Theuer, whose terms will expire at our annual meeting of stockholders to be held in 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each annual meeting of stockholders, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized size of our Board is currently eight members and currently consists of eight members. The authorized number of directors may be changed only by resolution by a majority of the Board. This classification of the Board may have the effect of delaying or preventing changes in our control or management. Our directors may be removed for cause by the affirmative vote of the holders of at least 662/3% of our voting stock. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#8217;s successor is duly elected and qualified.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board Leadership Structure</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board is currently chaired by Dr. Theuer, who has authority, among other things, to call and preside over Board meetings, to set meeting agendas and to determine materials to be distributed to the Board. We believe that combining the positions of Chief Executive Officer and Board Chair helps to ensure that the Board and management act with a common purpose. In our view, separating the positions of Chief Executive Officer and Board Chair has the potential to give rise to divided leadership, which could interfere with good decision-making or weaken our ability to develop and implement strategy. Instead, we believe that combining the positions of Chief Executive Officer and Board Chair provides a single, clear chain of command to execute our strategic initiatives and business plans. In addition, we believe that a combined Chief Executive Officer/Board Chair is better positioned to act as a bridge between management and the Board, facilitating the regular flow of information. We also believe that it is advantageous to have a Board Chair with an extensive history with and knowledge of the Company (as is the case with Dr. Theuer) as compared to a relatively less informed independent Board Chair. The Board has not appointed a lead independent director. The Board has a separate Chair for each committee of the Board. The Chair of each committee reports periodically to the Board on the activities of their committee in fulfilling their responsibilities as detailed in their respective charters.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Role of the Board in Risk Oversight</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. The Board also maintains responsibility for oversight of cybersecurity risk management, and, to that end, the Board typically meets regularly with business personnel responsible for cybersecurity risk management and receives periodic reports. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the committee chairs to report findings regarding material risk exposures to our Board as quickly as possible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board Diversity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with the Nasdaq listing rules, the Board has self-identified a number of attributes that identify its members&#8217; diversity. The following is a matrix showing the makeup of those self-reported attributes:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.54%;"/>
    <td style="width:16.22%;"/>
    <td style="width:12.02%;"/>
    <td style="width:13.32%;"/>
    <td style="width:14.9%;"/>
   </tr>
   <tr style="height:13.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="5" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Board Diversity Matrix (As of February 29, 2024)</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Number of Directors</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:45pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Female</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Male</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-Binary</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Did Not Disclose Gender</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Part I: Gender Identity</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Directors</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Part II: Demographic Background</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">African American or Black</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alaskan Native or Native American</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asian</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hispanic or Latinx</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Native Hawaiian or Pacific Islander</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">White</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Two or More Races or Ethnicities</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LGBTQ+</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Did Not Disclose Demographic Background</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.54%;"/>
    <td style="width:16.22%;"/>
    <td style="width:12.02%;"/>
    <td style="width:13.32%;"/>
    <td style="width:14.9%;"/>
   </tr>
   <tr style="height:13.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="5" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Board Diversity Matrix (As of February 29, 2024)</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Number of Directors</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:45pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Female</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Male</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-Binary</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Did Not Disclose Gender</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Part I: Gender Identity</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Directors</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Part II: Demographic Background</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">African American or Black</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alaskan Native or Native American</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asian</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hispanic or Latinx</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Native Hawaiian or Pacific Islander</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">White</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Two or More Races or Ethnicities</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LGBTQ+</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Did Not Disclose Demographic Background</span></p></td>
    <td colspan="4" style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board Committees</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board has established three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Our Board has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. Below is a description of each standing committee of the Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audit Committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Audit Committee consists of Mr. LaRue, Dr. Worland and Ms. Pelletier. Our Board has determined that each of the members of this committee satisfies the Nasdaq and SEC independence requirements for members of the Company&#8217;s Audit Committee, and that each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. Each member of our Audit Committee can read and understand fundamental financial statements in accordance with Nasdaq Audit Committee requirements. In arriving at this determination, the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board has examined each Audit Committee member&#8217;s scope of experience and the nature of their prior and/or current employment.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. LaRue serves as the chair of our Audit Committee. Our Board has determined that Mr. LaRue qualifies as an Audit Committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the pertinent listing standards of Nasdaq, as in effect from time to time. In making this determination, our Board has considered Mr. LaRue&#8217;s formal education and previous and current experience in financial roles. Both our independent registered public accounting firm and management periodically meet privately with our Audit Committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The functions of this committee include, among other things:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">monitoring the rotation of partners of our independent auditors on our engagement team as required by law; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and discussing the statements and reports with our independent auditors and management; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing with management and our auditors any earnings announcements and other public announcements regarding material developments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparing the report that the SEC requires in our annual proxy statement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and providing oversight of any related-person transactions in accordance with our related person transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing on a periodic basis our investment policy;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and establishing appropriate insurance coverage for the Company&#8217;s directors and executive officers; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and evaluating on an annual basis the performance of the Audit Committee and the Audit Committee charter.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board has adopted a written Audit Committee charter that is available on our website at www.traconpharma.com. The information on our website is not incorporated by reference into this Annual Report.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Compensation Committee consists of Dr. Mattingly, Ms. Lam, Dr. Twiford and Mr. LaRue. Dr. Mattingly serves as the chair of our Compensation Committee. Our Board has determined that each of the members of our Compensation Committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act, and satisfies the Nasdaq independence requirements. The functions of this committee include, among other things:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full Board regarding) our overall compensation strategy and policies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing, determining and approving (or it deems appropriate, making recommendations to the full Board regarding) the compensation and other terms of employment of our executive officers;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and making recommendations to the full Board regarding performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and approving (or if it deems it appropriate, making recommendations to the full Board regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and making recommendations to the full Board regarding the type and amount of compensation to be paid or awarded to our non-employee board members; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing policies with respect to votes by our stockholders to approve executive compensation to the extent required by Section 14A of the Exchange Act and, if applicable, determining our recommendations regarding the frequency of advisory votes on executive compensation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">administering our equity incentive plans;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing policies with respect to equity compensation arrangements;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation policy and strategy in achieving expected benefits to us;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and making recommendations to the full Board regarding the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing with management and approving our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparing the report that the SEC requires in our annual proxy statement; and</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and evaluating on an annual basis the performance of the Compensation Committee and the Compensation Committee charter.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee Processes and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Typically, our Compensation Committee meets multiple times per year and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with our Chief Executive Officer. Our Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. Our Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of our Compensation Committee grants the Compensation Committee full access to all of our books, records, facilities and personnel, as well as authority to obtain, at our expense, advice and assistance from internal and external legal, accounting or other advisors and consultants and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising it. In particular, the Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other advisors only after taking into consideration the six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that any adviser be independent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the past fiscal year, after taking into consideration the six factors prescribed by the SEC and Nasdaq, the Compensation Committee engaged Aon Consulting Inc. (&#8220;Aon&#8221;) as a compensation consultant. As part of its engagement, Aon was requested by the Compensation Committee to perform analyses of compensation levels for purposes of developing recommendations that were presented to the Compensation Committee for its consideration.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of its engagement, Aon was requested by our Compensation Committee to develop a comparative group of companies and to review our cash and equity compensation program to peers and to review our current pay philosophy and executive compensation program. Specifically, our Compensation Committee requested that Aon evaluate the efficacy of our existing compensation strategy and practices in supporting and reinforcing our long-term strategic goals and assist in refining our compensation strategy. Aon ultimately developed recommendations that were presented to and considered by the Compensation Committee in approving compensation levels.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under its charter, our Compensation Committee may form, and delegate authority to, subcommittees as appropriate. In 2015, the Compensation Committee approved the formation of a CEO stock option sub-committee of the Compensation Committee, currently composed of Dr. Theuer, our Chief Executive Officer, to which authority has been delegated to grant, without any further action required by the Compensation Committee, stock options and restricted stock units (&#8220;RSUs&#8221;), to employees who are not our officers. The purpose of this delegation of authority is to enhance the flexibility of equity award administration and to facilitate the timely grant of equity awards to non-management employees, particularly new employees, within specified limits approved by our Compensation Committee. In particular, the subcommittee may grant options or RSUs only within pre-approved guidelines. Typically, as part of its oversight function, our Compensation Committee will review on a regular basis the list of grants made by the subcommittee. During the years ended December 31, 2023 and 2022, the subcommittee did not exercise its authority to grant equity awards to non-officer employees.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, our Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held toward the end of the year or the beginning of the following year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, our Compensation Committee&#8217;s process comprises two related elements: the determination of compensation levels (including bonus amounts based upon performance objectives for the prior year) and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to it by the Chief Executive Officer. In the case of our Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which recommends to the Board any adjustments to his compensation as well as awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current company-wide compensation levels and analyses of executive and director compensation paid at other companies.	</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee undertakes its work with the intent to implement two overarching policies: maintaining an overall compensation structure designed to attract, retain and motivate management and other employees by providing appropriate levels of risk and reward, assessed on a relative basis at all levels within the Company and in proportion to individual contribution and performance; and establishing appropriate incentives for management to further the Company&#8217;s long-term strategic plan and avoid undue emphasis on short-term market value.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board has adopted a written Compensation Committee charter that is available on our website at www.traconpharma.com. The information on our website is not incorporated by reference into this Annual Report.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The specific determinations of the Compensation Committee with respect to executive compensation for fiscal year 2023 are described in greater detail under the heading &#8220;Executive Compensation.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee Interlocks and Insider Participation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the members of our Compensation Committee is, or has ever been, an executive officer or employee of ours. None of our executive officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our Board or Compensation Committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nominating and Corporate Governance Committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Nominating and Corporate Governance Committee consists of Ms. Pelletier, Dr. Johnson-Pratt, Dr. Mattingly and Dr. Worland. Our Board has determined that each of the members of this committee satisfies the Nasdaq independence requirements. Ms. Pelletier serves as the chair of our Nominating and Corporate Governance Committee. The functions of this committee include, among other things:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, reviewing and evaluating candidates to serve on our Board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining the minimum qualifications for service on our Board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating director performance on the board and applicable committees of the board and determining whether continued service on our board is appropriate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating, nominating and recommending individuals for membership on our Board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating nominations by stockholders of candidates for election to our Board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considering and assessing the independence of members of our Board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing a set of corporate governance policies and principles and recommending to our Board any changes to such policies and principles;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considering questions of possible conflicts of interest of directors as such questions arise; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and evaluating on an annual basis the performance of the Nominating and Corporate Governance Committee and the Nominating and Corporate Governance Committee charter.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Nominating and Corporate Governance Committee believes that candidates for director, both individually and collectively, can and do provide the integrity, experience, judgment, commitment (including having sufficient time to devote to us and with an appropriate level of participation), skills, diversity and expertise appropriate for us. In assessing the directors, both individually and collectively, the Nominating and Corporate Governance Committee considers the current needs of the Board and of us to maintain a balance of knowledge, experience and capability in various areas. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, our operating requirements and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, including gender, racial and ethnic diversity, age, skills and such other factors as it deems appropriate, given the current needs of the Board and us, to maintain a balance of knowledge, experience and capability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nominating and Corporate Governance Committee appreciates the value of thoughtful Board refreshment, and regularly identifies and considers qualities, skills and other director attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall service to us during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then selects a nominee for recommendation to the Board by majority vote.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board has adopted a written Nominating and Corporate Governance Committee charter that is available on our website at www.traconpharma.com. The information on our website is not incorporated by reference into this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Procedures for Stockholders to Recommend Director Nominees</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee at the following address: 4350 La Jolla Village Drive, Suite 800, San Diego, California, 92122, Attn: Secretary, no later than the close of business on the 90</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day and no earlier than the close of business on the 120</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day prior to the one year anniversary of the preceding year&#8217;s annual meeting. Submissions must include: (1) the name and address of the Company stockholder on whose behalf the submission is made; (2) the number of Company shares that are owned beneficially by such stockholder as of the date of the submission; (3) the full name of the proposed candidate; (4) description of the proposed candidate&#8217;s occupation or employment; (5)  biographical information for the proposed candidate; (6) a description of the proposed candidate&#8217;s qualifications as a director and (7) any other information required by the Company&#8217;s Bylaws. The Company may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the Company or that could be material to a reasonable stockholder&#8217;s understanding of the independence, or lack thereof, of such proposed nominee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Governance</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During fiscal year 2023, our Board met eighteen times, the Audit Committee met four times, the Compensation Committee met one time and the Nominating and Corporate Governance Committee met one time. All but one of our Board members attended 75% or more of the Board meetings during the year ended December 31, 2023 that were held during the period for which he or she was a director (if any). All but one member of the Board who served on the audit committee attended 100% of the committee meetings during the year ended December 31, 2023 that were held during the period for which he or she was a committee member. Each member of the Board who served on the compensation or nominating and corporate governance committees attended 100% of the respective committee meetings during the year ended December 31, 2023 that were held during the period for which he or she was a committee member.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have a formal policy regarding director attendance at our annual meetings; however, we encourage directors to attend. All but one of our directors attended our annual meeting of stockholders held in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Involvement in Certain Legal Proceedings</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of our directors or executive officers has been involved in any of the legal proceedings specified in Item 401(f) of Regulation S-K in the past 10 years.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delinquent Section 16(a) Reports</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 16(a) of the Exchange Act requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock. Based solely on review of the copies of such forms filed electronically with the SEC, or written representations from such persons that no additional reports were required, we believe that all reports applicable to our executive officers, directors and greater than 10% beneficial owners were filed in a timely manner in accordance with Section 16(a) of the Exchange Act, except for:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Form 4 filed four business days late on February 9, 2023 reporting the grant of stock options to Bonne Adams, M.B.A on February 1, 2023.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is available on the Corporate Governance section of our website, www.traconpharma.com. The information on our website is not incorporated by reference into this Annual Report. We intend to disclose on our website any amendments to, or waivers from, our code of business conduct and ethics that are required to be disclosed pursuant to SEC rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Executive Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, our Chief Executive Officer and Chief Financial Officer may be required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of Section 304 of the Sarbanes-Oxley Act of 2002. Additionally, as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act and in accordance with SEC and Nasdaq requirements, we have implemented the TRACON Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy, which generally requires that, in the event of an accounting restatement, we recover incentive compensation that exceeds the amount of incentive compensation that would have been paid if the amount of the incentive compensation had been determined based on the accounting restatement.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our named executive officers for the year ended December 31, 2023, which consist of our principal executive officer and two other executive officers, were:</span><span style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D., our President and Chief Executive Officer, </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scott B. Brown, CPA, M.S., our Chief Financial Officer, and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bonne Adams, M.B.A, our Chief Operating Officer. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the compensation awarded to, earned by or paid to our named executive officers during the fiscal years indicated below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.32%;"/>
    <td style="width:1%;"/>
    <td style="width:8.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.44%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-equity</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incentive Plan</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Salary</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Awards</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Compensation</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Compensation</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and principal position</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">632,343</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">432,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,258</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,078,633</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">608,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461,153</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">182,407</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,264,851</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA, M.S.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388,960</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">187,387</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,139</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">590,486</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">353,600</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139,216</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,864</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,180</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">590,860</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bonne Adams, M.B.A.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">332,495</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,829</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,950</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(5)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">475,274</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Operating Officer</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334,718</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139,216</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,332</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,180</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">567,446</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. Adams resigned as our Chief Operating Officer effective October 15, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards computed in accordance with the Financial Accounting Standards Board&#8217;s Accounting Standard Codification (Financial Accounting Standards Board Accounting Standards Codification (FASB ASC)) Topic 718 for stock-based compensation transactions (ASC 718). Assumptions used in the calculation of these amounts are included in Note 6 to our consolidated financial statements and notes thereto included within Part IV of our 2023 Annual Report. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting or exercise of stock options, or the sale of the common stock underlying them.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts shown represent annual performance-based bonuses earned for the respective fiscal year. We have not yet determined the annual cash bonuses earned by each named executive office for the fiscal year ended December 31, 2023. For more information, see below under &#8220;&#8212;Annual Performance-Based Bonus Opportunity.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise indicated, amounts shown represent 401(k) matching contributions made for the respective fiscal year and payment of life insurance premiums for the employee&#8217;s benefit. For more information, see below under &#8220;&#8212;401(k) Plan&#8221; and &#8220;&#8212;Life Insurance,&#8221; respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(4) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. Adams 2023 salary (prorated for time served) includes $41,012 earned during her term of service for unused vacation pay that was paid out in connection with her resignation as the Company&#8217;s Chief Operating Officer effective October 15, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(5) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amount shown includes compensation of $7,050 paid to Ms. Adams for consulting services provided to us in 2023 following her resignation. Ms. Adams provides consulting services to us on an as needed basis in our discretion at a rate of $300 per hour.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Base Salary</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The compensation of our named executive officers is generally determined and approved by our Board, based on the recommendation of the Compensation Committee of our Board. The table below shows the annual base salaries for our named executive officers for the year ended December 31, 2023:</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:80.236%;"/>
    <td style="width:1.94%;"/>
    <td style="width:1%;"/>
    <td style="width:15.823%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023<br/>Base Salary<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">632,343</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA, M.S.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388,960</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bonne Adams, M.B.A.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">368,190</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As discussed in &#8220;&#8212;Summary Compensation Table&#8221; above, Ms. Adams 2023 salary was prorated for time served. The salary actually paid to Ms. Adams was $291,483.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Performance-Based Bonus Opportunity</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash bonuses, which are designed to incentivize our executives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these goals, subject to certain employment criteria as described below under &#8220;&#8212;Agreements with our Named Executive Officers.&#8221; The annual performance-based bonus each named executive officer is eligible to receive is generally based on the extent to which we achieve the corporate goals that our Board establishes each year. At the end of the year, our Board reviews our performance against each corporate goal and determines the extent to which we achieved each of our corporate goals.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For 2023, Dr. Theuer was eligible to receive a target bonus of up to 50% of his base salary, Mr. Brown was eligible to receive a target bonus of up to 40% of his base salary, and Ms. Adams was eligible to receive a target bonus of up to 35% of her base salary, each pursuant to the terms of their employment agreement that was in effect during 2023, as described below under &#8220;&#8212;Agreements with our Named Executive Officers.&#8221; Our Board will also consider each named executive officer&#8217;s individual contributions towards reaching our annual corporate goals. There is no minimum bonus percentage or amount established for the named executive officers and, as a result, the bonus amounts vary from year to year based on corporate and individual performance. The annual cash bonuses earned by each named executive office for the fiscal year ended December 31, 2023 have not yet been determined, but are expected to be determined in the first quarter of 2024. Ms. Adams will not receive a 2023 annual performance bonus because she will not be employed by us at the time 2023 annual performance-based cash bonuses are paid, if any, as described below under &#8220;&#8212;Agreements with our Named Executive Officers.&#8221;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arbitration Bonus Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, our Compensation Committee approved a one-time discretionary bonus related to the results of the Company&#8217;s arbitration with I-Mab Biopharma (the &#8220;Arbitration Bonus&#8221;). The terms of the Arbitration Bonus establish a cash bonus pool equal to 1% of any award in the Company&#8217;s favor resulting from the arbitration to the extent the award is at least $30.0 million and no more than $50.0 million. Payment of the Arbitration Bonus is conditioned on, among other things, (a) receipt by the Company of at least $10.0 million from equity sales or otherwise by June 30, 2023, including from the arbitration award, if any, and (b) employment in good standing of the recipient at the time the Arbitration Bonus is paid. Dr. Theuer was eligible to earn 25% of the cash bonus pool, Mr. Brown was eligible to earn 17% of the cash bonus pool, and Ms. Adams was eligible to earn 12% of the cash bonus pool. No amounts were paid or are due to be paid associated with the Arbitration Bonus.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-Based Incentive Awards</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our equity-based incentive awards are designed to align the Company&#8217;s interests with those of our employees, non-employee directors and consultants, including our named executive officers. Our executives generally are awarded an initial new hire grant of option awards upon commencement of employment and additional grants are typically granted annually. In the fiscal year ending December 31, 2023, stock option awards were the only form of equity awards we granted to our named executive officers. Vesting of the stock option awards is dependent on continuous service with us and serves as an additional retention measure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our outstanding stock option awards granted to executives provide for full acceleration in the event of the holder&#8217;s cessation of continuous service without cause, and not due to a death or disability, in connection with or within 12 months following consummation of our change in control (as defined in the 2015 Plan). Such awards are also subject to accelerated vesting in the event of certain involuntary terminations not related to our change in control (as described below under &#8220;&#8212;Potential Payments Upon Termination or Change in Control&#8221;).</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreements with Our Named Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below are descriptions of our employment agreements with our named executive officers. For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see &#8220;&#8212;Potential Payments Upon Termination or Change in Control&#8221; below.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement with Dr. Theuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  On February 5, 2019, we entered into an Amended and Restated Employment Agreement with Charles P. Theuer, our President and Chief Executive Officer, which amended, restated and superseded in its entirety Dr. Theuer&#8217;s employment agreement entered into in February 2017. Pursuant to the amended employment agreement, Dr. Theuer is entitled to an initial annual base salary of $552,921 and is eligible to receive an annual performance bonus of up to 50% of his base salary, as determined by our Board and subject to employment in good standing at the end of the calendar year applicable to such bonus.  Dr. Theuer is additionally entitled to certain severance benefits pursuant to his agreement, the terms of which are described below under &#8220;&#8212;Potential Payments Upon Termination or Change of Control.&#8221;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement with Mr. Brown.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On January 28, 2020, we entered into an Employment Agreement with Scott B. Brown, our Chief Financial Officer, which governs the terms of his employment with us. Pursuant to the agreement, Mr. Brown is entitled to an initial base salary of $254,400 and is eligible to receive an annual target performance bonus of up to 40% of his base salary, as determined by our Board and subject to employment in good standing on the date of payment of the applicable bonus. Mr. Brown is additionally entitled to certain severance benefits pursuant to a severance agreement that we entered into with Mr. Brown on December 4, 2019, the terms of which are described below under &#8220;&#8212;Potential Payments Upon Termination or Change of Control.&#8221;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement with Ms. Adams.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On February 27, 2017, we entered into an Amended and Restated Employment Agreement with Bonne Adams, our Chief Operating Officer, which governs the terms of her employment with us. Pursuant to the agreement, Ms. Adams is entitled to an initial base salary of $288,779 and is eligible to receive an annual target performance bonus of up to 35% of her base salary, as determined by our Board and subject to employment in good standing on the date of payment of the applicable bonus. Ms. Adams is additionally entitled to certain severance benefits pursuant to a severance agreement that we entered into with Ms. Adams on September 27, 2017, the terms of which are described below under &#8220;&#8212;Potential Payments Upon Termination or Change of Control.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential Payments Upon Termination or Change in Control</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regardless of the manner in which a named executive officer&#8217;s service terminates, the named executive officer is entitled to receive amounts earned during his term of service, including salary and unused vacation pay. Receipt of the payments and benefits described below are contingent on the executive officer&#8217;s execution of an effective general release of claims.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dr. Theuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  If Dr. Theuer&#8217;s employment is terminated without cause or he resigns for good reason, in each case, other than in connection with a change in control, he is entitled to continued payment of his then-current base salary for 12 months, payment of premiums for continued healthcare coverage under COBRA for himself and his eligible dependents (or in certain circumstances, taxable cash payments in lieu of such premium payments) for up to 12 months, and full vesting of any unvested time-based equity awards.  If Dr. Theuer&#8217;s employment is terminated without cause or he resigns for good reason within 12 months following a change in control, he is entitled to continued payment of his then-current base salary, and COBRA premium (or taxable cash) payments as described above, for 18 months, 150% of his target annual performance bonus, and full vesting of any unvested time-based equity awards.  In addition, if Dr. Theuer&#8217;s employment is terminated as a result of his death, his estate would be entitled to a one-time, lump-sum payment equal to 12 months of his base salary and accelerated vesting of any time-based equity awards as if he had completed an additional six months of continuous service.  If Dr. Theuer&#8217;s employment is terminated as a result of disability, any unvested time-based equity will vest on an accelerated basis as if he had completed an additional six months of continuous service.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mr. Brown.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On December 4, 2019, we entered into a severance agreement with Mr. Brown. If Mr. Brown&#8217;s employment is terminated without cause or he resigns for good reason, in each case, other than in connection with a change in control, he is entitled to continued payment of his then-current base salary for nine months, payment of premiums for continued healthcare coverage under COBRA for himself and his eligible dependents (or in certain circumstances, taxable cash payments in lieu of such premium payments) for up to nine months, and accelerated vesting of any time-based equity awards as if he had completed an additional nine months of continuous service.  If Mr. Brown&#8217;s employment is terminated without cause or he resigns for good reason within 12 months following a change in control, he is entitled to continued payment of his then-current base salary, and COBRA premium (or taxable cash) payments as described above, for 12 months, 100% of his target annual performance bonus, and full vesting of any unvested time-based equity awards.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ms. Adams.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Ms. Adams resigned as our Chief Operating Officer effective October 15, 2023. No severance payments were made to Ms. Adams in connection with her resignation. Ms. Adams continues to serve in a consulting role. No additional severance payments are due to her under the terms of her consulting arrangement.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outstanding Equity Awards at Fiscal Year-End</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth certain information regarding equity awards held by our named executive officers that remain outstanding as of December 31, 2023.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.112%;"/>
    <td style="width:1.299%;"/>
    <td style="width:11.855%;"/>
    <td style="width:1.299%;"/>
    <td style="width:11.675%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.136%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.316%;"/>
    <td style="width:1%;"/>
    <td style="width:1.299%;"/>
    <td style="width:1%;"/>
    <td style="width:9.856%;"/>
    <td style="width:1%;"/>
    <td style="width:1.299%;"/>
    <td style="width:11.855%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option Awards</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant<br/>date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vesting<br/>commencement<br/>date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of securities underlying<br/>unexercised<br/>options (#)<br/>exercisable</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of securities underlying<br/>unexercised<br/>options (#)<br/>unexercisable</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option<br/>exercise price<br/>per share<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option<br/>expiration<br/>date</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/3/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/3/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,257</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/2/2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/3/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/3/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,137</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/2/2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/26/2015</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/26/2015</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,721</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143.40</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/25/2025</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/20/2017</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/20/2017</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/19/2027</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/21/2018</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/21/2018</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/20/2028</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2019</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2019</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120,633</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,567</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/30/2030</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.14</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,979</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,021</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/27/2032</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/01/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/01/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">332,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.70</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA, M.S.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/31/2015</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/31/2015</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,352</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104.90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/30/2025</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/20/2017</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/20/2017</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,332</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/19/2027</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/21/2018</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/21/2018</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/20/2028</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2019</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2019</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,541</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">459</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/30/2030</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,104</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,896</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.14</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38333</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,667</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/27/2032</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/1/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/01/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.70</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bonne Adams, M.B.A.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/03/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/03/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,015</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/2/2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/03/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/03/2014</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,078</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/2/2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">03/25/2015</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">03/25/2015</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,122</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146.20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/25/2025</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/20/2017</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/20/2017</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/19/2027</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/21/2018</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/21/2018</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,591</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.50</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/20/2028</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/29/2019</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/29/2019</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2029</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/31/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/31/2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17233</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">367</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/30/2030</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/29/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/29/2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40104</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,896</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.14</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/28/2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/28/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/28/2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38333</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,667</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/27/2032</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/01/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/01/2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.70</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/31/2033</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> All of our option awards vest over four years of continuous service provided by the holder following the Vesting Commencement Date indicated above, with 25% of the option shares vesting after one year of continuous service and the remainder vesting in 36 substantially equal monthly installments following each month of continuous service thereafter. The options are also eligible for accelerated vesting in connection with qualifying terminations, as described above under &#8220;&#8212;Equity-Based Incentive Awards&#8221; and &#8220;&#8212;Potential Payments Upon Termination or Change in Control.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the option awards were granted with a per share exercise price equal to the fair market value of our common stock on the date of grant, as determined in good faith by our Board prior to our initial public offering in February 2015 and by reference to the closing stock price of our common stock on the date of grant thereafter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option Exercises</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option Repricings</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not engage in any repricings or other modifications or cancellations to any of our named executive officers&#8217; outstanding equity awards during the year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Health, Welfare and Retirement Benefits</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, and life and disability insurance plans, in each case on the same basis as all of our other employees. We provide a 401(k) plan to our employees, including our named executive officers, as discussed in the section below entitled &#8220;&#8212;401(k) Plan.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">401(k) Plan</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a defined contribution employee retirement plan (&#8220;401(k) plan&#8221;), for our employees. Our named executive officers are also eligible to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a tax-qualified plan under Section 401(k) of the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;), and is also intended to qualify as a safe harbor plan. During 2023, we made matching contributions of 100% of the amount of each participant&#8217;s contributions, up to 4% of each participant&#8217;s compensation. The 401(k) plan currently does not offer the ability to invest in our securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonqualified Deferred Compensation</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of our named executive officers participate in or have account balances in nonqualified defined contribution plans or other nonqualified deferred compensation plans maintained by us. Our Board may elect to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prohibition of Hedging and Pledging</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We prohibit our officers (and other employees) and non-employee directors from engaging in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to our securities at any time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Life Insurance</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our standard employee benefits to all employees, including our named executive officers, we obtain life insurance coverage for the benefit of the employee and pay the premium on their behalf.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Director Compensation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board adopted a new non-employee director compensation policy in February 2023. This compensation policy provides that each non-employee director will receive the following compensation for service on our Board. Prior to the effectiveness of our new non-employee director compensation policy, our non-employee directors received the same cash consideration as described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an annual cash retainer of $40,000;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an annual cash retainer of $60,000 for service as chair of our Board (in lieu of above);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an additional annual cash retainer of $7,500, $5,000 and $3,750 for service on our Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee, respectively;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an additional annual cash retainer of $15,000, $10,000 and $7,500 for service as chair of the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee (in lieu of regular committee member fees described immediately above), respectively;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an automatic annual option grant to purchase 18,000 shares of our common stock or a restricted stock unit award of 7,875 shares of our common stock for each non-employee director serving on the Board on the date of our annual stockholder meeting (including by reason of his, her or their election at such meeting), in each case vesting 100% as of the earlier of the date of our next annual stockholder meeting and the one-year anniversary of the date of grant, with the form of such grant determined by the Board or the Compensation Committee prior to our annual stockholder meeting, and with the option grant being the default award type; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon first joining our Board, an automatic initial grant of an option to purchase 31,500 shares of our common stock that vests ratably in annual installments over a three-year period following the grant date.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of the option grants described above will be granted under our 2015 Plan and will vest and become exercisable subject to the director&#8217;s continuous service with us, provided that each option will vest in full upon a change of control, as defined under our 2015 Plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Summary Compensation Table</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes director compensation for the year ended December 31, 2023:</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fees Earned or Paid in Cash<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option Awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen T. Worland, Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,649</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Saundra Pelletier</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin A. Mattingly, Pharm.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,149</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">J. Rainer Twiford, J.D., Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carol Lam, J.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William R. LaRue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lisa Johnson-Pratt, M.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,149</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to the non-employee directors&#8217; compensation policy in effect in 2023, each member of our Board who was serving on the Board on the date of our annual stockholder meeting received an option to purchase 18,000 shares of our common stock in April 2023 at an exercise price per share of $1.82. Amounts shown in this column reflect the aggregate grant date fair value of the options computed in accordance with FASB ASC Topic 718. For more information on how this amount is calculated, see Note 6 to our consolidated financial statements and notes thereto included within Part IV of our 2022 Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023, the aggregate number of stock options held by each of the directors was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:80.22%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:16.3%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Number of Options Held</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen T. Worland, Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,249</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Saundra Pelletier</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin A. Mattingly, Pharm.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,249</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">J. Rainer Twiford, J.D., Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carol Lam, J.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William R. LaRue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,410</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lisa Johnson-Pratt, M.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides information as of December 31, 2023, with respect to shares of our common stock that may be issued under our existing equity compensation plans:</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:10.700000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.24%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(a)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(b)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(c)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Plan Category</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>securities to<br/>be issued upon<br/>exercise of<br/>outstanding<br/>options, warrants<br/>and rights</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-average<br/>exercise price<br/>of outstanding<br/>options, warrants<br/>and rights</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>securities<br/>remaining<br/>available for<br/>future issuance<br/>under equity<br/>compensation<br/>plans (excluding<br/>securities<br/>reflected<br/>in column (a))</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans approved by stockholders:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2011 Equity Incentive Plan</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,065</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated 2015 Equity Incentive Plan</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,985,807</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.16</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350,035</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated 2015 Employee Stock Purchase Plan</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">429,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans not approved by stockholders:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inducement awards</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,280</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.72</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,720</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Effective as of January 29, 2015, no additional awards were granted under the 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;), and all awards granted under the 2011 Plan that are repurchased, forfeited, expire, cancelled or otherwise not issued will become available for grant under the Amended and Restated 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) in accordance with its terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The 2015 plan allows an additional 200,000 shares of common stock to be used exclusively for the grant of awards as a material inducement for individuals to commence employment with us in compliance with Nasdaq Listing Rule 5635(c)(4).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to an &#8220;evergreen&#8221; provision contained in the 2015 Plan, as amended June 10, 2021, on January 1 of each year until (and including) January 1, 2031, the number of shares authorized for issuance under the 2015 Plan is automatically increased by a number equal to: (a) 5.0% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; or (b) a number of shares of Common Stock that may be determined each year by the registrant&#8217;s board of directors that is less than the preceding clause (a).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(4)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to an &#8220;evergreen&#8221; provision contained in the Amended and Restated 2015 Employee Stock Purchase Plan (the &#8220;2015 ESPP&#8221;), as amended June 10, 2021, on January 1 of each year until (and including) January 1, 2031, the number of shares authorized for issuance under the 2015 ESPP is automatically increased by a number equal to the least of: (a) 1.0% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 250,000 shares of Common Stock; or (c) a number of shares of Common Stock that may be determined each year by the registrant&#8217;s board of directors that is less than the preceding clauses (a) and (b).</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth information regarding ownership of our common stock as of February 15, 2024 based on information available to us and filings with the SEC by (a) each person known to us to own more than 5% of the outstanding shares of our common stock, (b) each of our directors, (c) each of our named executive officers, and (d) all of our directors and executive officers as a group. Each stockholder&#8217;s percentage ownership is based on 45,092,627 shares of our common stock being outstanding as of February 15, 2024. Unless otherwise indicated, (i) the address for the following beneficial owners is: c/o TRACON Pharmaceuticals, Inc., 4350 La Jolla Village Drive, Suite 800, San Diego, California 92122 and (ii) we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.98%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.36%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.34%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and address of beneficial owner</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>shares<br/>beneficially<br/>owned</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percentage of<br/>shares<br/>beneficially<br/>owned</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5% or greater stockholders:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ikarian Capital LLC</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,765,530</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.13</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100 Crescent Court, Suite 1620</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dallas, TX 75201</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Directors and Named Executive Officers:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,021,103</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.23</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA, M.S.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191,686</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bonne Adams, M.B.A.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165,153</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William R. LaRue</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,173</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin A. Mattingly, Pharm.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">J. Rainer Twiford, J.D., Ph.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,639</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen T. Worland, Ph.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Saundra Pelletier</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,795</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lisa Johnson-Pratt, M.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carol Lam, J.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All executive officers and directors as a group (10 persons)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,684,547</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.70</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*  Represents beneficial ownership of less than 1%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)  Includes 621,686 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)  Includes 166,558 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(3) Includes 165,153 shares of common stock subject to options exercisable as of April 15, 2024. In accordance with our 2015 Plan, Ms. Adams&#8217; options continue to vest during her consulting period given her continued service to the Company. Ms. Adams will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">required to exercise any vested options to purchase our common stock within three months of the termination date of her consulting services, with any vested options to purchase our common stock not exercised by such date forfeited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(4) Includes 38,410 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(5) Includes 39,249 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6) Includes 1,058 shares of common stock beneficially owned by Brookline Investment Fund, LLC, 4,938 shares of common stock beneficially owned by CSA Biotechnology Fund I, LLC and 9,346 shares of common stock beneficially owned by CSA Biotechnology Fund II, LLC. J. Rainer Twiford, J.D., Ph.D., one of our directors, has voting and dispositive control over these shares. Dr. Twiford disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Also includes 1,797 shares of outstanding common stock held by MCT Investments, LLC. Dr. Twiford&#8217;s spouse, Marsha C. Twiford, has voting and investment power with respect to the shares held by MCT Investments, LLC. Also includes 36,750 shares of common stock subject to options exercisable as of April 16, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(7) Includes 39,249 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(8) Includes 36,750 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(9) Includes 47,250 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(10) Includes 29,750 shares of common stock subject to options exercisable as of April 15, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(11)  Consists of the shares of outstanding common stock and shares of common stock subject to options exercisable as of April 15, 2024, if any, referred to in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10).</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRANSACTIONS WITH RELATED PARTIES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following includes a summary of transactions since January 1, 2022 to which we have been a party, in which the amount involved in the transaction exceeded the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Sale of Common Stock and Pre-Funded Warrants</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, we issued and sold 174,508 shares of our common stock at a purchase price of $1.38 per share and pre-funded warrants to purchase 2,013,999 shares of our common stock at a purchase price of $1.37 per share of underlying common stock with an exercise price of $0.01 per share of underlying common stock (the 2023 Pre-Funded Warrants) for net proceeds of approximately $3.0 million in a private placement with Opaleye L.P. (together with its affiliates, the Purchaser). In accordance with their terms, the 2023 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of our common stock would exceed 19.99% of the shares of our common stock outstanding immediately after giving effect to such exercise, unless approval by our stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). At our 2023 Annual Meeting held in April 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the issuance of shares of common stock upon the potential future exercise of certain outstanding warrants held by the Purchaser, including the 2023 Pre-Funded Warrants, that would result in the Purchaser owning in excess of 19.99% of the shares of common stock outstanding immediately after giving effect to such exercise. Additional detail regarding this stockholder and their beneficiary ownership is provided under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022 Sale of Common Stock and Pre-Funded Warrants</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, we issued and sold 841,989 shares of our common stock at a purchase price of $1.32 per share and pre-funded warrants to purchase 2,205,018 shares of our common stock at a purchase price of $1.31 per share of underlying common stock with an exercise price of $0.01 per share of underlying common stock (the 2022 Pre-Funded Warrants) for net proceeds of approximately $3.9 million in a registered direct offering with the Purchaser. In accordance with their terms, the 2022 Pre-Funded Warrants may not be exercised if the Purchaser&#8217;s ownership of our common stock would exceed 19.99% of the shares of our common stock outstanding immediately after giving effect to such exercise, unless approval by our stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). In connection with this offering, we amended two existing pre-funded warrants to purchase shares of our common stock held by the Purchaser to extend the exercise periods and to permit exercise in excess of a similar 19.99% limit following approval of our stockholders of such exercise. At our 2023 Annual Meeting held in April 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the issuance of shares of common stock upon the potential future exercise of certain outstanding warrants held by the Purchaser, including the 2023 Pre-Funded Warrants, that would result in the Purchaser owning in excess of 19.99% of the shares of common stock outstanding immediately after giving effect to such exercise. Additional detail regarding this stockholder and their beneficiary ownership is provided under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Policies and Procedures for Transactions with Related Persons</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related-person transactions.&#8221; For purposes of our policy only, a &#8220;related-person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants involving an amount that exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director or a holder of more than 5% of our common stock, including any of their immediate family members and any entity owned or controlled by such persons.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board) for review. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related persons, the benefits of the transaction to us and whether any alternative transactions are available. To identify related-person transactions in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our Audit Committee or other independent body of our Board takes into account the relevant available facts and circumstances including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risks, costs and benefits to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms of the transaction;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of other sources for comparable services or products; and  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms available to or from, as the case may be, unrelated third parties or to or from our employees generally.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of Officers and Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into, and intend to continue to enter into, separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our Bylaws. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-10.294%;padding-left:9.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.	Principal Accountant Fees and Services.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents fees for services rendered by Ernst &amp; Young LLP, our independent registered public accounting firm, for 2023 and 2022 in the following categories</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Fees</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">448,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">467,200</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit-Related Fees</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax Fees</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,287</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All Other Fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">467,287</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">484,700</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Audit fees consist of fees billed for professional services by Ernst &amp; Young LLP for audit and quarterly review of our consolidated financial statements, review of our registration statements, issuance of comfort letters, and related services that are normally provided in connection with statutory and regulatory filings or engagements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) Audit-related fees consist of fees billed for professional services by Ernst &amp; Young LLP for assurance and related services related to the audit of the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(3) Tax fees consist of fees for professional services performed by Ernst &amp; Young LLP with respect to tax compliance, tax advice and tax planning.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Audit Committee has established a policy governing our use of the services of our independent registered public accounting firm. Under the policy, our Audit Committee is required to pre-approve all audit and permissible non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair such accounting firm&#8217;s independence. All fees paid to Ernst &amp; Young LLP during the years ended December 31, 2023 and 2022 were pre-approved by our Audit Committee.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	Exhibits and Financial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Documents filed as part of this report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements of TRACON Pharmaceuticals, Inc. listed below are set forth in Item 8 of this Annual Report for the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:94%;"/>
    <td style="width:1%;"/>
    <td style="width:5%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#report"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_63af7d8c-b6b8-487b-879f-c3bb840a58d7" contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#bs"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#pl"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#equity_stmt"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#cashflow"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Notes to Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Financial Statement Schedules</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These schedules have been omitted because the required information is included in the consolidated financial statements or notes thereto or because they are not applicable or not required.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:12.7%;"/>
    <td style="width:1.48%;"/>
    <td style="width:85.82%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Document</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.1(1)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000110465915006650/a14-18029_14ex3d1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.2(2)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459020056580/tcon-ex31_40.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.3(1)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000110465915006650/a14-18029_14ex3d2.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated Bylaws</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.1(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000104746915000290/a2222709zex-4_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Common Stock Certificate of the Registrant.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.2(5)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459020007520/tcon-ex49_1187.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description of Capital Stock</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.3(4)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Common Warrant dated March 27, 2018 (attached as Exhibit B-2 to the Securities Purchase Agreement).</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.4(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000104746914010118/a2221572zex-10_16.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant to Purchase Stock issued to Silicon Valley Bank on June 4, 2014.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.5(10)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459018012554/tcon-ex49_470.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant to Purchase Stock issued to Silicon Valley Bank on May 3, 2018</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.6(8)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001394319/000156459022031017/tcon-8k_20220902.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Warrant to Purchase Common Stock dated September 2, 2022</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.7(17)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000095017023020649/tcon-ex4_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated May 8, 2023, by and between the Registrant and Lincoln Park Capital Fund, LLC</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.1+(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000104746914010118/a2221572zex-10_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Indemnity Agreement by and between the Registrant and its directors and officers.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.2+(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000104746914010118/a2221572zex-10_2.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRACON Pharmaceuticals, Inc. 2011 Equity Incentive Plan and Forms of Stock Option Agreement and Notice of Exercise thereunder.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.3+(11)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001394319/000156459021035226/tcon-ex991_6.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRACON Pharmaceuticals, Inc. 2015 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise and Restricted Stock Unit Agreement thereunder, as amended June 28, 2021</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.4+(18)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459023003313/tcon-ex104_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">TRACON Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended February 1, 2023.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.5+(12)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001394319/000156459021032656/tcon-ex992_6.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRACON Pharmaceuticals, Inc. Amended and Restated 2015 Employee Stock Purchase Plan, as amended June 10, 2021</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.6+(13)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001394319/000156459021008957/tcon-ex106_550.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRACON Pharmaceuticals, Inc. Bonus Plan, as amended January 29, 2021.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:12.7%;"/>
    <td style="width:1.48%;"/>
    <td style="width:85.82%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Document</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.7+(14)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459019005597/tcon-ex107_767.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated Employment Agreement by and between the Registrant and Charles P. Theuer, M.D., Ph.D., dated February 5, 2019</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.10+(5)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459020007520/tcon-ex1010_390.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employment Agreement by and between the Registrant and Scott Brown, dated January 28, 2020.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.11+(5)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459020007520/tcon-ex1011_389.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Severance Agreement by and between the Registrant and Scott Brown, dated December 4, 2019</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.12+(3)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000104746914010118/a2221572zex-10_8.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRACON Pharmaceuticals, Inc. Severance Plan and Summary Plan Description.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.13*#(5)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459020007520/tcon-ex1018_453.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration and Clinical Trial Agreement by and among the Registrant, 3D Medicines (Beijing) Co., LTD. and Jiangsu Alphamab Biopharmaceuticals Co., LTD. dated December 20, 2019</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.14(16)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459020056580/tcon-ex991_6.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capital on Demand</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> Sales Agreement, dated as of December 9, 2020, by and between the Registrant and JonesTrading Institutional Services LLC</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.15 (6)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001394319/000156459022010503/tcon-ex12_185.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amendment to the Capital on Demand</span><span style="color:#000000;top:-3.9865pt;white-space:pre-wrap;font-size:5.695pt;position:relative;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> Sales Agreement, dated as of March 15, 2022, by and between the Registrant and JonesTrading Institutional Services LLC</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.16*#(14)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001394319/000156459021054044/tcon-ex101_290.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaborative Development and Commercialization Agreement by and among the Registrant, Eucure (Beijing) Biopharma Co., Ltd. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. dated October 8, 2021</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17(7)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1394319/000156459022023665/tcon-ex101_135.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Securities Purchase Agreement, between the Registrant and Opaleye L.P., dated June 21, 2022</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18(17)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Securities Purchase Agreement, dated May 8, 2023, by and between the Registrant and Lincoln Park Capital Fund, LLC.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19*#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement, dated November 17, 2023, by and between the Registrant and Inhibrx, Inc.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;23.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;24.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney. Reference is made to the signature page hereto.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;31.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;31.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;32.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Executive Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;32.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcon-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">TRACON Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The cover page for the Registrant&#8217;s Annual Report on Form 10-K has been formatted in Inline XBRL and contained in Exhibit 101</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.86%;"/>
    <td style="width:1.46%;"/>
    <td style="width:94.68%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indicates management contract or compensatory plan.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#8220;[***]&#8221;) because the Registrant has determined that the information is both not material and is the type that the Registrant treats as private or confidential.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Schedules (or similar attachments, including exhibits) to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission or its staff upon request.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on February 4, 2015.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 20, 2023.</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.86%;"/>
    <td style="width:1.46%;"/>
    <td style="width:94.68%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-201280), as amended.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 23, 2018.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to Registrant's Annual Report on Form 10-K, filed with the SEC on February 28, 2020.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-3, filed with the SEC on March 16, 2022.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 21, 2022.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 6, 2022.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2018.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 30, 2021.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(11)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 11, 2021</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant's Annual Report on Form 10-K, filed with the SEC on February 25, 2021.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 1, 2019.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-Q, filed with the SEC on November 3, 2021.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(16)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 9, 2020.</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(17)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on May 10, 2023.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18)</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 8, 2023.</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signatures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60%;"/>
    <td style="width:40%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 5, 2024</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">                                                                                          </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:       /s/ CHARLES P. THEUER, M.D., PH.D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:31.2pt;vertical-align:top;"><p style="margin-left:31.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that each person whose signature appears below constitutes and appoints Dr. Charles P. Theuer, M.D., Ph.D. and Scott B. Brown, CPA, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.66%;"/>
    <td style="width:1.68%;"/>
    <td style="width:54.66%;"/>
    <td style="width:1%;"/>
    <td style="width:16%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Scott B. Brown, CPA</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer (</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Financial and Accounting Officer</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Lisa Johnson-Pratt, M.D.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lisa Johnson-Pratt, M.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Carol C. Lam, J.D.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carol C. Lam. J.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ William R. LaRue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William R. LaRue</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Martin A. Mattingly, Pharm.D.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin A. Mattingly, Pharm.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Saundra Pelletier</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Saundra Pelletier</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ J. Rainer Twiford, J.D., Ph.D.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">J. Rainer Twiford, J.D., Ph.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Stephen T. Worland, Ph.D.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of the Board of Directors</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 5, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen T. Worland, Ph.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>tcon-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 10.19</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:right;" id="a154709"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">License Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This License Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), effective as of November 17, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is by and between Tracon Pharmaceuticals, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and Inhibrx, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; or each, individually, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Licensor owns certain proprietary technology and information relating to SOPs, quality systems, etc. that serve as the basis for an efficient approach to clinical trials; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Licensee wishes to obtain, and Licensor is willing to grant to Licensee, a license under Licensor&#x2019;s proprietary rights in and to such technology and information, on the terms and conditions set out in this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="a248310"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Capitalized terms used but not defined elsewhere in this Agreement have the following meanings:</font></div></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="a150247"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; of a Party means any entity that, at any time during the Term, controlled by, controlling, or under common control with a Party.  For the purpose of this definition, &#x201c;control&#x201d; (including, with correlative meaning, the terms &#x201c;controlled by&#x201d; or &#x201c;under common control&#x201d;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="a540589"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Field</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="a124985"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any and all proprietary rights provided under (a) patent law, including any patents and patent applications; (b) copyright law; and (c) any other applicable statutory provision or common law principle (including trade secret law) that may provide a right in the Tracon Product Development Platform or the expression or use thereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensed Technology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Tracon Product Development Platform and all Intellectual Property Rights relating thereto, or covering, claiming or disclosing the Tracon PDP, in each case to the extent owned or controlled by Tracon or its Affiliates.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="a796647"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means worldwide.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tracon Product Development Platform</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tracon PDP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all of the following, as may be described more fully or enumerated as applicable on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: (i) [***]; (ii) [***]; and (iii) [***].</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="a305155"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a867944"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensor hereby grants to Licensee a non-exclusive, non-sublicensable, and non-transferable (except in accordance with Section 14) license to use the Licensed Technology in the Field in the Territory solely for the internal business purposes of Licensee, which license shall become irrevocable and perpetual upon payment of the Upfront Payment. No license or rights are granted to Licensee by implication, estoppel, or otherwise, other than as expressly granted by Licensor under this Section 2(a). </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For clarity, internal business purposes shall include the provision of services to third parties with respect to development of drug candidates that are in-licensed from or out-licensed to such third party by Licensee, or the subject of a collaborative development agreement with any such third party, but excludes contract services arrangements.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a111218"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sublicensing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee may not grant sublicenses under the license granted in </font><a href="#a867944"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section</font></a><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 2(a); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that if Licensee divests a drug discovery program or drug asset to a new entity or to a third party (either is a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Divested Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and if Licensee used the Licensed Technology in connection with such program or asset prior to such divestment, then Licensee may grant a sublicense under the license granted in Section 2(a) to such Divested Entity solely for use with respect to such divested drug discovery program or drug asset. Each such sublicense shall be pursuant to a written sublicense agreement that includes terms and conditions sufficient to enable Licensee to comply with this Agreement, shall refer to and be subject to this Agreement, shall be consistent in all material respects with the terms and conditions of this Agreement, and shall name Licensor as a third party beneficiary to such sublicense agreement with rights to enforce it against the sublicensee.  Licensee will promptly notify Licensor upon execution of any sublicense under this Agreement and shall furnish Licensor with a true and complete copy of each sublicense within [***] ([***]) [***] of execution; provided that all such sublicenses shall be considered the Confidential Information of Licensee, and Licensee may redact economic terms or other technical or business information from such sublicenses which Licensee determines in good faith to be necessary to protect any of its or its sublicensee&#x2019;s confidential or proprietary information, or which are unrelated to Licensee&#x2019;s obligations under this Agreement.  Licensee&#x2019;s Affiliates may use the Licensed Technology pursuant to the license granted in Section 2(a) and License shall be responsible for its Affiliates&#x2019; compliance with the terms of this Agreement.  Use of the Licensed Technology by Licensee&#x2019;s Affiliates, or by Licensee on behalf of its Affiliates, does not constitute a sublicense. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="a253894"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Technology Transfer and Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Promptly after Licensee&#x2019;s payment of the upfront fee in accordance with Section 6(a), Licensor shall deliver a complete and accurate copy of the Licensed Technology to Licensee in such form and media as may be reasonably requested by </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensee.  If Licensee identifies any item or component of Licensed Technology that was not received, Licensor shall promptly deliver the missing item to Licensee.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon Licensee&#x2019;s reasonable requests from time to time during the first six (6) months after the Effective Date, Licensor shall make available a sufficient number of its technical personnel to provide Licensee&#x2019;s personnel with reasonable technical support and assistance concerning the Licensed Technology in a manner designed to enable Licensee&#x2019;s personnel to understand and effectively use the Licensed Technology as permitted herein (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Technical Support</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Licensor shall provide up to five hundred (500) hours of such Technical Support (including in-person or by phone/videoconference as requested by Licensee) at no additional cost to Licensee, except that Licensee shall reimburse Licensor for reasonable travel and other out-of-pocket expenses incurred by Licensor&#x2019;s technical personnel in providing such Technical Support to the extent that Licensee requests its performance outside of San Diego County. Any additional hours of such Technical Support shall be provided at a reasonable hourly rate as agreed by the Parties in writing. Licensee may require Licensor&#x2019;s training personnel to comply with Licensee&#x2019;s safety and security policies while on-premises or accessing Licensee&#x2019;s systems or networks.  For the avoidance of doubt, subject to the license expressly granted to Licensee under </font><a href="#a867944"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section</font></a><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 2(a), Licensor retains all right, title, and interest in and to the Licensed Technology delivered or otherwise made available to Licensee hereunder. Licensee shall not use the Technology for any purpose beyond the scope of the license expressly granted to Licensee under Section 2(a).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Improvements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As between the Parties, Licensee will solely own all right, title, and interest in and to any modification of or improvement or enhancement to any Licensed Technology (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Improvement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) made by or on behalf of Licensee&#x2019;s employees or independent contractors to the extent necessarily using or derived from any Licensed Technology or other Confidential Information of Licensor delivered or otherwise made available hereunder or in the course of providing the technical assistance contemplated hereunder and no license or other rights are granted to Licensor with respect to any Improvements, expressly or by implication, estoppel, or otherwise.  In the event any Improvements are made by any Licensor personnel in the course of providing the Technical Support, such Improvements shall be owned by Licensor and shall be included within the Licensed Technology subject to the license granted in Section 2(a).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee agrees and acknowledges that performance of the terms of this Agreement will place Licensee in a position of confidence and trust, whereby Licensee will be exposed to Licensor&#x2019;s confidential and proprietary business information and the personnel attributes of its workers (including their particular performance, expertise and compensation, contracts). As a result, Licensee may obtain knowledge of the &#x201c;know-how&#x201d; and business practices of Licensor, including with respect to its employees/consultants, in which matters Licensor may have a substantial proprietary interest and desires retention of the workers it has recruited and retained at its effort and expense. As such, for one year following the Effective Date, Licensee agrees not to solicit for employment or consulting arrangements any then-current Licensor employees or consultants that have been engaged by Licensor in the development or exploitation of the Tracon PDP; provided that in the event that Licensee wishes to consider for employment or retention as a consultant any specific then-current Licensor employee or consultant, Licensee shall so identify such employee or consultant to Licensor and Licensor, in its reasonable discretion, may </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provide a waiver of such non-solicitation provisions with respect to the applicable employee or consultant. For avoidance of doubt, in the event that any person&#x2019;s employment or consulting arrangement with Licensor ceases during the non-solicitation period (including, but not limited to, by reason of layoffs due to bankruptcy, dissolution, or similar circumstances), or in the event that an employee or consultant resigns on their own accord (provided that such resignation was not the result of solicitation by Licensee in violation of this Section 5), then Licensee may solicit, hire or retain as a consultant any such former Licensor employee or consultant, and it shall not be considered a violation of this Section 5. Further, (i) Licensor agrees that Licensee may solicit and hire [***] as a full-time employee, or retain her as a consultant, at any time, whether or not a license transaction is consummated; and (ii) in the event that Licensee solicits, employs or retains [***], this shall not be a violation of this Section 5 and Licensee shall not object to the continuation of Licensor&#x2019;s then existing consulting arrangement with Bonne Adams.  Licensee&#x2019;s general solicitations not targeting a specific then-current employee or consultant of Licensor shall not constitute a violation of this Section 5, And Licensee&#x2019;s hiring or engagement of a then-current employee or consultant of Licensor shall not constitute a breach of this Section 5 if such person independently approaches Licensee for employment or a consulting arrangement, without any solicitation by Licensee or by [***].</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="a819597"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a587006"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upfront Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Within ten (10) days after the Effective Date, Licensee shall pay to Licensor a non-refundable, non-creditable payment of Three Million US Dollars ($3,000,000) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upfront Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a558601"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the (i) completion of five hundred (500) hours of Technical Support by Licensor personnel as provided in Section 3, or (ii) six (6) months following Licensor&#x2019;s delivery of the Licensed Technology, whichever is earlier, Licensee shall pay to Licensor a non-refundable, non-creditable payment of Two Hundred Thousand US Dollars ($200,000).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="a601468"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee shall make all payments due hereunder (i) in US dollars by check/wire transfer of immediately available funds to a bank account designated in writing by Licensor; and (ii) without deduction of exchange, collection, or other charges or withholding or other government-imposed fees or taxes. If any payment is not received by Licensor on or before the due date for such payment, Licensee shall pay to Licensor interest on the overdue payment from the due date to the date such payment is received by Licensor at a rate of [***] ([***]) [***] or if lower, the maximum amount permitted under applicable law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="a266555"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Proprietary Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a516362"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Preservation of Licensed Technology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="a700979"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensee acknowledges that: (A) the Licensed Technology is Licensor&#x2019;s Confidential Information and subject to the confidentiality and non-disclosure obligations under Section 9; and (B) elements of the Licensed Technology comprising trade secrets (as defined under applicable laws) derive </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">economic value, actual or potential, from not being generally known to, and not being readily ascertainable through proper means by, any other person or entity.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="a978122"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensee shall use reasonable efforts to preserve the secrecy of the Licensed Technology at all times during the Term. </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="a613650"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Without limiting Section 7(a)(ii) or any of its obligations under Section 9, Licensee shall implement reasonable administrative, physical, and technical safeguards designed to protect the Licensed Technology from unauthorized access or disclosure that are no less rigorous than the practices implemented by Licensee to protect its own proprietary technologies, including:</font></div></div>
  <div style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.33375%;text-indent:0;display:inline-flex;justify-content:flex-start;">(A)</font><div style="width:100%;display:inline;" id="a632461"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">securing physical premises, facilities, networks, databases, paper files, and information technology and other equipment where any Licensed Technology may be used or stored; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and</font></div></div>
  <div style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.33375%;text-indent:0;display:inline-flex;justify-content:flex-start;">(B)</font><div style="width:100%;display:inline;" id="a523758"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">implementing appropriate personnel security and integrity procedures and practices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a883908"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Filings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee has no right to, and shall not, (i) file or prosecute any patent application or seek or obtain any patent claiming any Licensed Technology; or (ii) subject to the license granted to Licensee under Section 2(a), claim any ownership or other right, title, or interest in or to, or voluntarily challenge Licensor&#x2019;s ownership or other right, title, or interest in or to, any Licensed Technology (except as part of the defense of a claim first brough by Tracon against Licensee alleging infringement).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="a165494"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Enforcement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee shall notify Licensor in writing promptly upon becoming aware of any actual or suspected misappropriation or other unauthorized access, disclosure, or use of any Licensed Technology within Licensee&#x2019;s possession or control (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unauthorized Use</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and shall provide Licensor with any known details of such Unauthorized Use (subject to compliance with obligations of confidentiality and preservation of legal privilege). Licensor has the first right, in its discretion, to bring any action or proceeding with respect to such Unauthorized Use and to control its conduct (including any settlement).  If Licensor does not commence an action or proceeding within [***] ([***]) [***] after receipt or delivery of notice hereunder concerning any Unauthorized Use, the Parties shall discuss in good faith and determine whether Licensee may bring such action or proceeding on its own. The Party not controlling any action or proceeding brought under this Section shall provide the other Party with all cooperation and assistance that such other Party may reasonably request in connection with such action or proceeding. Any damages, profits, and other monetary awards resulting from any such action or proceeding will be retained by the Party bringing such action or proceeding. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="a581085"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Party shall comply with all applicable laws and regulations in the Territory in exercising its rights and performing its obligations under this Agreement. Without limiting the foregoing, Licensee shall comply with all applicable laws and regulations concerning the export or re-export of any Licensed Technology and any associated </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">technical data, materials, or information, including any requirements for obtaining an export license or other governmental approval.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="a177062"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Party acknowledges that in connection with this Agreement it will receive or gain access to certain non-public, confidential, or proprietary information and materials of the other Party in oral, written, electronic, or other form or media, whether or not such information and materials are marked, designated, or otherwise identified as &#x201c;confidential&#x201d; (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Without limiting the foregoing, the Tracon PDP constitutes the Confidential Information of Licensor, and Improvements constitute the Confidential Information of the Party owning such Improvements. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exclusions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Confidential Information does not include information that: (i) was already known to the receiving Party without restriction on use or disclosure; (ii) was or becomes generally known by the public other than by breach of this Agreement by the receiving Party; or (iii) was received from a third party not under any confidentiality obligation to the other Party; or (iv) is independently developed without reference to or use of the other Party&#x2019;s Confidential Information. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality Obligations; Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Party shall maintain the other Party&#x2019;s Confidential Information in strict confidence and not disclose it to any other person or entity, except to its employees or independent contractors who have a need to know such Confidential Information for such Party to exercise its rights or perform its obligations hereunder and are bound by written nondisclosure agreements. Notwithstanding the foregoing, each Party may disclose the other Party&#x2019;s Confidential Information to the limited extent required to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or a valid order issued by a court or governmental agency of competent jurisdiction; provided that the Party making the required disclosure shall first provide the disclosing Party with: (i) prompt written notice of such requirement so that the disclosing Party may seek, at its sole cost and expense, a protective order or other remedy; and (ii) reasonable assistance, at the disclosing Party&#x2019;s sole cost and expense, in opposing such disclosure or seeking a protective order or other limitations on disclosure. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Special Confidentiality Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In light of the[***], as a precautionary measure, the Parties agree to cooperate to jointly pursue protective measures to ensure that no [***].  Licensor covenants that it shall not disclose [***].</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="a692024"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Representations and Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a571869"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Mutual Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Party represents and warrants to the other Party that, as of the Effective Date: (i) it is duly organized, validly existing, and in good standing under the laws of the state or jurisdiction of its organization; (ii) it has the full right, power, and authority to enter into this Agreement and to perform its obligations hereunder; (iii) the execution of this Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by all necessary corporate action of such </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Party; and (iv) when executed and delivered by such Party, this Agreement will constitute the legal, valid, and binding obligation of that Party, enforceable against that Party in accordance with its terms.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a927007"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensor Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensor represents and warrants that: (i) subject to the license granted herein, Licensor owns the entire right, title, and interest in and to the Licensed Technology; (ii) Licensor has the right to grant the license and other rights hereunder; and (iii) to Licensor&#x2019;s knowledge, use of the Licensed Technology permitted under this Agreement does not infringe or misappropriate any Intellectual Property Rights of any other person or entity. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For clarification, Licensee acknowledges and agrees that Licensee may require additional licenses from third parties, including as set forth in Section 10(c), in order to practice the Licensed Technology and that no such licenses are granted hereunder or otherwise by Licensor. Licensor represents and warrants that the license granted to Licensee herein is made by Licensor, and is not made by any of Licensor&#x2019;s personnel in their individual capacity.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensee Representations and Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee represents and covenants that, to the extent necessary for its use of the Tracon PDP, Licensee has obtained or will obtain and maintain during its exploitation of the license granted hereunder, as required: (i) [***]; (ii) [***]; (iii) [***]; and (iv) [***].</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="a862624"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclaimer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 10, LICENSOR DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, CONCERNING THE LICENSED TECHNOLOGY, INCLUDING AS TO THE ACCURACY, COMPLETENESS, OR USEFULNESS FOR ANY PURPOSE OF THE LICENSED TECHNOLOGY. LICENSOR SPECIFICALLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT AND WARRANTIES ARISING FROM A COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE, OR TRADE PRACTICE. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="a311158"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a210748"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensor shall indemnify, defend, and hold harmless Licensee and its Affiliates, and each of Licensee&#x2019;s and its Affiliates&#x2019; respective officers, directors, employees, and agents against all losses, damages, liabilities, costs (including reasonable attorneys&#x2019; fees) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) resulting from any third-party claim, suit, action, or other proceeding (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third-Party Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) arising out of Licensor&#x2019;s breach of any representation, warranty, covenant, or obligation under this Agreement or alleging that the use of the Licensed Technology under this Agreement infringes or misappropriates any third party&#x2019;s intellectual property rights.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a698693"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee shall indemnify, defend, and hold harmless Licensor and its Affiliates, and each of Licensor&#x2019;s and its Affiliates&#x2019; respective officers, directors, employees, and agents against all Losses resulting from any Third-Party Claim arising out </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of any bodily injury, death of any person, or damage to real or tangible personal property caused by use of the Licensed Technology by Licensee.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="a944772"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. EXCEPT FOR INDEMNIFICATION OBLIGATIONS AND LIABILITY FOR BREACH OF SECTION 5 OR BREACH OF CONFIDENTIALITY (INCLUDING LICENSEE&#x2019;S OBLIGATION TO PRESERVE THE SECRECY OF THE LICENSED TECHNOLOGY UNDER SECTION 9(A), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR ANY LOSS OF USE, REVENUE, OR PROFIT OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, OR PUNITIVE DAMAGES, WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, REGARDLESS OF WHETHER SUCH DAMAGE WAS FORESEEABLE AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="a509748"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term and Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a592160"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement is effective as of the Effective Date and will continue in effect until terminated by mutual agreement of the Parties or in accordance with </font><a href="#a268159"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section</font></a><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 13(b). </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a268159"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="a504271"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Material Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Either Party may terminate this Agreement in its entirety immediately upon notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach within [***] ([***]) [***] after notice of such breach from the non-breaching Party; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that if such breach is capable of being cured but cannot be cured within such [***] ([***]) [***] period despite the breaching Party&#x2019;s efforts to do so, and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable in the circumstances to cure such breach, provided that such additional period shall in no event exceed [***] ([***]) [***].  Any dispute regarding the existence or materiality of a breach specified in a notice provided by a Party in accordance with this Section 13(b)(i), or whether a material breach has been cured within the applicable cure period, will be resolved in accordance with the dispute resolution procedures described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15(j) or Section 15(k)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No purported termination of this Agreement pursuant to this Section 13(b) shall take effect until the resolution of such dispute, and the period for cure of such alleged breach shall be tolled during the pendency of any dispute with respect to an alleged breach.  If it is ultimately determined that the breaching Party committed such material breach, then the breaching Party will have the right to cure such material breach after such determination within the remainder of the cure period (or extended cure period as provided for herein) which will commence as of the date of such determination.  Any termination by any Party under this Section 13(b) and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled. </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="a549017"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Insolvency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Parties intend that the license granted to Licensee hereunder is, for purposes of Section 365(n) of the United States Bankruptcy Code (11 U.S.C. Title 11) (the &#x201c;Bankruptcy Code&#x201d;), license of rights to &#x201c;intellectual property,&#x201d; as that term is defined in Section 101 of the Bankruptcy Code. Nothing in this Agreement limits the Licensee&#x2019;s rights under such Section 365(n). The Licensee is not in this Agreement making an election under such Section 365(n).</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="a881083"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Licensor&#x2019;s Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any transaction or series of transactions resulting in a change in the person or entity holding, directly or indirectly: (A) fifty percent (50%) or more of the combined voting power of Licensor&#x2019;s outstanding securities; (B) all or substantially all of the assets of Licensor relating to this Agreement; or (C) the power to direct or cause the direction of the management and policies of Licensor, whether through the ownership of voting securities, by contract or otherwise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, or any similar change of control or by operation of law, Licensor shall require that the surviving entity(ies) comply with the terms of this Agreement, and the Parties intend for this Agreement including the license granted to Licensee hereunder to continue in full effect thereafter.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="a521511"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Expiration or Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="a407435"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expiration or termination of this Agreement will not relieve the Parties of any obligations accruing before the effective date of such expiration or termination. </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="a508002"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Parties&#x2019; rights and obligations set forth in this Section 13(c) and Section 4 (Improvements), Section 7 (Proprietary Rights), Section 8 (Compliance with Laws), Section 9 (Confidentiality), Section 11 (Indemnification), Section 12 (Limitation of Liability), Section 14 (Assignment), Section 15 (Miscellaneous), and any right, obligation, or required performance of the Parties under this Agreement that, by its express terms or nature and context is intended to survive expiration or termination of this Agreement, will survive any such expiration or termination (including for clarity the license granted in Section 2(a) following Licensor&#x2019;s receipt of the Upfront Payment).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="a926906"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Licensee shall not assign or otherwise transfer any of its rights, or delegate or otherwise transfer any of its obligations or performance, under this Agreement, in each case whether voluntarily, involuntarily, by operation of law, or otherwise, without Licensor&#x2019;s prior written consent (not to be unreasonably withheld), except that Licensee may make such an assignment, delegation, or other transfer, in whole, without the Licensor&#x2019;s consent in connection with the transfer or sale of all or substantially all of the business or assets of Licensee relating to this Agreement or similar change of control, or by operation of law, or to an Affiliate of Licensee. Any purported assignment, delegation, or transfer in violation of this Section 14 is void. This Agreement is binding upon and inures to the benefit of the Parties and their respective successors and assigns.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="a414868"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="a674460"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Party shall, upon the request, and at the expense, of the other Party, promptly execute such documents and take such further actions as may be necessary to give full effect to the terms of this Agreement.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="a861204"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Independent Contractors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement creates any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the parties, and neither Party has authority to contract for or bind the other party in any manner whatsoever.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="a875227"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Public Announcements and Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Parties acknowledge and agree that Licensor may publicly announce this Agreement and the transactions contemplated hereunder; provided that (i) if Licensor issues a press release or other form of public announcement, that press release or other form of public announcement shall not name or otherwise identify Licensee, and the content of the press release or public announcement shall be reasonably acceptable to Licensee (as confirmed by Licensee in writing); (ii) if required by law, Licensor may include disclosure regarding the Agreement in a form consistent with the disclosure set forth in Schedule 3 or otherwise reasonably acceptable to Licensee (as confirmed by Licensee in writing, and only naming Licensee as required by law), in a report filed by Licensor pursuant to the U.S. Securities Exchange Act of 1934, as amended to date (the &#x201c;Exchange Act&#x201d;); and (iii) if required by law, Licensor may file the Agreement as an exhibit to a filing pursuant to the Exchange Act or a filing pursuant to the Securities Act of 1933, as amended to date so long as Licensor requests confidential treatment of those provisions of this Agreement identified in Schedule 4.  Notwithstanding the foregoing, nothing herein shall preclude Licensor from incorporating any information disclosed in Licensor&#x2019;s public filings in any public response to inquiries posed to Licensor (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, analyst queries).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="a787216"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All notices, consents, claims, demands, waivers, and other formal or legal communications hereunder must be in writing and sent to the respective Party at the addresses indicated below (or at such other address for a Party as may be specified in a notice given in accordance with this Section):</font></div></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:30.55pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:30.55pt;text-indent:0;font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">If to Licensor:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4350 La Jolla Village Drive<br>Suite 800<br>San Diego, CA 92122<br>Phone: (858) 550-0780<br>Attention: CEO</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:30.55pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:30.55pt;text-indent:0;font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">If to Licensee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inhibrx, Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11025 N. Torrey Pines Rd, Suite 200</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla, CA 92037<br>Attention: CEO</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="a257244"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices sent in accordance with this Section 15(d) will be deemed effective: (a) when received, if delivered by hand (with written confirmation of receipt); (b) when received, if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by email (in each case, with confirmation of transmission and receipt), if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the [***] ([***]) [***] after the date mailed, by certified or registered mail, return receipt requested, postage prepaid.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="a348786"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Agreement: (a) the words &#x201c;include,&#x201d; &#x201c;includes,&#x201d; and &#x201c;including&#x201d; will be deemed to be followed by the words &#x201c;without limitation&#x201d;; (b) the word &#x201c;or&#x201d; is not exclusive; and (c) the words &#x201c;herein,&#x201d; &#x201c;hereof,&#x201d; &#x201c;hereby,&#x201d; &#x201c;hereto,&#x201d; and &#x201c;hereunder&#x201d; refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Sections and Schedules refer to the Sections of and Schedules attached to this Agreement; (y) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement will be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing any instrument to be drafted. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="a155806"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement, together with all Schedules and any other documents incorporated herein by reference, constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter, including any term sheets, and any &#x201c;click-through&#x201d; or &#x201c;click-wrap&#x201d; terms. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;" id="a283827"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Third-Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement is for the sole benefit of the Parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or will confer upon any other Person any legal or equitable right, benefit, or remedy of any nature whatsoever, under or by reason of this Agreement.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;" id="a220721"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment; Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No amendment to this Agreement will be effective unless it is in writing and signed by both Parties. No waiver by any Party of any of the provisions hereof will be effective unless explicitly set forth in writing and signed by the waiving Party. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power, or privilege arising from this Agreement will operate or be construed as a waiver thereof; nor will any single or partial exercise of any right, remedy, power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="a943567"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;" id="a119623"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Submission to Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement is governed by and construed in accordance with the internal laws of the State of California without giving effect to any choice or conflict of law provision or rule that would require or permit the application of the laws of any other jurisdiction. Any legal suit, action, or proceeding arising out of or related to this Agreement or the licenses granted hereunder will be instituted exclusively in the federal courts of the United States or the courts of the State of California in each case located in the city of San Diego and County of San Diego, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, or proceeding.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;" id="a258968"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equitable Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Party acknowledges that a breach by the other Party of this Agreement may cause the non-breaching Party irreparable harm, for which an award of damages would not be adequate compensation and, in the event of such a breach or threatened breach, the non-breaching Party will be entitled to seek equitable relief, including in the form of a restraining order, orders for preliminary or permanent injunction, specific performance, and any other relief that may be available from any court, and the Parties hereby waive any requirement for the securing or posting of any bond or the showing of actual monetary damages in connection with such relief. These remedies are not exclusive but are in addition to all other remedies available under this Agreement at law or in equity, subject to any express exclusions or limitations in this Agreement to the contrary.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;" id="a579505"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">[signature page follows]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:73.45pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRACON PHARMACEUTICALS, INC.</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Charles Theuer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br>Name: Charles Theuer<br>Title: CEO</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:79.2pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INHIBRX. INC.</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Mark Lappe</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br>Name: Mark Lappe<br>Title: CEO</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="a703630"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LICENSED TECHNOLOGY</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tracon Product Development Platform</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SCHEDULE 2</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LETTER OF AUTHORIZATION</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SCHEDULE 3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SCHEDULE 4</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">[***]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tcon-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.84%;"></td>
    <td style="width:3.06%;"></td>
    <td style="width:1%;"></td>
    <td style="width:92.1%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="text-indent:43.9pt;vertical-align:top;text-align:right;"><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-270372) pertaining to the Amended and Restated 2015 Equity Incentive Plan and Amended and Restated 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263591) pertaining to the Amended and Restated 2015 Equity Incentive Plan and Amended and Restated 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-258077) pertaining to the Amended and Restated 2015 Equity Incentive Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-253546) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-236732) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-229988) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-223333) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc., </font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-216347) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc., </font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-209592) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-201808) pertaining to the 2011 Equity Incentive Plan, 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(11)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-1 No. 333-272100) of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(12)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-1 No. 333-239574) of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(13)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-1 No. 333-234651) of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(14)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-270589) of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(15)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-263590) of TRACON Pharmaceuticals, Inc.,</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(16)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-248593) of TRACON Pharmaceuticals, Inc., and</font></div></div><div style="margin-left:0.24999999999999994in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.961362202199304%;text-indent:0;display:inline-flex;justify-content:flex-start;">(17)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-224809) of TRACON Pharmaceuticals, Inc.</font></div></div><p style="margin-left:44.25pt;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our report dated March 5, 2024, with respect to the consolidated financial statements of TRACON Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of TRACON Pharmaceuticals, Inc. for the year ended December 31, 2023.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:86.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:41.58%;"></td>
    <td style="width:58.42%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 5, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tcon-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Charles P. Theuer, M.D., Ph.D., certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of TRACON Pharmaceuticals, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">c. Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d. Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:61.12%;"></td>
    <td style="width:38.88%;"></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 5, 2024</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Charles P. Theuer, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.81in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tcon-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Scott B. Brown, CPA, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of TRACON Pharmaceuticals, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">c. Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d. Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:61.12%;"></td>
    <td style="width:38.88%;"></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 5, 2024</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Scott B. Brown, CPA</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.81in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tcon-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Charles P. Theuer, M.D., PhD., President and Chief Executive Officer of TRACON Pharmaceuticals, Inc. (the &#x201c;Registrant&#x201d;), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)	this Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the &#x201c;Report&#x201d;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:58.66%;"></td>
    <td style="width:41.34%;"></td>
   </tr>
   <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 5, 2024</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Charles P. Theuer, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of TRACON Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tcon-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Scott B. Brown, CPA, Chief Financial Officer of TRACON Pharmaceuticals, Inc. (the &#x201c;Registrant&#x201d;), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)	this Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the &#x201c;Report&#x201d;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:58.66%;"></td>
    <td style="width:41.34%;"></td>
   </tr>
   <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 5, 2024</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Scott B. Brown, CPA</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott B. Brown, CPA</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of TRACON Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>tcon-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of TRACON Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Nasdaq Listing Rule 5608 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Incentive Compensation is deemed &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Company&#x2019;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee or, in the absence of such committee, the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each current and former Executive Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lookback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#x2019;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverable Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicability of Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Generally.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of this Policy, if there is an </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#x2019;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Impracticability of Recovery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Recoupment may be determined to be impracticable if, and only if:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sources of Recoupment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification of Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#x2019;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of Administrator.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No &#x201c;Good Reason&#x201d; for Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#x2019;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Other Remedies</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#x2019;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SOX 304</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment; Termination</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10.	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Filings</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*	*	*	*	*</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form of Executive Acknowledgment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the TRACON Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with TRACON Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreed and Acknowledged:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">__________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: ____________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title: ____________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: ____________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img19885085_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z FP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7]*T[Q-9Z7_PD5_+&=T4,7]HB2U+'HNQHHV!STXZU[E7A'@W3)?$.L:>C+J
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M*Y?P)KNO>(+2[NM8CTV.*.=X(A9AP2R,58MN)XX&,4 ==1110 4444 %%%%
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MO"<GDLUI;[+<+"BB=@BD9VY7=@M\QP2,\UH:58:-H-K<16)CAC5]T[/.7(.
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M3 -EP0XR%&0P/.>:LZUI]G!XL\-7,5I EP]S(C3+& [ 0/@%NIZ5U=<[K_\
MR,?AC_K[E_\ 1+T 9'CWXG6'@&ZLX+RPN;IKE"ZF%E  !QSFO._ 7QCTRPV:
M.^EW;27NH.RR!EPOFR$C/TS57]H__D,:)_U[O_Z%7DWA7_D;='_Z_8?_ $,4
M ?< .0#12+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ^]7M9TNPMO%_AN\ALX$NGN)$>=8P'91 P +=3T% 'DO[1__ "&-$_Z]W_\
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M;6_"D>NW%JUF&)S;B42.!G /&.M<-^T3_P BEIW_ %]'^5>6?"C_ )">I_\
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M[0G_ "(]K_U]C^57?!__ ",4/^ZU4OVA/^1'M?\ K['\J<@1YY^S]_R/\O\
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MD!YYX!_Y'W1/^OM*^B/%O_(PS_1?Y5\[^ ?^1]T3_K[2OHCQ;_R,,_T7^5-
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MKUCP5_R,*_\ 7-OZ5Y/\(O\ D&^(?I!_-J]8\%?\C"O_ %S;^E-; 8_[1/\
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MUX5\)97A\:&2)V1UM)BK*<$';2&?7M4-9UK3_#^FR:CJER+>TC(#R%2V,].
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M0QHG_7N__H5>3>%?^1MT?_K]A_\ 0Q7K/[1__(8T3_KW?_T*O)O"O_(VZ/\
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MU/ __(8D_P"N1K+\0_\ (>O/^NAK4\#_ /(8D_ZY&F(]!KY(^-/_ "4[4?\
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M$OB/P)>P:G:WUC>R3M]DV"&0A1)P6..PKWG6=8M="TV2^O/,\I"%"QH69B>
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M .8N+3Q3-<RRCP=J0#N6 \^#N?\ KI6SX<O_ !)HIG,O@G5)/,QC;<6_&/\
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MV*13S0-%'<; S1YP>/;(&1[5/H6E?V+H]O8&ZGNWB7#SSN6=V[DY_EVK1HH
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M&>Q88S0,I>#/!D?AZ(WEQ+/-J$\2+()I XBP/NJ< D#IDY..]==110(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ANK2WOK62VNX(YX)
M!AXY%#*P]P:FHH C@@AM8$@MXDBAC4*D:*%50.P Z5)110 4444 (RJZE6 *
MD8((X(H5%1 J*%4#  & *6B@ HHHH QO%.BRZ_X?N-/AN/(E?#(QSM)!SA@.
MJGO7/>'O"-U-826GB.(M91RAK>Q>X\]!CWQG&>5!Z5W5% "*JHH50 H&  .
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M8\OR\<CTH N?\)]X;^SI.M\[1N,HWV>4!O3!*XY[>M4].^(VCWL*W$SBT@:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !14%XUTEJ[64,,UP,;(YI3$AYYRP5B.,]C65]J\5?\ 0&T;_P &TO\
M\C4 ;E%8?VKQ5_T!M&_\&TO_ ,C4?:O%7_0&T;_P;2__ "-0!N45A_:O%7_0
M&T;_ ,&TO_R-1]J\5?\ 0&T;_P &TO\ \C4 ;E%8?VKQ5_T!M&_\&TO_ ,C4
M?:O%7_0&T;_P;2__ "-0!N45A_:O%7_0&T;_ ,&TO_R-1]J\5?\ 0&T;_P &
MTO\ \C4 ;E%8?VKQ5_T!M&_\&TO_ ,C4?:O%7_0&T;_P;2__ "-0!N457LGO
M)+8-?P007&3E()S*H';YBBG]*L4 %%%% !1110 4444 %%%% !1110 4444
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M=CJ?IBM:?29+^(V^HW1FMRJ<0;X'#CJV]'!&>.!T]367%X,CMM#U;38+^?\
MXF#N?,GDDF\L,>F'<Y/OD9[T=6"Z$FJ^(+C3[K0@9+2*"_8B=IE/RX7=\IW
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M& 2.QJ+7=%&MV\<#21HJ$MEHRS*W9E8,"I'J#69>^%+R\OK>=M8RD$D<B)+
M6(*C!Y#@'/N,^])#+O\ PE^B;BHN9F(#$;;64[MOWL87G'?%69?$&EPPQS/=
M 12!6#A&( ;@$D#Y<^^*Q8?!DT7V;_B9(?)%P/\ CV//F_\  ^WZT^T\(S64
MUL\5_ P2%89A+9[RVWHR$M\A_P"^J%Y@SJ@<C(Z5FKK^EM<R6ZW8,D>[< K8
M^7[V#C!([@5H@84#TKEI/"=W+K'V^35D<CS556MCD*XQC._''L!0!<'C+0V4
ML+J; 0/G[++]TG&[[OW<]^E2-XBLK>6^>YO8O(M]F0D#[DW#C)YW9[8%9/\
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M,\>N,5R</A[4]1U?5HKNZV7"-:2PWGV%TB=HRQ^Z6Y[9PW>M-?!T\7E31:C
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MVFAV0W$7_'L>?-/7[_;]:<W@IW@GC?4E_>64=J"+?&"C;@WWN>>WZT?U^?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!-96M
MQ())[:&5U& SQAB/Q-3T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img19885085_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %R I # 2(  A$! Q$!_\0
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M<<U+10!E6%Y>MJ]Y97;V\BQ*KHT43)P>QRS9^O%:M8]K_P C5J'_ %PCK8H
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M@ HHHH **** "BBB@ HHHH ***H:E=RQ>7:V@4WD^0F[HBC&YS[#/3N2!ZD
M'-^.=$MO&VES:(\TD=O;GSYYHL95U!VH,\9.<GTX]:W_  YHT/A[P]8Z5;R2
M216T017DQN(]\5*UI'9:-/#&2V(G+,QR68@DD^Y/-78_]4G^Z* '4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% #)94@A>61MJ(I9CZ <FO*+G7?"^H:T+SPUK]V=4N;I28'EO(K:0]#D
M(F,].O%>IWK^78W#Y0;8F.9 2O [@=J\*T?1KH^);37[K4M$$9FB(33))+5<
M.?ERBP MG_:;ZT >]1ES&IE"B3'S!3D ^QIU%% !1110!CVO_(U:A_UPCK8K
M'M?^1JU#_KA'6Q0 4444 %%%% !14-TURML[6D44LX'R)+(44GW8*Q'Y&L.>
MX\9%1]GTO05;//F:C,1C\(!0!T55;73;&Q>1[.RMK=I3F1H8E0N?? YZFJ]C
M/K3&0ZC86,2A<I]EO&E9CZ$-&@'US6-X8O-6N-?U=-4ANHFV0R+#(\92'.\;
M5VL>P'/<@^PH0/8Z-["SE5EDM('5Y!*P:,$,XQAC[\#GV%)_9UCB$?8[?$*%
M(AY2_NU(P0O' (XP*XW^T=07Q%=K?3RQZ.M\8XY(YV!$OEH45_[J9)P >6(S
MUYQHM7URUTC2[5[N\FGFLY;J&YR6,B&(DJQ[LC'C/8KZ&A:K^NW]?(-CT0Z#
MHQM4M3I-@;>-BZ1&V38K'J0,8!J:/3+"*]:]CL;9+IAM:=8E#D<<%L9[#\JX
M.\OX!:WJVFNR&T3<;%Y=1D1)9/+7(^T<EMI)(4DY)(_AXOZ#JLDGB!4N)'GF
MN7XC^VR"2W41*?WEL0%49!YR>6'K36K!Z(ZR32M.EN);B2PM7GE0QR2-"I9T
M/!4G&2/:F-HNE-,\S:99F5T,;N8%W,N,;2<<C'&*YG^TC#XC!EU!TN5O95N+
M=[@B..T$;$.4)VJ,A#OQU)&:F\07M[97U]=6FHS;!I$T\,?RF-'4C# 8Y_'-
M)=//_*X^MOZWL=%/I=E<1R*;>)6<EC(J*&#;=NX''7;QGTXZ51TGPKI6D17*
MQ6\<K7/$S20QC>,8VX157&!TQSWKE;O6=>T][@QZG-=M'<FW5)((N0;;S=WR
MH"2&Z>W8]:ANM=N[RUUFTL]>DO5MHFG6XB9$90(0=NZ, ??;]"*=K E>R.MU
M?PEI>LD>?$J*?]8L<,1$G0<[D)!P ,C!QWK;1%CC5%&%48 ]J\UF\4:I'I=R
MU[K']FW4$$C;-L1'FC[L8+J=PQM/J=WX5Z/:NTEI"[G+,@)/J<46T)):***0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:[K
M&C.[!4499B< #UH AO;R.QMS*X9B2%2-/O.QZ*/?_P#7TJ#3K.2'?=73![R?
MF0@Y"#LB^PS^/)ZFH;%'U*Z74YN( /\ 1(B.@/\ RT/^T1T]![DUJT 5[_\
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M4NZZO=3L[<2:H;F225I8IWE$+(KJ5 W'9D#TY]>:JVMB$[I,]'$D9D,8=2X
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MEMG88$L04LOTW C\P:Y'4_#/B">^2:#Q!?2^2 T#R-;H4?G.0+?!&,#\2.]
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MATFVU1C''91:A.NYBJHLL@]3W(K@-4TF+1)-]]I\#:>\15+4O$JM,8E&\;F
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M:3>?;X;=+HO ;=8421EYC523L1B.5XXQ@\D4#P5?WNDZ>9Y8H;R#,I4.VW<
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MQSJP?+G*OT ++QC.#Z]:[5]6D.LM;VL*ZIKBC_4))BVL%/'SOCAC]"QZ  4
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M)=37!,49!E"@KUX&U1Q6_0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444R66.",R2R)&@ZL[  ?C0 ^BN.\7?$K
M0_"-A#=RL]\LK[-MDROMX[G(%:]IJ]_JUE;7.GZ;Y,4\:R"6\D48!&>%0L3]
M"5^M &U5>ZOK2R -U<PP[ON^8X7/TSUK,O(UC0?VMKC1*_2*%A;AO88)?/T:
MFV[16ZL=&T4ER,&>=?(4_P"\S#>?KM- %DZM+.X2PTZXGS_RUE4P1C\6&X_\
M!4U%=374*JVH:M:Z>C'A80-WT#OP?^^!61<^(;>21[9]8DN[D##6FAP&1AZA
MG&[;]24HLK/7YY7-EIMEH,!&/M%SBZNY/<X; /\ O,WTH L;+1&,\>G3794;
MWO=5<HB=^#(,K_P%<51N/$KWP,6G7%UJTA.WR]%A"Q GLUPY*CZJ0?:M2'P9
MIKW0N]5DN-8NA]U]08.B?[L8 1?P7/O70JH50J@!0, #M0!Y+J'@K5M6UV&Y
MNM-GL;=2@DBL;H2M<+GDR3.X;<!TPN??@&O4=.TZSTJRCL["VCM[>,?+'&,#
MZ^Y]SR:M44 %%%-=UC1G=@J*,EF. !0 ZBN6OO'FE0JPTX2:G)DJ&MR!#NQG
M!F8A/P!)]C6'J5_KMYI[3:SJ,6C6;_*4BE^RH!UPTT@\UC[(B9_O4 =CJ?B+
M2M(D6&[O$^TO]RUB!DF?_=C7+'\JP)/$FLZDS1VEM'I2\X%PAN;LC'!\B,X3
MZNWU%8=BJ&T-MX8T>YODD()F\HV5I)[N[9EE]P20:VH_!VHZG L6M:D(K3.?
M[/TY/(@Q[[3D\]BS#VH Q7;3X=0:>\DDU/64!(CF_P!.N8_]V"/$4'KDGZU>
MBM]9U@BX<) 3RIEQ>SKSV4;8(C_WU776/A_3-.A6&"U01K]U-H"+[A0 H/T
MK3H X#4_ +WEF[Q%WU.3)^WWMRTTJ<'@#A5'.-JC'.>PKKM#L3IND06C1"-X
MQAOWA?<W=MQY.>O/-:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>+ZQ826_P 4FO+G28IXIKR,
M1W=S;WA*<<!77$?;C.:]?U"5X--NIHSB2.%V4XS@@$BO+?#\&L^(CI>K:IX=
MU*[64I*UP=;"P$CH_P!G!P/7&* /6Z*** "BBB@#'M?^1JU#_KA'6Q7%VWBO
M2E\;7D,EPL4<D:HD\IV([+U )_GT]*Z3^W='_P"@K8_^!"?XT :%%9_]NZ1_
MT%;'_P "$_QH_MW2/^@K8_\ @0G^- &A16?_ &[I'_05L?\ P(3_ !H_MW2/
M^@K8_P#@0G^- &A16?\ V[I'_05L?_ A/\:7^W-(_P"@K8_^!"?XT 7Z*H?V
MYI'_ $%;'_P(3_&C^W-(_P"@K8_^!"?XT 7Z*YS5_&^C:2(OWZW;/EF6UD1R
MB#&6//09' R3V!K23Q!HTD:NFK6)5@"#]H3D?G0!HT5G_P!NZ1_T%;'_ ,"$
M_P :/[=TC_H*67_?]?\ &@#0HK-/B#2!_P Q*V/TD!J.3Q-HL0R^HP@>N30!
MK45@-XV\-*<'6+?]?\*;_P )SX:[:M$?HK'^E '0T5YW_P +AT-O&J>'8;6]
MG#CBYBA9LMMS@)C<1[X_3FNH.N:C*FZS\-Z@^>C3O#"/R+EA_P!\T ;E%<X\
MOBV[;,5KIMA%T*RRM))^! VC\0:IWD.HQ-NU+Q)9VB <+-*1^J&']<T =:[I
M&C/(ZHBC)9C@ 5G+X@TR5B+>Y-UMZFUC:<#ZE 0*Y%KWPE;+YEUXJLKB?.2T
M(AG;]5D?]:G7Q'H\P_T:/Q3J?HUO:7,:_F BT =3_:-W(/W&DW)ST:9TC7\?
MF+#_ +YJE?:C>VQ'VK4-'TI3WFD,I/TR4 _6LP2&>/S(_!.IW+'H=0F@/_H<
MK,/RJQ:KKL09K+PKHMBYZ%[W!_)(3_.@"6.[LKH<ZUJ-\@Z_98VVY_WH4!_6
MG1V^F&X$T.@W=W,O(GN(LN/HT[!ORJ$VWCBY.'U+0K)?6*SEG8?BSJ/TJ:'0
M=<93]L\77K$_\^UI;Q#_ ,>1S^M &/X\N]0ET9-OAP2PB0;Y+I(IC'Z80%NO
M3/:I_P"V4LK6UAUW4TL;N5!LTG38\R@>@"[G/U7;BH->\'++%&;S7KN>U)/F
M)J%^T:,?X?N;1P?:NC\/Z%9:-I\2P6EG'.5'F36\8'F>Y;J?J30!CV[:K*7D
MT/P]%8O*.;[5Y"9&^J*6=OHS+5K_ (1'^T(@/$.J7>J9'S0;O(M_^_:8R/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%<[XA\42:'<+'%IKW:I%Y]
MPZRA/*CW;<@'[QSVXK?BE6:%)4/R.H8'V- 'E^F^._!2_$K4H6:.TNMOE_:9
MT6*/>OWOF)X)]>,UV%QX_P#"%J,R^)M)^B7:.?R4FO)=-\,>%_\ A8$]_>JG
MDR3%ML]U ZJQ)Y96SN&>V!BO1_[$\!?WM _[\V?_ ,10 ]_BOX'3/_%06Y/L
MC_SQBH7^+GA!1E=1C<>HFB'Z%P:>=$\ D8+: 1_URM!_)*8/#OPZSEDT-O\
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M+<7B>\/A\Y_\>N37JO\ PD.B_P#08T__ ,"4_P :/^$AT3_H,:?_ .!*?XT
M?-LWC<W/CU=4D_M0WH^07$%C;QS[-N,A&#@-VSGI79V_C!7?<^F^.[XGM+?B
M$'\(BM=P?#W@ ^)_^$C^U6@U;S/-^T#4V'S8QTWXQCC&,5T__"0Z)_T&-/\
M_ E/\: /)_[8MIWWGX7Z[>GUNKF2X_\ 0BU7;?7GA<&V^#LD3#H1:A#^?E5Z
M7_PD.B?]!C3_ /P)3_&C_A(=$_Z#&G_^!*?XT <?!XU\5E0D/P[N$4= UWL
M_P#(574\1^.)AE/ T"?]=-74?IY=='_PD.B?]!C3_P#P)3_&C_A(=%_Z#&G_
M /@2G^- '.G5_B P^7PKIL?^]J6[^2BHSJ/Q%8\:+I,8]Y"__LXKIO\ A(=$
M_P"@QI__ ($I_C1_PD.B_P#08T__ ,"4_P : .:^T?$A_NV^A1_[\+G^4U1R
M67Q.GY76?#]M[+9N?YL:ZG_A(=$_Z#&G_P#@2G^-'_"0Z)_T&-/_ / E/\:
M/$/B?IGQ!@L[3[;J/]K[V(6*PL#A/<X7^==?X6\+^,-0\-V,MSXUU&S1XAB!
M;2-73V.Y0P_.O0/^$AT3_H,:?_X$I_C1_P )#HG_ $&-/_\  E/\: .2_P"%
M8S7.?[2\:^)[E3UCCO?*0_@ ::/@QX1)W3QW]RW=IKQR3^(P:Z__ (2'1/\
MH,:?_P"!*?XT?\)#HO\ T&-/_P# E/\ &@# M_A;X0M4VQ:=.ON+Z<?R>KJ>
M _#T:[4MKH+Z?;[@C_T.M+_A(=$_Z#&G_P#@2G^-'_"0Z)_T&-/_ / E/\:
M,X> _#.<MI:O_P!=)9'_ )L:D7P1X67_ )E_3F_W[=6_F*N_\)#HG_08T_\
M\"4_QH_X2'1?^@QI_P#X$I_C0!E_\(%H$>H+=VUA;6HR"T4%M$H8CWV;ESW
M(S735F_\)#HO_08T_P#\"4_QH_X2'1/^@QI__@2G^- &E16;_P )#HG_ $&-
M/_\  E/\:/\ A(=%_P"@QI__ ($I_C0!I45F_P#"0Z)_T&-/_P# E/\ &C_A
M(=$_Z#&G_P#@2G^- &E16;_PD.B?]!C3_P#P)3_&C_A(=$_Z#&G_ /@2G^-
M&E16;_PD.B?]!C3_ /P)3_&C_A(=$_Z#&G_^!*?XT :5%9RZ_HS,%75[ DG
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MN))H(XMTP9B=I0?.,$'<V3SU] #T*BBB@ HHHH **** "BBB@ HHHH ****
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M/\2?"HGM(HM5BF%R[*'0_+'M&3NS@C\JLV_CWPI=7*6\&O63RNVU5#]3C/\
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MY^=9_P#!U>?_ !V@#<HK#_X1/3O^?G6?_!U>?_':/^$3T[_GYUG_ ,'5Y_\
M': -RBL/_A$]._Y^=9_\'5Y_\=H_X1/3O^?G6?\ P=7G_P =H W**P_^$3T[
M_GYUG_P=7G_QVC_A$]._Y^=9_P#!U>?_ !V@#<HK#_X1/3O^?G6?_!U>?_':
MVHT$<:HI8A0 "S%C^)/)^IH =1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS!'%?2W$<)B\H@1[E=@P8OMD5MF%8,,YZ9XH!Z7\CLJ*I:3<75SIT;WRP+=
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M2(!4/J . ?>I9K*UN9$DGMH973[K/&&*_0FN3'CB[\HR'2(0!:K=_P#'X?\
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M:\NK%K8121Q-(%>8H\B[<[E^7D=L@DCTK.'C"2UT^R-OIQF#V)NSYUV=P52
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M/9LC&<UJ.LZZ45EE/GB'YY$X^;')'XTF[)L?5%B**.")(H8UCC0;51!@*/0
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M(K..]6/S +D0*\:NK<;_ #%P,KCH35OQ?-<Q>%[U;.&>:XE3RD6&)I&!;C.
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img19885085_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )V K0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR,XJY5/2M/CTG2;33X23';0K$I/< 8S5RG*UW;8F-[*X4444AA1110 4444
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M?\)9IW_/MK/_ ();S_XU6Y10!A_\)9IW_/MK/_@EO/\ XU1_PEFG?\^VL_\
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M?\)9IW_/MK/_ ();S_XU6Y10!A_\)9IW_/MK/_@EO/\ XU1_PEFG?\^VL_\
M@EO/_C5;E% &'_PEFG?\^VL_^"6\_P#C5'_"6:=_S[:S_P""6\_^-5N44 8?
M_"6:=_S[:S_X);S_ .-5AWG_  C5_<W$]U8ZQ,UQP_FZ#<28&,8!: D#Z&NX
MHH YZV\2:3:6T5O!::RL42A47^Q;S@#_ +95+_PEFG?\^VL_^"6\_P#C5;E%
M &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/
MMK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU
M1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_
M^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E%
M &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/
MMK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU
M1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_
M^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E%
M &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/
MMK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU
M1_PEFG?\^VL_^"6\_P#C5;E% &'_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_
M^"6\_P#C5;E% %+3M5M]460V\=X@C(!^TV<UOG/IYBKG\*NT44 5-0U*#3(5
MEGCNG5FV@6UK+.V?<1JQ ]SQ6=_PEFG?\^VL_P#@EO/_ (U6Y10!A_\ "6:=
M_P ^VL_^"6\_^-4?\)9IW_/MK/\ X);S_P"-5N44 <]/XDTFYCV2VFL, 0P_
MXDMYD$<@C]UP:D'BO3@ /L^LGW.BW?\ \:K=HH P_P#A+-._Y]M9_P#!+>?_
M !JC_A+-._Y]M9_\$MY_\:K<HH P_P#A+-._Y]M9_P#!+>?_ !JC_A+-._Y]
MM9_\$MY_\:K<HH YZ+Q'I4+R2+:ZR9)#EW.BWF3Z#_5=!4O_  EFG?\ /MK/
M_@EO/_C5;E% &'_PEFG?\^VL_P#@EO/_ (U1_P )9IW_ #[:S_X);S_XU6Y1
M0!1T[5K;5/,^SQWB>7C=]ILIK?.<]/,5<].V<?C5ZBB@ HHHH **** "BBJ]
M]?VNFVC75[.D,"E5+OT!) 'ZD4 6**IZIJMGHNG2ZA?R-':Q#,DBQL^T>N%!
M.*KV_B"PN9[>%/M:M<9\HRV4T:MP6^\R = 3UH U**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH]JZ.4+;A@-Y9&/KFJOA?4-.M] \,RR>)C-(D42+IXDA)9V3:%"J V1GN3@
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MG .,@9Z''&<4= +5O;Q6L"00($C08514E0VMU#>6R7$#AXW&0?Y@^A[8J:@
MHHHH **** "N(^(=Q!#<>%A+-&A&M0-\S <8;GZ5V]%"W3[!T:]3A/B-<0)=
M>%@]ZMK_ ,39'\W>H*+L;YOF!&/<C%7K;7])TJ74YG\0?VF%A^TR.9(F\E5
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M:] *EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%25#:W4-Y;)<0.'C<9!_F#Z'MBIJ "BBB@ HHHH *XCXAW$$-QX6$LT:$:U
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MG8V9/VB: B, XR>N/QZ5K3V\=PJK*NY58-C/&1TSZU+0U=6&G9W."O/$\*>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+>>)(;:\O+:&RO+Q
M[*-7N3;*A\K(R!AF!)(&<*#6U7G?BHV<>H:EK&DZJ=+\0V"A'B=@4OE"AE0Q
MG[^=P4$<@G%)C2N=U+J-M#I3:E*^RV2'SV9NRXS_ "J*SU:WU#1(M6LP\UO-
M")D"X#$$9QR<9_&L*_U&;4(-'TH06\>H74:75Q92S>7L1,$J2%8_>*C&.0#6
M5X6OET2[U[PQ?R6T!MBUW:HL^Y5ADR2H) ^ZV>PZBG+3F_K;^OP8HZV_K?\
MK\3>TSQ<-6TJVU.UT35&L[@J%D/D\ MMR5$F<#OQTKHZ\J\&:AIUKX&T.:X\
M3E&@._\ L\20Y<[F 0+@.221@9ZULI*8/'"2(+:_@N+QE]+JSE$9!S_>BP/;
M&15->]8E/W;G>4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M17I=%"TM_76X/7^O*QYA;ZI9IXOTLVUR%W:I=P7+3R#SF)5L(XP-JY V Y)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS!XDU*\\2ZMHUMI=H3IPB+2RWK+O#J2.!$<=/6M6'58X].AN=4>VL'<$E6N
M4X]&.,C'.<"CS#K8T:*0$,H92"#R".]+0 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,L=O;I.;B*<.I#$C! Z8QZ]ZXN2WU>ZC\2&"TO7:X%I-&K6DD(F1 N]%#=\
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MIPRGW!!%6JYWPC%(L>KW#9\FYU*:6#C&4X7(]B58_C714=@ZL**** "BBB@
MHHHH **** "BBB@!HB02F4(OF$;2V.<>F:=110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ! (P1D4R&&.")8HEVHOW
M5'0>P]J?10 4444 %-DC66-HW&588(SC(IU% #418T5$4*BC"J!@ >E.HHH
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MD'GIP >3CWH Z.BJUA+=36,4M[#%!.PRT<4OF*OIAL#/'? K"3Q?&T$=]]E
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MOY][?_8E'VUMHR"5<-Y7(('H,&MNRNM1EO)H+VRMH41%99(+HRY))R""BD=
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MG YQC)[4I;749]'\1J;.^D=]0@N8P;.1/,C!0DHI&3T/ R:]/HIIV=_ZZ/\
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MS\I^?WZ]*ZG0X)K70K&WN(S'-'"J.A(."!Z@D4=/Z\Q=?Z[(T****0PHHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445A_9?%7_09T;_P4R__ "30!N45
MA_9?%7_09T;_ ,%,O_R31]E\5?\ 09T;_P %,O\ \DT ;E%8?V7Q5_T&=&_\
M%,O_ ,DT?9?%7_09T;_P4R__ "30!N45A_9?%7_09T;_ ,%,O_R31]E\5?\
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ME]RA#ONY6P <@#+<<^E-N[=@6RN8?AO6+R;5=0T_49)BTR?:K8R1O'A#U49
MZ'TJGX2ENKG3K&>==5E(FE+7+WK,C8)PI4N<@^X%=;<:-8W5];WLL3FXMU*1
M.LKKM!ZC (!_&JUOX7TFUACAABN%AC<NL9NYBN3[%L'KWI &AZZNL_:!Y2PR
M0MM>(R$R(?1E*@C]0:KKJLSZKJQ".\>G*JI"K[=[$9))/'YUJV>F6E@[/;QL
M'8!2SR,[8'098DXJ"YT2UNI[EI%!BND"7$?(WXZ'((((H!>9S=_XCDU&QB>W
M+VTL.I102>3,2&!Y/( R*UO"EQ/<1:F)YI)?+OY43S'+;5!X SVJ=?"NCHA4
M6\Q!E68[KJ4Y=>AY;K5ZQTRTTT3"TC9!-(99,R,V6/4\DTU9?UZ?Y!_7YF/+
MXHD&LMIT-BKLLWE-NF*N.,[MNT_+[YJ"'Q;=RZ5_:+:5$ENSLJ$W8_ASG=\O
M'3@#-/C\/WK:U/=S.4#R[Q-!J,ZY7L#!Q'^.36@?#&D&SAM/LT@AA=GC N)
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MS)!.\#-C[VT\'\L5I32K!!),_P!Q%+'Z"LZWT.WMGM7CDE!MV=CB1@)&;J6
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M>M.F\-:3.9O,MW_?0B"7$\@WH.@.&YQGKUH?6PT]K_UM_P $JP>)4_M-+"6
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M%I=0P'_5R3A0).2#C#$\$=\5IU1T?2XM%TN&P@EEDBBSM:4@MR2>P [^E7J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5NT+0[MJQEB-IR-N=QSP:BT[PZVG7M[<I<Q227$LDR2/!F1"_8MNY4<< +P
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M() %(ST*DU.NAN\EO'<3PO9VDHDMH4@*LF 0 S;CNZGL*E%A>-*MS=W$-Q+
M',"QP>6 3ZY<Y/;J*;:O<%L:E8&K^)8[.'5(X%(GLH0Q>1#Y>]ONC/'J/SK8
MLS=&SB-Z(Q<[1Y@BSMS[9S6+/X7-T]UYUX&BN;M+B1/)ZJO1,Y]AS[=*5M;
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MBO7!E22VR"H3:%'S\8ZCT]^M-[NPEYFQ_;$$EY D5S&B-&\LB30NK%5X)!.
MN#ZBAO$6E)!-,]ULCA02.SQLN%/1AD<CW%9MQX3DN4E234W8/9): M'EACJQ
M.><\9''3K4MWX6COQ(;FX#/-)$9L185HT.1&!G@'OUH U=/U2SU1)7LY3(L3
M^6Y*,N&P#W SP1S6?XFU]M!LDEBA$TA==RD\)'D!F/TS^>*M:/I;:5#<(]P)
MFFG>8L(]N,GIU.<# _"J&K^%EUJWU!;N6W>:X3RX)6MMQMU]LMR<\Y&.WI2[
M O,O:CXATO2I/+O;KRW\LR[1&S':#@G@'UJ*Z\0VL,][;[FC-I )9)GB8QIN
MSC..O0U1O/"3WKRS2WRF>2*&'?Y&0$0Y88W?Q=^>W>I+GPQ-<IJ*G41_ILT<
MAS!G"+CY#\W.<'TZ]* 1MI*R6*RS.A<1[G95*KG') )R![&N2\/^+K[59K$.
M;*>.Y2:206R,#;HI.QF.X]0!QQUK<U#0OM5M>BWO+B&YNH3$9))I)8TR,9$1
M<(#] *E.E/'X<&DVLZPLML($E\O(7"XSMR/YT/J_ZZ_\ %T1S\/BK4HM!M];
MO$M7M9KSR1'%$ROY9DV*P)8Y/?&.?:M_Q%J<FC^'[V_B"&6&,M&KJ2&;L" 1
MW]ZHVWA8"TTRSO+E)[33@ABACA\L.ZCAFRQS@\XXY]:75?"_VVU6WM;Z6)3=
M)<RBY>6Y#[6W;0&D^4$]AQ[4W;;^K:?\$$];FH9[B#1O/NGA6X2'?(P0[ V,
MGC.<?C3-#NKJ^T.RN[U8TN)XA(RQJ5 SR!@DGICO534-'U'4M,O;.?5(E^TJ
M$!CMB B=QC><DYZY].*V8T$<2HN %4 8'%'<78Q=:U\Z7J.FVL<(D%S<)%,Y
M/$2L<*?J6X'XU8N?$6E6=]]BGNMMSNC4QB-F(+G"YP. 3QGI6=J/A+^T8'>6
MXM_[0-TEPMV;7+($8%4 W9Q@8Z]R<<TZ7PJ9=1>^-Z!-)>)<R'R<Y5%PB#GL
M?FSSSVI+S_K;_@C?E_6Y//XB@9;Z."3R)+:=+82SP.R&5L8&!@G[P'7O4-KX
MH@?7[VPN941([A+: K$_S2;-S!GY4=1@''0]:1?#$PCB1M1W;=0:]<^1][))
M"_>ZC*\\_='%-3PBIB>.YO3(/.FG0I'L(DDW#<QR<E5; Z=/I@Z?UY?\$;_K
M\?\ @&K%K>FS2F-+I<^6T@+*55D4@,P8C! )'(-93>+K9-:>*1RFGK'$/--K
M+GS9&(09Q@+@=2,<CFF77@_[7IIMWO569;5+6%T@PB1@J2-F[G=M /(X&.*9
M=Z#*;#5K.XO)+FXU8GRWCMBJPD( ,D$@ 8R,D?B:>E_Z_K;\1;G2VUU%=HSP
MLQ57:,[D*D,IP>"!^?>L^YUNUL[R\-S>11VUI$C2J8GW(S$X.[H0<= ,UH6E
MO]EM8X=Q<J/F<]68\D_B<FL*Y\*_;)[PW-X)(+J]BN7B,758PN(\YZ94'\QC
MG-+J'0V+#4K34XY)+24R+%(8G)1EPPP<<@>HYZ5;K.T;2WTJUFB>Y\]I;B2<
MOLV_?8MCJ>F<?AVK1H **** "BBB@ HHHH **** "BBB@ HHH/3B@#EK_P 7
MO8WNI1_8$DMK"6"*243D,S2D<*NWDC<IQGG-= VH627"6[W<"3N<+$T@#DXS
M@#.>@)K&T'PX+.2[O-3MK*749[R2X$R+O* G"@,R@C"X%5+/0=;AOK269[%D
M@>XE=A(Y:25_NO\ =XP"1CM[T= ZFS'KEK=K"UC-;S![@P_/-LSMSNVC!W$8
MZ?CFK3:E8H\J->VRM$,R RJ"@]^>*YVU\.:I#!I$1N+539VTJNZEB?.8 !QP
M,_Q>G7I4$7@^X?P_'ITX@61S$ES*+AW+QJVY@"5&,GMCN2233L!T<^NZ7;VI
MN&OH&B$HA+(X;]X3@+QWYJPE]:27)MDNH&N ,F(2 N!QVZ]Q^=<W!X;U&+[.
MI>S"+J3W<@5FY3#!!TZ@%>..G4U?T72;VSU.\O+HVZBY"L8H6+@2]'8$@8#8
M7CU&:%_7]?>!JI?V<CR(EW SQ.(Y%$@)1CT4\\'VJN^K6_G0B*>TDA9'=W^T
M %57N!SN&>O(Q6)J_A2ZU#6)=0@O$B)D@DC0@X#IPS''4[> *DO_  _?R7%V
MUI);JC:>;6 NQ#*[$EF. <9R.>>G2IZ?UV#J6)/%=B+C3S'+!]CNXGE:YEE\
MM8U7 !Y]2V.2*W'FCC@:9W41JNXMGC'7-<CJ'A*]O-[*UKN6UAM8E+,%5 V9
M.QZC@?TK>U&PN+V&VM!Y8M-P^TXD9&*CH%P/7'<=*I[:"7F-T378-:TIM0"&
MWC621&$IP5V,02?3I45CXDLKS4[FT\^V18Y?*A?[0I,[;0S;1[9YQFL9/"^J
M6T$UO;O:FV;4_M8BDN)#OC/.UF*DYW8/?..M3KX:U-].MUEN+5+Y-0-VTJ!F
M7!W9QD#G#<#^=']?D/\ K\SH7U33HX$G>_M5A<921IE"L/8YP:5M3L$F6%[Z
MV65V"JAE4,2>0 ,]:YJ^\-ZH\]REF]G]GE,"HTKL&6)""R8"GJ<G.>^/>AO"
MEXVJ&_,EL)I+SSI&W,<(J%8P!CD@<D<<]S2!G4+>VKW+6RW,+3J,F(2 L/PZ
MTU=1L7CDD2]MV2,X=A*I"GT)SQ7.IX=U+_A%7TQGM$O!'L6Y5V)DRV6R2N5W
M#@]>O>DD\.ZC$UE)9)9(8M[RQR3.P,FT*C[MOS;>>, <\4 ;6CZL-7M9KE(E
M6%)GCC99-XD"G&X<#K531?$$NL@3I:1):$N&D^T9>-E.,.NT;3^-3:9I][IO
MAR*S5X/ML<> V24+>I.,_I6//X8O[B;4;D-;6KW@B$D$,K%)"K99F.T8+#CI
MTI];!T-G4M>M[33);NT>"[9'2,(DHY9B !D9QUS5F+4%:6X$KVR10!=SB<$J
M2.0PQ\OY\UB3^&[R:\BNA) &:Z266+<=JHB[55>.?7G%0OX>UG[0)Q)92$WS
MW+QM(X##&$R0O.WT_6E_7Y ;>EZN-52\EAB0PP3-%&Z2;A+MZD<<<\=ZS$\2
MZB=3NK-]+M$%I'')/(;\@(&/3F,#('/6M+0+"YTW1X[>[:%[G):1HL[68G)/
M('\JQ_\ A']5-CK>XV?VS4+@.I$K%?+! "D[<@[1CH:-F!T9U"R&[-W;C9C=
M^]'RYZ9Y[]J9#JNG7,JQ07]K+(V=J1S*Q..N #V[URT?A'49+:XM[R>V=+F^
M6>8JS9:)1\J=/8#'H.M,B\&ZA"&*2VB220R[W5FSYKMSCCIM &>WI1_7X =>
MNHV+B0I>6["(9DQ*IV?7GBHAK.EE=PU*SV[MF?/7&[TZ]>:Q+GPS=7%K<[7@
MBFF@CM%16)1(@<MSC))Y[=ZFO- GDO\ 3VM%MH(+,KM<,=Q3&&4KMP0<#O3
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M.HV-RSK!>V\K(NYA'*K%1ZG!X%<T/#>J)%$B26:B.P-LGS-\LC'YF'R^G?\
M2H4\(WUK;W,%H]KY3)#'&K.P+*O+!B%.,GGO3$=;;WUI>%Q;74,Y3 <12!MO
MUQTJ'5M2BTG2[B^E5G6)"P1>K'T%96E6VJZ;>R_:;>WF-Y<%B\#L!%&!\N<K
MSCIBK>IZ7-JMT$GV_8DC)0).Z.9#QD[0. />D]M!K?4BN?$L-OI&G:AY:;+Q
MD&))0@0,,DDX[5HG5=.$44IO[41S<QOYRX?Z'/-<S:^&=5BLM'AE:RD;3UD
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M22WB%]:Q6\I0D>2%SG8,<@[N,XZ4AZ%R37\G1FMK=98]3(P6DVLBE-^<;3G
M'J*:OB2)IQB$?96N_L:R[^6DZ<+CIGCKZ\4L>D3IK]I<!85L+.U,,"!SN#'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img19885085_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &] K0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.=!)
M!(A+ ,I&58J1]".17D@O+BW^'4$*R2.MQK;6\K.Y8LGFX()/)R!CFCK;^M[
M]%?^MKGK]%><:%K%[#\-_$,Z;O,L)[N.W/HJDE0/89Q^%,^&MY/_ &M<V628
M&TVUN3Z>8R_,WU/?Z4TKO^O4'HK_ -=OU/2J***0!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8D9P,9IOK;^M_P#@"ZK^NW_!,KP3JFM:M9FZU.)_LTT,4UO,_E L67Y@ AX
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MPK_T+.C?^ $7_P 31_PA?A7_ *%G1O\ P B_^)K<HH P_P#A"_"O_0LZ-_X
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M0 S_ (0OPK_T+.C?^ $7_P 31_PA?A7_ *%G1O\ P B_^)K4@NUFNKBWVX>
MC/.<@C@U8H I:?H^F:0DB:;IUI9+(07%M L88CIG:!FEU#2=.U:)(M2T^UO8
MT;<J7,*R!3Z@,#@U<HH P_\ A"_"O_0LZ-_X 1?_ !-'_"%^%?\ H6=&_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A<M]X>A&.OO72:/<27>B6%S-_K9;>-WSZE030M5?^NO^0-ZV_KI_F7:***
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MW6C6<VF,K631+Y.WH%QP/PJEJK_UN_Z^\3WM_6R_K[B]1112&%%%% !1110
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MFD$S_P!HW$$L<BH2BA=N[+ 8&-IZUVU%"T=P$4;5"^@Q2T44 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LJ\\0V5C=/;30:FSIC)@TRYF3D9X=(RIZ]C[5JU5U+4(-
M*TVXO[DL(8(R[;1DD#L!W)Z"C8$KF;_PEFG?\^VL_P#@EO/_ (U1_P )9IW_
M #[:S_X);S_XU5FXUVS@L;&]&^6"]DBCA>, \R?=)YZ<U-=ZI#9ZC8V4B2&2
M]9UC90-H*J6.>?046%=%#_A+-._Y]M9_\$MY_P#&J/\ A+-._P"?;6?_  2W
MG_QJMRB@9A_\)9IW_/MK/_@EO/\ XU1_PEFG?\^VL_\ @EO/_C5:\\S0M$%@
MEE\Q]A,>/D&"=S9(XX[9/-/DD2&)I)'5(T!9F8X  [F@#%_X2S3O^?;6?_!+
M>?\ QJC_ (2S3O\ GVUG_P $MY_\:K4CNQ--&L<4CQ21^8LXQL]AUSGOTJQ0
M!A_\)9IW_/MK/_@EO/\ XU1_PEFG?\^VL_\ @EO/_C5;E% &-%XGL)IDB2WU
M8,[!07TBZ103QRQC  ]R<5LT5ER:Y']NN+.TM+F]FM@/.\C8!&2,A279><<X
M% &I17.GQ?;F:&&/3-0DDEM#=A0L8*H#@@Y<?,/2MFPOH-3L(+VU??!.@=&Q
MC(- %FBBB@ HHHH **HVNJ0W>I7E@B2+-:%?,+ 8.X9&.?2K,ES#%-%%)*JR
M2DB-2>6QUQ0!+1110 4444 %%%% !1110 4444 %%<_=^+K2SO;ZWELKTK8[
M//F54**&Z'[^XC\*9)XSLHIKM6L[SR;21$FG C*+OQM/W]Q'([4+4#HZ*16#
M*&!R",@TM !114,EU#'.D#2+YS@LD>?F8#K@4 345%;S-/ LK020EO\ EG+C
M</K@D?K5:TU6"\U"]LD219;0J)"P&#N&1C!H O4444 %%%% !1110 4444 %
M%%8R^)+>2[D@AM;J9(K@6\DR!-B.?4%MV/?% &S17/CQ9 6OB-.OS%8R^5<2
MA8R%XSG ?<1]!6Y!/%<P1SPN'BD4,C+T(/0T 244A( ))P!U)J.WN(;J%9H)
M%DB;.&4Y!YQ0!+15*TU2&]OKVTC219+1E60L!@Y&1CFDTW58-3-T(4D4VTQ@
MD#@#Y@ >,$\<T 7J*** "BLQ=;BDO[NSAM;F6:U:-9 H7&'S@C+=!CFM.@ H
MHHH **** "BJ6KZG%HVE7&H3QRR10(7=8@"Q ],D#]:Q[GQK96EM=2W%E>QO
M;PK<&$K&6:-NC+A\'GWS0!TM%9=OKD,NH1V,]M<6EQ*A>%9PN)0.NTJQ&1Z'
M!K4H **** "BBB@ HHJ*YF:WMGE6"6=E&1'%C<WL,D#]: ):* <@'&/:B@ H
MHJEJ^IPZ-I=QJ%PDCPP+O<1@%L>V2* +M%0P7#322J8)8PA #OC$F1G*X)XY
MQSBIJ "BBB@ HHHH **** "BBB@ K)U:UN=0N[*U598[16,TLZ&,X9?N+ALY
MY.>A^Z*UJJ7>J:?821QWE];6[R9*+-,J%L=< GF@#BE\.ZH-!_L273VN+.RU
M6.2W,CQ'SK4/N(QG'&2,'&0!3SX1D5M/232X[G38KZXF^P'RRL,3H0J[2=N-
MW. >,^U=M'>VLUI]KBN87MMN[SED!3'KNZ8JLNO:.Z2.NK6++$GF2,+A"$7^
M\>>![T>7]=/\OS#?7^NO^9R-CX2O8[RV6YMUD$&FM'!<2,KB&;S"R8YSE1@;
ML=NM6]/\--?Z/>VVH:=-9S7-LL,IDEC96D4?*Z!..#SN.&/&1Q74VFI6-^6%
MG>VUSLP6\F57VYZ9P:M4=+?UU_S#K?\ KI_D<:^BZH]IHL\]HCZ@+]+F^,3*
M JA"O4D9Q\O3/2LZ30-:N+Z_ TQH8;FSO(&W3HX9W;,;,=Y9AUQD#;G&!7=2
M:A90M,);RW0P@-*&E4>6#T+<\9]ZLYR,BAZ_C^*L-.UOZV=SA&T+5YC"+6S:
MP?\ L62T$A>,>7,2,?=8^AY&:CU3PYJ-W;R-9Z8;=)(K9)+0/&-[+*&9N&V\
M)D9SD]*[^BG?6_\ 6[?ZB2MI_73_ ".!;P[J/]G75K%8/"!J$T]JB^2\00J<
M!HRP!4Y(P"",YKK-.@,=S(\NG)!.T,:R7",I60@'Y1SNPON.]:5%+I8 KFM.
ML;[0];U=ULI;RUOY_M*20N@:-MH!5@S#TX(S^%=+11Y@<3K^@ZMK.OK/"DMJ
MATYH?/28;1(7#;& (8J1P<#O5B;2]2N]-L%BT<6S0Q!&@779[-8R.P$ 8,/<
M\UUU(S*BEG8*H&22< "C96_KK_F'6_\ 7]:'&/I&I)/ EWI!OK-X#$81J+7!
M@DW$[S)-M<@@CD9(QP*==:%J4UQ=J;<&9[R*:VO0Z_NHQMRG)W= PP!@Y^M=
M=#/%<PK-!*DL3C*NC!E8>Q%24^O]>H'G%OX2O/.MGN=&1\R7GV@L8CO5SF,'
MYN1[=O:H'T:>XGT[3-1TS[3>#1638[1MY<H; ;); (]1DUZ=4)L[5KL79MH3
M<JNP3%!O"^F[KBE_7X/_ #!_U]Z9Q!T/78&U!D@>8L;8Y\R/-RJ( X&XX!S_
M 'L XJ?_ (1^YCN='N+;3)4C@DF+1RRQL\.\#!Z[< YX4G':NVHH Y7POI=W
M:S^??6,\%VL7DRS--&4FP<AE"')[\O@UU5%%-NX'$WWAV^N-2UZ\AL5%Q(8S
M9S,R98 +O4')V[L$<@=:CN- O)M-7[+IMS;2M*TWDS/#(H;;@AT#;=IY^Z<C
MKWKNJ*0V[GG5[H[ZIXBU*W^P(UZD-LT4ZE<6S#DE23N'0].M:-OH&IJ]L)H?
M]+@NWDDO@R_OXB#\O7=SD<$8&*ZY+.UCNI+I+:%;B0 /*J .P'3)ZFIJ!'G>
MD^&M2LU3S-,EC,EA)#<-%-$'=RQQSNY.#P3Q4QT/6$M[>&XL#=68:1)(H/)C
MD8-C#L&;9GKDJ0>X%=]10'F9FF3212?V<UI-&MO$F)FD#JV>V<YR/<"M.BBA
M@<@OAR:^\4:S+?Q7":=<B+8%D0+-M'(.#NQD>V:S;OPSJDNL:I>16;M!]IBE
MCM7F41W2*H!! ;@@C(SQQ7H-%"T!ZG)ZEI&IWMX9X=/(1E'!\27=J1QT\N)2
M@_ UASZ*^I>(M5@2Q!O83;-%<F0/]G( +8=B'.1GG'.>:](J&.SM8KF2XCMH
M4GEQYDJH SXZ9/4T+1AT.$&BZU]MNW&ER(DMM/$<31MO<\JQ8OD_B!CTJS9^
M&9+&[T>XCT9/DM7CN0GEY60@<G)Y^HS7<44=/Z\_\P_K\O\ (\XFT#6SX<LK
M-=*=KF.%QN\^,^6V[(X+@=/XAD_2ND\/6-_;ZQJ=S>6KPI<+#L9W1BQ5,-]U
MCWKHZ*=]P"N&N/#M\9M9O(=.7[4]RKP,6CW2Q<;E!).,^AP*[FBEY@<1<Z!=
MOIL"V6GW,$@E>813R12*I(Y#INVX/^P>.M9RZ-)J>OZHB62)?0S6S)=+MQ;X
M7Y@I)W?D.:](J&*SM8)Y9XK:&.:7F21$ 9_J>]-,'JK'''P_JC11JUOB\BFE
M=[P,G[]"#A>N>>!R,#%4M.\-:C:PRQMIDT23:>L4OD2Q*S2[\Y^]@G'<\=J]
M$HI+0.M_Z[G!'0]8VV\-YIYN;0J\;1VIBB922")"&; /KL.1VKKM/N)&DDLW
MM98Q;JJB5G#B3CL<YX]P*OT4[@%<==:-?R:]#J>GV4MA>BX"W,J3)Y-S".[+
MN))QTXS78T4EO<.ECC+2SUBT/B")=)E8W]RQAD,L6P*5QN;Y\@>V,TS_ (1?
M4K6WMK:WM_M"0PK'YG_"17EIDCK^[C0J/SKMJ*/Z^X&SD/[%U$:XEPMK^[,8
MCE\^43*/E(RDA(DSS@[AS[5D2Z!JX\.VEA%HK":))5+B:/"L2<,%W@<_WN2/
M2O1J* ZW//QX5O;J]FN9M/\ +O'>W>&\9HRT6T?/R&S^7!J1]&UA&NG^P2RP
M2:D\SVZ20[IHF0*"-QV\'G!Q7>44[_U]W^0+3^OZ[E+2;7[%I<%L(WC"+@(\
MF]E'H3_AQ4/B&VO;S0KN#3VVW3IA/FQGVSVS6G12>H+0\[D\/ZG))?36^AM:
MK//:ND7F0@@(?G/ROCI[\U?GT36#>ZI+91>5]ICDV/.4+J^!C8ZG.TXZ,./6
MNUHH!:'#/HUZ=-S#H5PDDTR-+!+<1':0,;@BL$(Z=\GJ1Q4=AH>M(-*DDM'$
M]LBQRBX:*2,@,>00VY6 P1C(/0BN]HHZW"QQVE6-_IT\]]>:9</=VXE'G">(
M)<*6)&T Y)Z??QC'!KK;>4SVT4IC>(N@8H_WER.A]ZDHH QO%EG<ZAX6U&SL
MX3-<30LD:!E7)/NQ K$UCPS-)X3NQ;6\]UJUS;1PMYLJ;@%_A'(4 <]*[2BA
M:#OL<K>Z;?ZSJ-A*]E):PV"NP\VX"-,Y0J &C+%1R>>OH*I'1M1M+6[EN;/R
MXA;R9;_A(KR[_A/_ "SD0*?Q/%=O3)8HYXFBEC62-QAD<9!'H12>J8+2QYE;
M>&KJ[\*>=ING>3]JTJ&-HE:-?M$ORGS#\V,@9Y)SS6W>>&IEDOH;;34-M/:J
MMIY91!:2Y)8]>,D@Y7/3Z5V,$$-M D%O$D42#:D<:A54>@ Z5)5R=V3'0\]A
MLG/B+S[FVNKNWBNT_P!-58F7S @0KDR!]NXYP$/.>?1T'AO4+33UG72BUP;^
M5[F)&A\R> LVP L=IQN! 8CIVKM4TO3XKUKV.PM4NG^].L*AV^K8S5NI'_7Y
M_P"9Q?\ 8%[#=Z:]G9.L=L$'EW,B2H$WY(SD,CJ,$%<CMR *J7_A_5Y+#7(K
M>Q+B[AE\D2M&)1(7R '#?,IZC=@KT^G?T47 Y>?P]-)K]O=Q11K:W$*+?HV,
MEHSNC^O.0?:H](TF]CUUY[ZSF,T4\K1WHEC$<D;DX7 .\D# PPP,9!KK**=P
MZ6"N'\6Z)JFI3ZI''IWVZ*ZLTBM7WQ@6\@8ELAF!&<J<KG[OTKN**76X7.)F
MT/4)I-;!L[B);JZ@E@>-XCC:BY)5FP1N'*G&><4R31-5FDM(K[3C-;M:1QA;
M22.-;:56)W?,=R@_+]PDC;CFNYHH6@'!RZ3K!\0O=+I4P@+7*2-'<INE5T 4
M[B^[&5'&!MXX/6A=%UJUT^WB^Q&YMXKO=)#&L,<T\1BV@L"WE%E..XSC/!KO
M**%HK 8^D%[#[-I LITBBMMZRO*L@4!L!&.<[L8[8X."<5L444-W **** "B
MBB@ KDO$MU;VWC/PLUQ/%$H:Y),CA0!Y7O76T4 >8ZG'-<7U[J-BK2>'FU2T
MEG\L$I*J@^;(H'5-WEY(X.TFNA\57>D7OA76+JVN+>>9-,G198G# *R]"1QR
M0, _AWKK:*37NV_K:PT[24OZWN>?:%<O'JSSWDZ0W@TE$L/+A:2.:$#<6VJ=
MSN&."HP<8QUS5H^(]:CM+R9)?M<D-M))'#_PCEY:[F"Y'SR.5_#&3VKMZ*IN
MXHJQYA-K BF\2ZI8ZLERPTZT9+@B-ANR^1@#'?IC/-;E]XAU&VU:ZCMW%VBQ
M,T$5OL;#B'=LD7&X9/(8$@Y XKLZ*'J"T9Q$?B24Z1/?KKMO);L\ 61$5S"2
MP#H6PJ@G_:^[GGM52U\6:C/964S7:.5FEBN(X3'YQ"S;58*1AN.H7!^;([5Z
M%11?470Y/1=<N]2UIHGOH4:&6:.?3R 9% ;Y&P%!48'4D@YXJUXAU@Z?J-G:
MS7PTVUN(I,7C*I E&-JY8$<Y)QWQ7144NPSBKC7-45[U%NBMW;RP"VMC$J_:
MHV"Y;!&[DE^AXV^QJHOB+4VUH1'4B8Y-1GL_("1X55C+*00N[<"/7OTKT"BC
M^OR \ZT+5KZYM_#-C'K4BM<VTC7+8C=]Z;?E.Y3CJ0>]7TUS49?LY:XS,US-
M#=V3*H\F,!L-TW#&%Y)P=WTKMJ*):@M#G? [*W@?2B'&!;+R#TXK!@\07XT"
MWU"?7#ONKAXE7R8@!MWX"M@ 9P/O9Z<=:] HIR?,VP6AYQ;^);Z>:VU'[27E
MDT7SDMU(VR3 G< .Y&!D#FNBT+78YXGN;C6;6ZMIG1860@['(Y0L  3D'C&1
MWKI:*+_U\[BM_7R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q/$FM2Z+%92KY<=O-<B*>ZE0NENI!PS $<%MJYS@9R
M:VZRM6TN[U))X8[R*.VGMS#)%+;^8.<_,/F'.#W!I,:$&LQ6-NJZK<0K<JF^
M7R(V**I; 8XSM!]2>Q]*G?6M/2X,#7&)1.MOMV-_K&7<%Z?W>?I65%X1BB2>
MV^UL]E.8?,C=<N5C55";\_=.T$C'<^M,7PE)_;T.IOJ6[RKN6Y6(0X!WIL )
MW=0H SCIV'6JTN3T-(^)-*%S);_:6,D;%& A<@,"!MSC&[YA\O4TZ7Q!I<%F
MMU+<E8F#D9C?=A/O';C=@8Y./YUGKX6:*"Q\J]47-M>R7K2/#N65W#@Y7<.S
M\<\8%37/AUKK6X=2EN8Y"EN(6CF@WCAMVY?F 4Y]0>@]*2Z#-:*\AFN7MT+F
M1$5VS&P7#9QAB,'H> >*GJ&W2X1IO/G256<F,+'MV+@<'DY/7GCZ5-0!S?B'
MQ#)I6LZ;8QW5E;I<)-+-)=*2$1 ,$?,O))'ZU2B\8S1II,VI1I9I/:27-VIB
M=F0 @+@#D9R3T. *VX]'=?%$VLR7*N&MEMXH?+P8P&+$[L\Y)'8=!535O"_]
MJ7=W<_;!').D,2YBW;(T?>5^\,[CUZ?C0NE_ZW_X /\ K^OO-&YUO3[201S3
MG<2BX6-GP7.%!P#C)/>@:WIQFGB^TX-ON\UF1@B;<;LL1MXR.]9+>%[IKX3#
M50(?MPO&C-OEGPNT*6W=!QCCC'>H[CP=+=17GG:F/.NS TAC@*H[1MG<R[N2
M0 #@C@"A?U_7W@=!9:A;:BDCVSLPC;8^Y&4@X!QA@/45GZAJEW#XETO2[40E
M+A)9;@NA+*BX P00 26[@UHV-H+*U6$"(8R3Y4>Q<GT&3_,U3CT>1?$\VL27
M*NK6RV\</E8,8!))W9YR3Z#H*?7^OZW#H/U^_N-+T2YO;6 SRQ*&V;2V!D9;
M Y.!DX'7%4;?Q 8[>TFN)8KM+^94LY+.)@&4KN)(RV,8;\JU;V"[F\DVETD#
M(V6#Q%U<8Q@@,/YUCV7A3["]@8KW"VSS2L@AX=Y#DE1GY0.<#G@]:2!FE'KN
MFRRQQI=#?()"H*L.(SAR<C@ GJ:RYO%MM#JD@9R--A@1Y9OLTI(9V(7! ^[@
M=<8Y'-9X\!3F*0/K)9WM/LV[[/Q]_<3C=T;N._J*OMHCVUMJ<=[<O>-J:^2J
M16K!8_DV@<%L+QG)(^I- _(W[>[ANO,\EBWEML;*D8/7N.>O45!=ZO8V4ICN
M)]K  L C-L!. 6P#M!/K3M*L3IVG0VSRF615&^0C!8]S63>Z$BO?7$\TLMK<
MSQSRPQ0EI#M"@*"#RN0#@"A[B6Q9L=6GU+6+J&W"K:6C^6YDA?=(V 3M;(
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M'J^2>3CCH,<\\UD1^#)%TZQM9-25Y+&RDM8)!;XV,P $F-QY"C&,]SS2Z/\
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M9C)+(ZAA_JT9V94_#<?SI=1T>>]U2&]BO?),-O+"B&+=AGQ\_4=,=/?J*'Y
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M5-2@TFQ>[N=Q12!A<9))P ,D"N9\-^';W3-7@N;F D_9G,DS2*3YCMN*\'.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $%S9P7@C\Y6)C;>A5RI4XQP00>]+;6L-G"(8$V(
M"3C).2>223R34U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img19885085_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &7 MP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **^._&?_ ".>L?\ 7T_\Z])_9\_Y"^M_]<(__0C0![W1
M6+XN_P"10U;_ *]7_E7E^@>";W6?"WAF_L[/2=*^S()Y-0MY&-U.,="!&HY[
MY9J /:J*\"8:#_P@UK_9?V/_ (2[[:?L_P!DV_:M^\_>V_-C'][BO7]>;5%\
M$W36Q8:D+3DIC(; W8]^M &Z&##((/TI:\T\2ZS+H/@C0G\,7B6L=S<11-+%
M&CD[L!B=P(W9SD^M1>'?$?B^\76+6*7^TYK&_P#($ILX2VS;GD>=".O<9^E
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M/% &[HWC+3]:U1M.B@N[>?RO.B\]% FCSC<N&/'UP?:IM)_Y&;Q#_P!=(/\
MT4*R-)^'UO::BUSJ=U%J4*VWV2&WDM@$$><_."6#G/L/I5_PW86>F:YK]M86
MD%K;B6$B*",(H)B&> ,4 =)1110 4444 %%%% !1110 4444 %%%% !1110
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M[N/I0!WU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB*RCB=/LLQPP0 C(3'6O,O[3L/\ G^MO^_J_XT".N_X3WQ+_ -!+_P @1_\
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M&7_0PWO_ 'V/\*!'UO17R1_PLCQE_P!##>_]]#_"O<=$^,'A/^P=/_M77?\
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M+@\"?]!W_P E)_\ XBC_ (7!X$_Z#O\ Y*3_ /Q% '<45P__  N#P)_T'?\
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MHZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#_=- &AJ_\ QXG_ 'A6!6_J_P#QXG_>%8% !6UHG^IE_P!X5BUM:)_J9?\
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MVUXEXX_Y&V]^H_E0!SU%%%,1]"1?\@I/^N _]!KFZZ2+_D%)_P!<!_Z#7-T
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M.U 8<WCC>W<-^Z^4>XW?05)!)J320">TM$1HR9C'=,Y1^P4&,;A[DK]*N44
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M],^T:_\ 8B_]FZ;]K\S B_M"384Q][?Y.=V>VW'OVK5HH IR2:D+F18[2T:
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MVDUJWG0CRYBA; B'/R,PP?KGZ4 ='1110 4444 %%%% !1110 4444 %%%%
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M -%"@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,#5_P#C^/\ NBJ%7]7_ ./X_P"Z*H4Q!75P
M_P"HC_W1_*N4KJX?]1'_ +H_E2 ?1110,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJNI71L-*O+Q5#F"
M!Y0I[[5)Q^E 'B/BY=2?Q?J.G7VOP26K2RW26RZDR%E"92+:!A"N,\XS7KOA
M".XC\):8MU?)?3>0I-PDGF*_'9OXOKWKPJ[BUBYU^YF34])LKEH)=7)A8LC%
MDPR?."=Q&1C./0"O;? 1A;P+HTEO#Y,;VR-LW%L$CGDT ;EX]VELS64,,T_\
M*33&)3]6"L1^1KQ77-'U^Y\>RWDVBW7G&]M60P123@(,[C'<[0J)ZJ0">G%>
MXT4 >5>$-)UF'Q-+-96<NG#["$NYKNU?RY;C=][;E?,X[@_C78^&TO(]<U];
M^>">X\V'+P0&)2/*&/E+L?UKI*P])_Y&;Q#_ -=(/_10H W**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"O-96\\F^6/<V,9W$4S^R[/_GC_ ./'_&K=% %3^R[/_GC_ ./'_&K2
M@*H4= ,"EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 4]3TJRUBR-G?P^= 65BFXKR#D<@@]:S[GP?H-WKUOKD]AOU
M*W $4WG.-N!@?*&P>/45N44 9&D>&-'T&ZN[G3;/R)KMMT[>:[;S]&) _"M>
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HK.U#4KNSG6.#1+^_4KN,EL\ 4')
MX/F2J<_ACGK53^W=1_Z%/6?^_MG_ /'Z -RBL/\ MW4?^A3UG_O[9_\ Q^C^
MW=1_Z%/6?^_MG_\ 'Z -RBL/^W=1_P"A3UG_ +^V?_Q^C^W=1_Z%/6?^_MG_
M /'Z -RBL/\ MW4?^A3UG_O[9_\ Q^C^W=1_Z%/6?^_MG_\ 'Z -RBL/^W=1
M_P"A3UG_ +^V?_Q^C^W=1_Z%/6?^_MG_ /'Z -RBL/\ MW4?^A3UG_O[9_\
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M/4\8/M5@W]F)8XC=P>9* 8T\P9?/3 SS7+'PMJ#07:%K=7FOGN8I8KAT>,$
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MLK2WGEF@M88I9CF5TC"LY]6(Z_C6)-XJ0V<<UI87$SR7(MT0E!N)&20=V#@
M]^OI5O3/$$.J.L:6EU#)OD1UE" QLAP0V&/KQC-/4"XVE:<\YG:PM6F+AS(8
M5+%AT.<9S[T@TG35BDB73[01R??00KAN<\C'/-+>ZA#8B(2!WDF?9%%&,LY]
ML\?B:Q+OQ#)>M8VNFK/%)=2NCR;4+1!/O<$D$YQZBD@-X6-FLXG6T@$P  D$
M8W>G7K2#3[(/&XL[<-&Q=&\I<JQZD<<$^M5=9U,:#H,]]-NG:!!C. 7;H.G
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MM5W5-,MM8L)+*[5C$^#E3AE(.00>Q! -7** ,JYT-+W3YK.\OKRX29/+=G9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img19885085_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1 M0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G>:K8V$\,-U<".
M28X0$$Y^N!P/<T7FJV.GS0PW5P(Y)CA 03GZX' ]S7GWQ!ANFU]3'NPUF%CQ
M_>\Q:J^,[DZGJBS6$XG3[(85:,\>:)5W#ZT1UL#T/3+75+&]NKFVM;J.::U(
M694.=A/0'WJW7*^'01XO\1@]?]'S_P!\M7'>(KS44\5WZ1:MJ,,?V@1B..Z<
M*%\EFX&<#D#I0]!K4];K-L-?TS4[ZXLK.Y,EQ;\RKY;*!R1P2 #R".,]*X#2
M]3\07%[:W1O+A[=+:&6X8.#&(S$Q.X'(W%@.V?>J5C=/I?CG3H)UEBM[NU@,
MTL<K)ME<NRJV.H+'!SQ5<OO6%?W;GKU17-S#9VTES<2+'#$I9W;H .]<?X.D
MURXU:\FO;B>6R'F*2SAHVD$K ;.I "@#@@>O-7_B"DLG@?4Q#G<(P3C^Z",_
MIFI[#2]ZQLQZM8RZ8VHK<+]D0,6D8%=NW(;(/((P>*J3^*M$MK6VN9KY4BN9
M?)C8QM]_=MP1C*\\'.,&O/[BZQX"\16'GJ+J>[NIX(L\M"L@WD>W6DE$LOA'
M6((;FW^V+JDUY%;2*&:XBCE4E0.N"PQQ32NU_7:_]>0NGS:/6:*XSQ[+<K;Z
M*D-W=6AFO-DAMIVC)'E.<$J1QD"N.TK5M;N-.5/[2OI_,-C)(!,QE;S(&+!"
M#D98*2!V!]Z71OL';S5SU+4M?TS2+BVM[ZY,4MRP6("-VR2RJ,E00/F91SCK
M6E7D?B-]6.B_:KM?M.JV7]FP,A*C=<&02.N5  SF,<"KS:AJVI0Z VA7EZPG
MLUD \XLZR>=&)3)NR" I<#<" 0<#.*I*^GG;]1-]?(].JG?ZK9:9Y7VR<1>:
MVU,@G)_ <#D<GCFK@Z#->;?$Z*Y>[@,08JVFW2)C_GH6CP/K4]2DKG?7FJ6.
MGM;K=W4<37$@BA5CS(Q[ =ZMUQ'B"^MKVRT(03I,]OK$,,VT_=<*V0?>K/C^
M2X2RTQ+>[N;;S;T([6\S1L5V.<94^PH>BOY_Y?YB6KMY7_/_ ".NK-U37],T
M:2"._N#$TYVQ@1N^3D#G:#CEAU]:\QTC5M9ETF<'4[R4NMC(^Z9C)A^'"'.0
M3@<#WI=<;6&\/23WX:XU&S2U39(5#>8TN_:2!Z%!3:L]>X+4]?!R,T5Y>VHZ
MMJ-CH;Z+=WA>: L4$Y9UE#J'W[B00!N'(('I7IR!A&H8Y; R?>AJPDQ)I8X(
M7FE<)&BEF8] !U-5K75;&]LFO+>X#P)D,Q!&,=<@C-9WC))9/!VK+!GS#;MC
M'Z_I7,^#M5LM,M]274KV&!)[EFA\XX!"J,GTX-):W*>R9VNE:Q8:W:&ZTZX$
MT(<H6VLI##J"& -7JY'PG%<VUCK<4\D<H%U*\=S$-OF!AG/'<>U<%I.J:LEY
M9.=8U&3=) 2DMT[J=S,""">F .*:U=O3\1=&_4]FN+B*TMWGG?9%&,LV,X'X
M57TW5K+5X'FL9C*B.8V)1D(8=1A@#7GMM+KET\T-W<SR6EU.(,L^Y&D\S/R9
MYP%'8@5G:;JES!?^);**22UE1Y9+1Q.51_F ;C.-P[4D#[>9[!17/^$!J?\
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M)/#;>,]2<5H:NNI3^'KR#4S,QM[/4;J(3D%TCP8X0>^=K,?FR?4TGM?^M/\
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MDL+06&G6UFLCR+!$L8>0Y9L#&3[TMG=+>VJ7"QO&KYP'QG )&>"1SC-3T !
M(((R#U!JE!H^F6L<<=OIUI#'%(98UC@50CGJP '!Y//O5VJ>JZC'I&E76HS1
M2RQ6T9E=(@"Q Y. 2!^M%[:AOH3P6MO;>9Y$$47F,7?RT"[F/4G'4^]43X;T
M)B2VBZ<2<Y)M4YR=WIZ\_6LJU\=Z7=)>.L%VB6A(D9@G)^7 &&/7> /QZ4Z3
MQGILB+#"TZ3RQG!VK^Y;Y@ W)YRC#C(XH>FH+4K6GP]TNV\3RZX4B>:21I&
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M 4?.V<%5YZ@\<XK-LO%KW?B>:"%IY[2:WC:"%4C#1L<[B<D' QSR:+7#8O\
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M+9(T9$FW)([C!/%&Z_K^NP;/^NYP.D^#M6T"UL4GFLCIVFW)N0%ED9E3;\P
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M.2!GD5WE5;._@O@WDDY4*V&X.UAD'Z'^E6J;OU$@HHHI#.=\5^%8?%$=DDS
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M[.M?._UODIO^N!FL6Y\1Z5=P^5+;:T8R067^Q;O#>Q_==*F_X2S3O^?;6?\
MP2WG_P :I _Z_#_(W**R[+Q!97]TMO##J2NV<&?3+F%.!GEGC"C\35G4-1@T
MR%99TNG5FV@6UK+.V>O*QJQ XZD8H MUQ6M%5US6_MK1K:M8VJKYA 4@R.&'
M/X?I6S_PEFG?\^VL_P#@EO/_ (U4+>(]*:[CN?LVM"5%*9&BW?*GL?W7J :
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M4QDE0L: #D@9)8*?S]*Z>BJOK<5M+!1112&%%%% '.IH5XGB4ZH)+?9),SR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HKE[G7+I->D1)<6L-W':O%M&&WINW9QG.2!UQ744=+@]'8****
M"BBB@ HHK(UV\GMUM(+:7RI;F81^8%!*C&3@$$9H UZ*SM"OVU/1H+J3&]LA
ML=R"1_2M&FU9V ***:^[RVV8WXXSTS2 =16)HDNI+>ZA:ZA=?:EB*,DNQ5V[
M@<IP!D#'7KS5>YU>\.F0WL$JHLM\D(4H#^[W[#^)YYIV Z.BLJUO+F3Q)J%G
M)(I@BAB>-0N""V[.3WZ5";V];6M4M5F41PVT<D("#@G=G/K]T4AV_K^O4VZ*
MKV%TM]I]O=*,":-7QZ9'2K%#T$%%%% !1110 4444 %%%% &/XFTN;6=&-E
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M]X(.3_WTS#\*U** "BBB@ HHHH **** .?GT":36VN%>(6LEPES("3OWJFT
M#&,=#G-=!110 4444 %%%% !69K.GS7T=O);&,7%O*)$$A(4^H) ./RK3HH
MI:18?V9I<-IN#% 2Q'0DDD_SJ[110W< IK[MC; "^. 3@9IU% &-H=OJ\2W
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M *DFF6<J7"-$<7"!),.PRHZ#@\=>U5VT6UC:::UC\NXD4C<SLRJ2 "0I. <
M=.M:=% $5M;QVEK#;1#$<2!%'L!BI:** "BBB@ HHHH **** "BBB@#,U[5)
M='TS[7#;)<.9HH@CRF,?.X3.0K="P[5C1>+;^XO19P:/"]PB3-,AO",-&P4A
M?W?S9R""=OOBKGC.&:X\/>5 D[2&ZMR/(B,CJ!*I+  'H 3R,<5FR01Z!XCM
M9(;34+B/[',7D2WDE+RO(K?,RK@$G/7 'L*%_G^0WMI_6IU.GWT.IZ?!>VY)
MBG0.N1@X/K5FLOP[8S:;H%G:W  F1,R '@,>2/UK4IO<2"BBBD 4444 %%%%
M !1110 4444 %%%% !1110!%<S?9[:68(7\M2VT'!.![U7M-12YT>'477RDD
MA$I4G.T$9QFIK[)L+@!68F-L!023QZ"L);:>3X?);*DD<_V(+M=2K*<="#R*
M.C*23L7SK6VXM(I+9D6XA>;?N'R@#.,>N*SXO%OFJJK9#[1-Y;6\9EXD1\X8
MG;QPI)&#2WT37E_IOE1RF-[20>8L9*KN48RV,"L"WTJ\2ZTZ_>SN0NG106[J
M(VW.0K*Q"XRP&0<CK1U_KS_X!*UC?^NAV6EZO'J:KA#&S1B0*6SQG!'U!&/R
MK1KE/#]C-:ZC8JX93'92F5#U4R2A@#[]?RKJZ;$@HHHI#"BBB@ K'U775TRZ
M6+R/-58Q-.V_;Y:%PN<8YZDXXX4UL5R7B;3;BXO[H1032"_L5M T:DA&$F<M
MCH,.3D_W:.J![,ZT<C-%(HPH'H*6@ JEJ6H?V>+8^2TGG3K#D,!MSW-7:Q_$
M*N\5B(XI9"+R-CY<9; &<DX' ]Z.J^0=&7[N[6U\E=NZ2:01HN<9/4_H":S9
M/$&PW:"T/FP7*VR*T@'F,P!SD X&#[]*EU56_M32)>?+$S*?J4./Y&L2YM)Y
M+V_N!;7!6'4XIP!$V741A25X^;&3TSTH7]?>@?\ 7W,NKXMC=H\6OR@)]H8R
M?ZHLQ0 <?-R/;K6Y9W:W<3,!M9'*.N<X8'!K@H="O8Q/$;6X']HO%*#L.(\2
MER&_N\8Z^M==HJ,+C4Y,YC>Z.S\  ?U%/I_7D(UZ***0PHHHH **** ,:+7T
MEU?[%Y&(C(T*S;^LBC)&,<#WS6S7(6NF7,>OK$8)=B7TMT92IV;64 <]"<]J
MZ^CH@>X5'<2F"W>4(SE1D*O4^U25'<3?9[>28H[[%+;44LQ]@!R:3!&?HVJS
M:C#<_:[/['<6\ICDC\SS!TR"&P,\'TIHUL2R6T5O;^9-<,QC4O@"-3@N3@X'
MIUZBJVB7 O\ 2KR2.UO()9BS/]JMGA)<CLK@'   S7.W.E2W%E9RK;S2W L/
M(@FC0DQ3!AW'W>AY/'%5U [*SU$WUU<)#%FW@;RS,6^\XZ@#'(&>N:SEUW4X
M]2FM[K2(HK=(GF21+O>[*K <IL !.<_>-9.C64NCWOGFSNO,C$_VHQ1,?.W/
ME".S'GMTYK;F5_M>K74JLL2VZQQEA@'@EB/S'Y4GHKCZV-E'62-9$(96 (([
M@TZJ.BPR0:%I\,V?,2VC5L^H49J]3DK.Q*U05CRZU-#K]O8/8,+6=FB2Z\SD
MR!-^-F/NX!^;/48Q6Q6!-J"2^*X;1[*_8P+^[E%I)Y.YARQDQMX7CK_$126X
M^AH7NK6]C),)CA((#<3/G[B]N.Y.#^1J!M7G5;*)K(+>WA)CMS+]Q ,EG..,
M @$ 'D@9/6LC6["6[O-:B\II1-:6S+&!S(J.Y=1Z\8X]Q6-=Z',SW<T5E<F)
MXKE-, B<-;NQC9.,90%E8@G &.V:%J[ SK=>U74M+B$MCI<-Y$J[I6ENC#MY
M  7Y&W$_AV]:T+6[%P\\979+!)L=<Y[ @_B"*SKYY;^WMK807 _TU$E9HR!B
M,[RW^Z2H /?-2:>K'Q!J\H/[O]S'_P ""DG]&6A?U^ C6HHHH&9^L7]UI]D9
M;.Q^V3#)\KS/+& ,DEL''MQR?SI3JD7]D1:@%.R54*(>"2V H_,BH/$5]]BT
MMAY%W*)SY1^RVSS,JGJ<(">F>?7%5]2_>Z+I\L<,D423P,8W7:RKD#!!Z=10
MOU0/_,L_VU&);PM&%M;)3]HG+]& R548YP.IX]*E2]O)-)-VE@#.PW16YEP6
MSTW''R^_7'O7&WF@7#R7D<-K/YS37$EPX1@L\3.'5<]&.. .W-=!H.;%IX5M
M;I+6:5GMU,+ 1J%&00?NY;.!1T!Z,GTO6[JZ"KJ%C#:2-.\ $5P9EW+VR57T
M/;M6W7+_ &>8:;HZO&R7$MZ)G4CE20Q;/YUU%, HHHI 4=,U+^T1<GR6B,$[
M0D,P.=IZ\53OM<G@AEFM+#[3'#)LD8R[, '!QP<GG@=_44>'DD0ZGYD4L>Z]
MD9?,C*[@3P1D<BLIH5FT.;398[PW#W,FQH$?"N&R"S+P!]>#0-[FU'JUPVLQ
MV;V!2"5"T<_F9)(Z@KC@>AR:;-J]U#JIM&T\^2T;-'-YO+%>H*XX'H<G-4BK
M'6X;Y([XR6L#170\N0++P,; >&YSRM..V\UZ+4(8[V$0PNEQYZ.B%2,C ;Y3
MSZ4/_/\ 42-VWG2YMXYHSE7&14M97AR*2'0;9)/O88_@6)'Z5JTVK,2"HKF=
M;6VEG?[L:EC^%2U%<Q1SVTL4W^K=2K?2I>PT4-(U@:GYR/"(98@CE ^X;6&5
M.<#WJE?>)FA>SBM(+:6:[F:.);BZ$.X+U(^4Y.<\=ZC\-Z4]I'J$^^X99]L<
M!N  _EH"%S@#U/49JE-!%>^&;;2WLYY;I@WE2B!F6.17/)<#"'ODXJG:^GD)
M7ZFU9Z\MUJ9M3!LC9G2*7?G>R8W#&.._<]#42>(]]Y)"MKF,&18G\SF0IC<,
M8X[XY['I6196=Q8:A$TEK=NEA)<3,R1%O,#] O\ >/S'@>E%GI\\5^@D@F2.
MTDN9VD=2%82#@ ]#]X_3%3T^0_\ ,[&&9+B".:)MT<BAE/J",BGUG:!&\7A^
MP20$,(%R#VXZ5HU3T8(****0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !01D8-%% #8XTAC"1KM4=!Z4ZBB@!BQ(
MDCNJ@.^-Q[G%/HHH **** "BBB@ HHHH **** "BBB@!DD23)MD4,N0<>XZ4
M^BB@ ID420QB.-0JCH!3Z* "BBB@ HHHH **** "BBB@ HHHH *9'$D08(H4
M,=Q ]:?10 4R6))HRDBAD/4'H:?10 4444 %%%% #&B1I5E*C>@(5NX!ZC^5
M/HHH *9'$D((C4*&8L?<GDFGT4 %%%% !39(TEC:-U#(PP0>XIU% " !0 .@
MI:** &&*-I5E*@NH(4GMGK3Z** "BBB@ IBQ(DCNJ@,_WCZT^B@ ILD:RQLC
MC*MP1ZTZB@!% 50J@  8 ':EHHH **** "F)$D98HH7<=S8[FGT4 %,EB2:-
MHY%#(W!![T^B@ HHHH **** "BBB@ HHHH **** ,+Q?'>RZ ZZ=<O;7OG1>
M3(K$#=O'!P1D'H1[UR]SJPU&"WOC/J$*R7EO'/#!<3;D.U@Z!4.?O#D =J[G
M4K.6]MXXX9DB*S1R$O&7R%8-C (ZXZUC7?A(&[FNM/NH[62:]2\<20&12ZKM
MZ!EZ]:%^O^0/]/\ ,U=%,9TR-HFN3&S,5^U,[2 9/!+_ #?@>:T*JV$%S;VY
M6\N4N)F=F+I&8U )X 4LV,#WJU0P"BBB@ HHHH **** "BBB@ HHHH ****
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M)&O(_P!RK+:;8,&+(Q\WS?-^E(;"[67[5=W*73P*WD+'!L()&#D[CG\A0_\
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MCF5IX0&D0=5!Z9_*F'4K-9YX#.OF6ZAY5 )V ]"?R- %JB@$$9'(HH ****
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ML9CYK6S[75$5@0/,XZD'D]*W=+U>+4H(.&CN'MTG:(J?E#9QSC'8T+4#1HK
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M%CO9HS]K:2/8%4#<<!MV3C@8K<TBWV:EJ<ZD^6[HB_\  %P:V*155%VJ !Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7VE[K5G>>1%(([+:8XVM79I9 0<I@C.,8S@T.UQ(["::.W@DFE;;'&I9CC.
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MM0W5W#96TMQ.^V.)#(YQDA0,DX%97A,77]@1->?:Q,[R/MNRQ=0S$A3NYX!
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M %%%% !1110 57OK*WU&SDM+I"\$HPZARN1]00:L44 (BA$5%&%48'-+110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img19885085_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %\ J@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QK
MXM>,?%&@^+K*PT/6/L-O)8B9U^S12Y;S&&<NI/0#\JX;_A8WQ#_Z&O\ \IUO
M_P#$5T'QL_Y*!I__ &#!_P"C7KS^@#H/^%C?$/\ Z&P_^"ZW_P#B*/\ A8WQ
M#_Z&O_RG6_\ \17/T4 =!_PL;XA_]#9_Y3K?_P"(H_X6/\0_^AK_ /*=;_\
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MGG)7'VE?O@9V=>N.U54T&\ELGN8S"^P9>)909%&<9*_Y- %W_A8_Q"_Z&O\
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MUKJ/VGR'C28>243+ G"/GYL8YX% $G_"Q_B%_P!#7_Y3K?\ ^(H_X6-\0_\
MH;/_ "G6_P#\16/)9W$5E!=N@$$Y81MO4DD=>,Y'XBM%-%MW:&$7<WVF2W\\
M+]G&P?)NP6W9Z=\4 3_\+&^(?_0V?^4ZW_\ B*/^%C?$/_H;/_*=;_\ Q%5K
MOP[?6T,<\:":%DC8LC+N7>,@%<[@.V2,&F?\(]J?FQQK%$S2!BI2YC9?E&3E
M@V%(')!(H N?\+'^(?\ T-A_\%UO_P#$4G_"Q_B%_P!#6?\ P76__P 14'_"
M+ZOY8D^SQ;"H<-]IBQM/\7WON^_2H8= U*>XDMXX4\Z-MA1ID4EO1<M\Q_W<
MT 7?^%C_ !"_Z&P_^"ZW_P#B*7_A8_Q"_P"AK_\ *=;_ /Q%9_\ 8>I?9/M/
MV9MAZ#<N\\XSLSNQGC.,58B\-WOG^7.%B!1V#(ZR_,HSM.T\'V/- %C_ (6-
M\0_^AL_\IUO_ /$4?\+'^(7_ $-?_E.M_P#XBJD7AS4YEPENQEW;=@=.#MW8
M)W<''8BHSH6HK<B Q1ABF\-Y\>S;Z[]VW]: +_\ PL?XA?\ 0V'_ ,%UO_\
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MY6/0D''M2P^)[6VN99K;2W@:8.9)8KK;,&8@_(^WY1UXP>#UJ_\ \*1\>_\
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M^2__ !JC_A2/CW_H*>'_ /OY+_\ &J &/XS@^QBW2TN" TC R3 A=RXV@!0
M!5"P\0PVNP203%5@2)@D@P^TDD,I!4@Y[CBM+_A2/CW_ *"GA_\ [^2__&J/
M^%(^/?\ H)^'_P#OY+_\:H S9-?L[F)K>:Q>.V92-D$@7;\VX8R#QVI;CQ,D
M]U;S?92JP3;U7?GY0H4#..O'6M'_ (4CX]_Z"?A__OY+_P#&J/\ A2/CW_H)
M^'_^_DO_ ,:H Y_2M9FTG[9);/-%-/%L22*0HR'.<Y%6=.\0-#/<7&H&YNKF
M4+MN?-!E7!SPS ]>G'-:_P#PI'Q[_P!!/P__ -_)?_C5'_"D?'O_ $$_#_\
MW\E_^-4 9U]XFCO+N"86SJ([HSD-)DG(48SCK\O6J-Y<VYTYTB8EKBY,Q0\F
M, $ $^IW'\JW_P#A2/CW_H*>'_\ OY+_ /&J/^%(^/O^@IX?_P"_DO\ \:H
MXRBNS_X4CX]_Z"?A_P#[^2__ !JC_A2/C[_H*>'_ /OY+_\ &J %^!'_ "4O
M7/\ L'_^SQU]%5X!\&]'OM ^+GB+2]2D@DN[>P D> DH26C(QD ]".U>_P!
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MF6^U/+/NWYST . ,8QQ^ ZUV=% '!1Z3XE>X/VK<;5%"Q11SD8.W&3\W(]L
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M#R<#!1R<#C.\5@VVBZYI&DLEBDMKLCE:8+Y(,C[3M*^6O.#_ 'LD\>E>A44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !12'@5D-K837QIC+$ 8O,#F8;CSC&W&: -BBD4YYI: "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !1110!RDO_)58/^P.W_HVNKKE)?\
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M_L#M_P"C:ZNN4E_Y*K!_V!V_]&UU= !4%Y.;6RGG 5C&A?#-M!P,\G!Q4]%
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M*I.%_ "@:-% 6-K+-;G/2-SC\CD54AL]6L;^YNC<17B38^39Y;# QUR0?R%
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M!T%<UJ/_ "4+0_\ KSNOYQT =-37(VG-.KGM7N4MM8@F:=U40/\ (T[)&S9
M&1G&>>N* +5H1>:O+,DI,< \K:DIQN[[DQC(]<FM>J.F0&"U169V.,DN^\\^
M_>KNX9Q0 M%%% !6?_S,7_;I_P"SUH5G9_XJ+_MT_P#9Z -&BDS1N% "T4FX
M4;A0 M5!>M_:9LS:S >7Y@G)78><8^]NS^&*M;A57.=67_K@W_H0H MT444
M%%!Z52>UF:4/]NF '487_"@"GJT6LM<*VF3P)&8V#"7^]D$$<'T(_&H+<^)F
MGMOM(TU8@P\_RRY)'.0N?PZU8U"UN)IE$5WL!A="6D(.3CYL#@XQ[=:JRZ5J
M;PQ-9ZF8]J\*OSJ>IQSUZKS[4 3LFN2-<)YUK$I_U+H"67YNX.0>,^E0%?$Y
M*@2::BY3+%&8[=OS=QSNZ>U4CI>N&>.Y^W8E5&4V@D^\I(*@MZCD$U?NM+UN
MX2 QZM]G(A"3(B [VQR0Q'!SCG'3M0!#*OBLP3*CZ<)&P(V7=E?EY)SD$[O;
MTJQ<KKTKF:Q:*%&B.(KM0VQQG'W#T/'\1J@VAZY'#-G7)993RN[;D'=E2,
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M2%")!Y@Y7:Q./K@UU)('>N>E_P"2AVW_ &#)/_1BUHR:CC5EL#;3 M$9!/\
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ML1F@#-T66.2XU$HZL/M)Y!SVK7JE9:38Z<TK6=I! 96W2>5&%W'U.!S^-7:
M"BBF2RK$A9@Q _NJ2?R% #ZR)O$NF6]T]M-.(Y$<HP;MQG/T-6(M5AEF:,).
M-OK"_P#A69?76G_:YTET^UG*R(CN0I/S=<@C.1Z#- %^+Q!IDWF>7=HPC!+G
M!P,>^*BE\2Z=$JN928V!(<*=O';/XUER:QH>G3W-N-*\I8W"NRPQJC$CKU&>
M,TZ#6='EF-G+IJIYDFPAHTVL&/!()!(/'0&@#3/B;2MS*+D%E7<1M(P.V<C
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M67[+]G&Y@$XYP>3[<YJ_0!@44 %%%% 'C_A'_DXWQG_UY)_*&O8*\?\ "/\
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MMV,YZT :5%%% !11D49H ***J_:I?[1^S&)/+\O>)/,.<YQC;CW]: +5%%%
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M10 4444 %%%% !1110 4444 >/\ A'_DXWQG_P!>2?RAKV"O'_"/_)QOC/\
MZ\D_E#7L% !1110 4444 %%%% !1110 4444 %%%% !1110!RDO_ "56#_L#
MM_Z-KJZY27_DJL'_ &!V_P#1M=70 4444 %%%% &+::I>2WEZCVA986*I%&
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M/FXZUU,ACC5IW7[JG+!<G'7MS6,]_IRZE'JC7+A'MO*0>0^&&[=P<<GCIUH
MS_\ A+=:^V_9/^$+U+SS'YNW[9:_=SC.?-QUIQ\4ZX+@0?\ "%:EYA3?M^V6
MO3./^>M=&)K<PB]&"I3(D"Y.WK]?PK/.IZ:;K[?]L 5;4N05(PFX?,>..>U
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M1110 4444 %%%% !1110 4444 <I+_R56#_L#M_Z-KJZY27_ )*K!_V!V_\
M1M=70 4444 %%%% !5.;38YK^.[9WS&.$!&TGG!/&<\GO5RB@ QQBL:Y\-VM
MX\[74UQ+YLBN 6 \O!! 4@ XX[YK9HH 0# Q6+<^%M.NGW-YJ?OA.0LAP7'?
M!SS[]?>MNHKF8V]K-,%W&-"VW.,X&<4 2 8%9MSHT=U+O:XG7,HD8+M(?'0$
M$'@5F1^,[4H3+:SQR*!YD>!E"1GG)&?PSZT#QI:F62/[%=AT#$H0F6VD#CYL
M=3W(H Z8]*P)O"&F7%TUQ(K&5I/,+ */PX' ^G/O19>*K74-3CLK>-RS*S%F
MP -O4<$\YXJ.3Q2]M<217-@25=E46\@<L <9.[:!^M '02Q^;"\>XKN4KN7&
M1^=82^$X J+)?WLJQIMC#E/W?^T,*,&I=*\36VKSF*WM[E"H!9I$  )YQD$\
MXJ:'63)K4^G/;NH3&V4$%6XR1UR/RH NK:(EB+2,E$"; 1C(&*RHO"FGQP>6
MQFD)C\IG9\,PSD9VX&1]*;?>)?L-\T+6C/'G:)%8?>R!R#T'/;-;=O,MQ;QS
M("%D0.,CG!&: (DLDCTU;*-W6-8A$K9RP &._>L23P7I\T;+--/(6C6-F.P%
M@O3.%P?H>/:NDHH K_9%%A]D61U7R_+#YRP&,9R<Y/UK''A*T$8 N;@.(5A$
MJK&&VCU.SG(X.>U=!10 V-!%$D8Z*H4< =/IQ3J** "BBB@ HHHH **** "B
MBB@ KRK1_P#DY77O^P(G_H4->JUY5H__ "<KKW_8$7_T*&@#U6BBB@ HHHH
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M27_DJL'_ &!V_P#1M=77*2_\E5@_[ [?^C:ZN@ HHHH **** "BBB@ HHHH
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M0B&G_9Y&N954*QD+$8,B'IM]N:RO^$A^.?\ T)NA_P#?Y?\ Y(KU^B@#Q_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?:NK74K!KE;9;VV,[$@1"5=Q(Z\9SQ2G4;%6E4WMN&A&9 95R@]3SQ1?^OQ
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MNT?/<&,L[,%"@!6SU]JM6NJ920:@;2TE1E!07(?AONYR%QD\8Q0OZ_KYA?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img19885085_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! @@# 2(  A$! Q$!_\0
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MEH?M4A1XVF5,D!$P-KAF&,=1C&,T2^"]5ENIVDOUF61\M*\NUI4WJ=K 1YX
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M3=+L8-*:UO\ >8GG:0.HC4,^[''?C'XUUM5)]-M+G4+2_FAW7-F'$#[B-F\
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M<X &3DX'6EJ)--Z#04444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M*=7DOYVMGLX[1M0NIT2*?RF"RLK(^?+8!D *CK[$5Z'_ &=XE_Z&&U_\%O\
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M .@18_\ ?;_XT?\ "]M7_P"@18_]]O\ XUZW_P (KI'_ #ZK^5'_  BND?\
M/JOY4>TI_P GXARS_F/)/^%[:O\ ] BQ_P"^W_QH_P"%[:O_ - BQ_[[?_&O
M6_\ A%=(_P"?5?RH_P"$5TC_ )]5_*CVE/\ D_$.6?\ ,>2?\+VU?_H$6/\
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M*2W=S)Y<2R-M48!8LQ]  ?TK+$4*5>')5C=&BJ.&J)+*P6T7<V'F)/SX[''
M]!P*N5F:5J,]U-=6=[%''>VI7S!$Q9&5@2K#//.",'TK3JJ-*%*"A35D@<^?
MWF9^HZ2FH21S+<W%I<1@J)K=PK%3U4Y!!' ZBIK"P@TVU%O;AMN2S,[;F=B<
MEF)ZDFJ>H7^H?V@+#2X+>298A-*]PY554DA0, DDE6^F*L:3J*ZI8+<>68I
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MBCF?<+(K6]A;6HN!%'Q<2M-(&.0S'&3S]!5;5="L-9B2.[24!%9!Y4K1G8P
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MHB1%O,C\S[A)/#=1G &/?%=#23N3&2>Q!>6<%_:O;W";HVP>"000<@@CD$$
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M1110 4444 %%%% !1110 4444 %%%% !7E?QU_Y%K3?^OS_V1J]4KROXZ_\
M(M:;_P!?G_LC5K0_B(BI\++GP:_Y%&/_ 'G_ /0S7I%>;_!K_D48_P#>?_T,
MUZ143^.7JS1[+T7Y!1114B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YGQ?X>U/7A8'3=2^PO;.SELL"20 ",?C^==-6?
MKFK1:%HEWJDT;R1VT>]D3&3],T<O-H1.*G&TMCA8? GBZW\SR?%3)YCEWVN_
MS,>Y]^!4G_"&>-/^AOD_[[DK3\(?$;3O&%[/:VUI<6[Q('S*5PV3C P:[)F5
M%+,0% R2>@%2Z/*[,Q6&IVNK_>_\SS1_ /BQYS.WBIC*4\LOO?)7TSZ<T^#P
M-XOMH$A@\5M'$@VJB,X 'L*[B+7M(G@EGBU.S>*%=\CB9<(OJ3G@4^[UG3+"
M80WE_;6\A4.%EE"G:20#SVX/Y4>R0?5:6^OWO_,X?_A#/&G_ $-\G_?<E5I?
MAWXGF2X23Q*&6X(,REGQ(<8Y'?@"O0O[8TPWQLOM]M]J#;?)\T;MV,XQZXJV
MLB.SJKJQ0[6 .=IP#@^G!!_&DZ:!X6F][_>_\SSL>"_&:@ >+G '  =Z/^$,
M\:?]#?)_WW)7HD<B2QK)&P9' 96!R"#T-.H]FA_5H>?WO_,\P3X=^)XU@5/$
MP"P,6B 9\1D]P.W4U9_X0SQI_P!#?)_WW)7H$MW;02QQ2SQQR2$!%9@"Q/8>
MM34>S0EA::VO][_S/-IO WB^XA>&;Q6TD3@JR,SD,#V-,3P!XKBG$Z>*2)0@
MC#[GW;?3/I7IE-DD2*-I)&"(HRS,< "CV:#ZK3WU^]_YGG?_  AGC3_H;Y/^
M^WJ.;P)XNN-GG>*F?RW#IN=_E8=Q[\FO2J*/9H?U6F^_WO\ S/-(O ?BV!Y7
MB\5,CRMND8,^6.,9/KQ4O_"&>-/^AOD_[[DKT:F+-$TSPK(IE0!F0'E0<X)'
MO@_E1[-!]5IKO][_ ,SS=_ 7BV2X$[>*F,P4H'WOG:>V?2O0=-LDT[3;>TC5
M0(HPIVC@GN?Q.35JBFHI;%TZ,*;;C^=PHHHJC4**** "BBB@ HHHH **** "
MBBB@ HHHH **R==U*ZLDM;;3H8I=0O)?*@68D1K@%F=L<X"@\#J<#O4 L/$Q
M W:]8 ]]NFG'X?O: -VBN7MI]4O+R>SMO%FDS7-N<30QV.YH^<?,!+D<U<^P
M>)?^@]9?^"T__':+ ;E><?$KX=?\)+&VJ:;\NIQJ T><+.!Z^C8[_A75_8/$
MO_0>LO\ P6G_ ..TGV#Q+_T'K+_P6G_X[51DXNZ$TFK,YKX<^!V\,QM<3'==
M2+MD?MC^ZOM_.O0JP'L_$44;._B&P1%&69M.( 'J?WM.%CXD(!&OV)!Z'^S3
M_P#':3;;NRFUT5C=HK#^P>)?^@]9?^"T_P#QVJUQ_;-K/;P7'BC3(I;ABL*/
M88:0CJ%'F\TA'2T5A?8/$O\ T'K+_P %I_\ CM+I&IWYU.YTC5Q;_;8HQ/%-
M;J52>(G&[:22K C!&3U!SS0!N4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<Q\1/^2?:U_U[G^8KIZXOXI75[;^"+Y;:Q^TPS)Y<
M[A\-""1AMN/F'KR,5=/XT*6S/,O@O_R,MU_UR7^=>]W<;36<\:<L\;*/J17S
MK\*;VZL_$S?9K,3K(H$CL^T1KGKT.3[5]$7=S]FT^>Z";O*B:3:3C.!G%:8A
M?O6$/X4?G^9R=QX1O[JTTNV>^E;;$D=R\RQL(T0!A&JJHW9=4Y.>$]^8QX<U
MV;3[J&:Z9)4LH[1-CKLNU1Y?O\%EW(RC(((+'TJ=/&ER\T=L+.R%P\ N0QO?
MW00KNP6V??QVQTYSBET[Q;-+,ZR0EOM5PJV:NP4C(BRA '\(DW=^C>E+WR?=
M+MCH$K7-U+=S3Q0/>K<QVBF/9\JIM)(7=D,O3=CBF?V)=_\ "327.)5M9+T7
M+LMPP#J(%105![.N<8P01UQQ53QC?+9Q7EQID @:"VN&$5P6<).2J@#8 6!4
MY&?SIVE>,+O5%M@NF1PM/.B@O<?*(VCDDW9"YR!&1TP<CGK2M/5AH9\/AG7F
MTY1<7-W]J\IU8B_<<^0H3HV/]8"?YUK>'].UJTUNYFOGE>WEBY,LY?#Y7&T!
ML8QNZJ". ">M9D?Q"FFANFBTQ6,)A8$2O@QR+(VX#9N.!'V4\'/05=LO&XN]
M0=!ITS6665)X0TC,5 .0@7)!SVYQ@D>C:G;5 N4S[GPSJ[?V<SK<7*1N)KF/
M[<P9FW-]TEN#MP.,?AS5B+1O$2R1>;+.\G[HQ2K>E5MT#9=&'\;%>-Q!]>U7
M]+URZO->=)'86LDTT4<;1A2"JQL,@C<#@N3GU IA\3W44TBK:))##*WFN\V&
M"_:7A&T!<'[N>2/3)ZT7EL&AB'P_XJ:PAA^T72I')(?EN\2L2J;68[R, A^A
M[YVYK?UO2=4O94:">4^7ILT8*3F,&X.S8Q (SP']AFLQO']PJ+'_ &2#=O*%
M2(3$C859@V[;AL[#C;D'!Z8JP/%6HW1M+B"SMX;4W"I(LMP-S9M3,1G;M Y&
M#GG'8&F^?>P:%;5-/U33S+?--=M:,\K74:7+DNINE9 H!^3]T6&1@ <$CK5J
M.#5+WP3$EI'<+-)<R/MEF?S!"97*\EE)^7;U8<>O0V+?Q9++X5U#5Y+)4N++
M.ZV\QNNT, 6*CJ&'(R/>JE_XWNM.F:WDTD27$+2>=Y<_R!5V'Y6*C)PXZXQ^
M-+WGI8-"I9>'_$\<2R2WDXNXY(51S=,RA!N#DKG!X*]1DXK:\,:7>V-W>37<
M,L?FP0)F6Y,S,Z;]YR2< EL@>_;I26_BF:XU./3QIY65Y?)W&3Y0Z<S=NBJ5
M(/\ $3CBJ8\4W5CJFL)=^1+:PW<D<69=KQA;59<%0OW<JWS9)RW2A\SN@ND=
MC17$Q^/)RBM)IJ(J7+0W#F1_W:A8VW;=F['[SN,#'/45I>'/%,FO7<L;:>;>
M((9(G,FXL VWD8&#],]Q4.$DKE*29TE%>46^MZYXC_M;4(]<_LZ*Q5I8K;@%
MEY(!Z9X &3GFNL\/:_>:@=&:YP1?V<S,H7&V2)U&X>S!OT&*TG0E!7O_ %N2
MJB;.KHHHK L**** "BBB@ HHHH **** "BBB@##U;_D9O#W_ %TG_P#11J/Q
MGXE3PMX<FOL%[ESY-K&!DO*P.WCT'7\*3Q+<1Z=?Z-JMR=EE;7#I/+VB#QLH
M9O1=V 3VS4EY_P (UJ=[97UW=64\UFQDMF:Y&U&/\6-V">!@D'':JC:^HG>V
MAYM\.I[.R\;VT<0NA-=Z4_VN2YB9#)<"3>S#/48XS[4W_A)?$-UX*O/%8\0S
M)+'J7EV=FL<8212P&QN,DX)/T7WX]"UZ+1=4B>ZBO; :K%;30VD[W6T1F1"I
MS@\CIV/M61X?\)^#])L=--Q)ITVH6J*SR_:LH90.6"DXSGH2,\"M_:1?O,SY
M7LC+OM;U?53XNU./6IM,M]"=X;6"()AY$!R9,@[@Q  'O^;;/Q'KGB7Q%HNF
M#5'TR.71Q=WWDH@8L<\J6!QD%3[ UU%[HG@G4=0>^NUT^2XD(:0_:<+(1T+*
M&VM^(-9*^&M!U#Q'K6I:W=Z9<1731+:+%=E6BC1"I!((QGN 2*2G"VP^61R4
M^H:KXK\):%I=UJLKF]UA[0RB-?\ 2(%(/F'UV^G?OTK6O=6U^;2_$VL?\)#-
M:QZ'.;.VB2-!YLD>T%I!CG<3P.F3[5V%SI7@ZZM+&UE-@(+ DVRQW.SRR>N"
MK#KWSUJ.ZT+P1>ZD^H7*:=)<2.'DS<_([#H63=M8_44>UCV#D?<YO7-=UZ>V
MTR^\S4$T[^RXY[W^R3&9H)V&XEU;)V =N._/%6(M7N+[Q)H<<=_;7B6VBR7Y
MNKFW1-S/\B$DC*=L@$5N:CH?@K5;Q[N[^P-/(H61DN_+W@= P5@&_&I_[.\'
M^?<3$Z<6N+=;60&<%3$N $"YP ,#H!TI<\;;!RLY/PKJVM_\)-86&NZGJEMJ
M,ZR.UO-%%):W2@$_NF7[N ,]\^O:NO;_ )*0G_8(;_T<M0Z5I/@[1;L75@UE
M'.$V+(]V9"B^B[F.T?3%+IUS#K'C>YU"QE6>SM+(6C3H<HTI?<54C@[0!GW;
M'K6=22D[HJ*:6IT]%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %(RJZE6 *D8(/>EKB_%UCX@OM>T^#1M6:S66%RZ!B  AY8X_P!Y
M!^-*3LB*D^172N;FF>&=+TB5VLK6.%78OL1<#)ZFM2>!+FVE@D!,<J%& .."
M,&O,[/0/&MW<7=N?%+1RVL@1U+L<@@,&!QT(-6_^$0\;_P#0VG_OM_\ "I4W
MO8S^L3DO@?X?YG;PZ/IT-BEFME;FW0@A&C4@L/XCQR?>G/IEJ^H0WK1_O8=Q
M0 X4,PP6Q_>QQGTKSH:!XWDU*>RB\4,SP1+([&1@ 6SM7IU^4G\J73- \9ZI
MIT5Y%XJ=%DR"K.V58$J0?H011[1]B%7DW;D?X?YGI8M;=0H$$0"A5 "#@*<J
M/P/3TIL-E:6_^IM88_G,GR1@?,1@MQWP2,UP/_"(>-_^AM/_ 'V_^%9,VF^-
M8=+OM1_X225H+.1U;$C;F"'#L![$-]<4.HUT&\1*.\'^'^9Z?_9&F;&3^SK3
M8Q!*^0N#@DCMZDG\34R6EM'<M<I;Q+.R[6E" ,1Z$]<5Y^GA/QLZ*Z^+LJPR
M#O?I^5=;/>R>'/"GVK4)3<S6L"B1P?\ 6OP.I]215Q<I.UC2%1O>+7W%ZTTR
MTLIYYX8E$L\C22.1EB3C(SZ<#BIOLMO\W[B+YNOR#GDM_,D_4UPK>*/$FE6U
MGJ^K6UFVF7;*/+AR)(@W(/Y<]_PJUK?AOQ7?:Q<7.G^(_LMHY!CAW,-O !Z>
M^35U82IV;U"52R]V+9U1TO3S%)$;&V\N1M[IY*X9O4C')]ZE:TMF&&MXB-P?
M!0?>  !^H '/M7FVH^'O&NGV37#>*7DPRHJ*[99F8*HY]R*C.A>-H]8BTZ7Q
M0RR30--&XD8JVT@,.F<C</SK'VC[&3Q$D[.#_#_,]+CL;2*V:VCM8$@;.Z)8
MP%.>N1TI9+*UE96DMH797\P%HP2&_O?7@<UP/_"(>-_^AM/_ 'V_^%5+GP]X
MVM[RTM1XI9Y+EF P[ *%&23Q]!^-'.^PW7DOL/\ #_,]-$48?>(U#\_-CGG&
M?Y#\JB-A9F:28VD!ED!5W\L;F!X()[C@5YO:>'_&MU<7=O\ \)2R2VL@1P78
MY!4,&''0@_H:M_\ "(>-_P#H;3_WV_\ A0IOL"KR?V'^'^9W0TK3E6-5L+4"
M-MZ 0K\K>HXX/ J:*UMX))9(8(HY)3F1D0 N?4D=:\U'A_QO_:QL4\3EV2$3
MNQD<* 6(4=.IVM^5>@Z3J0U6P%QY1B<.\4D9.=CHQ5AGOR#S34V]&73J\[LU
M8S+OP1H%]=?:)[+,A<NVURH8DY(..V2:UX=.M+>X2:&%4:.$01@# 1,YP!VS
MQGUP/2K5%:.<FK-FJBD%%%%2,**** "BBB@ HHHH **** "BBB@!" P((!!X
M(/>J)T322<G2[(G_ *]T_P *OT4 4/[#TC_H%V7_ (#I_A1_8>D?] NR_P#
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MI;3>A2"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7(>+? \7BC4(+IYWC,47EX5P.Y/]T^M=?12:3W(G3C4CRR6AYA_PJ&#_G\D
M_P"_H_\ B*/^%0V__/Y)_P!_1_\ $5Z?14^SB8?4J'\IYA_PJ&#_ )_)/^_H
M_P#B*/\ A4-O_P _DG_?T?\ Q%>GT4>SB'U*A_*>8?\ "H8/^?R3_OZ/_B*/
M^%0P?\_DG_?T?_$5Z?11[.(?4J'\IYA_PJ&#_G\D_P"_H_\ B*/^%0P?\_DG
M_?T?_$5Z?11[.(?4J'\IYA_PJ&#_ )_)/^_H_P#B*/\ A4,'_/Y)_P!_1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img19885085_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %C I4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN?[L7_?1_P *7-S_ '8O^^C_ (4 345#FY_NQ?\ ?1_PI ;KGY8?^^C_ (4
M3T5#FY_NQ?\ ?1_PHS<_W8O^^C_A0!-14.;G^[%_WT?\*,W/]V+_ +Z/^% $
MU%09NL_=AQ_O'_"ES<_W8O\ OH_X4 345#FY_NQ?]]'_  HS<_W8O^^C_A0!
M-14.;G^[%_WT?\*3-U_=A_,_X4 3T5!FY_NQ?]]'_"ES<_W8O^^C_A0!-14.
M;G^[%_WT?\*,W/\ =B_[Z/\ A0!-14!-UCA8<_[Q_P *7-S_ '8O^^C_ (4
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MW#.*E>V@E4J\,3JW4,@(/>I%4*H   '0"@"*7_7P?4_R-35#+_KX/J?Y&IJ
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MZNTM8Q,)FQA63')_^MS]*G7_ )&>?_KR3_T-Z&!Q-U_Q]S?[Y_G4)Z5-=?\
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M75QY,TK3"(%<([*0Q!QGG<3S3)?"5I),T@N;E1(<2J",2)A/E/' _=CISUH
MMP^(]'N+G[-#J,#S9*[0W<9_P/Y&KMG>VU_!YUK,LL>XJ2.Q'4&LE?"EDH7$
M]P"NW!#@$;=^.W_30_I5K0M#@T"Q>U@EDD#R&5FDQDL<9Z#VH O2_P"O@^I_
MD:FJ&7_7P?4_R-34 %%%%  >E<KJD21:_P"=>3MY;)NB$46XI@=6XQ@8;KG\
M,5U5<EXG>!]3M!.CM&BDAH@A8/D<'=U&* .L4Y4$'/'6J>H:59:I&B7D D"'
M*GH1R/\ "KB_='TI<T 8P\,Z:(XT*2L(V#J6D).<]?T ^@J5?^1GG_Z\H_\
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MJ:O:?;7UOJ6E.;/4%MQ<W!5&?(AA880.-WKSWP* .IEL('BN4C7R&N0?,EA
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MJN<I)W16\5C_ (G1X_Y9K6'70R_#'2YWWS:OKTC=,MJ#$_RJ+_A5FF]M=\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8,.#QU'6KE% &?<Z4ES&R&:1=SER1C.3Q_+(_&HDT&"."2%990C\#! *C&%
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M=&_G7ZCF/\*!XV)V15KT32?^05:_]<Q7G=>B:3_R"K7_ *YBL\J_B2]",/\
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M*22WGBE\M(TV32-DMQTQZC'/N:UJ* "BBB@ J*Z_X]9?]PU+45U_QZR_[AH
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ML5S?B#5[[3;I5CN(8(BA=?\ 0I;EV"_>)"$;0,CUH N?VKJO_0O7/_@1#_\
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MD<&H6*_,F[[3 _R$XZ%3\RGVY^M !%J6I/,B2:%<1(Q +F>(A1ZX#9K0NO\
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M_P#M=,=LUWAZ5P&HW5S9^(I?[/@M8)%GPT,+R)+*@7<6*@%"#R,X_'- '?*
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MG>NWKC?&$IM[R%X8K.*8PNZW,K21NS C"*R<DG/0_E0!U=G;QVMJD42!%Y;
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M%% !1110 4444 %%%% !1110 4444 %%%% $%XS+8W#*6#"-B"O4'';WKF?
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M=P8[L,3G9DC'%=N*X22!H=8WM#!+/+<[EM8I&S =_#M'OPP*Y.[ P><5W8H
M*XK6[,_VM? 0LPN$5BPM4G<#&/E8L"G3N, \UVM<+KGD&^U0Q0HDL1#37;3H
MDJ H 0BD?,I7L2 3G'- ':6A9K.$LA0E!\K,&(X[D=:FJ&U55M(50DJ(U W#
M!QBIJ .+\9P27DHALI]3>Y$/[RVM6<1["?O-MZ-P<=<XQBNKT]X9-/@>WE>6
M(H-KR,2Q'N3SGZUS?B:#=J*7$OD1Q1Q+@&<PR7.2=R*P=>0.0"#R>U;NB;QH
MMH'@\@B/B+;MVCL,=N,4 :%<QXP:Y^SQ164DK7,RN@MD5B)5X))*_=Q@#/\
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M*)X2T<2%1C<X0B-MV6!)_2NX-<CJMK=S:O=Q6VEW[0R*AE:*^6&.?(P>#SG
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M5!:'^S_LI'^UC +#WKI:Y[0+:[6ZEN+VSNHW,85);B\68[<] !C'8D]ZZ&@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img19885085_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( E$# 2(  A$! Q$!_\0
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MJ 3Z4 =9NI<FF[06SFG9'2@09I:8!S3Z!A1110 4444 %%%% !1110 4444
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MKUM/"/AV+2Y]-31;,65P_F30+"-CMQR1Z\"IF\.Z5-I!TF;3X&TX*%6U:,;
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M32&/2FJBEMP;-2T#$Y II!)P>E/HH ;C'2CD]13J* &9;=C'%"K@''>GTF:
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MM+UJY\$CP^^C7<HMT2V22UO$B9PJ#Y\EAQGC!Y-<E<_#CQ1=Z7;P7-H'GM]
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M2BDS0 M+3<\TZ@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@!*44E+0
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MQ'J&J37FF2W-U;Q R,'=PV0!V4';65I&N:KX@LDM[K5KJT41:C>Y23RW+QN
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M[6&%3R?+0#)JV<8P:8H.,"@8.,'(H#-Z48.:?D 4 )@THS0&!I: "B@'(HH
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MHP".U([(.&H 0N .M"')I (V;:!S3U4"@!U1L>:>QP,U'C=0 ]33J:.*7.:
M#=2;N:"*:<+R10 XFHGD&,9Q^.*?N79NQ7 >/]>TZ*."V$DSW,=PC,MO*4*J
M""P;!'4<4XQ<G9"YDMSO);B*&(R2L$0#)8GC%<9?^([W7IVLO#$;'8<27KK\
MB_[OJ:IZ?'J?C6)?M#O9Z(C;4BC8^9,!_>)KN;#3K33+2."TA2*%!A548_'Z
MUI90>NK)^):&/H'ANVT,M(VZYOY^9KAN3FNA "< <4X8[4M9R;EJRDK# G.:
M=BE!I:0QO2ES2$4 4@%I:2C%,!<T9I"*3- #J*!10 4444 %%-S10 C,$Y/"
M^M5YKR&)PLKB,GGYG"_S-17ETD.F7$TCF*..)I&?^ZHZFO"M*B\':_?6\6L'
MQ9J=Q<R*AN[YW1(R^3&#AQC<!D>U 'ORSQRK^Y99!W*L#BG&3"C:,GO7!Z9\
M,K30=7MK[1-7U6TA1P9+5+AGBE'<,&)KOE0*[/W- &+XJO!9:%+<MJ,M@L8W
M>9"BN['L@5@<D_2O/-6\9>(M/T/2+2[O$LM56".ZU&1T&<%@HC Z9;))(Z;3
MTR*](UOPYIWB*WCAU".1UCF69-D[QD,.ARA!SS3)?#&E3:8--G@\^W7D>?(T
MC=<\LQ+'D=S0!Q3>(M6$SZHEZQA_MMM.^Q;$V-$ PSG&[<< ]<5)X4U[6+O4
M_#CW>H_:8M7L);B: 1H%A==I 7 !  ?!SGD5U<7A'1QJQU(V:&Z,GG??;8'V
M[=^S.W=COC/O3]*\(:+HMX;G3[,0RE2N[S&;:I.XJH8D*">2%QF@#7 /ELN<
MC!YKQ.\U1K[]I#1T:VE@\B*6 %ND@".0P]C7M[*HC9!W%>'7VJ1:G^TAHT<<
M4R-:)+;N73:&(1SD>HH$>OZAKEAITJ+=W B8C(&PG^0K#U'QU8Q,%M]\HSRR
MG:/U%=-+86]S*7FACD.,#>H./SK-NO"NE73[I+2/(Y^7*_RQFN:K&N_@:.JC
M+#K^(F11^,=',2,UV Q RIC;(_2N;\2>,M377Y+'2;RRL;*VLDO[F^N+=YOD
M9MJ@(N#FNWBT?3XXE06<&%''[L?X5A:]X%L=9OEOX[N]T^[$/V=I;*8QEXLY
MV,.A&:T@JB^-F<W3;]Q/YG%7_P 3IVN--M4U>RB@-FEU<7_]GRRQREGV@!0<
MH.#RU=OXC\90>&H],+VMQ>/J$GE1"W )8[=W K,F^%6A26MI:I/>0P16ZVTR
M13$?:(PQ8+)ZC)/3FG>,O"%SK=SX>BTZ5[>#3[KS)'BD*.B;-H*'U^M;(Q92
ME^,&BKIMI<K!>/)*LCS0*%#P+&VURV[ .#V')[4C?&#2(]1DA%CJ,L*W(M1+
M'&&4R,N5 [Y/3%37'PG\/B#3XXY;B":V+9G#[GEW-N;=NR#D^U71\.-(6??Y
MTP']HIJ6W(QYB+M Z=*0SG9OBM+-J6D7-AI]U):W$=TL]B(P9A+$0",]!@9-
M:J_%/2&N[=(H+^2!K-;YYT3Y(X3NRS]^"I'2I9/A5IF])+;4M0M9$DGD1[>3
M:P\T@N,^G&*O6?P\T*T+Q*CF%[ :>T)8E6B!8\GKDECWH YC6OBH6\-ZA)I]
MI<V6H1)#/"+Q.)8'E5=XQV.>AYJ8_$AM(MM:FNX+J]@L]0-J&MXU3R1M4@<M
M\V2QY _"M"3X6Z'-9SP7M_J%Q(ZQQ)+-,6:*-'#JB]L9'?FEO?A7I&H7+S?V
MA?1-)?'4"L;+CS<* <$=MOZT +;?%&PFB)DL;N&1+^"P,;D;M\B@C/L,\U5;
MXM6;W+P1:1J<DA::* (@Q+)$?G53[ 9R>*MM\+=-?41>R:AJ#O\ :8;QHS-\
MCS1XP[#U..:OV?@+2[6>U=)I2UK/<SIG'WIP0P^@R<4 9TWQ4TJ&'2+CR+DV
MFHHCF?*XAWL5 9<[C@CL#5#PM\2WFU-]/U:WN"9M2GLX;I8L1;PQV)ZYQWZ5
M-+\&=!D-O_I=X/)A2+'F<-M<L"?Q)XZ5I6'PVTFQUF.\-W>RB*Z:]CMGE/DI
M,QY<*._;TH MVWC?3+_5M7TJVND%Q9QJXDR&5\J2=HSSC'-<K:_%J&RTBV6Z
MM+R^G&G)?33Q1A L;,1N*Y.,8]37>1^&-+AOKV\BM(TGOE"SN.N "!CTX/:N
M 7X2 ^('MWO;B+1!ID=BOER[7F 9BR-Q]TY]<T /?Q_?7&M0P:;=I-;RZO;6
MVUX-I$4D1? ;)SG YP,40?%J#3]*MGO(+R_G>WENG>&)4"QK*R'(R>F/6NC@
M^&^BV=\EW"\RF.\BO$3/ :-"BCZ8-58_ACH<<#P"XG*O8S6)R1]R1RY/URU
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MM%<&UBD@EW1E<L$<G&>HYZT >Y?Q4-2+DG)Z'I3C0!$68'@T[:67&:-O-.!
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MAJ=S]FA,I*E5X8,>QX-9G@IW3PAID;1%?+MT0_4#FD_L-[@^=JL_GN,LL8.
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MG%4[3POJ>KR"X\47AF3.Y;-/E1/J1UKI-,T:QTR,+9VJ1 #KCYC]3U-:#KN
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MCVI<^8<U(:C4Y<YIYH *6D%+0 4444 %%%% !1110 4444 %%%% !1133S0
MZFMTI1THQF@"($DT^@KZ4H!'6E889I<TUCC&.M5[N^AL(&GNI8XHE&2S-32$
M6&8 _=S5#5=;L-&MC->3I&HZ GEO8#N:Y23Q+JOB.=[7P];&*$G#7TV0H'JH
M.,U?TKP596,ZW-^\FI7?4R7+;AGU /2M.11^,F[>Q0_M+Q%XK8KIJG2].?\
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M3N;W6;BV>94BT^W09:68\X]<=JX?0-6AU#Q'=6UZDL2LX59UN(\2''HI)/\
M+UK&4[O4WC221ZPSQJ!DBHVO+9>L\8^K"LU?#E@<[EE?W,K<_K1_PC>FYYM
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MZG+;L \?2I #W.:UBXQ^!)&4HN?QR;^9RL7@722<W+S7K=S/)_A6U9Z)IUB
M+>SACQZ+FM#:.PHP?6FY-[L%3C'9#,%1\JBN<\811R65D)44C^T;4<C/65<U
MT4A94/-<AX\U"^L[&R^R:<]V3>P-UQAED4@>^3Q4M%HZV$*L04#"C@8]*?@=
MJJ6;3365O)+&8Y9%#/&3G8<=*N*FWJ:!"C@49IU-V^] PR?2C<?2C;[TNWWH
M ,T9I,4A!H =@4U@>U +?W32YH RM:\Y-&N&B60R@':8HO,;\%R,UB_#IYV\
M":<TWF[A @'F0^7Q@=.3D>]=+>RI%%M9PNX,!SC)Q61X,(C\)Z5:NW[Y;.,L
MAZCBD%]#=#$BI%!J-?O$5-3"X4&BB@!M%+10(6BBB@84A-!--S0(6F;</N S
M^-..0,U0O-4TZTDC2YU"""5SA(WD"L_.. >30!?&0W X/4YIIW"0_*-OKFJA
MU6P6_2S-]";MAQ;[QOZ9^[UI;34K*ZN;B*VOH;F2(@2)'(&*'G@XZ=#^5%QV
M+>,9/;%>'WUG=VO[1VB"\OVN1+#(\0,87RE*/A1SS]:]P&?F;/&#Q7AVH6M[
M;?M)Z0;N[,RS1R/"NW_5H4?"9^N: /<0 '.*=FFC_6&G8YH$&:-U!%&<=LT#
M$W9.*<0,4A(')XK/O];T_3%W7=Y#"V,A';!_*DVEN-)O8O%5.<5E:UX@T_P]
M;I+?R,D<C;5*KDYKG[[XB6ZHZZ?97-Q(?NO(H6/\\Y_2N,U75=6UI@=2N+=8
ME.Y;:$9 /U/-<U3$1BG8Z:.%G.2NCO8/B)X;N#(OVW:47=\ZE<^P]36!J7CG
M5-5D-OH-H\$1X^U2#)/T7%<M$8H27:W4R'^/;TJ6.YD9\_:91])?+'Z"BCBU
M)<S_ ";-*^$Y'9*_S2-ZST"Z+?:98&GO6&6N+U\C/^RIX%79-)-X,ZKXF@A0
M<>3&ZG'T)/'Y5SBVL,O):P)/7SKEC_6M*#3H3MV7.B0G'4.Q(_/-:2K*>ZD_
ME8Q49P^%QC\[EZ.#P)ITH+S+=R]V=S)D_2MJ#Q1HD4>VPTZX8=O(M<#]*SK2
MTPN!XFL8O:%4J[_9\4B_OO%LA_ZYRJ!0II?#3?WHF492^*JON9*?%6HR,5M?
M#EW[-,2@/Z5&^J>*YP=FGV5JOJ\^2*1?#6E2#]_J\LJ]LS@YJU%X1\/8S@2>
MYE)JO:5>D%]Y'L:?6H_DC+>Y\0.3Y_B'3K7U\LJ_^%5_)1WS>>,R2>HA 7^1
MKIE\*Z.IRMI&1ZEB:MP:380, EG ![J#3]IB.ED+V6'ZN3.)O(O#0MW#:G=W
M4^,*3*Q!/TKF+ 6W]J(MQ'))"[X*1$[C],=Z]E:*WCB=FC5%7D[1U'X5PGAO
M3K6#Q9=3>7J*C)$9N!$8]QY^7:<]*QJ+$R::D;4UA$GS0_$@>RMMY^PZ7KL?
MN)G4'\P:5=.\1-_QZ+J,*_W9I]P_4"O2&"$YW8/UIX!'<FM+5GO-_<B+T%M3
M7WO_ #."MK+QFN MTD8_VRIJZUMXQ5>+JS/Y"NO8D\8/Y4T%AU!/X5/L;_%)
M_?\ Y%>VM\,4OE_F<%=6_C1Q]]#_ -<W%9[1:\K8O+#5I?4PW) _+%>GY)Z<
M4;\<&J6'I=5?YO\ S(>(K=)6^2_R/-E2Q9<7VBZW[EF=ZK:F?#/V!UMX;RVN
M5Y7S8VR?SKTY4#N2<_B:XKXD?8;?1);FYC:25%(BC5U7GUP2,_AFB="@U;D$
ML1B4^93*.DWVE66GHMKI5WJ5PWS,_P!EW#/IGG%:RZSK,HQ9>%5A]YGV_P!!
M6EX6CL4T)&L@5B;YMN]6*^Q()'ZUNL5P,R[?J16D(4X*RB9RG6J/FG/<Y,#Q
MC=MS]CLU/]PAL?I4A\,:Q<C-YXCG]UBB"C\\UOR7MI ?WE[$F/[S 57;Q#I2
M<'4K8G_?%:<_;0S]DNK;^9E1^!M-;F[NKJY;U>9OY9K1MO"NC6OW+&*3_KI\
MW\Z9)XIT9>/ML;-Z)R:B/BVVQ^[L[Z0>L<!(-)SD]V4J<5LC9CLK*'B.U@3V
M2,"I?+3LHKGG\53.O[C1M19NVZ( ?GFJ[:YX@FR(M$V^AD<BIN6HG4CY>,?F
M:<0&(.[\C7)B^\6.1&+33XMW&2[$C^=*=+\47+ R:G##_P!<\G^E*X['27DT
M=K;23S,!$BY)-<EX*O[>>YU>.(X>74YIU&T@F,XP?I5F;P[K!C8OKUS*Q&-F
MP*#^-8F@>&6EFO0M[<QJD[V[F%MN67N?44R;'H_1,M3?E/.?UKED\%J%^;5;
MYO\ @0_PIW_"&Q8_Y"5__P!]#_"D/0Z<NB]Q^=)D?Y-<N?!B'[NHWN?=A_A2
M?\(/%U-]=Y_ZZ_\ UJ=PL=6"*4L*Y0>!X?\ G^N_^_O_ -:C_A!X<_\ ']>?
M]_?_ *U '3F5>AKFO$UU'+%;11-\ZZA:LVXD<"52<?A0?!=J%_X^KPG_ *Z_
M_6K#U?PHMMY;23RB)KF*!#YFXDR.%R>!C&:&".]M[J"6#S(W&WL34,NJV<7^
MLNK92.NZ4"L2S\#Z:(A]J1Y&''WSBK1\(Z*F +,<?[1/]: ++>(])CZZA:_A
M*#523QIHT;%?M&X_[()JU%X<TR/&VTC'_ :O1V4$*[8XT5?0(!2 P_\ A-M,
M;_5I<2'T2,FD/BP2#]QI&H2_6(BNA\D$8_I2B#U/Y<4P.9;Q%JC_ .J\/SD]
MC(Y'_LM-_M+Q7+_JM'MXQZO-FNL"A:"&[-^E :')[_&,O\%K%]#FGK9>*91B
M3588/I&#74@GO2GGM0%SB[[P[K=Q;E)=:>7?D$",*./QJ[X09AH=LT<0,4L*
MRI+W((Z'WKHYR/*;)(X/(K"\$X/@O2#G_ETC_#BD%]#>"XY[FG*::QH7-,0\
MGBCM2-T'UIU QM%.HH$%%%(30,&I%%.HH 9*"8F"]<5YI\2[>WGMX]D$9NT
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ME6Z8KJB>..M( 0?K0 U"2GO3MWM2]*.O:@!-U&:#QVHR/2@0%C0&)HZ]J.E
MP)..:Y_Q6LDMG:""VFG9+V"9A$ 2%216/4CL#70;@>*,>F!^% $*2[H5(5E)
MZJW4?6I$+?Q"G':#TYI00>E "TF3Z4N:3<* $+'THW'TI>HHQB@ !)I::6 I
MI?- $G%(:8"13MPH KWEBEY9R6S2S1J_5X9"C#Z$=*J:-H5MHFF)I]M+</ G
MW1-*7*CT!/:M3/I498@]* ) ,#%+C%,5\T[-  1FEHHH **** "F]Z=10 44
M44 %(2!2U#)G=GL* 'DX.3TJ*&>.9W5'1MIP0#D@U6U433Z+=+;,1.86\L@X
M(;'%>;> ?LS>(-$.G*\4BZ(4U)&0C=+N3!;(^_D.2:+A8]4(#905XK?V;6OC
MFT\+L0+R]WRQL#A-H#'D]1]T]J]JVJ<N>!@@UX?XCT7QG<_&K3KRV:%&6-_L
MMRUNS11IM;Y7YY/7N.HK&M0A5LIFU#$5*-^1[GK6@Z+#I>FPPO#!]H5<.Z*.
M3]<9K8. ,*1^)K@QIWQ++'.N:(/^W)O_ (NFMIGQ,#'_ (GFBX]?L;__ !=:
M1@HZ(SE)R=V=XH(;JOYTYCZE?SKRV&7XHS:Y/I9O=+1(H%G%R;1MK$DC8/GZ
M\9K173OB:XS_ &UH_P#X!M_\75$GH0*XZC\Z0L3T*X^M<!_9?Q+X4Z[H@)];
M-_\ XNLO1[CXGZL;SS+S2;7[)<- OF63_O@/XQ\W2@#U/([LOYTH]MN/K7 #
M3/B4P+#7=$^GV)__ (NHYK3XFPVS2+K.BNRJ6V"R?)P,_P!^@#T)AGN/SI0!
MZC\Z\RT;_A9^L:7;ZA)J.CV;3KN,$MD^Y.<8/S^U7_[.^)@_YCFB?^ +_P#Q
M= '?;5]11N0?Q#\Z\TUD_$_2-)N=034='O&@3>+>*R?=)SC ^:K<%G\39X(Y
M3K&AQEU#%#8OE<C./OT7"QZ!E?44!L^F*X,Z;\3 0?[>T+'_ %XO_P#%5F:K
M+\3["ZL(8[[2;A;R<0-)%9/B$'^,_/TH ]/^3/44?+ZC\ZX'^SOB8%_Y#FA<
M?].+_P#Q=*FG_$MADZYH0^MB_P#\70!WW0<8I.,9.*\QD?XHP:_!I8OM)DCF
MA:<W(LGV(0<;3\W4UJMI_P 2F/RZYH./:Q?_ .+H [<L.@(S]: "1\YY^M<'
M_9_Q*5B/[;T)O^W%_P#XNLJUN/B?=ZW?Z<;[28H[$*5N6LWV3;@3Q\W;% 'J
M8VCN/SIORD\$?G7"+I_Q,(S_ &[H1!_Z<6_^+IITSXELX4ZYH8![BR?_ .+H
M [_ZTI _R:\NT&?XHZS8M=S7FD61\QH_+GLGSP<9^_WK5&G?$PK_ ,A[0O\
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M_P#0Z#IWQ+$BH-:T4@_Q"R?C_P ?H [T.<X+)^=/R/45Y=:M\3[W6[_36O\
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M<8KU2W??SSWZT#8L<00GOFCR]KE0N5;DDFIL 49H$1^4%Z=*< 1VI^<T4#&
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7%% !1110 4F#110  4M%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img19885085_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &A EX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>.*-0(T 5 .P QBN(^)OP\;Q]8V<45Z+6XM9&=9#'O\ E(P1U'M^5 CP8B]
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M4H.: %I&I::SJ&"D@$]* !<"D9N:1^&'( /K1\IZ$9H 7=@5P?Q@.?A;K/\
MN1_^C%KNCUQZUP_QA 7X6:R#U\N/_P!&+3$CJ]#(30=/YY-M%_Z *674K6#<
M[S1#;U!D&?RIFBJKZ!8 _P#/K$/_ !P5S<_PWT6>9Y F&8ENW4_A64G+HC6"
M@_B=BG%\5=/FO([;[%<[I'"@Y  !_&NY%Y =O[Q/FZ8?->20_"?58KN*26[M
M3 &^9 S9Q^5=G;?#S0;>ZBN1#\\3!OF Y(_"LH.MU1O4C0TY693_ ! U/4]0
MN4T#1O/T^TN?L\]S/<K$'<8W!,]<9J_?>,=1TSQ+IVG7&C&.QO[K[+;W'GAG
M9L9W;/[OXUQ&M?"_Q"8M4TBQ;1[G3;VZ^U02W;,LUJ[$%M@ (YQC\:V]-\+^
M,+/QZ-7OO[(O+)0D$0DGD+V\0X+1J1@,1U]:Z3D.KUGQ4NB>(H+.YFMDM&LY
M;N5FW>8JH1D@8QC&:R[CXG:%/:22Z'J=G<S121>8DQ9!M=@N0<>]8_Q)\/W]
MS=7^N*Z"UMM#N+=U).\LW(P,<BN8LOAYXC\1Z9I6JW#:9;I'IMK!:I$[_,@=
M'+/D<-@=!GF@#LK'X@7EQX@-E<-91Q1ZI=V0SN5F2)<[AUR?;@5J#XJ^"?WC
M?V_;_*H<C:W(]N.:Y8_#O6/^$D6[\VU,0U._N?OG)2:/:@Z=?6ELOAUJ]K8:
M9&RV326^B7-D[!SD22,2I''3!Z^] '<R^.O#BQ7+/J"".VBCFG;!PB2#Y#T[
MY%5KGXC>$-/OC97&LP13*P4JX/&1D9...*\YO/AEXI.G75G92:6(K_3[2WG>
M:5@R/#C(3 Y!V]:U;CX<:O(NJ "SD-SJEI<KN<_ZN(#=GCKUQ]: .PF^)?A.
M/2(]3.K1&T>4PB0(WWP,D8QD5CI\4M(M/%%W8ZGJ%O!IWDP2V4X!)F$@)[=N
MGYU@:K\.O$\]Q?M93V2V]QJ-S<&![ET5UDC559MHYP5/'O6='\,/%MKIT]A&
M^C;+W3(;"=I)GW)M))9?E]Z /3?%OBH:!IMD]I;->W>HW"0V<*OM#LP)R3Z8
M%-\*>+)/$>@7%VNGM#=6TLD$MNTHXE3J-WH36?XN\(:E>:!H,>CS0?;M$N(9
MXC<$JLNQ=I!(!(SFJ_A70/$GAG3GM2NFW$E\;F[N&+MQ.V2D:\<KQR3[XH 3
M1_B;:R3:H-?CBL%T]XXWN$F\V%F?[H! Z^M:MA\3/"6IW-K:6VL0RW-R_EQ1
M@$$MZ=./QKA)/AKX@OWO;J6'1K#[3=6C_8K-V$($;99ON_>-:C_#_5#J%U<Q
M_8\'Q'#J2_.?]2N,@\?>]J!Z'7CQ[X8.O'1$U:'^T!)Y/E $_/\ W<XQFN>U
MKXA75M?216$$;6R:Q#ICSR-D,61FDQZ;< 9^M>:WC:C8:S;Z3IBV>K-I^LW%
M^HM-YG4D$XDR HY(Z$]*[6^^&][J7PUT'1&F1;H7B7E^Y?!)97WX.#E@7_'%
M CK6^(WA&WL(+F;6(EAGD>.-B&^8K][''3WZ5T>E:G9:MID=_ITPGM91NCD&
M<,/QKPO5[#5O!L&DO?7>D1WL&FW&G)$[2?O8B<JR[5^^>F..:]5^&MA<Z;\/
M='L[N%HITMOF1AR,\\^_- '6+R,T[%,SBG!@: %IIIU(: $%.Q2"EH ,4444
M %%%% !2$4M% "8HQ2T4 %%%% #2*6EHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!I&:4#%+10 W
M/S8K$\21WCZ!?FSNVM941G#*F[("YQ[9K=QWK.U?28-:T^6QNO-$,HPQBD*'
M\Q0!Q=U?WUU\+=+U.2ZU#[2]E',_V),O)(8\\_[.3DUCIXAUJ]TJ?64UAE_L
MV&R'E1X\N=I%1I"P[YW$#TQ77_\ "!:.NEP:8OV]+>+.U$OY%." "N[.<<#C
MM4DO@'0);NVE%FZI;I$BPI<.L9$?W-R@X8CWS2'H=$O,:OT9N>>U>=?&C5X+
M/X?7]A.9/-NPJQ%8RPR'5B"0,#@=Z]),0VJ 3A3FN$^,*C_A5^LL4!.R/!]/
MWB4Q'5Z!SH-@_3-M%Q_P 5>&TGCCWK/T<.="T[R^]K$"?3Y!6+-!XPW2&/4+
M%4!.!LR<?]\T[$N5NAU88,2C=:  IPW->:K?^+'U9]BLDA 4R-'\AQWQBNA@
MMO&'GQ-<7]DT6X;U1.2O?^&E%7ZD^T=]F:U_K^DV-TMO<ZE9P3<?NY9 &]N*
M>-=TS[;]C.H6INQQY(D!?\NM>$7LNJ>&'UB)M-SK\VI&=9)K#[4EU"Q&Q5;!
M";>3SBNBU">34_B?H"Q13S_99\W%J+$PB E,-)YN!O'MF@L]<EU&R6Z-F]S
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MX'''6@1[T"=Q3<3WR1UI P'S;@0O4XZ5X1'J_CBSL%NEU'4+NZN]"-PZR6X
MMY ZK\O'WMF>._6H]/\ &6H0'78+75M1U'?;V]MIZ7J;'^T3'!XP#@$L>?2@
M+'MMEKNFZC?R6=I>6\\J1B0K&X8[<XS^8Q6@I7>1GG&2,5\^ZIINM>$/%BV]
M@ETFGP:?:0WUY:1;Y/+WDOM!^\23D]ZGD\1:Q#XHMXFUC4XKB36XH$MA#^X-
MF2-IW%>2>??UH'8]X$89]R87'8KTIWEE6)SD>F.E.0L%&>3WIXSW% B.2-7X
M;.#QQ_C2G ^49YIVXYZ4O4>] QI'%)&.33@#2@8H 6BBB@ HHI,T +1110 4
M444 %%)FC- "T4E(,]Z '4444 %%)10 M%)10 M%%% !1110 4444 %%%% !
M1110 49I** %S29HI*0#LT9IM%,!U&:;1F@0ZC--YHYH 7-&:;0#0 ^B@=**
M!A1103@4 %%,\P9Q3L@B@!-WS8I2<#BFL,=*4#CF@!%4$[F S2L<?=I>@Q2'
M % "@\<UP?QA/_%K-:]-D?\ Z,6NZSQ7"?&'GX6:S_USC_\ 1BT".KT//]A6
M '_/M%_Z M7O*PVX8S]*S]%8IHEA@9'V6(G_ +X%4Y/$BK(56SN<@XY7@TBE
M%O8W2"!R132A /3\JXM?%E\Y2V:WD&9<"X\OB0==N.@.*V8_$@EECC%A=;V8
M)RO S04Z<D;,B@[#O=2.=J]_PI1L#Y ;<1TYKP;4?$FKZ@FJ>(KK4]5C@L;]
M[9;.P\M1;HI #2%L%@Q/:K\OQ+74OB7HT:ZM]ETZ"=K62#8V96*'YVXP!N(4
M#)Z$TR#VQD!7/4^HI"%+C"G)X/%<9XF\:76C^([31-.TV.ZFFM9+G?)<^4%"
M=1T.:Y,_&EYH[<Z=HDTCO:+<21%W9B2Q&U<*<^N3@4 >O.@R!\_!W9&>:0^6
M9@S;MX& !Z?2O,+KXJZFM_Y<&@1R0'5SI2N;O:S2 '!QMXZ>M91\<ZMK?BKP
M_<V=BMO<QF_M9K5KO]VQC7&XMMYQU'% 'LQC3D@L><\'/X4,%*@_,@4YXXS_
M (UYC9?%.[OFL#9Z(NV33YKVX!N,>6(W96P,?-]W(Z9S67KGQ$U*^\*3)=:>
MMG_:>D7%U9RP7)9TV#^(8&.HYH ]B$:N22[Y)SP2*;OVN5*MMZ=*\BTCQ<^E
M)J5VS-)+8Z982S/<WA$;AHR3M 4X;^=:EI\4=0^QWLFI:&EK/;Z3_:8B^T[M
MX)PJYV\<'- 'H&H:?;:MITMI,L@BD!#;"5;\^M96F>#M T89M+!3*7#F68&2
M0L. =[9.0.G-<=J?Q4O[=+VXMM#66"RM;2XG/VO:<3A> -O8MU]JE/Q-N8IK
M^WN-,A@O[:XC@6(W+2>8&C,@P%0G..O'XT >E;=I^0C/IBN>7P9H8\0#66@F
MEND?S4$LC/'&_=E0G"FO.X_'6IZIXFTW7-.M!MET2:>:SENMB QRL&.<'GY2
M.G>NC\2^+[V[^%=KKFF$V$M^84W'#&(.^TGD?K0%CT120N_!P>@VX(IROOX!
M/Y5P/@>ZU'[5XFT.XU.6Z33KI8;:[D.]P&3.">Y4^OK6!I7BG4O"^D^,)[VZ
MDUB?2[Y(8C*PB\P':".!@8+=A0![ .E199)"3DKCL*\LO?BKK%G/?K<^'HDC
ML+BWAN&2\S@3 %2/EY^\..*DN_BO<6E].8-'26QCU5=,\QKO:YD.!NV;3Q^-
M 'ITL^S;RPSVVYIS$L@93FO&_$NK:GJWAOQOXBBO98;.U5;'3Q&Y7E''F2#Z
MEL?A6KIOQ+N9M"T^:TTH3?:KY=-M/,N=I9@N6>3Y3MZ' Y)H ]01^,'(/O3S
M7(^#?$EQXFM]0DNK1;:6TOI+1E2;S 2O<' XKK 5' .: '44M-W#.*  T TU
MF %.7!&:!#J*0D"DWC- Q<4M-+@&G=: #%&*:7 .#0SA1F@!0#2U&LH8X%28
MH 2BBEH 2BC-&: %HHHH **** "BBB@ HHHH **,TE !29I<9HVT )2T8Q10
M 48I<TW<,T %'6EX-(QV*2!F@!01TS2]:JW$B1A6YWOT /6IXV4J-IS^/2@!
MQ%-%*6YQ29H ?10.E% !37^[3J8#0 B(,9(IVX<X[5#<3"&)I"K, "0%ZFO.
MCK?Q(OY)KK2]$TW3[(MF--5E82N/4A>!^= 'HZS*\FP _E4A8#-<EX4U_6]0
MGN=/\0:,;&\A0.)H6W02@DCY#U[=ZUO$=_=:?HL]U8P1SSPJ6VR2%  !G)(!
M- &LKAU+ 'CVHWJ<<'\JY!M<\17W@_3=9TJ'3%EN;2.YE%Y(ZQH"H8@;03WX
MK#3XAZO<6R:K;:?;?V=;16S:@LKL)%:7;_J\#& &!Y]: L>E@5P_QA'_ !:O
M6O:./_T8M=PK[H@P.01QBO/_ (QW=O#\,-5BFE59)E01J3RQ\Q3Q0!U^@G_B
M2V/_ %ZQ?^@+6@P&>0">V:H:",Z%8,.AMHL'_@ IDFMZ;&Q!NX\@X(+B@"V]
MM"88X5C7RT8,JXX!'-3@#.:PSXMTM'V^>O;O_G_)JU%KFF3RJ([V(NW &\<F
MG87-?0Q]3^'?A35-2EO[W28);F9@SN5/S'WP>:VI]#T^XN[&YEMXS+99-NP'
M*9&./PK@;CXCZQ>7]TVD6FEPZ7;71M#<:C<&-IY%QN$0''&>]/LO'FK:C\0K
MGP[$=)CMK:?R\33NL\B[=V44 @]?6DF-HUO$?@"Q\3>+]/U._"36=M;/ ]NP
M.2Q.0<@UHR> ?#<T]I*VG0@VD0AAV%E*J.@X/(^M.U[QIH?AVYBM-3O?(GE4
MNB^66+*#R>*JW'Q"\+6IMMVK(4N8Q,K %AL)P&)'W1GCFF(NOX-\/M-YC62E
M_MAON2<>>>K_ %JC<_#KPG='%SID<@\UY0.1AWY8\>N*;<_$WPE:W<EG/J@6
M:*4P,NQN''45D7?Q4TJ'6]%^R7D4FD7B3FXF,;%U=!PH'KGVI!8ZRU\+Z'I\
MT,MO80QM#;&TC"KPL1.2N/3)K,M_A[X5MC<+:Z9"BW$303#YC^[;JHYX'TJ9
MOB+X9#:>HU)&:_026X"GYUW[,^V"#^59.I?$W16T35KC1KN.:_M;62YACE1@
ML@0<X/<?2@=C6N_ /AF^AD2;38V5Q&K#D9$8(0?@#5>7X8^$)XE632(G"J5!
M+$G!.3SFL_2OB%E[F75Y[.*UAM;64K"LC3*TJ%CN&,8)Z8/%:VG?$/PSJ%I=
M75MJ(>*V@-S(=C#;&#C=^= K$[>"="ECN4ELU*W*11RJ"0&6+A!^&!^5,U#P
M-X9U.9Y;O38FFD97=P""65=H/Y<56O/B3X5L;E4N=56)ML;G*-@+( 5.>V01
M4D7Q%\-W-I-<V]X\JQ2F)U2)BP;!;IC., G/H* &2_#3PC/#:V\VDPO%;1F.
M%<M\JEBQ'7IDG\ZV+WP]IEUH8T>:R@;3]@C\@J=H4=!BN1N_B=I]KXET]#=1
M?V)=:<UX)Q&S.6WE<<= ,'/%=U8ZG:ZAIL5];S+);RIO20' 93WH&8EMX%\/
MVD-LL&GQ1BV=Y(_+R#N8;6)R222*J6OPT\)6@G^SZ8H6Y39*"6.Y=P;^:K3=
M>\77=MX9O-<T2**\CLY2LL39SA6P^,'M@_E7.7WQ7N1#-J=E!;-H2ZA!9I=2
M$@MN!+GTPN,4 =K>>$?#]\+K[18H3=O&\Q!/SLF-F?I@5QNK_"7^V_$4FH2S
MV%G;FZ%R&M;=A.^!QERY7KSG;1J?Q5@AN-6CT_[/?06<%N;=XGSYDTKE-IQV
M'7\ZC3XEZS';SZ5+I5G_ ,))'J*6"PJ[?9\LNX-G&[ &: .UM?".D)X93PY+
M"T^GHFPK*>9,G)+8QDD\UE:W\.=.N;69--M["!YI$DD%S \B$J" V%=2&Z<Y
MKGK[XG:[%X+?7(-"M9)+1Y8;[?,=D4B,%PHQD@Y!KNM<UW^QO"%QK-RO_'O;
M^<T:\9.,@?GQ0%BAX)\(#PAHTMBD_FRS3M/(ZIL16/\ "JY.%';DUU<15LX4
MY'4D5Q'@GQCJVM:K=Z1KMC;VE]%;QW:"W8LK12#CKW' --TOQO?_ -O>(;+6
M;&.SM=)A6?S58LQC;/)].!G H [S(Z4$ =JX8_%7PA&C%M6 V@.!Y+9*GH>G
M3WJW>?$GPM8ZD;.?4U5UVAB$) 9@" 2.^#TH ZIF0.%*GGVIY(0>U>=^-_'U
M]HMYJ%OI-M#,=.T_[;<R2Y(1F8+&O!ZGD_E6I%\0M%ATDW-W>IOB9(I]BD@3
M,NX(/4]>E '7G#<]J#M0;B#^58%GXTT.^T*ZUBVO ]I:Y$S[""I R1@\YK.\
M7>+KW2X-)@T2VANM1U6;RK=)6(1<+N9FQSP!0!V"E7&X#\Q0L@)P 1^%<9HG
MBR^U_P #2:S;PP0WT0E22*9RL:2QD@[FP3MXSGT-97AKXHI<Z;=7'B 6MOY5
MY]CBN;-FD@G;&?DR,_\ ZZ /1WP>U"A7&/2N3L/B5X4U&YA@M]55I)MVT%&4
M9498$G@$#M3]%\>^'=:U06>GZ@)9Y59XTV$;E7JP/<4 =6%1>@%!<+UXKRRY
M^)U^OB"T\N*UBT.?4I;07,A)8I$F7<=L9SCZ5T%Y\2_"]O##-+J)19(?/7,3
M'*= 3Z9([T =F&#=*7-5;"\CU"RANH3F*50Z-TR#5N@!M%(_ XJ+<<BD!/2T
M@I:8"&B@T9H 6BBB@!,\TM-8_+4*ERW(XH E[TM*.E+Q0 "BFDGL*4'UH 6D
M)Q2,>*C+E>V?QH ?G-&!FHFG5!EQM'UK)O/$VBV!)N-1A1Q_#NW?RIJ+>PKH
MW>E-8_(:XJ;X@6\Y*:787M[)V\M!M/XY_I59M=\8W,; :;9:8A_CN9.<?AG^
M54Z4NN@<VMA_Q*MFG\/F1)(4>*:(CSE)X+J#MPR]LD^P[5UFBVXM]+MU1X77
M8/FA7:I^G)X_&O(_%=O>7%K'+?:XMY(& ,,:D(,GL<#/Y5Z7X+T]],\.P127
M;7&_YP2<A01]T>PIN$5&Z=QZ]4;S'+9H!IY4$4T+S47%8<.E+0!1BD,7M3.Q
MI]1D8S0)D%T0;>0&4Q *3O!QCCK7@&M^(+C4VM]/FU*+6--LIQ.+Z:RD9=IR
MO[V(C,H!_B7(XKW^YB$MLX9%?Y2 &[DC%>-:#<0^!]6N3>^"_$$MXL9B4VK-
M=P)&3G";B,*?<4,:/1_ UG%IW@^PMH-0BOUVNZ31*54AF)PH/0#.,>U7]=M+
MR[T6YM=/FCAN9ALWRQ^8 I&#QD=O>LCP7JNK:N+B:304T?2E&+2.7B9R22Q9
M1PH]JZY3ECD<B@#SN?P-XAN/"NE:,?$%JL%B5!3[&=LZ(H"*XWC(]1G!XJ>3
MP1J$DLD<^J0"WOUA-_##;;1(T6W&SYOD!"@$<UWA5CG#D?A3E&!RV:+!<C$?
MDQ;8N@[5Y[\8]/M;KX:ZI=SVT+SVX1H79 60EU!VGMP:]&;FN$^,/'PLUK']
MR/\ ]&+0!U&B$KH.G!>UM%_Z *8_AW2I&;.GVI+$DGRAG-.T 9T6RS_S[1?^
M@"KZLI)&[F@#%;P;I#,&-K&?8J,?E5F/P[H\)#1Z=:(R\AA$,@^M6TU&V>Y-
MLLJ&5>JAQD?A5AV'W1R2*2DGL-QMT/+-7^$DERU[9V6MQ0Z7>S_:6MI[02M$
MY(),;D_)G':MB7P%=W_B33[R_P!4B>RTZ99X+=;4+)D# #2;LD?A6I>^/_#V
MFZD;":^\RX4A72&,R>63_>*@@?C5F;Q?I,>MIHWVEY;YVVM'$A81\9&XXP./
M>F+<X_QCX=UG6OB)I<FGRFS0:;-"UTT7F(I8XQC(Y(-5/^%.6]M<Z=]FN[>5
M8;9;:>.\LQ,K@')898;2?QKU:26.':)'56QP2P'\Z&GC4*S.JLW1=P^:@#SN
M3X9*+E9!J48<:Z=553%VY_=YSZ'K^E5(_A;J%E<QWMGKL5M<0W-W.C-:[QB?
MC!&X=!FO3C/"[8:55<<8WC-95]XFT^QUNPTN=W,U['(\++M*809;)SQ0!S6C
M_#.WTNXM,WIFBBTN6P<%,%_,<NS@YX^\1BLL?"JZGL&L[O7EFCM=/FL;)5M@
MIB63@E_F^8XQZ=*].%Q&K(/,!#\@EQ5'6-:L]&TF]U.>5WAM(C+((L,P4=<"
M@#@+KX7WWV?48+;7OLK7UK:VLC+!D[8E((^\/O9%177PNU>ZC<0Z_;VXFL#I
M\JP605&A!RH5=_&,<\G-=WIGBBQU:>2.+SXA'#%,SRIM7$@RH!/!X'-:XN(R
MI*2!L#)PR]* /.KSX8&\LM6@75$7[;:V5ODPYV>1MYZ\YV_A[U#J_P *9[_4
M[R\BU6-%NKF&=XI(=T9"1;,,NX!N>?;WKTII8%<#SP&_N[QWZ4INH5A+F50J
MG!)=>* /+H?A3J5A:V2V>O0P206,U@S&TW;TDD9B0-PP</@?2N[TSPU867AB
MU\/R1I=6]O L6)E#!L>HIL_B>PA\1PZ1+(_VB6W-S&1MV%-VW.<^M;!GAB19
M&<#?]W)ZGTH YW0_!6F:%I]]:V-K;Q-=F0/((@&*L2=I(ZJ,X ]*PO\ A6B+
MX$T3PT]Y&%L+U+IY3%Q+AF)4C/&=V.]=='KMO)K5QIO[U)X(5F?>N% )P,-T
MS[4NJ:_::;;0RR^:\<LZ6X:%=Y#,<#..@H Y+7?AG:ZK?:I-#-%8_:[6!(4M
MX0/*DB?>'XQDGI].]5C\+IFLVO6UMO[=:_74#>^0-N]1@+LW=,<8S71:/X[T
MK6[R.TMOM0=Y9X@7BX!B.&R1D#\:Z/[7%T$BMC@G>O'ZT >:WOPTU"Y\+_V!
M#K\=O%<F26]:6UWM/([;BPPPVCH,<]*ZNY\-/JO@N3P_K5ZL\DT)B:>*/9]#
MC)Z<5NSW 4,RGA.&.Y>/\*<EU!@*TR%SS@L,T".&T7P/JVD2M?\ _"11RZC(
M8(&G>VX^SQ CRP-W!/4GVJG-\/\ 79-6UF\F\26[)JUNUM/']C/W K"/G=U&
MX9XKT7[1 T>\SJ$S@-O7FLUO$EBOB%M%+2?:EM!=\[0ACW!>N>N2.*!G)7GP
MT^V0W(&I(IFT./2N(<X*'._K^GZUP>L^#=9&KSZ%I,=Y+:W5];SW)DM@(QL
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M:2,7XIW]O;:7'8:8;**[\R-V1XR"%$BME<# Y7)]AWKK_!&I6NH:.WE3PRW
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MBC'% ;/6@L%X]: &DXKA_C ,_"O63_TSC_\ 1BUW6W(KA/C"<?"O61_L1_\
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MHI>-;H;N)2L<Q7E5/4 U<*MCAL4!<\,N? FLW&IO<R6EV99/$;,\WF$$V9#
MXP>AJG#X)UVVFL1=:%=WUE97%^!;B0 F)\"/!)Z=\>U>^?/]W-'EN?XZ /&-
M(^'_ (@>YTO^TA+BVTB41.\IVQ7'FLT8;G)*@KV[5GP^#/$1TFZ@@T>YM9QI
M%Q!?.]P&&H3L/D*C//.>3CK7O6UNYXIA5RQPV.: N>(W'A_Q!#9ZS%_8,E^;
MC3["&VCF;Y8Y$C(=N"/ND_RJE8^%/$NF6%U#8Z)J,@O=&>U!EG7<DX;)9N<
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M<1:98%'P/],=?N_,,DG]/QKC/#RI;ZW;QV]U++,95"-']TDGC->YWT5NNG/
M$B$1&-NT=/QKS[PG'IVDZQJ4^IO%&AN-\#2NAV@*HX  (Y4GBHFIS:NS2G7I
M4TTD=#+I?B:ZB*_;8$'0AW8_H*H#P!J-R2;O79(Q_=ME_P :W9?'&@1 G^TH
MW;/2,'G\Q5;_ (3VUD.VVL+RY)Z>6@YI_5[[W,OKEMFBBGPVTT?\?.JZA/[-
M(H_D*NV_P_\ #4!W&S\T^DC$FI5\2:Q/_P >_AFYQZS.$I3=>*;G/DZ?8VQ]
M9)22/R%'U>*Z(EXN<NK+T'A?0(<>5I5L#ZF,5HPV-O;@"*&% .P4"N9?2O%U
MR.=<@B'<1Q X_2HQX.U*;FY\2W3*>H5 OZYJU3@NJ1DZU1_9;^9U<DD:#YWC
MC [Y%5)==TBV7;+J=HA]YES_ #K ;P=HMLNZ_O9I\=?-F9?Y&JY_X0C3_NI"
MQ'8%G_4U,JE&.\BXPKS^&)JR^.-"A8@7WFX_YY#-0GQU:S@BTTO4KG_KE!FJ
ML?B;1R?+L=',Y'3RXEJPNM:XV%L_#PA4]Y& _3BH6)H?9NR_JN(^TTON_P S
M!\8:_#?Z:EM=:+)&[%2IO(^5P0>A'M79>&KJWO=(@EM%54"[6"C !';%<1XL
MBUF2*.ZU.&)(ONY3'!/0'O74^!+::VT$B52@:0E0<=,#_P"O6<<1S5.51:-)
M85PA[1S3\CJ/>@&F D#!IPK6YD.I,T4@JR1]- S3NU-Y[4#*U[/%;VTDD\BQ
MQ(NYF8X  KQ3QMKEO%XGCUO2M2T*]%]IJQ&'5"?D3<QWH01UST]C7M\L*2QL
MDBJRL,,I&01Z8KQ7X@ZS9Z+XXTS39M,T2#3(/LRL;JQ1WDA>0A]C$<*H!_.A
M@C6^'7@_[+=:1KEK>VES:KILD,\T''FN9"<8]%'&>]>EZMJUOHU@]W=;Q$@Z
MJA;] ,UA?#W45U7P997*06\$3&4+';Q")-H<A2%' R,'\:O>)[CR?#=\&LKF
M[W(T:QVZAFR5P#R1ZT!U&7?BS2;72K/5Y)7^R7:(\3"-CD. 5S@<=>])?>+M
M(T[4HK&[DD\Y@I+I&S)'N.%#L!A<GUKBKFYNW^%&G:4?#VK?:TAAM1&(4R'C
M5<M][[O!P:;?0:EJ#:O;)HE^C:^;:6*65% M]A4,)/F^7&TD8SU[4AV/5V?
M';)Q7"_&%6/PMUK&,".//_?Q*[=%*0QHYW$<9_K7G?QKL99_AW?7"7D\*6P4
MM$F-LP+*,-QTYS^%,1VVA$?V)8CO]FB_] 6M,5D^'@5T*Q4\D6T7/_ !6L*
M!JB(.ZI&H H !2/P.*=2&@!$)QS3LTVB@!#UIP8T;:3- A]%(**!ABEI,T4
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M#S-D_:(IW$QYZ[4POYT,$>J>#SJ[>&+5]<LH;*_93YL$( 5,< #!(Z8[UT(
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MPQ^(JY_PE?B"_P B >4#P/+AW'\S2+:ZY<L&N8-2N5/WE\T1 _J:GVU)[/\
M,ITJJZ6]6BQ'X3\/V"_Z9J-FA]BN?UZU*C>%;;Y8!=7;#M&AQ^@ I;?1+D?.
MOAR(/_>N+CS#_*M.&P\1+Q -/M1Z+'T_2G[6*?NQ?W XU'\4TOG_ )%0>;*A
M_L_PL?9[A0O\ZSM:T[5VTPR:A%96=JIY6*/)7W[FNA_LGQ+(")-:A4'LD/\
M^JL_4_"VK364B-J[W#.,>64P#^M5[>HOA@S/V%.3M.:_$YW0-(L+D,[:J+<J
M3^\C_=X&>.6[D<_C6P]EX:A;$NL7MW+_ '4<L#^0_K3- \'W"W+G5X?W2KA
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M28%+10 $ TWRU]*=10 F!2XHHH **** $P*,"EHH **** "BBB@ P*,"BB@
MQ1110 4444 &**** "BBB@ P*,"BB@ HHHH 0GCI2+QUIU-;H?2@"&<)/')
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8UPGQ@ _X59K7'_+./\ ]&)0(ZC0AC1+''3[-%C_ +X6M)6YQ6?H7_($L?\
MKVB_] 6M!1S0,<U-IQI,4 %+2 4M !12XI,4 %%&*,4 %+110 4444 %%%%
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M4F*,4 &:#1BC% " TN:3;1MH =FBDQ1B@ S2YII% % #J**0C- !FDHVT;:
M%%&:,48H 6BDQ2T %-)IU-*T (32 \T%30%.: )**** "BBB@ HHHH **,48
MH **,44 %%%% !1110 4444 %%%% !1110 A.*3<*&4FFA#0 \'-+30,4Z@
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M,7%'%1AB#R3C_=IWF+Z-_P!\F@!P.::S@&C>H[-_WR:3<A['_ODT *'!IQ8
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ME&8DW8ERQP?0$,!G_9KT*F-L?@@&@#/T*RELM#L;65CYD,$:-SW"@&M+.*
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M"3.[H:;RQQFD3 9@KJ?8'I3 ZJ=WFI@GCF@5R8K\F":X_P 9:?(;JRU*T_M
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M&8$9_P!ZNL8[5P *<N,9 H'<7J,]*6BDQ0(0\T8IV** "BBB@ HHHH ****
M"BBF$T *3SBEVCTJ/-.#&@!]%(.:6@!#2TAH% "T444 &:;NYH:H\T 2X&<X
MI:8&-*#0 ZBBB@ S132>:!0 ZBDS03Q0 C#O3 26J3K28&: &E<'->9?'7'_
M  K:=B N+F+_ -#'^!KU'%4KZPL=1C^SWMO%<1]?+E4,OY&@1X7X\UG2_&EU
MX8T?PT4U#4HKB-VFMUW"%  "&(]^?PKE_&.O22:OJ^IV&H7%O=VFH"%?-U$^
M:<<'9"  $X/))KZ4LM#TNQ<M9:?:6Y P6BB53^8%17'AK1;B:::32;.62;EW
M:%22?7.*+#N>+:UXIU'X=:]JDLDDL]OK>G+<6.6)6*8C! ],'G\JH^*-,O=#
M\/Z"MUKJ2^19?:+W3)M1\B:5G8G<O=L=,?[->@ZC\-M2\3>*[:]\1:K#+I>G
MREK*T@C"E5X.&..>@_*NYOO#NDZE=+<7NGVL\J@!6EC#%0.PR* ,WP)<17O@
MG2+N);@1R6XXN'W.!ZD]_K7B_@KPQKWB[PYK>B6US8VVD2ZH_P!I=D)FR#GY
M><8X%?12QQ1Q"WC540#:%4  #V J&STRSTQ'6RMHH!*V]_+4#<?4T ?.]\;5
M]<\267B#Q%?Z:VB1B+28$NO+!5%PI /4L #@=VI?$%]JVH>"/#&IZIJ\?F06
M;R76FSWYMIKI Y"R+W8[<5[[>Z!H^I7BSW>FV<\P_CDB5B?S%+>>'='U"6*2
M[TZUG,*[8Q)$I"#T''2@#YWN[+2[KQAX,OKK4-1L;'4+(,TMQ= -&5)7 <C@
M' _.O9/BE97=]\-=7M],$CR^4&*IRS*""?KD UTMYH&EZ@(1<Z=:S)"1Y8>,
M'9]..*N;/X%13&1@KVQ0%SY]N?B"-*\#:-_PC&KV-L8(XH)]+>$><TG1WZ],
M\UL6FFW7B7XO>)$N-5OX(K!;:XCM;>7:DKB-<9'/&><>]>LGPQH*W?VDZ/8"
M?L_D+G^57(-.LK>YEN8;:))YL"255 9L=,GO0%SYDN+Y;GPUJFOWGB74(_%\
M>H&."Q%S@@;P,"/KC!/Y5U]OXBDTKXB:Z^O:D+4RZ%&\*32;%\TQ+D+GOD-[
MU[#+X?T5KW[5+IED]R3D.T*[L^O2I+S0M*O[J.[NM.M9YT&T-+$K''U(HL*Y
M\[RZK+-X4^'GV[7+VRM[F>\2[N8YBK!=R#)/Z<U:BU">RT3X@6.DZS=W>BVL
M49M+EYMY\S(W!7'7KV]*]0\4?#R+5];\.W%D+.WL-+EE>6T9/ED#A>@Z?PUU
MD>@Z5'8/81Z;:QVLG+Q+& I/N,<T#N>(Q6EWXC\9>'M*N-4U"U@G\-12RK:S
M%6<A0>3[GDUA1:[JI^'6E65SJUY!IK:Y):W5V)#OCB 7 )].6/X5](0:-803
M)*+2#S8X_*CD$8#*G]T>U<YXF\*W4^C1V'AU=-LLS^9,ES:K)$XP<Y&.N<<]
M: N>?_#B:VA^,&JZ?I6M7.IZ3%8CR9)9_-!.%S@]#@Y%>XH-O&<UY_X&^'\O
MAG5+S6M0O8;K4+H"-OL\0CB1!V51T[?E7H"[?X.E F+NPQ%.S3 O.:6@!PZ5
M&_%2"D(YH&-5STQ3P*: *?0 444AH 6BFDXHS0 ,<"F;STIQYIN!0 \*#@XI
MU(O2EH *9WIYZ4PT *#3JCIZ]* %[4VG5$QP* )-H-' J$.:<&)H D%+2#I2
MT %%%% !1110 4444 %%%% !3"#Z4^B@"+:?2G >U/HH 04M%% "&BEHH *2
MEHH :0:CVMGI4U% #0.* #FG44 %%%% #"#FE IU% "4'I2T4 (*,4M%  :C
M=,_,!S4E% %5UF5AL!P>M2X8)P.:EHH%88 QZTAWD]*DHH&5V1\[@#FD?SB1
M@'%6:* &!?ESCYJ1 V>1Q4E% #)0VP[>M11K(.H-6** &!<G+"E(X.!3J* *
MD4<AD+2*>O&:L.#C@4^B@5B!5DW\CCO4C ]A3Z* L11A\_,#2R[]IV=:DHH&
M0HKE?G'Z5(JA>@IU%  >E,P?2GT4 )0:6B@!F#FGT44 %)2T4 -(-&#3J* &
MD&F[3Z5)10 @Z4M%%  >E-(-.HH CVGTIZ]*6B@ J-U)' J2B@"$(?2G!3Z5
M)10 @Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img19885085_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img19885085_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '( N$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "4=Z*.] !0**!0 4AXH)Q32V[B@ 8_+4:D]Z)98X0 [8SWIP9&3>#QZT /
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M7!%28IH.12YQ0(7'-!%)WI30  48YH%'>@ Q1BBB@ QS011WH-  !1CF@4E
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M _ 4B6=NMRUPL"+,PVEPH!(],U(1M7*]:<A)P: '%0>M&?2FDG!QUI$/KUH
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MI0>E " \T[/%- YIQ%  #32>:<!32.: '=J,T8XHQ0 9YH)HQS010  T9YH
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M8HI.] ",VTX/2N'^)>HZ78Z)$VH69O69R((!(4W-C^]@XX]:[AL,"M<+\2M
MEU?1(KBVN1;WEBYFA<@'YL8[D#\\T >3PZAI-O937FI^%VB2#YI%^V9VJ3A>
M@Y[5]$6+0/91/ /W9'RBOG8>&_&5_,^FZM-';66I 1R2;H6WA/F' ((Y Z$5
M]$6%E':VL4<9^51BD,NCI2$4 BC/-,0!<4N*,TF: $(R:7'%-)YIW\- '@_[
M10Q8Z/\ [TO_ +3KT+X3_P#),]$^DW_HYZ\^_:,_X\='_P!Z;_VG7?\ PF_Y
M)IHG^[-_Z->@.AW H(XH'2@]* $ YIQ%-'6G&@  II'-.%-/6@!V.*,4=J*
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M &;&-/GF[L^BE<,BL.C#(I2N14-OM,$>S[NP8^F*G'2NA'E,:%YI^*04M,0
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MS2]=0OHTA2XN!O9XG 0,RY/3MBN:HKS/;P=5QP[1[A:<6D*D8(C7^53\8J*
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M9+='G[.4!(Y<<'&>E>J*"/I4PAS>](O$5U2_<T5:Q5.F6GV1K58E6%E*E%4
M8^E<\?AQX=SG[(O_ 'PG^%=;BC%;<J9PQJSA\+*=CIMMI]HEM;IMB10H& .
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M;_T:]<%^T:!_9^C$#&6FY_[]UWOPG_Y)GHG^[-_Z->@#N<T9XJ)7);&*EQ0
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M[1+Z?[M>YV;F6UCD*;"P^[G.* .#\>ZMHGABX-XMJ)M:NP4C0NPW9 4]05&
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M&*.,T !H%!Q0,4 '>BCC-'% !1WHXHXS0 4"CB@8H .]!HXS0<4  HH&*.*
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MO?K2>)[-)(0H0C*A1Q0!;4'/-*13%8D<CFG9S0(,44N:* &'K3ATI#UI>@H
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MQS0#1WH ,4 4&@4 &.:,4=Z* #%&.:*.] !B@"B@4 &.:"*.]!H  *,4"B@
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MI1O8(<RC:0\\"O./B5XM?1(K:"V.9&D5S] 3Z@UZ,>:X;7_AO:Z_J,EW<73
ML3A=G3]:<A55)QM#<WO"^LQZUX?M;L-\YC7>/1L GL/6MM3D9KFO#'A&/PW
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M3_G[A_[^"D-Y:'_E[A_[^"OFP> /B@?^8M+_ -_YO_B*#\/_ (H?]!:7_O\
MS?\ Q% 'TI]NM<?\?</_ '\%)]MM?^?N'_OX*^;/^%?_ !0_Z"TO_?\ F_\
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M HHHH **** "BBB@ HHHH 2BEH[T )0*6D% !112T (*.]**3O0 4F,FG4E
M"=*H:D+J2TG2U<+,5'EDC.#FM"F.H- 'F%O>>+_"5E?ZKX@DCU"UCV;888A&
M>6V]<G^\/RKBAJNE7/Q$T>_\*2M<W%PLWVI7<OLP@5<;L8XW=*^@&MQ(NUP&
M4]015"UT'3[.0R6MNB,>^*0[FE'N*AB,9ZBE1]Q-.P1@=J H'(IB \TA%.I&
MH 3:#UJ">.01,(FPW;BIPW:EQQ@T >6P77BGPK%=:MXIU&WN-/AQ\BP;.N5'
M.3W*UPOA/Q1H_B7Q9%J_B'44$^[;;6>&&S(P>@P>0#7T%>6EO=0&"= R-V/Y
MU3AT#2XV#"T0.O((H&:PQBE[4B]*""#F@044HY%(/O8H .@J*0E@0*F;I2!0
M.: /.]%TWQL/$2/J][;RZ7A@T2VX4GY>.<^M8=U#%;?'#38HHE1%M)P%4 #^
M&O7A&N[=WJL]E;_:Q=M$#,!@-[&@"TAR.F*4THZ9IN?FH 0$@T_-(PR*101U
M- #9!O&*8L9'%3 8-*: /(?C)$]M=:-JKC_1[60"1NPRZ\U4\)7D'B+XO7FM
M:?()K*.&6,2+T))4CK7K]U9P7L+1W$8=#V-1:=I=II\>VWB5!["D.Y;0EEY&
M*<JA12'(?VIP;-,0$9-)BG4TY% #J3I3?FSUIQ'% %2_@CN+=Q+&DB!2<.H(
MR._->7_"[ \6^+ @ 'V^7&.G1*]8=@%P:K0VMM;2O)#&$:4[G([DT 6E7*CZ
M4ZE&,<4WGDYH =VI,9HSZT%@!S0 TKFD6,)DTHE4G&:7- CFO&OB>U\+^'9]
M0FQN *Q@]WP2.WJ*\C\!^(=&UKQ?'K.M:FDNJ7,@BMK8!AY>YU91TQD,2*]V
MN]/@OT,5Q&'CSG!JO!X>TRVF62&U174@@^A% R\)2.,<>M.49.ZGE1C!I /2
M@0^BDZ4[M0,;C-,9>.M(Y.>*D RM &3K^JIHFBW%^ULTZPHSLBL 2 I)Y_"O
M#=0UK1-3\9:%JOAV1WU.YNX3<P22%_+5F+,HSP,,0.*^A)%$D;1NH96&"#Z5
MGVWA_3K:Z:XAMT60G)..^<T#1<LY&:VC,@VR%1N'OBK'7FFB-0<CK3QTH$%'
M>EH[T )0*6@4 )WH-'>E- ""BE%)0 44M% "=Z#2]Z#0 E'>EI*  T4IHH 2
M@T4&@ H[TM'>@!*6BB@ HHHH **** "BBB@ HHHH 2CO11GF@ I!2YH!H 2E
MHS1F@ %)WI0:,\T %(3BES36H 0M2CFF4Y30 _M30,4X&C- !0** : $HH[T
M-TH 8R$\CK5+5=6L]&TV2]OY?+AC W'&>X'0?45?W84FO'/C]<.-*TNT!(AG
M>02^F!L(_6@#1'QP\/F<!HYEMR<"4Q28_P#0/6O2++4+>^LDNK9M\+_=;\<5
MS][X=T&Z\+_V?=PPBPPIPS?*/F#=<^M<5XRUT^%M(T?0/"CI MWD1R1,"% <
M9QG(_B-(9ZXLBM]T@FGE@ <GIUKPRYU#Q5X \1Z9%?ZS+J-K?.L;)($7:S,%
M!^44V/4_%GB+QKXATBVUZXM;6V:9T*(AP%( 7D=.: L>YAQ_">.M"2*[':P^
ME>$Z)X]UK3/"?B2*^NGN[K3[BX@AF< 'Y%4#H,=<G\:O:/I7CJ?3[+7[?Q$\
MIN")'M93&B;"-P&[&>],+'M3, .6 I-X SGY?6O _$7C+6=4\7-I U6YTVW@
MB0R-:QB4LQ'/!'J*BB^('B$_#K7U>[N!?6/D>5=/&%9M\V#QC'3B@+'OZL <
M[A@]!69J/B33M+OX+*ZFVSS_ .K4*3GG'8>]>(:KJ'C+3/"^G>*'\0W!,KX>
MVV)M4>8$X.,\]:B\7V^IZG\2-$N%U"2)KI&DB(4'RU#*"!]?>@+'T0KCG+"D
M9E!^\ 3T->%7MYXOO_B$WANSUV>() Y9PJ<X8#/(]ZM^*I]<T^6ULKCQ3<P)
M;VBJWV:..5Y)%+ L5QQG_"@+'L.H7]OIUC+=74FV"-2SMC/ K U+QOIMEX>_
MM=0\UKD@%5;/&.P&>]>,C7=;\2?#77H+C4YY5L6F)>1%5I(E  4C''6I5GUK
M0/A$M[%JTV9,B-=JXC^[TXI!8^A+*Z2[M(YUX5U!&>*G8Y7Y2*\8\0>*]>U#
M5=&\+Z/>O:7%RA,LZXS_ *L..HQV/YTECK?B/P=XX@T'5M3DU*TNTD,4D@52
MI2+>>%'JP_*F%CV;>H'+#WJOJ5]!8:;/>3MB**-G/T )_I7@_AZ^\8>*K;6I
MT\17-O%98("HAW?*3W'M39/%^IZM\*XA>SM+.]]#;/(<996!![>](+'M7AG7
M8/$.F"]@4K"YPF<\@@$'D#UK: V@C/TKQSQ/J>H>%O"_@ZVTNY:VC>YM(9-H
M!WH0P(.?7 J[XP\1ZM9Z]X0CM;Z2*.\EMA.J@'>&#9[>PI@>K!L#YB!2,X((
M!Y%>*)JWB7QOXWOM-L-:FTZWL8P<1*C;F#%2?F%5?#'C#7;:3Q4=9U*2X738
MH?+#!<<N5SP/I2N%CU3PKXGM?$4$TUJ"(XSCOSRP[@=Q70B12#DBOGO5;W6/
M!?P]T%=*O'MYYY+DR%0#N_>@CJ#T#&IM6F\9Z#XTLM*_X2&XG-\K\NB#;M4<
M\#WIA8]WN[F*VLYKACE8D+MCT R:Q_"WBW3O%UI/-8L2L,GEME6&#@'N!ZUY
M=I.J:]I?B[6_#.HZK+?P"QN'5Y%53\L?H![UI? <YT35#_T^'_T!:!6/7A@*
M?05R]QXNLK?Q?%X>93]KD19%//1B0.V.WK73CE6%>+:_<K;?'6VF<?*EG$3_
M -_&H!'M!E3(#'%)(!D>E>(Z5-XP\?76HW=EKTUA;V\K1PQ(J,"0Q7G(R.*S
MY?BMK47@"X0R$:I$Y3SQC/$N/3'2D.Q[XJ1#+;@16;X@\1V'AS3)+N]E"J@Z
M<Y/Y5XKXMD\9>#]+L9F\2W%Q]IDPX9(QLPZCC YSNKI_B5X0BU72;C6;NZ=U
MA0[(2HQR.N>O:F([S3/%EEJ7A9-=SY5JT)FS@G@ GTSVKGM)^+?A[5M9CTV*
M616D<)$S1. Y+!1R5QSFN'GN7M_V?=/"-@NB*?H5;-4/$EO;6GP\\!W=N@$_
MVNQ)/K\C'^8H"Q[)IWBNSO\ Q+<Z*?W=S"ADP<_,N[:#G&.M=*O2O$O$<\EC
MXR\':E$=LEW%:V\N.ZG<Q_6O:(Y"8D/JH- $IH'2@'(I: $%%*#2$T (3S0#
M36-.7I0 4[M30>:=GB@ H[T9HSS0 4"C- - "=Z4T9YH)H !24H-&: "BC-&
M: #O0:,\T$T %)WI<T9H #1031F@!*4T9H)H *.]&:,\T %+24M !1110 44
M44 %%%% !1110 E&.:*.] !B@"B@4 &*,4E+0  48YH%'>@ Q1BB@4 )M'I2
MXH[T4 &*,44E "T=J*!0 WG-.(XIN.:=0 QNF!U-<KXX\(0>+M!DL9\),?\
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M)BO7HT"QA<?=&*S+/0;&SU*?48[>+[5-G=+M&[!.<9QG&:U10 GTHYI<8I:
M "C% H[T )MI0*#0* #'-&*.]% !BC'-%'>@ Q0!10* #'-!%)WI30  48H%
M)0 N*,444 &.:"*.]!H ,48HI.] "D48H-% !B@BDI30 8HQS11WH *6DI:
M"BBB@ HHHH **** "BBB@ I.]+28H 6D%%&* "EI,44  H[T8HQ0 M I*,4
M'>EI,44 +248HQ0 M I,48H .]*:3%&* #M35X/-.Q2;>>M  2,<57*/NZFK
M!4^M&V@ VY%&*7%&* &;,G.:<1QBEQ1B@!JKM%(R9.:?BEH 8%Q2Y&*7%)M/
MK0 UU+#@TJKA<&E -+B@!"@I&&!Q3L4$<4 ,C!!.32L@-*%([TN* &XP*4"E
M(S0!B@!H4!B<<TXC(HQ10!&4QTJ3M1BC% #2F6S05..M.HQ0 @&!2T8HQ0 W
M'/6D933\48H 1>G-(1GO3L4 8H :J!<\4I-*12;3ZT  IK)FG!<=Z7% #0I
MZT!3GK3L48H .](32XI-I]: %%'>@#WHQ0 $TM-VGUI<4 '>EI,44 +2=Z,4
M8H 6@4F*,4 '>E-)BC% "BDHQ1B@!:*2B@!>]!I,48H 6D[T48H #2TF** "
M@T8HQ0 M)WHHQ0 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>tcon-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-04T17:46:10.0261+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.traconpharma.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:tcon="http://www.traconpharma.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/TemplateLink" id="TemplateLink">
        <link:definition>100000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100010 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100030 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100050 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995453 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurements">
        <link:definition>995463 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>995473 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt" id="Role_DisclosureLongTermDebt">
        <link:definition>995483 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995493 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995503 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="DisclosureCollaborationAndLicenseAgreements">
        <link:definition>995513 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995523 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995533 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlan" id="Role_Disclosure401KPlan">
        <link:definition>995543 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995553 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995563 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
        <link:definition>995573 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>995583 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables" id="Role_DisclosureLongTermDebtTables">
        <link:definition>995593 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>995603 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995613 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995623 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995633 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>995643 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in the Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails">
        <link:definition>995653 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Available-for-sale Securities and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995663 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995673 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995683 - Disclosure - Balance Sheet Details - Schedule Of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>995693 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails">
        <link:definition>995703 - Disclosure - Balance Sheet Details - Schedule Of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails" id="Role_DisclosureLongTermDebtAdditionalInformationDetails">
        <link:definition>995713 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails" id="Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails">
        <link:definition>995723 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt and Unamortized Debt Discount Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" id="Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails">
        <link:definition>995733 - Disclosure - Long-Term Debt - Schedule of Exercisable Outstanding Warrants for Purchase of Common Stock Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995743 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995753 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" id="Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails">
        <link:definition>995763 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants for Purchase of Common Stock Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails" id="Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails">
        <link:definition>995773 - Disclosure - Stockholders' Equity - (SBC) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>995783 - Disclosure - Stockholders' Equity- Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails" id="Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails">
        <link:definition>995793 - Disclosure - Stockholders' Equity - Summary of Company's Outstanding Stock Option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails" id="Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails">
        <link:definition>995803 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Fair Value of the Employee Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails">
        <link:definition>995813 - Disclosure - Stockholders' Equity - Summary of Allocation of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>995823 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>995833 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995843 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
        <link:definition>995853 - Disclosure - Leases - Supplemental cash flow information related to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails">
        <link:definition>995863 - Disclosure - Leases - Supplemental balance sheet information related to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>995873 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
        <link:definition>995883 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
        <link:definition>995893 - Disclosure - Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995903 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails">
        <link:definition>995913 - Disclosure - Income Taxes - Schedule of Changes in Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" id="Role_Disclosure401KPlanAdditionalInformationDetails">
        <link:definition>995923 - Disclosure - 401(k) Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails" id="Role_DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>995933 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="tcon-20231231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLongTermDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/TemplateLink" xlink:href="tcon-20231231.xsd#TemplateLink" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="tcon-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="tcon-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="tcon-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="tcon-20231231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="tcon-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="tcon-20231231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:href="tcon-20231231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt" xlink:href="tcon-20231231.xsd#Role_DisclosureLongTermDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="tcon-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="tcon-20231231.xsd#DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:href="tcon-20231231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="tcon-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlan" xlink:href="tcon-20231231.xsd#Role_Disclosure401KPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tcon-20231231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="tcon-20231231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:href="tcon-20231231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="tcon-20231231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables" xlink:href="tcon-20231231.xsd#Role_DisclosureLongTermDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="tcon-20231231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="tcon-20231231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="tcon-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails" xlink:href="tcon-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:href="tcon-20231231.xsd#Role_Disclosure401KPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2" xlink:href="tcon-20231231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PatentCostsPolicyPolicyTextBlock" xlink:label="tcon_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ReportedAsAbstract" xlink:label="tcon_ReportedAsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AccruedLongTermDebtTerminalInterestCurrent" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InhibrxLicenseAgreementMember" xlink:label="tcon_InhibrxLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" xlink:label="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RemainingAmountAvailableUnderTheSalesAgreement" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanAMember" xlink:label="tcon_TermLoanAMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBeSold" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterINDBeforePhaseOneAMember" xlink:label="tcon_AfterINDBeforePhaseOneAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" xlink:label="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" xlink:label="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CharlesPTheuerMDPhDOneMember" xlink:label="tcon_CharlesPTheuerMDPhDOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" xlink:label="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanBMember" xlink:label="tcon_TermLoanBMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBePurchased" xlink:label="tcon_MaximumAggregateValueOfStockToBePurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InhibrxMember" xlink:label="tcon_InhibrxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" xlink:label="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PlusRateMember" xlink:label="tcon_PlusRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanCMember" xlink:label="tcon_TermLoanCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" xlink:label="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrphanDrugTaxCreditMember" xlink:label="tcon_OrphanDrugTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ImpairmentOfPrivateCompanyEquityOwnership" xlink:label="tcon_ImpairmentOfPrivateCompanyEquityOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryDomain" xlink:label="tcon_MilestonePaymentsCategoryDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FirstPhaseTwoClinicalTrialMember" xlink:label="tcon_FirstPhaseTwoClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpLoanAgreementMember" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationFeePayable" xlink:label="tcon_TerminationFeePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonCancelableOperatingLeaseTermToBeExtended" xlink:label="tcon_NonCancelableOperatingLeaseTermToBeExtended"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtCurrentGross" xlink:label="tcon_LongTermDebtCurrentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CapitalOnDemandSalesAgreementMember" xlink:label="tcon_CapitalOnDemandSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DeferredTaxAssetsRightOfUseLiability" xlink:label="tcon_DeferredTaxAssetsRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" xlink:label="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfBiologicalTargets" xlink:label="tcon_NumberOfBiologicalTargets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyThreePreFundedWarrantsMember" xlink:label="tcon_TwentyTwentyThreePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" xlink:label="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LossContingencyPaymentWriteOffAmount" xlink:label="tcon_LossContingencyPaymentWriteOffAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LicenseAgreementTerm" xlink:label="tcon_LicenseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TrainingPeriodDuration" xlink:label="tcon_TrainingPeriodDuration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromMaturityOfShortTermInvestments" xlink:label="tcon_ProceedsFromMaturityOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DirectOfferingsMember" xlink:label="tcon_DirectOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock" xlink:label="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" xlink:label="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonRoyaltyConsiderationAmount" xlink:label="tcon_NonRoyaltyConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkCapitalFundLlcMember" xlink:label="tcon_LincolnParkCapitalFundLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RisksAndUncertaintiesPolicyTextBlock" xlink:label="tcon_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InitialCapitalContributionFromInvestors" xlink:label="tcon_InitialCapitalContributionFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityPlanMember" xlink:label="tcon_EquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationAgreementPercentageOfCostBearing" xlink:label="tcon_CollaborationAgreementPercentageOfCostBearing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TaxCreditCarryforwardExpirationBeginYear" xlink:label="tcon_TaxCreditCarryforwardExpirationBeginYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BonneAdamsMBAOneMember" xlink:label="tcon_BonneAdamsMBAOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterPhaseSecondMember" xlink:label="tcon_AfterPhaseSecondMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BalanceSheetRelatedDisclosuresTextBlock" xlink:label="tcon_BalanceSheetRelatedDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" xlink:label="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentOfOwnership" xlink:label="tcon_PercentOfOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SignificantAccountingPoliciesLineItems" xlink:label="tcon_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" xlink:label="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RoyaltyPercentageOfNetSales" xlink:label="tcon_RoyaltyPercentageOfNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" xlink:label="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkPurchaseAgreementMember" xlink:label="tcon_LincolnParkPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BispecificAgreementMember" xlink:label="tcon_BispecificAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ResearchAndDevelopmentTaxCreditMember" xlink:label="tcon_ResearchAndDevelopmentTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" xlink:label="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SalesMilestones" xlink:label="tcon_SalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ValueGivenToAssetsAcquired" xlink:label="tcon_ValueGivenToAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationAgreementMember" xlink:label="tcon_CollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ClassOfWarrantsOrRightExercised" xlink:label="tcon_ClassOfWarrantsOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ComputerAndOfficeEquipmentMember" xlink:label="tcon_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AdditionalCommonSharesToBeUsedForSpecificAward" xlink:label="tcon_AdditionalCommonSharesToBeUsedForSpecificAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NetProceedsReceivedFromIssuanceDirectOffering" xlink:label="tcon_NetProceedsReceivedFromIssuanceDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OnOrPriorToFirstAnniversaryDateMember" xlink:label="tcon_OnOrPriorToFirstAnniversaryDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InterestAndFinalPayment" xlink:label="tcon_InterestAndFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScottBBrownCpaMSMember" xlink:label="tcon_ScottBBrownCpaMSMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityOwnershipLicenseRevenue" xlink:label="tcon_EquityOwnershipLicenseRevenue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OperatingLossCarryforwardsExpirationBeginYear" xlink:label="tcon_OperatingLossCarryforwardsExpirationBeginYear"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ImabBiopharmaMember" xlink:label="tcon_ImabBiopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryAxis" xlink:label="tcon_MilestonePaymentsCategoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" xlink:label="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfAmendedPreFundedWarrants" xlink:label="tcon_NumberOfAmendedPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EmployeeStockPurchasePlanMember" xlink:label="tcon_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ConsiderationGivenInExchangeForAssetsAcquired" xlink:label="tcon_ConsiderationGivenInExchangeForAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" xlink:label="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" xlink:label="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationFinancingPayable" xlink:label="tcon_ArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationFee" xlink:label="tcon_TerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationsDisclosureAbstract" xlink:label="tcon_CollaborationsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrganizationAndAccountingPoliciesAbstract" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SiliconValleyBankMember" xlink:label="tcon_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BusinessCollaborationAdditionalPaymentAmount" xlink:label="tcon_BusinessCollaborationAdditionalPaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BonneAdamsMBAMember" xlink:label="tcon_BonneAdamsMBAMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" xlink:label="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborativeArrangementsMilestonePaymentsPotential" xlink:label="tcon_CollaborativeArrangementsMilestonePaymentsPotential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LoansAndSecurityAgreementMember" xlink:label="tcon_LoansAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CharlesPTheuerMDPhDMember" xlink:label="tcon_CharlesPTheuerMDPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterPhaseOneAAndBeforePhaseSecondMember" xlink:label="tcon_AfterPhaseOneAAndBeforePhaseSecondMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="us-gaap_ConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityIncentive2015PlanMember" xlink:label="tcon_EquityIncentive2015PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FinalPaymentOnPayoff" xlink:label="tcon_FinalPaymentOnPayoff"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfInitialCapitalContributionFromInvestors" xlink:label="tcon_PercentageOfInitialCapitalContributionFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" xlink:label="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PotentialPaymentOnPerformanceObligation" xlink:label="tcon_PotentialPaymentOnPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivateEquityFundsDomesticMember" xlink:label="us-gaap_PrivateEquityFundsDomesticMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommercialSale" xlink:label="tcon_CommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FirstPhaseClinicalTrialMember" xlink:label="tcon_FirstPhaseClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonrefundableUpfrontFee" xlink:label="tcon_NonrefundableUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumCapitalContribution" xlink:label="tcon_MaximumCapitalContribution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="tcon_CollaborativeArrangementMilestonePaymentsPotential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AdditionalPaymentOnPerformanceObligation" xlink:label="tcon_AdditionalPaymentOnPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanMember" xlink:label="tcon_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="us-gaap_OtherAssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SignificantAccountingPoliciesTable" xlink:label="tcon_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfClosingFeeAmount" xlink:label="tcon_PercentageOfClosingFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfPropertyAndEquipmentTableTextBlock" xlink:label="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" xlink:label="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OneTimeUpfrontPayment" xlink:label="tcon_OneTimeUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashPaidWithinOperatingCashFlows" xlink:label="tcon_CashPaidWithinOperatingCashFlows"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" xlink:label="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" xlink:label="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LoanAndSecurityAgreementMember" xlink:label="tcon_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfTranche" xlink:label="tcon_NumberOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" xlink:label="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockOptionsMember" xlink:label="tcon_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpMember" xlink:label="tcon_RunwayGrowthFinanceCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfFinalPaymentFee" xlink:label="tcon_PercentageOfFinalPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwoThousandTwentyThreePurchaseAgreementMember" xlink:label="tcon_TwoThousandTwentyThreePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" xlink:label="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationAwardInterestExpense" xlink:label="tcon_ArbitrationAwardInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FairValueTransfersBetweenLevelsAmount" xlink:label="tcon_FairValueTransfersBetweenLevelsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationSuccessFees" xlink:label="tcon_ArbitrationSuccessFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RestrictedCashFairValueDisclosure" xlink:label="tcon_RestrictedCashFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TjFourThreeZeroNineAgreementMember" xlink:label="tcon_TjFourThreeZeroNineAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BeforeINDMember" xlink:label="tcon_BeforeINDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InterestExpenseNoncash" xlink:label="tcon_InterestExpenseNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TransactionPrice" xlink:label="tcon_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" xlink:label="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" xlink:label="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkCapitalFundLLCMember" xlink:label="tcon_LincolnParkCapitalFundLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationAwardNonCashInterestExpense" xlink:label="tcon_ArbitrationAwardNonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyTwoPreFundedWarrantsMember" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EnvafolimabCollaborationAgreementMember" xlink:label="tcon_EnvafolimabCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_JonesTradingInstitutionalServicesLLCMember" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonCancelableOperatingLeaseExpirationTerm" xlink:label="tcon_NonCancelableOperatingLeaseExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" xlink:label="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsMember" xlink:label="tcon_WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term, options outstanding (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 capitalized research expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for patent costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ReportedAsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reported as.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ReportedAsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported As [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ReportedAsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reported as:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued long-term debt terminal interest, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Long Term Debt Terminal Interest Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued long-term debt terminal interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InhibrxLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inhibrx, Inc.(Inhibrx) License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InhibrxLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inhibrx License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InhibrxLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inhibrx License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments and Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum period of selecting candidates for development and commercialization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Period Of Selecting Candidates For Development And Commercialization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum period of selecting candidates for development and commercialization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining amount available under the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Amount Available Under The Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining amount available under the Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net change in the total valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty two pre funded warrants and common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty Two Pre Funded Warrants And Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in exchange for services (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assets and liabilities measured at fair value on a recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate value of stock to be sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Value Of Stock To Be Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate value of stock to be sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Utilities, Inventory [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Utilities Inventory [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterINDBeforePhaseOneAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After IND before phase one a.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterINDBeforePhaseOneAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After I N D Before Phase One A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterINDBeforePhaseOneAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After IND Before Phase 1a</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration may three two thousand twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration May Three Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 3, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase price of one point three two per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Price Of One Point Three Two Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price of $1.32 Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current portion of long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount of long-term debt, net of long-term unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Net Of Unamortized Long Term Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt, net of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of proprietary antibodies under development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number Of Proprietary Antibodies Under Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of proprietary bispecific antibodies under development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CharlesPTheuerMDPhDOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charles P. Theuer, M.D., Ph.D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CharlesPTheuerMDPhDOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Charles P. Theuer, M.D., Ph.D.one [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CharlesPTheuerMDPhDOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Charles P. Theuer, M.D., Ph.D.one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Debt Security, Trading, and Equity Security, FV-NI, Held-for-Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of debt and equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan B.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumAggregateValueOfStockToBePurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate value of shares committed to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumAggregateValueOfStockToBePurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Value Of Stock To Be Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumAggregateValueOfStockToBePurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate value of stock to be purchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Runway growth finance corp loan agreement1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Runway Growth Finance Corp Loan Agreement1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Runway Growth Finance Corp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InhibrxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inhibrx</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InhibrxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inhibrx [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InhibrxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inhibrx.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, options vested and expected to vest (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Current portion of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of gross proceeds, required to pay for common stock sold through sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Gross Proceeds Required To Pay For Common Stock Sold Through Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds, required to pay for common stock sold through sales agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PlusRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Plus rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PlusRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plus Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PlusRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plus Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan C.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan C</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After the second anniversary date but prior to the maturity date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After Second Anniversary Date But Prior To Maturity Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After Second Anniversary Date But Prior To Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OrphanDrugTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan Drug tax credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OrphanDrugTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Tax Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OrphanDrugTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of warrants to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of warrants to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ImpairmentOfPrivateCompanyEquityOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of private company equity ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ImpairmentOfPrivateCompanyEquityOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Private Company Equity Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ImpairmentOfPrivateCompanyEquityOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of private company equity ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MilestonePaymentsCategoryDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments category.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MilestonePaymentsCategoryDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Category [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MilestonePaymentsCategoryDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payments Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FirstPhaseTwoClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First phase two clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FirstPhaseTwoClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Phase Two Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FirstPhaseTwoClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Phase Two Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, additional disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Runway growth finance corp loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Runway Growth Finance Corp Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RGC Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets (ROU asset)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination fee payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination fee payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon cashless exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuances of common stock upon cashless exercise of pre-funded warrants value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuances Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonCancelableOperatingLeaseTermToBeExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cancelable operating lease term to be extended.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonCancelableOperatingLeaseTermToBeExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cancelable Operating Lease Term To Be Extended</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonCancelableOperatingLeaseTermToBeExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Cancelable Operating Lease Term To Be Extended</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtCurrentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtCurrentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtCurrentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LongTermDebtCurrentGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CapitalOnDemandSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital on demand sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CapitalOnDemandSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital On Demand Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CapitalOnDemandSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital on Demand Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DeferredTaxAssetsRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset right of use liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DeferredTaxAssetsRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DeferredTaxAssetsRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, restricted cash, and other assets fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Restricted Cash And Other Assets Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents, restricted cash, and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfBiologicalTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of biological targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfBiologicalTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Biological Targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfBiologicalTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of biological targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyThreePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyThreePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty Three Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyThreePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty three pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accounts payable and accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Expenses Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of common shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; authorized shares - 60,000,000 and 40,000,000 at December 31, 2023 and December 31, 2022, respectively; issued and outstanding shares - 44,269,976 and 23,125,250 at December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LossContingencyPaymentWriteOffAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency payment write-off amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LossContingencyPaymentWriteOffAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Payment Write-off Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LossContingencyPaymentWriteOffAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency payment write-off amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TrainingPeriodDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Training period duration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TrainingPeriodDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Training Period Duration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TrainingPeriodDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Training period duration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromMaturityOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the maturity of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromMaturityOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturity Of Short Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromMaturityOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from maturity of short term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DirectOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct offerings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DirectOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Offerings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DirectOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for clinical trial expense accruals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Expense Accruals Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial Expense Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic collaboration and clinical trial agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Collaboration And Clinical Trial Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonRoyaltyConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-royalty consideration amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonRoyaltyConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Royalty Consideration Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonRoyaltyConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-royalty consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkCapitalFundLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park Capital Fund, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkCapitalFundLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Capital Fund, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkCapitalFundLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln Park Capital Fund, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties [Policy Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks And Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants vesting (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InitialCapitalContributionFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial capital contribution from investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InitialCapitalContributionFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Capital Contribution From Investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InitialCapitalContributionFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial capital contribution from investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses (lease liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Plan Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt, principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationAgreementPercentageOfCostBearing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement percentage of cost bearing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationAgreementPercentageOfCostBearing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Percentage Of Cost Bearing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationAgreementPercentageOfCostBearing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cost bearing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TaxCreditCarryforwardExpirationBeginYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration begin year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TaxCreditCarryforwardExpirationBeginYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Begin Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TaxCreditCarryforwardExpirationBeginYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward begin to expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense related to property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities and Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of effective tax rate and federal statutory tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BonneAdamsMBAOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonne Adams, M.B.A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BonneAdamsMBAOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonne Adams, M.B.A. One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BonneAdamsMBAOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonne Adams, M.B.A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments, Cash Equivalents and Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of exercisable outstanding warrants for purchase of common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of options vested during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterPhaseSecondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After phase Second.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterPhaseSecondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After Phase Second [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterPhaseSecondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After Phase 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BalanceSheetRelatedDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Balance sheet related disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BalanceSheetRelatedDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BalanceSheetRelatedDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Utilities, Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Utilities Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt and arbitration financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from long term debt and arbitration financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from long-term debt and arbitration financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Purchase Commitment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of outstanding stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants in connection with debt financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax interest or penalties expense for unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentOfOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percent Of Ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentOfOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percent Of Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentOfOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenditure amortization period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenditure Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenditure amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RoyaltyPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty percentage of net sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RoyaltyPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Percentage Of Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RoyaltyPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of pre-funded warrants to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise Of Prefunded Warrants To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of pre-funded warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln park purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BispecificAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bispecific agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BispecificAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bispecific Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BispecificAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bispecific Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price Of $1.37 Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Price Of One Point Three Seven Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase price of one point three seven per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ResearchAndDevelopmentTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ResearchAndDevelopmentTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ResearchAndDevelopmentTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After the first anniversary date but on or prior to the second anniversary date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After First Anniversary Date But On Or Prior To Second Anniversary Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After First Anniversary Date But On Or Prior To Second Anniversary Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of future minimum principal and interest payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestones payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ValueGivenToAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value given to assets acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ValueGivenToAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Given To Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ValueGivenToAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value given to assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ClassOfWarrantsOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants or right exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ClassOfWarrantsOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Or Right Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ClassOfWarrantsOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Product and Service [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Employee Related Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Plan Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution, plan name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer And Office Equipment [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AdditionalCommonSharesToBeUsedForSpecificAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the additional shares of common stock to be used exclusively for a specified award of the entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AdditionalCommonSharesToBeUsedForSpecificAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Common Shares To Be Used For Specific Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AdditionalCommonSharesToBeUsedForSpecificAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares to be used exclusively for grant for Inducement awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, options exercisable (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development and Orphan Drug Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NetProceedsReceivedFromIssuanceDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds received from issuance direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NetProceedsReceivedFromIssuanceDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Received From Issuance Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NetProceedsReceivedFromIssuanceDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from common stock issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OnOrPriorToFirstAnniversaryDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">On or prior to the first anniversary date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OnOrPriorToFirstAnniversaryDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">On Or Prior To First Anniversary Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OnOrPriorToFirstAnniversaryDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">On Or Prior To First Anniversary Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestAndFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal and interest payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestAndFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of interest and final payment of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestAndFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Final Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestAndFinalPayment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less interest and final payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, period of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScottBBrownCpaMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scott B. Brown, CPA, M.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScottBBrownCpaMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scott B. Brown, CPA, M.S. [Member[</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScottBBrownCpaMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scott B. Brown, CPA, M.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and warrants, net of offering costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuances of common stock and warrants, net of offering costs shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuances Of Common Stock And Warrants Net Of Offering Costs In Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term, options vested and expected to vest (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityOwnershipLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Ownership License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityOwnershipLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Ownership License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityOwnershipLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity ownership license revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OperatingLossCarryforwardsExpirationBeginYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration begin year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OperatingLossCarryforwardsExpirationBeginYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Begin Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OperatingLossCarryforwardsExpirationBeginYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOL carryforward begin to expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ImabBiopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">I-Mab</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ImabBiopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IMab Biopharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ImabBiopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IMab Biopharma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MilestonePaymentsCategoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments category.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MilestonePaymentsCategoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Category [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MilestonePaymentsCategoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payments Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Change in cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental schedule of noncash investing and financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuances of common stock net of offering costs value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuances Of Common Stock Net Of Offering Costs Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock outstanding owned after sale agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Common Stock Outstanding Owned After Sale Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock outstanding owned after sale agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfAmendedPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of amended pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfAmendedPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Amended Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfAmendedPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of amended pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to employee stock purchase plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of stock option activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ConsiderationGivenInExchangeForAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration given in exchange for assets acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ConsiderationGivenInExchangeForAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consideration Given In Exchange For Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ConsiderationGivenInExchangeForAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration exchanged for assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of weighted-average assumptions used Black-Scholes option pricing model to determine the fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt and arbitration financing payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Of Long-term Debt And Arbitration Financing Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of long-term debt and arbitration financing payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal and accounting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease asset amortization and liability accretion, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Asset Amortization And Liability Accretion Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease asset amortization and liability accretion, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationFinancingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arbitration financing payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationFinancingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arbitration Financing Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationFinancingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arbitration financing payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long-term debt and unamortized debt discount balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase price of one point three one per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Price Of One Point Three One Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price of $1.31 Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Irrevocable letter of credit provided to lessor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of components of deferred tax assets and deferred tax Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborationsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Accounting Policies Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to Silicon Valley Bank Loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BusinessCollaborationAdditionalPaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business collaboration additional payment amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BusinessCollaborationAdditionalPaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Collaboration Additional Payment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BusinessCollaborationAdditionalPaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of allocation of stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BonneAdamsMBAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonne Adams, M.B.A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BonneAdamsMBAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonne Adams, M.B.A. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BonneAdamsMBAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonne Adams, M.B.A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration september two two thousand thirty two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration September Two Two Thousand Thirty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2, 2032</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborativeArrangementsMilestonePaymentsPotential_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of potential payments that could be paid under the collaborative agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborativeArrangementsMilestonePaymentsPotential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements Milestone Payments Potential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborativeArrangementsMilestonePaymentsPotential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LoansAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to the loan and agreement with Silicon Valley Bank dated May, 2015.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LoansAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LoansAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan And Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Purchase Commitment, Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CharlesPTheuerMDPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Charles P. Theuer, M.D., Ph.D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CharlesPTheuerMDPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charles P. Theuer, M.D., Ph.D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CharlesPTheuerMDPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Charles P. Theuer, M.D., Ph.D. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for interest or penalties for unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterPhaseOneAAndBeforePhaseSecondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After phase one a and before phase second.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterPhaseOneAAndBeforePhaseSecondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After Phase One A And Before Phase Second [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AfterPhaseOneAAndBeforePhaseSecondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After Phase 1a and Before Phase 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityIncentive2015PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to 2015 Equity Incentive Plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityIncentive2015PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive2015 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EquityIncentive2015PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FinalPaymentOnPayoff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Final payment on payoff.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FinalPaymentOnPayoff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Payment On Payoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FinalPaymentOnPayoff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment on payoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfInitialCapitalContributionFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of Initial Capital Contribution From Investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfInitialCapitalContributionFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Initial Capital Contribution From Investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfInitialCapitalContributionFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of initial capital contribution from investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. This does not include accrued salaries and bonuses, payroll taxes and fringe benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Expenses Excluding Accrued Compensation And Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets recognized in exchange for new lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuances of common stock net of offering costs shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuances Of Common Stock Net Of Offering Costs Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock, net of offering costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PotentialPaymentOnPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential payment on performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PotentialPaymentOnPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Payment on Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PotentialPaymentOnPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential payment on performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common stock warrants issued in connection with long-term debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Warrants In Connection With Long Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants in connection with long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivateEquityFundsDomesticMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Equity Funds, US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivateEquityFundsDomesticMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FirstPhaseClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First phase clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FirstPhaseClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Phase Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FirstPhaseClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Phase Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Excluding Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term debt, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonrefundableUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrefundable upfront fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonrefundableUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonrefundable Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonrefundableUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonrefundable upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumCapitalContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum capital contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumCapitalContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Capital Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumCapitalContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum capital contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborativeArrangementMilestonePaymentsPotential_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of potential payments that could be received under the collaborative agreement..</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborativeArrangementMilestonePaymentsPotential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments Potential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CollaborativeArrangementMilestonePaymentsPotential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Operating Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, authorized shares - 10,000,000 at December 31, 2023 andDecember 31,2022; issued and outstanding shares - none</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AdditionalPaymentOnPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment on performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AdditionalPaymentOnPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payment On Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_AdditionalPaymentOnPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payment on performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price (per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price Of $1.38 Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Price Of One Point Three Eight Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase price of one point three eight per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuances of common stock and warrants, net of offering costs value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuances Of Common Stock And Warrants Net Of Offering Costs Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and warrants, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuances of common stock upon cashless exercise of pre-funded warrants shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuances Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon cashless exercise of pre-funded warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon cashless exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2018 SVB Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Eighteen Loan And Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfClosingFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of closing fee amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfClosingFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Closing Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfClosingFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of closing fee amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of holders ownership interest in common stock after exercise.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Holders Ownership Interest In Common Stock After Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of holders ownership interest in common stock after exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OneTimeUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One time upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OneTimeUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_OneTimeUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time upfront payment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashPaidWithinOperatingCashFlows_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid within operating cash flows.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashPaidWithinOperatingCashFlows_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid Within Operating Cash Flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CashPaidWithinOperatingCashFlows_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid within operating cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price (in dollar per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of operating loss carry forwards available to offset future taxable income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Operating Loss Carry Forwards Available To Offset Future Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOL carryforward available to offset future taxable income, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement received, net of termination fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Amount Awarded From Other Party Net Of Termination Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation settlement amount awarded from other party net of termination fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fee awarded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Damages Awarded, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and Security Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan And Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NumberOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable and Accrued Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone payments to be paid under license and option agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory Based Milestone Payments Under License And Option Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory based on milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Runway Growth Finance Corp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Runway Growth Finance Corp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RunwayGrowthFinanceCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Runway Growth Finance Corp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 4, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration June Four Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration june four two thousand twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of final payment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_PercentageOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of final payment fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration march twenty seven two thousand twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration March Twenty Seven Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 27, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of maturities of operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Operating Lease Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term, options exercisable (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandTwentyThreePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandTwentyThreePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwoThousandTwentyThreePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and warrants net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock and warrants, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationAwardInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationAwardInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arbitration Award Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationAwardInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arbitration award interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FairValueTransfersBetweenLevelsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of transfers of assets or liabilities measured on a recurring basis between levels.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FairValueTransfersBetweenLevelsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Transfers Between Levels Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_FairValueTransfersBetweenLevelsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of transfers between levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Amount Awarded from Other Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationSuccessFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Arbitration success fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationSuccessFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arbitration success fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationSuccessFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arbitration Success Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationSuccessFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arbitration success fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RestrictedCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RestrictedCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_RestrictedCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TjFourThreeZeroNineAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TJ4309 Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TjFourThreeZeroNineAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TJ Four Three Zero Nine Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TjFourThreeZeroNineAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TJ four three zero nine agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BeforeINDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Before IND.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BeforeINDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Before I N D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_BeforeINDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Before IND</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration January twenty five two thousand twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration January Twenty Five Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 25, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development and Orphan Drug credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestExpenseNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of noncash interest expense included in interest expense, excluding the allocation of debt discount and premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestExpenseNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Noncash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_InterestExpenseNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium/discount on short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination of agreement upon completion of clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Of Agreement Upon Completion Of Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination of agreement upon completion of clinical trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan [Abstract].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Pension And Other Postretirement Plans Disclosure Abstract1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Pension and Other Postretirement Plans Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Shareholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkCapitalFundLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln park capital fund LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkCapitalFundLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Capital Fund L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_LincolnParkCapitalFundLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationAwardNonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationAwardNonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arbitration Award Non Cash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ArbitrationAwardNonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arbitration award non cash interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental balance sheet information related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Balance Sheet Information Related to Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity plans (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty two pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty Two Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of reconciliation of effective tax rate and federal statutory tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EnvafolimabCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Envafolimab collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EnvafolimabCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Envafolimab Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_EnvafolimabCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bispecific Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jonestrading institutional services LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jones Trading Institutional Services L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jones Trading Institutional Services LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonCancelableOperatingLeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non&#8209;cancelable operating lease expiration term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonCancelableOperatingLeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cancelable Operating Lease Expiration Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_NonCancelableOperatingLeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cancelable operating lease expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in exchange for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The addition or reduction in the number of reserved shares that could potentially be issued under the plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Other Increases Decreases In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares that could potentially be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, options outstanding (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of total number of shares of common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities (lease liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less debt discount, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North America [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North America</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change related to prior year positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOL carryforward</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PatentCostsPolicyPolicyTextBlock" xlink:to="tcon_PatentCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ReportedAsAbstract" xlink:to="tcon_ReportedAsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AccruedLongTermDebtTerminalInterestCurrent" xlink:to="tcon_AccruedLongTermDebtTerminalInterestCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_InhibrxLicenseAgreementMember" xlink:to="tcon_InhibrxLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" xlink:to="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RemainingAmountAvailableUnderTheSalesAgreement" xlink:to="tcon_RemainingAmountAvailableUnderTheSalesAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TermLoanAMember" xlink:to="tcon_TermLoanAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" xlink:to="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MaximumAggregateValueOfStockToBeSold" xlink:to="tcon_MaximumAggregateValueOfStockToBeSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AfterINDBeforePhaseOneAMember" xlink:to="tcon_AfterINDBeforePhaseOneAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" xlink:to="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" xlink:to="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" xlink:to="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CharlesPTheuerMDPhDOneMember" xlink:to="tcon_CharlesPTheuerMDPhDOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" xlink:to="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TermLoanBMember" xlink:to="tcon_TermLoanBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MaximumAggregateValueOfStockToBePurchased" xlink:to="tcon_MaximumAggregateValueOfStockToBePurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" xlink:to="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_InhibrxMember" xlink:to="tcon_InhibrxMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" xlink:to="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PlusRateMember" xlink:to="tcon_PlusRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TermLoanCMember" xlink:to="tcon_TermLoanCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" xlink:to="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_OrphanDrugTaxCreditMember" xlink:to="tcon_OrphanDrugTaxCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ImpairmentOfPrivateCompanyEquityOwnership" xlink:to="tcon_ImpairmentOfPrivateCompanyEquityOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_MilestonePaymentsCategoryDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_FirstPhaseTwoClinicalTrialMember" xlink:to="tcon_FirstPhaseTwoClinicalTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RunwayGrowthFinanceCorpLoanAgreementMember" xlink:to="tcon_RunwayGrowthFinanceCorpLoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TerminationFeePayable" xlink:to="tcon_TerminationFeePayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NonCancelableOperatingLeaseTermToBeExtended" xlink:to="tcon_NonCancelableOperatingLeaseTermToBeExtended_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LongTermDebtCurrentGross" xlink:to="tcon_LongTermDebtCurrentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CapitalOnDemandSalesAgreementMember" xlink:to="tcon_CapitalOnDemandSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_DeferredTaxAssetsRightOfUseLiability" xlink:to="tcon_DeferredTaxAssetsRightOfUseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" xlink:to="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NumberOfBiologicalTargets" xlink:to="tcon_NumberOfBiologicalTargets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TwentyTwentyThreePreFundedWarrantsMember" xlink:to="tcon_TwentyTwentyThreePreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" xlink:to="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LossContingencyPaymentWriteOffAmount" xlink:to="tcon_LossContingencyPaymentWriteOffAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LicenseAgreementTerm" xlink:to="tcon_LicenseAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TrainingPeriodDuration" xlink:to="tcon_TrainingPeriodDuration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ProceedsFromMaturityOfShortTermInvestments" xlink:to="tcon_ProceedsFromMaturityOfShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_DirectOfferingsMember" xlink:to="tcon_DirectOfferingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock" xlink:to="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" xlink:to="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NonRoyaltyConsiderationAmount" xlink:to="tcon_NonRoyaltyConsiderationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LincolnParkCapitalFundLlcMember" xlink:to="tcon_LincolnParkCapitalFundLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RisksAndUncertaintiesPolicyTextBlock" xlink:to="tcon_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_InitialCapitalContributionFromInvestors" xlink:to="tcon_InitialCapitalContributionFromInvestors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_EquityPlanMember" xlink:to="tcon_EquityPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CollaborationAgreementPercentageOfCostBearing" xlink:to="tcon_CollaborationAgreementPercentageOfCostBearing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TaxCreditCarryforwardExpirationBeginYear" xlink:to="tcon_TaxCreditCarryforwardExpirationBeginYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_BonneAdamsMBAOneMember" xlink:to="tcon_BonneAdamsMBAOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AfterPhaseSecondMember" xlink:to="tcon_AfterPhaseSecondMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_BalanceSheetRelatedDisclosuresTextBlock" xlink:to="tcon_BalanceSheetRelatedDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PublicUtilitiesInventoryLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" xlink:to="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentOfOwnership" xlink:to="tcon_PercentOfOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="tcon_SignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" xlink:to="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RoyaltyPercentageOfNetSales" xlink:to="tcon_RoyaltyPercentageOfNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" xlink:to="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LincolnParkPurchaseAgreementMember" xlink:to="tcon_LincolnParkPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_BispecificAgreementMember" xlink:to="tcon_BispecificAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ResearchAndDevelopmentTaxCreditMember" xlink:to="tcon_ResearchAndDevelopmentTaxCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" xlink:to="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_SalesMilestones" xlink:to="tcon_SalesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ValueGivenToAssetsAcquired" xlink:to="tcon_ValueGivenToAssetsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CollaborationAgreementMember" xlink:to="tcon_CollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ClassOfWarrantsOrRightExercised" xlink:to="tcon_ClassOfWarrantsOrRightExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:to="us-gaap_DefinedContributionPlanPlanNameExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ComputerAndOfficeEquipmentMember" xlink:to="tcon_ComputerAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AdditionalCommonSharesToBeUsedForSpecificAward" xlink:to="tcon_AdditionalCommonSharesToBeUsedForSpecificAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NetProceedsReceivedFromIssuanceDirectOffering" xlink:to="tcon_NetProceedsReceivedFromIssuanceDirectOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_OnOrPriorToFirstAnniversaryDateMember" xlink:to="tcon_OnOrPriorToFirstAnniversaryDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_InterestAndFinalPayment" xlink:to="tcon_InterestAndFinalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScottBBrownCpaMSMember" xlink:to="tcon_ScottBBrownCpaMSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" xlink:to="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_EquityOwnershipLicenseRevenue" xlink:to="tcon_EquityOwnershipLicenseRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_OperatingLossCarryforwardsExpirationBeginYear" xlink:to="tcon_OperatingLossCarryforwardsExpirationBeginYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ImabBiopharmaMember" xlink:to="tcon_ImabBiopharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MilestonePaymentsCategoryAxis" xlink:to="tcon_MilestonePaymentsCategoryAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" xlink:to="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" xlink:to="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NumberOfAmendedPreFundedWarrants" xlink:to="tcon_NumberOfAmendedPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_EmployeeStockPurchasePlanMember" xlink:to="tcon_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ConsiderationGivenInExchangeForAssetsAcquired" xlink:to="tcon_ConsiderationGivenInExchangeForAssetsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" xlink:to="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" xlink:to="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ArbitrationFinancingPayable" xlink:to="tcon_ArbitrationFinancingPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TerminationFee" xlink:to="tcon_TerminationFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CollaborationsDisclosureAbstract" xlink:to="tcon_CollaborationsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="tcon_OrganizationAndAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_SiliconValleyBankMember" xlink:to="tcon_SiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_BusinessCollaborationAdditionalPaymentAmount" xlink:to="tcon_BusinessCollaborationAdditionalPaymentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_BonneAdamsMBAMember" xlink:to="tcon_BonneAdamsMBAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" xlink:to="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CollaborativeArrangementsMilestonePaymentsPotential" xlink:to="tcon_CollaborativeArrangementsMilestonePaymentsPotential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LoansAndSecurityAgreementMember" xlink:to="tcon_LoansAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CharlesPTheuerMDPhDMember" xlink:to="tcon_CharlesPTheuerMDPhDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AfterPhaseOneAAndBeforePhaseSecondMember" xlink:to="tcon_AfterPhaseOneAAndBeforePhaseSecondMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleCommonStockMember" xlink:to="us-gaap_ConvertibleCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_EquityIncentive2015PlanMember" xlink:to="tcon_EquityIncentive2015PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_FinalPaymentOnPayoff" xlink:to="tcon_FinalPaymentOnPayoff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentageOfInitialCapitalContributionFromInvestors" xlink:to="tcon_PercentageOfInitialCapitalContributionFromInvestors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" xlink:to="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" xlink:to="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PotentialPaymentOnPerformanceObligation" xlink:to="tcon_PotentialPaymentOnPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:to="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivateEquityFundsDomesticMember" xlink:to="us-gaap_PrivateEquityFundsDomesticMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CommercialSale" xlink:to="tcon_CommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_FirstPhaseClinicalTrialMember" xlink:to="tcon_FirstPhaseClinicalTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NonrefundableUpfrontFee" xlink:to="tcon_NonrefundableUpfrontFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MaximumCapitalContribution" xlink:to="tcon_MaximumCapitalContribution_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CollaborativeArrangementMilestonePaymentsPotential" xlink:to="tcon_CollaborativeArrangementMilestonePaymentsPotential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_AdditionalPaymentOnPerformanceObligation" xlink:to="tcon_AdditionalPaymentOnPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TermLoanMember" xlink:to="tcon_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" xlink:to="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="tcon_SignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" xlink:to="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentageOfClosingFeeAmount" xlink:to="tcon_PercentageOfClosingFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock" xlink:to="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" xlink:to="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_OneTimeUpfrontPayment" xlink:to="tcon_OneTimeUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CashPaidWithinOperatingCashFlows" xlink:to="tcon_CashPaidWithinOperatingCashFlows_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" xlink:to="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" xlink:to="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LoanAndSecurityAgreementMember" xlink:to="tcon_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NumberOfTranche" xlink:to="tcon_NumberOfTranche_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" xlink:to="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_CommonStockOptionsMember" xlink:to="tcon_CommonStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RunwayGrowthFinanceCorpMember" xlink:to="tcon_RunwayGrowthFinanceCorpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" xlink:to="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_PercentageOfFinalPaymentFee" xlink:to="tcon_PercentageOfFinalPaymentFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" xlink:to="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" xlink:to="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TwoThousandTwentyThreePurchaseAgreementMember" xlink:to="tcon_TwoThousandTwentyThreePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" xlink:to="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ArbitrationAwardInterestExpense" xlink:to="tcon_ArbitrationAwardInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_FairValueTransfersBetweenLevelsAmount" xlink:to="tcon_FairValueTransfersBetweenLevelsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ArbitrationSuccessFees" xlink:to="tcon_ArbitrationSuccessFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_RestrictedCashFairValueDisclosure" xlink:to="tcon_RestrictedCashFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TjFourThreeZeroNineAgreementMember" xlink:to="tcon_TjFourThreeZeroNineAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_BeforeINDMember" xlink:to="tcon_BeforeINDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" xlink:to="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_InterestExpenseNoncash" xlink:to="tcon_InterestExpenseNoncash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TransactionPrice" xlink:to="tcon_TransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" xlink:to="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" xlink:to="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_LincolnParkCapitalFundLLCMember" xlink:to="tcon_LincolnParkCapitalFundLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ArbitrationAwardNonCashInterestExpense" xlink:to="tcon_ArbitrationAwardNonCashInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_TwentyTwentyTwoPreFundedWarrantsMember" xlink:to="tcon_TwentyTwentyTwoPreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_EnvafolimabCollaborationAgreementMember" xlink:to="tcon_EnvafolimabCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_JonesTradingInstitutionalServicesLLCMember" xlink:to="tcon_JonesTradingInstitutionalServicesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_NonCancelableOperatingLeaseExpirationTerm" xlink:to="tcon_NonCancelableOperatingLeaseExpirationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" xlink:to="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_WarrantsMember" xlink:to="tcon_WarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/TemplateLink" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationFinancingPayable" xlink:label="tcon_ArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="tcon_ArbitrationFinancingPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationSuccessFees" xlink:label="tcon_ArbitrationSuccessFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="tcon_ArbitrationSuccessFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" xlink:label="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" xlink:label="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" xlink:label="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromMaturityOfShortTermInvestments" xlink:label="tcon_ProceedsFromMaturityOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InterestExpenseNoncash" xlink:label="tcon_InterestExpenseNoncash"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" xlink:label="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" xlink:label="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityOwnershipLicenseRevenue" xlink:label="tcon_EquityOwnershipLicenseRevenue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ImpairmentOfPrivateCompanyEquityOwnership" xlink:label="tcon_ImpairmentOfPrivateCompanyEquityOwnership"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="tcon_ProceedsFromMaturityOfShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcon_InterestExpenseNoncash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcon_EquityOwnershipLicenseRevenue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcon_ImpairmentOfPrivateCompanyEquityOwnership" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CharlesPTheuerMDPhDMember" xlink:label="tcon_CharlesPTheuerMDPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CharlesPTheuerMDPhDOneMember" xlink:label="tcon_CharlesPTheuerMDPhDOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScottBBrownCpaMSMember" xlink:label="tcon_ScottBBrownCpaMSMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BonneAdamsMBAMember" xlink:label="tcon_BonneAdamsMBAMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BonneAdamsMBAOneMember" xlink:label="tcon_BonneAdamsMBAOneMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_CharlesPTheuerMDPhDMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_CharlesPTheuerMDPhDOneMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_ScottBBrownCpaMSMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_BonneAdamsMBAMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_BonneAdamsMBAOneMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrganizationAndAccountingPoliciesAbstract" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BalanceSheetRelatedDisclosuresTextBlock" xlink:label="tcon_BalanceSheetRelatedDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tcon_BalanceSheetRelatedDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationsDisclosureAbstract" xlink:label="tcon_CollaborationsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_CollaborationsDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrganizationAndAccountingPoliciesAbstract" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RisksAndUncertaintiesPolicyTextBlock" xlink:label="tcon_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock" xlink:label="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PatentCostsPolicyPolicyTextBlock" xlink:label="tcon_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="tcon_RisksAndUncertaintiesPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="tcon_PatentCostsPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrganizationAndAccountingPoliciesAbstract" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfPropertyAndEquipmentTableTextBlock" xlink:label="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" xlink:label="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SignificantAccountingPoliciesLineItems" xlink:label="tcon_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrganizationAndAccountingPoliciesAbstract" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SignificantAccountingPoliciesTable" xlink:label="tcon_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CapitalOnDemandSalesAgreementMember" xlink:label="tcon_CapitalOnDemandSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_JonesTradingInstitutionalServicesLLCMember" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkCapitalFundLlcMember" xlink:label="tcon_LincolnParkCapitalFundLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBeSold" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RemainingAmountAvailableUnderTheSalesAgreement" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="tcon_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_CapitalOnDemandSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_JonesTradingInstitutionalServicesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_LincolnParkCapitalFundLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="tcon_SignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="tcon_MaximumAggregateValueOfStockToBeSold" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="tcon_RemainingAmountAvailableUnderTheSalesAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrganizationAndAccountingPoliciesAbstract" xlink:label="tcon_OrganizationAndAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockOptionsMember" xlink:label="tcon_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_OrganizationAndAccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcon_CommonStockOptionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivateEquityFundsDomesticMember" xlink:label="us-gaap_PrivateEquityFundsDomesticMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RestrictedCashFairValueDisclosure" xlink:label="tcon_RestrictedCashFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="us-gaap_OtherAssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" xlink:label="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_PrivateEquityFundsDomesticMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tcon_RestrictedCashFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_OtherAssetsFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FairValueTransfersBetweenLevelsAmount" xlink:label="tcon_FairValueTransfersBetweenLevelsAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="tcon_FairValueTransfersBetweenLevelsAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ComputerAndOfficeEquipmentMember" xlink:label="tcon_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="tcon_ComputerAndOfficeEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PublicUtilitiesInventoryTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AccruedLongTermDebtTerminalInterestCurrent" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PublicUtilitiesInventoryTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="tcon_AccruedLongTermDebtTerminalInterestCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_DebtCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanMember" xlink:label="tcon_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LoansAndSecurityAgreementMember" xlink:label="tcon_LoansAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumCapitalContribution" xlink:label="tcon_MaximumCapitalContribution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PlusRateMember" xlink:label="tcon_PlusRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OnOrPriorToFirstAnniversaryDateMember" xlink:label="tcon_OnOrPriorToFirstAnniversaryDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanAMember" xlink:label="tcon_TermLoanAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LoanAndSecurityAgreementMember" xlink:label="tcon_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InitialCapitalContributionFromInvestors" xlink:label="tcon_InitialCapitalContributionFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpMember" xlink:label="tcon_RunwayGrowthFinanceCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" xlink:label="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanBMember" xlink:label="tcon_TermLoanBMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsMember" xlink:label="tcon_WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfInitialCapitalContributionFromInvestors" xlink:label="tcon_PercentageOfInitialCapitalContributionFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SiliconValleyBankMember" xlink:label="tcon_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" xlink:label="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanCMember" xlink:label="tcon_TermLoanCMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfClosingFeeAmount" xlink:label="tcon_PercentageOfClosingFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpLoanAgreementMember" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationFinancingPayable" xlink:label="tcon_ArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationAwardNonCashInterestExpense" xlink:label="tcon_ArbitrationAwardNonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationAwardInterestExpense" xlink:label="tcon_ArbitrationAwardInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfTranche" xlink:label="tcon_NumberOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" xlink:label="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfFinalPaymentFee" xlink:label="tcon_PercentageOfFinalPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InterestAndFinalPayment" xlink:label="tcon_InterestAndFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FinalPaymentOnPayoff" xlink:label="tcon_FinalPaymentOnPayoff"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_LoansAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_MaximumCapitalContribution" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="tcon_PlusRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcon_OnOrPriorToFirstAnniversaryDateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_LoanAndSecurityAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_InitialCapitalContributionFromInvestors" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_RunwayGrowthFinanceCorpMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanBMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_WarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_PercentageOfInitialCapitalContributionFromInvestors" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_SiliconValleyBankMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanCMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_PercentageOfClosingFeeAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_RunwayGrowthFinanceCorpLoanAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_ArbitrationFinancingPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_ArbitrationAwardNonCashInterestExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_ArbitrationAwardInterestExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_NumberOfTranche" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_PercentageOfFinalPaymentFee" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_InterestAndFinalPayment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_FinalPaymentOnPayoff" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" xlink:label="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtCurrentGross" xlink:label="tcon_LongTermDebtCurrentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtCurrentGross" xlink:label="tcon_LongTermDebtCurrentGross_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="tcon_LongTermDebtCurrentGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="tcon_LongTermDebtCurrentGross_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SiliconValleyBankMember" xlink:label="tcon_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborativeArrangementsMilestonePaymentsPotential" xlink:label="tcon_CollaborativeArrangementsMilestonePaymentsPotential"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tcon_CollaborativeArrangementsMilestonePaymentsPotential" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBePurchased" xlink:label="tcon_MaximumAggregateValueOfStockToBePurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityPlanMember" xlink:label="tcon_EquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkPurchaseAgreementMember" xlink:label="tcon_LincolnParkPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyTwoPreFundedWarrantsMember" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_JonesTradingInstitutionalServicesLLCMember" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DirectOfferingsMember" xlink:label="tcon_DirectOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyThreePreFundedWarrantsMember" xlink:label="tcon_TwentyTwentyThreePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CapitalOnDemandSalesAgreementMember" xlink:label="tcon_CapitalOnDemandSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NetProceedsReceivedFromIssuanceDirectOffering" xlink:label="tcon_NetProceedsReceivedFromIssuanceDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" xlink:label="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfAmendedPreFundedWarrants" xlink:label="tcon_NumberOfAmendedPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" xlink:label="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBeSold" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RemainingAmountAvailableUnderTheSalesAgreement" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" xlink:label="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ClassOfWarrantsOrRightExercised" xlink:label="tcon_ClassOfWarrantsOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" xlink:label="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_MaximumAggregateValueOfStockToBePurchased" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcon_EquityPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_LincolnParkPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_TwentyTwentyTwoPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_JonesTradingInstitutionalServicesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_DirectOfferingsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_TwentyTwentyThreePreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_CapitalOnDemandSalesAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_NetProceedsReceivedFromIssuanceDirectOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_NumberOfAmendedPreFundedWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_MaximumAggregateValueOfStockToBeSold" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_RemainingAmountAvailableUnderTheSalesAgreement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_ClassOfWarrantsOrRightExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" xlink:label="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityIncentive2015PlanMember" xlink:label="tcon_EquityIncentive2015PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EmployeeStockPurchasePlanMember" xlink:label="tcon_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AdditionalCommonSharesToBeUsedForSpecificAward" xlink:label="tcon_AdditionalCommonSharesToBeUsedForSpecificAward"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" xlink:label="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcon_EquityIncentive2015PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcon_EmployeeStockPurchasePlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="tcon_AdditionalCommonSharesToBeUsedForSpecificAward" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="us-gaap_ConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityIncentive2015PlanMember" xlink:label="tcon_EquityIncentive2015PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EmployeeStockPurchasePlanMember" xlink:label="tcon_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcon_EquityIncentive2015PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcon_EmployeeStockPurchasePlanMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EnvafolimabCollaborationAgreementMember" xlink:label="tcon_EnvafolimabCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryDomain" xlink:label="tcon_MilestonePaymentsCategoryDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FirstPhaseClinicalTrialMember" xlink:label="tcon_FirstPhaseClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationAgreementMember" xlink:label="tcon_CollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryAxis" xlink:label="tcon_MilestonePaymentsCategoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationsDisclosureAbstract" xlink:label="tcon_CollaborationsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommercialSale" xlink:label="tcon_CommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ImabBiopharmaMember" xlink:label="tcon_ImabBiopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BispecificAgreementMember" xlink:label="tcon_BispecificAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FirstPhaseTwoClinicalTrialMember" xlink:label="tcon_FirstPhaseTwoClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RoyaltyPercentageOfNetSales" xlink:label="tcon_RoyaltyPercentageOfNetSales"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InhibrxMember" xlink:label="tcon_InhibrxMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" xlink:label="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BeforeINDMember" xlink:label="tcon_BeforeINDMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" xlink:label="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TjFourThreeZeroNineAgreementMember" xlink:label="tcon_TjFourThreeZeroNineAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterINDBeforePhaseOneAMember" xlink:label="tcon_AfterINDBeforePhaseOneAMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ConsiderationGivenInExchangeForAssetsAcquired" xlink:label="tcon_ConsiderationGivenInExchangeForAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InhibrxLicenseAgreementMember" xlink:label="tcon_InhibrxLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterPhaseOneAAndBeforePhaseSecondMember" xlink:label="tcon_AfterPhaseOneAAndBeforePhaseSecondMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ValueGivenToAssetsAcquired" xlink:label="tcon_ValueGivenToAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterPhaseSecondMember" xlink:label="tcon_AfterPhaseSecondMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationAgreementPercentageOfCostBearing" xlink:label="tcon_CollaborationAgreementPercentageOfCostBearing"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="tcon_CollaborativeArrangementMilestonePaymentsPotential"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" xlink:label="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationFee" xlink:label="tcon_TerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationFeePayable" xlink:label="tcon_TerminationFeePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonrefundableUpfrontFee" xlink:label="tcon_NonrefundableUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PotentialPaymentOnPerformanceObligation" xlink:label="tcon_PotentialPaymentOnPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AdditionalPaymentOnPerformanceObligation" xlink:label="tcon_AdditionalPaymentOnPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TransactionPrice" xlink:label="tcon_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TrainingPeriodDuration" xlink:label="tcon_TrainingPeriodDuration"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LicenseAgreementTerm" xlink:label="tcon_LicenseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" xlink:label="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationSuccessFees" xlink:label="tcon_ArbitrationSuccessFees"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LossContingencyPaymentWriteOffAmount" xlink:label="tcon_LossContingencyPaymentWriteOffAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonRoyaltyConsiderationAmount" xlink:label="tcon_NonRoyaltyConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BusinessCollaborationAdditionalPaymentAmount" xlink:label="tcon_BusinessCollaborationAdditionalPaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" xlink:label="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OneTimeUpfrontPayment" xlink:label="tcon_OneTimeUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" xlink:label="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SalesMilestones" xlink:label="tcon_SalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfBiologicalTargets" xlink:label="tcon_NumberOfBiologicalTargets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_EnvafolimabCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_FirstPhaseClinicalTrialMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcon_CollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryAxis" xlink:to="tcon_MilestonePaymentsCategoryDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_CollaborationsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_CommercialSale" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_ImabBiopharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_BispecificAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_FirstPhaseTwoClinicalTrialMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_RoyaltyPercentageOfNetSales" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_InhibrxMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_BeforeINDMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_TjFourThreeZeroNineAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_AfterINDBeforePhaseOneAMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_ConsiderationGivenInExchangeForAssetsAcquired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_InhibrxLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_AfterPhaseOneAAndBeforePhaseSecondMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_ValueGivenToAssetsAcquired" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="tcon_MilestonePaymentsCategoryAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_AfterPhaseSecondMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_CollaborationAgreementPercentageOfCostBearing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_CollaborativeArrangementMilestonePaymentsPotential" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TerminationFee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TerminationFeePayable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_NonrefundableUpfrontFee" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_PotentialPaymentOnPerformanceObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_AdditionalPaymentOnPerformanceObligation" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TransactionPrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TrainingPeriodDuration" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_LicenseAgreementTerm" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_ArbitrationSuccessFees" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_LossContingencyPaymentWriteOffAmount" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_NonRoyaltyConsiderationAmount" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_BusinessCollaborationAdditionalPaymentAmount" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_OneTimeUpfrontPayment" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_SalesMilestones" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_NumberOfBiologicalTargets" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonCancelableOperatingLeaseExpirationTerm" xlink:label="tcon_NonCancelableOperatingLeaseExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonCancelableOperatingLeaseTermToBeExtended" xlink:label="tcon_NonCancelableOperatingLeaseTermToBeExtended"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tcon_NonCancelableOperatingLeaseExpirationTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tcon_NonCancelableOperatingLeaseTermToBeExtended" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashPaidWithinOperatingCashFlows" xlink:label="tcon_CashPaidWithinOperatingCashFlows"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tcon_CashPaidWithinOperatingCashFlows" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ReportedAsAbstract" xlink:label="tcon_ReportedAsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_ReportedAsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DeferredTaxAssetsRightOfUseLiability" xlink:label="tcon_DeferredTaxAssetsRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="tcon_DeferredTaxAssetsRightOfUseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" xlink:label="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ResearchAndDevelopmentTaxCreditMember" xlink:label="tcon_ResearchAndDevelopmentTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrphanDrugTaxCreditMember" xlink:label="tcon_OrphanDrugTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" xlink:label="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OperatingLossCarryforwardsExpirationBeginYear" xlink:label="tcon_OperatingLossCarryforwardsExpirationBeginYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TaxCreditCarryforwardExpirationBeginYear" xlink:label="tcon_TaxCreditCarryforwardExpirationBeginYear"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentOfOwnership" xlink:label="tcon_PercentOfOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tcon_ResearchAndDevelopmentTaxCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tcon_OrphanDrugTaxCreditMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_OperatingLossCarryforwardsExpirationBeginYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_TaxCreditCarryforwardExpirationBeginYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_PercentOfOwnership" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" xlink:label="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" xlink:to="us-gaap_DefinedContributionPlanPlanNameExtensibleList" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwoThousandTwentyThreePurchaseAgreementMember" xlink:label="tcon_TwoThousandTwentyThreePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkCapitalFundLLCMember" xlink:label="tcon_LincolnParkCapitalFundLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_TwoThousandTwentyThreePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcon_LincolnParkCapitalFundLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" xlink:label="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" xlink:label="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CharlesPTheuerMDPhDMember" xlink:label="tcon_CharlesPTheuerMDPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CharlesPTheuerMDPhDOneMember" xlink:label="tcon_CharlesPTheuerMDPhDOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ScottBBrownCpaMSMember" xlink:label="tcon_ScottBBrownCpaMSMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BonneAdamsMBAMember" xlink:label="tcon_BonneAdamsMBAMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BonneAdamsMBAOneMember" xlink:label="tcon_BonneAdamsMBAOneMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_CharlesPTheuerMDPhDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_CharlesPTheuerMDPhDOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_ScottBBrownCpaMSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_BonneAdamsMBAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tcon_BonneAdamsMBAOneMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SignificantAccountingPoliciesLineItems" xlink:label="tcon_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SignificantAccountingPoliciesTable" xlink:label="tcon_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CapitalOnDemandSalesAgreementMember" xlink:label="tcon_CapitalOnDemandSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_JonesTradingInstitutionalServicesLLCMember" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkCapitalFundLlcMember" xlink:label="tcon_LincolnParkCapitalFundLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBeSold" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RemainingAmountAvailableUnderTheSalesAgreement" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="tcon_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_CapitalOnDemandSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_JonesTradingInstitutionalServicesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_LincolnParkCapitalFundLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcon_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="tcon_MaximumAggregateValueOfStockToBeSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="tcon_RemainingAmountAvailableUnderTheSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockOptionsMember" xlink:label="tcon_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcon_CommonStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivateEquityFundsDomesticMember" xlink:label="us-gaap_PrivateEquityFundsDomesticMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RestrictedCashFairValueDisclosure" xlink:label="tcon_RestrictedCashFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="us-gaap_OtherAssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" xlink:label="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_PrivateEquityFundsDomesticMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tcon_RestrictedCashFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_OtherAssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ComputerAndOfficeEquipmentMember" xlink:label="tcon_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PublicUtilitiesInventoryTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="tcon_ComputerAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AccruedLongTermDebtTerminalInterestCurrent" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PublicUtilitiesInventoryTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="tcon_AccruedLongTermDebtTerminalInterestCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_DebtCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanMember" xlink:label="tcon_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LoansAndSecurityAgreementMember" xlink:label="tcon_LoansAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumCapitalContribution" xlink:label="tcon_MaximumCapitalContribution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PlusRateMember" xlink:label="tcon_PlusRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OnOrPriorToFirstAnniversaryDateMember" xlink:label="tcon_OnOrPriorToFirstAnniversaryDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanAMember" xlink:label="tcon_TermLoanAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LoanAndSecurityAgreementMember" xlink:label="tcon_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InitialCapitalContributionFromInvestors" xlink:label="tcon_InitialCapitalContributionFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpMember" xlink:label="tcon_RunwayGrowthFinanceCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" xlink:label="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanBMember" xlink:label="tcon_TermLoanBMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsMember" xlink:label="tcon_WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfInitialCapitalContributionFromInvestors" xlink:label="tcon_PercentageOfInitialCapitalContributionFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SiliconValleyBankMember" xlink:label="tcon_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" xlink:label="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TermLoanCMember" xlink:label="tcon_TermLoanCMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" xlink:label="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfClosingFeeAmount" xlink:label="tcon_PercentageOfClosingFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RunwayGrowthFinanceCorpLoanAgreementMember" xlink:label="tcon_RunwayGrowthFinanceCorpLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationFinancingPayable" xlink:label="tcon_ArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationAwardNonCashInterestExpense" xlink:label="tcon_ArbitrationAwardNonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationAwardInterestExpense" xlink:label="tcon_ArbitrationAwardInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfTranche" xlink:label="tcon_NumberOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" xlink:label="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfFinalPaymentFee" xlink:label="tcon_PercentageOfFinalPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InterestAndFinalPayment" xlink:label="tcon_InterestAndFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FinalPaymentOnPayoff" xlink:label="tcon_FinalPaymentOnPayoff"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_LoansAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_MaximumCapitalContribution" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="tcon_PlusRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcon_OnOrPriorToFirstAnniversaryDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_InitialCapitalContributionFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_RunwayGrowthFinanceCorpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_WarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_PercentageOfInitialCapitalContributionFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_TermLoanCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_PercentageOfClosingFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_RunwayGrowthFinanceCorpLoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_ArbitrationFinancingPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_ArbitrationAwardNonCashInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_ArbitrationAwardInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_NumberOfTranche" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_PercentageOfFinalPaymentFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_InterestAndFinalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcon_FinalPaymentOnPayoff" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SiliconValleyBankMember" xlink:label="tcon_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborativeArrangementsMilestonePaymentsPotential" xlink:label="tcon_CollaborativeArrangementsMilestonePaymentsPotential"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tcon_CollaborativeArrangementsMilestonePaymentsPotential" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBePurchased" xlink:label="tcon_MaximumAggregateValueOfStockToBePurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityPlanMember" xlink:label="tcon_EquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkPurchaseAgreementMember" xlink:label="tcon_LincolnParkPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyTwoPreFundedWarrantsMember" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_JonesTradingInstitutionalServicesLLCMember" xlink:label="tcon_JonesTradingInstitutionalServicesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" xlink:label="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DirectOfferingsMember" xlink:label="tcon_DirectOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwentyTwentyThreePreFundedWarrantsMember" xlink:label="tcon_TwentyTwentyThreePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" xlink:label="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CapitalOnDemandSalesAgreementMember" xlink:label="tcon_CapitalOnDemandSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NetProceedsReceivedFromIssuanceDirectOffering" xlink:label="tcon_NetProceedsReceivedFromIssuanceDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" xlink:label="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfAmendedPreFundedWarrants" xlink:label="tcon_NumberOfAmendedPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" xlink:label="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumAggregateValueOfStockToBeSold" xlink:label="tcon_MaximumAggregateValueOfStockToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RemainingAmountAvailableUnderTheSalesAgreement" xlink:label="tcon_RemainingAmountAvailableUnderTheSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" xlink:label="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ClassOfWarrantsOrRightExercised" xlink:label="tcon_ClassOfWarrantsOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" xlink:label="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" xlink:label="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_MaximumAggregateValueOfStockToBePurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcon_EquityPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_LincolnParkPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_TwentyTwentyTwoPreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_JonesTradingInstitutionalServicesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_DirectOfferingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_TwentyTwentyThreePreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcon_CapitalOnDemandSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_NetProceedsReceivedFromIssuanceDirectOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_NumberOfAmendedPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_MaximumAggregateValueOfStockToBeSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_RemainingAmountAvailableUnderTheSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_ClassOfWarrantsOrRightExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" xlink:label="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" xlink:label="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" xlink:label="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityIncentive2015PlanMember" xlink:label="tcon_EquityIncentive2015PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EmployeeStockPurchasePlanMember" xlink:label="tcon_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AdditionalCommonSharesToBeUsedForSpecificAward" xlink:label="tcon_AdditionalCommonSharesToBeUsedForSpecificAward"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" xlink:label="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcon_EquityIncentive2015PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcon_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="tcon_AdditionalCommonSharesToBeUsedForSpecificAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="us-gaap_ConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityIncentive2015PlanMember" xlink:label="tcon_EquityIncentive2015PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EmployeeStockPurchasePlanMember" xlink:label="tcon_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcon_EquityIncentive2015PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcon_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EnvafolimabCollaborationAgreementMember" xlink:label="tcon_EnvafolimabCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryDomain" xlink:label="tcon_MilestonePaymentsCategoryDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FirstPhaseClinicalTrialMember" xlink:label="tcon_FirstPhaseClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationAgreementMember" xlink:label="tcon_CollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryAxis" xlink:label="tcon_MilestonePaymentsCategoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MilestonePaymentsCategoryDomain" xlink:label="tcon_MilestonePaymentsCategoryDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CommercialSale" xlink:label="tcon_CommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ImabBiopharmaMember" xlink:label="tcon_ImabBiopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BispecificAgreementMember" xlink:label="tcon_BispecificAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_FirstPhaseTwoClinicalTrialMember" xlink:label="tcon_FirstPhaseTwoClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RoyaltyPercentageOfNetSales" xlink:label="tcon_RoyaltyPercentageOfNetSales"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InhibrxMember" xlink:label="tcon_InhibrxMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" xlink:label="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BeforeINDMember" xlink:label="tcon_BeforeINDMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" xlink:label="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TjFourThreeZeroNineAgreementMember" xlink:label="tcon_TjFourThreeZeroNineAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterINDBeforePhaseOneAMember" xlink:label="tcon_AfterINDBeforePhaseOneAMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ConsiderationGivenInExchangeForAssetsAcquired" xlink:label="tcon_ConsiderationGivenInExchangeForAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InhibrxLicenseAgreementMember" xlink:label="tcon_InhibrxLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterPhaseOneAAndBeforePhaseSecondMember" xlink:label="tcon_AfterPhaseOneAAndBeforePhaseSecondMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ValueGivenToAssetsAcquired" xlink:label="tcon_ValueGivenToAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AfterPhaseSecondMember" xlink:label="tcon_AfterPhaseSecondMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborationAgreementPercentageOfCostBearing" xlink:label="tcon_CollaborationAgreementPercentageOfCostBearing"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="tcon_CollaborativeArrangementMilestonePaymentsPotential"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" xlink:label="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationFee" xlink:label="tcon_TerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TerminationFeePayable" xlink:label="tcon_TerminationFeePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonrefundableUpfrontFee" xlink:label="tcon_NonrefundableUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PotentialPaymentOnPerformanceObligation" xlink:label="tcon_PotentialPaymentOnPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AdditionalPaymentOnPerformanceObligation" xlink:label="tcon_AdditionalPaymentOnPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TransactionPrice" xlink:label="tcon_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TrainingPeriodDuration" xlink:label="tcon_TrainingPeriodDuration"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LicenseAgreementTerm" xlink:label="tcon_LicenseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" xlink:label="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationSuccessFees" xlink:label="tcon_ArbitrationSuccessFees"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LossContingencyPaymentWriteOffAmount" xlink:label="tcon_LossContingencyPaymentWriteOffAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NonRoyaltyConsiderationAmount" xlink:label="tcon_NonRoyaltyConsiderationAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_BusinessCollaborationAdditionalPaymentAmount" xlink:label="tcon_BusinessCollaborationAdditionalPaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" xlink:label="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OneTimeUpfrontPayment" xlink:label="tcon_OneTimeUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" xlink:label="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_SalesMilestones" xlink:label="tcon_SalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_NumberOfBiologicalTargets" xlink:label="tcon_NumberOfBiologicalTargets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_EnvafolimabCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_FirstPhaseClinicalTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcon_CollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcon_MilestonePaymentsCategoryAxis" xlink:to="tcon_MilestonePaymentsCategoryDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcon_MilestonePaymentsCategoryAxis" xlink:to="tcon_MilestonePaymentsCategoryDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_CommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_ImabBiopharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_BispecificAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_FirstPhaseTwoClinicalTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_RoyaltyPercentageOfNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tcon_InhibrxMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_BeforeINDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_TjFourThreeZeroNineAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_AfterINDBeforePhaseOneAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_ConsiderationGivenInExchangeForAssetsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_InhibrxLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_AfterPhaseOneAAndBeforePhaseSecondMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_ValueGivenToAssetsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="tcon_MilestonePaymentsCategoryAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcon_MilestonePaymentsCategoryDomain" xlink:to="tcon_AfterPhaseSecondMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_CollaborationAgreementPercentageOfCostBearing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_CollaborativeArrangementMilestonePaymentsPotential" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TerminationFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TerminationFeePayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_NonrefundableUpfrontFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_PotentialPaymentOnPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_AdditionalPaymentOnPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_TrainingPeriodDuration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_LicenseAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_ArbitrationSuccessFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_LossContingencyPaymentWriteOffAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_NonRoyaltyConsiderationAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_BusinessCollaborationAdditionalPaymentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_OneTimeUpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_SalesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tcon_NumberOfBiologicalTargets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ReportedAsAbstract" xlink:label="tcon_ReportedAsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcon_ReportedAsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" xlink:label="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ResearchAndDevelopmentTaxCreditMember" xlink:label="tcon_ResearchAndDevelopmentTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OrphanDrugTaxCreditMember" xlink:label="tcon_OrphanDrugTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" xlink:label="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_OperatingLossCarryforwardsExpirationBeginYear" xlink:label="tcon_OperatingLossCarryforwardsExpirationBeginYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TaxCreditCarryforwardExpirationBeginYear" xlink:label="tcon_TaxCreditCarryforwardExpirationBeginYear"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_PercentOfOwnership" xlink:label="tcon_PercentOfOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tcon_ResearchAndDevelopmentTaxCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tcon_OrphanDrugTaxCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_OperatingLossCarryforwardsExpirationBeginYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_TaxCreditCarryforwardExpirationBeginYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="tcon_PercentOfOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_TwoThousandTwentyThreePurchaseAgreementMember" xlink:label="tcon_TwoThousandTwentyThreePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LincolnParkCapitalFundLLCMember" xlink:label="tcon_LincolnParkCapitalFundLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcon_TwoThousandTwentyThreePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcon_LincolnParkCapitalFundLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameOtherMember" xlink:label="us-gaap_RetirementPlanNameOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="tcon_ArbitrationFinancingPayable" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationFinancingPayable" xlink:label="tcon_ArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcon_ArbitrationSuccessFees" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ArbitrationSuccessFees" xlink:label="tcon_ArbitrationSuccessFees"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="tcon_ProceedsFromMaturityOfShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcon_InterestExpenseNoncash" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcon_EquityOwnershipLicenseRevenue" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcon_ImpairmentOfPrivateCompanyEquityOwnership" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" order="11" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="12" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromMaturityOfShortTermInvestments" xlink:label="tcon_ProceedsFromMaturityOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" xlink:label="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" xlink:label="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_InterestExpenseNoncash" xlink:label="tcon_InterestExpenseNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" xlink:label="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" xlink:label="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_EquityOwnershipLicenseRevenue" xlink:label="tcon_EquityOwnershipLicenseRevenue"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_ImpairmentOfPrivateCompanyEquityOwnership" xlink:label="tcon_ImpairmentOfPrivateCompanyEquityOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" xlink:label="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="tcon_AccruedLongTermDebtTerminalInterestCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_OperatingLeaseLiability" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="5" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_AccruedLongTermDebtTerminalInterestCurrent" xlink:label="tcon_AccruedLongTermDebtTerminalInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="tcon_LongTermDebtCurrentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtCurrentGross" xlink:label="tcon_LongTermDebtCurrentGross"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" xlink:label="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcon_DeferredTaxAssetsRightOfUseLiability" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tcon-20231231.xsd#tcon_DeferredTaxAssetsRightOfUseLiability" xlink:label="tcon_DeferredTaxAssetsRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tcon_TerminationFee" name="TerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ArbitrationSuccessFees" name="ArbitrationSuccessFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_LeaseAssetAmortizationAndLiabilityAccretionNet" name="LeaseAssetAmortizationAndLiabilityAccretionNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_PercentageOfClosingFeeAmount" name="PercentageOfClosingFeeAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" name="CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" name="WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ScheduleOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_IssuancesOfCommonStockNetOfOfferingCostsValue" name="IssuancesOfCommonStockNetOfOfferingCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" name="DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_NumberOfAmendedPreFundedWarrants" name="NumberOfAmendedPreFundedWarrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_TwoThousandEighteenLoanAndSecurityAgreementMember" name="TwoThousandEighteenLoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_NumberOfBiologicalTargets" name="NumberOfBiologicalTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" name="CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod" name="ResearchAndDevelopmentExpenditureAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_LongTermDebtNetOfUnamortizedLongTermAmortization" name="LongTermDebtNetOfUnamortizedLongTermAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_TjFourThreeZeroNineAgreementMember" name="TjFourThreeZeroNineAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" name="MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ImabBiopharmaMember" name="ImabBiopharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" name="PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" name="PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ReportedAsAbstract" name="ReportedAsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" name="CommonStockPurchasePriceOfOnePointThreeEightPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CollaborationsDisclosureAbstract" name="CollaborationsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" name="LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_LincolnParkCapitalFundLlcMember" name="LincolnParkCapitalFundLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_EquityIncentive2015PlanMember" name="EquityIncentive2015PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_MaximumAggregateValueOfStockToBePurchased" name="MaximumAggregateValueOfStockToBePurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" name="IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_PatentCostsPolicyPolicyTextBlock" name="PatentCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_InitialCapitalContributionFromInvestors" name="InitialCapitalContributionFromInvestors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_PercentageOfFinalPaymentFee" name="PercentageOfFinalPaymentFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_NonCancelableOperatingLeaseTermToBeExtended" name="NonCancelableOperatingLeaseTermToBeExtended" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_RoyaltyPercentageOfNetSales" name="RoyaltyPercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_AfterPhaseSecondMember" name="AfterPhaseSecondMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_LincolnParkPurchaseAgreementMember" name="LincolnParkPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" name="MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_BeforeINDMember" name="BeforeINDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ArbitrationAwardNonCashInterestExpense" name="ArbitrationAwardNonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_CommercialSale" name="CommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ArbitrationFinancingPayable" name="ArbitrationFinancingPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_TwentyTwentyThreePreFundedWarrantsMember" name="TwentyTwentyThreePreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_PercentageOfInitialCapitalContributionFromInvestors" name="PercentageOfInitialCapitalContributionFromInvestors" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" name="IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" name="IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_RunwayGrowthFinanceCorpLoanAgreementMember" name="RunwayGrowthFinanceCorpLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_FirstPhaseTwoClinicalTrialMember" name="FirstPhaseTwoClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_NonCancelableOperatingLeaseExpirationTerm" name="NonCancelableOperatingLeaseExpirationTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_CharlesPTheuerMDPhDOneMember" name="CharlesPTheuerMDPhDOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_MilestonePaymentsCategoryAxis" name="MilestonePaymentsCategoryAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_AdditionalPaymentOnPerformanceObligation" name="AdditionalPaymentOnPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_MaximumAggregateValueOfStockToBeSold" name="MaximumAggregateValueOfStockToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_RunwayGrowthFinanceCorpMember" name="RunwayGrowthFinanceCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" name="WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" name="WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" name="CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" name="TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_InterestAndFinalPayment" name="InterestAndFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_TaxCreditCarryforwardExpirationBeginYear" name="TaxCreditCarryforwardExpirationBeginYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ProceedsFromMaturityOfShortTermInvestments" name="ProceedsFromMaturityOfShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_OnOrPriorToFirstAnniversaryDateMember" name="OnOrPriorToFirstAnniversaryDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_FirstPhaseClinicalTrialMember" name="FirstPhaseClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_RunwayGrowthFinanceCorpLoanAgreement1Member" name="RunwayGrowthFinanceCorpLoanAgreement1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_LossContingencyPaymentWriteOffAmount" name="LossContingencyPaymentWriteOffAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ProceedsFromLongTermDebtAndArbitrationFinancing" name="ProceedsFromLongTermDebtAndArbitrationFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" name="CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_EnvafolimabCollaborationAgreementMember" name="EnvafolimabCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock" name="ClinicalTrialExpenseAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_OrphanDrugTaxCreditMember" name="OrphanDrugTaxCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_EquityOwnershipLicenseRevenue" name="EquityOwnershipLicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_CollaborationAgreementMember" name="CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" name="AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember" name="WarrantsExpirationJuneFourTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_BalanceSheetRelatedDisclosuresTextBlock" name="BalanceSheetRelatedDisclosuresTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_AfterINDBeforePhaseOneAMember" name="AfterINDBeforePhaseOneAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_TerminationOfAgreementUponCompletionOfClinicalTrial" name="TerminationOfAgreementUponCompletionOfClinicalTrial" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_CollaborationAgreementPercentageOfCostBearing" name="CollaborationAgreementPercentageOfCostBearing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ConsiderationGivenInExchangeForAssetsAcquired" name="ConsiderationGivenInExchangeForAssetsAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_IssuancesOfCommonStockNetOfOfferingCostsShares" name="IssuancesOfCommonStockNetOfOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ValueGivenToAssetsAcquired" name="ValueGivenToAssetsAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_TrainingPeriodDuration" name="TrainingPeriodDuration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_OrganizationAndAccountingPoliciesAbstract" name="OrganizationAndAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_AfterPhaseOneAAndBeforePhaseSecondMember" name="AfterPhaseOneAAndBeforePhaseSecondMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_BispecificAgreementMember" name="BispecificAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" name="CommonStockPurchasePriceOfOnePointThreeOnePerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_TermLoanAMember" name="TermLoanAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_BonneAdamsMBAMember" name="BonneAdamsMBAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CashPaidWithinOperatingCashFlows" name="CashPaidWithinOperatingCashFlows" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_FinalPaymentOnPayoff" name="FinalPaymentOnPayoff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_FairValueTransfersBetweenLevelsAmount" name="FairValueTransfersBetweenLevelsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_CapitalOnDemandSalesAgreementMember" name="CapitalOnDemandSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_MilestonePaymentsCategoryDomain" name="MilestonePaymentsCategoryDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_LongTermDebtCurrentGross" name="LongTermDebtCurrentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_RemainingAmountAvailableUnderTheSalesAgreement" name="RemainingAmountAvailableUnderTheSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_InterestExpenseNoncash" name="InterestExpenseNoncash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" name="PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_InhibrxLicenseAgreementMember" name="InhibrxLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_NonRoyaltyConsiderationAmount" name="NonRoyaltyConsiderationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_MaximumCapitalContribution" name="MaximumCapitalContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_TerminationFeePayable" name="TerminationFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" name="WarrantsExpirationMayThreeTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_OperatingLossCarryforwardsExpirationBeginYear" name="OperatingLossCarryforwardsExpirationBeginYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_StrategicCollaborationAndClinicalTrialAgreementsMember" name="StrategicCollaborationAndClinicalTrialAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_PlusRateMember" name="PlusRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_NetProceedsReceivedFromIssuanceDirectOffering" name="NetProceedsReceivedFromIssuanceDirectOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_CommonStockOptionsMember" name="CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_BusinessCollaborationAdditionalPaymentAmount" name="BusinessCollaborationAdditionalPaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ImpairmentOfPrivateCompanyEquityOwnership" name="ImpairmentOfPrivateCompanyEquityOwnership" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember" name="AfterSecondAnniversaryDateButPriorToMaturityDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_BonneAdamsMBAOneMember" name="BonneAdamsMBAOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_JonesTradingInstitutionalServicesLLCMember" name="JonesTradingInstitutionalServicesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_OneTimeUpfrontPayment" name="OneTimeUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ScottBBrownCpaMSMember" name="ScottBBrownCpaMSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_AccruedLongTermDebtTerminalInterestCurrent" name="AccruedLongTermDebtTerminalInterestCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_DeferredTaxAssetsRightOfUseLiability" name="DeferredTaxAssetsRightOfUseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_LicenseAgreementTerm" name="LicenseAgreementTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment" name="MaximumNumberOfProprietaryAntibodiesUnderDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_PercentOfOwnership" name="PercentOfOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcon_EquityPlanMember" name="EquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_InhibrxMember" name="InhibrxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_TermLoanCMember" name="TermLoanCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_RestrictedCashFairValueDisclosure" name="RestrictedCashFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_WarrantsMember" name="WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CollaborativeArrangementsMilestonePaymentsPotential" name="CollaborativeArrangementsMilestonePaymentsPotential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_TwentyTwentyTwoPreFundedWarrantsMember" name="TwentyTwentyTwoPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_DirectOfferingsMember" name="DirectOfferingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_LoansAndSecurityAgreementMember" name="LoansAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_TransactionPrice" name="TransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable" name="RepaymentOfLongTermDebtAndArbitrationFinancingPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_SalesMilestones" name="SalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" name="IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_NumberOfTranche" name="NumberOfTranche" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_TermLoanBMember" name="TermLoanBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" name="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_NonrefundableUpfrontFee" name="NonrefundableUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ResearchAndDevelopmentTaxCreditMember" name="ResearchAndDevelopmentTaxCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_CollaborativeArrangementMilestonePaymentsPotential" name="CollaborativeArrangementMilestonePaymentsPotential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" name="ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_AdditionalCommonSharesToBeUsedForSpecificAward" name="AdditionalCommonSharesToBeUsedForSpecificAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" name="IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_CharlesPTheuerMDPhDMember" name="CharlesPTheuerMDPhDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_ArbitrationAwardInterestExpense" name="ArbitrationAwardInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" name="IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_TwoThousandTwentyThreePurchaseAgreementMember" name="TwoThousandTwentyThreePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcon_ClassOfWarrantsOrRightExercised" name="ClassOfWarrantsOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcon_PotentialPaymentOnPerformanceObligation" name="PotentialPaymentOnPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656803269296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TRACON Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001394319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text"> No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,504,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">34-2037594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4350 La Jolla Village Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-0780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656797248864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,564,000<span></span>
</td>
<td class="nump">$ 17,433,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">526,000<span></span>
</td>
<td class="nump">795,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,090,000<span></span>
</td>
<td class="nump">18,228,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">905,000<span></span>
</td>
<td class="nump">1,123,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,105,000<span></span>
</td>
<td class="nump">19,469,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,544,000<span></span>
</td>
<td class="nump">3,923,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,211,000<span></span>
</td>
<td class="nump">7,184,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">427,000<span></span>
</td>
<td class="nump">1,457,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,807,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,182,000<span></span>
</td>
<td class="nump">22,371,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">732,000<span></span>
</td>
<td class="nump">969,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ArbitrationFinancingPayable', window );">Arbitration financing payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,280,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, authorized shares - 10,000,000 at December 31, 2023 andDecember 31,2022; issued and outstanding shares - none</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares - 60,000,000 and 40,000,000 at December 31, 2023 and December 31, 2022, respectively; issued and outstanding shares - 44,269,976 and 23,125,250 at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">239,646,000<span></span>
</td>
<td class="nump">229,737,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(240,499,000)<span></span>
</td>
<td class="num">(236,911,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(809,000)<span></span>
</td>
<td class="num">(7,151,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 10,105,000<span></span>
</td>
<td class="nump">$ 19,469,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ArbitrationFinancingPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Arbitration financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ArbitrationFinancingPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656803244096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">44,269,976<span></span>
</td>
<td class="nump">23,125,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">44,269,976<span></span>
</td>
<td class="nump">23,125,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656797282960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible Enumeration]</a></td>
<td class="text">us-gaap:CollaborativeArrangementMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:CollaborativeArrangementMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,277<span></span>
</td>
<td class="nump">$ 13,888<span></span>
</td>
<td class="nump">$ 11,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,666<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
<td class="nump">17,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ArbitrationSuccessFees', window );">Arbitration success fees</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,318<span></span>
</td>
<td class="nump">27,894<span></span>
</td>
<td class="nump">28,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,273)<span></span>
</td>
<td class="num">(27,894)<span></span>
</td>
<td class="num">(28,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(7,304)<span></span>
</td>
<td class="num">(994)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">12,989<span></span>
</td>
<td class="num">(247)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="num">(1,241)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,588)<span></span>
</td>
<td class="num">$ (29,135)<span></span>
</td>
<td class="num">$ (28,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">32,745,708<span></span>
</td>
<td class="nump">20,919,118<span></span>
</td>
<td class="nump">17,252,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding diluted</a></td>
<td class="nump">32,745,708<span></span>
</td>
<td class="nump">20,919,118<span></span>
</td>
<td class="nump">17,252,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ArbitrationSuccessFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Arbitration success fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ArbitrationSuccessFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796233248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 25,072<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 204,166<span></span>
</td>
<td class="num">$ (179,109)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,478,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockNetOfOfferingCostsValue', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">13,385<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">13,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockNetOfOfferingCostsShares', window );">Issuances of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,926,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,667)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">11,714<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">219,471<span></span>
</td>
<td class="num">(207,776)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,445,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue', window );">Issuance of common stock and warrants, net of offering costs</a></td>
<td class="nump">7,874<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">7,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares', window );">Issuance of common stock and warrants, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,232,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue', window );">Issuance of common stock upon cashless exercise of pre-funded warrants</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares', window );">Issuance of common stock upon cashless exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants in connection with debt financing</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,135)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="num">(7,151)<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">229,737<span></span>
</td>
<td class="num">(236,911)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,125,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue', window );">Issuance of common stock and warrants, net of offering costs</a></td>
<td class="nump">7,916<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">7,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares', window );">Issuance of common stock and warrants, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,231,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue', window );">Issuance of common stock upon cashless exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares', window );">Issuance of common stock upon cashless exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,867,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,588)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">$ (809)<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 239,646<span></span>
</td>
<td class="num">$ (240,499)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,269,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock and warrants, net of offering costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock and warrants, net of offering costs value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock net of offering costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockNetOfOfferingCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock net of offering costs value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockNetOfOfferingCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock upon cashless exercise of pre-funded warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock upon cashless exercise of pre-funded warrants value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656804822608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,588)<span></span>
</td>
<td class="num">$ (29,135)<span></span>
</td>
<td class="num">$ (28,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_InterestExpenseNoncash', window );">Noncash interest</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount</a></td>
<td class="nump">7,325<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium/discount on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LeaseAssetAmortizationAndLiabilityAccretionNet', window );">Lease asset amortization and liability accretion, net</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_EquityOwnershipLicenseRevenue', window );">Equity ownership license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ImpairmentOfPrivateCompanyEquityOwnership', window );">Impairment of private company equity ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and related expenses</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="num">(26,239)<span></span>
</td>
<td class="num">(22,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ProceedsFromMaturityOfShortTermInvestments', window );">Proceeds from the maturity of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">3,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ProceedsFromLongTermDebtAndArbitrationFinancing', window );">Proceeds from long-term debt and arbitration financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable', window );">Repayment of long-term debt and arbitration financing payable</a></td>
<td class="num">(20,500)<span></span>
</td>
<td class="num">(1,680)<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts', window );">Proceeds from sale of common stock and warrants, net of offering costs</a></td>
<td class="nump">7,916<span></span>
</td>
<td class="nump">7,879<span></span>
</td>
<td class="nump">13,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under equity plans</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(12,539)<span></span>
</td>
<td class="nump">19,684<span></span>
</td>
<td class="nump">10,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(8,863)<span></span>
</td>
<td class="num">(6,572)<span></span>
</td>
<td class="num">(8,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">24,072<span></span>
</td>
<td class="nump">32,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">8,637<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">24,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 7,491<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt', window );">Issuance of common stock warrants in connection with long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_EquityOwnershipLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Ownership License Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_EquityOwnershipLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ImpairmentOfPrivateCompanyEquityOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of private company equity ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ImpairmentOfPrivateCompanyEquityOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. This does not include accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_InterestExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash interest expense included in interest expense, excluding the allocation of debt discount and premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_InterestExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock warrants issued in connection with long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_LeaseAssetAmortizationAndLiabilityAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease asset amortization and liability accretion, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_LeaseAssetAmortizationAndLiabilityAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ProceedsFromLongTermDebtAndArbitrationFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from long-term debt and arbitration financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ProceedsFromLongTermDebtAndArbitrationFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ProceedsFromMaturityOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ProceedsFromMaturityOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of long-term debt and arbitration financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656802039600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,588)<span></span>
</td>
<td class="num">$ (29,135)<span></span>
</td>
<td class="num">$ (28,667)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656801021664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_OrganizationAndAccountingPoliciesAbstract', window );"><strong>Organization And Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization and Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Business</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc. (TRACON or the Company) was incorporated in the state of Delaware on October 28, 2004. TRACON is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and utilizes its cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, TRACON Pharma Limited and TRACON Pharma International Limited, which were formed in September 2015 and January 2019, respectively, and are currently inactive. All significant intercompany accounts and transactions have been eliminated.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has devoted substantially all its efforts to product development, raising capital, and building infrastructure and has not realized revenues from its planned principal operations. The Company has incurred operating losses since inception. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">240.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its product candidates and works to develop additional product candidates through research and development programs. At December 31, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is classified as restricted cash as it is pledged as collateral for the Company&#8217;s obligations under its corporate headquarters facility lease. The Company&#8217;s ability to execute its operating plan through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financings, or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company&#8217;s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, management believes that there is substantial doubt about its ability to continue as a going concern for a period of 12 months following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company plans to continue to fund its losses from operations through its existing cash and cash equivalents, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. In addition, the Company may fund its losses from operations through the Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sales Agreement (the Sales Agreement) the Company entered into with JonesTrading in December 2020, as amended in March 2022, pursuant to which the Company may sell, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the common stock purchase agreement (the LPC Purchase Agreement) the Company entered into with Lincoln Park Capital Fund, LLC (Lincoln Park) in May 2023, pursuant to which the Company may sell, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global economic and business activities continue to face widespread macroeconomic uncertainties, including labor shortages, inflation and monetary supply shifts, recession risks and potential disruptions from the Russia-Ukraine conflict. The Company continues to actively monitor the impact of these macroeconomic factors on its financial condition, liquidity, operations, and workforce. The extent of the impact of these factors on the Company&#8217;s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company&#8217;s business</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company&#8217;s consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these investments. Cash and cash equivalents include cash in readily available checking and money market funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of money market funds held by the Company&#8217;s financial institution as collateral for the Company&#8217;s obligations under its facility lease for the Company&#8217;s corporate headquarters in San Diego, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets, which is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or estimated useful life of the related assets. Repairs and maintenance costs are charged to expense as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are recorded as other assets, accounts payable and accrued expenses, and other long-term liabilities within the consolidated balance sheet. The Company currently does not have any finance leases.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#8217;s leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company&#8217;s revenue has been derived from license and collaboration agreements. The terms of these arrangements included payments to the Company for the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. In accordance with Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 606), the Company performs the following five steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.  The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. Once a contract is determined to be within the scope of ASC 606, at contract inception the Company assesses the goods or services promised within the contract to determine those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of intellectual property:  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method.  Performance milestone payments represent a form of variable consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Achievement of milestones that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis and the Company recognizes revenue as or when the performance obligations under the contract are satisfied.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing Supply Services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its out-licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company receives payments from its collaborators based on billing schedules established in each contract. Up-front and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its collaboration arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Expense Accruals</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the Company&#8217;s consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s objective is to reflect the appropriate trial expenses in its consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with the clinical sites and applicable personnel and outside service providers as to the progress or state of consummation of trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s clinical trial accruals are dependent upon accurate reporting by clinical sites and other third-party vendors. Although the Company does not expect its estimates to differ materially from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were no material adjustments to the Company&#8217;s prior period estimates of accrued expenses for clinical trials.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs, including license fees, are expensed as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the grant date fair value of employee stock option grants, employee restricted stock unit grants (RSUs), and employee stock purchase plan (ESPP) rights recognized as expense over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and ESPP rights using the Black-Scholes option pricing model. The fair value of RSUs is based on the closing sales price for such stock on the date of grant. Equity award forfeitures are recorded as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than&#8209;not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and comprehensive loss were the same for all periods presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted average number of shares of common stock outstanding that are subject to repurchase. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.18%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.6%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,766,246</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP shares</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,444</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,387</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,664,889</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,015,943</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_OrganizationAndAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Accounting Policies Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_OrganizationAndAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796173760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Financial Instruments and Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, which are classified as equity securities, and restricted cash consisted of the following (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.367%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.981%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.0009999999999994%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized (Loss)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized (Loss)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,083</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash and cash equivalents, prepaid and other assets, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1:	Observable inputs such as quoted prices in active markets.</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2:	Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between levels have occurred during the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the Company&#8217;s assets and liabilities, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.09%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Active Markets</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">for Identical</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800960400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_BalanceSheetRelatedDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Balance Sheet Details</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense related to property and equipment totaled approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts payable and accrued expenses</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal and accounting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued long-term debt terminal interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_BalanceSheetRelatedDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet related disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_BalanceSheetRelatedDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656805397504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Long-Term Debt</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Arbitration Financing Investment Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the Company entered into a non-recourse financing agreement (the Investment Agreement) with certain investors (collectively, the Investors) pursuant to which the Investors agreed to pay the Company a maximum aggregate amount (Maximum Capital) equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or a lesser amount based on the amount awarded (Arbitration Award), if any, to the Company in connection with its arbitration proceeding (the Arbitration) with I-Mab Biopharma (I-Mab). Of the Maximum Capital, (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (Initial Capital) was paid to the Company shortly after execution, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% was to be paid to the Company within 15 business days of issuance of an Arbitration Award, subject to the Arbitration Award size exceeding a prespecified threshold and satisfaction of other conditions set forth in the Investment Agreement, and (iii) the remainder was to be paid to the Company in tranches over a multi-year period, subject to the issuance of an Arbitration Award and the Arbitration Award size exceeding a prespecified threshold and satisfaction of other conditions set forth in the Investment Agreement. In connection with the execution of the Investment Agreement and funding of the Initial Capital amount, the Company paid a closing fee in the amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. In April 2023, the Company received notification of the Arbitration Award resulting from the Arbitration. As the Arbitration Award did not exceed the prespecified thresholds under the Investment Agreement, the Company will not receive any additional funds under the Investment Agreement such that, as of date of the Arbitration Award, the Maximum Capital is equal to the Initial Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to and contingent on the Company&#8217;s actual recovery of proceeds from an Arbitration Award or any contemporaneously resolved settlements with I-Mab and following the payment of applicable attorney&#8217;s fees (the Proceeds), the Company was required to pay the Investors an amount (Repayment Amount) equal to the sum of (i) all amounts paid by the Investors to or on behalf of the Company pursuant to the Investment Agreement, plus (ii) a low sub-single digit to low single digit multiple calculated on each tranche of Maximum Capital actually paid by the Investors to or on behalf of the Company with the applicable multiple being based on the timing of payment from the Company and whether certain events relating to the Arbitration occurred, plus (iii) a mid-teen percentage annual rate of return on the amounts set forth in clauses (i) and (ii) that begins to accrue if the amounts are not paid by the Company to the Investors within a multi-month period specified in the Investment Agreement. If the amount of Proceeds are less than the Repayment Amount, then the Company was only required to pay to the Investors the Proceeds recovered (other than in circumstances in which the Company accepts a settlement offer that resolves the Arbitration for an amount less than the Repayment Amount without the prior written consent of the Investors), and in the circumstance in which there are no Proceeds then the Company was not required to pay the Investors any Repayment Amounts and the Investors have no right of recourse or right of action against the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the Investors funded the Initial Capital amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which was recorded as arbitration financing payable on the consolidated balance sheets, net of debt discount, including the Initial Capital closing fee, and amortized over the estimated term of the agreement using the effective interest method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company agreed to and collected a settlement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in full satisfaction of the Arbitration Award. The Company determined an effective interest rate and term over which the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related debt discount was amortized based on the known timing of collection of the proceeds from the Arbitration Award resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f interest being recognized during the year ended December 31, 2023. At December 31, 2023, the arbitration financing investment agreement was paid in full and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> future amounts were owed.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Runway Growth Finance Corp. Loan and Security Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company entered into a loan and security agreement (the RGC Loan Agreement) with Runway Growth Finance Corp. (RGC). The RGC Loan Agreement was a long-term debt facility that provided a term loan commitment in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tranches: (i) a Term A loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with the full amount funded in a single disbursement on closing of the RGC Loan Agreement and repaid in January 2023 in connection with the Investment Agreement; (ii) a Term B loan in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to be funded in one or more disbursements at the request of the Company on or prior to June 30, 2024, subject to certain conditions being met; and (iii) a Term C loan in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that may be disbursed in a single disbursement in the lender&#8217;s sole discretion upon the Company&#8217;s request at any time from closing of the RGC Loan Agreement through and including December 31, 2024. In December 2022, the Company and RGC amended the RGC Loan Agreement (the RGC Loan Amendment) under which: (i) the Company repaid all amounts of principal and accrued but unpaid interest in respect of the Term A Loan (as defined in the RGC Loan Agreement) on January 3, 2023 without the obligation for the Company to pay the final payment fee or the prepayment fee described in the RGC Loan Agreement; (ii) on or before March 31, 2023, at the Company&#8217;s request, if the Company has raised at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net cash proceeds from certain equity or debt transactions (including amounts raised in connection with the Investment Agreement) prior to making such request, RGC will loan to the Company an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with the full amount funded in a single disbursement; (iii) the Company will not issue an additional warrant to RGC in connection with the loan, if any, described in clause (ii) above; and (iv) RGC&#8217;s security interest in Specific Collateral was subordinated to the arbitration financing Investors&#8217; security interest in the Specific Collateral. If the loan described in clause (ii) above is not made by March 31, 2023, the RGC Loan Agreement will terminate on that date, and the Company will not be obligated to pay the prepayment fee described in the RGC Loan Agreement but the final payment fee of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the funded term loans as described in the RCG Loan Agreement will become immediately due and payable. All other material terms and conditions of the RGC Loan Agreement remained unchanged and the transaction was accounted for as a debt modification. On April 5, 2023, the Company and RGC amended the RGC Loan Agreement effective March 31, 2023 such that the Company would have until April 15, 2023 to raise at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net cash proceeds from certain equity or debt transactions prior to making a request of RGC to redraw an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the RGC Loan Agreement, which RGC may, in its sole and absolute discretion, allow or deny. On April 20, 2023, the Company and RGC amended the RGC Loan Agreement effective April 15, 2023 to extend the time period described in the foregoing sentence from April 15, 2023 to April 28, 2023. The Company did not redraw the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the RGC Loan Agreement, as amended, by April 28, 2023, resulting in the RGC Loan Agreement terminating and the final payment fee becoming immediately due and payable on that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the funding of the Term A loan, the Company issued RGC warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150,753</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock (the RGC Term A Warrants) at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per underlying share of the Company&#8217;s common stock. The RGC Term A Warrants are fully exercisable in whole or in part at the option of the holder, payable in cash or on a cashless basis according to the formula set forth in the RGC Term A Warrants, and expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2, 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The fair value of the warrant at the grant date was determined utilizing a Black-Scholes pricing model, recorded as a component of the total debt discount and stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets, and was amortized to interest expense using the effective interest method over the term of the debt.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, long-term debt and unamortized debt discount balances associated with the RGC Loan Agreement were as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less debt discount, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the RGC Loan Agreement was paid in full and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> future amounts were owed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Silicon Valley Bank Loan and Security Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2018, the Company entered into a third amendment to its Amended and Restated Loan and Security Agreement with Silicon Valley Bank (the 2018 Amended SVB Loan) under which the Company borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, all of which was immediately used to repay the Company&#8217;s then existing loan with SVB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2018 Amended SVB Loan matured in June 2022 and in accordance with its terms, the Company paid a final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the payoff of the 2018 Amended SVB Loan. In August 2022, the Company terminated the 2018 Amended SVB Loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company&#8217;s loan agreements with SVB:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.459999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800118144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various license agreements pursuant to which the Company acquired licenses to certain intellectual property. The agreements generally required an upfront license fee and, in some cases, reimbursement of patent costs. Additionally, under each agreement, the Company may be required to pay annual maintenance fees, royalties, milestone payments and sublicensing fees. Each license agreement is generally cancelable by the Company, given appropriate prior written notice. At December 31, 2023, potential future milestone payments under these agreements totaled an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656916066528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lincoln Park Common Stock Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company and Lincoln Park entered into the LPC Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Lincoln Park is committed to purchase up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company's shares of common stock from time to time and at the Company&#8217;s sole discretion over the term of the LPC Purchase Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of December 31, 2023. In consideration for entering into the LPC Purchase Agreement, concurrently with the execution of the LPC Purchase Agreement, the Company issued to Lincoln Park </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">599,216</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock as a commitment fee, which was recorded as a component of stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets. Concurrently with entering into the LPC Purchase Agreement, the Company also entered into a Registration Rights Agreement in which the Company agreed to file one or more registration statements as permissible and necessary to register under the Securities Act for resale of the shares of its common stock that may be issued to Lincoln Park under the LPC Purchase Agreement, which occurred in May 2023. In May 2023, the Company also issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,735,207</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the Initial Purchase Shares) of the Company&#8217;s common stock to Lincoln Park pursuant to the LPC Purchase Agreement at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5763</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Initial Purchase Share resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company's special meeting of stockholders held in September 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the potential future sale and issuance of shares of the Company&#8217;s common stock to Lincoln Park in accordance with the pricing terms set forth in the LPC Purchase Agreement that could result in Lincoln Park owning in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of the Company&#8217;s common stock outstanding immediately after giving effect to such sale.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sale of Common Stock and Pre-Funded Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">174,508</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,013,999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock (the 2023 Pre-Funded Warrants) for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in a private placement (the Private Placement) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2023 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise, unless approval by the Company's stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). The 2023 Pre-Funded Warrants were recorded as a component of stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">841,989</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,205,018</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of underlying common stock (the 2022 Pre-Funded Warrants) for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in a registered direct offering (the Offering) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2022 Pre-Funded Warrants may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise, unless approval by the Company's stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). The 2022 Pre-Funded Warrants were recorded as a component of stockholders&#8217; deficit within additional paid-in capital on the consolidated balance sheets. In connection with the Offering, the Company amended two existing pre-funded warrants to purchase shares of the Company&#8217;s common stock held by the same institutional healthcare-focused fund to extend the exercise periods and to permit exercise in excess of a similar </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% limit following approval of the Company&#8217;s stockholders of such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the Company's 2023 Annual Meeting held in April 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the issuance of shares of common stock upon the potential future exercise of certain outstanding warrants held by this accredited institutional healthcare-focused fund, including the 2023 Pre-Funded Warrants and the 2022 Pre-Funded Warrants, that would result in it and its affiliates owning in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of common stock outstanding immediately after giving effect to such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-The-Market Issuance Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, as amended in March 2022, the Company entered into a Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sales Agreement (the Sales Agreement) with JonesTrading, pursuant to which it may sell from time to time, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock through JonesTrading, as sales agent or principal, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of December 31, 2023. Sales of the Company&#8217;s common stock made pursuant to the Sales Agreement with JonesTrading, if any, will be made on the Nasdaq Capital Market under the Company&#8217;s effective registration statement on Form S-3, subject to limitations on the amount of securities the Company may sell pursuant to its effective registration statement on Form S-3 within any 12-month period, by means of ordinary brokers&#8217; transactions at market prices. Additionally, under the terms of the Sales Agreement, the Company may also sell shares of its common stock through JonesTrading, on the Nasdaq Capital Market or otherwise, at negotiated prices or at prices related to the prevailing market price. JonesTrading will use its commercially reasonable efforts to sell the Company&#8217;s common stock from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay JonesTrading </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of gross proceeds for the common stock sold through the Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had the following outstanding warrants for the purchase of common stock:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.459999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,369,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2, 2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,867,504</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock upon the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,245,984</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants. During the year ended December 31, 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">390,668</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock upon the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">398,093</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Compensation Plans</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2015, the Company&#8217;s Board adopted the 2015 Equity Incentive Plan (2015 Plan). Under the 2015 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. Initially, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80,103</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were reserved for issuance under the 2015 Plan. In addition, pursuant to the June 10, 2021 amendment, the number of shares of common stock available for issuance under the 2015 Plan will be annually increased on the first day of each fiscal year during the term of the 2015 Plan, as amended, beginning with the 2022 fiscal year until (and including) January 1, 2031, by an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year or such lesser amount as the Company&#8217;s Board may determine. The maximum term of the options granted under the 2015 Plan is no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Grants generally vest at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the vesting commencement date and ratably each month thereafter for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, subject to continuous service. In addition, pursuant to a June 2021 amendment, the 2015 Plan was amended to allow an additional aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to be used exclusively for the grant of equity awards as a material inducement for individuals to commence employment at the Company in compliance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under all Plans is summarized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,089,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about the Company&#8217;s outstanding stock options as of December 31, 2023 is as follows:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,446,873</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.47</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of employee option grants during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The aggregate intrinsic value used in the above table of options at December 31, 2023 is based on the Company&#8217;s closing market price per common share on December 29, 2023, the last business day of the 2023 fiscal year, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1751</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options were exercised during the years ended December 31, 2023 and 2022. The total grant-date fair value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchase</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan (ESPP)</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2015, the Company&#8217;s Board adopted the ESPP, which became effective upon the pricing of the Company&#8217;s initial public offering on January 29, 2015. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible compensation. Initially, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,346</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock was reserved for issuance under the ESPP. In addition, pursuant to the June 10, 2021 amendment, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2022 fiscal year, by an amount equal to the lesser of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (iii) such other amount as the Company&#8217;s Board may determine. Stock compensation expense for the years ended December 31, 2023, 2022 and 2021 related to the ESPP was immaterial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.265%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.564%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.325%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The Company bases the risk&#8209;free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The Company considers its historical volatility when determining the expected volatility.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The allocation of stock-based compensation expense was as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.992%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.437000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the unrecognized compensation cost related to outstanding time-based options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and is expected to be recognized as expense over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance was as follows:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,766,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Awards available under the 2015 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available under the Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">429,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243,817</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,515,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,406,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800977168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CollaborationsDisclosureAbstract', window );"><strong>Collaborations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Collaboration and License Agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inhibrx, Inc.(Inhibrx) License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Company granted a non-exclusive, non-sublicensable, non-transferable (except in the event of the transfer or sale of all or substantially all of the business or assets of Inhibrx) worldwide perpetual license of its&#8217; CRO-independent product development platform (PDP) to Inhibrx for a nonrefundable upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million plus an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the completion of certain training. The Company is obligated to be available over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period beginning on the date of license transfer to provide up to 500 hours of training to Inhibrx. The PDP license allows Inhibrx to use the Company&#8217;s configuration documentation with a widely used software package in addition to use the Company&#8217;s validation and qualification of the software package and the Company&#8217;s standard operation procedure documents, policies, work instructions, and clinical operation templates in the administration of clinical trials and related research and development activities.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, Inhibrx has sole responsibility for funding and conducting any such clinical trials and related research and development activities. The Company is not obligated to tailor any of the related documentation and is not involved in conducting any of the related clinical trials or research and development activities.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this agreement and identified multiple promised goods and services, which included at contract inception: (1) the PDP license and (2) up to 500 hours of training over a six-month period. Management evaluated these promised goods and services and determined each was a separate performance obligation. The transaction price at contract inception included fixed consideration of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment due upon the earlier of the completion of 500 hours of training or six months. The total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million transaction price was allocated to each performance obligation based on relative standalone selling price. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million amount allocated to the PDP license performance obligation was recognized at the point in time Inhibrx could first use and benefit from the license, which occurred in the fourth quarter of 2023. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million amount allocated to the training performance obligation will be recognized over the six-month period in which the Company is obligated to be available to provide training.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eucure and Biocytogen Collaborative Development and Commercialization Agreement</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Company, Eucure (Beijing) Biopharma Co., Ltd. (Eucure) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen), Eucure&#8217;s controlling affiliate, entered into a collaborative development and commercialization agreement (the YH001 Collaboration Agreement) for the development of YH001, a monospecific investigational CTLA-4 antibody.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the YH001 Collaboration Agreement, the Company was granted an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including sarcoma, microsatellite stable colorectal cancer, renal cell carcinoma (RCC), and K-ras positive non-small cell lung cancer (collectively, the Initial Indications) or one or more of bladder cancer, endometrial cancer, and melanoma as substitute indications, which may be substituted for Initial Indications at the Company&#8217;s discretion (each upon such substitution, a Substitute Indication).  The Company is responsible for, and will bear the costs of, preparing and filing all regulatory submissions and conducting any Phase 1, Phase 2, Phase 3, or post-approval clinical trials in North America for YH001 in the Initial Indications and potentially the Substitute Indications, while Eucure is responsible for conducting, and will bear the costs of, the preparation of chemistry, manufacturing and controls activities for YH001. Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to the Company for clinical trials pursuant to the terms of a clinical supply and quality agreement to be separately negotiated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During a specified period, the Company has the option, subject to Eucure&#8217;s prior written approval, to expand the license to include the development and commercialization of YH001 for the treatment, through administration by intravenous or subcutaneous means, of all human and veterinary therapeutic indications in North America for a payment to Eucure in the low single digit millions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will be responsible for commercializing YH001 in North America, including booking of sales revenue in the Initial and Substitute Indications. The Company will owe Eucure escalating double digit royalties on net sales of YH001 in North America ranging from the mid-twenties to mid-double digits; provided that until the end of the first full calendar year following the first commercial sale of YH001, royalties will range from the lower double digits to the mid-double digits. If sales of YH001 exceed a pre-determined sales threshold in the first full year of sales following first commercial sale, the Company will owe a milestone to Eucure in the high single digit millions.  Payment obligations under the YH001 Collaboration Agreement continue on a country-by-country basis until the latest of (i) expiration of the last to expire licensed patent covering YH001, (ii) expiration of marketing or regulatory exclusivity covering YH001 and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the first commercial sale of YH001 in such country in North America. Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to the Company at cost plus a low double digit markup for commercial sales pursuant to the terms of a commercial supply and quality agreement to be separately negotiated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">3D Medicines and Alphamab Collaboration and Clinical Trial Agreement</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the Company, 3D Medicines Co., Ltd. (3D Medicines), and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) entered into a collaboration and clinical trial agreement (the Envafolimab Collaboration Agreement) for the development of envafolimab, also known as KN035, an investigational PD-L1 single-domain antibody (sdAb), or nanobody, administered by subcutaneous injection, for the treatment of sarcoma in North America. No consideration was exchanged in the Envafolimab Collaboration Agreement. Given no consideration was exchanged, no value was assigned to the Envafolimab Collaboration Agreement in the accompanying consolidated balance sheets.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Envafolimab Collaboration Agreement, the Company was granted an exclusive license to develop and commercialize envafolimab for the treatment of sarcoma in North America.  The Company is responsible for conducting, and will bear the costs of Phase 1, Phase 2, and Phase 3 or post-approval clinical trials in North America for envafolimab in the indications of refractory and first line treatment of sarcoma. 3D Medicines and Alphamab are responsible for conducting, and will bear the costs of, investigational new drug (IND)-enabling studies (other than those specific to the sarcoma indication) and the preparation of chemistry, manufacturing and controls (CMC) activities sections of an IND application for envafolimab. 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, envafolimab to the Company at pre-negotiated prices that vary based on clinical or commercial use. 3D Medicines and Alphamab retained the right to develop envafolimab in all territories outside of North America as well as within North America for all indications other than sarcoma.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue, unless (a) envafolimab is first approved in North America for an indication other than sarcoma and launched in North America, or (b) envafolimab is first approved in North America for sarcoma and subsequently approved in North America for an additional non-orphan indication and sold commercially by 3D Medicines and/or Alphamab, or a licensee, in which case 3D Medicines and Alphamab will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue. If 3D Medicines and Alphamab become responsible for commercialization under the Envafolimab Collaboration Agreement, the Company has the option to co-market envafolimab for sarcoma in North America. In the event that envafolimab is first approved in North America for sarcoma and within three years of the commercial launch of envafolimab in North America for sarcoma 3D Medicines and Alphamab replace the Company as the party responsible for commercialization, and the Company elects and 3D Medicines and Alphamab agree for the Company to not co-market envafolimab for sarcoma in North America, then 3D Medicine and Alphamab will be required to compensate the Company for its costs associated with preparing for and conducting commercial activities.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company has the responsibility for commercialization under the Envafolimab Collaboration Agreement, the Company will owe 3D Medicines and Alphamab tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits.  If 3D Medicines and Alphamab have responsibility for commercialization under the Envafolimab Collaboration Agreement, the Company will be entitled to (a) escalating double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits if the Company has chosen to not co-market envafolimab in sarcoma or (b) a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net sales of envafolimab for sarcoma in North America if the Company has chosen to co-market envafolimab in sarcoma.  Payment obligations under the Envafolimab Collaboration Agreement continue on a country-by-country basis until the last to expire licensed patent covering envafolimab expires.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3D Medicines and Alphamab retain the right to reacquire the rights to envafolimab for sarcoma in North America in connection with an arm&#8217;s length sale to a third party, provided that the sale may not occur prior to completion of a pivotal trial of envafolimab in sarcoma without the Company&#8217;s written consent and the parties must negotiate in good faith and agree to fair compensation to be paid to the Company for the value of and opportunity represented by the required rights.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party agreed that during the term of the Envafolimab Collaboration Agreement, it would not develop or license from any third party a monospecific inhibitor to PD-L1 or PD-1 in sarcoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Envafolimab Collaboration Agreement continues until the later of the date the parties cease further development and commercialization of envafolimab for sarcoma in North America or the expiration of all payment obligations.  The Envafolimab Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to envafolimab.  In the event the Company elects, or a joint steering committee determines, to cease further development or commercialization of envafolimab, or if the Company fails to use commercially reasonable efforts to develop (including progress in clinical trials) and commercialize envafolimab and does not cure such failure within a specified time period, then the Company&#8217;s rights and obligations under the Envafolimab Collaboration Agreement will revert to 3D Medicines and Alphamab.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">I-Mab Collaboration Agreements</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2018, the Company and I-Mab entered into separate strategic collaboration and clinical trial agreements (the I-Mab Collaboration Agreements) for the development of programs for multiple immuno-oncology product candidates, including I-Mab&#8217;s proprietary CD73 antibody TJ004309 (the TJ004309 Agreement) as well as up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> proprietary bispecific antibodies currently under development by I-Mab (the Bispecific Agreement).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the TJ004309 Agreement, the Company and I-Mab were collaborating on developing the TJ004309 antibody, with the Company bearing the costs of filing an IND and for Phase 1 clinical trials, with the parties sharing costs equally for Phase 2 clinical trials, and with the Company and I-Mab bearing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of the costs for pivotal clinical trials. I-Mab was responsible for the cost of certain non-clinical activities, the drug supply of TJ004309, and any reference drugs used in the clinical trials.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company would be entitled to receive escalating portions of royalty and non-royalty consideration and a royalty based on net sales if I-Mab licenses TJ004309 in certain territories or commercializes TJ004309, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The TJ004309 Agreement was terminatable by either party in the event of an uncured material breach by the other party or bankruptcy of the other party, for safety reasons related to TJ004309 or by I-Mab if the Company causes certain delays in completing a Phase 1 clinical trial. In addition, the TJ004309 Agreement was terminatable by I-Mab for any reason within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days following the completion of the first Phase 1 clinical trial, in which case the Company would be entitled to a minimum termination fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or following the completion of the first Phase 2 clinical trial, in which case the Company would be entitled to a pre-specified termination fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and either a percentage of non-royalty consideration I-Mab may receive as part of a license to a third party or an additional payment if TJ004309 is approved for marketing outside Greater China before a third-party license is executed, in addition to a double digit percentage of royalty consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed, in June 2020, I-Mab commenced an arbitration proceeding under the Rules of Arbitration of the International Chamber of Commerce before an arbitration tribunal seated in New York City (the Tribunal) after the Company invoked contractual dispute resolution provisions asserting that I-Mab had breached its contractual obligations under the TJ004309 Agreement and the Bispecific Agreement. In April 2023, the Company received notification from the Tribunal of the Arbitration Award. The Tribunal found in favor of the Company for certain claims and declared the Phase 1 clinical trial of TJ004309 Agreement &#8220;Complete,&#8221; as that term is defined in the TJ004309 Agreement as of January 2022. The Arbitration Award included the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million prespecified termination fee payable by I-Mab under the TJ004309 Agreement, which was collected in July 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company re-evaluated the transaction price as of the end of the reporting period and concluded the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million variable consideration associated with the prespecified termination fee was no longer fully constrained as it was determined to be probable that a significant reversal would not occur if the Company recognized the variable consideration as revenue in the current period. Accordingly, the Company recognized the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7148ed3a-8abb-4a16-af47-75112a2b7341;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration revenue</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> within the accompanying consolidated statements of operations for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the resolution of the arbitration, the TJ004309 Agreement and the Bispecific Agreement have been terminated and no further revenue will be recognized associated with these agreements.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million gain associated with the collection of the Arbitration Award in July 2023 consisted of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million collected amount less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million TJ004309 termination fee recognized as collaboration revenue. The gain has been included within other income, net within the accompanying consolidated statements of operations. Additionally, in connection with the Arbitration, the Company entered into a contingency fee arrangement with its legal counsels whereby counsels agreed to defer a portion of their legal fees (Success Fees) and would receive payment of the Success Fees in full or at a low single digit multiple depending on the amount awarded and contingent upon recovery of proceeds from an Arbitration Award. Success Fees in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were paid in 2023 and have been included within arbitration success fees within the accompanying consolidated statements of operations. In connection with the settlement, legal counsels also forgave approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in related legal invoices.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CollaborationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CollaborationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656916066528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Leases</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operating lease obligations relate to its corporate headquarters as the Company leases its office space under a non-cancelable operating lease. The Company amended its lease in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> extending the lease term to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease is subject to base lease payments and additional charges for common area maintenance and other costs and includes certain lease incentives and tenant improvement allowances. Operating lease expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the three years ended December 31, 2023, 2022 and 2021. As of December 31, 2023, the Company did not have any finance leases, nor any other operating leases.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.7%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid within operating cash flows</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU assets recognized in exchange for new lease obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.187%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.786%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.786%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reported as:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span><span><span style="-sec-ix-hidden:F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17;"><span style="-sec-ix-hidden:F_b539fbc4-b194-4f51-b5a6-68a58edce5fb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(ROU asset)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">905</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Accounts payable and accrued expenses (lease liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Other long-term liabilities (lease liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.36%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,171</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Und</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">er the terms of the lease agreement, the Company provided the lessor with an irrevocable letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">73,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e lessor is entitled to draw on the letter of credit in the event of any default by the Company under the terms of the lease.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656797309024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">754</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,962</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits and Orphan Drug Credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 capitalized research expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,361</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,361</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has net deferred tax assets relating primarily to net operating loss (NOL) carryforwards and research and development and Orphan Drug credit carryforwards. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 requires taxpayers to capitalize and amortize research and development expenditures over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for domestic research and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years for foreign research pursuant to Section 174 of the Internal Revenue Code (Code). Subject to certain limitations, the Company may use these deferred tax assets to offset taxable income in future periods. Due to the Company&#8217;s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company&#8217;s deferred tax assets, as it is more likely than not that such assets will not be realized. The net change in the total valuation allowance for the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had federal and California NOL carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">190.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">146.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal and California NOL carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, if not utilized. The federal NOL generated after 2017 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">106.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will carryforward indefinitely, but the deductibility of such federal NOLs is limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income. As of December 31, 2023, the Company also had federal research and development and Orphan Drug tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and California research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The federal research and development and Orphan Drug tax credit carryforwards will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, if not utilized. The California research credit will carry forward indefinitely under current law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Sections 382 and 383 of the Code, the annual use of the Company&#8217;s NOL and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% occurs within a three-year period. The Company previously completed a Section 382/383 analysis regarding the limitation of NOL and research and development credit carryforwards as of December 31, 2018 and did not identify any change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% within the preceding three-year period since an ownership change was determined to have occurred at the time of the Company&#8217;s initial public offering in January 2015. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since December 31, 2018. If the Company has experienced an ownership change at any time since December 31, 2018, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation under Section 382 of the Code. Any limitation may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act of 2022, which incorporates a Corporate Alternative Minimum Tax (CAMT), was signed on August 16, 2022 and changes became effective for tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The act is not expected to have a significant impact on the Company's financial position, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in the Company&#8217;s unrecognized tax benefits are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,610</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,096</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">532</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accruals for interest or penalties in the accompanying consolidated balance sheets as of December 31, 2023 and 2022 and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized interest or penalties in the accompanying consolidated statements of operations for the three years in the period ended December 31, 2023.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the valuation allowance recorded against the Company&#8217;s deferred tax assets, future changes in unrecognized tax benefits will not impact the Company&#8217;s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the United States and California. Due to the net operating loss carryforwards, the U.S. federal and California returns are open to examination for all years since inception. The Company has not been, nor is it currently, under examination by the federal or any state tax authority.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656801255264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. 401(k) Plan</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains a defined contribution </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0423c714-cd31-4fc4-8227-88bbd1c67cbd;"><span style="-sec-ix-hidden:F_46bdfe8e-ae21-43ca-ba32-3a33adf3437b;"><span style="-sec-ix-hidden:F_b40b095e-6fd8-4db7-9688-34b629bf1179;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">401(k) plan</span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain matching contributions to the 401(k) plan. Matching contributions for the years ended December 31, 2023, 2022 and 2021 totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656803296656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_OrganizationAndAccountingPoliciesAbstract', window );"><strong>Organization And Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Organization and Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Business</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRACON Pharmaceuticals, Inc. (TRACON or the Company) was incorporated in the state of Delaware on October 28, 2004. TRACON is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and utilizes its cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, TRACON Pharma Limited and TRACON Pharma International Limited, which were formed in September 2015 and January 2019, respectively, and are currently inactive. All significant intercompany accounts and transactions have been eliminated.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has devoted substantially all its efforts to product development, raising capital, and building infrastructure and has not realized revenues from its planned principal operations. The Company has incurred operating losses since inception. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">240.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its product candidates and works to develop additional product candidates through research and development programs. At December 31, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is classified as restricted cash as it is pledged as collateral for the Company&#8217;s obligations under its corporate headquarters facility lease. The Company&#8217;s ability to execute its operating plan through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financings, or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company&#8217;s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, management believes that there is substantial doubt about its ability to continue as a going concern for a period of 12 months following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company plans to continue to fund its losses from operations through its existing cash and cash equivalents, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. In addition, the Company may fund its losses from operations through the Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sales Agreement (the Sales Agreement) the Company entered into with JonesTrading in December 2020, as amended in March 2022, pursuant to which the Company may sell, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the common stock purchase agreement (the LPC Purchase Agreement) the Company entered into with Lincoln Park Capital Fund, LLC (Lincoln Park) in May 2023, pursuant to which the Company may sell, at its option, up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which remained available for sale as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RisksAndUncertaintiesPolicyTextBlock', window );">Risks And Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global economic and business activities continue to face widespread macroeconomic uncertainties, including labor shortages, inflation and monetary supply shifts, recession risks and potential disruptions from the Russia-Ukraine conflict. The Company continues to actively monitor the impact of these macroeconomic factors on its financial condition, liquidity, operations, and workforce. The extent of the impact of these factors on the Company&#8217;s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company&#8217;s business</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company&#8217;s consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these investments. Cash and cash equivalents include cash in readily available checking and money market funds.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of money market funds held by the Company&#8217;s financial institution as collateral for the Company&#8217;s obligations under its facility lease for the Company&#8217;s corporate headquarters in San Diego, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets, which is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or estimated useful life of the related assets. Repairs and maintenance costs are charged to expense as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are recorded as other assets, accounts payable and accrued expenses, and other long-term liabilities within the consolidated balance sheet. The Company currently does not have any finance leases.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#8217;s leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company&#8217;s revenue has been derived from license and collaboration agreements. The terms of these arrangements included payments to the Company for the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. In accordance with Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 606), the Company performs the following five steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.  The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. Once a contract is determined to be within the scope of ASC 606, at contract inception the Company assesses the goods or services promised within the contract to determine those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of intellectual property:  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method.  Performance milestone payments represent a form of variable consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Achievement of milestones that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis and the Company recognizes revenue as or when the performance obligations under the contract are satisfied.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing Supply Services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its out-licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company receives payments from its collaborators based on billing schedules established in each contract. Up-front and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its collaboration arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock', window );">Clinical Trial Expense Accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Expense Accruals</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the Company&#8217;s consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s objective is to reflect the appropriate trial expenses in its consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with the clinical sites and applicable personnel and outside service providers as to the progress or state of consummation of trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s clinical trial accruals are dependent upon accurate reporting by clinical sites and other third-party vendors. Although the Company does not expect its estimates to differ materially from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were no material adjustments to the Company&#8217;s prior period estimates of accrued expenses for clinical trials.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs, including license fees, are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the grant date fair value of employee stock option grants, employee restricted stock unit grants (RSUs), and employee stock purchase plan (ESPP) rights recognized as expense over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and ESPP rights using the Black-Scholes option pricing model. The fair value of RSUs is based on the closing sales price for such stock on the date of grant. Equity award forfeitures are recorded as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than&#8209;not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and comprehensive loss were the same for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted average number of shares of common stock outstanding that are subject to repurchase. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.18%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.6%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,766,246</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP shares</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,444</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,387</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,664,889</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,015,943</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for clinical trial expense accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_OrganizationAndAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Accounting Policies Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_OrganizationAndAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties [Policy Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800977168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_OrganizationAndAccountingPoliciesAbstract', window );"><strong>Organization And Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.18%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.6%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,766,246</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP shares</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,444</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,387</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,664,889</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,015,943</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_OrganizationAndAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Accounting Policies Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_OrganizationAndAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656805224688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-sale Securities and Equity Securities</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, which are classified as equity securities, and restricted cash consisted of the following (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.367%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.981%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.941000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.0009999999999994%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized (Loss)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized (Loss)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,083</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the Company&#8217;s assets and liabilities, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.09%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.798%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Active Markets</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">for Identical</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800958560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ScheduleOfPropertyAndEquipmentTableTextBlock', window );">Schedule Of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock', window );">Schedule Of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal and accounting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued long-term debt terminal interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ScheduleOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ScheduleOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656801146848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term debt and unamortized debt discount balances</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, long-term debt and unamortized debt discount balances associated with the RGC Loan Agreement were as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less debt discount, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of exercisable outstanding warrants for purchase of common stock issued</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company&#8217;s loan agreements with SVB:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.459999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had the following outstanding warrants for the purchase of common stock:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.459999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,369,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2, 2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656802103392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of exercisable outstanding warrants for purchase of common stock issued</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company&#8217;s loan agreements with SVB:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.459999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had the following outstanding warrants for the purchase of common stock:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.92%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.459999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 25, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,369,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 4, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 3, 2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2, 2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under all Plans is summarized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,089,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of outstanding stock options</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about the Company&#8217;s outstanding stock options as of December 31, 2023 is as follows:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,446,873</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.47</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions used Black-Scholes option pricing model to determine the fair value</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.265%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.564%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.325%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of allocation of stock-based compensation expense</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The allocation of stock-based compensation expense was as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.992%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.437000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of common stock reserved for future issuance</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance was as follows:</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,766,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,121,152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,246,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Awards available under the 2015 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available under the Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">429,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243,817</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,515,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,406,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800162480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.7%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid within operating cash flows</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU assets recognized in exchange for new lease obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.187%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.786%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.786%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reported as:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span><span><span style="-sec-ix-hidden:F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17;"><span style="-sec-ix-hidden:F_b539fbc4-b194-4f51-b5a6-68a58edce5fb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(ROU asset)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">905</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Accounts payable and accrued expenses (lease liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Other long-term liabilities (lease liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.36%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,171</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of maturities of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656802344448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of effective tax rate and federal statutory tax rate</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">754</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,962</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets and deferred tax Liabilities</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits and Orphan Drug Credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 capitalized research expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,361</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,361</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of changes in unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in the Company&#8217;s unrecognized tax benefits are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,610</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,096</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change related to prior year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">532</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656795933616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (240,499,000)<span></span>
</td>
<td class="num">$ (236,911,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents</a></td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading Institutional Services LLC | Capital on Demand Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumAggregateValueOfStockToBeSold', window );">Maximum aggregate value of stock to be sold</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RemainingAmountAvailableUnderTheSalesAgreement', window );">Remaining amount available under the Sales Agreement</a></td>
<td class="nump">41,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_LincolnParkCapitalFundLlcMember', window );">Lincoln Park Capital Fund, LLC | Capital on Demand Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumAggregateValueOfStockToBeSold', window );">Maximum aggregate value of stock to be sold</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RemainingAmountAvailableUnderTheSalesAgreement', window );">Remaining amount available under the Sales Agreement</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MaximumAggregateValueOfStockToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate value of stock to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MaximumAggregateValueOfStockToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_RemainingAmountAvailableUnderTheSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amount available under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_RemainingAmountAvailableUnderTheSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcon_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcon_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656795910416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in the Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">4,664,889<span></span>
</td>
<td class="nump">9,015,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">1,533,293<span></span>
</td>
<td class="nump">6,766,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcon_CommonStockOptionsMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">3,121,152<span></span>
</td>
<td class="nump">2,246,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcon_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcon_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800172432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Schedule of Available-for-sale Securities and Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Short-Term Investments, Cash Equivalents and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 3,616<span></span>
</td>
<td class="nump">$ 10,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure', window );">Total cash equivalents, restricted cash, and other assets</a></td>
<td class="nump">3,689<span></span>
</td>
<td class="nump">10,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Short-Term Investments, Cash Equivalents and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">3,689<span></span>
</td>
<td class="nump">10,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 3,689<span></span>
</td>
<td class="nump">$ 10,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, restricted cash, and other assets fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_RestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_RestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656805254400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_FairValueTransfersBetweenLevelsAmount', window );">Amount of transfers between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_FairValueTransfersBetweenLevelsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets or liabilities measured on a recurring basis between levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_FairValueTransfersBetweenLevelsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800291040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - Money market funds - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value, assets</a></td>
<td class="nump">$ 3,689<span></span>
</td>
<td class="nump">$ 10,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value, assets</a></td>
<td class="nump">$ 3,689<span></span>
</td>
<td class="nump">$ 10,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656804798432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule Of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryLineItems', window );"><strong>Public Utilities Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=tcon_ComputerAndOfficeEquipmentMember', window );">Computer And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryLineItems', window );"><strong>Public Utilities Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryLineItems', window );"><strong>Public Utilities Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryLineItems', window );"><strong>Public Utilities Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=tcon_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=tcon_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656795903104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense related to property and equipment</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796008416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule Of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryLineItems', window );"><strong>Public Utilities Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 2,544<span></span>
</td>
<td class="nump">$ 3,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure', window );">Accrued clinical related expenses</a></td>
<td class="nump">6,736<span></span>
</td>
<td class="nump">6,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_AccruedLongTermDebtTerminalInterestCurrent', window );">Accrued long-term debt terminal interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current portion of operating lease liability</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accruals</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total</a></td>
<td class="nump">9,755<span></span>
</td>
<td class="nump">11,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryLineItems', window );"><strong>Public Utilities Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_AccruedLongTermDebtTerminalInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued long-term debt terminal interest, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_AccruedLongTermDebtTerminalInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of trade and related party payables and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796549456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>Tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumCapitalContribution', window );">Maximum capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_InitialCapitalContributionFromInvestors', window );">Initial capital contribution from investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentageOfInitialCapitalContributionFromInvestors', window );">Percentage of Initial Capital Contribution From Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentageOfClosingFeeAmount', window );">Percentage of closing fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ArbitrationFinancingPayable', window );">Arbitration financing payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,280,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Settlement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ArbitrationAwardInterestExpense', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember', window );">Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpLoanAgreementMember', window );">RGC Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_InterestAndFinalPayment', window );">Principal and interest payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement | Runway Growth Finance Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long term debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment', window );">Proceeds from sale of debt and equity securities</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentageOfFinalPaymentFee', window );">Percentage of final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement | Runway Growth Finance Corp | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_NumberOfTranche', window );">Number of tranche | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement | Runway Growth Finance Corp | Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long term debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement | Runway Growth Finance Corp | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long term debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement | Runway Growth Finance Corp | Term Loan B | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long term debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement | Runway Growth Finance Corp | Term Loan C | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long term debt, principal amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_WarrantsMember', window );">Warrants | Runway Growth Finance Corp | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  02,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcon_TwoThousandEighteenLoanAndSecurityAgreementMember', window );">2018 SVB Loan | Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_FinalPaymentOnPayoff', window );">Final payment on payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ArbitrationAwardInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Arbitration award interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ArbitrationAwardInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ArbitrationFinancingPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Arbitration financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ArbitrationFinancingPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_FinalPaymentOnPayoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final payment on payoff.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_FinalPaymentOnPayoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_InitialCapitalContributionFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial capital contribution from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_InitialCapitalContributionFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_InterestAndFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest and final payment of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_InterestAndFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MaximumCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum capital contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MaximumCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_NumberOfTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of tranche.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_NumberOfTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentageOfClosingFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentageOfClosingFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentageOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of final payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentageOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentageOfInitialCapitalContributionFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of initial capital contribution from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentageOfInitialCapitalContributionFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcon_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpLoanAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpLoanAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_RunwayGrowthFinanceCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_TermLoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_TermLoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcon_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcon_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcon_TwoThousandEighteenLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcon_TwoThousandEighteenLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800377200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long-Term Debt and Unamortized Debt Discount Balances (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LongTermDebtNetOfUnamortizedLongTermAmortization', window );">Long-term debt, net of debt discount</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LongTermDebtCurrentGross', window );">Less current portion of long-term debt</a></td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LongTermDebtCurrentGross', window );">Current portion of long-term debt</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Current portion of debt discount</a></td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">$ 9,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_LongTermDebtCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_LongTermDebtCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_LongTermDebtNetOfUnamortizedLongTermAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of long-term unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_LongTermDebtNetOfUnamortizedLongTermAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656803309328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Exercisable Outstanding Warrants for Purchase of Common Stock Issued (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">1,533,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember', window );">Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">12,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember', window );">Silicon Valley Bank | January 25, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">4,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 51.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember', window );">Silicon Valley Bank | June 4, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">2,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 77.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember', window );">Silicon Valley Bank | May 3, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">5,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 26.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656801157504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CollaborativeArrangementsMilestonePaymentsPotential', window );">Potential milestone payable</a></td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CollaborativeArrangementsMilestonePaymentsPotential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential payments that could be paid under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CollaborativeArrangementsMilestonePaymentsPotential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796564352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tcon_LincolnParkPurchaseAgreementMember', window );">Lincoln Park Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumAggregateValueOfStockToBePurchased', window );">Aggregate value of shares committed to purchase</a></td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price per share</a></td>
<td class="nump">$ 0.5763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement', window );">Percentage of common stock outstanding owned after sale agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_TwentyTwentyTwoPreFundedWarrantsMember', window );">2022 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise', window );">Maximum percentage of holders ownership interest in common stock after exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_TwentyTwentyThreePreFundedWarrantsMember', window );">2023 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise', window );">Maximum percentage of holders ownership interest in common stock after exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock', window );">Cashless exercise of pre-funded warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,245,984<span></span>
</td>
<td class="nump">398,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares', window );">Issuance of common stock upon cashless exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,867,504<span></span>
</td>
<td class="nump">390,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Lincoln Park Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="nump">1,735,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RemainingAmountAvailableUnderTheSalesAgreement', window );">Remaining amount available under the Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_NetProceedsReceivedFromIssuanceDirectOffering', window );">Net proceeds from common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Direct Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_NetProceedsReceivedFromIssuanceDirectOffering', window );">Net proceeds from common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Capital on Demand Sales Agreement | Jones Trading Institutional Services LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumAggregateValueOfStockToBeSold', window );">Maximum aggregate value of stock to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RemainingAmountAvailableUnderTheSalesAgreement', window );">Remaining amount available under the Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement', window );">Percentage of gross proceeds, required to pay for common stock sold through sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2022 Pre-Funded Warrants | Direct Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2023 Pre-Funded Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Purchase Price Of $1.38 Per Share | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Purchase Price Of $1.37 Per Share | 2023 Pre-Funded Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,013,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Purchase Price of $1.32 Per Share | Direct Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Purchase Price of $1.31 Per Share | 2022 Pre-Funded Warrants | Direct Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,205,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of pre-funded warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances of common stock upon cashless exercise of pre-funded warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MaximumAggregateValueOfStockToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate value of stock to be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MaximumAggregateValueOfStockToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MaximumAggregateValueOfStockToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate value of stock to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MaximumAggregateValueOfStockToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of holders ownership interest in common stock after exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_NetProceedsReceivedFromIssuanceDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds received from issuance direct offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_NetProceedsReceivedFromIssuanceDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock outstanding owned after sale agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds, required to pay for common stock sold through sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_RemainingAmountAvailableUnderTheSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amount available under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_RemainingAmountAvailableUnderTheSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcon_LincolnParkPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcon_LincolnParkPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_TwentyTwentyTwoPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_TwentyTwentyTwoPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_TwentyTwentyThreePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_TwentyTwentyThreePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcon_DirectOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcon_DirectOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcon_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcon_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796827600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Outstanding Warrants for Purchase of Common Stock Issued (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">1,533,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember', window );">January 25, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">4,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 51.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember', window );">March 27, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">1,369,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember', window );">June 4, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">2,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 77.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember', window );">May 3, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">5,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 26.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember', window );">September 2, 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants to purchase shares</a></td>
<td class="nump">150,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (per share) | $ / shares</a></td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796314208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - (SBC) - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,515,700<span></span>
</td>
<td class="nump">9,406,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Grants vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Grants vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Grants vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcon_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">18,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of shares of common stock outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod', window );">Number of shares that could potentially be issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcon_EquityIncentive2015PlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum term of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">80,103<span></span>
</td>
<td class="nump">431,755<span></span>
</td>
<td class="nump">150,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of shares of common stock outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_AdditionalCommonSharesToBeUsedForSpecificAward', window );">Additional shares to be used exclusively for grant for Inducement awards</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_AdditionalCommonSharesToBeUsedForSpecificAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional shares of common stock to be used exclusively for a specified award of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_AdditionalCommonSharesToBeUsedForSpecificAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcon_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcon_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcon_EquityIncentive2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcon_EquityIncentive2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656803184288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity- Summary of Stock Option Activity (Details) - Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares)</a></td>
<td class="nump">2,246,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,089,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(214,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares)</a></td>
<td class="nump">3,121,152<span></span>
</td>
<td class="nump">2,246,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance (in dollars per share)</a></td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">8.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance (in dollars per share)</a></td>
<td class="nump">$ 6.53<span></span>
</td>
<td class="nump">$ 9.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796393904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Company's Outstanding Stock Option (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, options vested and expected to vest</a></td>
<td class="nump">3,121,152<span></span>
</td>
<td class="nump">2,246,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding</a></td>
<td class="nump">3,121,152<span></span>
</td>
<td class="nump">2,246,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, options vested and expected to vest</a></td>
<td class="nump">3,121,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, options exercisable</a></td>
<td class="nump">1,446,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, options outstanding (in dollars per share)</a></td>
<td class="nump">$ 6.53<span></span>
</td>
<td class="nump">$ 9.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, options vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercisable (in dollars per share)</a></td>
<td class="nump">$ 11.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, options outstanding (in years)</a></td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, options vested and expected to vest (in years)</a></td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">6 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656803161600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Weighted-Average Assumptions Fair Value of the Employee Stock Option Grants (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.10%<span></span>
</td>
<td class="nump">89.80%<span></span>
</td>
<td class="nump">90.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796051888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Allocation of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 1,969<span></span>
</td>
<td class="nump">$ 2,041<span></span>
</td>
<td class="nump">$ 1,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796826880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 02, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">5,515,700<span></span>
</td>
<td class="nump">9,406,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, options vested and expected to vest</a></td>
<td class="nump">3,121,152<span></span>
</td>
<td class="nump">2,246,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcon_EquityIncentive2015PlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">431,755<span></span>
</td>
<td class="nump">150,335<span></span>
</td>
<td class="nump">80,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember', window );">Common Stock. | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">1,533,293<span></span>
</td>
<td class="nump">6,766,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcon_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">429,500<span></span>
</td>
<td class="nump">243,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcon_EquityIncentive2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcon_EquityIncentive2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcon_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcon_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656794122912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>Antibody</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revenue from Contract with Customer, Excluding Assessed Tax<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:CollaborativeArrangementMember<span></span>
</td>
<td class="text">us-gaap:CollaborativeArrangementMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee', window );">Settlement received, net of termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Settlement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ArbitrationSuccessFees', window );">Arbitration success fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LossContingencyPaymentWriteOffAmount', window );">Loss contingency payment write-off amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_EnvafolimabCollaborationAgreementMember', window );">Bispecific Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_RoyaltyPercentageOfNetSales', window );">Royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_BispecificAgreementMember', window );">Bispecific Agreement | I-Mab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment', window );">Maximum number of proprietary bispecific antibodies under development | Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_TjFourThreeZeroNineAgreementMember', window );">TJ4309 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CollaborationAgreementPercentageOfCostBearing', window );">Percentage of cost bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_TjFourThreeZeroNineAgreementMember', window );">TJ4309 Agreement | I-Mab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CollaborationAgreementPercentageOfCostBearing', window );">Percentage of cost bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TerminationOfAgreementUponCompletionOfClinicalTrial', window );">Termination of agreement upon completion of clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_TjFourThreeZeroNineAgreementMember', window );">TJ4309 Agreement | I-Mab | First Phase Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TerminationFeePayable', window );">Termination fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Termination fee awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_TjFourThreeZeroNineAgreementMember', window );">TJ4309 Agreement | I-Mab | First Phase Two Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcon_InhibrxLicenseAgreementMember', window );">Inhibrx, Inc.(Inhibrx) License Agreement | Inhibrx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_NonrefundableUpfrontFee', window );">Nonrefundable upfront fee</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_AdditionalPaymentOnPerformanceObligation', window );">Additional payment on performance obligation</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TrainingPeriodDuration', window );">Training period duration</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_LicenseAgreementTerm', window );">License agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company assessed this agreement and identified multiple promised goods and services, which included at contract inception: (1) the PDP license and (2) up to 500 hours of training over a six-month period. Management evaluated these promised goods and services and determined each was a separate performance obligation. The transaction price at contract inception included fixed consideration of the $3.0 million upfront payment and $0.2 million payment due upon the earlier of the completion of 500 hours of training or six months. The total $3.2 million transaction price was allocated to each performance obligation based on relative standalone selling price. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CommercialSale', window );">Commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_AdditionalPaymentOnPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment on performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_AdditionalPaymentOnPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ArbitrationSuccessFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Arbitration success fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ArbitrationSuccessFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CollaborationAgreementPercentageOfCostBearing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement percentage of cost bearing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CollaborationAgreementPercentageOfCostBearing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded from other party net of termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_LossContingencyPaymentWriteOffAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency payment write-off amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_LossContingencyPaymentWriteOffAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of proprietary antibodies under development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_NonrefundableUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_NonrefundableUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_RoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage of net sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_RoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_TerminationFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_TerminationFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_TerminationOfAgreementUponCompletionOfClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of agreement upon completion of clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_TerminationOfAgreementUponCompletionOfClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_TrainingPeriodDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Training period duration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_TrainingPeriodDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcon_EnvafolimabCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcon_EnvafolimabCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcon_BispecificAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcon_BispecificAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_ImabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_ImabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcon_TjFourThreeZeroNineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcon_TjFourThreeZeroNineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MilestonePaymentsCategoryAxis=tcon_FirstPhaseClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MilestonePaymentsCategoryAxis=tcon_FirstPhaseClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_MilestonePaymentsCategoryAxis=tcon_FirstPhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_MilestonePaymentsCategoryAxis=tcon_FirstPhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcon_InhibrxLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcon_InhibrxLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tcon_InhibrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tcon_InhibrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=tcon_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=tcon_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656804802688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_NonCancelableOperatingLeaseExpirationTerm', window );">Non-cancelable operating lease expiration term</a></td>
<td class="text">2021-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_NonCancelableOperatingLeaseTermToBeExtended', window );">Non Cancelable Operating Lease Term To Be Extended</a></td>
<td class="text">2027-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Irrevocable letter of credit provided to lessor</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_NonCancelableOperatingLeaseExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non&#8209;cancelable operating lease expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_NonCancelableOperatingLeaseExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_NonCancelableOperatingLeaseTermToBeExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cancelable operating lease term to be extended.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_NonCancelableOperatingLeaseTermToBeExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656797260688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental cash flow information related to operating leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_CashPaidWithinOperatingCashFlows', window );">Cash paid within operating cash flows</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets recognized in exchange for new lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_CashPaidWithinOperatingCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid within operating cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_CashPaidWithinOperatingCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656795878464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental balance sheet information related to operating leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ReportedAsAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other assets (ROU asset)</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 1,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts payable and accrued expenses (lease liability)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ReportedAsAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities (lease liability)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ReportedAsAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 732<span></span>
</td>
<td class="nump">$ 969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ReportedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reported as.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ReportedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656796028352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656795918096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of effective tax rate and federal statutory tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes</a></td>
<td class="num">$ (754)<span></span>
</td>
<td class="num">$ (6,118)<span></span>
</td>
<td class="num">$ (6,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(182)<span></span>
</td>
<td class="num">(1,962)<span></span>
</td>
<td class="num">(1,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(1,569)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">7,438<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656794108192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 50,103<span></span>
</td>
<td class="nump">$ 50,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development and Orphan Drug credits</a></td>
<td class="nump">12,960<span></span>
</td>
<td class="nump">11,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_DeferredTaxAssetsRightOfUseLiability', window );">Right-of-use liability</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 capitalized research expense</a></td>
<td class="nump">4,253<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">69,450<span></span>
</td>
<td class="nump">67,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use asset</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred</a></td>
<td class="nump">69,260<span></span>
</td>
<td class="nump">67,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(69,260)<span></span>
</td>
<td class="num">(67,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_DeferredTaxAssetsRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset right of use liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_DeferredTaxAssetsRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656799704816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in the total valuation allowance</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">$ 106,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome', window );">NOL carryforward available to offset future taxable income, percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest or penalties for unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax interest or penalties expense for unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=tcon_OrphanDrugTaxCreditMember', window );">Orphan Drug tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TaxCreditCarryforwardExpirationBeginYear', window );">Credit carryforward begin to expire</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_PercentOfOwnership', window );">Percent of ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">$ 190,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_OperatingLossCarryforwardsExpirationBeginYear', window );">NOL carryforward begin to expire</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development and Orphan Drug Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforward</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_TaxCreditCarryforwardExpirationBeginYear', window );">Credit carryforward begin to expire</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod', window );">Research and development expenditure amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod', window );">Research and development expenditure amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">$ 146,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_OperatingLossCarryforwardsExpirationBeginYear', window );">NOL carryforward begin to expire</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California | Research and Development Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforward</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_OperatingLossCarryforwardsExpirationBeginYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration begin year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_OperatingLossCarryforwardsExpirationBeginYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent Of Ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of operating loss carry forwards available to offset future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenditure amortization period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_TaxCreditCarryforwardExpirationBeginYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration begin year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_TaxCreditCarryforwardExpirationBeginYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=tcon_OrphanDrugTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=tcon_OrphanDrugTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=tcon_ResearchAndDevelopmentTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=tcon_ResearchAndDevelopmentTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656801922960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Changes in Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of period</a></td>
<td class="nump">$ 10,096<span></span>
</td>
<td class="nump">$ 7,117<span></span>
</td>
<td class="nump">$ 6,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Change related to prior year positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year positions</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of period</a></td>
<td class="nump">$ 10,628<span></span>
</td>
<td class="nump">$ 10,096<span></span>
</td>
<td class="nump">$ 7,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656800952560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanPlanNameExtensibleList', window );">Defined contribution, plan name</a></td>
<td class="text">us-gaap:RetirementPlanNameOtherMember<span></span>
</td>
<td class="text">us-gaap:RetirementPlanNameOtherMember<span></span>
</td>
<td class="text">us-gaap:RetirementPlanNameOtherMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution amount</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanPlanNameExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanPlanNameExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MJM:+::AHW<6T"Y,<B%7'SFP'NOWZV4Z:00D4JG%!;.><U\_K'"<>K;EXE!F
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MNH'X?E44U?--_>;#\5V:V?]02P,$%     @ #XAE6-W*=PBW!P  -R<  !@
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M-VCFZ1N^A.?2_J)MG=OO.RBII.)% ]8=%)353_+2Z+ '< =' %X#\-X"@B,
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M_'T:+^437C,H/<LU-Z&,"-JU&$,IY1[E%IV#Y^8.<1S+W)WLT5<J^?F@VTD
MJ3MKSS:V=77/<YC^B/8VU%2$)YJ!HJQ>*OHQBGRE&4BL\MMERU# "D6JL6"H
MN[%KCE6+(0P/J:1&6[-F/F)6T5NFLFT0_PY(=Z<W)75/IB.D;#E^RAN'L$"/
MX(4*KF8UPP8,^L%1=1!W 1L [-3IEO'MA)H92 ,<U_#HW(7L.T! %(2NEUPP
MI6";( #DZ35U=GSB,$M/8\9&'F#@!BA*>5]7OTIB*-BBA"<1*^T<O-.FH^^/
M!T*<&^T-(UM"RM2HU*+,7&([W98!A(U$B!J^,(\ZK'1^&[Y ZY+#O$%PX R
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M[%UW$SOM;=8@H(V/@\+H=-+[L)'DDXDX/NE]T@Z5CC>UMU5ET[_>I>7Z/*X
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MN:H_-F6-LG4PQ.DM^ ?-"!FXK"RN1@+V;Q ,U$: 9SY5Q082_$>M-@#I;EV
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MM$Y9\'$6N5KOOO,O6>074<XPOLHSU X<MG"BNFU?'X^RI^6ZM61/0_8BUQ_
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M760_JAP\E]G-VD@)]K?VQ46+G6C]1>ZAOG90K_9 O;S*WNFZW=CLA[J0Q1#
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M]O3$-0+#0ZL;_K,D2]VVNN*/&RD02&@!?E]IW88'VB#^G9I7_P102P,$%
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M-Y&3%1?EDS/T5Y*?F[U#2LE>#1UA\9=AUOK=!+_D)WYQ N]UY0H+;ZH<\T.
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M1VDPIO "T+G+YB QTUFC\\-'A6[PX.7):[*F*/*PNKU7KQP>:KIC?-_X%?_
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M@.EDK]LX7;=2L]6.A*M=EO2E0.,-Z'ZGZ?'[C0\P?'N6OP!02P,$%     @
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M2> D<[K1X$8U;6=QV4515<51@9=@K]$H[=_!^TY+;E$(;UKQ)^M%27)\@@^
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ML@;M#/!_I93=3UR X?I?_ ]02P,$%     @ #XAE6"$(-@#6 P  !@H  !D
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MBM6%N96;G['5XPBFLM#N%S:M;>A!6FLCR]:9&)1<-/_LH<W#6QSBUB%VO)M
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MS.FAALH:T/I*2K,=V #=TV_^#U!+ P04    "  /B&58:O,)<3 &  !@$0
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MY>EC 6.PK3.0M@:>TT&)+WGB$-^S"76I/R#/[QSVC3S_1QQ^+S0G?\UOE)8
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MS'ZROL_7+UILS!WZ1FBXD9O'-6?@'A+ _E+ #;)Y007=GRJS?P%02P,$%
M  @ #XAE6+#I^E?^ P  ,PH  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&ULK59M;]LV$/[N7W%0MR(!LLB2;-E.; -)NF(%$B1(VA7#L ^T=+:(4J1&
M4G&R7[\CI2AVYVK#-L"0^7;//<=[>.1\J_074R!:>"J%-(N@L+8Z"T.3%5@R
M<ZHJE#2S5KIDEKIZ$YI*(\N]42G">#A,PY)Q&2SG?NQ.+^>JMH)+O--@ZK)D
M^OD2A=HN@BAX&;CGF\*Z@7 YK]@&']!^JNXT]<(.)><E2L.5!(WK17 1G5VF
M;KU?\#/'K=EI@XMDI=07U_F0+X*A(X0",^L0&/T]XA4*X8"(QN\M9M"Y=(:[
M[1?T]SYVBF7%#%XI\9GGME@$TP!R7+-:V'NU_0G;>,8.+U/"^"]LF[6360!9
M;:PJ6V-B4'+9_+.G=A]V#*;#;QC$K4'L>3>./,MWS++E7*LM:+>:T%S#A^JM
MB1R7+BD/5M,L)SN[O$8*R<#11[82:([GH250-Q5F+<!E Q!_ R"*X49)6QCX
M4>:8[P.$Q*:C%+]0NHQ[$=]A=@I)= +Q,$YZ\)(NQ,3C)?TA_GJQ,E:3"GX[
M%&0#,3H,X4[&F:E8AHN I&]0/V*P?/LF2H?G/01''<%1'_KR@4Y:7@L$M8:'
MNJH$DNHM$W#%3 'OZ=S !]F</R?D>Q3,8@Y6P6V%F@;E!IH@#T76Z_MP9'LD
M,D=B[4CP'1+ZE83J2(AFI[?, /W62I 5:8M+L(6J#9.Y.3X;_(),MVH!RC66
M*]0NWP.7;Y?TV'VB@8^^8CRG(V$+ GEUU'$R\!TD\9"^\71,WU$:#>YO/Y%[
M@]80RTQM)/^#/)$]/F4%DQLD9AHD%0S/%]1*\(V/RJ&]?3.-H_A\KQ6=1-$$
M>C(][C(]_G>9OF2"R0SAP1?B_Y#MO_&_ZW/5^FR*__^1W!.WQ5C9=F,MZA)H
M'')N,E5+"P2%I(##61_<8Z6T\\O,V>#6%K2@S>-1E]-C2L=L.&Z2$B>#B\PC
M&Q+*LRMAWA_+,ET3#C[1W>7+6T-(<+;B@MMGAQ(GJ4.935M70LG-#Y[RRS)^
MT'*2Q#!+9X./RFWB_K2S('[IM.&73@:?_;7@8GJDC23M:7179;>AS28EIPF,
M3I._KM[;.8@B6O=]^]<CQ[238_J/Y7C#;*V;"*CWE=3@^C7 0ZKK=7.XQEQX
M/[M*\/7^A-2$=,'MDG$C5ZJLF'SV9W)R;K[6Y5X&F,:^^D-N1JYL)"/7'$,R
MFKE&"DDZ=HT).&'MII>TY<Z,<3F=1(-K- 9X6=76UQ7*(!H+1\0_@>/6L(]?
MHY!#^0MW+O(2]<8_5PQX"31W>C?:O8@NFH? Z_+F.77#](9311.X)M/AZ80J
M@VZ>*$W'JLH_"U;*TB/#-PMZU:%V"VA^K91]Z3@'W3MQ^2=02P,$%     @
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MV.K0>PGO-9%O%T7WE,'G!T,++)Z:8O\,7"^Z;  =":4Z8M]#=OE[W>5''34
MJX#[9M8=H1VSWNLYWZJ=_G<#&)S40Q"U-X#OH>'\O8CS[?*KLP8P/.EX0;^=
M<*>RSCTX1LB)2,WIBD3FP[\Z46B>-B<XU^;<PMT/KXY_'K!(*9,H(VLP]2X'
M4'>B.E&I;A0OS*'$BBO%<W.Y(1B"I ? ^S7GZO5&3]"<:TW_!5!+ P04
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M7]F<*IJ!%@?7F#\*;=I\=UN:DQA(&V">[X1IJ=N!?4%WMMO\!U!+ P04
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MF. ]#H0NP/$YY^JCH:\*U<TP_ U02P,$%     @ #XAE6 '+0S8Z @  S 0
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M_H([+[6FM\"/P/@#R_X 4$L#!!0    (  ^(95B"0^&(EP(  -\'   9
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MJK:6*GOKT!%:78=-V>*VURU[I&KO9=7D[J9JJTU!T=[J$TR3=D/E TL4X;!
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MSNNAFH]J :J%E*:6?YN56_JL'%EFW>A?U]+?A8/;!0W74<U!-1?5/%3S42U
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MH783:'REE'TPW"7:/H'Q;U!+ P04    "  /B&58-*+NG&0#   !#@  &0
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M&NMX49TWJH;B>?F-O^1*GQC*VZT^HZ$P'?3[->?JT##'AN;4%WT#4$L#!!0
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MT0[G))@5/DQ@_ 4\WVHDV3E^6/JG+G\'4$L#!!0    (  ^(95AT2V5HX L
M "B1   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+V=76_;R!F%_\I
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M+$NJ0_5$%NEV&Q6%7)Z75EUBG%Q<VYV15?W3K^XSXY'T%1H21I$PAH1Q)$R
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M1MT.)\3J[)2&MLNA-(&BZ6IKO!#WS_%"S,WTEAW4"X'2J-NQR)/M=\H.ZH5
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M-WP)9]+^PK*)]1Q(YE+QH@'K# I:UO_DM?%A#1#TMP""!A#L"P@;0+@OH-<
M>M:96HKU(2:*1&/!ER!,M&8S#6NF16OYM#3;/E5"SU*-4]%4\>0YYRQ%(;_
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M*@0M]&5*<$*8,I#WUY2*PT MT)[3S7\!4$L#!!0    (  ^(95CW#TS%; H
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MDCO%LN*_?7*N&S#N;X )(.?%@L;L<J C1,'D$QM<_?UOSO'H'WT20L)\)"Q
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M+W=O<FMS:&5E=',O<VAE970T."YX;6RM55UOTS 4_2M6F-"08/EL-XTVTMJ
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MFD%9 _R^D-)L-O:"?MBG_P!02P,$%     @ #XAE6"H(B[ZP P  %@X  !D
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MG<P9>]63^W1L.3H@*""16@&KOR5,H2BTD KC=ZMI=:_4Q,WQ6OV[\:Z\S+&
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M0<C=UH&YVI\LMZ2P+J9A/U-R75,1<0,V/LU9\$C%@(RHX&/-@971G(NE&^[
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M"^(M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
M;T6]E4!O1;V50&]#O8U ;T.]C4!O0[V-0&\;O2PAT-M0;R/0VU!O(]#;4&\C
MT-M0;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;46\GT-M1;R?0VT<ONPGT=M3;
M"?1VU-L)]';4VPGT=M3;"?1VU-L)](ZH=R30.Z+>D4#OB'I' KTCZAT)](ZH
M=R30.XX^5OZGWKF<=BE?>[[7>/W_I+J<STW7RU^6WSM'-]0%YP _-SQ^ 5!+
M P04    "  /B&58%-1QY- !  "M(   $P   %M#;VYT96YT7U1Y<&5S72YX
M;6S-VLENPC 4!=!?0=E6Q'@('01LVFY;%OT!-WE 1!);MJ'P]W7"(+6BJ(A*
MO1LB8OO=%ULZFV3TMK7D>YNZ:OPX681@'QCS^8)J[5-CJ8DC,^-J'>)?-V=6
MYTL])R8&@R'+31.H"?W0UD@FHR>:Z545>L^;>-N7IADGCBJ?]!YW$]NL<:*M
MK<I<ASC.UDWQ+:6_3TCCRFZ.7Y36W\0)"3N9T([\'+!?][HFY\J">E/MPHNN
MXRRVJ9@/VXI\>K[$B1[-;%;F5)A\5<<EJ;>.=.$71*&NTEW1F_/)(>XP[7[Y
MU?E=F7.!<>;4&>OCB3FZ/.YP).WJOHV%R(7R_",>$V/IJY^/VM,NJ/AE=MS>
M#^.6W7EXUEVNW^.O9WRL?V$? J0/"=*' NDC ^EC"-+'+4@?=R!]W(/TP0<H
MC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM
MD56@R"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJP*15:%(FN&(FN&(FN&(FN&(FN&(FOVG[*^&[/\
MZQ?H[36M==D<\EGWE<+D$U!+ 0(4 Q0    (  ^(95@'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M#XAE6(5U1@_M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ #XAE6)E<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  /B&58O627
MQ]@'  !P,P  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ #XAE6&B>V0E=!0  A!8  !@
M ("!&A   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  ^(
M95B8_=V7" ,   H*   8              " @:T5  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  /B&5852[)6Q %  "O%0  &
M        @('K&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ #XAE6!.N@TH;!P  5S,  !@              ("!,1X  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  ^(95C=RG<(MP<  #<G   8
M              " @8(E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  /B&589JD#860"  "'!@  &               @(%O+0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ #XAE6"\L1Q8K'0
M1%@  !@              ("!"3   'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    (  ^(95A"1N\!, 8  -0/   8              " @6I-
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  /B&58;#.=
ML;(#  !H"   &0              @('04P  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    (  ^(95@X<D& +@X  $@L   9
M  " @;E7  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M#XAE6'S%^1P^ P  ;P<  !D              ("!'F8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  /B&58#.G@.+X1   ,.@  &0
M            @(&3:0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    (  ^(95B; 56'Y10  +-&   9              " @8A[  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ #XAE6&96@0\1!0
MZ@L  !D              ("!I)   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  /B&58*=1/R>L*  !^'@  &0              @('L
ME0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  ^(95C(
M9FW;Z (  '(&   9              " @0ZA  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ #XAE6)B5?']0'@  1&$  !D
M     ("!+:0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ^(95AJ\PEQ, 8  & 1   9              "
M@<C1  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ #XAE
M6+#I^E?^ P  ,PH  !D              ("!+]@  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  /B&583 98/@4%  !.#0  &0
M        @(%DW   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   (  ^(95AVTT9Z9P0  .,2   9              " @:#A  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ #XAE6.K1241Z P  YPT
M !D              ("!/N8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  /B&58]X5L1P\#   E"@  &0              @('OZ0
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  ^(95@!RT,V
M.@(  ,P$   9              " @37M  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ #XAE6()#X8B7 @  WP<  !D
M ("!IN\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  /
MB&58E4TZ'&@#  ")#@  &0              @(%T\@  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  ^(95CR[DXAJ (  .P&   9
M          " @1/V  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#
M%     @ #XAE6/VMCM)W P  # P  !D              ("!\O@  'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  /B&58V <W:O *  "&
MC@  &0              @(&@_   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;%!+ 0(4 Q0    (  ^(95@=#?I@C@(   X'   9              " @<<'
M 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ #XAE6#2B
M[IQD P   0X  !D              ("!C H! 'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6Q02P$"% ,4    "  /B&58317$L3 "  #V!   &0
M    @($G#@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M  ^(95AT2V5HX L  "B1   9              " @8X0 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ #XAE6$*?44NT P  NQ   !D
M             ("!I1P! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  /B&58H+,=N<$'   6/P  &0              @(&0( $ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  ^(95@ND;V"6 ,
M /8,   9              " @8@H 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ #XAE6&_"?^G: P  I!$  !D              ("!
M%RP! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  /B&58
M$;NYI1<#  "C"0  &0              @($H, $ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    (  ^(95AU],Y\2@,  (,-   9
M      " @78S 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ #XAE6)GH0P7J P  LQ,  !D              ("!]S8! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  /B&58]P],Q6P*  #67@
M&0              @($8.P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    (  ^(95@&OKU)_@(  #T*   9              " @;M% 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ #XAE6+C-B&/*
M @  ^ <  !D              ("!\$@! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  /B&58*@B+OK #   6#@  &0
M@('Q2P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  ^(
M95CWNG""W@(  *<)   9              " @=A/ 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ #XAE6%JG+7_H P  1PT  !D
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M=#4U+GAM;%!+ 0(4 Q0    (  ^(95BTU*L)2@,  / 4   -
M  "  ;!G 0!X;"]S='EL97,N>&UL4$L! A0#%     @ #XAE6)>*NQS
M$P(   L              ( !)6L! %]R96QS+RYR96QS4$L! A0#%     @
M#XAE6+)!2]ED!   TR0   \              ( !#FP! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  ^(95B\ =;!X $  .P@   :              "
M 9]P 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  ^(
M95@4U''DT $  *T@   3              "  ;=R 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     _ #\ ,!$  +AT 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995453 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995503 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995543 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995613 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995623 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995633 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995643 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in the Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in the Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995653 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Available-for-sale Securities and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Schedule of Available-for-sale Securities and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995663 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995673 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995683 - Disclosure - Balance Sheet Details - Schedule Of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Details - Schedule Of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995693 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995703 - Disclosure - Balance Sheet Details - Schedule Of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule Of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995713 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995723 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt and Unamortized Debt Discount Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long-Term Debt and Unamortized Debt Discount Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995733 - Disclosure - Long-Term Debt - Schedule of Exercisable Outstanding Warrants for Purchase of Common Stock Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Exercisable Outstanding Warrants for Purchase of Common Stock Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995743 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995753 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995763 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants for Purchase of Common Stock Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Outstanding Warrants for Purchase of Common Stock Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995773 - Disclosure - Stockholders' Equity - (SBC) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - (SBC) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995783 - Disclosure - Stockholders' Equity- Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity- Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995793 - Disclosure - Stockholders' Equity - Summary of Company's Outstanding Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Company's Outstanding Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995803 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Fair Value of the Employee Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Weighted-Average Assumptions Fair Value of the Employee Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995813 - Disclosure - Stockholders' Equity - Summary of Allocation of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Allocation of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995823 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995833 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995843 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995853 - Disclosure - Leases - Supplemental cash flow information related to operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Supplemental cash flow information related to operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995863 - Disclosure - Leases - Supplemental balance sheet information related to operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Supplemental balance sheet information related to operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995873 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995883 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995893 - Disclosure - Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995903 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995913 - Disclosure - Income Taxes - Schedule of Changes in Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Changes in Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tcon-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995923 - Disclosure - 401(k) Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails</Role>
      <ShortName>401(k) Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="tcon-20231231.htm">tcon-20231231.htm</File>
    <File>tcon-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img19885085_0.jpg</File>
    <File>img19885085_1.jpg</File>
    <File>img19885085_10.jpg</File>
    <File>img19885085_11.jpg</File>
    <File>img19885085_2.jpg</File>
    <File>img19885085_3.jpg</File>
    <File>img19885085_4.jpg</File>
    <File>img19885085_5.jpg</File>
    <File>img19885085_6.jpg</File>
    <File>img19885085_7.jpg</File>
    <File>img19885085_8.jpg</File>
    <File>img19885085_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="491">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tcon-20231231.htm": {
   "nsprefix": "tcon",
   "nsuri": "http://www.traconpharma.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "tcon-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "tcon-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 240,
   "keyCustom": 78,
   "axisStandard": 24,
   "axisCustom": 1,
   "memberStandard": 28,
   "memberCustom": 42,
   "hidden": {
    "total": 15,
    "http://fasb.org/us-gaap/2023": 12,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 155,
   "entityCount": 1,
   "segmentCount": 75,
   "elementCount": 655,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 491,
    "http://xbrl.sec.gov/dei/2023": 38
   },
   "report": {
    "R1": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100030 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "longName": "100050 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995453 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements",
     "longName": "995463 - Disclosure - Financial Instruments and Fair Value Measurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "longName": "995473 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:BalanceSheetRelatedDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:BalanceSheetRelatedDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt",
     "longName": "995483 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995493 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995503 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements",
     "longName": "995513 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995523 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995533 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlan",
     "longName": "995543 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995553 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995563 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables",
     "longName": "995573 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "longName": "995583 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:ScheduleOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:ScheduleOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables",
     "longName": "995593 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "longName": "995603 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995613 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995623 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995633 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
     "longName": "995643 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in the Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in the Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails",
     "longName": "995653 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Available-for-sale Securities and Equity Securities (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Schedule of Available-for-sale Securities and Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995663 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995673 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_aa5025a8-1fb4-4cdf-bae0-549dd0c077ec",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa5025a8-1fb4-4cdf-bae0-549dd0c077ec",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails",
     "longName": "995683 - Disclosure - Balance Sheet Details - Schedule Of Property and Equipment (Details)",
     "shortName": "Balance Sheet Details - Schedule Of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfPropertyAndEquipmentTableTextBlock",
       "div",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfPropertyAndEquipmentTableTextBlock",
       "div",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
     "longName": "995693 - Disclosure - Balance Sheet Details - Additional Information (Details)",
     "shortName": "Balance Sheet Details - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "longName": "995703 - Disclosure - Balance Sheet Details - Schedule Of Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Balance Sheet Details - Schedule Of Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock",
       "div",
       "tcon:BalanceSheetRelatedDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
     "longName": "995713 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_676e7f5e-a774-4005-88e2-f5d56efdc8e9",
      "name": "tcon:MaximumCapitalContribution",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_676e7f5e-a774-4005-88e2-f5d56efdc8e9",
      "name": "tcon:MaximumCapitalContribution",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails",
     "longName": "995723 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt and Unamortized Debt Discount Balances (Details)",
     "shortName": "Long-Term Debt - Schedule of Long-Term Debt and Unamortized Debt Discount Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_8f06370c-a07e-49f3-9851-fcdb008745c6",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f06370c-a07e-49f3-9851-fcdb008745c6",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
     "longName": "995733 - Disclosure - Long-Term Debt - Schedule of Exercisable Outstanding Warrants for Purchase of Common Stock Issued (Details)",
     "shortName": "Long-Term Debt - Schedule of Exercisable Outstanding Warrants for Purchase of Common Stock Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995743 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_3bdfeab3-03b0-41d5-bcd4-2f2f5ac6bc5f",
      "name": "tcon:CollaborativeArrangementsMilestonePaymentsPotential",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3bdfeab3-03b0-41d5-bcd4-2f2f5ac6bc5f",
      "name": "tcon:CollaborativeArrangementsMilestonePaymentsPotential",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995753 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702",
      "name": "tcon:MaximumAggregateValueOfStockToBePurchased",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
     "longName": "995763 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants for Purchase of Common Stock Issued (Details)",
     "shortName": "Stockholders' Equity - Schedule of Outstanding Warrants for Purchase of Common Stock Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_076a27be-5a0e-4964-acbe-3687b701e0a6",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
     "longName": "995773 - Disclosure - Stockholders' Equity - (SBC) - Additional Information (Details)",
     "shortName": "Stockholders' Equity - (SBC) - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c0640ea-6b2e-4706-b104-cc1b0629bca4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "longName": "995783 - Disclosure - Stockholders' Equity- Summary of Stock Option Activity (Details)",
     "shortName": "Stockholders' Equity- Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c0640ea-6b2e-4706-b104-cc1b0629bca4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
     "longName": "995793 - Disclosure - Stockholders' Equity - Summary of Company's Outstanding Stock Option (Details)",
     "shortName": "Stockholders' Equity - Summary of Company's Outstanding Stock Option (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails",
     "longName": "995803 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Fair Value of the Employee Stock Option Grants (Details)",
     "shortName": "Stockholders' Equity - Summary of Weighted-Average Assumptions Fair Value of the Employee Stock Option Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_5c0640ea-6b2e-4706-b104-cc1b0629bca4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c0640ea-6b2e-4706-b104-cc1b0629bca4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails",
     "longName": "995813 - Disclosure - Stockholders' Equity - Summary of Allocation of Stock-Based Compensation Expense (Details)",
     "shortName": "Stockholders' Equity - Summary of Allocation of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "995823 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Details)",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_639cfa51-d355-4e4e-883d-a0c36228443f",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "longName": "995833 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "longName": "995843 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:NonCancelableOperatingLeaseExpirationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:NonCancelableOperatingLeaseExpirationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
     "longName": "995853 - Disclosure - Leases - Supplemental cash flow information related to operating leases (Details)",
     "shortName": "Leases - Supplemental cash flow information related to operating leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:CashPaidWithinOperatingCashFlows",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "tcon:CashPaidWithinOperatingCashFlows",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
     "longName": "995863 - Disclosure - Leases - Supplemental balance sheet information related to operating leases (Details)",
     "shortName": "Leases - Supplemental balance sheet information related to operating leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "longName": "995873 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tcon:ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails",
     "longName": "995883 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails",
     "longName": "995893 - Disclosure - Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of deferred tax assets and deferred tax Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecaa62df-706a-45f3-889a-732b21b200f2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995903 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails",
     "longName": "995913 - Disclosure - Income Taxes - Schedule of Changes in Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Changes in Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_8f06370c-a07e-49f3-9851-fcdb008745c6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
     "longName": "995923 - Disclosure - 401(k) Plan - Additional Information (Details)",
     "shortName": "401(k) Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb97f606-1fe3-428b-be6a-b8b232235366",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcon-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable and Accrued Liabilities, Fair Value Disclosure, Total",
        "label": "Accounts Payable and Accrued Liabilities, Fair Value Disclosure",
        "terseLabel": "Accrued clinical related expenses",
        "documentation": "Fair value portion of trade and related party payables and accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts payable and accrued expenses (lease liability)",
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r659"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "tcon_AccruedLongTermDebtTerminalInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AccruedLongTermDebtTerminalInterestCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued long-term debt terminal interest, current.",
        "label": "Accrued Long Term Debt Terminal Interest Current",
        "terseLabel": "Accrued long-term debt terminal interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal and accounting",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r136",
      "r515"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "tcon_AdditionalCommonSharesToBeUsedForSpecificAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AdditionalCommonSharesToBeUsedForSpecificAward",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional shares of common stock to be used exclusively for a specified award of the entity.",
        "label": "Additional Common Shares To Be Used For Specific Award",
        "terseLabel": "Additional shares to be used exclusively for grant for Inducement awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r537",
      "r772",
      "r773",
      "r774",
      "r836",
      "r852"
     ]
    },
    "tcon_AdditionalPaymentOnPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AdditionalPaymentOnPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional payment on performance obligation",
        "label": "Additional Payment On Performance Obligation",
        "documentation": "Additional payment on performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r341"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrants in connection with debt financing",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AfterFirstAnniversaryDateButOnOrPriorToSecondAnniversaryDateMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After the first anniversary date but on or prior to the second anniversary date.",
        "label": "After First Anniversary Date But On Or Prior To Second Anniversary Date [Member]",
        "terseLabel": "After First Anniversary Date But On Or Prior To Second Anniversary Date"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_AfterINDBeforePhaseOneAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AfterINDBeforePhaseOneAMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After IND before phase one a.",
        "label": "After I N D Before Phase One A [Member]",
        "terseLabel": "After IND Before Phase 1a"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_AfterPhaseOneAAndBeforePhaseSecondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AfterPhaseOneAAndBeforePhaseSecondMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After phase one a and before phase second.",
        "label": "After Phase One A And Before Phase Second [Member]",
        "terseLabel": "After Phase 1a and Before Phase 2"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_AfterPhaseSecondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AfterPhaseSecondMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After phase Second.",
        "label": "After Phase Second [Member]",
        "terseLabel": "After Phase 2"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_AfterSecondAnniversaryDateButPriorToMaturityDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "AfterSecondAnniversaryDateButPriorToMaturityDateMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After the second anniversary date but prior to the maturity date.",
        "label": "After Second Anniversary Date But Prior To Maturity Date [Member]",
        "terseLabel": "After Second Anniversary Date But Prior To Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r694",
      "r704",
      "r730"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r697",
      "r707",
      "r733"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r698",
      "r708",
      "r725",
      "r734",
      "r738",
      "r746"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r380"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r442",
      "r646",
      "r647",
      "r766"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "tcon_ArbitrationAwardInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ArbitrationAwardInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Arbitration Award Interest Expense",
        "documentation": "Arbitration award interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ArbitrationAwardNonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ArbitrationAwardNonCashInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash interest",
        "label": "Arbitration Award Non Cash Interest Expense",
        "documentation": "Arbitration award non cash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ArbitrationFinancingPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ArbitrationFinancingPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbitration financing payable.",
        "label": "Arbitration Financing Payable",
        "terseLabel": "Arbitration financing payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ArbitrationSuccessFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ArbitrationSuccessFees",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Arbitration success fees",
        "terseLabel": "Arbitration success fees",
        "label": "Arbitration Success Fees",
        "documentation": "Arbitration success fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r138",
      "r160",
      "r191",
      "r204",
      "r208",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r411",
      "r415",
      "r434",
      "r508",
      "r573",
      "r659",
      "r671",
      "r799",
      "r800",
      "r841"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r145",
      "r160",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r411",
      "r415",
      "r434",
      "r659",
      "r799",
      "r800",
      "r841"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value, assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r690"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r690"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r690"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r252",
      "r506"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r252",
      "r502",
      "r777"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_BalanceSheetRelatedDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "BalanceSheetRelatedDisclosuresTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet related disclosures.",
        "label": "Balance Sheet Related Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_BeforeINDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "BeforeINDMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Before IND.",
        "label": "Before I N D [Member]",
        "terseLabel": "Before IND"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_BispecificAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "BispecificAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bispecific agreement.",
        "label": "Bispecific Agreement [Member]",
        "terseLabel": "Bispecific Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_BonneAdamsMBAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "BonneAdamsMBAMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonne Adams, M.B.A.",
        "label": "Bonne Adams, M.B.A. [Member]",
        "documentation": "Bonne Adams, M.B.A."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_BonneAdamsMBAOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "BonneAdamsMBAOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonne Adams, M.B.A.",
        "label": "Bonne Adams, M.B.A. One [Member]",
        "documentation": "Bonne Adams, M.B.A."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_BusinessCollaborationAdditionalPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "BusinessCollaborationAdditionalPaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business collaboration additional payment amount.",
        "label": "Business Collaboration Additional Payment Amount",
        "terseLabel": "Additional payment"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital on demand sales agreement.",
        "label": "Capital On Demand Sales Agreement [Member]",
        "terseLabel": "Capital on Demand Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r134",
      "r633"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r83",
      "r158"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r83"
     ]
    },
    "tcon_CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, restricted cash, and other assets fair value disclosure.",
        "label": "Cash Equivalents Restricted Cash And Other Assets Fair Value Disclosure",
        "totalLabel": "Total cash equivalents, restricted cash, and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CashPaidWithinOperatingCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CashPaidWithinOperatingCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid within operating cash flows.",
        "label": "Cash Paid Within Operating Cash Flows",
        "terseLabel": "Cash paid within operating cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of pre-funded warrants to purchase common stock.",
        "label": "Cashless Exercise Of Prefunded Warrants To Purchase Common Stock",
        "terseLabel": "Cashless exercise of pre-funded warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "tcon_CharlesPTheuerMDPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CharlesPTheuerMDPhDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charles P. Theuer, M.D., Ph.D.",
        "terseLabel": "Charles P. Theuer, M.D., Ph.D.",
        "label": "Charles P. Theuer, M.D., Ph.D. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CharlesPTheuerMDPhDOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CharlesPTheuerMDPhDOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charles P. Theuer, M.D., Ph.D.",
        "label": "Charles P. Theuer, M.D., Ph.D.one [Member]",
        "documentation": "Charles P. Theuer, M.D., Ph.D.one."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r142",
      "r143",
      "r144",
      "r160",
      "r180",
      "r181",
      "r183",
      "r185",
      "r189",
      "r190",
      "r244",
      "r264",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r301",
      "r302",
      "r304",
      "r305",
      "r307",
      "r434",
      "r530",
      "r531",
      "r532",
      "r533",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r561",
      "r582",
      "r600",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r753",
      "r768",
      "r775"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r189",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r530",
      "r531",
      "r532",
      "r533",
      "r648",
      "r753",
      "r768"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Conversion of warrants to purchase shares",
        "verboseLabel": "Conversion of warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "tcon_ClassOfWarrantsOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ClassOfWarrantsOrRightExercised",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or right exercised.",
        "label": "Class Of Warrants Or Right Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ClinicalTrialExpenseAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ClinicalTrialExpenseAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for clinical trial expense accruals.",
        "label": "Clinical Trial Expense Accruals Policy [Text Block]",
        "terseLabel": "Clinical Trial Expense Accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "tcon_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement member.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CollaborationAgreementPercentageOfCostBearing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CollaborationAgreementPercentageOfCostBearing",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement percentage of cost bearing.",
        "label": "Collaboration Agreement Percentage Of Cost Bearing",
        "terseLabel": "Percentage of cost bearing"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CollaborationsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CollaborationsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations disclosure.",
        "label": "Collaborations Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r119",
      "r128"
     ]
    },
    "tcon_CollaborativeArrangementMilestonePaymentsPotential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentsPotential",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential payments that could be received under the collaborative agreement..",
        "label": "Collaborative Arrangement Milestone Payments Potential",
        "terseLabel": "Potential payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "tcon_CollaborativeArrangementsMilestonePaymentsPotential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CollaborativeArrangementsMilestonePaymentsPotential",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential payments that could be paid under the collaborative agreement.",
        "label": "Collaborative Arrangements Milestone Payments Potential",
        "terseLabel": "Potential milestone payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CommercialSale",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial sale.",
        "label": "Commercial Sale",
        "terseLabel": "Commercial sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r60",
      "r509",
      "r560"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r258",
      "r259",
      "r619",
      "r795"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r772",
      "r773",
      "r836",
      "r851",
      "r852"
     ]
    },
    "tcon_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options.",
        "label": "Common Stock Options [Member]",
        "terseLabel": "Common Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "tcon_CommonStockPurchasePriceOfOnePointThreeEightPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CommonStockPurchasePriceOfOnePointThreeEightPerShareMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Price Of $1.38 Per Share",
        "label": "Common Stock Purchase Price Of One Point Three Eight Per Share [Member]",
        "documentation": "Common stock purchase price of one point three eight per share."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CommonStockPurchasePriceOfOnePointThreeOnePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CommonStockPurchasePriceOfOnePointThreeOnePerShareMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase price of one point three one per share.",
        "label": "Common Stock Purchase Price Of One Point Three One Per Share [Member]",
        "terseLabel": "Purchase Price of $1.31 Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Price Of $1.37 Per Share",
        "label": "Common Stock Purchase Price Of One Point Three Seven Per Share [Member]",
        "documentation": "Common stock purchase price of one point three seven per share."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase price of one point three two per share.",
        "label": "Common Stock Purchase Price Of One Point Three Two Per Share [Member]",
        "terseLabel": "Purchase Price of $1.32 Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r561"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r561",
      "r579",
      "r852",
      "r853"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; authorized shares - 60,000,000 and 40,000,000 at December 31, 2023 and December 31, 2022, respectively; issued and outstanding shares - 44,269,976 and 23,125,250 at December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r511",
      "r659"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer And Office Equipment [Member].",
        "label": "Computer And Office Equipment [Member]",
        "terseLabel": "Computer And Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r121"
     ]
    },
    "tcon_ConsiderationGivenInExchangeForAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ConsiderationGivenInExchangeForAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration given in exchange for assets acquired.",
        "label": "Consideration Given In Exchange For Assets Acquired",
        "terseLabel": "Consideration exchanged for assets acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Organization and Business",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r637"
     ]
    },
    "us-gaap_ConvertibleCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleCommonStockMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Common Stock [Member]",
        "terseLabel": "Common Stock.",
        "documentation": "Common stock securities that may be converted to another form of security."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r277",
      "r303",
      "r456",
      "r634",
      "r636"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current",
        "totalLabel": "Total",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r159",
      "r273",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r289",
      "r296",
      "r297",
      "r299"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r107",
      "r109",
      "r164",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r443",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": "tcon_LongTermDebtNetOfUnamortizedLongTermAmortization",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r109",
      "r300"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Long term debt, principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r274",
      "r443",
      "r644",
      "r645"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r443",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r164",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r443",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r38",
      "r41",
      "r57",
      "r58",
      "r59",
      "r61",
      "r93",
      "r94",
      "r164",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r443",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount, Current",
        "terseLabel": "Current portion of debt discount",
        "negatedLabel": "Current portion of debt discount",
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": "tcon_LongTermDebtNetOfUnamortizedLongTermAmortization",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "negatedLabel": "Less debt discount, net of current portion",
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities and Equity Securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r108",
      "r396"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Section 174 capitalized research expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r834"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r834"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r834"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_DeferredTaxAssetsRightOfUseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "DeferredTaxAssetsRightOfUseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset right of use liability.",
        "label": "Deferred Tax Assets Right Of Use Liability",
        "terseLabel": "Right-of-use liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development and Orphan Drug credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r834"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Other accruals",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r834"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r834"
     ]
    },
    "tcon_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract1",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan [Abstract].",
        "label": "Defined Contribution Pension And Other Postretirement Plans Disclosure Abstract1",
        "terseLabel": "Defined Contribution Pension and Other Postretirement Plans Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanPlanNameExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanPlanNameExtensibleList",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Plan Name [Extensible Enumeration]",
        "terseLabel": "Defined contribution, plan name",
        "documentation": "Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense related to property and equipment",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r31"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r194"
     ]
    },
    "tcon_DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "DevelopmentRegulatoryBasedMilestonePaymentsUnderLicenseAndOptionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory milestone payments to be paid under license and option agreement.",
        "label": "Development Regulatory Based Milestone Payments Under License And Option Agreement",
        "terseLabel": "Development and regulatory based on milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_DirectOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "DirectOfferingsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct offerings.",
        "label": "Direct Offerings [Member]",
        "terseLabel": "Direct Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r690"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r690",
      "r726"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r178",
      "r180",
      "r183",
      "r184",
      "r185",
      "r187",
      "r425",
      "r426",
      "r503",
      "r520",
      "r638"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r180",
      "r183",
      "r184",
      "r185",
      "r187",
      "r425",
      "r426",
      "r503",
      "r520",
      "r638"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, period of recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP Shares",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employee stock purchase plan member.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "tcon_EnvafolimabCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "EnvafolimabCollaborationAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Envafolimab collaboration agreement.",
        "label": "Envafolimab Collaboration Agreement [Member]",
        "terseLabel": "Bispecific Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r130",
      "r149",
      "r150",
      "r151",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r188",
      "r245",
      "r246",
      "r309",
      "r373",
      "r374",
      "r375",
      "r402",
      "r403",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r453",
      "r523",
      "r524",
      "r525",
      "r537",
      "r600"
     ]
    },
    "tcon_EquityIncentive2015PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "EquityIncentive2015PlanMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 Equity Incentive Plan member.",
        "label": "Equity Incentive2015 Plan [Member]",
        "terseLabel": "2015 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_EquityOwnershipLicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "EquityOwnershipLicenseRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Ownership License Revenue",
        "label": "Equity Ownership License Revenue",
        "terseLabel": "Equity ownership license revenue"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_EquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "EquityPlanMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity plan.",
        "label": "Equity Plan [Member]",
        "terseLabel": "Equity Plan Activity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r694",
      "r704",
      "r730"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r691",
      "r701",
      "r727"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Short-Term Investments, Cash Equivalents and Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r432"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r432"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r429",
      "r461",
      "r462",
      "r463",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r433"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r323",
      "r328",
      "r429",
      "r461",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r323",
      "r328",
      "r429",
      "r462",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r429",
      "r463",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r461",
      "r462",
      "r463",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r433"
     ]
    },
    "tcon_FairValueTransfersBetweenLevelsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "FairValueTransfersBetweenLevelsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets or liabilities measured on a recurring basis between levels.",
        "label": "Fair Value Transfers Between Levels Amount",
        "terseLabel": "Amount of transfers between levels"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_FinalPaymentOnPayoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "FinalPaymentOnPayoff",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final payment on payoff.",
        "label": "Final Payment On Payoff",
        "terseLabel": "Final payment on payoff"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r298",
      "r306",
      "r423",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r519",
      "r642",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r789",
      "r790",
      "r791",
      "r792"
     ]
    },
    "tcon_FirstPhaseClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "FirstPhaseClinicalTrialMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First phase clinical trial.",
        "label": "First Phase Clinical Trial [Member]",
        "terseLabel": "First Phase Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_FirstPhaseTwoClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "FirstPhaseTwoClinicalTrialMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First phase two clinical trial.",
        "label": "First Phase Two Clinical Trial [Member]",
        "terseLabel": "First Phase Two Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r734"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r584"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r690"
     ]
    },
    "tcon_ImabBiopharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ImabBiopharmaMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "I-Mab",
        "label": "IMab Biopharma [Member]",
        "documentation": "IMab Biopharma."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ImpairmentOfPrivateCompanyEquityOwnership": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ImpairmentOfPrivateCompanyEquityOwnership",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of private company equity ownership.",
        "label": "Impairment Of Private Company Equity Ownership",
        "terseLabel": "Impairment of private company equity ownership"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r585"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r585"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r383",
      "r389",
      "r393",
      "r400",
      "r404",
      "r406",
      "r407",
      "r408",
      "r535"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r126",
      "r176",
      "r177",
      "r195",
      "r387",
      "r405",
      "r521"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation of effective tax rate and federal statutory tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r385",
      "r386",
      "r393",
      "r394",
      "r399",
      "r401",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income taxes",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Permanent items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, net",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "tcon_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. This does not include accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase Decrease In Accounts Payable And Accrued Expenses Excluding Accrued Compensation And Related Expenses",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and related expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r698",
      "r708",
      "r725",
      "r734",
      "r738",
      "r746"
     ]
    },
    "tcon_InhibrxLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "InhibrxLicenseAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inhibrx, Inc.(Inhibrx) License Agreement",
        "label": "Inhibrx License Agreement [Member]",
        "documentation": "Inhibrx License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_InhibrxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "InhibrxMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inhibrx",
        "label": "Inhibrx [Member]",
        "documentation": "Inhibrx."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_InitialCapitalContributionFromInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "InitialCapitalContributionFromInvestors",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial capital contribution from investors.",
        "label": "Initial Capital Contribution From Investors",
        "terseLabel": "Initial capital contribution from investors"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r750"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r750"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r750"
     ]
    },
    "tcon_InterestAndFinalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "InterestAndFinalPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal and interest payment",
        "documentation": "Amount of interest and final payment of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices.",
        "label": "Interest And Final Payment",
        "negatedLabel": "Less interest and final payment"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_InterestExpenseNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "InterestExpenseNoncash",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash interest expense included in interest expense, excluding the allocation of debt discount and premium.",
        "label": "Interest Expense Noncash",
        "terseLabel": "Noncash interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r156",
      "r157"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of premium/discount on short-term investments",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "tcon_IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock warrants issued in connection with long-term debt.",
        "label": "Issuance Of Common Stock Warrants In Connection With Long Term Debt",
        "terseLabel": "Issuance of common stock warrants in connection with long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants, net of offering costs (in shares)",
        "documentation": "Issuances of common stock and warrants, net of offering costs shares.",
        "label": "Issuances Of Common Stock And Warrants Net Of Offering Costs In Shares"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuances of common stock and warrants, net of offering costs value.",
        "label": "Issuances Of Common Stock And Warrants Net Of Offering Costs Value",
        "terseLabel": "Issuance of common stock and warrants, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_IssuancesOfCommonStockNetOfOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuancesOfCommonStockNetOfOfferingCostsShares",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuances of common stock net of offering costs shares.",
        "label": "Issuances Of Common Stock Net Of Offering Costs Shares",
        "terseLabel": "Issuances of common stock, net of offering costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_IssuancesOfCommonStockNetOfOfferingCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuancesOfCommonStockNetOfOfferingCostsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuances of common stock net of offering costs value.",
        "label": "Issuances Of Common Stock Net Of Offering Costs Value",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuances of common stock upon cashless exercise of pre-funded warrants shares.",
        "label": "Issuances Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Shares",
        "terseLabel": "Issuance of common stock upon cashless exercise of pre-funded warrants, shares",
        "verboseLabel": "Issuance of common stock upon cashless exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon cashless exercise of pre-funded warrants",
        "documentation": "Issuances of common stock upon cashless exercise of pre-funded warrants value.",
        "label": "Issuances Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Value"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_JonesTradingInstitutionalServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "JonesTradingInstitutionalServicesLLCMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jonestrading institutional services LLC.",
        "label": "Jones Trading Institutional Services L L C [Member]",
        "terseLabel": "Jones Trading Institutional Services LLC"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LeaseAssetAmortizationAndLiabilityAccretionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LeaseAssetAmortizationAndLiabilityAccretionNet",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease asset amortization and liability accretion, net.",
        "label": "Lease Asset Amortization And Liability Accretion Net",
        "terseLabel": "Lease asset amortization and liability accretion, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Irrevocable letter of credit provided to lessor",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r110",
      "r513",
      "r659",
      "r770",
      "r793",
      "r838"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r133",
      "r160",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r412",
      "r415",
      "r416",
      "r434",
      "r659",
      "r799",
      "r841",
      "r842"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LicenseAgreementTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LicenseAgreementTerm",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement term",
        "label": "License Agreement Term",
        "documentation": "License agreement term."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln park capital fund LLC.",
        "label": "Lincoln Park Capital Fund L L C [Member]",
        "terseLabel": "Lincoln Park LLC"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LincolnParkCapitalFundLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LincolnParkCapitalFundLlcMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lincoln Park Capital Fund, LLC",
        "label": "Lincoln Park Capital Fund, LLC [Member]",
        "documentation": "Lincoln Park Capital Fund, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LincolnParkPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LincolnParkPurchaseAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lincoln Park Purchase Agreement",
        "label": "Lincoln Park Purchase Agreement [Member]",
        "documentation": "Lincoln park purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Settlement received",
        "terseLabel": "Settlement received",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement received, net of termination fee",
        "label": "Litigation Settlement Amount Awarded From Other Party Net Of Termination Fee",
        "documentation": "Litigation settlement amount awarded from other party net of termination fee."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and Security Agreement.",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan And Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LoansAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LoansAndSecurityAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the loan and agreement with Silicon Valley Bank dated May, 2015.",
        "label": "Loans And Security Agreement [Member]",
        "terseLabel": "Loan And Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Long-term debt, current portion",
        "totalLabel": "Current portion of long-term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "tcon_LongTermDebtCurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LongTermDebtCurrentGross",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Current Gross",
        "terseLabel": "Current portion of long-term debt",
        "negatedLabel": "Less current portion of long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_LongTermDebtNetOfUnamortizedLongTermAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LongTermDebtNetOfUnamortizedLongTermAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term debt, net of long-term unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Net Of Unamortized Long Term Amortization",
        "totalLabel": "Long-term debt, net of debt discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfLongTermDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt, net of current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment [Table]",
        "terseLabel": "Long Term Purchase Commitment [Table]",
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r33"
     ]
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fee awarded",
        "label": "Loss Contingency, Damages Awarded, Value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798"
     ]
    },
    "tcon_LossContingencyPaymentWriteOffAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "LossContingencyPaymentWriteOffAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency payment write-off amount",
        "label": "Loss Contingency Payment Write-off Amount",
        "documentation": "Loss contingency payment write-off amount."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_MaximumAggregateValueOfStockToBePurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MaximumAggregateValueOfStockToBePurchased",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value of shares committed to purchase",
        "label": "Maximum Aggregate Value Of Stock To Be Purchased",
        "documentation": "Maximum aggregate value of stock to be purchased."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_MaximumAggregateValueOfStockToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MaximumAggregateValueOfStockToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate value of stock to be sold.",
        "label": "Maximum Aggregate Value Of Stock To Be Sold",
        "terseLabel": "Maximum aggregate value of stock to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_MaximumCapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MaximumCapitalContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum capital contribution",
        "label": "Maximum Capital Contribution",
        "terseLabel": "Maximum capital contribution"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r339",
      "r488",
      "r522",
      "r552",
      "r553",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r629",
      "r630",
      "r641",
      "r648",
      "r653",
      "r660",
      "r801",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "tcon_MaximumNumberOfProprietaryAntibodiesUnderDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MaximumNumberOfProprietaryAntibodiesUnderDevelopment",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of proprietary antibodies under development.",
        "label": "Maximum Number Of Proprietary Antibodies Under Development",
        "terseLabel": "Maximum number of proprietary bispecific antibodies under development"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of holders ownership interest in common stock after exercise.",
        "label": "Maximum Percentage Of Holders Ownership Interest In Common Stock After Exercise",
        "terseLabel": "Maximum percentage of holders ownership interest in common stock after exercise"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MaximumPeriodOfSelectingCandidatesForDevelopmentAndCommercialization",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of selecting candidates for development and commercialization.",
        "label": "Maximum Period Of Selecting Candidates For Development And Commercialization",
        "terseLabel": "Maximum period of selecting candidates for development and commercialization"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "tcon_MilestonePaymentsCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MilestonePaymentsCategoryAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments category.",
        "label": "Milestone Payments Category [Axis]",
        "terseLabel": "Milestone Payments Category"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_MilestonePaymentsCategoryDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "MilestonePaymentsCategoryDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments category.",
        "label": "Milestone Payments Category [Domain]",
        "terseLabel": "Milestone Payments Category"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r339",
      "r488",
      "r522",
      "r552",
      "r553",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r629",
      "r630",
      "r641",
      "r648",
      "r653",
      "r660",
      "r801",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r85",
      "r113",
      "r131",
      "r146",
      "r147",
      "r151",
      "r160",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r182",
      "r191",
      "r203",
      "r207",
      "r209",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r426",
      "r434",
      "r518",
      "r581",
      "r598",
      "r599",
      "r639",
      "r669",
      "r799"
     ]
    },
    "tcon_NetProceedsReceivedFromIssuanceDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NetProceedsReceivedFromIssuanceDirectOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds received from issuance direct offering.",
        "label": "Net Proceeds Received From Issuance Direct Offering",
        "terseLabel": "Net proceeds from common stock issuance"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_NonCancelableOperatingLeaseExpirationTerm": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NonCancelableOperatingLeaseExpirationTerm",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non\u2011cancelable operating lease expiration term.",
        "label": "Non Cancelable Operating Lease Expiration Term",
        "terseLabel": "Non-cancelable operating lease expiration term"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_NonCancelableOperatingLeaseTermToBeExtended": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NonCancelableOperatingLeaseTermToBeExtended",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cancelable operating lease term to be extended.",
        "label": "Non Cancelable Operating Lease Term To Be Extended",
        "terseLabel": "Non Cancelable Operating Lease Term To Be Extended"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r725",
      "r734"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "tcon_NonRoyaltyConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NonRoyaltyConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-royalty consideration amount.",
        "label": "Non Royalty Consideration Amount",
        "terseLabel": "Non-royalty consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "tcon_NonrefundableUpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NonrefundableUpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrefundable upfront fee",
        "label": "Nonrefundable Upfront Fee",
        "documentation": "Nonrefundable upfront fee."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "tcon_NumberOfAmendedPreFundedWarrants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NumberOfAmendedPreFundedWarrants",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of amended pre-funded warrants.",
        "label": "Number Of Amended Pre Funded Warrants",
        "terseLabel": "Number of amended pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_NumberOfBiologicalTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NumberOfBiologicalTargets",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of biological targets.",
        "label": "Number Of Biological Targets",
        "terseLabel": "Number of biological targets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "tcon_NumberOfTranche": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "NumberOfTranche",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of tranche.",
        "label": "Number Of Tranche",
        "terseLabel": "Number of tranche"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_OnOrPriorToFirstAnniversaryDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "OnOrPriorToFirstAnniversaryDateMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On or prior to the first anniversary date.",
        "label": "On Or Prior To First Anniversary Date [Member]",
        "terseLabel": "On Or Prior To First Anniversary Date"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_OneTimeUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "OneTimeUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One time upfront payment.",
        "label": "One Time Upfront Payment",
        "terseLabel": "One time upfront payment fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r203",
      "r207",
      "r209",
      "r639"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Other assets (ROU asset)",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r658"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r658"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforward",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "tcon_OperatingLossCarryforwardsExpirationBeginYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationBeginYear",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration begin year.",
        "label": "Operating Loss Carryforwards Expiration Begin Year",
        "terseLabel": "NOL carryforward begin to expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "tcon_OrganizationAndAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "OrganizationAndAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Accounting Policies Abstract",
        "label": "Organization And Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r86",
      "r87",
      "r103"
     ]
    },
    "tcon_OrphanDrugTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "OrphanDrugTaxCreditMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug tax credit.",
        "label": "Orphan Drug Tax Credit [Member]",
        "terseLabel": "Orphan Drug tax credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Total",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r137",
      "r507",
      "r671"
     ]
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Fair Value Disclosure",
        "terseLabel": "Other assets",
        "documentation": "Fair value portion of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities (lease liability)",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r732"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r699",
      "r709",
      "r735"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r699",
      "r709",
      "r735"
     ]
    },
    "tcon_PatentCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs Policy Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_Disclosure401KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r652"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "tcon_PercentOfOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentOfOwnership",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent Of Ownership.",
        "label": "Percent Of Ownership",
        "terseLabel": "Percent of ownership"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PercentageOfClosingFeeAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentageOfClosingFeeAmount",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing fee amount.",
        "label": "Percentage Of Closing Fee Amount",
        "terseLabel": "Percentage of closing fee amount"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock outstanding owned after sale agreement",
        "label": "Percentage of Common Stock Outstanding Owned After Sale Agreement",
        "documentation": "Percentage of common stock outstanding owned after sale agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PercentageOfFinalPaymentFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentageOfFinalPaymentFee",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of final payment fee",
        "documentation": "Percentage of final payment fee."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds, required to pay for common stock sold through sales agreement.",
        "label": "Percentage Of Gross Proceeds Required To Pay For Common Stock Sold Through Sales Agreement",
        "terseLabel": "Percentage of gross proceeds, required to pay for common stock sold through sales agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PercentageOfInitialCapitalContributionFromInvestors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentageOfInitialCapitalContributionFromInvestors",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of Initial Capital Contribution From Investors",
        "label": "Percentage of Initial Capital Contribution From Investors",
        "documentation": "Percentage of initial capital contribution from investors."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of operating loss carry forwards available to offset future taxable income.",
        "label": "Percentage Of Operating Loss Carry Forwards Available To Offset Future Taxable Income",
        "terseLabel": "NOL carryforward available to offset future taxable income, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "tcon_PlusRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PlusRateMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plus rate.",
        "label": "Plus Rate [Member]",
        "terseLabel": "Plus Rate"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_PotentialPaymentOnPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "PotentialPaymentOnPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential payment on performance obligation",
        "label": "Potential Payment on Performance Obligation",
        "documentation": "Potential payment on performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r301"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r561"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r301"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r561",
      "r579",
      "r852",
      "r853"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, authorized shares - 10,000,000 at December 31, 2023 andDecember 31,2022; issued and outstanding shares - none",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r510",
      "r659"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_PrivateEquityFundsDomesticMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivateEquityFundsDomesticMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Equity Funds, US [Member]",
        "terseLabel": "Equity securities",
        "documentation": "Private equity fund investing in company domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under equity plans",
        "verboseLabel": "Net proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "tcon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants net of offering costs.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs",
        "terseLabel": "Proceeds from sale of common stock and warrants, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r530"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12"
     ]
    },
    "tcon_ProceedsFromLongTermDebtAndArbitrationFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ProceedsFromLongTermDebtAndArbitrationFinancing",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from long-term debt and arbitration financing",
        "label": "Proceeds from long term debt and arbitration financing",
        "documentation": "Proceeds from long-term debt and arbitration financing."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ProceedsFromMaturityOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ProceedsFromMaturityOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the maturity of short-term investments",
        "label": "Proceeds From Maturity Of Short Term Investments",
        "documentation": "Proceeds from maturity of short term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfTradingSecuritiesHeldforinvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale, Debt Security, Trading, and Equity Security, FV-NI, Held-for-Investment",
        "terseLabel": "Proceeds from sale of debt and equity securities",
        "documentation": "The cash inflow associated with the sale of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r146",
      "r147",
      "r154",
      "r160",
      "r168",
      "r176",
      "r177",
      "r191",
      "r203",
      "r207",
      "r209",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r410",
      "r413",
      "r414",
      "r426",
      "r434",
      "r504",
      "r517",
      "r536",
      "r581",
      "r598",
      "r599",
      "r639",
      "r656",
      "r657",
      "r670",
      "r765",
      "r799"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r135",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r505",
      "r516",
      "r659"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r122",
      "r125",
      "r514"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Utilities, Inventory [Line Items]",
        "terseLabel": "Public Utilities Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Utilities, Inventory [Table]",
        "terseLabel": "Public Utilities Inventory [Table]",
        "documentation": "Detailed information about the type of inventory held by the utility and the carrying value of this inventory."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r321",
      "r339",
      "r367",
      "r368",
      "r369",
      "r464",
      "r488",
      "r522",
      "r552",
      "r553",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r629",
      "r630",
      "r641",
      "r648",
      "r653",
      "r660",
      "r663",
      "r794",
      "r801",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r321",
      "r339",
      "r367",
      "r368",
      "r369",
      "r464",
      "r488",
      "r522",
      "r552",
      "r553",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r629",
      "r630",
      "r641",
      "r648",
      "r653",
      "r660",
      "r663",
      "r794",
      "r801",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r691",
      "r701",
      "r727"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r454",
      "r455",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r578",
      "r580",
      "r603"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r454",
      "r455",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r578",
      "r580",
      "r603",
      "r840"
     ]
    },
    "tcon_RemainingAmountAvailableUnderTheSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RemainingAmountAvailableUnderTheSalesAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount available under the sales agreement.",
        "label": "Remaining Amount Available Under The Sales Agreement",
        "terseLabel": "Remaining amount available under the Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_RepaymentOfLongTermDebtAndArbitrationFinancingPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RepaymentOfLongTermDebtAndArbitrationFinancingPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of long-term debt and arbitration financing payable",
        "label": "Repayment Of Long-term Debt And Arbitration Financing Payable",
        "documentation": "Repayment of long-term debt and arbitration financing payable."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ReportedAsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ReportedAsAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reported as.",
        "label": "Reported As [Abstract]",
        "terseLabel": "Reported as:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r277",
      "r303",
      "r456",
      "r635",
      "r636"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement [Member]",
        "terseLabel": "Research and development arrangement",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ResearchAndDevelopmentExpenditureAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ResearchAndDevelopmentExpenditureAmortizationPeriod",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenditure amortization period.",
        "label": "Research And Development Expenditure Amortization Period",
        "terseLabel": "Research and development expenditure amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r382",
      "r849"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "tcon_ResearchAndDevelopmentTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit.",
        "label": "Research And Development Tax Credit [Member]",
        "terseLabel": "Research and Development Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development and Orphan Drug Tax Credit Carryforwards",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r692",
      "r702",
      "r728"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r693",
      "r703",
      "r729"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r688",
      "r700",
      "r710",
      "r736"
     ]
    },
    "tcon_RestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash fair value disclosure.",
        "label": "Restricted Cash Fair Value Disclosure",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r761",
      "r767"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r95",
      "r512",
      "r526",
      "r527",
      "r534",
      "r562",
      "r659"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r245",
      "r246",
      "r373",
      "r374",
      "r375",
      "r402",
      "r403",
      "r417",
      "r419",
      "r420",
      "r422",
      "r424",
      "r523",
      "r525",
      "r537",
      "r852"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r835"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r202",
      "r205",
      "r206",
      "r210",
      "r211",
      "r213",
      "r318",
      "r319",
      "r489"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r631"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets recognized in exchange for new lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r658"
     ]
    },
    "tcon_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties [Policy Text Block].",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks And Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_RoyaltyPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RoyaltyPercentageOfNetSales",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage of net sale.",
        "label": "Royalty Percentage Of Net Sales",
        "terseLabel": "Royalty on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "tcon_RunwayGrowthFinanceCorpLoanAgreement1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RunwayGrowthFinanceCorpLoanAgreement1Member",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Runway growth finance corp loan agreement1.",
        "label": "Runway Growth Finance Corp Loan Agreement1 [Member]",
        "terseLabel": "Runway Growth Finance Corp"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_RunwayGrowthFinanceCorpLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RunwayGrowthFinanceCorpLoanAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Runway growth finance corp loan agreement.",
        "label": "Runway Growth Finance Corp Loan Agreement [Member]",
        "terseLabel": "RGC Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_RunwayGrowthFinanceCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "RunwayGrowthFinanceCorpMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Runway Growth Finance Corp.",
        "label": "Runway Growth Finance Corp [Member]",
        "terseLabel": "Runway Growth Finance Corp"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_SalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "SalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "sales milestones.",
        "label": "Sales Milestones",
        "terseLabel": "Potential milestones payments received"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accounts payable and accrued expenses.",
        "label": "Schedule Of Accounts Payable And Accrued Expenses Table [Text Block]",
        "terseLabel": "Schedule Of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "tcon_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common shares reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of common stock reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term debt and unamortized debt discount balances",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r38",
      "r41",
      "r57",
      "r58",
      "r59",
      "r61",
      "r93",
      "r94",
      "r644",
      "r646",
      "r771"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of deferred tax assets and deferred tax Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of effective tax rate and federal statutory tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of allocation of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of future minimum principal and interest payments",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tcon_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of maturities of operating lease liabilities.",
        "label": "Schedule Of Maturities Of Operating Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ScheduleOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScheduleOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property and equipment.",
        "label": "Schedule Of Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule Of Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of weighted-average assumptions used Black-Scholes option pricing model to determine the fair value",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfAllocationOfStockBasedCompensationExpenseDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r93",
      "r94",
      "r95",
      "r142",
      "r143",
      "r144",
      "r189",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r530",
      "r531",
      "r532",
      "r533",
      "r648",
      "r753",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtTables",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of exercisable outstanding warrants for purchase of common stock issued",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "tcon_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to operating leases.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to operating leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_ScottBBrownCpaMSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ScottBBrownCpaMSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scott B. Brown, CPA, M.S.",
        "label": "Scott B. Brown, CPA, M.S. [Member[",
        "documentation": "Scott B. Brown, CPA, M.S."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r549",
      "r550",
      "r551",
      "r605",
      "r607",
      "r610",
      "r612",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r632",
      "r649",
      "r663",
      "r802",
      "r850"
     ]
    },
    "us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r211",
      "r640"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Stock Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Grants vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of eligible compensation",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock options, additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Number of shares, options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance (in dollars per share)",
        "periodStartLabel": "Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price, options outstanding (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of outstanding stock options",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, options vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options vested and expected to vest (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "tcon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Increases Decreases In Period",
        "terseLabel": "Number of shares that could potentially be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of total number of shares of common stock outstanding",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Year One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Thereafter",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r345",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share price (in dollar per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Grants vesting (as a percent)",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Maximum term of options granted",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsFairValueOfEmployeeStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, options exercisable (in years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, options outstanding (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySOutstandingStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, options vested and expected to vest (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of options vested during the year",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r96"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock purchase price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r763"
     ]
    },
    "tcon_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Silicon Valley Bank Loan.",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "California",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r142",
      "r143",
      "r144",
      "r160",
      "r180",
      "r181",
      "r183",
      "r185",
      "r189",
      "r190",
      "r244",
      "r264",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r301",
      "r302",
      "r304",
      "r305",
      "r307",
      "r434",
      "r530",
      "r531",
      "r532",
      "r533",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r561",
      "r582",
      "r600",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r753",
      "r768",
      "r775"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r22",
      "r130",
      "r149",
      "r150",
      "r151",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r188",
      "r245",
      "r246",
      "r309",
      "r373",
      "r374",
      "r375",
      "r402",
      "r403",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r453",
      "r523",
      "r524",
      "r525",
      "r537",
      "r600"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r549",
      "r550",
      "r551",
      "r605",
      "r607",
      "r610",
      "r612",
      "r618",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r632",
      "r649",
      "r663",
      "r802",
      "r850"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r188",
      "r489",
      "r528",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r664"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r188",
      "r489",
      "r528",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r664"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r695",
      "r705",
      "r731"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares of common stock reserved for future issuance",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock in exchange for services (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock issued and sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95",
      "r530",
      "r600",
      "r614"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Shares Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95",
      "r351"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock in exchange for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r69",
      "r70",
      "r95"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' deficit",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r88",
      "r563",
      "r579",
      "r601",
      "r602",
      "r659",
      "r671",
      "r770",
      "r793",
      "r838",
      "r852"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_StrategicCollaborationAndClinicalTrialAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "StrategicCollaborationAndClinicalTrialAgreementsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic collaboration and clinical trial agreements.",
        "label": "Strategic Collaboration And Clinical Trial Agreements [Member]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r457"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r457"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r457"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r457"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r457"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of changes in unrecognized tax benefits",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r101",
      "r102"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "tcon_TaxCreditCarryforwardExpirationBeginYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationBeginYear",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration begin year.",
        "label": "Tax Credit Carryforward Expiration Begin Year",
        "terseLabel": "Credit carryforward begin to expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "tcon_TermLoanAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TermLoanAMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan A.",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TermLoanBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TermLoanBMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan B.",
        "label": "Term Loan B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TermLoanCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TermLoanCMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan C.",
        "label": "Term Loan C [Member]",
        "terseLabel": "Term Loan C"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination fee.",
        "label": "Termination Fee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TerminationFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TerminationFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination fee payable",
        "documentation": "Termination fee payable."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TerminationOfAgreementUponCompletionOfClinicalTrial": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TerminationOfAgreementUponCompletionOfClinicalTrial",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of agreement upon completion of clinical trial.",
        "label": "Termination Of Agreement Upon Completion Of Clinical Trial",
        "terseLabel": "Termination of agreement upon completion of clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TjFourThreeZeroNineAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TjFourThreeZeroNineAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TJ4309 Agreement",
        "label": "TJ Four Three Zero Nine Agreement [Member]",
        "documentation": "TJ four three zero nine agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TrainingPeriodDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TrainingPeriodDuration",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Training period duration",
        "label": "Training Period Duration",
        "documentation": "Training period duration."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction price",
        "documentation": "Transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesAndEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r298",
      "r306",
      "r423",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r519",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r789",
      "r790",
      "r791",
      "r792"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "tcon_TwentyTwentyThreePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TwentyTwentyThreePreFundedWarrantsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Pre-Funded Warrants",
        "label": "Twenty Twenty Three Pre Funded Warrants [Member]",
        "documentation": "Twenty twenty three pre funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TwentyTwentyTwoPreFundedWarrantsAndCommonWarrantsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty twenty two pre funded warrants and common warrants.",
        "label": "Twenty Twenty Two Pre Funded Warrants And Common Warrants [Member]",
        "terseLabel": "2022 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TwentyTwentyTwoPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TwentyTwentyTwoPreFundedWarrantsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty twenty two pre funded warrants.",
        "label": "Twenty Twenty Two Pre Funded Warrants [Member]",
        "terseLabel": "2022 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TwoThousandEighteenLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TwoThousandEighteenLoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2018 SVB Loan",
        "documentation": "Two thousand eighteen loan and security agreement.",
        "label": "Two Thousand Eighteen Loan And Security Agreement [Member]",
        "terseLabel": "Two Thousand Eighteen Loan And Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_TwoThousandTwentyThreePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "TwoThousandTwentyThreePurchaseAgreementMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three purchase agreement.",
        "label": "Two Thousand Twenty Three Purchase Agreement [Member]",
        "terseLabel": "2023 Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRevenueExtensibleList",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Type of Revenue [Extensible List]",
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r391"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrual for interest or penalties for unrecognized tax benefits",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax interest or penalties expense for unrecognized tax benefits",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "tcon_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions",
        "terseLabel": "Change related to prior year positions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r118",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in the total valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "tcon_ValueGivenToAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "ValueGivenToAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value given to assets acquired.",
        "label": "Value Given To Assets Acquired",
        "terseLabel": "Value given to assets acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySBCAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to Purchase Common Stock",
        "verboseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "tcon_WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration January twenty five two thousand twenty four.",
        "label": "Warrants Expiration January Twenty Five Two Thousand Twenty Four [Member]",
        "terseLabel": "January 25, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_WarrantsExpirationJuneFourTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "WarrantsExpirationJuneFourTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 4, 2024",
        "label": "Warrants Expiration June Four Two Thousand Twenty Four [Member]",
        "documentation": "Warrants expiration june four two thousand twenty four."
       }
      }
     },
     "auth_ref": []
    },
    "tcon_WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration march twenty seven two thousand twenty four.",
        "label": "Warrants Expiration March Twenty Seven Two Thousand Twenty Four [Member]",
        "terseLabel": "March 27, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_WarrantsExpirationMayThreeTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "WarrantsExpirationMayThreeTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfExercisableOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails",
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration may three two thousand twenty five.",
        "label": "Warrants Expiration May Three Two Thousand Twenty Five [Member]",
        "terseLabel": "May 3, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfOutstandingWarrantsForPurchaseOfCommonStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration september two two thousand thirty two.",
        "label": "Warrants Expiration September Two Two Thousand Thirty Two [Member]",
        "terseLabel": "September 2, 2032"
       }
      }
     },
     "auth_ref": []
    },
    "tcon_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.traconpharma.com/20231231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r185"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.traconpharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r185"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0000950170-24-026205-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-026205-xbrl.zip
M4$L#!!0    (  ^(95@O+!P]Q5$  ()<   1    :6UG,3DX.#4P.#5?,"YJ
M<&?LNP507-^:+[I)H\$MN$,@N+LG6 @>7(.[NS42(+@%2/"@27!W=PCN[NYN
M#7W[/S/OWCDSY]PZ<^O5N_>]>KOKJX+>N]=>WUK?^LGJW= YZ!J ]5Y:3AJ
M>P$ <+ 7 %T$W@+(B(A(B C(2$A(*"C(+]'PT-%04=&(<' Q\<B(*<C)B$E)
M*6E9Z2FIF6E(21GXWC"S<W!S<U/0"XCP<PJS<G%S_M4(' H*"AHJ&B$Z.B$G
M%2D5YW_Y@+8#V,AP@B]L07#4P ML.! V'+0;H(#U$P'N7P[@WPZX%R!X!$0D
M9)27J+ +:K" %W @T MX$ ("/#SLK!_L/ "/C8!#Q2&!B*OR"8G:"8\S,/X'
M,HUD10>^ZO@9+9>Q<Q#*RU<$A$3$=*_I&=XP<O/P\O$+"+Y])R4M(ROW7NVC
MNH:FEK:.B:F9N86EE;6+JYN[AZ>7=_#GD-"P+^$1"8E?DY)3OGU/S<G-RR\H
M_/GK=V55=4UM77U#8V=7=T]O7__ X,3DU/3,[-S\POK&YM;VSN[>_L'YQ>75
M]<WMW?W#7WG! 2"X_^OXNWEAP_)Z 0\/@D?Z*R^X%QY_78 -CT#%@8@CH8+T
MR0F7FC,0&4\R_D=%!PH-E^H9OK'S^,M7M-SK=.=_I?8OF?USB07]+V7VWQ/[
M'WDM &@@.-CD@; !,>#V@2$GX.7_&X*)];3;FR4T+]5MI= &8;/T'"\!< IR
M]N-'*LM7R+<1M*^SG24V.^)S+,(S#Z\*$J)X#[1(X2G#_9\4ZJ=E):Z+;\H<
M[&GJ:D,\Y)BC0U1.K'N49ZKG:OS(-WJMZ*+I5%)".LL[X(WBG/JST80PPPVP
MILI^5-7.*(\*V7Z10XL/,QE#- .R>AL;S]I";V]3RR*.)Y7/50UEPL3F$P:$
M_^1[D_T1KI3FBO-/.OD*U^E9UO'0]N6ZJN*JOSKE2UX6$\K\(&<8+6::I4F
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M><HG?M5':47!3$X$UUE>][KDG96#!:(U_C_.V6[\-]R+^J*#/9(+VHN+OX.
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M(;YT2>OG/Q+H3=VJOQ6]Z4"RH\HRF$:WT)F$B!4,_#Q(H5Z9X 3U?ZSEF@Q
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MLEZQ_L!?B?QI]:#W$%[=X)% 2(9?;F(V.B)^8%.0$R",NE$8!C'<7#P6]:%
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M1S"G?JC UWNV.!C]JK$I\ZTQ93J#'-IW1-\ZIKI9ZL"YFSJW:*+EH-]1R?3
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MU_X=9F)=!0Q1HR[V7WUL;^V!8P3^!)OTO<JP4D>+VJ"5>?LYSUR<$5W_B\0
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M?W9^<7EU?7-[=_\G7A  ),2_'_^4%^HKKS=04)!0L'_B!?'&Y4\7H$)!DS+
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M/ 7\R8CDGX_$VA%[@8C/-.'/XU/872H67MP5NP>>!A%B.[I"+>H8*L_[AJF
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M/ ?0/%YKB'Y/Y+:9N\$+,"1B2.18?(!D<NSW=/V(W2QCM=9?;J,WU21H6YO
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MP 06<A8G$T7CGV2J[@77<@D=?&U!RHYN@NB?%.=I08?-_%1WEY=EL0\NHB]
M9FGD,Q35[1B,/V;&4V,N:$RY]P5X@_YH^KPTP;=+\VHV?>"?F2&RA$U>16J/
M^!*SX@5H^_X"X/'5.D;>(\R] *L"H'# 5$[M!5AH$'V"M@2=DO+U)#PXB/VU
M<^C[CX'7V]$OP!<-XD<XF;.<?SA+DSK]:)-C1O9II72!5RU^1L@^B"&>^Q*7
M "EV#F]"YIWIA$A9<DVP,N!W_7WSFR-$SG\P&C70RM7K/\!8=I5,$+//"\!
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MO.W-%L>3A1!!6,3_^*<>$/YEKOJ$]G84";7*:SGGQF((^JHWUO,N'\C3-V#
M&^'ZP>1?OO-CH/!_F)*%Y;%:*V6DD\O5***,$W. 9'S'06$(/0I27WB@K'U\
MZ'YUD@@75NA?INE:R/N+) L&? J2\AS0?L+- ;F2:1/HD0VN1--[EQ HO^E:
M=Y8_/:S*74O:W-V$/M]BLF#\5ZWR+,W9'TP",&49Q66!H@/('G6UZ:9/'F\H
M)B0J$D+8TQ(\?-I(B!--*M:]/ZGN*>,YDLTPBRR>BT'Y2*(-J5[O(BJU5FJ
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M$+#.R@\SMHGJ5WM1_%D<$A*#,2>Q102A+8Z\XI*E_;95)E+N3"K5+&?IKM#
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MA[+[^4$? T!D,+B-[;]/!IS^Z/N0_[=ALI\<]>N!5@Q24VN(]#O;U]48F5]
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MSE!NX//FYQO89"UT9#!I9)>Z(GA[50L5[H+Q!+]0AW;M(HK![T BG622XOM
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M/\\<Y&U'Y8M"<TY-C?Y6<^E)UWSX^).@%]5]HE!F/C9]B<\%X@F+#6FV<#/
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MMO'OL1!*G(PIFFZ!!P 61MZ_R027R87C#U.YQGK[U^\N<)>FI;:/JYX.T"%
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M>/W;T672HQ:@]M]PD_]R%>TUDI:/6LA8@ [*1SS.0OY==.0V1UEJ7VG.L3*
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MRXKU,E&E8_X\M4LW/7=L:I;,U !<AD^%W2N_1R%KK<&^&A>W!7?WF7/1-%&
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M7I/@ #AQ+OG(_0R&Z=<,=$WZA5-.::D?A*8SY4ERXS:'BDSIEEJE^ZH@VR^
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M VF..GSQX:FOM9F&4/_ <X$-6Y%Y&J6Y)%.&7>/K4[M]-%O8E"B:4%F>_ ;
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MTL6+H9K]1R\?S3DZU29[A$NC:\=N &) <'RZ0#BK$\RVD'$D&T6/L:!@_V5
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M,90<0X%IRL+U]E'BNTKBPUBM("5>S_8==9 R4#S?^DB;"P1:C0_3PLL.50#
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M_05[?Z(1:D3SGK@T"8E" )RXQ4YD"XUW 1.(]%(;<M1NC=S3;L(2O9)Z*IZ
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M L(+^/[/;Z?^[R3\FU__#U!+ P04    "  0B&58(20E5N5>  !^9P  $@
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M-?T3GB *H:)0>"<HP RE9((%]!61 418$7*R R[$]MN ^=J)E^$?AZKMG,?
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M2C,+]>/PR@;?J(7DJ 53@*Y^1\9H"=U$%M+74?HCOLYZV!O;R>=<?'9-S,]
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M:$6U[X<ELUU-B\6OM!.B%-8?1A-?]#OTF9_$@)_$UJ$!Y($*K0[R]6YAZ#'
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MW(8%_!F<_&W1<@S<QPNS_"O:P3GJMP'S]?\(M6OG%#YQIIT$26S'EXR%E,'
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M866V7 \$,,CO/53,UF98*"BI2NU.F38R@A%83QM1^J,%^^<AS62DY#&0B:3
MN!;5/ZD1/W01+__$XX^!MO]D.OXK_!HTRDSJ8X-PPIGTRA.UI9$ GL +>50V
MV@,6SC#RNDG.T[(.8(3"^I"A'C$"&K;T']XLFV59?Q#33Q5_?@4L413WD'4F
MN"*.GOS2ISY59]-6@#O 1&2:\?M3<UC(>W?L"3W")C"?C8O10<[(C6N(K44]
M7RFJ5;54Z[S0F7 \,9KK;-WZT,%U;LXBZI1$ZX$QH9TN1!'/4*M?9=5NZ695
M0Z!3BH].A_IV]0A/N/Y7+P1Z%G;T;<DM[-S;4&?Q0?9'C"/B5#_U@!A#N)JX
MFO*V84:YPR)?Y-7<9 Z8E0:H %#TI].RA46)?3)X:69FG,-ER,"H&/6%3CEJ
MUCCG43+(T$0Y5Y9+9O.UW@"!+T*T6^2W74JDZ7"PN69G%[_9<K+XYN JYJIU
M;]^P&]DR^< 772/ (==Y&',JOFYKN-AK2[?66TAWJ/WK3'KJYGZ^Q5>PKOW6
MTI>#BSOK, 'ANB=M XJZI\*R;/U>&$5%:>JN,SB]G"R/>CJHQ;7^4Y:E<:3T
M;*-@1B+\=P=>/L+U69C#U.<(UM+&P/<OG@NRJ?W 3$^T_.$**RU4;8WG1:?\
M@JXHBU_;LR9J#>C-%:A7/0O/3S: 0NKNE(,PR/(\&",U+PS<(R\-$ $UD@=V
M%95L' 3_1!4GHQPY\,F*JBB[?R@NK)SV XXA0$_ UH30 XA 5FS %.[X5D:5
M_XK"3-_PD#&L*A_@3\%[\,'\9AP=.QR27ZF' POTHY1Z>''@?_H4P!"0(84A
M3T[-3U@-8%2 4_ @L_5?WJ; 0TH5+'""!$_>Q=!6YB=-V0TI8IX;\G .W5^$
M "'^MVL0% G@;RXN@ ($J,J;=).+!)HV6#/H7SRZNDNZ<%:=>B8#M?K\<S>I
MU<^I7TM+?K;?5\M$PBYK[,-YIRQW/XEID>F=,B6-W6XR-UHN[\)7'XY12W'W
MK'"X.ZO1A:(GLF,KJ[DC0VK9D4\47%0NE(49[ 14G$OQV'J)7FU:1A_\MB.I
MY#[EJC/-/,VHIK5UB>D&,VD:B_@R;8'3)V=2H"H]8=7<#65-BM$2_AO#K?M[
M('I58YOM_NM-<YC+/]21(]LJ/T6^\JG^+5MKYXC^H$S2R3P&3LY$IW%E6OU%
M4&MC:C!DO--SI+C_Y77[P\W1A;R\\RK?Q1XDJ_7J&:PDELY*9)2]>"J$AQUU
M#+4'OMI82[ZZ^'$<*M,MW.*R_GB4? XEX+9:F79 ?CWET(]?=>NYRVV/7OR4
M(UML[&YCUX/O;I<4B*H/. 8<<[&1WF3)+WYTNBN,HTL-OZ-CT^0L9PZMMY\4
ML")K9$3.)(.'VF]F=;Y:>1VQ\QJ0R1[)K0SHS"--?\LX0AS4Z]3KTMJ]K-ZM
MV,,O+NY4:8R;8!=/L9;-M6Z1I5+/2O2-#)N_MGOT@.5Y.IP83HT4;UQ39J"K
M#A5>MK6DP=WW>?A!*NA]J>X5PAEIB]U-C^=OR4]D94+V2^64'%\/^)&6^!\P
ME4C1/*"K"O:8)TZHY.@SY)Y;NQB2UDUWA)V5>^CP^04-=8V;TXM#O>%"ZA!V
MXBDP#WO%7I37D[FZ_%;QFIT9[Z,'R7%VT<,3P??X]QR0%<^++V>M*NYVP04C
MXO?LD '/$ >0>XY9'530*?WI?<9-<6Z,<MF'5)304G_-SNZS<Z<6(HH>S#+M
M"[3B"I0\#[!;3\CSMA.>!@(ON&>#AONVQ[W)N<6^O+<A7X[ TM,[U8KS+AM&
M*7.;/E<ZW:=_N9P3.CP&ZJ\)<31BECM# BZIBIO&I.V=JBF3>R:WZG;M1\(I
M:#=5;9JR^?>V8#,Z1)?JO8I'84%304I50R]%,](T%?7HXGMK(K9;6!2'+>\;
M^#"*@3 0QE>T_>9(JE]$/QYHT2W[K2='<U ><B%&^LF%(&R &I>AV U&*P-8
MP4 (>C/"2LQBFQ,%-_*ZT$//@\>&0M[]-K!I^2JW,ALG[<*F+DJGE:YT(80W
M.)\.@H<1.^\K:^=[91F#$LVE<J$L.>../9.HU:I#6]K,Z-G2HY_W=E?<""S?
MC,P::0N)8#H(6N$2'0<]T4!8/JKRQ?O'J@H_[&C*]O;/:;D$W2P>4^EG_\5H
M%K);-E&:G3FVK:ADUF=+'1.+BK:^5'(ZFYS.S.AAXJMA!:Z$XP #-2M1A1YY
M:&EL(K0;!CZYH0J'\-$ /'/HDXO-"H;JI9AMP#4&BK,"81!BF&T^ ,!#&*$
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MRTRW1PBFV29O4J@3"R4X_-RUZT"I\V;8854,]H<FB!*K.]CD)/BRS,M3NCA
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MQQ1Z -AMTB/$((Y>RO!LH45:'WC' HE7/D9K!,!2AU+7[DJ&@*N(6F*MD=5
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M*R7-+%NM<U;^&AAP+E<!.7Y$GL 0IC*G]^#@SHV<NQFCK7'<5GU7ZI^,G3!
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M,3DX.#4P.#5?,BYJ<&?LNW58G,^6+MHX!'>7(('@[D[P$%P;",'=G1 L:)
M 8*[NS2-N[LV[D[C'O3DM^_,[#DS^]X[>^\Y>\YYSE0_[S_]K>=[:GU5M6J]
M;ZUZF7]9!V IR,C+ &!@ 0"8WS_ RQ) "H",B(B$B(",A(2$@H+\"@T/'0T5
M%8T8!Q<3CYR$DH*<A(R,BI:5GHJ:F8:,C('O+3,[!S<W-R6]@ @_IS K%S?G
M'R^!04%!04-%(T)')^)\3?::\Z]N+QT ;&18=]@Z.!AJ "PV#!PVS$L/@/)W
M/Q%@_M0 _]1@8.'@$1"1D%%>H?XV &$!8&'@X&#AX1 0X.%_/_7]_1P CXV
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M#]"7EKTBFP,[K9BW,=5W2DW.2[W=<^U*YJ5]S8]N+B)SN6V_7D9'PI +10!
MTN_F..BZ@$E/T$!-<=IU-]'NY1F"Q?*HG>/1]-8A19&*-0'"]-3:R(ST*(!^
M3FW6G.O2MSQPQ![KR<#7OD[RI%,$9]YJ(F&X^7L2,;#K&N@I]9A2+'7[Y&+)
M(OEI]&ZI>4D@"YV$27#+8)K%@01BDU7S9HW]V+CZY*%Y'KTT8X&&AZ>^T,K+
M>"[Q@COQ4,=!P]X]C0S-] )3 0"6YGQKDD*;2*\=U6%F)@#O'>'[9RHR<%>_
M\%F"8V)QR&?8-""_08<81MM(B_G4C.SSZ+4FSYP&MLZBA O/"&^5K/#\I9E<
MAQ7'M!-99E^\-HG[_&7IJ)ZO^GI;15)61:X9W,)*KAO.:T#\-9%8E!LOG&I]
M_/N4%X!JG8U,T)"<,=AR?FC)/<.@ML/AO8N>TL83_M0&J>ST@CW0]=#N>[AR
MJ=,E93F6IY\TJ"%B<TVN*L*S=F>8O(;IC0P&,C&9YD=@6]Z2(AN73 1#'GM.
M! /@OQH5'_LS+Q!^)W95497/47J'C*TKP>GWC(9Z$HXEG0GFD?SPKC0B^\ "
M<F+9GB2[3]DKBLB45C^0/]VZ"VE\,:\XN'$Z6+0#_?CHC)S(<8>F40/L9)=@
MYFB("J(R0[(B1[ZBSLO"<!&/DV^1W^3+%#7UP'Z7?$P4B1UC6ZLI1!?;8K8)
M^A:.7E[UL6*!PX"A.HJ'QA=[@38,1S6:%D[(Y833ZY9[O^Z!@36_*61J52C<
M:?=]K/]I=#*5Z93UX:H6^;A(L*$RG"?O*@8;P0U"O^. <FIF%F9*6#_?(Q-E
MC=$+P,K/QK9/U$'H6'=\9WRJE41$=(BIH"EZ;(655"A?I\,EHY%__)/LC6_2
MXO/<C:+?[^\P[L#L<!#3&GE5T@:^;-]YECQX^KVQ)P]9N_.1O/,()^]*;&^V
MR1K*&VA0C?/Y!+OMG9X;?2]*T-*8T=6K1^IIEU^'*PUO=!*,P8MH_&%31EEB
M0,3&JWS#)D#H78A*,%SL@'J@[,3Z%TTR+=Z;Q''T2/9%1#(O503 _;IQW"0<
MQV<:VF">,(S/83P"<6B9&_S&2%7FGPS(M6MJ0I5!0$]"9!1C92UCYQ'?0=J4
M:EFCPZY_CF^UUZWV_=WW)H>"D6T&39S%1ES#['"_(,'.>O,4U!"Z*:J(L1-2
M.=)C#D5'D^Z!?%EI>\F3(]&SO+[R&2A>B,J0!+PIMJ*AVF+_XA=<ZQ2[XRD_
MRP-FYL*W?*N+ZTQPG5058GJS=9-7HXH&YX8!)%V)'@2)ISO2D<R1E<F Y]M7
M+D=OV^IQ+I^;*()T]2H:N(M_$Q@+0P/X@,+8X\<6ZLJ*6T-?P+C"T)E.<S/(
M3DH-K%-)HVKLB$1-+<5^P])\!@MZE*9U\K11]R)7_3),-4R&V62EO**4W6FP
MD)SXS!VXI4@2<R-3D%AN.E?=C/S%<PX^(!R#%)Z,3#-=K*=0M:ZFY9O,3"+D
M[+5\ZN!K*;3 #CDYRF CJR1VOZYXV<O<Q28!R:40."]3$VA*Z8:OU ?PA# 7
M<\8;+KG8=]\*PU_3I<=;JI3 F5HT\@-VZZS>\BRN%8N9B=X^8<QISC%SJYNS
MY5^,[G0M]9[L\3_R%[5(5'9O+#'\IO'V%M'R<5@L73C$T8@>G.<INVY0*V'#
MQ3I>R2%+.^,';N?622FT;@S]3Z39R((Q33:D!N=T;<UGTXI-B2<,]FTK#F1W
M;D-R-8#^#"&+ Y4F[\K&%\#'"-(7@%BKW\> _<2FO-I5EKHFS>N*;=8:Q1T\
M?IK(W'I,$:A,8Q3C<X?-+G_+.S?=$R. )&UX2[ZDO,E.@+\'S,"836$!C#2>
MVG])2"E[ NJ")C^%*.;_+*O)8]K)=DC^R3"X+\"3K5\8LQ,M0C ^$HLK&%S/
M1V9Q6RJYPL9-3EQ:8A-G51N6,WE->EGK RKI!R$U>AAZ7XTKU.99RY=9:=U_
M51E%<ZG8D0\,@1.YB1/3*]ST 8=*)+ LW=Y*VVW09"8/J/BA[9V5"RE:'AUM
M@,*,^4UT9KP![ Q OX]S1B9*1Q_M"6P:=Y=: Z^DCX#3M$9^UU%:=9!R!S?%
M8U&Z9/,:Y*ED7.O'A3ZNP8="D+GG9[DVVG.&S*=/C>'Q8I?CPZ1^:"%/UM$9
M@RY;'_$[\09W14!-D>P#0J:_LQR*M=>I!,_T-8UQ2]ACB;?.=;RWK(3#"2&>
M9-L62/#^&")]ZL\XWRBYA-X\L"U^&;YI84O8W;,7/'E88W6*O*V07.5M.@,'
MU_%'\S !&[Y,8CV<A86SC@AA"-XNBUAS.;P^HW^D^1V#PMM_!PPF,5'1R?:1
M_EOWQX4#33.?W_\GYOPI1,4N*6X*R9U:@'7LS8$>.H4IM&BQ0J[J8YM>E*YD
MIA;XUOT:2K+O'SX37/ZR:^@K U@ MJ@LLON)>UU2VI)OV$2GIJP,*LWCCC=5
M^*@6^>J],SI]B4/UG1RZM)/XZGGC1:8429>0XH@2WKF/.-7S4%D$#PC0GB_Q
M,&E@2F6!FD(N%EBI',\;!L1&**66\'E<OF#AV$%B'IO3U?QHILGL^Q\Q?5U_
MN'^:S?KS5-FM?#0C2.>69XTIKE'VN2$RE<!8H!TD,Q=W^NY%Y9H[(#R66'+(
MJU2D*U*SLKQ(0!5>_I/Y6U &"OR7A&\>6T1EP3GC>=:*++,;-7+5&!MO.+D>
M1HRB)> AY8FY++,S]1<'X,3(L H2/^;20+D.AN.!?H%^59D-Y]'\,BVMV"5)
MY&B>CL%!T>U;T6L>"Z!-(J'WRDDL6G,E\R2%Z15FFA_;C*9 RX?8NP@##!;6
MY\T3?H1.CI^!>+3^$E9(3@<R&]7-TII5+390$Z9%?;TJ=RF\#0\T,HL=6J-K
M(AYC>1R&17DB:BKFD7X S$P*A;]@Q%[H-^/X#[X*:_(S)]S7:IN[_%O=1<]T
M:AL#+P#_RZOR_3R<GC@&*G8T+H@_I31^9M'AF542+_N'N'@?OEA2*GC$3GNO
M*T1_;H:<9.[)I:Y+A243B43^?0:8*TT;$9E^U<C6A&U"1OXWQ' FT(A:<03\
M;R6><>AOS'!U#0=M:76VFZ+P^G$Y (C#B,*Q0X&(-I9D_K)2LC__G3KROQ0:
M?-JP4Q!@B#PM=K%=;(5NJ_^)):PU$Y+R.4?K[+12ZKM99G//%$V;6(R5$G$Q
M9QD1N6,@'R&V'G!0^ 2'H6_79%X%3BE/YMS>GXG=(#CI+FGB_G+\%X^(^:'>
M2D5LSF#)1Q3J$.YEE0K]!YB,NI2*1JO<_=$2_;Q=!/%M68K=SB>D32=Q$E<U
MN 2D:N(RXL^Z5HC%#E8\Z5>.RTK;TMZ3,:^WM^W&/)PE  F=U[GE0?FCQ[GN
M1^CS?3Y3<AFF[U.3/=#LU0-%$^+9PHYI6C-6/C4FVZT89UA^YWQW/*DL%+[M
M.^$4FZ992J[*0\YU? 8<WZG?(JF"28.+#,@();/ <X6=;6W1JJ+%HI*;^*2A
MD8!>/L.7..@$%QK5)_%L=$\Q7USTY]R,9I.\!VO94T>1VU(&!/=Y!(G(_DO"
MTJ3DBFCG9*7ZU[LH)U@#3QV1P\470,\"Y>AJ5LZ10^HNO,ERI";4SD]^*G]F
MUP_+SRHX])A3(.[-A::X2J,X@-D;S?32P [/%7S]9$EN[Q5\:>AI__#N7.3(
MW4GFHHYPJM=5?R">]^B["AJ3238_OOGAS<"C3I/[G%JG6 T-A;4BUO+G/O[A
M0$$7PRAIRC,_/,R/W9>-H_OW-[$V!7H=;FZ-4DXW_!4K 80XU^N5\#='G.CZ
MYUJ93J6>ZAI5=?P-&0M3HDYQLLK]^5:C#O@=$HPGR)T=X\3D7%"HVE1<4]5T
M;6/'Z*;EISOO25W#\FB0@R6-(B_*'G.V4^VPD<LX6*18;15=MM\]T3LO9+L@
MGFSU_6C7\*Z%>Z<_:<"$>\5-1.G#\MK<Q\LWD!C&Y_H7 ,UPD@8HIM?;J[;Q
M5;]Z8XA[AL0>CF95)#MO@?@BAC.@Y&9NT;?SK/G#&;J[R/MOZW>X3#_BA1[\
M/W!D<$1JETU*3G5[K]V?>%5$,0M&UR(MGO8('N<?%2A:KHOZ9!NSCP!_WJP'
M13HR3;+N>++0)?(L'^8%+_;3[V?%W[U*B3!@)K=WO*V?L%%JUXK;9G\HM\A^
M'\=P=4E.'#KKG@)U;<@.50KD)]G)T>Q*S=F5>KYY :2*Z8&E <X4;"GD,HN*
M!F+:J"4+ W%T<9Q\/W\A2&7#QSXVW5344._2<@(H+9>1RD4C!'4$@_^AJ_@W
M.1?D>'!O+;66_2$#Y%>VI6>6?42I?@' %'VVI!4T"]?_Q50$)#Y_&N=PR;1/
MF-)PZ<0?P42;+(OE9QSJIHK@!2<$-?9Y7J!_JFO5<JVK3ND3HD>>,F@2-BU>
M7H)_AQN--")T/]UBP)V[83?]D1GK/63HE2R'VR%'"&/>^;'!#XY?',R?D@,C
M8?OIS[GO>2<\%EX !J^4BW670#_4EAE;%Q8 T);@,1B*CCDNOTUE]$/!;0*<
M0XB1CGX( 92*C7DK6*7U \IX8\>136U.-/C-HLX6R)?K2,9'42#?O2U%L3Y<
M?#G(<G7AT ?ARIS<J;<=Q5!_=7[Q_:T\LX,MA9RQ)O821]_\3$ &(=5V?+_M
MG&*=_4I ,]&XMSSN2'B\"^M&U)"C[%1P#NG,WF<JVJ5RRE\>@GG/L@7\*S%W
M%/<'C$(^GN5&<E3BL5E=1<4,1T&EGZ3Q5&#^3X3^[ L@,F>Z()QN\II7_O1+
M-UK8ZR7:9)K( 0Q.3%J,A*DY['.,361[86:Z%&X:O8 V<[A(/C$%@@.ORA%!
M,=E?Y(;I1>22Q.3EK"R& FAV> \>L$*/9=U(5->E";W0LX5#49')N@>(;KEY
M38-YO1=&GY&ZU5(:[K!Q#??"ZW8(A&GI&CS'#!(@ _;#/+R+M7^M[7YBS*!=
MCR@BS5/>7E&/E/\"J.2:.D0%#OO,>-0GF^EL6\X7#Z 5PG]!;%E=TZA5)CPP
M7]QF/58[04W\'1DX&.=EB4BUJ6R1:/T9TT*ZUCH61YOJV)?[R[$9L^</"Z#^
M3D%1>5N+<9"U.8=+I,)KZ+-L^:2A?(7N 99?EW65M'6F67W@[HHV0)I#*AG+
M#Q4'B29>ZZ3BT\RU#91%74U1,9<6UVJ,BHTK2YIFT&Y^)P@6(/+!*M]11#*+
M,''WNNSKD+TF?!21<# ](+.'<JBEO1?%_/8+1\./OCG>>DB-^!2O'C&[E^$7
MK?%\!\DSV7,"JT"@R/+]>Q:;W>]M-H&_N@'*[TW]'=^R04^0P-<[SQ8NTDX4
M;(UM@OA9LVJ+@YEJX,C\<FA3BUF?%$[X+R.(82UBJEW9BJ5V_-)!RN?$ZBC^
MGZA&VXGLW[MQ[/O%E17$*KO6/4QT_*']LAQ#K.]^1QSQ>75^:-J>Z*QOLBIJ
M,X(F,6T:@"D4-\]0$%9WA[6)<,3STM/9)>;4H]?84KL^23 >J*=(NKB\'TG
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MG(^TXX</1')0$*L<?NP&#U^_ &B:0FZF=ND348O,HD0O\P(";[>C$Q+,-H'
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MQ5\^K35'/S$5G-6YZ!VF7.$NZ<N8MGG%KKY!'G *)(JDS*K(^>-S3S\&'+X
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M$ ULLV)Y)8MPI' +D?YT^,PKVNF&%?,A44"^WA6YGPC-R?\+:/^'JA_T] 7
M_MS.=B%0"4<[X6G/I/C-)NQ-0+*!>7A\>G^!+,VRDR[)>@MXYE&"#,('1O$U
MQYF28\DP&U![19YUO)?AR-22$UK$@@&G5)LHXJ>07@?-(I3E>-^W,+?[?&#K
M:-T^SS-P!7U@PFMH O%N'(_V(+[-_77Q:1#.L\_19G*_8.WZTI8@<RZ[^Q"[
MK3%+?]DJA6>V?$'N:Z:E?S=M !$N$1)\)$;K6S=4>1 I=%1F=6J'ZGG(DH(/
M[&9%MO<*+S+-Y]7Q?MXU0O;NC:#O1.;[:!'10W9N^=>V2X*,C?MYL?Z^48),
M5OE3C]08J9[TM8V:/UIS@X@ @<K#';<'AE'20E _J/L+0!6H# 7%<,U</01F
M4'-8@<UV9OX'.V\5%'<7?8DV@0 )EN .@0:"!G<)(5@([D[P#NX.00,$&FB"
MN[LW-.[N;HUKH'%W)M]WZ\Y,79F:_]1,S7VX#^?QI[7/V6OMO=<R<A_4$=47
M)Z'%Z*>$6KG"5OQ"66/E6^..Z6'QA.#E)!)-DMNJ'])9 E<57[,ADZMS=F<D
M.T^,X"/=7W\.N4NV7>^%DDSJ((;"C"0=Y&PB@LDPNN8RL?#U%,4FEY9@ _+%
M)N:'(!/^7B=XF1M4^>_UEYE3L[M8^1(>)DZ9*WHZ^CS9>ZL6,2C8(YBI+A\Y
MN:;XBS7N>$;*KH(F%Q0F6"_. =3F9[3?SD+:;STN+RNDLE/<W)Z:(/'Q3W55
M(^Z4))GC>6!W>O_6.8Y7W%]_@JP#D)##]RRSH_^S>\!_[VJ(PI%F<B_IGI2U
M<R!WDG\5MA4<IX?>+B1++'RGJ2@)<&KE"=!^$-2AUI)PP#Q[3S((#!^Y0]9P
M22D35(KGN[/I.2#B@)"P)+NW!A7R,X@@3'](H??G2V#:?Z[ZW*3LNP\.G/=2
MGNQJ\%__DS_N+,(LUQ"P+^WJK!*J]['!7.EP_F7G[FR5;3,[C*\*Y&DZU_7U
MWKZE4?9%*.T[6-PG30>6KDQC-!'^_V/<3)_%\7^4L^K3\<K,:BWRD6@0T_+W
MYT+1BL9NI!@)10S6:[:6]E7ET(@'[1LHNTNH>AN9OM/TAH=F*4L1?&Q'GDR3
M-J7\SUHNO?R*C31-V?0)74F8904/D@FR"(*9?!=[:)L<&7K!4.OBTG=SQ+B3
MT94N63;]I%"!.9E([<%+C14O)-Z^I00S*#G'CIIXDMH2;%LX!";H$C:: /-0
M[Z.5?_02<[T<==K3> 9 65IGZS*L8?=RF*6B1BO2>L&C5FDS+#U]W:RD;E40
M+<+!=>!O> U-/".4RP2PQF?HV3]E;9Z@=(]=!"H1V2XOHEO"KGH),]*+\^.S
MDR\+R*OIY?@TNSJGZ]?QKW)*[ ;-&38;Y3@[X(*LQ^;V&?@RA",5W-*WJU;J
M+9W[G?!\2=P')Q:E#*.I7HF8W$V$$UO$*C+,]F<8M"#J2ULM##9C&U%TI:V%
MM7\3/=!O9BR^N:VW=E%H:UT>%<BCSW,Q-%>O;S2(=P#NB"F7"%&-2K39I>4_
M_K3W^'<?LOO-;3Y).PM+9L5A\J0)@1(&T YE QFN!1^/;6MMK>Z%0)LA7O4T
M\:JA$UNO1WW\A><R$/%<@T^\['MS7^=XV5E>LE)=E[Z)8(0/H%&\AXQZ_7K\
MTJ5>,VL6<+F6/ _O...=UF,6T.M5_YTN@Y#_CGETQ!/)-NH2L*M2$V!NE"U@
MH6ZL*![@F3Y#/,=]-4<F3?3J:B;TBTG_'Z>HHK543:R*O6M<V4TNPA3G,ST=
MW5Q6BAI88KLC?O!MI<-DW3KX[ /9D*"X($89T_OUM+*T36V"U.B;7HZ8#NKT
MZ83+:V3XW3^FB*7QEIFA ]QAY"8E0@"TC>\55Z,)6Q)B5W$9L1S=*AZ(.@6'
ML]2U\SV]OO!2%P&HU?OC;IV(H2+=?M&>;S3!$?RL<:OO+G=IBA&\UJW4;;7-
MU=.K7Z99:<,_'-P;(7H/^U<9&0=&W<DO<^X> /M2U7[K[P498<^ !$-H6. E
M6=TF\=5EB>%BHT>(A\;5\N1+5D999&O*F[WQ.396BU^]2)&1\,YDAMAKK1"C
M[H-SCLCYZ])(0K(!'C5X_@K\XQUC'9@>&D?(@++!.2Q 3=7L>95[-37V%PQ1
M(RH2]IZL#P^%)?(,0&_V?WFAN$(*OP&KF?Q[[1W=16>^[RI!:^NTMQMA8#XJ
MVH'WZB81)U:CI:W+5J#UZ_JJ6<)15I'272V6I"VP8H* U"?7:(YZ[&4''=>K
M24O!NACJJ4O4296!PTUE/$4@B];;9FJ@J9%S>Q]]L9R7G^Z37V'"Y:.?+H78
M3Y>X4]0PU-SH6SE&:_K'Y5<4]B+,M*JG"F7Y>HM2=W2M0T-=5J^\=C3X1RE^
M_K;'%L)3N4%]5=;\#H35 YT]RQ$U2>:,X.P&8VF<0IWD"MWMNZQ<V'\J:9NQ
MMY^AZ.>:QJ%16/KA&OA// S8/2@7[YWMC<MGP\..;=/G&5N,2B*BVV_U M R
MRTK(RC[I%F6U5,."E=5*.AS-4%*WWBC+B(@)[C2[("_MBU+TU%Y4]KB;)I5]
MBPMGF^3\:D*;T5NVL**S9U,T4#!OQ169[I42RD:2=()/X_&KH=%U347W_]2
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M;*ILX#V[-0JV168&R-*^^TDBO%.+P.AJU+M2W8==RVZ/%2Y[K&B(<V2J2Z*
MN8('^LIL)^!;%/_AR8#_RWH-NS,+*4+_J515UQ1*'E0?9JKD8R]>E D+F24(
M62%>#T,EH%4J1JLDH/O?)=+Z]IC08WA!,M%VHOKA&0 <1]TF^'EE2. W;B'U
M#.CXVO80*[W@K?X75*>1/0-><CX#SN0!MLI:?F:GFH^HSG8/^$//@ %NG_]M
M-]&N>V/EL$0X[8(END&1BP*K<M=U*]])ZA4\C>J%%OY/<_/_G[E*]7G/].74
M9R6$^BA2.R=Y5,'>M:Y^3@D BWR1$1MU?NB?M;:&AM!#HH\DT3C-:T;L(F
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MKXTL-OA.*A;*=BDN/ 5BKA9J<MRZ95*CXA'8)-G"7KHJSU"<LN&N)\7@'W:
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M[7@9UJ/><&I]=;VZ\ Q8*)S+ &GQ/F8&W2;8V\"YX)-U9)*5D$4Y#V./G&C
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MH_RY]<ML<TK[9-MD"@?,R--J@@41P+I 31G6;/#.X*+LIO;6NU0 NE&3KYF
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MV(Y0"A]==[C:DBP,U^<4Y@H03<QYPGE RN$\[KEVY5B'SN>['T#.S.]E#>/
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M.'>(-A<MK]:E<*R\]C]Z>ZJY'9.AC3#4ZD5G7J:#&@_Y1N-R_M'#)L6AX^0
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M%@=W*%89:;-ZK!>UM.=IZ=)R"0?[6-Y%4#.LODBB3P*QY1%FGE8UAKVFO8T
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M+.QG=^;9,%3.!UKR8/&<TTE&[7U^#H?-'Z)"8M=08GJHG)MBQ;ML'P7Q$KU
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M)#<PT#^H$5H\/P_+T('F=9U]?@S9Y7ZK#V$6%AI2D]KSQ0 ,SWOHUD\';F+
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M?O#@MQ @\#L#S?]VC,?_;_^7'?)C.[U*$F#3(H&<+&$&H(P=@2^N:_%WFJ0
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M*DE42E6+J/C]?4CDF6%AV>V+>[-HN<DR4FB%=0'E[]WQ87\"1J?PV7.#UA4
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M$1W/6T96-DY.3E):/B%>=D%F#D[VWUX"@8" @(R$C(>"@L=.3D3._D]?+QT
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MO-:& \>^W$N.QQ@0=A^Q6RF(EF\)--Y/DT];6ARG'W3X;MUDX\2JE2VF1P8
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MG9=F1[+/$O:X!>_8!ZEB!#!+I)\\JT)*#@@<6M+FMAV8F4S6\87X\"C/H2?
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MD&]L;V(D#V0_!IG$"4"L9 5&!S!\;3]+L5R_/*YX ?Q(N7P!1"N_<F"SS!>
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MR?3O_OC"'DRY!)U4RK36.YNGXND)?#=2Y_-]B81T9_+^;/3]7Z.!)<R<[$-
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M!W:8N\1N9H#EW<5?0 C+[B/X+P!S)@BBI:HL^@;R%2W5J/SU#9H5'\Z/ 9V
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MQZAG)4X>.JZ;%36\KDR_EM;)\N7"];9;D!FWF/<8-NW,6JE7CZ1TXXM!L88
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MG[1-8[K@TFN=&N=S:&-X'8%\R>,1 @QK5Z<?GAY]-&)S7>U@T^NMG0''ISR
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M*W*6M#'BXT#BB(WBVO6,]#@]P09_&ED?,MA^_.R1$;.5A-0P_3)\_?W@5RI
M1$BSUDU_([;CWJJKG-ELR27(S$(9W<5EZUM]!H8'XR\%JD#">+_7(5H;I7C
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M*%G55WLQLJRXQBPU^D=[O\E7'I5'S$\U*C2[KGQ83"-<^R2&\RTNM%^?UH\
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M'?R6X"*^3I6(5_1:@BAG^TMQ1$G(IJ9^VG2/W"&H.-IZFHZC )="MGW>EP)
M*N7^TG4?U[ ^WXM1H/-4I'MBI\".EMC+3\1/G NR)F=UOE2W>J@NKXQQR/DA
M@X.D8=/FP].]IU-]'$T9;'!$QZ?<\#YZ^,-FW9K,N Q7KXZ$27-67>+9R]*7
M4(+(D],\FL!(,_OSR.RA;:N^MQ0_^V.A)/ETMK.P@7G\ZP44$(@N09Y=8!&;
MH\=S ^\024':GF2K*6DG#'1T=,222^ "HD7+4D:,]4N/2TO9" F9>?OM&5<!
M0_0NJR%2KLP\0?X#3OTPL%-&_)C/=G & :C ,VO/YN[2#A1XDSH3[Z(6>UU
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M-_:2)/]'.=?5U 0#;$-71*0* 2E"4*1)$0@E-.D( :2$*KV'WE%I@M0 H<>
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M(]WK,[TT:UNI:S[\ 1K[ZS#_4E,2^_VZJM+L=G#2GRO4$0]7,E%#-NK_VVS
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MQ_6-?HBEI*[H\+4=\[L*-_7]W^\>8,V5*1+??+C,#ZY9E)3Y4IM%4L))Z\?
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MUW*"S#+1 Z,"<[[K4HA]0:.FO:49U- 2;54AJYN([HX]2>[=J%\5*D;V_HQ
MR'_JX@7PN<%IE;)M5KW/8P^OHKB'' QKPGN<3O>1)BTP'5UT3V+21GW^@+OG
MXPR7P,$W1H$$FKY.]JJD801J1UG .>*F$&/ ])7(&WU#,(1X)+11P=*\R6BM
MGXJ-32!P<$4'?>FF5(M'N>!V5RG(+8G1IU4'=7J \=V2?BL#B#]H $%0T_EA
M'O=I.;-=57^EQ\*.9JSW&PD;O87[;\")OG]P_@(+E\U0E3UMTJ!7A *O)5B,
M$:JN!$ '$X10Q>6_@:Q &WC%ANZ!V,W[_)M*I-#:!^V]=_^H=T-DBZDUHV.G
MF6A?OI&V_4K(H& 0JV=IPFV9)*@!U)QZI\:8\OG'8O\O?_<5S,@J09)-^+;G
MC0,RZ#/<T,S<?9_6DK5O@O6,%*LRC7IRDK6W,CI!Q&G^()82KBVM:;I/31%\
M&HDPE2BH3HJ,#4_NG5=;+%G<,;JY31-D(\Z@>P8)#S?+3VU+;T$9>=1>2H[R
M<?VBE0+R<PVM47SJ#_+W_JR+0Q38;(EM@P35XNC2.O04[@BKR=(/" Y<+K,-
MS/X?IEF8*TXJ/ZBM5.L$1"U3UQ8/J8C>I<CP'NAI;OE1^>K\[K1N_5B_#_JX
M5,V.E>?6'2M[D A W6'K*ALKM@9_YX>QU$XNIZW3!5Q\XQ_:E:9AMQ^DH'?D
M@89"@.$ME;_W6K["]OT<HU3J<5^1E++M6^N$G[JL3I&>U>7(1Y+)5Q:</>;5
MV/N[TO 8YHU)12&$TO39&R\&YD!]-K_28R&U(#IS_L##C431B2("UW0TT@=J
MM6(!<P/EP&:9&5&,_\/U?2_K6/W3 O(2PFKY[;/"E]H9K-7CG>6Q=L0C!P[I
M/G>^?HT'9+*(9__M9Q.]5J^/KS9(55D.4?\XPVE%$?V\UCN341-(W*$DNFO)
MNQWZ4>^"E$IKWGS: D&][7O+XN!#H>D[\E!$EU@E!)C59'T[XS8AZIOU2BYB
MS@;%>%RT'<[6ZWB$'#'%,B&?H-FK4V<.*2\?:WY0GFE.QS</3T-+%!SL)+?O
M_*&_FF)%B4,I O<,TP._6!-L5[/[_K;^^4&N(!K1T$J?VK(@)48405VSP@U(
MO/RNK;$) ]J,XXTTVP)%Y+Q'9+RN(&D9$^$%6JLI>=6>_D1P Y"9_9>:@?PU
M 99/DN7GS0#QXJ'+M6F]E:):"YL"&SPB2$[+3"7L9"@=T(8>E3^( $:[+.XT
M79M[GG]%?8@DVT#^;*67^RXPQ&7 Z4@?+Z'4>LC+;%=GU@Q"#9O?J+3OP0&-
M2%L(V$B=6YXYPY=^4O[4U!0Q#=G-N)8B&.'F"+S5].71JIU;\RK_Q)[+%Q4N
M+4[@1F"$YG54W[(],X8&&3W7,U"B&!'>LA(<?4S9A9(Q@;.P:BD8Q7^FJ8V0
M8S:725*0P4Z4N0NPYXCJ::#&:$PYQ-$668<J>0&8<5@[".!]_P&[RT+5U:_\
MT3 _]3=]@S&M<ZYU$KNULU4-1'HAKNC':<D(PRZA\/=@K1K^E)FO/Y_*64[>
M(]QM$EZ/VV3XA-D^OX6LZ,O6]) E$4):H-I<].?",W<WJ%UZG\V</Z:HADI@
M?EE[HHL&/;<L.D^_ !84,HNDO&*B*D_6SU2!=DKW$#PZ-A(>U)*D6'H!E^B0
M,N"OVXCC!06@PD,)]1(+\DC2\%C4M 4?E#-[U[-K7FF3$(:4@8^BG8Z5R5;:
M3QW$1U"_*&S4XH"XP'RBYW.[#TN66]X^D(;116@TH4T-QS4LMJ";9(LAV$ X
MBJ7.:9-OV$"9)8VDDB2<1ZIN1)WH(BN-.B&27%V1,5@@=6+>#<+1<RUB.V<_
M#?[E*'J(-"0$ &#KX8[?3N\J@TZ/NCHS5Z$<"R'434:X"I$66;:I25P=A=%E
M55:I[V+!E3FNU8O%:N;(X\(F@"X5N7$IW9KVQMERBO;ZA-'&#-BXCNG6[Y>\
M%)CZ?B5"T27KRXH<$F>">KYS-6%B[V%KD)KQ86/:\C@[WG;,TMRZF'M07^C]
M^C#?89LT33#(3 G?31JMO*MI]R0),@QUT."RLU&>+']>*!XW#J6V1QSW5!OX
M"GNIYH]\WHJFK:>@J&HR5PGI^]I#G[I6\Y%E.Q:7^G39<T+-28^H95_]UOL<
M[<-H_^J$:DN8DIAK##ROV$E&^<#.T!5GYL)S_0L@A$1S>_AA\0K17&X]VG+9
MU9G.G+=?C!#G_ES %ZC=<=H74!U_SJPPT11BHW-,F/))1^X+'2VQ\#K5\44\
M6^J5C50*4S8P^3UOE&2DTXAI0A=,53:NHFY\QO2[\BBJWGOA=C<?NT)#K_,E
MX9' ;?XOMG&1U8!+(0Z]6O9\I=%N7(WX@6RRANY;Z_--.6 %R\G';^KU31K\
M!O, )@.=N\\6O,M9 Z?%'=LZA^5<0-(/(]=\O1WJ=I^A6?TQ!V](B)H-[4Z'
M&;^W_!@DD&YQ*^7VX?T5=[6GOY):6($V>EY85^+$6"W=XMS)O"C*JJR8'^GQ
MR%!Q0O<MSP+$AEP0W@5#/>^74&75LC$*=NO^(=[]D:W%*!;QH<LBB/%K_,5'
M?'!OA1N''I3@!X]@O!V&ZM+@=,RF77N^ UT0?H)5)NM\_>+24>CW(QO6'[F$
M23CK(8Z.?(0W^:#.Q '[3'<A]XCMSV_<+&J:DE7CM]?=U1VN0U86P3PD66EP
M=9%9!6X:X!KZE1%AJFGA,2?GQJDV[G,O-4ZC#O*'/,#6$\/H?48&*.OZS@)Z
M,4 B0,EE!N!L,^J&\_VI/4%8SV;<;,"XIM3+_D,FW%2YY!H$/ &STI>5\B8A
MR%\^L;2S:$-]ZND%$+@'NGD#61YP@@V2S2=.#'526\B07$C*0O0HOU@>Y9.C
M=([.'EJ,]M8B2RDYP)QP(_%NV/HBYEQV_2W$B!LS>.C@1&.^ LDV9;\EJ<0B
M7S>M;"]2)3BJFS#:+P*II()EO:,^8G_IIH<A5+J;$&'QPM#N!8"MD$$A5B+4
MDZ-;^18?%@^SW)^>MHHZ,W_^4U29-8\P-BAZ5:'IO6F33D%C]/HWW.5S6\(U
MLB+R*+Q?6Z0Q)KDEE@>>+4+9LZ29%\,?^=(((;^RH2LGYS("K7%4I2C^WV1H
ME*GSJ^N;7MD1,F''41E0=+[2WAH2BM7$;.:VW'QQ;%B/Y=[5F\$G6F7O]1>8
M+XEU*EF,,V6W$DV>)M7K,[]L1=-!KQ#Y)C:,+G!?NY\I\]POF89K9CUMP"MO
MJBAF_[[!;KO8XV8?W761O1X<'2 8HO9VTIF\?9!/[1>H<? LH<+59/@:S=&:
MA]D_K:AVAA]E;,"_YUH63MD<.!LN3Z]M,$Q,.'$3JL)_)M4"Q?0"0'<-?Y0A
MJ]KJ"F$/I(JF;-)\1H5'U'C($;Z:4LZUXE%+L9AA*OC^E7@50MCQL76(M-5;
M6\A_P^>'FQV+Y68+D-ZX*5[!-R[Y.^46+M^CS"BCC]1\]H*MUCF8/OX=LL9(
M(RT#<8UP[M=J@E6R4^:8T(;6##7(K*)3Y^CYW(+?#B0);OCL>5!OWP!/TLP-
M-9)5,T0,9Y]NS^C N70/A%1GGEA[9VGZ03+/FJR4=XU<WN):.F4'*/>48=6Q
M(&+A\-8%W?N0]\X?N6G .B'(D2-0OS#K#$%AUCX)PNQ@XD(8US87:0>U1,SK
M[,D@=YV[/OG[^/*!\8R@K:ZQ&1.TA2U95;])2$A"0M2U\!DAUX;_L[M-T>)R
M+XV,FX)OKFBIIL9WAA["35@_79RRS7;2BKPT?!@?YZ_XSBQSOD<3$/"^K]=>
MZD!HGUYD)L$9%5*ASS*VYY0!;(RM?.1/+JKF._\6E^ $B1E_U;+V=N&+PAE!
MCD(K,'/'C_EJ?2E,[=$:^)6#&V!Z>@  -EX4)I.1W.#6)>] F[N6">^ZQ#9?
MLKI7I;^O$5\M,L_=OXW (MUM[(BV3]5PM3#I^D;ZG#-TU+D8M[%?G[?'PF%8
M1JF]+*_PN, OOP]B21E5"B_7-<!%<@VZ 0I/P:K=V9(*]J(UA(IS3#[,UJL1
MRAN0*Z0'LZ19O-7]O-X!QYOP\"1\TZF7=/QS_ GS/3-%DX;=X+M(7O5]=EZN
M;Q6WPSVBL\(#'G;N$]OY@9L:8 E>I4,,V,BSZ>!- P:>9=9,BK<7NAG:*.?)
M8$=E 6G/S=7HP%E%BVX][I(".6.R+',[DLBTQU;'G#EO^D6-S=_2# ;X/_FU
M8G(KDYB9=P-$?FC)-J(M;9Y@>:ZAQDLC<,5X;5*Z^=(<?=B8_RA$VT!/=NT&
MQH%6UL\<6TTB)Y KV@>G>\>OC  Z%"RA\TV'( 2V;(,GF5Z%G56#A"R=IR<R
M\]L@8P<[VUAXNAIQ=1OLC+6\]R+Z,=8')C'#7ZE@07,H";,;:7:\S:!HHQ@"
M-[2&L[BK;BYFYGJT*\SO[(E&B%2P9%>*]5%L&SII2O66LZP:K/0 LFQ4CQ-M
M&Q&]N?7)RX7.I@@K$VE-8T38R'2+>-Z= &8Q"QL;:Q#H>K+//L\R@A,YP-O(
M*2*_@V1R*OA=5!$C"R+E'!3!7K2 EB29\/1N0_P:<)4A/X2B0"7)2!D&W1=I
M)Z7\=GC*EF6C.E6C!:]?=@>Q0!-T#-@5W%S&$=Y4R$[%[SGBD)C?FC/525T?
MP9*T99<;EV72(+\1GT\J6V<F5Z]I"K":5QEAK^9 ,6/B<>-;N_B5VB-,WY'T
M2S23BE>W8,G175JJ'YO6H4CD>$$BQS-DN1>OWT>'A4H42MA11>QR/490W:;(
MF+:*QU>V[?WZMX_(>^>Z2[&4'JN8'D<?"W=,[^>W<=3LUQ(C8@JLIO6'G*_Q
M*IPH;;WT<)E&?BNQRS3(D4;ELX>;- 12:V"&ZG2]E9&:*&I0UL\W%)XQGWT!
MU#T/?*Z[BY<)T>D:-A49R-S$\4)(:77+W=.N2SF^'.';H8"AKF;DAAK<BIX;
MM_F%7N_KO .6@*O'7"Y#G.:5/Z0.TG5GCWP2(YMS]5R6M_&BT6RBH=;00.81
ME@-4\0X,>V\6?-+QK/1I5] )X?N4R5Q&DT<I+?B=+6G$ C9R<R&5>Z%Z/-<
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MOL-,>>\%_-,=2-JQS_UXB"1=F]9N8TS^X&>JT+0":[-/FF4E"ZK349K_JHJ
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M4<0[N<W@F7;=IC.I#%##4S)-^V+"B!7>1R8O6_P3@,NL+Z,YJ9F4*T49:I!
MA,?!D[\>,D2DZD!U5E7J[5>G>$_H564\X<8=.F:V9'LE:94J\FB,=8,,M5DN
MNOK?-X+.\@^Z7YQ,G0!F5Q1^]:!9/QGT3HS*S:F\!KQ[1F4[]W>1]3+X= 3I
M']RON@<DQ&_Q=4!GDN#VY&LS!09$/>JXJ<\57W"1WP2&=)/+[]=_Q%D\N)[7
MQF,;GX3DL=?!$2-?:1'7915:][=6BF5;'?DXP8W^;JM=SOX$T\Q'8:3N[?#D
MBK5@FC1Y:6FR4&^C6X!6_'O^0S(*WM$7$0@?A46<P;9F76?0+4^\D@:C<9.
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M\0__:>[)AKP ?LJWY+8WJ7-_I/EFBR@*$]W\KH6?#KB"VF0'.F@\KSW&EB
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M18$G.(AG&SI1R#6IF575J/<);9VRM3>?2&%N$;"8+7Y7.6,]WA7T#P=0!4*
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MD,:&D"(RB.%FO/_JZA4IE?W#2_5'LOEL22(M$S$JC]G5N,LJR#(;?H!(BFB
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MA\6R#*$>T\C._&Q5H4T1(OAPA)#<GY1P.J !C4G6UF#&5).@T4#(@ZK$?J-
M+((.<Q?L_-K\TBM?]HT2QS,ZGF:\ND2Q.(.\V186L^"IS#>O)%'RTOBF=JE)
MF_M)]"&(Z6"_ANI?44MF2NTY7:46O;8X'AT.[N,.YY3PG[O$NZ7\F^$\-4:I
MD?6+T=%WN?BO@>^/=":X[8&R>#:LX% <%=5KVX/@H[%Z-RX9ZIAW%"$IGUX4
MEMI3+FS,W[ R9 IVQW>"QMUU'2A[F$X(OH 9+:G/>$6-K*I1W?XVP@"7;Y&3
M!"*.01^3%UOD"U[E[9*(J.YA5"P(2U0OY]2+.A(Q.T;!D':X .[Q.*BX'0JI
MVCJ/TS"ZW>'7G-FE4G%;#G@[,-_WSHCG#5UZGOS% .D%SU?A=#XW-4E3(N\^
MS*T$/P$^N+-515MXQ1%VO,.XBN ,*F/I!9!]7(IS:FBV\8*Z<B$U) P)[O*;
MNCB$?)9LCU%]U=!$"7^/GW/$'X>7^K:CM4_P=LXX+Q\S5D5IAZ]%2 R ]" C
MFCT7'^OW#Z(JEFW#1:KN'5'"EYC8%Z,=%5&<LAR=UZ..<V\=BHSZJRID,;SH
M+J"R&L76LVIH(ACC]H=[>\$( O*>(DSOKS0"ZO'ETW=:R>0]JS;01'/P'7[C
MM,9(P">R=*57V?GV=?;L2P^5XT?>A&=I6W$CYVA*(:3(PI0*MK,]M88RSLX[
MRBXC%AJ_G_'PLZG@H!6;Y)7;ICY[ BBT)0H9#M"EU8G!(5EX1N"A-3( 8-0=
M*J@%)=1Q@[3!EC!QJ3'R)94T4<G[E_=\A5VUIW&&QM7YYG0QL/2AP6UU',YM
MFR7(9,%9S17;<Y[\EXP01/V7/"@PRS*![;J5J9JLJ!-)8'R%)RE?7S%_Y69G
M[' D1O4J'U_IX_'X5YHZ"G^/G<8=W3L3B"=3;4_C(9E5!-):"LTY93)#7M/M
M_(*</HW^RP@=0(A0J$J9( NG1*[=K]%L#M9\G?$2]?1V%86Q'HB:CG#+],3A
MU16NZ<]9+]O$PY&M@=>!O!:(-<KO(K(<A@3!O#F)ORM)Y6H[+)X](M3M&)*:
M/[-8]JT0@3MZ9.B:;M\0M32TQR1A@/'0L7O&LYO:FQ JN%OVJ#.[VK61%2$K
M*W@64,Z''F2ZC,V89T@ "B")B .-874*XMP@>LA.>C9EI"9X) J\/>UW"A;I
MM3#><^=:'B5('HS<:%9F1\_@::V)38JQ0K(RQ^@D/DXGK.P<@YK,>+*RO64%
MIV)O*;06VCG%"/D"GM^0NHI]=C:8:&@EPA6V\E)$^4[NGM49^CN$6?!FNP/:
MV/C2"/=B6EX_G\J<JPUZ5U "N!Z5+RZG?&E_%GK7L=3_!'CV0OZ!Q/;#W!J-
MP1^)LPZL"?(L7B!Q/ I<8!\\:QMG,<5*-$2C6'(+$M0LDWE((,S!/TI6RZ/
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M7'/A[+3<3!(G_.<+\:YD)UW(A\(NXS_Z#IHR"0DM^O\6/K3#+%+(*-5 /Y(
M1 %J_B/T)N'IZVQ9,H=78;9$O=M*$9+-/=E%<6-HOX4U@?)5Q_04-4UY@@B[
M9=Y:8NN'ZT$^)=\]&@_GP:QJ8:P\/:N]KHNG+.T3H-,UX\Z"VS?8*ZK4IM3
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M@%?X,TGDZ: G8T$GZ9!2!TU#?0==PLF>)\!"=4IW(A_PM2^95]>'\09D!<0
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MEN=F'@8Q0A#49PLL.5-OWP9SOMQE8U=!9??M6IOS!FKKA8C3J4C0% HE@5@
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MQYY7T+BA(OZ@NM/)B7!](\3;@VX^']"6W'7 *6C=VLJ3(L)&F[R3*//EV1F
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MX.3N=YP)68WSX&YNC+!T\#VKI3(-/(&8&HT+"T;O3PKAX@;9T[)(?2PK=+-
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M"OH $4$QFKW\# OLJ3%D[8'J8C[+3;+FFKX083)VT#(F F8] F.B7Z*4\)^
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M(]D+#!P<Z]<,X5JI>ZTP2SUW*2++81DX^4;*:91KAPXY4=>FBG]\4W,_BSR
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M%8"'75I;VW$9TH.76XG;/6%[JZCY!0ZMQ5#RLJ+[2 &T6^'^'-=!_&H96]I
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M&'6A5U]M-1:X9<MG5-5V!K8>*"B\4YI$&.%<B=U3-7Z=CO1* N@6$%"D%(+
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MYX<D=_[,BA]J9UHF:C$5L\_=-$"5PZ;=0]9UMS^](0W!T!1A$Z,N-<&8Z;;
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M<ONDV7:S<8E*;UN"AF"E)\^DQM*69&PA1+2C8ZA@QBMASAD8RNS5&N]R8OK
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MX6'2QEHAS>ZWTA"L"1$7'"=(LS),\*I=_U1U"P@.J* 7)X]3+1\R9UJ_66/
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M+2+0Z/5;0+WD;N@]R_)I-A=(P'+4S"!"6#2/2M,DC/RW$[K8^8P@]?A]#21
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MG"!MRN7ZNL@BE26N<;B8:QD8UY/#5Z\;/1#>J\&!7]UP %OXE['F^D/[G>3
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M[X"TSX\@E'\>$%B%2VZY))]"CO/5/X9K>C5YT:T\6&6HOM.G"[ZSD,CX",:
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M#("<@!YXIUZ N@GS<G^ SX5YL^%?7YT+G8]H[YULL$C.MCV-99'?[5QV_X)
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MDRZ?<#]OI!&/[CX"G./KWS"?09ELYC20?W/P19#,)OCQ?L4780R@) %=4L,
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M"^!$9I#G8W8-33=P NQ6Y ':_KV:3M\>YF=@5FD#HS?)6;HB/0RWJ?:H7X"
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M?'KC\S5N*GS;G&[/WO27J5P (5'=$[S@.L.LX.[3"W :\XRUKXO7G/+0<]W
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MB>L<_FQE%*N'8DE;.T]1!PZ6^W:X@4'Q"^T)W(Y\T%7?<^!:-#*\%]I 72_
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MMQ@J=HY9():]'[LP2C&K/LQ0CFFA@.4Z!!/^ZEW']%2:@-$_>TZA"!48C\&
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MG;&:N'7.N-XPFI)AL[QN(C&1)E9SO^*O4;AMZ!G=T*&A_[CQEG)%2F&U6^@
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MF-1OZ@3^\XLP)?[9A_=;4P0>I$-<6IO$AS><Y:QZ2XRUC]JQ)7SF3[49P[%
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M^Y$K5'1N.&KU,,W'K$#"WDW+UHCK*N(44J8%V,0Y?BMHMM)0K>ZVM6\P+<8
MA&*F=T:.:_?IJJE?F0B+&/H!02=F%0(3]6V*,W KT895-J)^%Q6DDF["NN8;
M.I>?A#(_N-^TDHLA\U+C%[QSK'Y5Q<A#T3\(BE-(G"XL<C4V&6=2U7D]>>TS
M!:BX"/CF>^8-&YW;53E&08G7]T3*S3N#KIX-X?(\/&?DNH5*)Y98[OSB7#)-
MX7X)[^VLY%P]S"E'O.!]Z?O^[8T3^BYV7:23>!\"[<==X;-*"^,Z"#+9C6Y^
M5A>V?$ 9_[J.B%>@\24PDKRSZD&Q;NQ\5W> E",D&ZGM3;B-E]$ZYPNV-'\
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MH,_TD6$>YWWF]A\ "@.K[T\5\7%*FC:-*=W%%!9$J/Q:8:.,!:[RCCCME<K
M;]X\%17B]HBK5U^3W4AT:3SHD1)^MX3F4S[S@V:DDTU?B@SSFT^O,_=%AG=_
MOFP$N/W3@]2X%%Y%TD27Q%+7#9'%NALI9#O?TA*[1>++\SB>W3S^>QN!O5[$
MYBONV%K(K;U4E%;.?!9HY7WI'5O$'G4.1:+<A;31(YIR>27BB3*U>$)H=\*=
MK<*(GQZU"7S@01(,FY.Z\4>2, PRX8_/CU<,LJ7&H+7MG:YZ"&G] QCIW)60
M^IH-N VCN?[%+16.8=HKA;'CKWDE)7-9DM&Z:''L5_T)']-><6"4,"[4=8#(
MJ3]/;$X<C#1=UGW"P=VJQT7(7G!8@?2H@:K?F<F4 R6> B]3LKRRSLA"!3VB
M_/<5\G]69I#5W*PT>C:_#&%6 3)*1I+6S+^K354"+#.)$DQ 6HI(")U1*D!*
M_H:5;11<V&,745ZK=_0JVLGZ>J:USY-XPBS7#'&);#*(Q#::*&U 0][PYB=G
M:*7%T; ><$J$$#A#3(JY-F=FL]%(/B3*9D^O9G_SI/,'P,*$NSE\:E.N[/EE
MIY9:&TXV-?XHLL^F_\'M)\!YD& 1=2Y8"!<A);D9"K?0DB%7I_R!8,?[3LOO
M2MF(6SM&6@P"P'C3AZ-N$#>^HUK$I[L(ZDO+U4;Z[*#5]:J;*X@J'8^3[*.V
MC^0-4 2T?M/UVR@/MU1 /\LU"X3F35IL6X(C<EC*0ALA,UI@#M6:_8_AB,B(
M 3BRRG$2 K*VY@,+BZF]*P]JX%I;E48V((R12'_D6*%>]J0$G2.%X]O(RS^
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MPVA=\S@LLYMI>H'59^Y9T(3ZZQ/?]/K8XH5Z+HNA<3G[?8!^F^,H0Q#ZEFY
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MS8MM35<_9**XU;WIU)L#K$EY2F^V4;CZ'O1&$#LWO2M]7_,'X(^WD.MP%JM
M-T":@=<JR/Y+H07@+1 Z(A1GF;==KFH 4;N64&W:BN6))!7I UB2U(UL4_Y.
MI\JO65HRRM"[)=W@<55*W,=P#4P_8@?;V?CXI^%WGGEBPK4Y3R&<5DPK*R1+
MMRSM!;A8,.L(7-)5.RWQQA/3%:_-%8?5A(F/VFT2#0"2(<BS-%Q<A*E^>_*]
M*2B3,PBK!/_^%1%#*ZSO-]7\">='.Z8,W0B)Z_@:SY?MBW>IJHVIR+7F8O(H
M>T?25.I>.YN$:R<$JI9^#AR9!L:BC-XJU%QO1U,EYW.$!DWQA^S!$!</)ZNK
MV$;&7<,O;;B8YAK F;RO\7X62ZLLN/LLC+');1T7>H'TEY#(Z.Z6[-^_%XBP
MJ-CU6SD^CV@F= >6!8L_4IIJ7)V*4O W\>F#([7AI-[8K%ITZB_H7S$.GYEW
M(6X*EZ"9@29$R_)!"$T*W[#&Q4_5O&-^6*U?1.QV+;-L\%#YRA#5AP\Q"7IL
M9QJ!H?F51\1>=Q [*A5]# >EVEXE>NK3/#CP,(_JRK/+#S7:,M36HZU!;ZB[
MD271V<J:<QJ5A *C>D="07.^&W4[VE\.S-@2]ROC4,OA#Z#F4Z$(I+N",RZQ
MU/=UA#^CY79:.W'SFCKG &J&?>3:N70?TB-PI;4\A,O<V^JM.SVYGA49X%H*
M=5,OZ%LG')2S3+C*K\Y9(F0M9]KTD/5FT+_?+>2FSN];9VME\=%$N6V*X:I2
M0/U+5K=?::O>"E^0N^$!&]JQWV)W3VE]9N-VHN-Z%IHP5;ZRQ8J!X0BA"EE5
M^1I&,#!?&I40N-/@+W>5WA(?OU;KY'4XXD>=3-FAPPG8_DJP.O/A#'-'LAC_
M>-*K4K9" 5(Z!$(A&;?VP4' NMW;Z;&X4&S)&UTMM'?M"P$Q.\3F'?N1'4+K
M([.YOG#,*?\T'>-('K7J#M@#^2PG2J,S4T&!^VU!*X$("Z?8*<TFK<F_<]S'
M]<W!CD0ER9'^^-)#MN6#IJ^4=E3LG<Y8/GQ<"(]<QE((2A%5Z=I\7&SI1EO-
M4YQMXUHCFE(HK#-^!I:,[9"T^,5.'.W%6(H+7JMD%;OR)K6?I<8 CHLYDTCP
MPA[@WUT6XHL!"?"$46$[P)LM'"CM6 F"(*3 3?T#0C"E9N-!W@BB )60!B(<
M5ED<8W00C W/Z2B( 7^[E@,(9T?OD0R[W._D=W@Z#CE322U"?Q2'+BGQKXTX
MQTTXL;ZI0N,@1_*@T(XS^I+4D;)VP=@>0Q*7TO 6D3%ZEVC8]#[AE\F7FFY>
M<LI(?)/.Y]C?%Y55OOZ^^?$6IE"QY1]1JUHL2P^IP)<=^XX&6"UH0G$+&DX7
MCD+TWO+J<2%#P_=X[#XC0C)DNPN"!8WO//@=:-WNJ&9?"& &N*B1G*GHCW78
MC2L/(+AE>[+*E);P]K"Z*<H!M(!@,,L0SVN0=5+,NQG$BH+_O#E=FY5&^TZ0
M^NUQWJ>>-OK;^ Z?ST,N]T\!HOTYV3(C5?JLX@2FY/RG*M'LRUHV;E3[7PM7
M]JA#V5^&OL=$G#^LX_,]\(9%DJRA_+4[?M?3%-5/&?JHKC4XK,/O6%;X_!91
MR_SYH#,>?O9G!+KS$%H%%)7W[38QFFL\%O:][S%.7R8!%O=5E_JV6FNMQ9RA
MPT(^245=C:<A>A2I-_7B\]T?=SBE9.<XN2[P)S[HT7?"K=Q)^\V*>/YYYJ4O
M@\'H>N@-+P^^[+![;\/IDQ=$,JR6Q89E<2)99*9!8_Z\I:IEV(+>XD\>>S[7
MH/A%\6;\D>2U&53"#;KY3]-5C"<D0:VK:D_$@TNS@ &1X;,1P.V0TK:JGUX7
M_%GXEV_BBL7\*6-[-I ,.7P1#'0& E#[IWR(YH>V*2GL1K0$;1WC\KPV(2%W
M9YO-8EZ6O?P7ZG/=M$4_VB(.U9M?C;^ON^#-L4MMKXI@8&%.>4U:@.V,FS&1
M&T=E/W@A(-_[4@)RMP>;7=-E  Q+@NF3!I86VYHJXI.\B+875TH,\L]HBQ4H
MM.D-&%K/C04C:"GV?&.0?'\7UNF!YXK6U]"RXD(:\O?8<36OYN/>$6_Z%XLW
M?2F^)8*IF#NYL?H4)LC&81_C2(E.=E[6I;L_E4 3Z?,SV9\;LP^JR2ZV;(^+
M.41_TUEIWH\H\-(++&%)CV>MTM_4.0WF\<$735-&E+J;&IM:FU2><DYBO7+V
MK%<*Z+8.NKRA 9+"Z<BY))HCYR/W.L0]6X:4U@].NUT]L/-!*1NP0QEO9JS(
MTD A:2U-%7?\YTF8TYKZ@8ON'P!!N7V\X+R 'TN!(-C#)>@EGZ-Q7/\NF)"B
M8.MZ?O4^<5C#VTZ"IZ=V:/<8WT<3TQG=LLT+H9GI_D.ADCW8+G5#%DGG!,(G
MQTMM&\=KUN0;EPK+]HKKIG6K7;OWY135;0M3[_S)X%W"\B-',#1R\<20GE@K
M<Q<EIA-2.M[O?:W<)#[#HG') 6F9<.P3EHAD;J'W-YNCAUM]TCOF^]9&!U>A
M,$\;G4A'[%5_]WZ1&OU9D@:VFV 8Q=3*^7G@W,=+\&"]BV;OZ</LY:ZB_J\'
M&/"E*#MC+<XGJDOZ:"YIRM,I9FZR$OQ:D"P GM&&M\YQ1\=CC3\H32^!@J)J
M5S\D05MW-L?"O1=2L_!P^/:!_M/YA%0@1O)<:>JVSN<>AE9X"Z8^OM*>0ENJ
M/2XH=%<RUZ)>_UE\IA9SL.+@=0.9WQN]=-L0R[&3%+U?!3B6!O<5A@.^G[(#
M2B<S"O%EQ>FNA#-0TW6]1RSS(K.SGA4A=*L&V>>8U4L<MXAV9!L"Z@P0+53.
MGU:->[C?H SWAH63-N*OVQ[#!Q,:!U,F>:UC0,['L:NDE ^E/?>Z)7:ON87N
MPF]4&:_@&,,3B4(8P'[*UM]00.LFH0-3U&<.Q^UD[JT&W@[RMM&"N">LGQ\,
M=^9SUKKQP&2Y*<39+ @T@TUO SVT3U%<O:LAEVVJ 6]-QBKL</X P!%7Q?S^
MB2#O@89;X8/ZY7M,E9:\^3FPBL&TFZ@-M:^S+&[!V!# 1O5*6SF"DFYWM$,P
M.X;^\W5[I!\1,%,L >T46^.R;; M1SM 2J>MG0FB["?LF,$AU\V[E-<Q$I@.
M^HKB3HK]]=%XZ]I<L?' >=6H@?F*.2&]U/QR5:EQP;);R*LIJB[[3LPF[8&5
MG\J(Y6)U+IASU7OSW=?YE@"VE2/DH5R[G7<1NN,IGG$_X]R,:NN'*AR@L1\[
MH=V]N>"Q -"5_"L.AT%']M0X2_BB#W4$J-VIWHD.&L_<J]'<?A*,1G*S=5<'
M#,1'W$%M\UN-@LJ4*5CT&G69F)'&TKO\4@MPD\8-HMXTLM?H+ULO6;@^OEM8
M-<$ND6.0NR1G%ND[1"24N;+#EE)N]1OEYC[T\W'\LAVMP6'/3CLZ=I1H\&/K
MWJEH>9-QC9LOZX*N^^TTL/A-C&26@(Y4A"B%LSC"CFN]I4#T&+6K I?Z(J<T
MGK[_A[EZQY1E"'>Q#W-; B];.%>SC?WN4W> 3TGW??%'\VO.\+.!G)P<L\9T
MAJPW&5+OA(ZT52_;E#O3IASKBG/EG"A<AU<-Z%'7/OZJA/12V-YI?3OQ<*,?
MXASL*H$,97M@[.4/@(!:TSO#GRO&G!OT-OPS+.[61HDD9SZO7A^2'":XS#7=
M.D5OVLUR.KD/?68*>Q^Z<CZ;QG_F:1Z7@"ZFQF-OXO3I$7LHEWC2Q14?D[JA
M$#NLS=MY!+X7P$I[KU#<;^]"Z+4X#EN3=?^(^S.:?NU]V*V%+>*;Q9'67WFO
MYENBSFPB(#R*J89& $HKN3%4BL /B5M.1"<&>:V/GJT+"8MD#J*YG$ZD&J%J
M56NYR<G3"YVJ]/V/GNG%ID>E)9V)&C9^G[DHFK]/\0PEWNLXIEX>#+QMRSG-
M?(Q<*5'<,LP7?TA^\PF/+&]B"* #\]>LUO=.'-+);EH90_ELE^D2D,U7HQ')
MP,N<&DZ4MTD*'6[AQV;7)@D5*WYJ#$%TMIKR10PY=AN"" U,N-7:&50?/\8E
M5@Q>3I,K"A*9]6%9%D4($^9?UH(\FS.6U"498)8PDCV;<=DD7X\M#22A? +H
MJK'9LAS83US%C3+'J B71>W^F]43Q6&II7?YR&/=YSKENV;#@>)ET]7E-?$H
MO4SG22;>Y?>X@_/&*MO#M5(QLOH/.MEZ/2IS!F=+BC^$G;@=A:B>=SJ%)2GT
MUN]-8(KSE'7ZCKWK+F(XCDP,&>NG;H\:2/S^.K"Y\?%]]QZEE6,1+AT&F6[#
M\N=6^J=R6*WMV!6Y?*+2K--^TEN!-SGTR<%6\DB13HY2!GO/,I?C=RL;*YL#
MU_P@P6M#S,\7>8()S"+7HQA>-,\GS;!N@O+R2*@8YE+*@2HK_?6>(_"C$>(%
M_/:V ,=T<$-TP:$E]@$Z:[7BF)!1Z];+-RF5ZW*=^UR @.L+OX_>@:@/9&.)
M)GSQ@."2X(U9__2I#Y9&5D03?9X<LCW^#9P3B+<\2QES>YW=6#L)Y4N/V9)W
MS8%[])?9F:"I&K!REBX*A+=]7IO$,'H53D[-),8RC")ABRCZ<R<^+VD8\XF\
M@S$4C:DK98E]!'^B3V1:/$EXVL#R[T!,=E7"G!8U7ULLB'&&32;'G$\7D*OY
M"%1*#9R1>=?7QHY1"'G>W7V/"MR17GY'<(.8_>W*=*"#:KN%DEB*7S/ES/%M
MHOL,E*/Q] &C\AB59@8YNI<AR/;>=^[B;?30_N_".TR]NM?,M+V>9F+(6+Z/
M.D'AOUGE%]HL]3@Y6B?=!+XWE.%O,+A6MKNE#)H!=;O1+X]5@:=<M^3MYUR<
MNY\S&!@S1#XZ-"/X,#N^9M[(<;LL5X(V=S^A?SGG*O[,&+W/DBFVU*!+7Z#E
MBD:Z$RPH+K*;Y:\0Y%)>EA\ =D-"%WE-@YO>#+WT07*[7S0F[)I@?9KHKY>Z
M#]JFU)69;^'4-OA,9AAET18?. ,3?CLEQ*MYUD>RTP,D(EH?N9I!S$E61D'&
MP/75EL8B71_=R6.-\\*B!]BS&UP1?RG\AKUW<H!W/5S.,;*DK=3S2D)((%;P
M=SYWK97=!AT,9,7IY5X8J3CR_7L @&B:\0\@NEN=U%A2<.XT\;DUW865:LVB
M!92(?.3K]_ +P\G)+:.]76PI?Z1\V\!57HJ _O/73^.)[Z\4HJW^ -ZTDNGD
MK6%&IY&BW1&EUMVKR,U:M&;L&*Y65\=F#:8X^/#E1&8I:KA<IS[HEE4YD%#$
MF'/GLH5*'(G6@BE1"O)JPM15;&MHB6.;-IW.%\$DU++3ASH^YC#$N71-_KQ;
M)A1VO@@$.YE)(2?0,>"?&""@DHI2LC2@*"-[^4P:*'S80BOBD)!N<JM_1L7+
M/JA'_47R<D1<1_<38_;)-X. P5_X:RH@3'HEU@E\6T1_,H,8GKZ?6@?!9".
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MUE\[L[HO5:M2,3PZ?(?\3:I+$0_'N[ZR?:VZ/L6FVM SHG08^..ZY:2_$H+
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M(/I%/_?+40GM!X9,ZU-K4F?H).$8?7Q^"H9KD.*3JX[CYE>3GQ0MUJV+/1W
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M(E41Q]W&#0HI7L6;%63/[VE[QG=YOR2BV2+W7KJ#[E#I 5>XCKOFM^ODJV=
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M_@E[*X0,H1]P)BC^9 :/_$_26$)I=-R].G0OF[5?%\F5$>?''3\#6N3^HHF
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M0E>I+'_8*;*,BP*5A6.]78(D/=1(RU_T6.CR1K"E-&?4!3$?^2%,TG,]D@A
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M2*B@!E CQB/[F!)/P_>222UT;U&CD2<S[%A](/(GG>N29]NYVE9CH.*J;J+
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MO)D"$U'LQI2&H CR *]2T)QPF0#2 [R',M$ \;TS /OJ).P#B@CF*:$,H4J
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MO:]/?67N"AQ_W][_\^[7/QWL?=UR/HQV1HY' Y9<MAKMK)"/WS'ZT_L'@Q0
M=D"4JLA2U3U9VG7 45R[MM>@BK\NT+TAY5Q+Q4^$JS[M??\R0];%\=RB;9@)
MR/>\R*U^F4JK17SZX0<<3!W&B/%!=6:&22(P2RM6(O!#+;7VV2NGU92_:W/C
M8I).SM'Z43I]]Z&0-H4-CYOZL: N)7^=D=/2LOPR<.3].=*.*LW1G'U'V"AB
MR7R]F@4<!;[_TQ4+=@_.7:7[W *_+^$35T2!= 4&K4G@$Y8($@LA21"HV#5X
M@D"C=?')=IY/>?9=3XJR?N68HASS^H^O4IAAI27P0)$)GF5%#:IU/V3;?_TA
MB5CX_AJ.ZL% _\_VUZ^_;7]VOG_\MO?]P/GVV_?]W[:_'C@'>PYH+@>@GCBN
M[^Q]=]S@M7KC['UR#O[\T5E0:F8*S?;. ?[L)CY[\G(IN:M8*DJG/M*.22O)
M,^=,\]+1F.-YC:RZKK]+6-#(&"25-B21#&O_1!X13!@2@ &M/1W2));K8L%O
MUE/TL?$?+?'@.P7?D#'T<H2O$<7/",Z<Z/Q2T+GCA%V/\S",/>*R."(L-GAK
MD(Z)1^-0<?A(@WM/>&=:EGA49K?P'S"/F\[YPG0?AP8_@(IB?:'H]7L@^+GK
M6+<VPQ=8KR*B4I-0!I*PA#+"J?9(*'00&49#KLRZ^&).)Y_@FZH7)(#._^N4
MN9OI>,]0;S%AY#,1ND1RS,NAC!*1P+^2$."4:Q%IOC;B0*=C9>-&GIKNPIZ"
M[G+P??OK_JY54@;]91W @2=9:87G9\ZG--,.;#I*DHV - AL+_+=A.@@P"P5
M+R1)C)5W7&JHQ[1,='A?/OQH3]1P*LU,>K'(E+K$#T%S&^SM1_" A>OFU'E7
MWATE$H8FQ2%5Q"CD!$Z!H(.(@R4-2@QWX\ U:CV<\%T?VOR%O,8HX[5RP[63
MOVPC <1W *6_V<KZ4D]K+-=7;3F[N1S=DD.>B,?\KL#Q^N,IE[6#6^<4QIEO
MIL,K9[^Y$ %,S31W=NO*V8$%A:&_&>!DDW"RUB/:6QU(WG6FYP\D:RY TJ\@
M"CZMBV[K<!1XA U3P,=)QL^*:0TMGVKUONG%I70$&]B^(#$T9%+I=Y6>\!*,
MY>6MMFV_POYA &77^W%:I0)#(,_>=>^W#\%3:D8!MKL ^GKU]I(?W2M^0Q.F
M_?'GMW5Y?@SMZ3WRZ,H-.('Y$5%J_OL[^R?!+U:,TM[-#$C6;C?0RJK=?WCH
M6H:A2R02E9$;ZX 3G2A#F'8#DF@W(I2!* I$J+3VUB.1, 6OG+2U46UXD<V%
M*<]V"J4OFDL5/C$IBV-L9RT.E\O=*!D_X1AX<YT( BI2-]G^U=N=/'3(QRWB
M.&XVKZ=#UDD0:X^SF'A<QH0%H4\2-XQ(Q!,T-R0/PS69' ?\=+>-76QR2M=F
M?URV?3XC'O6C(&&WH-@K #!Z- ",>J>Z7:J06<!RBM+9JX_ 3EZ\0 XTM,45
M?]+S7 )I.]WRD.?IO^WG-VN#PG4M2-^A\.EL_.O=T??1_LAI4Y?+YT/12^#L
M?"U&*\EX%3X^#BCZ&UW:A^&.S<ZL[US_)';P25A$&W3A7:$\>MJ3P@0^T1$J
MCRK&V[BE)$+ZGN0F9ES?^^RY41ZWE2IU5;5_?4YS[6X0"ID?4.<S=_Z"%K?S
MMQ3^/-3.AS(]OL[V6:]'[#YGQ)=M&=-"N[XAL0E#PL+0@+Z?4!+[+ Y='B4Z
MH)O:,F^#6[8_A;>=F-)^;- U6D$?++_(A__7"2>>B+"B:Z))PF5$M*) $")$
M9\=:*6$'_KE7'A0GF_11[$.S'U)]6/2##N[.J("FG.I(D2!2L-0\DB1AGB32
M<X44(0\]NEY&M8;;7OFM+([37*[C).32(]7MP8-TU;R:D3PA)Y)@- Z%8<2/
M0Z [AL%%3"1X][H,I9>X@;]>*/E65#7/_C>=6)?HYB@U\5S/&YQ'#V9;M]N+
M1WG?2D"A=,(SY^.IEC;3V&F*/%2#>^49DP PM8-<?:7S ?[&,[>7<R+Y8L[S
M-Q)7E1CF18K'1(?&15TJ)#R1 E0KX4K&N?!U<N\8:91.@-]KDDCW7\HXN"Z:
MZO''^&9#20!@OR<T8L3H"/9;<+!OXU#"!C))P0".0W/O/!RLC)I].RKR/L71
M!0$E-(JO,X*?**A$=P65>5C0?_TA]MSH?>4<Z$Q/</?:@$X;7)5-,=S'03:^
M((,>0]0\2F#/O8*@;AOT^XS#H*[M;X-JQUWQ8U[+QRDMS^A2*V<R+:LIQM35
MA0-/V.,AUWLMWJ">CKE=V[)^]Z U'>[ +'==DI7;?VF F/O3+<+#DOC*Z+![
MQ8+YX8BQ*T*^/'<4AU>%A+FCZ"9!8='(NYUA>W$7SP^@79"V@LP,$-JOR[:2
MS(4?[/HO?K^4E$-'-,)J-.=,J'&J5*:O@*&ND:[;II4;>9WN 0!WEIY74_%!
M6F<V3E9S>>1(++UYG<EYV\T8%OW"HI?<:A7[9V/09UY?[[T8EOR^2]Z%@ULR
MUZ?R"$N7.R"UH"WX9B[:;NO#VQC8]1C5UJC7K'V[[WZ\(A,5<3?TB<="2IA4
M(>$T423@C#)CW$B+>Q]=M]K4F>L)B[SKFW=37M&Q]16W'- 7G&.L5>S\)VPE
M=9T)5I8\NGND;G^@YGD27R*I"V3'B D5)F,;+,LL%0F%HMQGD<_NG]W4BIU&
MZJQOT@<["]6Y!JKJ$U69,$QT$'HD!N(B#(B)) ;^,)SR,$JP7NV]O9P=I'UL
MA:K-F;N0DH B]Z[9")<2'MB97WFE^+\:V'.:"O'.Y\\[=SB@6WF L)C9?VT2
M_T,Z>M9JN_;ZO.1!'!>'2XX+YVN1Z\$9MNZ27M<RT)K=/[<BL_B.T]_-%<9'
M:T><.?)( PK!*']WTH::RGGV:5HYW#G1649^SXL3&*3F%9"9@A^J*7J;>>4H
M;=*\24[]/@6[G-&@H\L%<@82':$@_0?\NRU#8>7JE5+BNOE=%G,DA.$Q-\2-
M)"-,^3'A(14D4D;Z4>S)8%W)0'^'I?DKKLQ^NS"[=ET>8T^_;B)4[%XC<MI2
M::.U\-F:J\WTCL_RHG;P#I<4$1^ WF"5CM+6EJE62P ?\W5FGVP1E+D\6,%L
M&^$UK?'6ZY@2&?K :X9&).8)F**NXK$(/=]UUQ0[_;<BF^8U+VW1C_*NY9CN
M1]$#DST9)CLYTC9S[QRGO7;?.$<@M9"]E,.S;,9CB\PG=/L M+G,;TM\MB#?
M.DL">0]_QF)#CIKB+4OV49BPU-:!ZGJ.K2Y7.:^A/; YG&HJCYSJJ,"B#DYS
M;P.\P^OS8S_AU46(L"^W<W@# CE7SFNOF:, RP5^%_^$&>#S]E%X"4?1MF/O
M@[*#L(/D5>TDU%'\K!IM!B\"AM?&^I1$20+6G0<F'N?H,W EH &GU-?WKM'5
MX$5;[:\ISX4NA)K7=Z[B=B\*_8>N^@H;(!:^%L[YNF #A%P%(<A:P%7CM*Z!
M#W4&W%46.3IYLC-''^ORS-E%6X9+&^WY@=>\J;EU#F'F;2R*]T4=^KL^G&9-
M'N,^.7!>H]D2O7> Z$<S+1M4!T">"=:#V33>- .>P8BNWHPVI%7X- )^9Q$)
MN3"@2X0)X3'S260H0$!  Y.L2:M8V"G<J!8T!I0XCQ(#3-P6)JSMG,$TM,.E
M!)C : AE&0<-YWSEMV &Y&3E#]48\ 5Z*3MY!N0_AA4XVT*U!)H#68Y+=N@<
MEL5)?=3]/ (M1=NQ64/=EJRTD>D80^;1]Y>-T/[LON\>N_:!R\?7/8BJ2?OP
M)6/MGNQ<":XGB-<I6XL:UGEM=UV5CI+@(0L=N<G(=?VKBAV-@CBYZG<V\EET
M=0-)?%5X#!VYP57Q,]!#&%W50CCR@JM&X(V\T+U)!$Y\Y\026&<DAC^^\E^M
M@J(@&=$ &K\FFV*1:KI7%INAYP!D/5G+=\2RJ_V:E_WY>36KWU&\W"3F_P[I
M'Y:Y+CGP6M^Z_W-:U:DY6^O2GQ>.]\OI.3?7WN;TS+C/>W7)'-L\P(>?YCUV
M<[MG3'*K7,IUK>D&PIHNY9'UU6.Y3AS$H^B6TJ!YXS)A\*RJG%R%ONN:Z"78
M.U2J60?8/OTYWC=)]*E7X]F<(KQNY.M/O$5\1?$*YV;GS)?ZJ[D*31003^.%
M(]IPP@/J$ZI]92*FF:%KJN!MC[5V0.,X+,JS%<%(]B&KB\CVH77&)7U=Y7?8
MI#_J\<V'=0NP^RI&X6 \]&6.]]C*_<O\8/TRL_M0BN4*V-4!4U3ZBNA$*"S)
MYA+.F"2AX:[T?0K(*M8#NW:_?IU6::ZK:NVW^-SO%L'G82!Y3P2,[BU?UC71
M'AI(3V4/[R-0GLH<[XOOZYKG8QE(+AVYPV%!'P%PX_[YQX3 0:=^-)WZX^KC
MXF>M 8LP"A3\/S&>%Q$F&"-<F)#01'))@S#A<; >#;A;W3_9Q=UIUO9A->%K
M[Z1\Z-+M+T!#>"::[ J!_H+V\VG/ZYEKZT.9Q\=+17V8@$!S1>#=EI/>-/T'
M(XIM'+%6-@^H+IQIU03MP2PUK)]RZMF%TUW(+H;R8E_9&79^DD+7T*V3P[ +
M]#\>IY5UY.<\ERG/,/ '+V##AZN:YXJ7JG+PQK54799DZK_F;U;&WYV/!7WP
MI5]YHG.KGN]\.?5ZJ/WY!\ NI-FTWG"L78-1H+RN-=[WAS0&Y);6%324\T.;
MCC*K;<BK2E<5?M61H#9&VU#MO*VNC&^FJ&+G0-\XSK+(G )DR +9SQWQ4]B:
M><8<HVRA]ML^+P6'9LG>::;/;!;/:S=P?AOMCW9&3N2%6"CN#4Y\/LLV.5MD
MH+0O,)=)RW$33P]+/^'X$/"CS9A5=L1\JM*Z'==H4XEY@3 1C1,P T*E"#.^
M2Y((; &5N+XKF(J4<>]K/^Q*4V[C9(IR>[ZEGS)^N';SX?[$>V-#XX7QM'&J
M>1H;4.MM2R9>*N<686'.CO:>SR;MK+B8!VN+ES;)Y,UK;;*:R6P.&WPEB[+4
MW3U\5OR6)::O%<AMQVDQK;*SCME6];JIE)7(I9R;R"<*2_0R2C7A*E'PT?>E
MBB3U[I^R\J&04YS$IS3?K\?U1YSYSFP]!KY[4GQW-=.@)F?YHP!%L"'Q.>5W
M?+K 2U;>S)*U4.#*PJ:B@5S-SJJT$9<Y.J1 ?A+!43=$[5'G52.(,6$,?K(Y
MK[/>%[ES)ICU[":#PMYD4%:+F6<E:++'R,RS(;3ZZB*8-)EL'N8?T _$!40!
MOASRBVZ=7U0=Z2SK+ [G]4(Y#FCC8@X-P/4;6QG@0B&.K\5F8%'$'J;R180;
M/T)=A)/$\)#$<2"BV$0!-VQ-!_FX%*N\ETV&#XP[J^Y:TO[^ 'B3LWZD=I4>
MS]8^TZ=$I2W/8SK1=)R_5VDUR?C9._SU?!T?.L)B83B.]JB,CAB#;UHW7#<F
M^RX!L_(]B 2<&V9%S:KVG-[0*>[>H_+-_<JJW\]\<Y=<-;#>=MV/9J[D"=@A
MC=<8:!9&^8YG)_RL:E.8%C>H6_VVQ.G*I;_/"C]D;:X[+^<*]U>WIB\'N;>M
M>/W+-->.3[<<CWK^E@7<#"LJB#:Z".LJ7"%6QT5EA28T"2JL]>QH] B!%E?D
MJ,Q6$C39?TTYYFTWS?/#0V@(1<:X*2/7U,^\O(_CPIJH:(1CIFG[439U."M;
MD Y@U$H/FXEJ4 .']E<IZY@>SB>3LCA- 6HUC/D_[R="[G&*U,J>3S:5&Z;2
MWA(I(LDC[1$P>%W"_ #D#C6&B"@1T@2)3J(+-K#OQ[[!AWR/8\ O*/,)/$L\
MB6]0K63H7A0^WZP7X%-6\/J5,\W3IK7??ORV_^&5@_L&3X/,4EK"6F75'U^1
M8%E&Y=,Q445-VB=>_1*-PDY4=+-ZQ$1P>#J#$6PYC>)8-.:9S(H*Z6<"@NPJ
MJENBK_;=M@CB#I^D-9!U6P81?ESB(FST/^G(2Q:JP:ZGU,W#)VW>?QNP>&1N
M[_G =2FFM?7C6H<N+LP*)EV]!=P^"4LNCQS7+C2SW-PS]G6Y5&'D2Q(JCQ+&
M=4QB+##E\S@TB0K#.+IP=Z2FTG>3@)*(@RW.)+PM?#\AL?*$K[EGDBA:42O&
MKHXMR+EO5W)OOK9+_-RL\R(C[W[]= TGLV KH S^<_O#T+WDH0=3409%^R$4
M;6]0M!]:T7ZP$*;[W8!UYS4X^+Z]L_?5^08H/(;.IC94H+*77HWN@Z5K'N9B
MQMG-RQ4_'I^O>?J?]KY_<5Q*_FK+O;C>>V?[Z]??MC\[WS]^V_M^\,2O;[O[
MLK15]CXUAMP_-"^=C_9L_P,8?5:K\QMMS'_!Q'.P_>OGC\[>)P<8_>#CUX/]
MIU3W>VTQ!6LK:!0]9$&C>)1<=5F7.W*O^CD&??.J4D/N*+FJ5)$_\N.;%!JR
M>[2VY($;QZNMG4BY<U2B4?(',#Y.>*E^9$7Q.Y##C_FIT.6D;,SJ);#]@.52
ME/90Z)T-F<C27%^%:M@[^=ST[NS/>I^1-%]#2./#JVR;C+V=(^XFISJ+\%U3
MJ#:[=:+.,^.T:CJ&Q\]^%.9'F5:__S!@QA=7E:)>'YOM-UW;JJ#0M?.IZ7K@
ML6?&8\&#Y_Z^)/)XMA/K!]T_1.[G,Q,IH(C7/]+;2Y +IM?M1<JW[>\'SNX@
M0?K(2?>0(.'#L52OR.,>2[8+%HOCCEZL0%D\]'&]D7>##/C%5TCWSM(-B-V7
M#X&BL"+C'^Z/+M#B(13RKF3,(GZNB1Q?+B%>6_5T@.07!<G;+Y<5GCPF+WA(
M'@*/+_.*#)@\8/*JR?ON ,IW ^5?7RXO/'E0;A1E\6.:E[HJLF.M\+C(F!\8
M'_A01T:_S3K'TR)CG)VV\P&W!]_&U8KTC=WC V@O@_;.RV6$9P+:\H<\$[IL
MD[7/'@*H=Q8['!S% Y@.8(I@Z@U8^K2QU'L(\/Q6%A-<&3VHM0,27X/$@X/X
M;DCLOUP^>!Y([#\$$G_6ASQS (^EME=B#X \ /(U@!P-@'PG0&8OEP^>!R"S
MAP#D+_"CL\^-KL^<#VF%902FY: G#["\-EA^!E \1$0/$QLF]B0F]O("UA\S
M8GT(6>^E7-\@+PW2_*63^#"Q86)/6YKW:J7NZ^8)7JY=_3S</,&#N'F:FHYX
M3\WWBQ4)FYI[SL=_3=/Z; N>R.S%\[8(WQ'HA[ITON!%(65ERY7N8DG_TODV
M+>41KYI:AS^+\NTO30-X/4%[B<'@1GH)ZN9]W$CQ /MW@OUPX(-'M+PM<(</
MDDNC*UT>:S48V@/R#<B'R!<-R/?8R!<]C,IZX1HZ/*"<5E7:WEVWO7"?SJ?9
M_5([1:Z:RQGQ&<#/:=9<<+4WT4WGU6A T^>&ILF IG=#TQ><U]T;..4/@:?_
M'U[XE>*]D,?:0B-\D76?%T(_G&U13.ON%@C,Y1ZL^ %]KYQY[ WH>R?TC0<^
M>&SPC1\">^?:Z;PFK\7@_>EDDMG/6%'T Z_Y +8#V Y@NPFP308^>&RP31XD
M5?J(YX<:;Z.W$ NJ+3\L=0NZ?T_K(V>[N2&>VYNO\^YC=QO?'*SG6O'@,7AN
M,.K2(;'DCC@ZN P>'T@?Q&6P _\JBZQ156W2GAJ20P9L';!U<]CZ@BNZ]09;
MQ4-@ZUY]I$MG-V_N*X5W!E0=4/4:5!U"!NZ(JB^XY%IO4%4^!*K.+7:,<^6E
MO9'[4U$"/^!UYF5:J=1>+5PY]1&O0:G5Q_ FX' U:>X<'K3; 8?7AL// 'N?
M%20-$QLF]GPG]@)SGQ\U^7G(?GY^HOW&<82#:'_IU#Y,;)C8TQ;MO5JI>]?5
MIX.9_=A.'I<^C).GU/9RJ2WGXZF64QO!O&=,*KL,Y9VBG&![VOE3 6N#\1QZ
M\.L,RM^ZE+\!>I>A]P5?V-H;Z'4? GKG>+M3C"<ZKX:CRP%:;P"M'AV@]6[0
M^H)O..G'Q#:"HVV)G#-G[R0'I?4HG6"&\@Y,F*>Y\ZO.-6BS&(+<_&Z5VGE"
M=)O9?&F5GFYA!RQ^KE@\N!4>#(!?\,4FO=%M'^1ND@Y]+;!B) B@<K4$M0<E
M!XVW"1/9:I-+&E>$LPO-@SZL].!I>"$0?"]U>(CDNR,:O^!;37J#Q@]R,<FW
M,LUE.@$5>)ZMYWS2NLV;UN5Q*O50R>?Y8:-_8U?!,\##9P43P\2&B3W?B;V\
MZ+KC1PRN^]L@V)^=8'<'P3Z@Z3"Q86+]FMC@=KG>[?*";QGI@3K6N%T>Y**0
MCZ='J4C;ZG0KRM8Y^_)(JVDV5 $9%+[U*7PMW+*1_SSP]EG!T#"Q86+/=V(O
MR:U3P;>\QA)>#Q+C-.MM4!4&5>$:58%=Q9OP-Q>9MO_LQ0Z>Z_O*[FZZV3@Y
ME1[/II?I4Z)L> FR&RSN=)R_5VDUR?C9._QU=F]A-Y51D#;]M?A%1XS!-_^<
M5G5JSKJ^[;M$Y^J]*$YQ$M#$.P'XI4MHZ?2&I.-ZU\W[\F6>T^@MR6<-R^XO
MT1FLMUWWHQGT3_BA;I"=< .C?,>S$WY6O7_U]OP&=:MO*>Z2I;_/"C]-*IZO
MZ>:GZ*0*6R]/>*E^9$7Q.ZSSCVI68/V.]+5X>K&&%?K4C.^.(;F;&!'YW"S5
M0BWZ'HW.POX2**Z\O)6-7-__Z7R'"[05WAV?[NA!6\/D#X[2RMG.\RG/G.]Z
M4I0UUJ<&$L+T5O)7Y_72;V^VG#27V=06N:J/M%.U):P<C3>]9%HY>'661]_O
M3\=CO&"@,/9"%^<3;_(G[<_N^^ZQJW[;X'5<74_X0-O;K],*5,MJ/@I<(Y["
MU%I^)RV_.W-^=T[2^BC-[4J,-<_Q5^C'+@PWVCGB)8"P,RF+X[2RRX37X>+/
MOXWV1\ZW,CW&C-'Y[;7.9_CKT(X1!HZ%&IUM66.;;A($(^?OT \_PTUPJF*L
M'8F7X6XYTTH[: ]43C651PZONDGA_3L8TE3K\XLK=);JXPM?RV*:J?-?:I#F
MXQ5MZ%.L8';^VQ1)ZT(;..QS7X%:D5_XKD"ZA%V\\$.IL8[:Q:^+?ZX80W6T
M:AXG:7:AW1-\L/NNW9Q<'S9W%-F]+&!Q02R/V_C;*@7^XJ4#DP<[HYH7=@-Z
M.=9GSC27351O;8G?3-$><6S-MPH[**:UA*V#UNH"Q G.UIQAM]#-Y90V EH_
M6Z2\ECJ!X8YTJ2T-PA@X=)47]>*#, 9@<> OU. = ZQ6(0TY0CL*2]0K'(>X
MNN]/EW. [?D"A#0@H;<<,9T/*H.5JVU_6XLM<+S\Z=WE:FD+F_:J;#8*O/BG
M99WT' *OU#VAN[)^;[&6H&N[>B> <QI;\APJSX$2.O.CGQX+IMDH"@#TXI E
MGA^QR OF\TYS'#JQT[]BOJ@L 6&',VUI856;3EQ*S[?Z.&+(0N942@1@H.VJ
M23@"V&DAM9RC>#$M[8_X-PPN _H!5 ?YT4H)D%^'!;XF83J6Z.L2 *6:ZXRH
M+\ZUQH'47A:I74L_*)<J1$4%J)T5$_LT8/98EZA?0.?V71 ]:@K"6<+/J0(X
M&RALH+ 9F,T4&9"MF%HYQZXYS5D5M2SQ[ICY_5R6/$6:8:HFT*!U7( \A7^B
M]8_O0)N7MS'0X$"#'0UV9-01WK(\;!!N#/IK;>O6H,4"#R,-:JQLP^7LS8M0
MU^C"A:TH/RFJU*K+K9 >2' @P4[0EOIPFJ%T1>,%R>RPH; 5\,BKJ@#Y:BT$
MM&G0MAY(:2"E#LUFQL#6*CE9")M)B[^,T?B&_[86J8]/T N#L&>L$3[H;P.U
M745M( *U;)2V:6[X,>A:(FO]=DADAUDA +TTO%6,4XG^F$8[L_?[(7V)SJ'H
MF)EK4BZY)A>-VIEK<B#"@0@[(K1Z&5**TGB?)!+*N+DDG4NI)S46&6RLTTZU
MF]8SE8_G'>J!1+T =@.9#61VSO&&1".QQIJ]E[2EF&KN6 :YV3B.T7_M\&.>
M9HB) R4-E#2C)'2.6?%8%B?UT8*:WQZ+-?!UE1*V4KNK= GV97,6TS8QD-U
M=IV5N>B<M5K45DLEW07+T, 4C[ZFI3T8X).&MM*VMD-GF@XT-=#410?N@BDP
MYK(L9CJ_!3I=3 HD)=2^V@,#ZXC=FIW%8VO=F=08R0[C(J -DZ6 ?$+7)UKG
MSF^_EWB>V\0L8(P#W[)OGO!R]LQN57*=V4?^S,>\(5ZK*+;EHDH,IT#=S\F
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MJ.:2:?2>;"MH-;6^<712OO[T8?O-5D=T0+:\#6'1L(-+<??(+JUTV&J"8&!
MU73<9>.D.;I@\AJ/^?,6V!L/O_W5FAS8!K"/C3JRS]G>KN:'JY+*EGSV5K\2
M2ZXLZ..(E^-!\QE89VX4-(8 0C@>"J$U\'5G=Z'R37V4EHK@;Z!C8$X*QE_9
M2DW'5K%?K:P;Y^#[CDN]D;/;Q;:M;$@V,@.>2-%'/[&1-]?1^(+DN&X4%YMH
M)9?0LUJ-.-<%?Y3 HD(-'TZF935M C[SZ5C :D"33418XX,"KFZ//"X?\_S
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M1FY<3A@!"N0!&F?!-X'G:?(,\&$%]S?QKAN%>^-=O$%D&U5WH\ 6((=R367
MQK&P%ZD!_&9EW?V+\V2$BM)S38DV5BS+M!LG<PW<BDX"P)@,T9'R0>XFM+(*
MQDN9K;FM86YUK3N;L45@&JJUR!DRL<2W]V[[P*TK[='AL(7T$Z;'5EQ\Y?5U
MAV^!]@F@6,BE,U]# )AYX99./56S=^OGK?=?,S./^>HRM[D%DWI9O%"( L8"
MQ (-'1\_F"6KHE[2XS^EHQ?RJN>GO<,?S.>9 &%1I7\W1\DL <?VY='_@=?3
M^RW,XCHSO(Y_-]_7#]&G1B%/W\F3WM')#XK Z/A[_WGO^,F&OQ^?]-S7__>/
MR[(Y&,5L](]ZST]IN0?)\..D1 7U@9Z%DZ/3]'3<?19N:!4$,/)W@8W@%QV[
MWAR;KIZB1Q9+P6691>5=\7\?D! =]@Z? E]RG98,>=(WT;->6)R)002UGE J
M0$4>\97!*-U0G\Z%O ?&9#FZZW)^5\NFTCCF_[LCQ=!:.C!<X)^YJ/IKLR*[
MU;YUM3G,\DICNUVK_EEJJ3\^>?YT=!^UM%8-?2_Z9H-!\T4VTBL$O>WP?*T5
M[)CM]Z3!OYU6^9X6\@[ZXT^I"=] I@<>LT)Z0-7A&Z]/>\].3:+(<#>>X&GA
M2.17WU;G;'*BUFWR%5Q5]8NO/$XH4SVSO]6*YT\L[*52/FBL_"^ECWSA/OQ:
M@OS%5_SWA1);:-$[FT&@9>_W7T3_V3<UFOY._,5G_!.7NP;S["A*_6(6X-&S
MI/_D7H[IE[< OTL[3^ ;7TK3/F)]^A@-N>]_N38=]N/>TS]KK6V/4_<Y.EJV
MQ?_OWX#"$"3FSKCZO$5]WP(!_J7LJ[_"$@, N$F9T/\B8/_56QP\>!IC5R3[
ME9-S3W=%LKLBV2]/TR\\^:F 3M=3W.]=7EPJQT8Z7]!EPAGA8;) *85EUA^N
M>A%@N4!,ETQ\[S&ON]96L1*V)3G)[)S1=6!1XT+6JJK+A&E1NL;#M25>\_'Q
M.,E*,/45]:+2!T:H*F(,++X0=C5M5MUJ>8$60Y9I11\:*IU*S:VATRKM^(#4
M"J, 0/%%%>,2+=L"/]>U(#A__ZY2M(1DO\-A,*"J"-8MEAJ'>3%*A<=+""L5
MV]5<=N[[#K#ZW%2$%D Z&#B90.-#3$B5"9$-EP("X(EWC[*E+51HPAQ]"+_9
M+5>%)3N:5 &37(*)'\BNC&0NO+),0@7 <LE_X)E:2=/:"=TP!ZINK!G709C*
M#]D.:.?9"CCN=.E:/W@/MH2!:'2]4K8+\SD2<#SF-<#+Y:>8?ACVHCW]YWX;
M-\.40M'?CGN.J*5>C,L"N+DT=?/D,AXW6>]5I'#2LJ(++NA%N,@6W C0UF,L
MDI4!5)@7&"(L>I'M]^G8L6PW7-EX@:+'($#+KJ4JG1[EJ#?BL*D!]MHT(Y#2
MM7\D>56E@DQR>)_"\)"E:SM=,*N(\I3G*:D>03(EVF* D6PBR@>V-X<PRFM]
MH#OX9$/66E<$WC:IN*U<9[Y7-;J@DAC_GG,YX:O?][N+_/F(+;,JU5;!&&)6
M 7-L%]#;HC27]JO3E F+RCIGD0XX_)MG^0]70G63"KF;OVH# >E-I  A$;@_
M2) @Y#R?SG&;!B-FMQ-6.@>B$;/JXT$U39AGR30RGF:XR$H2*=Y]UT_34.'(
MNYIM5AX25;S%L&+<FI-">!5%2!)T%A@)8J\#7-=H@H/SUFZHX/7#$9R;5HSS
M?<CU"74^3Y?,B N!0]>)SVG;].S[:-M$>_ ;K;DK<+ABS-JE:N9S@UFS8>3N
MS//WV>SJ[N6SIOT5A(P;T&SOL9;^.UJ%QC54![8Z:N777EERFJ#D*Z7+$5PH
M"H*]3BKZ3%*":[(P?^#ZJ]@G]R#3)HGRFDT5L!M+[99^SO">JMTOE2>,?M7J
M,F^L7"FS2$D]H 5T5LU[T=N:K@L4K]$H[3T5-%@2HI=*-[__HRR![6;%-E&[
M<ET1W-9L&,R*X4>M@2#C.QD:.#N7,(G9O@0CZ(1>3M.2MS U&_UTI)=[4:7^
MX[AC3?<S?].'XO$QV\-)/5';US+H:#&<JX+#^Z"EQ;;7LE &="M#AWPO1;&M
M*W4'N4?)A MHW5Z49AB./">Z+);,2.31QWCC< ,8J4V!Z;$A.[9U7KKPZVO;
MHKVW5^>_G>_'T;K:MTE">P3:(_VWJ<&+H_?GYS&X0,2(RTF,[8=<UZB*W(0Y
M%SHVJN>&5Z9\CJPV*\?F[]]_W\"[J](SYIAXU2@7N/3.WI4<M^U5L?[B"-O7
MZ&R@IYXF3F*8SJ2P8<8MX9VFP*?OT_O,.&3,#_W/^CI!U3M<=]\Q['=4A+%[
MIV;Y>F>+"\9LN8LC)A6.'M.:$$:>7UAA:T-0P8A@A65%>J-&W:51O6<:GV '
MZ>V;R[-]U[7!ZB?2(%RR^B-J4NVAUN42LNP&3X.L7#"MNY0]>Z6X/E<+.NEH
M-8''.@%8.G@%I&FCT5\O/X#:/V@:8DHY9<@TKKJ[@>*MC>R8VED?'99#;7&!
MR%57(T$./G'C$&G/.9PEE:G0M;>7J6C7@OJ<KS^L<9UG_T+]CWJJ:DV,Z?28
M?DMP[.F.%),B3_A#L]5!,039@^&XTW'P:1@F\U3KY&<S.EE5^%906,'VHI_U
M0PE=7S/FR)+?]J)W>?13.BB99.-)K'TF36&GJY2T%/30.3$Y"(-9=IT9AC>R
MG>C1RD\<2\!HQ%UGA )D^*\ZD^)0&C5M-"V3_HC(S"+-L6YU2?]9?R=^_S+7
MTN^\O:2EF;2!E;W?6&:43;(EB0E9$EQ F8S'J!MSJK\7O91@%"M7JS[Y05+;
M%):4,BUYP.7-J"'A_V>CG=XBAD C^+E<+5@!=Q%+\) 'Z1(E>98R@*61W7*$
MN^1W)G(CD:BJ*Q20R'? 0Y?FINTBIE)KE7M59U)E!!'<=,4UZ'2XB8-A@C!'
M4@[[O-98=-";K0!7WH+.$IC[02BG7]=SQK^&V4Y.3E'5PMW"]X^X&]6J6DJ@
M+;DN:)!U?J-D02.AY6S24*"1 !?=(S8>N^67\V6.*6W[WF_[/K=XN,,+-K8S
MILR8)K+$7@\),/4@#M"J5/-2:C[T];AWC&,8Y#L;A[ SL4EB4"Y?\'$[0*_Q
MZN^@,\+UUSJ8[JSHRQ[HI![W3DZ>/N\_[Y^<]@^?'#]_ZJ:=Y1CY <]^PW21
MB7MV=/3$IN*\1=5*LL/#YE._[O3N;IV_E/-K4B#L 69,&JMY)=/@C[YR3>H<
M\?&'"Z_VHJMNN]:H%J["UM!\V,,5IY<-(G-2A!H@G8T/[&.:BFJP>7%"VZM,
M)S2+_(6+ ",;ZW*RGW?4V"W<G;7OXJR]3V>).G&57&8TR&J>''"J*+C['O*(
M?9AN&%BS*#Y#6K<Y+>-E^EGL\0S&L?(6:<P'!XBM86Z4$MSGX>G%H!#P$T/[
M\E=8U.-LEC:N2Z]3AF\\5)PSDAN6&8JYES$R3I7TO9>8U0OHB-WAW1W>[C!X
M<&]8E()$,\G121_!R6WZ&=TF/]XB-O<&Z][/MII.X9LG+JB.D/8;$?T&H3-F
M;"-_ A:92\38/^+MIX<G??W(X4)SBEBQ'H:JI7?[R=Z!_KZ&6#[;@?YVH+\O
MSV 6Z!&3L$-H#,28DJYAM%:EU-6.,!/YG%3^&#K1-S[VB]7,4>^D_\OSPTMA
M%PL"'Z#X(4W%[34T'XEF:$O!T10>P6Q(3:;I5,LOZ7-)GL'>^1]2>D,-_OJC
M0]\,$["SGKWS9CI\_ > O^S""SNK*8BV+TOPL]N\,U-]RX4N8;6'=G28<Y:Y
MOUL#1 9] .1 @CB?Y;>LTF&9\@>4KY:^_/JGMP)C>_W;P5$O^H5N) 1%FY]$
MU-&U]6YB;:NU:\4QS2Z%%^JO/8O!8UK"Z->WA\>G^R%282I#8[TQ7!G=*+^<
M)S 6\?!L;N#)LDL <@1S].;F!XP]?4GJ<#:KS6M-LUNKN,;9A!9UG5'VW=[6
MP>1\E?BD]^3)TQ\"LH'CWNG3_E<E#,OFDZ@JA__G/^B'_O-GSTX/GYW^?X>]
M?RXF_Q$ELV7G[T,*K:<GBT\OU ([.CFD?Y#9]B<.\ZTV[E>]> YWU\[W<>VH
M O;P1L8-?"SN.12IT9;"6\V=FR44;9J^PCE>%GG*UP4XP-%\EFS-PUZ?B:=C
M^NE8**CQO'[O4/[!%-%RYW!Z::,FGM![IG&7J<G!](7"N'@5)V5QPW$VVR#6
M),>T@<TG[OKM_3VX? "2 SWJ ;UHI&$X9I:^[1KH.,.AICPY>?;M-65_C:;L
M=VC*T\,C3U,^.Q9-:>Z'G=+:*:W_^\;EKAY55/%L+*2[)M?6R "H)F-%!N7"
M0Q^D4LF1HTH#:DLR\8K]3$998=NR<0.MF3K?.7I62G63&J6JK_PW<JF<4O"?
M'D73HBXKY@;V40 ?-K]N[6,'Z?(&K1SZ_%PQ:D_U'1@C"=J2QJCM*;P,AQVR
M"9U6]82\\645).<UI3A":B,;U)TI%4.&S,/_$R;R=PLIM<4-'RR+\AW*&+[_
ML-@9+T6SH\1Q$PPTTI;NAF??:]H:'WIM6P7HO63\8-#;]:G%-P)S;YM*-"M3
MNT"+L6E344;_2&B!?-PDSEN(4T3%WR*DUW(@R1;&,QBX@5"V>T<%N!GT5 I:
MPZ*'8 ,S;IYQ[+>DNN/C /II_BZ9D4V'%[W\<-XQU':+#^%7YYZ\"Y*C1M^/
MCC7^W$=YN-//?03OZF?@W_^Z_OPN@_25U=KS70;I&V>0OM$4'RR7KYKM EKL
ME=-LH5UA%>(6&Q0Y*"_(#TT&2)8)/OD@*><;+P?_7FBW%&D"DSN;4IFE%SM^
M<^<5Z:3)C_\S#<"T>W;8 LQKIMA_'O8;7=.@$Q^4+IV-)^W9]IV7\AUI3!Y'
M_:> /OU3PB@<"7)M4;1)3[C&"UY[T\Y:&XRPZ?<F647]6 =[YDRWHV>;WT&/
M"3H!8C)>$(D#0KD6=4L3-.[=7;./UQC>%N#\[ZYI1)&@ J*H'A0WV]G9U#:A
M6W>:6536]KA221#<OT'D,9OP!V[#%+2S"4(&?LF:#_N3,*>3U*#-+'.PB5.L
MS1J% K4Q)3-F2^W!$[20P5@[Z$Q0FV(*%KQ L0D4[,2X)<;2[-RU#NO02KUO
MT 1[?>L?IPU'Q4*:",^+43;.Z$<.#!Z^./Y?Q_Q3_X69CJ(Y,)T#+N_@QD'%
M)Y&.O8O?/NP;6>)ITEU2C$2ITA6PJAB3+O+:V>@+ IU]TOYD57?X/K:Q^QCA
M)OWIU,3S.;A_:/X%.&X$,IX5R7KZ,=K[SS_V&Z>H!T^P#*N#;'9 1A)S<^Q$
MZF1HR=:O3U+9/LKTW#7'7QIYLYJ05/F\R(%OX<6T&/F4;F+6!J8:AJ8!?WWO
MPZNS5]4^G6HY@_P<Y?_A*STM@>?%D\T-_/[5^>NK#^Q?8UOZO?[NQ/K "]DG
M:7O7/J</?17-DW^2;"QM>\2J=830G1CP*,Y!T9$KM;0J&^( B,EF!0MIKN&P
MD$Y>&CUMF5ITR)ZTWA?TQG."J@!UY9H)6GSOY?^G?[HOD:\<#V<-,BJ3&W3\
MIC^2&)\)^Y=$F-70LJ_TF>58[GM1_SC:>_JD=_K#?O?'[, .&&SOOOAABH;C
M>_VGO2?KOENE4K/,WXB1K9HR^U*.(!2?+J_[JYIXS=?!F,3WHYE\QELHNWX6
M!(SGZDA83T"!,(-8ZSUYL>QZU]LB(JW+WRM3D$ND(UN^ ],"?\!72Z1,\86+
M=)ED,VO-\$P=Z-AI0,\(;MK8F[OK<H]+TT6N(X?*90]WTC^*\_C>8@CWP;4\
M[?5/OFXCO,YL[=&:;.U15[;V^-!E:T^ZL[7;MKV[,.=7OAG[A[LXYPXI_]4M
MPU?-@I@'@(G?R5@[C5!#2'=Z.T#&[IAA ] 2?PD+)N3+K*K,FD;VB]S*O,C'
M&;L1E^^#Q"-9+._/SZW5HO>[\<2LQR1I._*:IBE2C4,TL9XE^20K'#.4>8:U
M.DY#OTN8#.E!2/ZU/NR\//ET@\U@C-[&=DID_8"B<V3*+M5:%?.3EL]^T(58
MR?N<T6>6/ ) )@X,*DC!$L[U(E/QUEVB5;XI.DQ<=+W&@GM6FL<TLOF]NL6?
MF.%SI$ .GM\@)7/+[^:+1PY2S.::,=665<'".YIB(2:BB1/<:8H[J^XQ6W7'
M:ZRZX]NLNN.3_IVMNK_VU7"W5MDWY'N58QRBQ8Q.+2+^FPZ8NEJD99PR;CCQ
M>&H0]:V"6@KR4&%M@9V4'@9V1OE)6&%)34EW>U:-1EGL#NQ?_L">K#FP)UT'
M]HE_8/M'6W)@[P&$*V##5 \-$+V#-><K@O03P\,Y/N^RB9I8\O-(-$Q$Y/-$
M"I'D*D<->< 0;1-$<]Z@1'H)W"FN8]/,CZ=D<MO4U2ZL\+7#"OU=6&$'GWH8
M^%0+FOK(]>Q?VVZX$XKK?K#>S? MK=D -:_+B@3['22,.[%;Z^!-ZF!LPG4=
M'?:?&90564*<H3/?L\U4#.8+D2)#)^PP7Z^NWKQC"N%WPV4A],?]9[?BO/ M
MP7/Q3TT\U[//PG,%D0G%<_VCGJVBTUA&M3L[CT+[!9"N1PR&^1R\5^.XMZ!4
MW"5AFH#!.D4(3HZHCP/!)QJ6_"8D6 OM-2NDL,H:]<  I,N$RZZ&]\6 M<;J
MX\!L.IJ3RH)H\:>Z'A*V.X&/X 3> 8WVL"B7/X-& _[ASX#.DF%9T&5H*)T]
MZ-FAPYX='ML?_Q0@[3__N /\S%:J?W/XF8'*[*!EVP$M(R./WHSV-;:ZUN/J
M;MJOSQE$:4))J/"3,/03?/CX2/[*+ H->RP6B%H#3[;7)W'Y89].)?H+.)M/
M\TW]?IB1O#?\#'74K;SFYJ<8X%<NH+I[?!,#+Q99KLLH;3;H?EUF$[ #"?%9
M7@A(S]H.IE'B4-LFTL6\E+4 !3O]O_1Q Z]T@48%'EB.3.<[X>4^=./AH.$F
MI%10JHFS/@ !I/8*''E<UDF%5B9\RY,L%:2'\FI,RJ0"E.X0,+S8__0LR6$E
MK/NL$,.OYHLI-SQ(S.\#()M%HUD>:GIJSD%+X<P8J37IU*K@WP3BMK,\'H7J
M,]B)1ZG\6F'XEG/*M48&5-'R4N\$JF@JD$V0"N[-U<8X6$N [ ;%1.S9O**O
MMI_C%E].JWV+F>"2;ZC#BD^OEGVWWF"!&_8-=\-17%TH=N)I5U;SLU 4[81E
M:U?0JJ6-$_Z3&(JD^C80BKO,[W\/RA__[\.=C+]BEO1T39;TM"M+>NJ1L!V?
M/MEE29OQZE_]6,2CT]N>IV@Y7C7"N<EPY8(EU\.9VYM9F\5U991HBKB#.-_B
M$@8,86\0)P4]^ %WP>X(\H9,XD>'AT*(LS-+'H> /U(80(?]L0X&,$ZNBTX8
MP-W*0=>C!:3K0Q7RT)$O0>*;3$SGM6:<+XS_^S%#GV&FD9Y@[\EPN0:QF&5T
M?$@VO=;LG:C#.5BMZV"U0P3L$ %?%1%PM$,$[! !7P,1T$8 ,!W4SDSXKK/^
M0OGE,;7$OM<XP@7*.?2N##<82R2@^GP=>TL'E\K=65GTGEY+R,)C5W'M(F<Y
M>G(;<<J:V>QLX\>AFOYB#"QK,O#W(&"Y)=W. H\FVZ%937.]SH2!Q1BRGTN\
M<L^D>\#3LLNZ/_*#)%G9!P^7A&Q5AC=X)&W-YN3Q90?=*"N32H;[E;1O/L7M
MW"FYSD%D+[?>SIBS?)^N39/'RIW<^>&C=E(=)P\/02BXQOFVN(*[9-)[T4\:
MU^=GZT-B)J=Q@'J^@C4UA3P L]*;&/IG9]^CFLX*4\7.<4VS!A $WK#,H"D2
M;2T>LL*<?S@_>[5O$_$GO<,_F<:/?JIG,^BC*D$KUUR2;.Z[[.UX47:3E!NN
MAC.(VY["+R0C@2QBE=K'&14XA'TP5 L&LL]/89JILJ"%B,[GR2=#GJ;)8^DE
MM907[>)JCT3EB;P_JIC:1GLU;INA,?+SN&HM[;-E33FSQ@>)+QO.:2>ZH!/*
MT(N._BR4X7,0"9K_OQ^_3DBQN/?DM'?RP_Y=^'5B33R2481,GX$6='\ZVAO2
MZ1^4[/>.80'!@PA8;%B%E\JZ0_LB#SSY\703P8_]@D?%/095MB'V";6FA:4(
M";T+3=[*L;/3.H]#Z[QZ!*UJ[JMW&""CR )RF4-[X@[(@@[_>3/6H%MYU+G_
M&;&8!&W$QEI'4A_?"O+_R/UW\AF,,B\7_[EL!CLY[TK+/J2DO]Y0DQ%_R20L
M22/LONNDS PIV7,&&?:?/-/^(F)^)L9_%[O1L._2[?L3-\TC.Y1A'(VQ-[V8
M+SSX2R^[!HM7FINP]T$?G:%SX<A+(G,*&WV8JWJQ8-H35/2CG%\M77HYU(MU
M9KBQA$=M:9"76YX,>^0XE2=K<"I/NG J1UXU_]'S;:'?^*NE\5]]1HK^+@7Y
M]TO1T\/G6;4F0=\L[F\$35U*XG'F\;]'/;5+VG_MI/WQ+FF_2]I_4?M;&VNM
MZ7K2:+$EZ9_OWW]9FTZWC<@V9\>EJQHPDV$:SKB^+J0%?[>YOFR7T^.7F6G6
M>E9/2 UJ7;H@N>6NXE?D17[0:DHF_BO?G0%NL]\_[&J1YD#[Y^_/O:N<?%[P
M'L-@S[2_]S2Y3B6*V)$OU";F"1*##%5'+TMT(Y-(U+SF!HWL"$?C65V0@[$J
MR1H8,;%7\8EV> 'O*T?M3E:BV"8=HD,<!^'8B_<RD7:@\6>.- #QL^^.S*GA
M&+?S0/0_X<9WW+R-'"&S0#8WU#^%5="0@T9;"Q$+6 PS2:"\>_^>]W#II87I
M;EL4&9RC=,P15[(MNK(87,Q@0 Z*XQ"PQ#E",T>'1X?1?V7E$FB'JR%&BQZ5
MY,(5DS*91_CW<I:.8I,KNO+ME]=^H\_+BX/?^M$9?6%0C%:!;;BG[>4AH\;@
M^Z!"C/5]DU4D=\/IP?MTD61E=$%SPEB&J]@DIM;FJ6\2K^<,;V42'1_]X$6
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MA./V$49\>L;8K7"8LOO=2///&&>C?84;MNB0:\X%56@K/"8/MRC1(91$(T^
MJ_$-A@7V\%%FA[\W;V";_(!W+.WOM*-OH[?R-AO\'5U_VY$FT'B'1CN9)<<7
MPC4%'<L&$JF F;/A+6H4B:\ IBN_7@OX2[WZXU;?X9;).DGG0]K[ 8WB0% Q
M01MBU+,F:B[?\E'I6,RZD:ZO-5:KS4<$0;-R'EY1-]D,% '&3UHZ_%/#8O[/
M/V)^[T3>ZXU0' +?.$%6#N B9#($SZPF@EUF:&O&Y"P-7SG;#-'Q\PZ?2%#1
M !(G9>J^2G^F*_=D"Y)XMYV)HUN<8%HIV@[:*VTCB W$W^@K43+,R/.0J[HN
MZ5^SUGX&LK?WT[O??GKW__9MUQW.NDJRU?>E[74=MN\6 ID:59 VKZLMG)1C
M+<EKB''?)I[A7=%_!HA%HX>1AT._JVME/*M7M_4:;XV:+ 7^L4BK8C$EUXA>
M],\Z%X]L[^<??W[UCWV=FL7W05(Y=FV= GIR_S0T]#M2\:;66\[*JP0=&>D(
M%*202C$^+%/>S[19BVCOU?F[G_<-8 Z#@-99UA*WZ..USP[98G7%]<IW83M^
MP6EJ;-'>LR>]IR#,.).E7I(X<JDN)D8ZH1B/)9N)MI$@RQ#;ZH!&A/<^48-9
M\_W#85V6L,OP"($?\N@.:61[<!(8=J,8OJ?'/7*H]N17T?'!R;ZRR!35TB4K
M%?ES<*+/LYPB>5K35I'7"1!JS9Z[2:">8$XP.LGH2TAP>H<_B D*(4]G*??.
MXM@J_9&&</PCR60/1(:>B\O3PU]]9 /]X>\R\/T>WS,DK<8O"?IBZ=\N?Q*7
MXTGOF5FI^YLZ_6</H[!N)"P]*&:C+Z'!K'ESQ<SS=&Y1QQ*=T\9D0,#QP>W3
MH?KP_KQ_>/09Z_0G\@L/L$[W,!/INN2X"ITJY-6B5Y^&&7LZ&N"Q+=I2D/EG
MU1R?/+.AI,T+^OW?G5BS@]2L62EKMO?RU?M]-@.57N03+^.X)DL.%QO\8W)1
MZUE2PKD<PB:L%62MRA-_KV#6Z".Q!1=OSTAYSB'AP\1^WET]I+6R(7GKI/_3
M8<84 ?C:<,9FI_1C:'PX^I@C'L>]_#ZN^)Z>2.0N\/H_T-?("(WI]62##I)_
M&WMMD%4'9!%/::F+=#E=S0[(8"Z+BFR -*%U.'_[^W[LFO&"\Y%D.5NF'2_Y
MB?XW*<5,.Z/+=9F8\AI9(4CH*X3(Y@4*4[ :,&HK79/F:JQBS4%K:9GT]J/[
MS8CN)%G83#$>!L, 3)@)6Q/) E!N6#88O(T^T"_VSB[WHRI;&FN4XRMD-D//
M#+B'-UO2P/94:6G+U>BW]$;9TFI92/"9 3F(%W&4BD?!E].0;N^7*_F6SC\.
M10.=SX=9.:SG (@VRVS(I>![.MSS;6A_O.Z@OLX9]*![#T%"FWK-)10+E]^Y
M25;8I&S.4;,0V-AUA%Y$H/<@-1KC:X#PXDR1"$U2AFEG\F)$F>R+319C*6"K
MK%F<29+U1\INR@AL'F!KFZBJC?;H$$V+3ZN$ZZVFJQ&)!\Y?-DKW1;H$.$Q2
MEL%Y'#)*C%7"F)M;-57 8&7&B+?0 'OF51D2XV6]($'"N.F#2/Z,--<Q+,CL
MI,6E?Y)/P$<8+@$<XTLY'S%"^S2:I:F)T#^P*\P%$HP+<0#2_-^K.?Y*GF=5
MS(6/[?5KDVL:SM($)U]&1_*%L@LZ,XV##BN?K,6Y"1G3JGO'FW/IE9*QE-ED
MHB>*E7&R*!;+@M8MAL6^$/,?QAD^07N1+*<<8"1OMS:8%NO ,(J/,7Q_WW)X
MVPXV\K5A(R<[V,@#-I7\CH_NU]S2[A/SG4_OP0I[Y0HW-[.!8^)^-)?<@Z_-
M=[CUG7CJIVOPU$]OPU,?'VT+GGI3QX.,64G4E+/2"W/4V*F [<PXMDG&:)7.
MA+R [4K?:3*&Y'*UR*0A ;(%Z:<%]QAIFIT<,LZ+W."=E^IY:4>#F]87(GT2
MUTXUC51)5PRS2MF"R:^?)4-3LF[A'?BDNOR26MYJERU 11S2]L')S6E)ATJ;
MNJ@'I 2MG6^]*(XQJV7^3_+)4$+_]1/L]R@*$*D\)X%ZP+P_.T%P<S.$R><%
MG1MV@[*\8CY)\O\*%60.H#Y]@6:?7AQ0RF$E_BU9"0^K4TFX?99]Q*F4N,>B
MD(8<-L>C(11R$8= \+= ;&_LH'ZB;Y"'Q5ZT+%\5O?ID_=97GX;I0LD2WFL&
MA -HEE7< M2F-+D9)JA"9*5F;%[!04\.I PRR91@LCD.L'V)SL;!CD(@HJHF
M33.]/7^MP2S]+%=J9<DD%P0AON$U1&$("4:).@JN.@9^!"@O41V*!]*P'/]2
MW@<ZB!:01K(L_IN96H.&SKIHS:R6T[*H)U(3J;64-BG'.#=+G>S8A6<T ;SZ
MY-2@G73^+ D8-V-F-<W3BRYHR@Q4<[(GM:..0D>';>5/MD4I52OZ<CYD9NJQ
MKSKI2U/X.ZY@C6,N8@2)SUZEM 1:>*(@O2P($>%QB'KHL]QUTXNN-)B"*R2.
MWOS\YH.G^@7FR ,3[8ZBEP*@L#E'2$U-/^W9^[.+TT/TS.#N!N#>U_>.BII+
M<KR0A4XM;CU^DN8I9&9>&] HB.L+"9A.0<Q3_'LUH1MSJ60COLX4'%D535<+
M!(4JP1L;HEH_VXM8?TO<A)&:8XT9Q[0X+LV,M'F*H"52L%W[HI0:<RD(0J)4
M9B&7<E/X=)MLNJ'7N>;)K"H<7PEM,9W=184B)<;']?L^/BU(HCJJ#C^?+*$D
M>DF2\SO\?O%<B4\/#:J;$EN=;(&BQ3!S*H'+E=[;DF-C=V NL$Q2I!B%FL4T
M3C@T^#3>$E>K[/2HYISU6;QY,#0DD%86@[I:HLZ3UVMDL;HP1FSO LQSP%7>
M2+Y/,\&:3&99,<!YIBO$ U9R--Q@WQ@4VRT8-F>MHN0W;'N;UF5Q8)/0#,#H
M/PO74F3PI@A'ONP>%F>?7;UJ59?7V370](C"AUJY/5(IS[48/T;V66PY;;O_
M%0"2M=.L 8[[Q6B5$-6QG3)(9U"93..CH"(/X] ]#;>4<?M5_I@S)+]+4@Y+
MM28Y5)Q5PUIF,*Y+AG]I]-BA*?U&'ZJ<D:T@@^&OA3_\;O.QNL$7WL:ACZ&>
ME>WU!9S@#U)(N$JV0+^Z4Q[V*"$AX+*;S01(@!BFKTGJD4^59B2%? 79-2]_
MV<JC<,K&&%91MA00$/ (J+\ @Q[?IJF].G$>]67FXM1_9AYH&X4S*&6A34D5
M  Z'V%S@>[,:<V)[V'74*,H% .BCLIX$'Z:UQIA)^<P30&)4M0E@T;ZR.37)
M34OQ4Q.-*%4>QJ(/]%KLK^$7?(<TY9G+%LW2^B.@..RL"UJS6<O%>G4N"5<:
M0O_PT+O/=#.FMC1E4A0-'C0I<;ZE<+D%C//SZ9K^[I:>;4[*_H&\V4R\D-=O
M+R >UC2%I6#SD-&;I"2[Z.CP\%E,WA\=E3]2P;7=]_M/1"S)(0N_VOWQ_G',
MUFQGG=^:*H@VL69K:/QBLMTQ"J$=)#<O97A;Q2GDQC>:(K)+L'WM!-OI+L'V
M@ FV[U/;O<Z9"DM"F8N"PP^IUS:;&4X7,VLA-*^Q=?VRCPX%QKP>P=R+HHNR
M%_U:#/^]NA& ]+EZU+^0$65;:)_SD?/>80G&>9"!BFS=>$/6.::LT)@R:VE$
MP@HS9A17%/I=7K;N\;Z%X\?.0L-.QEG/G1OWMD KK96AV>N?A$\*P@7&5V1"
M$]]5U#? &[4,RC8X5JVO<?-&9@(<T1LC#.[[PA>(* >*W2SR)&3-!3J3'Q<W
M-D2>'"LQ-$=<)>!FK!C[4/ICL<S0\7E&;C0MWF1F Z)THT&27F:5D2.\_!R1
MG'2*D!K-V :W-PF3#>9TRQ+L(^<"0QA:/:11)5_]JT[FL*_Y'W-<U0S5\:QB
M6DON_N8!Y\.H3=ZQ66')(\@S&U+<$?P,P]I\\3,Z'8AOK<JI+-\.2R3YWN#3
MM0D+G[BS$7MK+ @&@9"-6\+6\H1+ );@]!,3VL8:B'IW_MO9ZS?-F@\7N,EY
MY/3NXR<_6!CPY=GYZY]>G]_A6Z?]'SK'=<=M<PL>!'"Z91M!S&2((G&S0@\9
MSM@"WLO;6H8D%5EO?'J8QJYYDYDFV(8J6?M+^&Y7'%W^2O]_X<###:?+*1 ;
M3)8^CAOOAS77#__-NJK-+]'92Y8(P"#,;MBOQ#$,HHJM+X:N -W_PC(I78.]
M$+I.?):Z0#%K#.[1VQ&P0"&;K\/ !%Z9A)PTN^+VDQLS4^Z29L8#IM^L L)O
M9:GH]_J:=W*4P7!2FET-5">9\QM439=\I6I!3]"UDWX?Q'&O+CS=VUA.HS9:
MRF(O5-+[<90N,KZ]<26"G1%PZ76?16)M#S>_][N[JJF]PJWS/BC(F&MQZ95!
M-3[0:'/:^'.*HM14"? [/S%-$XGYYNGP8^=G(I,TJI:=?V>G5&/5:E0B)51-
M96L?4Y[\M8U72WH2S[@HZTGU@.I=\A5DHP5Q"'L#.GL^<299!D*3ZS2',.GY
MFY"]D7<:/YX>2M:QX7%^Y''O'8+62X0MEP^^64][S';3N$)\(P]]CK72SAC!
MON8)8H[#:5F@$$1^.5SAL)LX9-REO(SZ];P%?Z,MWEXCQ*-0##CA2S>DW#?0
M/W)=,./W+][5M"P^94/NW)!4:G'RG0+XO\_)XQ?:V.LT62Q24S<^+$JA%#=)
M(U/]*+U%;9::ZV[N=0X:LF\/Q:P[B.I=K&M/@E_(FT@OJ'F[H=1IIP1LVO+&
MK2$:MRX+:.AA:5FA[\9E^WU:>Q\$V=*UYYV.Z0:'S]MIB-ZB:C*T<+#?G$)'
MO;.4C;?'/*3B7TR3<IX,]7QP.8M EI!&6MYP"0ZBNG3U(U=2^3E645W(Z @=
ME7Q-?'"E%O>ROY?OJ]M$*-Y@1HA-]^O[LZL#&QABBB(%#Z$".1L%1 =-8 *_
MWT,/5&G ?:3'Q&=4,/&6 EQ;IBF*#4 P+DOA(</"E$;? QN"C ][U3(YKWK1
MNLR<SZ+G[[U/1J=]@+Z>/WWVXN"7H[/_A^_\B"*<MX.JOR_KSD!0.:O<*P$]
M$[!2P)8H_1#TLL%]Q#;W1>OLO;XC#D/S_7TQ2JP,:VA%&]FW8OTP&*W0#U9V
MER".9^?O51R?F_<S-@2(43MQQGJVY 6/O06N0&HLNDB'#A09P'D>F07@H1R_
MP;C6C2+PE#Z\^9\ OR3'F<^;[GE5#R9,BP"*L1!\$NY6B^T*>X.^ 33EHA,[
MY/NLO+TTF)803,HDKV=%E8B2:%Q#W-G(1M2X=*^%Z+"RZ!-<'#<O1W*.1MX-
M>73<VW3D.RT4C/_&9,^M4=*>TL_G[\Y[T44MYHBAU<(.D2;C)_A@)'.TI:>Y
M3PB9:8L&;XP6QECY.=J 49KT$/E,UR0R6#ESOC FTP)KNV_PIB9WX0&C?F[\
MN(!GBQVYJSW<<#H6S-;1P&N)T^(UI[D#.JQMTGF8<,N>>C>DH@VSQ-&@=G@Z
M/#OD/C+UOI:Z$[0E5HTPWK0COH^(B5'P9ZY7"(8<SLFV1U.50S>%11TZ>6?,
MK $:!B3FM&KG;(IC?L)]@77P AC17O^P=_K#?J-#.H#>2J%BK>A!FI."$]JZ
MN2Z$ZP3IKP 81P;I"M!#M)<ST9SH9<$9!2]#$KP57\/&>A",OH$':TH#ZRC$
M38?F+UW)$F7C<D9C6U2% *=+^FB@& F@C3Y)HS<6D?( LOGV0$"[3 8@U1F3
MV6I85*M9(NTY;,%' KM##!H1=,,=)KQ:/I28QN!#E?C#E8$?BUHWM_VK\9AM
M.U2D,ZGH> 58(Z/[UH\&$%JA.[1C$L: 0>H!;>C39)X(<M<.W=, UC7TZ;+8
M/91.7H)-$H(Y8S1+]?KV*E3K$#0Z%K?HIJXU66L4VSK#NI'X\33:@EENTNY<
M([2T9+T<.=2:2#AG:!CX[<<UC:X)7&^-7',K!N'7HKD<.2_%T>4E48O NCN+
M!5$-LUEQT,X3=SS\0&&N&M4EI@/BK48)2:L)+]-PA#P.IT]^8!U0VM"&411M
M8NB"65HW?XBYO\Q)=<1T@W0"XX\UNKD!C)4EVJI!73=PZ0NEHSO=(7Z^->+G
MR0[Q\V@Z,6P;+=E__W)XV-_>2Y.GKPCAK)'QF9*RS_D6.?_PV]G!2?1Z\C.;
M;,5PQA](E,:>[#O[G"9&G.Z15_40_"R=0$ZXV)Q6E*O/(:8E5_ENN"P<,_<-
M>&J6['1R?63"K8&30:'DBG[-A=#DS.=I"3XN0]>=D &:.O2/C@R??9DAG5!,
M0$I4EU6=".[9-/VDRVTI&5BIVD-;J6NT.2#%*0 4?7GKQ:E9&[A/)?+C]">:
M9/=Z6"":L@;Q5-V:/,)*D>__C*CT9V*X%\LTR[VJKT+,O0\'4J(.[U:$1BP-
M_91:F*@L35&)!&'A$J<RU=@WQV0R^KK4SDH\;,'?)T$9&\92. GV.PD3@C+9
MW30=?A1W44N+M>>WC(MLL3G,H-(OS_7K\Q% ,_,TK%F.ILO6#K3;L-!:S.$-
MFPR=7SW12C68+@#:R82_; 3>$W,_D_?VZORW\SAZ?RX%N$R8WQ'_>X0'XWLS
M([:)PMV:#WXU&!V]+;<6I,.Y38(<]V.]F>6*LRW1A8N<5(P+//F=8P):\#.F
M<YMI2.ZF\.!DW6GGRC<W&),K-@=J8C-UFQ7B!-=7HR1KGM6IIIJ&4*C7H$D+
MI\-D)JQ6B](W>+:J7>&V* 81H]?1!7*VKUQ[XW;/-RO76ZPN_%8,L=H-!TDY
M=WCT1I?H-@N^-9Y;IY1Q#A<'?>N& ,5:9HN$V>%C"\417>+OB$2,NMI ^"@*
MVU1B;?''D005SR1/\J8%?3DZ:G1,;40F-0?!#_&;CY%6/?%ZI3//O$>-X TM
MZ5;(C]$<^G[$_>[:XHII&LB?!,GM0_8@[@S36J*7.YY&282M:Z42%.Z:5L9L
MLG^XN.-!=IZ'=Y"9,<:>A5O*/5WVS)NE&;="W]-&\^)U,/==I_3/.;G?Q2TO
MYW:4 MS?>T#\C-?9*!D5"\GNS(N1!(:4I^OX?QW;QB4ZXBMS7I2ORAT^9(\-
M:(TNLL/>H30+BNG'OOWI6'_J]P[UIR/[TXG]">?FB?X+9N_K_Z)1HJ-(I9@]
MY(P8%**%7.C6&95U?@"82EIFQ2A6#AB)F%1KA]W2&4<GVB*T904$ND,ZB[NW
M5QQU8YB+-#7:792/X\#Q/?*0-Z1VRFF94AT]<Y)/W#/'H:Z4&:Z%[C3 3A%C
MID02^+5<>YZ<<CO,2$Y2UKONK1'<FIL8H*!D!18X0&,*6-5;D/6_NRR]4F/^
M(<_VV1Q]UHZ.O4($1&41(!$C@W9]PJK1=;2-DNLDFS%<(+E-& ]8&EF/&40T
MBLALX9@?054:&TM""-FKR\*4: 7M0D>F?:W0C+4:@C;\+4;F<R\$^F:U]#&&
M.^OI0>;;28+\; T)\K,.$N0G1R<>"?+Q:1<)\@X1\;41$4]WB(@=!\K7SW(P
MT!RHQ8>.3:R!OJOAU,:YBR%D+":VK$)\O&]<M6JV?9#Z79BD=H'\[\_%OWL@
MGQ,\W[^!_?6#^*V /*_L8W3!=P?[L4GG/0XVV:(._(>4\!;W7'^-%GOI@5T0
MR9$+\"8;IG'C9'(5NJ3 %]D,40XDTGSRT!9&2'A1)>_]\LV5^(3R5&6*E^Z/
MIJ1D46!H$M%4DM;J[X]0!6R)F^IY"CI,#.GOQ[UCG(; CPOFV^FN5<ND7+[@
MF1W0'.;5W]&4$ZS;K35P@]17/=!Q.>Z=G#Q]WG_>/SGM'SXY?O[433K+,?(#
MGON&Z6)AGQT=/;$KZRVIO -49(VG/A9E>55S')Z+_Z^SZ\*9QE8=H)##*H,.
M "!38[0-\$4Z'Y1D1/];=4@C2.^KC3=I.?SXT!Z(TU 3>N[4;S0I*%UI?@$\
M[Z0L;N K@.H'<Q'H>H3F+!.G6UW>B)W-#I?3/W /%!EZOB8R]+PC,G1T^MQ%
MAOI/M3W60^KLSBGU#]?,R?PAG-234V]2SXYT4MM@$.Y4_U:K_C> 9HHUYNB(
M%*SI%/Y#JF5GF\[O-%9N/#,KAA^98R&T5!4Z?W[Q[/#'9T\\LKX.W>^I?JZ+
M>4R\'GQ/+\OB 2UF91#@)CO)JE&<SQP1"@*RCC_L"[=+,"B83<;4)J!]3#9.
M%3,0]L26YE"6/(@;*^G."F^+;&COMKOV>U3@C\F0Z/?7W;K]CEOWN-_W;MWG
M1QL[;79<3KYS!C7^[/MTSK8E9--9;=&LE]OJ(,Y9/:$;24O^&ZTX%2SPT\69
ML,F:4,VRJ_V%UAQZ=![<5%!#N3\VF>\W S?3_#JAN],E68I/15D/LF&6AU$C
MAR/  *IB3$/.JJH&@+0<<L.:SFI(_:M-TG!-J,_!):OAN \$#M.@9V_/:BV(
MU0+!%5E&'T>XNLD,P4L2;YJ_HS&;T_5H)U+5 ^&$HX?,TJR8KPKS)\E2C;(Q
M=R/1^<RR1? !'98T*>P>ELS#&UDKR<5D="!1Z!I5,KM."Y#3\RZ!K#[R!S"<
M%OFH-&/J13\SGBF@M[/#80&\>'/.Y8QI.<=(TP8Y@[)S79C/OWK[7V=79TS&
MIN*G6^K/R,Y"+0$;5?COM+PN5BP3X/M,N5'E1IB_*U!:IGG(I&-[?=[MU5C[
MH >HP?O+2&1_M4\<TQERE*3,\B$2E2&9&,\ 'RZ$[F746+6-POVY1Y:[:+GB
MA)!0TN?P]VH1M%!U[5B8PD2)V4+^*+"BB>(Z+_)<>4,^B%*P;$V&G$J96F2$
M,VR61X7#"QV6Z;5VK'$R.S20#-4V@U;0+8B9DI55,%Y7*SUKK7"8Q-+:)66-
MJC& LJ08UA%%[HA'OC7,YMD.9K,C'OG"Q"..D4(YHWY3CH@SPSVQ-A_Y=4[8
MHVZZ^1JN?OFIO4A;;>X']R0; Q/3<9:9C!T!"2-PZ3=H5UV-M9.%826A:PH(
MX?/W[WC%%BDO6W1Y<8D+U"R]L;RE>"3&Q<I<.1QH"^LY?/)"O0H%^SYC:Q6V
M W?O$UO6(V.1<)L2 QM@LONM/(&M)MA=$[2Q1^NH<49OF]"7R$*=9VHXN6IL
MO']/"D NC03MBRO!ZU2FXYKL42Q)O2!3!OY'RLORM^/>842[,D._&HX!>H\
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M=>M5<((U-U6F%J+B"X<U.VVR5_H[YW($Q> 1A:RU)4C/\E>WV)]HJ:S4(5V
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M(SOTR(.21[RJAR;#_S(KAJME,4FW&TSR;K@LE.ZG+[P1G6O4!)D,W2I?IW?
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M^0NYMW^]X(]Y6CKV4#^,I]7Y9D!#4OSH3::L%*ST!;/LMU\U!"LFHESC4;N
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M1$M^GW;;778V>49_.) B)MX+F\K- @*84-C6+7PO.K/D2S/IA.5@Q@-RTND
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MTCW%O3X.GN5;7B%UD3S*G!O@.?4"T=8K1BR5?&1DF_:V#J?IE2C_M'MI&*_
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M;:+P\,:N&(2+C<AX@O%@.0W%(? $2.$.ZC>.;;YMGGKPJM@1V$J/:F_INM9
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M9L9C<3$/HH]I$?^NVODW"OOMSX'2X/687=0GH!KG2N.O7&G\X%QI/%<:?^F
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MR(X0OE=(F6A#-SLB5(UII A"M9>N8/Q<K+^ 7($D,.A@^F<K"GHBV.B$J<*
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M^FKLJ0+:*V,<QK!7-_FZIC4.1FFL?RKC1O<:4Y4'_W4EFO(ELI!(@:P330!
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ME-\/RO"YIJ8/LS6SDP3I"!_$7K% 4*0.K1NG8+T[6NL7<[J 3B4YBA0%DI
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M8ZA!2<;G]=P-"@&:B=I^TQ+"%RJZV[:N5H?YR5&2IW6U00C%]](+.I6K_(X
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M L<G98'1CW*L&86JB*P]=D0W\J7?,^R>!(!Q5C(M6GBTP%G:!N6 *9 5$=N
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M?7IAT/\Y!%^)9O_QP\>/V&I(<.[ML"5Z[_#:0W! 4&T27J18Q(,7&R<KM[B
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MZ@719<N P<4JA=.$X#E+Y'7'5,^3R\K5K7E2PA?773X40XT"(M"15ZRKQQ^
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MZ@<&_ZDNK4G=DFOB^AP!<8FN2I'O\L17D?X<)6<UC^54W4/GC6+WAL]NS@S
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M-U^_I1]/W(O1$0-4ZKL1;="1Y63%>ZZ^EI=OGFG'0-G["_#90MZUG%CVDC1
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M%S#6^R;A6%K\TR7A'E<N/"502,?808W#1XY)HOA(U=!"U9ET^5XSA:G+8"Y
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M0[^<\:&S),Z\3?[\VZ1&G#A^BVN$LP+<.0 A4=]\(WT3]'-9"[V1I.P/G4-
M/%C&8LO-,,J>Q!DC+NWG4&,?MBU.=^\ R%[<SWVH0$.D22G*!JP[:GY$-K>+
MB3!2(/R9DF'T?4$'32=XCUUX \BIY1@G;./!5_2[$P7%5+TJ Z/XB.3Q=DO,
MMGJ&CR[I,W8)%DI:G1P([JT8ZN.'3[2V;^G-OPKQQ+G+A/^=<ML\+.GNK:'W
M"!>W#\Z"?=OGSU%G+9N+_$+ 1H)FS@ESE1?<YYJ@@!V_G: (\\9@59HQDK7
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M.)Z"+9UD8=S;2]+@6"'R%34G0^(V^JM3_.J45+="P,^6U-XBU7$/LF\(ZX6
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M6$.I3-1I<VZ4RP^?G9UKC\$DW26!=41 )N@D8*!V1P909LR]J2AE5_T!@@^
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M&E/0I[44(>]@2 61N#2E,?>JL;LV,\>AML\621IQ[#N(PY!O(Y=-&]L\E1#
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M;M^$!8M1)405PK+7H!&/8[7%4Q[N1TU;?QSGXVK>DIZ?"8X3I;]ZSVJ*]T%
M+GPS_FX;GF%L<-]2M5$21FK,"EZE>G<N6[MJ)^V!@19/8AQ<5YNDUL8/-D':
M]#CT)K9FGH?T&GAWQ'1'8Q7,_5COLKBN;<B8G9:"N?#+L5>^T<2/6AWZQ@B]
MUYW ()"/U*C_^"H7%:B2*4&E8[[&3^T>\'D)?,&C)E8I1T _XWR.CDDS;+S0
M,HQY@\_).E;M=N<WZSM]'Q)BA_<H W;8^Z\/G.46[WQIF&M:J[\"PO%8:E+^
MZD,;51D<'1[W@]]4\'><NAK\(X;_G8*PR*DNXU,%>PS.^OUPS7#'9\/!<,CU
M?1,UYG*4*XTS0W'.&#4RQO@$T/-)>#H\"@J<'0D*%DTBG\B> @)"L*CRHJ(V
M_>RU.Z^F6-XZ[ \'LJ "<HUXS B>4M[R=8%S;G$3YW#N!']PVHU%_-E9?R==
MUM\=9OW=!V%P^"\J2?R7-QYMI9+H\/Z5"QWV_NLWZKC]P>U[A\7''ZX9D53D
M801+DM913TI=;$L& 'H7W@M>-X/0?@VW&=P4>!E?,MF'ZGZ;RTFW"U;VS8-2
MI$CAWF8#G5[PL3;LT XZK(]-W'K"(75@*B3WGL9CD9'V/2,/6V.+5,4((JBR
MAA:KC3XLR))[<_!6C3A.R#%>*7/$."V6>4N([^WJ((F7<3&NJ",:O>$\5<FR
MB E*SD-T49N-_=$5,KZW(#:!)C'(Z"Z)D$XE0-@(0CX89?;H7T 3^E^%FNAR
M^2]IRH=Y;"M<[.C^<;&CWG^]Q5$JGVCW=-FR^QWF99O+##N=\$?KA*>=3GAO
M1F5_\Q$-!A'[0S7@7W%\/\S^#^<?/P=OWMR\8<_/O.YK&>>VM[TS9[L-O> [
MH>!$_?']0'62\<?W2.D =8.GM6&L#'1N"@M[VB;V6P M\M6_*^J\\E'TV4\X
M7 W'B()&_);GKY*F^083#_/@ VC-,T5-72?RV^"3FP!W<VJX([7EEH$MH/:B
M-KNKT[WG5FV(7#RI#^R-)*9::@F8O5-%I/X=7*@%IE % CQ.HL3ORWC\!>.N
MRSG<CS&8/E^\?R>6S>/O +<.MG\CPB3B$_HE>MU=9#LG6  &C6?!($3/\A%%
M+G/-":Z4"_ U1G](L@P&_4$P<R#$TJX\,M:]C[.]X$+"E<5,Y;IH>X:\,-0<
M"AX3) 4>JW5I#/!4R33;<E9Q>$MRGM,* \LTNT2G>A*399]=I;(O2H&5%TN+
M<-MEVS?J:89]ENLIU;GRHKM+&R]CS T':'_ LL*N T>0:DP@PQ&N"J<U8^23
MVW$OT2]&L"I,H],Z\L,*SK7($P8XCX=( A."W&3J295* :/7&M5UU(ZIT1S5
M3>&3A+/-;F#4:K?P'&VU)ME7MD$:#F>E7N,XI6')]=C+8*R*F7<@CRX*K66+
MN"F>S"P;I);ZMN>=%P-F/Y]@$A6H2HO8$?I((YI/3&>(BS' P]NT1*-QQZZE
M+&7@A]@]%QVBOI\Q7-_]N[5O68B-BV/NL^9FBM8[IIMI#;R(*SHS#=%6O9W>
MSB,-&JQ)U=I=-N*TV>#<S?I )1I58"K\84U%M%_,6-!IP8CT 6N!=Y?S^%E+
M:F3*O30#:NP#BHJF4;B!/,OR1<:EI2BW@7Y'V-J2:I+&%*3@@IH!$@G5V+QY
M\^:&GNQ'C[6;[3(92VN,.(HN3"9QPH5:YK?Y#F/NNRQ=W^7NT6//1YZ;_HG:
M@ ,"87-&=!AHU!NV,.]W##_N($5Q&\@?]P9'/]+G=C,G^K4AD5MQ/0X&JZ['
MG^)V/+D?E$NB\>1>N1T_:BQWUE$7S?O9T;RS+IKW #.\'B8P[AL8'&<^O4><
M^?1><>8?F'.TI6IX_(!50WYTF\KO?V954,QD3J2*Q!^5)#S*)JJ#7'D@I[$Y
M+2WK.>&LQ5,$UO%4DS_']C'!TKXLH;E'D;<8359PE6T\")F]7FEF1G2(:ZAU
M K)U/.NDT%?D86]M:=$+/F5SV_G$7X'F3+A9F_##M:# HCN*7.)\I<WOJW?4
M=6\C@&"9DDPQ0=BPU\'OT\P%XK6>-&4\E^$>QIEY:<&V:3"5V8BF&2)7*H\.
MDBS[0@6&#OC4?@0C!S@JG-V#=K "S2J98,<VNT\>/:;<5%'3M87*S,.@2J6N
MBL=#<&/+:KZ07,L:)F*YHY^3")N)D]*E)/KM2DP( U>4KU_+H7Z30WVRAS(/
MM_IDN*33OVJLYY_C5UA*8/R0/'6(=BJYG54>.+<FH;Y!7'=#A<;^R8B4EZ9H
MC]O9^-U=I( )&Z1$=A)+S-$4G)#!)=SB-%YW;PWDW8*@R8U.KD*:N)IF7JL;
M:H&YB&302['QS>1XG^ YS2FQ^-6O.0Q(FV.W-,U/:;T'[!+CEC+==SC]=@<&
M3JX-5U]B<R9]M;N^#4DH5SA!:H%=;N %E6N13F&=###<!?"; 9R5(9"(@FD&
M#P4EG%A3; 58N%K0PCQD:8RXR\Y(^# A4T(D6$$3\; W*#90L(,>,:)#D5Z_
MU6BP=_'Q_3Z-',* BW1NH & _C:!I9;4H@R[E?$X1I&9)/.2> )\<<R-%6RO
M,1Z33(NLG!/%$1Q1F6G5^,;VZ5<[[#9[DP8O]9C*J(-A?_",QVFF[%BDK@/8
MX3%)U"C+E55UZFV? C7--:?M[R%L7Z67"IAO/%<CT$S]WYZ;!_?Y:@]?\A!B
M:@%UD?7"X+<RZ@5[_N?[],:_QRJ=%E5PG@ !X,*_-$FAMH!Y;)\0N4D1V*7#
M[3'D E4.X*LB^.]W_<-C[$!0[V"%Y2TO#WX;!%@ZD>B#*)OS@,<R'F71,M@K
MHG-XGYGE2 #$.(E:Q!$V>QY7( LTSU7X4VH.S.9*+&0U6RN @F!MQ-1WI%^=
M TK#";FD]M6[?YQ_.O]X$7S B$ P#!;Q95;:J^ +,,_09_LT*2HU \'/^@$.
M@V:-J0Q.^OWYM $1%&,YU]=BEH;^4O#$[AE*J8O0T)#9*!RN7"[8,0WBU'2K
MX]C%(M'9/,L7LWAL?[#W^X=/?*WSY==L$H_RS'[U]O6G_5[P#A/Q83G8K"ED
M+X(],%R'QT_W$:P@J%-.LG!<!5T[.6DCI$CM_?+FXB/WZ,!9L!P]QNA6,5E*
M83,<-L?!Q=$BBUT#4X8DU^#'Q&)0V,.=2@-1&1.&CS+2'#T%S>%/F;]N"^^I
MM<?>^X^P!UCX'UF)76' L!N<'KT(]A;J/QGRL-$^%_)G*:Q,X[=?9QE'J5_F
MU;31,2;8>_WR?/^ &VC@'BSB3"A[0.Y55.M)3KH;K/OA$VH7 -M><#Z>Q?K2
MMDML@0&?SSQACP@G<3/7\!M0D&.6%%C8G6@.$?+>>!"@CU.BP<'^&9$%RAB)
M-^-_54D%J65P=O(T6&17.F?^/@=XDCG 4]OHBU&&R0IR8\^.G]J)'&/NA9OC
M%F![4X00#\U, W@,<%<K:H<W(]M$>N^9<]4>QZ7EX-X-NC;IF'V43<!XH::/
M/N%B.RS@U5^P$#A.<=8\*9M2V(Y0PH'M^"(KL+$RGRT*N8K"G*Y.SB:_X0+[
MM##*?>;WOT_'W(3B4S:F%I_8Z9:M+N DEX;)#P\[>6=!0?(.ISRBG1:QD=,"
M\YF*A(7"0\#.-"/(:=_<$7+5!,>S1HX*/9Y)?)WD!@A+Q"&?,BP1]TSM$:$!
MZE=JO*06DIPK!W!@WB;Y#D<G[F5V=R2TS7MAQ1@IXI->E/ZA5>K/(I9%I$<#
ML@?JH=7&U$9^7T<:U(?[,60$[\HUF<T($Z2;]N>1K ?'3YD1S%&;S#G V?)&
MW!3F%BTUVM\Z94+/YRQ>D<?S,NNX>5%6()UC>S(C9N%\N$&<P..$C06GE35T
M.:99:H.?X<M9C&%+ES2(JMQUF3/[AW_7F$H1?\5.[N6,LBL4=6,">S_#1O-N
M]SU2@-:M:=Z=ZSF;O&O?T$#W1@<9_SQN+6[CAYVQ-3#G,A/.OMM<HTE!U["-
M=NW,<0[60V*AE G95]+2I, $6+SN0T_WD5)=H'@?[]A%)2+$\S^*#RE+69%
M;QA-'&>?XYN7;R\<>S$4[&D^[.3):(""IBZ/S-J8T.CGE@^1K(WG0;&.<Y%S
MYWI.1=NVV@Q1VUJ&B?WWS$Q> .!5!B X<#^F*2B&);'AC#K4O)KC2P9#46E1
M/S$[-<-0R"?W67B7J+GP4YJDXI^AQA76[Q- -SA\NHX)(JS.>J=/'1_S+2>@
MX(Q-\B4MM(XLKV5 !F%HD78^<=\3)QXM5_E[!:+'BF3?F"':\29^H&<C+DN-
MD^*  />-8YLEM<)>V&.#6.B_W8HL'3_R99_^=T5XEL.OLCEE5ZZ0ZEJ<IP%W
M]-S+I@4P!;F>LE8T'YG,7J*@?X*ZGBV9\OPO&PMXSP913'&1FG50+(%$J#\G
MJ0GS!:55H_VV;K>2OFQ2C;71\HB/./WM94<@=]+[+"-WN2^;4!ML4\2/;8-]
MT<)K;@X*#&%2_'B<5VR:MBCY,E![+(GF(^T)&;%>M;,Y00<%O16;,95<*8*E
M+63E\2)NJ!<-=3>$N98@3=2B;5DOEN&OI?B7QM THR='VNO$R9:"8Q$DO<4P
MK$?FZ/4.I,-^B\AV^\"'G4[DZ00DG<FLIQH'M)QN)'^#/=V;]D(2ZQ>?69CO
ML]&+_P.HTP RO895'"OS_/$(#%QSSE81*343]KRVHUX30U)?M9JI9.(N_AS#
M>@3XK.#AGMS[_XIQDMA0-0(>SGY\,-31SY[$8^Z.XLW7V/OEM_-]TYOQ]<MS
M;%5",:=6-TN<F@V45&W!C6,05C10 'T=9. X7=*W2^M6C"Y;G4+L%+8 EW :
M@P*/Q*$U,[K"MLM$5T^78O:34\R>=2EFW>C06X8"NH_)-Y2:=K \7*??.R-/
M3J^/-5Z:YEX%@WX_A,W4W&#(#:XT^CM3;*F;L-$"[ SLY[)P/:5='2A811BA
MA*V-3='$&E?K2C0O9 X$  #V2%M%C@E"#-C$W/1L;+RN=XP'&<)!2H*)/29W
MHG[[^E-]M\3Z%8[IX?HV#/$7Y&9OC2^2P)+7F_DV6%)-@_L\=31.FUY[\W9V
MO+,-2!W%%78\I>R!PA0%5 L\Q),A !^N-^&<H-7=$'C0GV!ZC+-: 4R?AD;I
M>5S-C?1Q53X?7AX,8+E9/(HI'>3] @@A"_92^%_@W!AJ [C\MUZ6>16I8&\!
MB@$H#?%_^#N;55.+C\48L &C(*N*9-D")7NT)I!@I7PU_L1)2%+&:Z<VC6=Z
M_(5=@K)_A SB,[D3/0,B:H)Y#80'UT!XASUEV%N  _8V1ER4J)QF)CAA8O^@
MUT64!.<:4W_^>#'H#T,7>H.[G:-B-L\2/:X2P0I[=>C:C3D.P_ZV =&+\;WQ
M3*+V("N<!K<)5S@''2VIT,*F=(<PF,*'HT05.*]7)L8G8&R6U3R35AO__%N_
M/ZAM$YTUF,B&K957PL;C99F5P&S&P>>#9#E?@!J^!.![D[@ )B76U1T%>Q>?
M?SL_.-JW<>70ZG*B*D:LG;ZJQC0V_A<=_PD$O.\"XGX<G)_B6"L\@#L!Y$8(
MU2+G;A7OM^YY3-X(W@-3$O?GH#.'[\0<)O)HI0M4Z0V]^9D.9(-R?T;0_V-.
M1R-3Q" K<,=Y5DO](6\E\TF@BI?OSLG-C%'AN.!:[(6*<\"/5Q_W*9Y@'*2-
M86!$9M:<''@J02B43I1<S#"^/,6@-_LT1^P*%]<,I5QR L^<NU8B91P0-3HV
MW^944LF7I;2^Y*P_%.VE&@$U8_=]=^YE.XN0]">SZ9Z_Z77L!]9I<!_XTN<U
MC>A@8\LDNDQLOWDSP3G(OU+9! (-I\GU5QWM4T:&S[;"(,/>H"JU3(TX'&=(
M :IBQFK2/. W[.@S_!VIW&RIA#__ ^O/0:O8EV18G[=^QZL*.3V?@8S$,J9T
M'?*&HU?H*ZJ7"OL J#EH"#AD@:SIN*>!I]&"]E- W/-&!+YV;WC_<MV\-^]D
MP=[GM_\?L<1ZOL4T5VF59(4*QKBE^@V0]]V%_QL1@<($]=\9F7'!OWH#FDE<
M8DO3O7<7;_;-8Y(1E-I(/[:;,=1GTP#VSC]=O-\G][+19$Q&@.F*8OW/['M5
M5$]/N;222T["1R#!-V:B'@ $.E0C&G%#L.S]>O'^ F[C9953)PBP_ZDEN0S'
MIC=D(ZY7P[4GU*P6%$(:[N48BIV8X9^!M%N>4^RQ#X]G4!+N3*M+8,-X.R:L
M@YL2'TDGZNZD:Q!@BDFZ%^P3?HHV!#FRLEQB7]BUQ'EH@4S(D)!6*-,D&]%P
M7D"7:[)%C7AE7R" UTQZ)R'GJ3_]D%UK-(X#V[8L4,!%F*W%:3S">-Z_?+GO
M7(GHR$,Y(Z]I%3EURIG3+6 ._E3T5.?&]+E]+WA_<@#"8+9,II4B9Q]*;?X$
M>\H58,0A4>V]_?7MYWWLR$R9NV-*B_"I2UI"I/J IY1B[H*O#3MZ(XG*4Z0D
MPP(Y)K $_$*.:/.DA&L99H5'?Z>K/#NPK(J<F(.SNC'&#M^K+,!MVUV7[5LB
M1S-0>9*E4XT)E_EE?$EI?""I:^':QBXY-9_&$FN>LX">@YA,4I0-YG$G441K
M0!'B)U> ?E.-K!,73O3C.<?V%4\B3RZ !=\A0Z-$V]H=-RZ#6X)Q!A! L''Q
M=?)8T61ZP2]>/D3A.>"-$JF<'Y_C+ D22SL^,3Z'J_?N[Q?HYTKEV+91F!%-
MLY)R$QR_6^5D#/LZ.6V^1?ICJBE%-VHI.C;%@T,]+H%0- $0\8Q\EW%>^B+>
MYJ0T JIU1<@_#%OF^+:5+*S"L,7!L<1J4%C7[T-%EXJR87 T2D)A8U_W,S1(
MDTZ,ODS70>KKWT%+P)@#G&48&DXNI@4G3'KAZ!5=K7$HKAO(K:?+.!8X?"43
M(6T9'L5J*DP8K1KI>'Y>F0,*YP3'<U)5::O')T^):^(02,=*,,$;,Z@M+]K[
M\/K3/N<%,P:+A$.S+%+,;\>(0;#\Z?'3:QY:)%4A)_,S:D=ZJM)&&-NH>4-6
MRM?&.268=-PI/7?K.UOQD87&YQ07;84),T#<E"B#W4?!F^FO W)*C1-ZP%8I
M2!6?"6M'66&"OR!G:U19>&H6D(OXFUK5%CN'0B@=G;$]LQ5R5Q@'%^ =31LF
MCO;Y "T"6T8I7Z"##[0U,^O>."HH(X6\#W; N/D]^Y;'-(]8^>Y>&K))G@R,
M-//H/OX14.^\J@5%,;^%MT^+RBA .8)Q>YODD[UX$2<8T$;7-KOR)1WU[2?G
M'[#&+.VKEH-"7H%$I<;%:!]M,XP9)UCZQ,R*YSC>?4&.'ZNF>MIAFJ4'["&B
MP];<F[DFGR1^#FQD'-,>]CY>7$A%1CS&:HP2OH^)(0#?88_, 5W+WMM/;P[^
M1LY^,*CFJAS/C$?(">J]Z.W;C_M6++^T"4?.T!X@[FDS[9'$JQ'-YQ5J!TFL
M$+<([]?Z"R@JX;E*LQQ'=G%5#^D2JP)S*].9>*549[YE@=J3K;38O!P6. KF
MT[]^F=KL(\]6]O9E @;#(R\_Q29M6GWRD'NE#ECLCZOR()M,*!N&,?-:(%[,
M %@.@"LH&'I<P!,6B *F]2)+74U6$IE81NSB2WO!N\S0AU&,D-0-(KMRCS55
M3JO1O$[JW%$6HAL3-UR7V(SWB!;6.-&<5(>)P TIA.^BFJ6]-^_ \O536@P*
MB#XGJJC5 _\Z;)846L1%7&MGB\T\OBC[FN75"*L&N<"AO4BJ#?&"1ED(@\$I
MGYZ8=+2WNFFLEJ3$(RF/6\WT<A5F2'I-U5QD_(:#F2V8;K M%7B)CK/YTA;4
M,4$WBO*2>%%[0+8596# KMF6E";5PK!U_9_BQ>2>:=F52BYUAD-+"?Q8WQOX
M&QC/LC2R58"]X%=*%>4(M/ ?NYW2Y*!CC-HD;J[)VUR3Z8=CJ?A*5])+2R?V
MK=+$4E^\/I+WOFUB+5"9!Z=9YOQ&V[T:88\U@7[>';W'2R)W_0T*D_M@AE?6
M[$PZ 3XLJ?W-;->-R+U1%F] V4;A6U33!<"<7%,7L'$O9$.*^[Y9W';S^CC>
MH>3HV;*'S47#?.P&9:[)4 %*P%1,RFK@"C[4L]32,A@O8+9&6G-C\56XDQJ;
MU51#T18I/L::>)>#]W,EZFF_R\'K<O!^P!QP+_N:_&\R-/L_L !6$?K-E7*:
MX4@-.U*>/M#@9=3'HYZBLYJ9\_Q6U.*'B65X7@$SOUDV2MWR5%5F+X3<<"](
M?;!U?/P 6&=6 0N,O^KH!;_JV7&O_]0\3^TT%H5^;J2" 0$%J7CIO^#KX?V6
M95S&1<QF^'/S>WD(GHHL<.AM1R>]X=%3X28MWP^>]0Y/-GQ_>-1S/_\_?RWS
MYF:$_PR&O6?' .Z1&G^9YEB/?R"T<#0\UL>3=EJX B@P\WO.+! _:+GUYMX$
M>L()%R6G91F@TJWXG]>:&_9[_5/DE9<XVAP07MX$:[VP/-.(MY45<F&VO,0/
M9JSM<JL5D#?@EV6T+3@?%=@$&R?T?ULVK%K;OQUUT6\$JGQL(-)!^UIHD\?P
ME00IVJ#^36QI,#EZ=AK=A"VM94./A=]L4&ANY2*]BN;KB.='0;#EM(^)@_\\
MKO*8 +D%__@N-N$KR+#@(3&D.V0=OO)ZVCO#[=1Z0A_A:O6=\$<_E^=L,J+6
MS@-"KXNX>#YY'<9,[<S^3C.>[P#L!^E=(F&?!\6/?.3N_RA$OG6(_[Z0#BW2
MO8'4(&H%/G@1_,_ %!O[-_' 3_R:ZK9KYVRIKKXU#7!XI@8G-S),;U\#?)1Z
M'N<AW1:GO<?\]#XJ<H\?7)N(_;!W^KW:VNX8==_"H_E:_/_]#1.*.*6X4ZZ^
M#:@?5[)9'Y1^]1! C)FLFY@)_!<=]KL62<*A!]3.77-BYOI.['L?7GZ0TGT]
M7P"64JC)3+DU#>#'RUZ J:N84YQ3?W:O0;@_,Y=;FMD1-R%V.>)23[#=<I[0
MT;8?'JYBTS[59*+B''O99=6BD 4#K+NA/%'\@0S3;8:Y),PN"?A2+ICK AX:
M2Y<&'&S!Q0.K#W U+:;(2PY.0;E[MHJ;UG6=\B\^OB\DHX##:O5M4-)15H-;
MR%4 \RS2W.F*6SI*_E,3[&:>B"2B<SE3E9J4*TX>K^=-%#'WQZ!B.4R"Q'='
M<6E3^9NI@'Z2N[DM5Z?$-ZJ*6J\UA0<_X%N)^"P$66K3A$F].7U!)[68)M4%
M<F$N\;@!,ZH4,+41?!W(-9(EYCKKTDTH\!:V+?7@J=%2JNC-<X#@-+\6$WSS
MKR'\8]P+]N3/_=7<$AZ5\N2PYQI 5(M)GF%NF=;NG%3HX@[KO2J*L1P[GBQY
MGX+NBWBAJ1;%5"PLU-)$:LT+3*LH>!$FF 'V8Y:TZ1]E.NL+>G.Z=DAS72YC
M,]7%E?2']=[[-%I*>N9S<=??55H4FK-W7$Y,9CIUZ;4#&:A;@;333C6P'L[V
M4=()G[*]&)4/[ @);GPN%72.\$$X55)Y@YW-S/ >>AC7>57EP%\ C7]/J>#N
MU>_[[67P1&)E7 ! *!$1MQ@7F)=K >A=D4XI[ LX3WU0\BHEE*ZUFF_2\A^N
MR.A*<_LS'VHC3F2;<I*^XI1X[*V"2$[G:=VWF8-A;EL1TSE@CA@77PZ*F:+V
M+?)@,8M1D.6 4G3[3.B<:L0M-OA=S6D@=YEYN\.IMR@UIQEW'F0D4=@ /^*L
MMI8$M,:LEI@G637KXMS8%LX%DYIJDH>4PU^E<UU2SUA$.!R.L,,=:[A!.I(_
M_F-ABC>'_?X1Y4L2/X=[R$HJ*QUA'5;)<ZL\D=50$F0,#B??>GQH@A/3"A[L
M1GD\64T,N,P;O]97% CZYZH\/' 2S<R+0]4EP2%26+ZP0!Z9E\M0QBQ0]3#W
M$N;2$V_ Q"7F%"WL4#!6A'P5#G] M3R\'89:R\MZ@>W=:4"(S5I-8Z6(.A5B
M9Q+DCR0?# BXUQ+WCBA*((90&CQRE3>5_[OI>C:1U'6*XM'JA9V)'1I96KC4
M6TJEY/106V1#<XUJ@VZL2 T;U>+!2*5?X&)')75=;!9M',JA4= 5,Y%X\ _<
M&K4DHTITK-<%$#XYZYT872+$ S#/?M+O#5R/*=24=#1ET4&[+.G^S&P\-[>L
MX(%F<IQ\D5':Z0S@*"U%"QSHQAU6<-;&^IGJCY_R_\",=\)+[$"3&<0"G$WA
M#_BJUO6R^8R T?)@P5]X884C\ZJ<&JP68+* "A@B$P::';$^@[2%:=F2>VSG
M9TD:.);>HT3'M;.\!36-N+=U%>ZMVG"DECY;TE('*3:-ZLG.&9ZWR&P76AJC
MN-NX06P'N'!%2EJ2864',QR/ 9EQ,E3Y6ZR*$C:-P38Q"U!5&A@0ENCI5IX,
MGWGT;FX5%\6\>&1\*TR&?L>U*C)$$U@;=M';R)&P+F8\KN852PHNV2/=XLGP
MJ-\[-GO8[:MW5.]3".%"S=& SU'U*"E;C!7 TPVNH+%H1AKA?:9P/)!,E\2[
MZ7)7T -U]4F"^CLU-'?O,F,R36=HV(_Y)[Z<\ \^P__Z_9&)=T@%.5742M_C
M-?J).0\U2N%9+J;!L*M1D<)!VZ#=>@S6M-5.,72)2X3,U;B4=S+!";)43-E,
M,_82X/V\A:/>\?#L:;T\H8%LK74(H+'EY0M"JP,<0%T\QZ8*:&ZO(*##"1R%
M?/KTKC#RJ'=Z/!R<GIT</1L>GAZ=#H_=N>,4MWY Q]]P7O3;GPV')S:>XD%5
M\H#[_>:J=T-Q5HG5M:E$JP(,*>K:T9:DK5F,PE(!5S#08=9N819V3J_YCJ5K
M>EUG\S",V\Y68^QDCB,#EJXW1M/G<SV*=>55/Z2\:M"55W7E53_,%G2ZG]<&
MVCHKBC9O104Z8H(:=COC:$JL;$2MZ5K8$AOT.(TNYQ+B-L>03*RT*AXYFVF"
MN0K2BM1^4,1$O7PSP2>O>2.>K_5-OB:\JOVN#I6V^J/Q1.$L9Q]4H6M\'IK2
M96L6XVS2<495:PE76]/14LT+Y2HNM.^!\Y4%"2E(&\LY=FKG:?1V$CUJPFS6
MDB^)_67_KH [F[!)@L[W!8UX2;FS^X0ZL=><<30? [!/HI)VY!J;W-H*B=J8
MY!8?8.A_6/?:K'-"N4U<S31Y=LF@QW8CKA\A&G"Z*!&)G =XD96:069\80Q]
MZD7 $,(_4V4<"%QYOXHM9L9'N_0DPP/O!FO/2S>%A$!+HABN<4)S6^MN/!/?
MX 9Z 2T>7U)9/[OS2.\;E33F)<5J.W:,T.%L^/9E[0F UR10ERI.,)H32A3D
M,DLNT8(!8E;4S%\:M,%- AXZKZ:W.?' F+[$EA0\[!-7(&!,?9?X6^\Q.8P=
MSD((C?M"/H0$BNT,3#^CG%VF$W69<6M4>'%E=P,W//Z"@P(U4OEK/@71#*XW
MTH!0YD?\&F\;> .T$ EQ+K<'SF4:#5$_NZFA"L0N&9^,G@FW&]HJ6[A@T.'\
M&^H6@P1!#1\B;CL]5^,\PXS.; XWBU@VU=D">S W*0-PDG:AN'V&J5N=(]BQ
M 1O._03LP"F@Y17V5_K]2XX3*VG1C]C_0 7B.)%IHCBVF=#Y"HQC\ZLW1:XT
MT^??U%P5EA ,S\+ &G<G23#<@K@Q%28C.PC-"\@=;FE+N NPM+Q:6/>0(I%
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M4+C>-#7PA-6>\U69:;@D&.O9'_O7"#4>),5*(7K8*3?-Y+&)9T>9T(2F7&]
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MR<@NL.R'DB5/3'HH7T-_$K"VZNCP)!0'[3H/K0NAFXZ;:V+FU(0T&"<JGGL
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M=<;%+1@7G471<>(N<M(=]K$=MHN<=(=]/(?=X!:D))U5*3X&36TR_CXI[F>
MT6NNEWU^<@_]Q%^COR&![&=G.:W/"7.C9Z]-_GI^F\K"ST\D_(FLU5''CSPY
M)7[=!WZS"\?ML/A17NN.';?#XD=YK3MVW(>+Q3?7;(U_ZAN4V"&NV+KQFVFV
MPX>HV;Y*+]4D2^*Y&EV'9-\(HH>%>>L.G&;WZ[CU*U]WSB>W>*?W@WE^!ZH?
MAR?#LX=\Y[>'S1WY=N3[T,CW-#P^[3_D.^_(MR/?W27?X_"T?_20[[PCWQ\8
MD.C,MIM1$TVX[W"N8Q^/4%(,P^%19Z=U5'L?CMM1[;9W??BL,\XZFKT/Q^UH
M=FN:[:[Y45-L%T;[:0EB-)>J0[IOY1_75^L\9@YSHUJEAREJ!H/;$S;;5",]
M9G3I>$/'&QX3;S@\?=;QAHXW=+RAXPVK>L/1C;3JCC<\2MYPG2&[K;VZ-@"Y
M4M1T"X;LPZQTRDJ<:'23>J=K>P[<J SML:'NC2'QN/QLMW'Y#UZ(G8;/SJY5
M<3ODZ#A#=_D[QAG.PL/#CC-TG*&[_(XS-/-ESXXZSK#-D3>UIKHWAWZ($=V=
M-H1_3U>G#G:^F,Y/V_EI6V%V% [/;B]IM_/4=MRAXPZ/ASL<A\?7*[,==^BX
M0\<==I([#)^==MQAY[G##X_RWF\H?G?4MHO4WB.O:YT-#7M#Y$-15N',XSN4
M6[?4N> V,&4;"#UXV388AL/3:X7;#T:WAROW.H[4<:2.(]TN1SH,SZYWU74<
MJ>-('4?J.-+/J0T+!T<G'4?J(N*/9GS50X#<HS_;UFW0'_@YN[,]S+-U^-F=
M[3Z?K<//[FSW]&Q&ZX/_*E#?Z9_WXBB-=V]\W;:GKAW.SZ,\Z@T.#Y_>HV3*
M6SA]6]XE<**TB(LR6.0Q;!J6"[))D%5Y$*.]"[\(%CHOLC35"06_)FH<)S$5
M+R:TTC@KRJ)W*S ]N>Y@]Q&J?V@"YK@DJ(VK/,>X8((Q0@3EM9'#H,S@\S&8
M1X4&H ?#_O HN(K+65#.-$!WODAT&6<I+J;3/$L2^CG\A=^_>O>/\T_G'R^"
M,H_AKN#W_S.@)>R-_'R(!#N-#&.5IED)5PKD X]IOLLQ2 D%)+6D6RMC^&:*
M=QBG<1DKO-^0OHFJ7/%MY\W[)T+#WQ@<@T<F55GE&HA7CQ-8"L00G+>*8M@L
MXIO]D+"#?KS(LZ@"9(5M1G$$%%S .S4B(;XN3F<:UP8V4*6P:A2/20H$J:(7
MT0+N7;5W>,C="R[\1_R?^"0 8-#PN2[X[+"UD1HQ=X$7%=5XK(MBA7 8#K#_
M((HG$YT'<S@%G@\V/<FSN9 C@;'H!7 E*@4)'2_@,7B/*H,KO)0D@1]^T?:B
M^/E $4$"?@#)ML *OEM4>5%IVM8LNPKF%3PYJ> )N%&DY3A'9@#_TJIMC0"N
M$O:>I=,,?S%2P'Z1;H%1+& #]BK@[RKA"S?/$O^]T8V'L,RT D:=Y4L?B/PP
M,BR[=@&\J)#OBO7;_W_^U]EP</H"!<=\KO,Q<IU%AN@/_R)H$VA3#:(!%LE5
M#$<JJE%1*GHD4%$4(ZCAGV.UB$OF6GAB/EHO>)/:AT*\*Z&H209G5B"JUE[.
M7"V#$;WM3[D"@180?Z)&&9,6 .5JIE/$+^#*>:[2J>9ST\YQ 0TDIJ,PB"<!
MH M@5DCP(L102-O37.NV!;(JB0(%6"GBP,?;1:)2N20Y=Z[_70&VT&]W6()^
M)CYGF%N#90',*X9:G7$2\/E7>.V7"A"\@'/$$_@U,3"@+,!!H#9060#_"[FO
MVA!9A'047UIOL5=:<]0['IX]?1'%!5S<\ODDT5^;D/ZS*LIXLC1'H6<. -'S
M\@7!] #@-2^>XT:0S:U WP$$7G9X^O2NKN.H=WH,1'UV<O1L>'AZ=#H\=N>.
M4]SZ 1U_PWE1MSX;#D^L<NU!E5\RZ/>;J]X-NB$> 9Q) !E.SX@$'(8$KLJ1
M80917DT!]8!_ .L 03Y:<O>. +MW ,-UA@0<5OZW0ZC=0R@PD  E ",0HT@-
M)W3JT*-##\-OTFH^ BQ!N16CIA*GXZ2*0#R)ZL/"KL.8#F,,QHRS*@6L(%P1
M(>40A802/(\*L(XZM.G0QJ!-HM-I.2/O$/S*6!ADNK#S*( ;F\9HTHO(ZKA.
MASXM<LI@!WM,2.,5%THGLCKDN09YHHP<VXPY@D>Y'NOX4G<(TR&,09@HSQ8'
M646>;-@3?AFG%?N_<_+H>8RH0YP.<<C:-LYFWY-<J(DNE\$\2^,RR\E%"(P(
M<"RWWG%4A72!$<O1TO>*JZE.QYTWI\,OGS'9*)SE/YX*A%_4E" .S(!RG5T=
M5(L.D3I$LGYF"@61')NK<9YI^#J;QV/"F*G.%ED2E\VX:,>*.@RR&+2885X(
MZM1>*%&2/U9"H"^"#G,ZS'&\!SC+>$F\1A0DP)A)G.@-" 3_ZG"HPZ&-<=+U
M(5$38R?L>G?QIG<]+A%P.&D&%*OG<+9JGM;1:8&:?CKU&L_$O&UI8<(?M$)=
MI]&+4?8500$K/+=U:E^WS- =#+\]H\*5#/[\RSNM%_T9N,]L(=<"[!XNS3I0
M$]CF<Y5<J67QXB]_;5Z0@3YEO;:#_GL@_# 3AQU(?S 2?0]_N^([&F5)=!,@
M\*/XJN>8IA2/UX+E5YWJ7)+\SB-X*BY*M)PN=?!JM3'.CJ4U^<!1=>!LSKXN
M5*)RD]!72[.F#!4]7R394G-D4'_5XPK7#(-)G*ITK%?>AUETXRQ?8/J;KJF1
M+3LKJ@4\6&)"XUB2Y3A6C3Z5HLS&7PXXKPKS9. ,; W;\^"*(S@W0*+H!>_9
M >.RLL#DN1XF$AL/$CU%SX[.+^.QIGT48);#"<,@&X\KN$_0;0@L8:#&%"^E
M3=H?F*0Q? ;A>@E0S2H&>I5@/N(N9]VUY,5BQN(V-T1YDKF>*TI;3>C;9&F0
M&3%+\MC7@G<'>243PYL4"$<'>\(>]W<7_]X0BAR&XJ:-&3".$0HV%<964?DH
M%GX6J"N54Q%=HC$! M'M[Q7\AA<D7932P;/)I- E:JE4S:*!#QA^"BHMHKN_
M*C-02H;&_%YDD:'HO5>@TBY4'.&*^+9)E22UMU+6,OQC:,XCQ++F0.NVDV1P
M#?;M!=<.?/K'+_X^3+JZ.3>HX?QB)-F/50IJ7/!KGEW!+U^+2+@ ]M];O\8Y
M;#(QM\$@@T\1C#70R151CCW5NJAB%F""P:5*;$YYG%["LP1$$""7,5H%CY\-
MK$/RBUS<>^=.0'W(@$T8\?[)$XY_KZ*I2\Y_!5#$RH8=UJ#>5UC<D2I.K[>5
M!Q@JK(J"& %*J50E2RRB +H2$J84S)2C0Z)%N6**A98Z@ !^8Y/$":'A0VQG
M2G3AE@++O61Z-"0T4R .1UJG6(<!=,)DA$I('A'!$=UZ2@D0&*RU2.#8(F"!
M(<#W>E&Z),#?TQC_^E12Z'/OU_/S#_N]X#/Y:30E)4M( AXN]/6[-=D_!6;0
M X.A<A=MT(IA5Q35?,'0(!5 :A>X  4U05A;S?$8!#RL$A'\3&*NU8E)U0)6
MI8$EBN5O?YJ#MIE6\C*K/T05A>C<DP0B#=I95-"!L1(.74+D:9"@'F[$W/9_
M.(I72<KV#"LP2!W&5'^IL8CS<37'JA.K"YHZ(?\'#$H'E#%5<*!^F3?+4D!A
M&I$O%KYR/Q#4F0%GSW(B=3PFJ.]&%8<'C.+)DL&4(YA2I)%.8@ 3WM ( :**
M+*6:JPIH6ZK ZH=IE <Q3@(DYO0-5Q0A8.#"$;)_.KXRPF@[K:CR?(E? N^N
M]/JK%:R :\ 2'-A<A*),+1#I@66Q+& U'\  N^L%%PZZ'K+EN.6)D]<>BO!!
M)E+QQGA0RWK$JAX2/5_2["KM 3,M*V[*2K_$^H\UI6#-ZV60\L-D 7GX3\G_
MPC1VVC"8D8>XJEMN/C.S HRH,]>D#F%]63'.XY%C:( R7#*W%7-%K-**.(-.
M"GV%E8B\$J#S>9KBE7\DK EK9(,(2G1* 5C6/.I[7?IJ5KW R.II\)N\PEAN
MS"QLCD;CV(AOK$)"U$$2C$PIGD;:4?0:/*#%:'<XP=!OT7_.'I3^L[T99 M#
M/Q/XQ0Y"_8C O[MD=UZPQNU",U3]RA6W"Z:+;944+?S62_X5%NB$,.,FKFH5
M^FP$,!#=B#DE;B\GF4H:#0CS"$17Z(B(RAE8O'IN%23;,?8,(!^25$!SNCJ^
ML%'CQSJ..PH:)T5-SY$]4)$?2_*E[)\-E26YLR9 _B*PHHSD%9Q8\N9%NPBR
M2S@5"Q8C*XCS&Z\1 0Y@?QEC=08#04H-91<[+!G>$XY@;2VZ@V)B[2+4V41?
M .1 U26'DL]="2&V$P*4G(5Z-&N(65'S#+9J"/6[TSEJ0J(MZ@G\(1$K6@9N
ME4O"6408K<-_"ZOQ4LTMI @6>6$]$7PT4'7GH*MAH3!NVJ8)R</&\JA7K1I-
M4!4+DQ=B5Z1]N;8!(I \Y:5D=0[L\<SNW[.%V.98+(#[DOI8[]L!BE\!.&V
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MN,JL2!178&B9><DUZ$;6:$.XK:\V[R+?/R3R?=I%ON]/Y/MAF3&;8S<7V!H
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MX8K;&_. <,%K(;B.AVQFLLA?%6=<B,,=N2+Z^CG=;0JO+TR[-;"+R>,);^*
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M&D19-2H1$+#\U4S3;G%-_14D%A]F'?3:H337FL'N;9_6G^DE/$VZ#UI[*.)
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MY?812\"B4;[]H-C/75D*WU@7= .J)7G5T2HG/Y--P!8!?IZ##F93;%/0[JC
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MI*.1C30R[&BDD\6=+.Y\!-_.1?8HK)-5A4JCXMK!.?<7)C^>5UPS!?$6F06
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M? ]FOKH2H9X3%S.-N X,)#+/FY<R-=(ZR%#0L\;PP!2\"M0*NK,XPI?7'[
MFN;953D+;<HB?5NE>KY(,JX:(I VLL"6DHQHEP%<XWWT@C><R28<S]NN@4JD
M,3^,4FSAO269LACI(Q:4:L071'ABD'#ELI"CVGGF)XV%_#=JAPF_3KY/*JP[
MZ@6O@),C.T/MK,D*;-6GI)2JI,B0STF.6D1!R S>M;0>3&0)\!8L1Q%7$YGU
MB4H)J<G#KX OLK!F[D)XH&QBG.4.&L0!\AD.F8^J J\'4,#EY_IA C^U-^4C
MV,#I:E#5FF141V36#K+1GUR0)?R9\PX1*F.F6=ZQR^&#S>?SQOY<(I.?6TA[
M9": EB2*RF)M>N?]*')X]D-J\._'V6ZWP4!7A?2CJY &71723ZY"\@V>@\&@
M=W0T>&I15_KM]H8GIS^PA4801__W+VAZ_^M4_=S*I;6E^K"9X/3\>W*J;WE'
MO?_ZGPKU/E!GT;6"8@8^2,S?+\'"2+("-<7@G+22MZ1H!!]!D]WA\H)WF77?
M@DUVWWL3W!']W;>6/7?.AL[N$1<ZNU=,Z+55OS^Y2B;J"H!)8_0WFBTO5:GN
MN=;;:88/2S,<=IKAO:E/_^[9WL1J<XW%>?>#U7[47"@X"=ZD7&N'7I^/>AH7
MZ%2+@@_5")2(X'P\SJJ4O!*OXWQ^<Q9WVZ7]=R.M?][Y?@YW^9QQ+Q7LK3(#
ME#(U0_CA+QEVB</"=>+I68XNGSN6;3\)*A_/+]Z_"SZ@\PO6KLA=7X1 (N.=
M$N[K[*73G]=7LCOOW;*U.Z'>6Y9Q[Q=Q2I'8E/A:FRI_CVR-M09SAX$/17[\
MH27H(STQ5IIEU)IDC%1"P?MBIC6'53;)GV /5[O@M?;7MI9!(8X=X\):>+?V
M7J\E1RV4$W*K-5$':+#CZ0L3B-N+-+:J*?==IYM)DEUQ(I16V*>"(X#E+-?<
MS(Z"BEY[BS6M#,.58'2:8>QQSW2VQ3:"\-U$YQ*;DV YY?/T7US;>(2>&[S8
MIWXRW!F#^ *#Z/J^)8 A!2K'$Q7GV- 0X]M)XN)ZTNZPX/7<$A3S]OKRRMT%
MJJ4+DG=O7LC:A-LH=%X/N>%'MWL+'$"&A>9XW]0 Y_?>IYYDS&!,D',]L"&0
M,PH6>0RG723ZO@?]=H-_W;),^NS05O@!>MMMT/DB\W-C?J74E0O.C>D$:X>8
MMVB8;12DK5R;!/$(DY\X[9WZP175G%M:22<KPY(IT^VZ3"],:JL*Z>7[#F14
M,$ BV$J(A+77S> -V/N-'"U@8U<YU2%CMW)M^K#6V3W]HE2L5,#F5_N$Z:\Q
M94I3+*QLH=MM<]K>JE1QRJ']J?1<\V09)DK:.E9)2RFD'\3*SSE-)M=3E4?2
M48R2Y$IJL4=9A)B!$^EBG,<C'[Z4\[C%94N&-2=1<4J1BM"=S%\3R.;(5$RR
MGNU*ZQ6/E;.X\+.=.H%V#_C&+<N"7U01L[8DQF%WQW=_Q]\M&PK=SA:0M7C9
MG[%PP+H^;MF4XUS<P:[QJYB20_77A73V,F:$<2\TEVO=$8^,D-0_,A,+:K9)
M3#!8L,_=4Z\G<3ZG7%SQRI-:CF\3][R1*)Z;_CUF&1*O8T?NWN\I&:/D]"CV
M@[T/%^?O?V$[#E_K9SV.L*VF"P?0V\2\,:+.O)&S?+,\(AO6[HM,AHF.J.4J
MUI5)7FVBKIR'V24H!'EE2F^D=I<$B=S0)_=[?.+55T[^Q3U(NPV[)!VJX]@/
MGIK_('&/U1@Z\HAD';JA$A0!EEN483P M0%[";AO!<E9$[C2I)*81O1H\C):
MXJMH?,R(.EIA:G26$IJZ4@M6L*YFFNINZA9_@_5,T :'?5E/ 2*M>22T:TCV
MN\YS[%"<P\]@(ZSY6&(K2+_Q217UVQ ^S;FO*M:II%,UY2_E5.A,D%.)%X%2
MYB6MGY+<LTM=;R^*84&::0 :+U:LV6$0? ]7>H5I"+24S)$@H$NEWM:O"T8
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M%.KB>U0>KM%)=VGAX:*PMPOKE(JS@RA[8*Y:$5_3&D%U*RU\F6J\\M''NQ6
M9>/.QH>Q'AAZ8Y1!]1:M'&N7(UZ:MIK3V;_6P9#E)/7%Q]$L-M'(KX-/1?!-
M9Y>I9S6;RS4/W0S];KJ$->ELU[6&^6BQ'F'8-$R<7X^O7KICUN''M9:Q2MBX
M.%_Y;2XGNZV]6-=O4S2=L^2J*Z=Y[OHLC9MP]:U1<Y5EL\ F2[M^:=L>#?=2
M57I'O8U'?NVFVTAQO)(X<Z?F^(V2JS_V=L?F+>&E;R<_^^&YWJ3TT7SP+:FF
MH24W^%BVKW:$NU@F'Q9V=&O7W[R.F W_6FJU\[(E+BYK1)ZB";R["?S_3C_7
MR-_S&.O1K:ITED9PW>\:T6R(K$_BXE@M8FH>&V]JH72-G2_C#<N)U[>DFER%
MH,:,O<-J'=8P>\V-67?M747NFXR392)-K=!:CO&MT',9K%_=[TYY>V66RC?9
M65'P:FS]!C U(?#19!6!NI:O<_WQRX/6,,\J$C]KXA3?DGW6F5B+98_7NV]X
MY2&+_+V66]$TS"[J0(VEK$3H.JGBCBU=#0*Y#-K?E@=Q;;OKA_W51O:C29/9
MV(P N_+,WT;(+;T7ZU_+M0J$KU2D&]+A)AG$:;@XNYJ%\*_T]=M(N[7VTI#3
M:-U4=WBM?_FRW?GP^JBH&^>W*A:KVM@R&N7J%1M2^3:C?+X*<2U;_P^N-%6O
M,]'GB\NRNQKP&X7+AZL]4L,Z/;7F=M3[U'R-*[>I90CIWQ>-+%RK<.5NS9:M
M;[:Z[#KF."U\/)HTM-"(X<L,SO7G+B^T[@A[)67COEX8[$MQI'TI_C+_R^ V
M??@!ER[//?KR;#*=O*F]<&LWX/C7)[_^,\A(J=<:LC0.A# !K+ <E)<N::)\
MSO1)0_9E'WY/^:]/7OPS>ZNS(@IH3AP$,QY\4@Z\\8PSQB57ZLE@4G#AKT]B
M&CUK](;I[$WYPZ/LWJM9Y>?_*.SYR^"_BR;\8?#;;^\N2>?:KOSG*465<7%'
M!P3K4OIYFGUJ2O=NU[:6#%=;QA?)P0BECYTML3M0":.M(%$#U2Z!",2#DYI"
MYIK)*(@CBK<$5+]-ESDYCW+"[\L-7X[2A^EP\*+L9U%5)R/73; ZS(;\GT:O
METUP3"""]61Q&!#<=T!08$"P/XT2.Y'_W6X?N#88J]$-_+P;V_/B:@3I;ZLN
M1N\;#_7C[$XG=N6GIE!F>C%WDU@=1%]JLYS!_*-;#?D\3[/5;]77__-)J#2#
MF[U7KN44K!ZY:7;M+A;37]I+,KCF,VZNO5/:@5)/">7?22R@3[^7=D"_]QY[
MJM1W+]W%VPIUGRR*ZKWW+OSKPVQZ,8FPHKG<_-=J7&I)]7>(87-H*=QJ8*47
M2RLG7]_YZQ/VY/O+O.69]KCL]N3'W?FVWY(>MSOX+NP(4CE2.5(Y4CF*>B2/
MUD#PTGVR]G15:ZF:E8,U*'4!%-J$R5KTL!U)?&>OEBQ&>"=V"WD$>61G'F'(
M(ZWPR*U/LD\_4^-M.;SJL7N6ZZ;B$@JYY/#+0\"G$^ZZ^[#8\_G\NJ?V5IKJ
M_I[L&9$?N 'W@Y8]QTOV@"VX#<@.N]'!\0N?=OBA[_NP,O9/8!]^I(P\OB/D
ML961.T/'J\99KM%!GK5I_!TSN)X SYR8O8)4?*+'BLL]WN7^T,FPJS_AZGS)
MN]T6/\:+JYDSS76N7IC<S-SIHAY01Y==3I*K/3 _N7&:[."6V'(GCQ!Y'[(3
MDVFW]N$ZR=RU 7\Z!!5T [EVX*%5]<BOLV6=YZI\Q!H?LV$6F!,>! T4?'89
MLA=&:JV(%N1F^4@*SBD6,VBB' B9.1AC'6C./*.>$9+9NGSD8@X?G#M_5CGX
M^236'Z^^L>_SQ0LWF]417?_EQA?IR>!B,EK>Y>___/O[ET55*.=0KL*?#&(*
MHS,WGO_U"93?:L&R6_SUR>C+XMGDX@SB= &K3SSY3S.42JQK0M;K_<]>,L@!
M, '1L:N'C^BX=W0DU(A4\"U+JZ&\$F"#*?_$8 *+2KNL;Z*CR41Q30(XHA,(
M6[YMC:200_2$&"UD4(^)CE0/!><(CSOX+(^.,1[=D7E/2P@-GM49O*M#2$?Q
M6P>RE0OT1R1[<H+[WNCSX]R8H\.G!QSV@S*#^B3!HU,T^6B!Q%KJSE,";V0"
MF0+1.LM8_FO#OEDQ[*H)>9'E;RO7+G,G5E&,EN2W9.K!PKL-+KG,BNHSGR H
M(BCV'Q0ME]$0RT :JD"$F, *SH"EG)DO_],YM&'6' X4M94(BOOBDVYPP;$$
M;;HM;7;J;;FH?12OI62@A['7'L;'=R]W WM:E\#*$ZHXB\ =R<4L"1YL+O\H
M9ZCDPBJO71MFR3YDK1T22]!_B.$5!#\$OVW 3\I@#+4*G*,4!"UH9B(W8%)D
MC%%NJ=^(.6]C?NP#_*@9,F80_3!ZTKWH2;?%RD[1D.EYJM-<:CBD9G^=+Z>[
M3](/QRYT>T\>T_=W=(!R=+C1NN#,3+LLC08M;1&"T7HPS'!PU$KJ)9."YG:"
M&4M^>S=VD\7S27RU9KDWJ2TYRO7^_'5]IFP$J=X<94]!2@;KDK04G*0!A!89
M/,\:.,E%85<Y4J?:"2[L':0D19 Z7LK&@,$CJ^V_I_EB-@JU[6^MVT!W&;K+
MT%WV<(%*K2MR4 I0-# 0@M111+F(5F:C2D1YDTT;6O\W=JUYR&^FD]!NB!YS
MCC%F@""((+B=56%<#((2$*Z8%J*.8BNPF($98G,2,66W$3#=QJK8,PBJA[L]
MD \P=("A@VW1Y"T63V">,.8);QEO2%8FDCAXT0Q!30&,)028"[((4>>*==&&
MY7$E+;BM'"6"^< 8@T#P0_#;&OR\\4)DI4 [7H.MK@!9-AIH)HPRFUERL@V+
MHWWPHT/*'NYL0?A#RP*C&P\MA\ RB$-[]:[##WO**O[$Z46=%/B( KE#S5CN
MLT/= +'6A3973/D4BL6B*0.1K00K7'43^NP$X3)O"NWMZRK:DM=D2+>P5_;,
M2L<KRQ%M$6T1;0\1E$E.1.$5U(HU$($ZJ"%IT-I*F:@JJ-I*4*9=M+5#H2RB
M+09K.A>L.95V_\W=[C-[Z+>1:V9NC\H#U=J/]XMI^-?'\HTTF__'_S*,ZE\&
M+U,>A=$/"T$ZLS_851W;C.-L *1BI.(^+Q<'$.XZ\V?\3?;_</!/]S=DSWB)
M8\9P'Y AD"&0(7#^X.&S1[%M]WI6<@AE&Q?SP;G[ZOPX8=+5$97'MA13.#JW
M9_N94SG8D(4$2K@'$5,"$V4 R9)1SF>BQ<;4C*V"L"MN>[=DMG8;/;&A% \?
M(M1E^L;\4(0JA*H;4$6DT8(GT,P:$%0K,)9&2-)1F;6PDK<3P=PG5/&AW6>^
M9Y^AJAMD?2RYG*CG?]/S9Q<I#M*RLSWF?QXP(^GHX BKNN\4O\$8%I,L]H'@
M%H3F"GST BB/UE%O+&NGH=V*7Z^D$[0\?F+(Z,-[12$O(!#BX2,0%B TT5"N
ME8>0G2I :"4XDP)HRGF4*AMA6VF:MW\@I 9'+V/6) 8INF^\A.E9M5Y< T,U
MNW*6QF[Q *OFY&1V?^'HZ%"G_2Y[A@3IL@$?J 3!& ?OI8.H3**:.9HWV]9N
M8XJ\.CL?3[^F]/N2V?8FB07##ML(5:=]E#V%JL"4XR1)T*X E B<@J<^0G*2
M:YN,T!5V=C<6#@55="@D@M6)@14&*PZE[_\VG7R  GYGA2?]8G@YP?-\.JN,
MABZ[QZJF[D4KJ?9+J'O98ZJI5F2/2V)]JC%&#$(,0@QJPYH021)?S E(QB@0
MU&9P05K0,@=?;(00-K,UM[$FJAKR1]%"7A8EI.V!Q(8\1E_M$X%:#$Q@[^T=
M.N2%S7I.-(#1E]%5U&A=OB;*6" \@8S56V=8!J^HA.0\=RD9FNV&MVZ;P,+^
MW'-D2 U#_QS"TTD?94_A*9KD)"M:O%=)%O7?R*+^AP">YDRS"T:XC13,K=3_
M?<$38T.N<5#G$=/TL404NHW[.P_)&5_&"1Z@JA_I9G72,W=T2(,)O7=[U;@6
M*:D(B8981:0 IXJ<5%28)(60E-/61N=<D:U[&-OY<-4?60%Q$ \?<; VY)?2
MF> U4.4#"&T$V, 89"Z#ED0*%FUK4W3VB8/V47I&]X 5,'R X8/MZA1F?K28
M+<L3\FCB)F$T^8"=E="?T77DV'^:$!XV\FV?CO+H^?:.FB(GG$F*@0LN+4-_
M-@<&47L5I57$)+Z+\KLH7WUV14S^NI:2JS9#K?478H:@@_UX"1M[FN]"--?W
M$N8IP.@+?!S%F";/?OUGBE%);3Q(ZBV(:*N%:QDD8J(TD5D2TLT#V;B(*TNE
MVA(P.NMR$>EJ':( SXS5,45EE&L1KEY,S\Y&B[-46Y76RM_Z3H&-5,#CBLO_
MMA^MZ3F5R'YZ,UVD@?P9NUEC-VOL9HWMW9$AD"&PO3O.FSN4A_&V<7)Q.4[N
MAR-G.K/^/2/M"3#0B8VF0BH^T6/%Y1[O<K%=PJ&4@G>SE--LENJ6%?5@./A3
MR[Z/VWW%CN?$<Q2@) LU^8N!)2H#-\:DG)4ATK21,':YO$;Y>>=F;V?O%[6]
MRW^Y\45ZEV;O/[K9#<]Q>5D_7SXU?YN?GZ59(8&7T_'8S>:K3W_S)K]^\^L/
MW,FWK]^&9+D7#&BV!(1(&5S6&I25B0I'O:"BC421QU\_>4K(;?GJ=_C76_6X
MG;O9X%-=Z'#@+A8?I[/"B870ZR+F@U7P<7 0>N=!A9"E!"U\!F&X Y^D@RP2
M229++T-LG]Z;XYH_OUSZM7->;D,KQ.P(=8%;\#7<(Z*)A9B]@>"3BMG[[.1&
M]N?NQ-SZXB@9EM.N_WLD<G6+_\?/_K+Z9?/?ERFD,Y]F TZ' T88;YS9-_]:
M*'HTG]>.E_7=Z<5BOB@O1I,/=US[,;@A"R,%5QX\]QR$J^@7. .=F&:41A,\
MV1<WO&XVYX'$4B,8E6"JFC%/D[O6Y263AOI"S\I:$)0;L*$\;5%#7 XN2:WV
M@.K[7Y?@)FOC1&7PLBY',UCK(Q@O9&0J*J9;:5Q_V[K>?J/@_2PN>%V.A5H@
MY?3* 1@"3I!4?HV4T2@)91O$V-:AM;BXLK!T']RZ+[)AZC?FN_8P]?L'D>G,
M)=,V<(B6U/)UK< Z*D!DJ7.F,2N[$=YN,0'N^@^D.P0=//S^@P[/(6M*)!!>
M%"11  <\,0X<-3398#UW$4&G W2'Q1T='%I1MJM?+MF:KC:='-8?ZQ6-GB<!
M-A(-M6"W&$'E'T%% 25-+!6I#0MON;:..6.IUMH6PPVH2PQ$T 0LD]6=98(D
M+*NL6NDP_LB+[X0G]I?']L1J9:A1V4.RNNCU5=>O)9M BL*?A"&.6MDRI;?N
MJ53?\U3NPS$YB8<Y'.*MS(;)HOI4HTNZLM'"%QM,QT =\93$T#(GMGXXXM"'
MTXK7>#@H"SU/Y3D_I?'7NWS(@PXYD9/D3!%34)NI(K)\4N!I"% D%C$Q&I_T
M!JVTPLA;>5KO*XN"R$KELHP0N"^RB'IPSC/(0GL=-(^DG?YY&ZO:WA5Y"PN(
M(5-V:+5ZK$C*H0 K$>NB"Z1HC=F ( 5WO"G"A9!HB2YZE->MA+X.2X1%!;*,
M"P&&^4*$T@OPLBA$A.?,8TJ\I38&>R5"QH>4R2&3CQ?.VX#9N\#W#EB]"LE8
M2HH5=UWU+[1?2BJ\*XBCBPA3!4Q2++"BN 2?C+:UU7@1^2U+P<8,:VL:W<.'
MPB(U(S#UZ2A["DQ.U=ESRD"0K*KGAH'13@)-FAEG>,BV;7VO36!B'('I>*D9
MDZN/S)/_/,9193(W'IR[42R//@CN?+1P8PQX8\"[QP'OO<E?%CSEE"5PEA 0
MG+ B59F"4/8U9\N4U*UDCG[CW'>%<5]/7BS9]HI8;DTBVZ$2M_G)D"T0$_'P
M$1-_'-&4UGN2(LA ,XCL9<$WQD$HXXWQM>FL:L,F.1PF,CO4_#%FW/6 +3!'
MJ8,Y2KTT;D*X.+L8UQ26=1L)= 5NZSSIX9C:!QSV"4RC_>D@X>@0F ]>!V#*
MR&(>B5JH)2RHE#TG2MMD-E2!;<RCW]/"C28IOG*SR6CR87X%"UXNH>#^JL"\
M;'=Y]2.=0)"AL ]O2M\&!S[F>-OK)'(7-?RPIR B+R(O(N\>D=>XJ(-U&7A(
MJAA4VH'WP4"4U(8@@Y&LE;GBCX"\7 TMW>/(043>4S3$<#[A]P>)S^_NUH>.
MTL,Y2GNH'K1!'J@WM*0W"&.%DK&VFR"\3@QC8*/5$!CS- D7@VPET^UJ\\]7
M_[X8+;ZVK2<8\A@CP_JM/""2(Y(CDA\'DA>3C285"G1'5E#9,P-6R +-+A:X
M]M8$WTK1Q/Z17 ^I?+B]AUB.H;INA>JZ+21WMA"OS*UORHIVL!B[O5/=<0^S
MIZR"4IQ>^'%Z3+WA?ICTI[UYBF_?B&[ 4_M%GLKG5%OS6,I);1E RBM!(,L0
M<HS>"+TQV&X;&^W*0.?GD[B+G/]1GU-*Y*'\N3<HY3$%.=8Q(48B1N[)CY45
MR4)PH,%$$"+38O@4ZR<R&:06C'"UT2)V&^OG4!AIAT(=+-O@%#&R&WRP1U.F
M X.HZ'$)G%ZN[=[C>8Y\G;BVXUP;TB>NK:-K6TO5\K/.=V]>[E-#^*:'/%!5
MOO$LW[W]';OP/J6!"V%Z5N[\M79:FTP7:?[TRK;L>_7W/L@65KMQYKU?7!Q]
MNES>.'V!.)JEQJ9X5NCKXFSR2QS-S\?NZ[/Z[B_G+M8>6%="(:/E_5;^\>4?
M_N=BOACEK^M;-U^%-(G%NOA2UU"N\.S2T/AR3_V:LA\MNYL,9.0U""G[W>S[
MQTM]_-Q]2$L-&UPNC_G,C3^[K_-?GOSEY@&M=[^AN-NW?I<=/DXB_K:EW87@
MS\LC\M-Q;&,/_OC]^8NW;P;O/KK96;G912-<Y\/!ZTG8 IC;8*S&V7(^[L;V
MO)A.FNAL4P'6="D^*V_,!],\>'N>9JZBV_QQ]JD3^_/3:#)8?)Q>S-TD%JI)
M7T*J >W:RK")UY4]6OU6MM#]_,C2\# H/1C<6&:CV5TZGZ[41+J+Q73M)JO/
M4:&V+*)^'(J<G%X4>3?ZDN(OR]M00IZ2/Z^_$&J3[/-Y>C9/YZY08EKO1N,$
M6E[[R4V'S:?1?-3X%K\^6W__MJ!R<SO)GEIF_[P2'K=\@#YEWWMWV_?H4VK-
MME]^:M6I/%.1TO)^S]1-UYWIOG76]Z5=.D8HO_]@[?5#[7'=M\NX@QUJCQ;[
MG00D\]W\(T0!1('=$FD?C76VT87OVKK_3FXV'[R:Q'2]I_5V='*?[,\N["""
M3[<XM,=+NP0?Q)Z;.U>;Z2/.H$:'7/- KF'(-<@UR#4/Y!J*7+.;3GM'1<^Z
M1*S%BIZ;\T"[XS^_:T-_3Y_2Y")A OI1+7B' W]0SGF_&I8>789PZYGR2E(O
MHF! ;28@L@E@1<Z0;.3!4\4LW^CXD+W561$%-"<.@AD//BD'WGC&&>.2JULZ
M136H\NML>O:B7*P^Q#]&BX\O+N9EX6GVZDL87]0TA^?S>2K_'_]P7]I*GF=#
M(O988-1GHD?D1N0^>B(^>N1>#;+%P^XF R-B(6(A8MU#U^14<6MC410=,W5&
MM@1G$H4L34C),&W,1N5Z5M0$2AEXH2*(R$WM9.H@AB2D<D$K0[JC:_(M9N?T
MB^*W;Z/28B3Q^)PNJQ35R8=!^G*>)H4NG[5:7W-D\J_+L/@HY6[]6SHN%YGV
M.(\2F1:7BTQ[9$>)3'L"R]U[Q+=9QT/'K=VT1J[6%1U^UMKUC8=Y"C#Z A]'
ML=S^V:__]"D:%:0'IF0 H44"SVV=(<(-%28:O^P$]-V+Q.0$H<2 YJI<A!7S
MW7IO(0IALQ76YDA:C5C/DYN%CTT=6RS&_WAZ7HO_+DGDUA]'Z7I[7%]CK\"B
MOSZ8HS[=UKV.3D9GA,NU[24!$0JB6<D#!!>-=#05P OM1+B7*/1\$E]^PZ!7
M2W=.>[%LIA\^BA;)&]$:T;I?Y-R-TVT=K6.T1B7%P# C0&0G"UIK#J[ -8DQ
M4)$V9H8*$SQO,I>T\R"HST5G51:D5,$*)KE1]%'0F@^-,8C6B-9'P\^(UGT^
MW=;16F<;0U0*A#.Z*-@Z@*]A?<*XHR$XH_@&6F\7T3\ 6M,AQ?#]OJ>@],"#
MU@(W_>\T23,W;AQ6+I9/C>:+&O__A&471P^R*$+[?+KMCRH@1*;("2BEBL$C
MK0=77>?*:F-)S"Z8C5$%V[BG5I!3).CS:X#3KA!5P[*,$Y>A"-?'Q- (UWT^
MW=;AFF1FBMTB(3!!0&C)P6M"(2@?B$B:9L':\$\=!JZI&!*">(UX?3P<C7C=
MY]-M':\93T(YR4 ;ZHJJ["FX&!,XI:6G(7L921L>J@/AM1Y*<>KQ7\SR.HB/
MZOG,CQ;+ONF#^44(:3X?Y)3F*$*W7_"QC+=_3"'[XSTZ"I3J.86T7QP:O=")
M4DA%UH*028/-U<5%5& Q%7N)FEW\8(ORU6=7,.W]$M)^+8C6DG!F0ZX/-LCX
M]NY=?>8,%!8=A0(4%B@LCJ;W":(HHF@G>011%%$44;3[OJ0'YCOULT?L'].%
M&P^F&TU+4%#U'X904*&@.G2.%'>:)V*A"A8023JPE K06DHIN,HL[.0;6@=Q
M+KLPK:(VK7F&Z)#3/1:"]$8<HZSH%Q*@K$!9<6!986,.)H4,ECA9XP@$C,P4
MG#,B$:9I,*T4$.Y-5NBAL0)E!<J*$T,"E!4H*PY=;)Z<5#[:(B$L*[(B%#&A
MF((LG!-6BF@H;2,Y;&^RP@R5Y2@K'C]EK)]NOM^F->=K-CU;N_JF$W3Q'7V.
M+690]_ET=V#WG]:;L5>A2[BULO85I-(4 <IU D^U+5+4!26R*[@K6G7FO9Z$
MZ5FJ6'9_L3LO^UM>_4#^VB'3>Q2_CRXL[CK8GU$('#M,H!#H\^EV7@@$JU@,
M+H!Q28)0K& YBPJ"(5%32XS;K'K?R4NW/R&P;X<=2@&4 B@%4 KT4 HD$C+U
MID!XY@J$C!(L]Q*4)"8;*F)V&\7T._G?]B@%S)#WK#)S!RF 4\"VFP*V^)AF
M@U%#I(.?5DEU/^,DL([B:YO+Q?DDN%QDVB,[2F1:7"XR[9$=)3+M"2P7>\0<
MQ&!Y7>DDS1?K J#A8)(6Z!8\=L<1N@7[?+J==PLJYY6TS$%B,8,HP PF,P5<
M9IVT<I:1S;2\+3($UNBU] JN<O/>3">7=8UOTJ)M/Z$><H+!(I0*1X@;*!7Z
M?+J=EPK1YR ]E67!UM9.GA&<CPQXEHEQ98S*K:0,/(94L)A @#+A&%$#94*?
M3[?S,H'K(A4\H07?F0&AF08G/8-HB+,N".58*P4\CR$3]MHQX+AD0C>GDMVR
ME4?OT+L] P'=>B=288DUN%B#>^ :7.)9$L)34"05$\U; I9G <6T\UHXZX/:
M'-"P33E01;:K(ON:+&]K/@,;6F.Q(!>;-YP8+*#@0,%QY+9DD#%&12,XFS2(
M%"6X5*11S%ES35FVFW6I6Y4DM22([IF7OL^D](Z*(_0^(NJ@7$*YU ^YY#+7
MFE *UMH$0D0#UEL+AI*8?"!9^G::%!U6+J%4VJ?_$]L7_7+9I?Q6ER8*__Y#
M.PI_%/Z'[E0>>12B6(T^2PM">PG6*5_LPY1]%BI[WHHW<]^.3#E4!F?9H1_S
MU  !10:*C".W%S6G/!*6P'&507A1[,7$ W!61)!+QE-BV_!C'LQ4I$,FZ,G)
M(G1B(N2@4$*AU ^AE$40@FL"DN8(PAD!1A$*(5H5HY$I)-V&$_-@0HDS@B*I
M0QF<_?1@ODF+P7@ZQZ;KK6$X>\HJ-\7IA1^GQY1A.U#%G_8$-)W9FT[1!DKX
M^\YHS(ZS"-:0VM%7.7"QV)'6$Z$%E=(KWXKG,RWVU\61#Z4YV)S&&^1VI)(=
MQ1"*(11#*(8Z(H84YUJ&*$%E6<00-Q9\%@:4=40Y2@-WH17OYS[%$+-#R@\6
M?D,YA'+HT;$6Y1#*H3[)(48\%2X7J\9S R(0#XYQ#U)Y1:U04;$-.;25PW.O
M<L@,E3I8_4 _Y-!MGLZ[\S./O]T]=MG%WJNW+!>[[.)RD6F/["B1:7&YR+1'
M=I3(M">P7,R?V"E_8G">RK9]=+,T''@W'X6!F\1!'(TO%BFB-Q&]B>A-1&]B
MA[V)+CDE-37@ R$@;.#@>;;@A- ^1I%X2&TD5[QRL\EH\F'^+LW>5[3\6\7*
MZU[%\C+%]PNW2/.W^?E9FI6#?SD=C]ULWGSETN=(KOH<V7U=CG>DCTIF1-86
M G<4!#&D[ 2SD&+0@EOBG-KHS=+&^E\N)<1!=X \I;=5.Z /%F.!*+U1>G>)
M-E!ZWR\U4GO"39'9+/L$PB4-7N4ZV29RD:7TP;=2D==5Z:TXE](*#CG76"@3
M32\;!]H*[VEY5XA6)C=T07K3I_RV_I\HO5%ZH_1&Z=TEVD#I?3_IG5.U(P40
M40L;ZO A$XD#$A(C)FJC12O]U[HJO4TH2ZG6LW&Q:"_:ZB*]A06:Z@PF$\K6
M[&7]CR.]E4+IC;WJ#B_Z_M%L48K@RE+<A[2,5LP'TXO%?.$FL7 &ABY.07WJ
M3K.'SFQ)ITCBZ+6FVZ6\I"I+QB(DZXJ-'B4!IXNJPR.ASE(2E')M>-C7./=\
M"7-O+LY\FKW-C?">O_T&=IO:SQ(0KXIULI4^(RB-F7,*.B@*0DD-CL2BFR@6
MO:.$)[K9BJ*]E:[4FHT%[[A6SH9:R*$FMY6OGIS^@HW\4&JBU.P02?14:JH0
M(B&, R5>%=M84W Y:-!1L")*2&)DH^G!-I[MQY>:.O.8K2Q&&ZW3E[TR8+EC
MP)PMSTU=M&2CL6V+*]V3U&1D:*D=TEM';:+41*F)4A.E)DK-EJ4F-2)Z+SQD
M(XO4Y)2!,3& ",9++@@1MI7:V,>7FDH5:>EI$7Y22Q Y"'#4)?"1).4=\S9L
M1+Y;7.F>I";50R;94/';2H-1:FZ5S']W G^+)<+?%[_TN"0-KNW(UG;O0J4C
M7R>N#=?6M;4A[^':<&W(>WB&6VOKY:<KQD;S<I\VQC=+_X%&^(UG^>[M[]B%
M]RD-7 C3LW+GK\50'$RFBS1_>F5;]KWZ>Q]D"ZO=.//>+RZ./ETN;YR^0!S-
M4F.G/ROT=7$V^26.YN=C]_59??>7<Q>KM^#*'(+1\GZK?*[E'_[G8KX8Y:_K
M6S=?A32)Q6+_4M=0KO#LTGC_<D\+G;(?+;N;#&34-0@I^]WL^\=+.__<?4A+
MRQU<+H_YS(T_NZ_S7Y[\Y>8!K7>_H;C;MWZ7'3Y.(OZVI=V%X,_+(_+3<6QC
M#_[X_?F+MV\&[SZZV5FYV44C7.?#P>M)V *8VV"LQKF9_GTQ6GS]YWQQMNC&
M/KV83IH9*6Z1XJ!)$3XK;\P'TUQ^FX9_?2SW2;/Y?_POPZC^9?"J>?[!3R]3
M'H71XN?'V<I.[-Q/H\E@\7%Z,7>36 @K?0FI#IRI?N%!V4ZWQ=X<.JVVA5VH
M&MZU93;JWJ67=_G(]?&>N8O%=.V/KL]1\;<LHGX<BO"<7A0A./J2XB_+VU!"
MGI(_K[\0:K;Z^3P]FZ=S-RM4NMZ-)O:RO/:3F][A3Z/YR(_&A6"?K;]_6V9T
M<SLAGG)+_[R2*+=\8-OW]%-B[;;7?2K$EE_E3ZU^A-OJIU)K>^6_PS^"?2JL
M(=_^V_I0N_ ([/+=;H8_3/<MT0?UO%H_QQZ7>KL0ZY#KI!=GBDOKZ-*0.'N]
MM)/%TKXM'!?;U\4B2>-B>[98)&E<[+T6J^M4Z.XO]SOM ,QW^Q:CW7_"_(&F
M%2ZMLTM#XNSUTDX62[NP\&TBH'?MR_,81S6WQ8V1$$YNL4=%]7C*N-B>D72;
M0/['=($8CHX#=!P@1MX;(]4/,/)Z.3&I/#%HT@=O*[[O!8J^F)Z=32?+7,CM
MB.4[>W99@-V%74/N00WC8;SQSHTBC"9(!2>WV),E^><A7)Q=C-T]N@AW=T.0
M[)'L'T;VMY2"($6@98F6)2)F2XAY>I;ELK\8VI3(-\@W#U+!SXJ462#?(-\@
MWSS(D^G.1UM'A)!QD'%.E7%6O0Z0<9!QD'$>PCC?:1:"'(1NI1^YE9J>)/?U
M%-T](+'3 Q9VZ!+_-S=VDY &;C%XF4*JO<L'G X'C##R(\(ZTMW: XO=:R>^
MVV+]$?;A $O^P>'?"@_'/V-!^*RM=@F8MQZ$=@9<D *D)<P2)6V*[.;D 2FY
MXIIKX(8Z$$)R,(:1\JN32D9%G0LW)P^T/EM #H4V0VUNFRV #(#HUZ?#O]^8
MY3\A#&X-@]Q((DUFP(PQ((C58'+D0)PDE/.L9=X8:[H5#%X)*R^-A>MSR]^_
MO)Q,SJ_"(? ?XB'B(.(@XB#BX$XXF(+2S-BB#@I."J8Q"\T$+BV9"8:8Q.+&
MR"V;O;,BU[F6,8)(QH&UBH!7EF@FO==6'@P'&1%#JA2"(8(A@B&"X3W)Y*?U
M+NT57)WFT;!0-MJ;QM8N2B9G"ASU7IDD@PX;2J8F3L7D-<B4BV+*>02G78 <
M=::,Y<22:1-<YV5[RZL?3O:S0TKL::#L_1CMA[Y^A-L3H *$VQUL<.Z,9;3@
M8;#%GHY6@&4N XW*6Z*8+#BY,015N\2<DQ"2U,5N%P*,)AP"*]M:OFV#VAB"
MNC_=4PZ+PGL:H-@V GPO=[JODZ+NB@#>O3OW# TVRQA-8GF054QQNVU=;4\S
MS*"YSM4+DYO#%#H8,7P]GU\T(<-I+L#1U+7.*_<7?B_</UC.)AF<C]WDAVG)
M)R>E^XL^*&HIT<93F8"*Q$ (3\#&4.P++PV-@A2C@]P4M3QPFE-.H).D13P3
M#X8P"<G89&4D1$5ZJZBM3)CBRXO9:/+A79J-IJM!X\V_?W/S%%],S\[39.[J
M$^X8%Q1D**C8WWCQ/A,[XE9OCO+H<:NIN61XV,BW75@N\NV.GD^:N&<Q@912
M@> B@4M< 0DJ,N$X]3S?U#=\^4:QWA/88"4(K3VX+(N.8ADW.@=*I+JGOO%?
M;GR1[J%N[!!^%P]WAB+!(W;UZ2B/'KM0YT"^[<YRD6]WTSFLC]X$S8%I770.
M:3R88#2P0+*QUE.>-\,)BII *0,O5 01N0'O@X,8DI#*!:W,[>$$U#F.B.#[
M&SG8N78((P=7^S^!KZQ;(P>7O#M(7^KKA-'^7D?['S^S[NBE\CVU:20/Q 8\
M?,0&) _$!CQ\Q(8[K/G(,Z66*BA6>,V#EK18YJ[LDXK4*Y(%%QMURMM$$)['
M_[F8+\[*H\S_F'Z;#%4;?[^>K!I*-5:]OVG5_UZSB>9EH>_3[-,HI*4;X/<4
MIA\FS54:CT!;MO]0:ZSX0SQ%/$4\15T+L0&Q ;&AO6R-F(06BA1%27 H+S(X
M)C,$IFR@T;%H3!N1$]2U^LY26-6!51V'J^H8#B9I4?\XS3G52&QY=[[ R@X,
M I^.[$Y)*B*# $5<+@(\>+"<$/ IJV"YT=1O9%H^I+)C4;[Z;,V \[=Y.2VP
MB9:^28NW^>V*]5Y4SGN_*M_8J:*##RU30TT>7EB)=(Z0U:>C["ED:2<"=3H"
MCUP5^*E]U**,8!DS43L69(@'@ZPV#0<L0T/$.NVC["EB!2&-YB* )ZR@CTH:
MK'06O(O2>J\5H7278-2C(1;E0VXHPA;"UDD?Y='#%E:R(-]V9[G(MSO&8Z3T
M7)@$TM.B,%"JP-@@@6DB62+44+)3)<OCJAL/#ZT@K?<Z4()%+&W!2>'>P7@Z
M_V$$!!,AVHO:_GCHV=&A4AOD\:!9<,<IO ^6:'6?^7 G262(08A!B$&(08A!
MB$$=)0_$(,0@Q"#$(,2@'@QT,9*QP F#:&4"D;T"9RFI22G!BLB8HQM%B5D;
M&34)(&2T(*@TX$4((*VFA.H0577F7D^4?Y,6KR=A>I9^F\[G;<]R86:HU&-,
M4>TH?..X%\1QQ/&3PG$EI.8R,; \1Q":,G!1,:#6>:MTS(JK-@J>$,?[@.-8
MU-1B45.WI>$.2/,W-VYJE-QB\#*%=.;3;,#I<, (HYB]@A']D\E>H4%I5V==
M\DQ5K4@J1E+V%AAU6D1'1!3RIG 56L;,B0 >O2_?*4:2,R)"%#[$+(PQ7&ST
M86TJB]Y>+.8+-XFCR8<=ZXZH'0HAAY9P3%!!9#KIH^PI,EEI)54\0732@G Z
M@(^$@DF*.2^HBF2C5G(K9-K7P$F*#: 1FD[[*'L*39'8[)PH""-2+- D&5B;
M*#BGN<I6D;#9[JYH4UYZFJ%H7 0$3P2,2@88"3$J(6+!L\/-PJWJD\92(L2G
MTS[*H\>GPWA@N5.26L<@,6L*WE$)+N2BF:5DB5:6D;AA)!))HDLF0>*JJ&^>
M%GC,24&D4MCHA+#\]@%A6^+=/=VP1 ^U5KT"OI9<J8B '5HN(N".,2.O"S*Y
M#%95]"%.E5?"%%N2-/TL9.3N)F+99 I@$0*1<5F^4Z#.\5QC1E1;0:C1PA[.
M>*1#C9.2L?@*BZ_V$P"ZJTM=X=["RX/4\/+@?.PF6)]UP%R2HX,E;%1[IPR6
M0B8K# >CBQ05BCJP+DN0(@8E.8W4;CAP92B"6:@,SM7>+4)K\-9DR)KKF%V2
MA&WDW]TQXF\9<;K'C+^'!Y^D&C+U<.\)L@=B(Q[^B6$C-OA';,##1VQX0$I.
MIB%2;2!SIT!HYL!87@/?7O%@G,EAHZ&,C2KGHF^!=\2""-F"D]R##I:+%)B3
M+G=F-++%?OT(CPB/"(^H.B$V(#8@-K2F.GFGI3%>UG1! X)1 5X'!<PHSQBU
MY2V[D3-H@N?9!+#:>1#49_ U9"VE"E8PR8VBJ#H=.8=@51"..FH_B-3  #3S
MSVH0Z9+9!^E+?9TPY0+#TSV4O=B_&OFV.\M%OD6^1;[%H^POW]YNZ^;$>&!2
M@(AUEJ .!)S/18$W5D5.=,AJ8\S--F&"(YD#S(9$8$$+8MUI'^718QWJ*,BW
MW5DN\NUN.DJ**AJI$EC-;!T$FL''8$";&&)(T2FVH:-LXX]'':7O#-)?=SS6
M=.R]IL--XN"SF\U<P8?A8)(6]1/3U=RL\M'Y HL\,.*.$?<M)+RSE'GA#% E
M%8A@))@4.2A":-;4QL!V*O+XSO2[YY/XCQ53;P[">SUYORKKV*G2@P\99T-!
M#8;=,2L),1(Q<BLK*%$2F'-@K2\8*5W!.Z5-[6<L*:7!>+^1E70(C&S3M'EX
M&T;D$01(/'P$R%HI;+/CQA!((1$0RD:P+AG@WD6EB(A$[!3*Z@) ZJ'9HN$:
M\@F")![^B8$DUKT@-N#A(S8\H-T9"]+Q8F%2X4T=6R;!4TF "2N+ 5ET(4UV
MB;-U18%Z>$,TY!.L?L'JE\.&VR[.R\O@YA_':3X?I"]I%D;SYF/UFKEV6/L6
MC\-\& SWGXR<=I(*RT( PTP$(;4 3W(&F;3Q29-HPX:CHR5/\-\+4[Y8\>2K
M%4N^S>]FZ=>&']<RO)VHF25#I1X>,T/21Q3KTU'V%,5(9$+S9( ((D 8PL%+
M'L%:PB5G*C&UT0[^L"C6IMV!"7L(8Z=]E$</8UA4@'S;G>4BWR+?(M_B4?:7
M;^\8Z.F%%-YS2$7IAV)!>'":AZ)I:V*\RBIDO:<@!9H-QT+[_0T\8)W/W@,/
MZYC"8#2I.#))2_CY/%I\+*SK%X,\FI0OCB8?,-$ $PTPT0"3D# )";$!L0&Q
MH4OD@=APPH=_]-AP1^*#LD')8O8[FXL=KY('ZQD'DHV)T7%-PD;(<%_-RE;6
M_K)]=UN=/:3%U$2$1X1'A$=4G1 ;$!L0&]I2G3C5,@AJ@7JM:X<5"YY$!E06
MG<D+$[B)A^JAAJI3AS@$JSJPJJ/]X,J;M!B,IW.LR]@Z/.L+A:79Y:,^E>>+
MP7PZ'L7!^D".#GP><-@_7OW1R^FVTY*^LV5+%".\UR2#^(#X@/B ^(#X@/B
M^(#X@/B ^'#*^/#3>KOVZU?,1&0O/+B4(P@?#'A*'$CM$N.24N<V_(HN6Y64
M$9 4D2"T5."T3!"IDX1HRQ(5-_V*;]+B]21,S])OT_G\_C[#>=G9\NI'SD,[
MI/SA,Y&/'5JO$\-=Y_XS8BQB+&+L(V*L)9X$&2FHP!B(3!7X@J$%OZC2W$2:
M22NQ&\38'F-L#\(S.]>^=%M2[8 ;?W/CII3%+08O4TAG/LT&G X'C#"&&1.8
M,8$9$UM(7:MYU#0!8=H6*T4D,,PF8-E3JBFGBF\4FA(G&+56 9'EDT+7:0U4
M9+!!AR@3]SK*FU)WV2OK[<5BOG"3.)I\V+%M%N-#RN2028()$9@OANB'Z+<5
M^N7(LN4$ E7%?F!!@^71 (DA$UF +9*-:3-;H5\MN?TX'1?=??[JWQ>CQ=>V
M$L)PE@S"'\(?PM]6\!>I2U1S#DS9ZJ+.$0Q7M+I<! ^.*"(V!A)R8[@PUH"2
M*8"0B8"SQ(!3GM LLV2"' [^F!UJKA$#$0,1 Q$#N^#&UE8KXW1U8V<.(C$.
M7@D+B2?J+;54.[;AQF;)V>PBR,R+&DJ*)>Z9DG7$5_!"^RB\:A-3[^G+YFIH
MZ8G,X6K)@XTH>]14@"A[)"AK2-"*%\1D*N::D%&T4*8EJ&A)M#8G[3=0UF2B
M:O$\.**+X6X+/%LC*>00/2%&"QD> 67UD$K$V-TP%JN[L+JK_7#CW3-[RAIF
M@]3 P>!\["98 (;].?LHRV^7O=0S9R(30#(CQ<*)!DP.MDA4S[VUC@IM;NE/
MXS.A I10# 0C'KPKEW""IF!S4%1L)$,VLG=9/OWRHH[)>Y=FHVE<1A*;?__F
MYBF^F)Z=I\G<U2?<,:@HY%"JAU=8([$C;O7I*(\>M[ 7/O)M=Y:+?+MC\87E
M1C/K($>G0"CBP$4?BA81&<\V!F4V;'UMJ"%$&:!.QJ*CI/*=8'UY%;P*-@GM
M-Q*#[] WFD;W]U WMH]BB3TF#/>9WA&Z>G.41P]=J'(@WW9GN<BWNZD<21-"
M+?= G!,@LO?@"5/ @[8L:II%5C=5CNRMSHHHH#GQHIR8\IVD''CC&6>,2ZYN
M#R^@RG$\]-[?N &.W&D+4AJF!E\YM\8-+EEWD+[4UPES"#"' ',(L/$S9G$B
M-B V(#9TB3P0&T[X\(\>&VXWYK.23F1N(:B<0)ADP<3RB@O/C>694.G;B!_<
MIRE\8]3[FT;][S67:%X6^C[-/HU"6GH!?D]A^F'27*758;M#NT6. [(4XBD>
M_HGA*>I:B UX^(@-]]>U%&5:,LLA$$V+KD4%&!M#49Z,2$H+:O)&.YEM B>H
M:_6=I;"F VLZ#EC3X29Q\'DYL6L^'$S2HGYBFG.J4=GRT?D"BSPP(GPZ@MQ1
MKIW,$;(,"01G12B+(J.M#,9*SUDD?)<BCT7YZK,U-\[?YA<-,S:AT^>3N)J=
M-W^3%F_SVQ47OJA,^'KR?E76L5.E!Q5#QNE0R8?W3T*J1P#KTU'V%,!TR,GQ
M4$R/+ H8D5"M"L[!&*UCEM(ZNM';Z!  UJIY(1"]$+U.^BA[BEY*:N*23^!9
M4B B+TBDG(+HF;/.$^OSAOKUD)A5%]!+#RUA"& (8"=]E$</8%CY@GS;G>4B
MW^ZF>)"H<B!"@@_.@; \@R%! ??4)NN-RISN$L#IB.)!%2H>6/^"]2\'C;%<
MG)>7P<T_CM-\/DA?TBR,YLW'ZC5S;:OU+0B#&1B8@8$9&%MTRR QZI #<.(L
M",43&"H]B)RC%]E3PG?JSO4= ?[WPM\O5NS]:L7=;_.[6?JU8>VU<&\E@*.&
M1NFA) _W@"*[(%;BX2-6%JP,,JLL)(/H4D%(52P>0[T#2K.FFC 6\D9EP&&Q
MLE6S!Z$2H1*A$J&R"PW<J5+4BH*;FGL-0D8)EC@-FG";C3!)AYV:NAT<>N_9
M[?TT,!BG:2 8(Q@?+KB&Y('8@(>/V(#D<<>2L9H(JXG:CW2]28O!>#K'RJ"M
M8^6^4%B:73[J4WF^&,RGXU$<K _DZ,#G 8?]X]6?BI!J@V"6*$9XKTD&\0'Q
M ?$!\0'Q ?$!\0'Q ?$!\>&4\>$PT4II8B32&U!6"A#!!; %*H!P3RG1S FV
M,0]"D, =$Q&4"@$$M0&<"@F4B<)1S[64[&9;HS=I\7H2IF?IM^E\WG;LD0^E
M,?M+>^\HLK84BD2(18A%B-TCQ)I(E:2. -?<U*G"%IQ)$D*D3&MBK?6NC<YQ
M"+']A=@>!&=V+D/JMJ#: 3;^YL9-59%;#%ZFD,Y\F@TX'0X881R3!0Z7+' =
MA-A35E$H3B_\.!VOQ&^#0.ZS,4>O#-S18C\1S7TV0)R.(,I5BWWD*=@42?(^
M4L$VVKZ2P(RD,D L&PU") 7>.P>9&YN4Y+E<<F->7E,G]/9B,5^X21Q-/NQ8
M123$D"D[M/KAY<![9J3C=48AUO8>:^^G\/T)07>OH*N5EYH% BE6ZR>$#"9R
M#I:HJ&P@S,6-5@U;@6Y-FO\X'9=]GK_Z]\5H\;6M(:2/4;R)J(NHBZB+J+LM
MZC*O<XK"KWQ./&;PS-0B>Y==*O]G](:JZ[*)VCL/A#L)(I5_O)8:%-$I>6:S
M(^%@J,NX'2J!"B]"+T(O0F\WH?<P(0?E ^.F:+]\6<I?6Z48IPM ,Q>H94FG
MS1;1PJ2"XA%BB*Y\LG9*\TP7:>!UR())PU.;4'Z_N ,39"CL8TR:Z2RF8PDJ
M@CN"^^F"NQ!.DDP4.)JKGBX$.)\91*M4<N5@K-OH@Y6"<XH5C5X35<!=YCHN
MP#K0G'E&/2,D;Z3L[!_<#4%@/P2PGV*-8/GIRHDV+_=YD-^0ZH>+N7'W[][P
MONM^G.7= ]-:6.S[E 8NA.E9N?/7.JQL,EVD^=,#KO[>='J,1_OHBXNC3Y?+
M&Z<O$$>SU B!9X6^+LXFO\31_'SLOCZK[_YR[F*-BU[)$1HM[[=*,EG^H0[/
M'.6OZULW7X4TB07UO]0UE"L\NQ0 7^Z)\I3]:-G=9""CKR%DV>]FWS]>YN><
MNP]IF9,#+I?'?.;&G]W7^2]/_G+S@-:[WU#<[5N_RPX?)Q%_V]+N0O#GY1'Y
MHL>UL0=__/[\Q=LW@W<?7='K0KIH=(?Y</!Z$K8 YC88J]&*:^_E/)Y^[L8F
MO9A.FN1%MTAQ\'Y1?C3S?&L_Z-J>:_!K>=+YX^Q6)_;GI]%DL/@XO9B[29S_
M_,@B[S!07!72:\MLM--+-_V5?A'N8C%=VRCU.2J>ED74CT,1AM.+(M1&7U+\
M97D;2LA3\N?U%\IBQNY\GI[-T[F;%<);[T9CZBZO_>1FEN:GT7SD1^-BX#U;
M?_^6O,SE[:1^:BW[\TI"W/(!^I2;[[W]O??(4\6^>^V3O>]MR;4/L_/NFW[[
M$'O0=-\<[/O2RLG7=_[ZA#WY_C)O>:8]+OL!5O$^SA07>\2+19+&Q?9LL4C2
M/5_L=XJ?S'<;TZ&J=GJJ&B4_0($'E=X^&NMLXSRX:^O^.[G9X%4S)NMJ"=QV
M9'*?8M(N;"!B3[<8M,=+N[<"<GK0<Y\J6\09Y)$3YQ&&/((\@CSR71ZAR".[
MZ:MW=''_7KKIE@IKV9['3_';C>":4'(->L\'>38]&TS/T\PM:IY43:7\-%J,
MT@_[M_<RK7L;;]LC)AP_AK_M%):+5-S+8SVQY2(5]_)8>[7<O<_EN4_E0G<U
M.ARR\T"6Z?+\KI9JZAYPIMV BLZ7Q2G"LG'9 )/,@PB*@]>U^CDE1ZCUA+33
M9O7=;%H>YPA[K':66;!%=?_.% 'PX !H922,$PDND0)[V24P).J"ARHF*:P.
M:J-_CS#!\VP"6.T*:%*?P7-E04H5K&"2&T4/!X#,#BF7B("(@#TX4T3 @R,@
M93(ZQ2@X(2((P5-1 74$Z500Q@HEL]]0 14U@5(&7JCRG<@->!\<Q)"$5"YH
M9<@!$= ,E=*(@!@IVH$YGL=:!;TL.5Q,![-4W@JC<1I,5@Z'^M?ZNE9-#LYG
MTT^CFGCGOPY^NIB7%Z/)S[<&DYZA!_-D7'HGYL%$*C[18SVQY2(5]_)8>[7<
MO4>3FG6,)K'VAUF.)MHBO'2U9+^YR-6KDILM SJH)3;MW<"[JO'5'DMI,G?5
MV$!7Q!$95P>;!M@-A&E_O ]501!*03!2K'_GZ_A3;H$(SI(VE%JV,6EBFZ!1
M,][G;Y777EQAM9;ZGM.A50]OI(ADC0C5IZ/L*4(9*9Q27( BWH*(@8-AKN@Y
M7EBK560BD3:B.GM%*#8D@B)"(4*=]%'V%*%B3LK6:+,77M0(B@"GF 9/F%0D
MIA3]1MQYFZC+GG4HK?L5>3YD80X:W@_@HI>I?"2,&NH=N$D<N+-I6?'_1>N[
M_RR&DN-:QE**W%.N01A+BA0HXL.S:EAK;HL97O34R-NPOJ]R7'D]3O7%\TE\
M?H7QVI(C#Y_\B!2.8-6GH^PI6'$CG(O"@7*<U?&(!:Q2JNGF2GMADHE$M&&(
M'Q*L'CXK$2D<P:I/1]E3L!+&9*U"J'&-5(''@:&:@!*)!>6S=S*V89.C9M5E
M\QSCXMM494XG35[DJ*)!FB]0;O2:JU!N7)4;DD1B!>&0K31%R:4<O P$;,S$
MLR(\B-V(-CW$(E^4KSY[O>*L5U^J%S>M&*XE,=&S"DK4:1&;$)L:;&+)Y)R$
M <-S46P#H6"M4\"+[>VMC-E8NXL!OG]LXH(C."$XG?11]A2<#$VT&,H*2)8,
MA">Y&-Q"@0Z.&:D\]7HSE/$ @WO_X*1./4$'P]^'J4Z\XAJJ$Q%C\HM!',U#
MV5DTMOO-8B@SKLJ,%!B5TE.HK8F*S(@*G,H4)#'$22*$H#L9VVLG[56.>YM_
M'4W<I$Z5?#&=+^;/)_'EBO<>4,S^74&BAYR=>BH58M:I'V5/,4L&1Y0-&7*V
M1<^-B8)C00 E(0A'>2!J(["T313\P)@E>M9V"!$+$0L1:QD*IUY)1C5DQHN6
MI5( QST':0.)01KG VLC%'Y@Q&)HKF,X_!',]?*%L]'%V5_6%ON@_'G^L7P&
M"F*<#4:33VG5>PBE3*_Y[U2ES'_\+\,HP\-&ONW"<I%OD6^1;_$H^\NWAVD=
MZR1EW/@,U!,/(B</3C('AOFHHQ")6MF&E?CZ4C]^/0G3L_0F+:X;CFL[L9B,
M[Y:J=EOYT[VR%Q^EJRP:C@_@L]^2FZ>!F\_3XEJ%<U/R/!XY/QJ/%E\'+H19
M4S4PK"UI488=$0^B#-MU8(.S,<<$G# -0EL+UFD!3 M*7#9:LYW*GYN<H88-
MGU<NO"IGBG3Y;<V"S]<<6&116\Y)TBMA@WHW8A9B5H-97C.E&"NJD6 5?WBJ
MS7X\J,AX\"+E:':*_SX>9LE3KR]$S#KUHSQZS#J,KR![DX361?,2KF"@SQ:*
M]N4@4:*DXII;N5&(\N!<[WUAX/WFT.A^%:H<U%N 8>8M..W5OR^J-V#Z>9)F
M\X^C\\%X%&J-PV"6/J7)14*!=43LA@(+@U*H:.)1(M_B82/?]N@HCYYO#V,@
M>D\8%SZ"HH36J2*F]NS7$*6W1$:;#=DIY;@Q$)<:\]NUPOS;4E_^?:DNMSZ7
M5/2K52"&C[MN$+X^.W>C64V46&8=CSZY16H&5;G)UT&Z82ZBN#HBYD-QA6HF
MJIEXE/WEV[OR/8PS=;J<#3*#8,Z 4]Z#R9X;9:)*:6-0RL,;6%W*S;?YW5)J
MOE@*S1L*8UNI'CW3#!&O$*].#J].4L_8/K)WV]9N;=WUW9![\=%-/I1[CR;+
M9.#YM03@49H_PU'F/5XGKNTXUX;TB6OK\MJ0/H]Z;0?UHK,VO.CL&)6O=[-T
M[D9QD)8=8Y>ZUW3Q,<U6RA@:M+VV<4[5H+UCA!MUT5.5@<5<BWR- "]B !J"
M3,[RP'TK#3=?3\*LIN^^3,N?KR<K/GR9<IK-4EPU<'X^B6\K+S9IO@]H#'7/
MF*VRZ)E#(#OIH^PID&45D\^1@I9*@TB2@J6: 8T\6^X,L6&G2$*W@ QQ#''L
MQ(_RZ''L,(EW5H0DA0U@0A8@1%-1SP509Q4UFB6SV9UXNRXN^\7%[T\XZU=Q
M_;'49IVN$^%Y6':N'9R[K\Z/4^-$J'U;+M(WSP+*K2/B.91;W9);3GMBA3/
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M'[>]CX$<M/*Q"3CR+1YE3_CV0&6UB=N8J ,I2 )A/ ?+B //F38I>6]);B.
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MNU ([B<4=)0$F<XH":,@Q^%3C#"?Q80I%<?*3P/%]%["^$VMYP=]/E\6YD9
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M@AW'PX02JJCO9UF<BERL&X"9]I,H]05A?JH(S<$ S+,X(%I(#@^E-!;)<QN
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MS!Z^6%9L7FNSO?Y0Q1Q_:TAL>F5_TBB&7"V_*34'@%1?8*$%0UNF , !%_9
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M%8&.8$Z:8%XU?89?.Z)Q1..(YDY$$SJB<43CB.9N1!,YHMFC?6CZ:VX:B )
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MAOM@[=W7ONZVD,+#P2%W'.^Z5W3NN09:C7<NEBSQHR0D8<@TH3K-":/<)U%
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M_,PA=<%(Q[?<E9X WZ(AJ+$:.$\H@I30(-&$Q[E/5)C1+)%QF#.QH>%J/XE
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M=)V>O!E(X5(ZS?U96--_K4#L;IJK?:C*JO0FZH58.!:7A\>7@E@ E]&")%'
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MV+&7EHH;9+N#)OFZE^8S]@77,CGF'48CG9C4=2.@URIB7I[A)$0:Q3K+2,8
MSVG"!6&!E)B#)1,M1.('T3JR1XG*\?\1SP'90RQGU(#[/IA95,@(!/Z>72BG
M93B]'=1B;51+8/V4,HC6ETI\8U75Y&8C>N[ =D38OEIW) !LFG!C0_'RJVI5
MTJ^O<<5>7V@]FT/)]\DF^ K8ZQ03&"JSHQJUW[(":K1)7.4U$=DN<[%YT?;W
MX/-;WM6E#AN"O/Y86.N!0)PQJ3"I>5V<[5 J#/";>8++)BT.Y!<FQ$VZO-:-
MF^*=S!XGRMY=$AN=8X=T/[Q2,)V%7&9^BCU0L*ERK G/?4&H3KF6DNG,UQOR
M$PS;/%$"Y&<2$,I!B'(?+-\DCJ- R!3LVF1G*1@ZS*<?+5!^4>JVE6#TII;)
M9P=6E=KE0%XG82ROL2IRZ^ZO/:.!KN/9N[]O172N1 GJ?3&;*5G :Z97GES9
M?*DF,?3,.X??V01YS-&L,+D3WU:WY3JMC;O;++!%IK";U5Q<LOF%ZBL_!T+=
M!CCLT'HE;:8\1CR,\)^5LJM[._,^M)5R\61;]N'MS(<^66S,&OI"LS&MEZNI
MM'GLL$%XM]U!T&P!J=YH( >L[6H5QSJ4&1%A[A.:@1S/0QT3R@)0"U(_#Z.-
MPDT?Y+Q/4T54JK$IAXH(HXH37\DPY;X,%/6=MOO(VNZZFLJ&/BI$;40^)2OV
M[06JI3)E.HV#A,B(4D)ESDDFDA3;3,=A+*C4\49DC[%8<YZF1.5)C#($Y$Z$
M9IS(PY"F8*#1C3%5I^H]ZLMJ-YG@I$F&Q6]F[ J3^4WG%N,L,IX0#G^NED//
MT01])^4WBZGSJP$W#OV]L.--Q@H7KUJ!@>ZHIMQL0\RAW^*B-(8<!NPQLFYH
M;'/%9L-9FU@XRBENBJ ;BL*%#XYH A:R1')*\@139<,L))G&3B$Z4GF8!31)
M-H)@H08^#BR>Q)0G0&@QL/\XH81)#BQ=J!3L0D<TMR$:DZ9ML'F"IL48F2;C
M+.M=KM+&Q##LO,'M397?Z&=FH=T:VLA&.>4ZN6V&\%I+CD'P>\RDC*EM^51C
M89MZ63 I0&,%I>[0Z#\20OJI'Q.E(C"W(HJ9P5H2K8(P%SSG(MI(#XYX1)F2
M"<Z#A&=4"#PCQ9!+F/A!*F4B%5^G_W=35M<?]/^U,/E0_8E9:VW.1*_.O0.1
MH.1/5\WOZN:'XYY!]24#RKAK4-&?I'%T2"S"'L-T  (DP>RJ$K=0BB]]1*+!
MLQ8<KVTP!5O)5 )M!& 8MBW.P0F6A"6,R0A$@U1@G2<J)3D-8Q)'H.XG(J5)
MOJ&-[0VQ?F[@\Q'!TWW985,PECKPIY*?EL#U8*%STYJ5O4=?455_PCNZ(Z:=
MY?DAH1GH.%8*3:^,0H,G6@M)=[ZZ(1+V^8-K2&A*OM$U>=7BH9$>IBX<U3W0
MY^#O!:N6;:BG7 SKB[#MBZHFG=A!IQN:,[;U C/_, 7MG-6%M>0K.6B$@-!?
M3=EF-Z8M>[6N-O5]450/YKT[VO<F:<)%D' 2^0%H4%&"C2:9 AP6J8HHSX2D
M^T#T]DCG<VFQ^,-JB27Y")K?V=+X/M\##H_1$V6Y[:V JQ')KDRG+8(I9L_1
MI*5/C44E)PH[-6.]C_1ST8M%>\V*ROO*IJN.5%I_>8/2%^8?IG/0-^,HZ\H'
M5\MB:K+E 95_FC+QA7P22!?&^C:NZUDIU70RKJE&TEN4\T$OAF6)9<_CNCZ3
M*8S$:6FH\WUCI%@4RZZG1N_FQY@S,11FRZAO4YYMFI*,*@B!\CJONK+U;;<I
MINXKLX?UV'BDD7JYO9MV<$]RU"S(,TSH50$%T@+3AK%(DEAR7W,=21IO)'O>
MIYLV7*J2*_1)C4V;^A:-M4] C3XWBLUZQ@80_5K>.>+::MYCVAC?&\Q$7W1=
MBL)@:Z>2;PNZF(XD==-GR41W/<R&J.$U]>LWIUJ=U;;R-YW\N]$ =K.XL3=L
MM2S;(0:X'ZSU@>WCS\F4796K);SBNY)O[>L"'ZSM']L'L(*8+6KUIE8@].&.
M6CB8=BQV[1^V3??Z6M2%G9C\IEUCU]@N\]K,/PNCY$<L8=K](U"_Z$T_N>G[
M^"P+HSLM<L, L^S: <7;T. N0\WN,JPF>WFS:H[U>( %^*UI+WGM4;?LZQ&/
M_K#"QF$YVB[8#*7"_1'@$*"R1Y1P',1QD$?C('<:.'L4/ :5S?NCQFV&JQX"
MQ)Z._SSM"%8 U?-/E;L3<'\;F35N[N!#)ZH]^^T_U4S!8YT7F*6YT"$E>9 Q
M=/\SPH,\)303J6)^%"A_;_,">^?+.U95Z.6^(;9\QP&"_@2 \K@#!%_D:,#;
MBXE63[V#F!BZ9<RJ]Y$;0Q^'662XJO]4?IZ'B!4S*&3<)[/IGBGLE$QO@:ZS
M<NY$SGZ'>&Y3DI_>8GC2\<9WLA*N%5;[ LF^996)EX1/AC8W3'X]/,1Q1L >
MC8#M?8X=GSX97<E9!*.B ; $8C]4),5.2C0%8X#[8484931/=)BKS2X\=[$(
M3(D/4B"F@*!9\(=:?M!_];'%]KMS^P&[=E:G,Q&<B?""3(0U8P"ESM1YI ["
M/#A "GUV^^!@1=>K>R:>W3$W-I>A5DE&DA!SE&+FDSS/<I)3EOB^#N(LV"BZ
M>) H?&?9P]^KLMX]S/?P1-[]3:L#<!2_=D;64QI9SAWVJ/(N/ N1^F2YPA2R
M9Y1XSQ.EN0TP7KSP>WSOV!K@GI.)'[AM<YR\^YTS4X[0.^8"YWMM5ATG22HY
MR4,>8G.M&#1^*8BF4D:ASG,_8LXV.'IWF%/W=XL,%T]QCBWGV#I$QU;(@YAE
M<4B4E#&AL8]97UE&$AWS6"CLSO,@X;4]ZVL0XWG?<(6&:^Q+GN6[&P<X1]>>
M'5W.6+JML61\7T[^.4>7<W3M0W@IZL>*1I($,07AE6 KK%!+$OF)XBR@.F#^
M/H37%N-K3W(JGV1^^I22ZFC]>8=1:F=Z(+PPMGNTY[MUL=T1G/6(SS>D>/@;
M6QQLZ3YCYG\>0(N()VK6L7,:]H[QD0<_]3KV(S_+41!'DA*:@DF:!0(,41#R
M*DEB/U!R8^IU'$8:&QHK(36A/$M(GF0!B4.?PS\HS]?ZB;<3W\_G<MA.W$V\
M/KZ!P&Z\]1,B6YZX\=9NO/5FK?\=8&%_BJ^Z:;SUIP*^!;GQ#^P\>N7]Q.9?
MW%CKK6UQ?V<X8S/(KAUHO;PL*FF;&MOVQ*7I;GK>].PV/;Q!9)I.7M> V7;Y
MVG8WIC4J;J-;\],_?C)+C>:UC?8(=%VAL#J\+JDA"V*6Q)KX<<@)94E \C37
M)(VSF/$D4?'F) 7)0(M(8TFB),*>]1&%9R3'0HI<9CY727[M)(5?ZWJ%7=4^
MZ*$G8E^-N-.#[,-M>LVC!]4B!^JPPT[8J]HV.313=K9V1H7/L.UN49M&VV9L
MD$71?_QT]HS'\[Q394B?=[$!G"ZSLAS)SE;%5C#-),FFF:SI=FFN#WF3&4(S
M9FIVLN-:'_5#[+*<4JDSGN:$A;Y/:*Y\PA(9$\EC'_Y?AU&P,7?P+OS#V#E#
MX^;#'/XHM=[3F!7_[*!:<K==^[>UFUR8<[=-3+>BGIE'>KZZ &5^RS32;AB8
MO&:%9SS\S2U9[]DAF7/-(AV@?,,ATS*FA,M0$C"K.6=^&H;9AI![6$O63X,>
MN3^;>3A_E$NUW@9\5Z=6LY5BOE+R?'G;_?^_X-0:O.[T&?6#6YMI%*89*XK-
M8;OPLN]>W4]*:(?4=N,2,+%_V!B_&:^P8UKANM V8IJU.F7=2>S;-(*]X=)>
MIN5W)(U@:726AS?T9PW/;FSS>M,*T<-;R89G<?;P;= X'_PGW6=GVAN2,!XG
MVK6O=H1[(\I[>[MV4=[/.'& W;80Z44E!;WX)I:'BS5V'@X*/3L;YA :6#XR
MM XA<NFHY452R\^C(4B.5EYL4<*A5"[=";[_Q>8K5EUYH1T&28^RNNFY4S-?
M3![9B[[E1YC$&T5!I'TB!,/YNX*13,4Q"8(LDT$FDB#>'"H:Y;GT>4XB%FM"
M<QX0GBA.8C\(,\XH3T)U:$,%Z21)=L]Z<Q1PF$S_!)F:J]#=(W?+>,13/V,D
MB-.,4,$5R?- D# .5 2?^7$>/QIW>\[)EG%P1EU5[S[<:GM6H&>%E%/U_(SE
M;@HTQF:I4YZ/2<XXY?GAXB6G+,_\5) D88I0I33)04P0)7B4Y#+)1+P1TL_]
M(&%:2!))"<_((""YIIIDFD6Y'V62T_30E.=PDON)DR9.>3[T*W7*\SX+,X+
M9S3,"1-)0B@+4\)UEA$="9V(D-&4Z4?C;L^I/*>I4YZ=]WE?Q(6YV)'1G>.C
MY#O/+69<3YP3Z(FSPWG->*Q !2>AT;]I'I L!;D3^/!!F&092S;<.T$H.),R
M("#4!*$!S0C\*B9A$,I8^)S[+#@T_3N>1,EIMK5Q.KK3T8](5NZ= T:<QUP'
MC.@<U'.JLX!PS@+"HH!G2>;'L=K(U]X;!WQ.'3U,S@*GHQ^@@_NH>>E)'OHE
M=N1Z1OW[I!IQ42&E5#HA?I0PD#_2)SG/(Y+F\.\DS53JYQL^(I'$DJ6,9+&?
M$9HG$<F5T"14(=<:=/J0QX>F@0?A)(\RUZ_+\=#[)?Z>%@!.[=!W:%2U]5-X
M]#"._TB%;/NM4?45RZFD"8FS)"0T2D/" C\F(O:3P)=A$$?!/FI4WY6S6;$T
MY8CG<_FNQ$+3"S47(&>P=_&TK%>5VE68^MQV]=[;M.RZ[_C,&P#*%.^/0'7'
MIE//56'[Z,UK?@,;>5ZKOF_*=LC<J7_=RRQ'_CPJ/*[';6F^LJHH5[4W;< U
M* E>K"KLAF(:U6PVCF'B7ZL"EVF>K/%G H0-*^:XM +-4"Q7V"2B*A?P^=69
MASL9O  P5E6@05YYE6H6 ]BL%KJ"O7<[TDHAED^PLKDN9\H3#-XV@6>*&8<M
MJK8#Q8+A@8$1U<OZS#N7LD"=$=>?-.UO%(-#=!L8EV3/V)7'5;\3. TV/&'S
M.9YAQO!(<],= S:$KR^OV!1UX FV1E#ULIRKMA^&)<L:-$ES!JSCQH?.O)]Q
M QN@]HHA+ 2^9&JJD/FHX<K$NRB^JKG'%@C1"GLP8'U/67G?0!N'W7GS$D2]
M@K-O+4!?E B?XO^S]Z;+;23)FNBKP.I.WRN9(7ABSPC5V)BI5%4]ZNDNR:K4
M9^S\&HN51!<(L)$ )<[37_?(3.S<*1(DL\U:!0*YQ.+Q^1(>GT-O6L:Z/>UN
MQ@E>NBD*\RDLMF9ZW#%\?8SO/D32#RIR3DI(DIR*1(:LB*$^DXHZ"HZ294'O
MI-<+'W-R7H!/Y2F1+"KB0Y2$9YZ5@QN"RAND'Q\PB@;>@YO#?+Q'S^>X&:=_
M= /:,H+4G[LA?R!.$'MT>5K0XP-+QPGRI"P_&S9B;^S=U]B++D;CE<(%!,9>
MKC2Q27FPXWR,*NA<!?D@A"08%-B@(0&;KWSY$\![[!;0JS?W]-%@G;&EY>\8
M-$-VGW7WP.W<3[9U>*;4(]B=$VC+9/#9S?XLECKHIC*#@\\=<\L.8^)!=N0F
M]&DOTEY>\CENL_:@4;<QO1N6-%[Y]\\?]DSSL#6?P6P['T6TE$\<?+DX ]'
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M5H/2LY!$9H1G!6Y)"H;8;.">0(-F*5$1W.'G58LAXVS(%'],3;8E6\]/E_7
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MTS%(/2:&/G_-TYO?O;JY"T>TC$+*BA'&\+!F3)8XI03 KPM&4>4C.[P81+>
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MW[+:=YJ=CT*Z),XZ'D]#^?0I_Y["]'@"G8Q-5=D/TWI>?TD/6P#PL)?6514
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M(%((05R,B;A42>]]!FS<29*3EE8F!0$V/&=$4FV)X\Z1Z!/ ;\K6IIV@Q-.
M)I=B:%A?1J4/@!\8'/<ZZ)F06C^A%GI57-:>IF0KR4FD6%C<8;XB-9E4083
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MG3\C.#\8J!RD$.WJHJ+(P#,+G2E9U-M^?39HBYM.&M-P=)Y:MV<\G<#'!.\
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M; 3R68((BSDB-8[XIJS#TO^*6XOXWQ&,R=X@+_R^(?PK$>JD^[5B[UV"3MN
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MOG )EX4+$T9)XJ4N]D..;=MU@RA8N_'UPRRFH<=(ZB:"^+:@).9!3!+?<8*
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M?^6/'<_[]?5#LLJ5N2^=[MHP@AUO.#_GBO$[TM*@ZVYL_,RU!1A9?B:(S^*
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M58V+7O8/Z3>B%MM7*'N+P)H6.%0)E&%M\H7?X# Z;5EC79LJXSN)&S)!T*]
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M/+"%U=.GMZ+1HT(;L+18D+H<#"TA &UH &B3  I$/!2>"VPL7C/,PR"E(LI
MI-I^"%HY>L(]VR%! ((U2VP1B.#^T<8;;^]2_7!8,]2A[LYZ>C:;--ATB,%^
M='??H3SE;D180#/B@]Y$:)H(8H<1_),E@#-K?E&6I3:+A4=<EX+FE7!!,%"
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MSO].MU_ZGT$![RX'X'? K5F.<%XG-;J\".E\_U)E_5V>DG52U@TO<7QXXKW
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M.=G2"S[%0&O0J&:R]&YZ(6^LUB?H(Z>VQ.NEG#U>6:!&>L1Q4> EA-(K-CO
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M%$SF1;_NT M_4ZCZXR@ QAN'?N)ZD1^YP7+K>8&K)Q("EVP9%7S@EV&GX?<
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M[35XAATK90MV61T8YY#D((-6!VO/94@<Y7A1!K-@J:NF5'H<'0!9X7'1RZ
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M3M,1<&ATC#P2DP2J1]F-L!IL89@_\'O=.8TT*-0=+%,N YU>VDL0Z.L [2;
M*^H@R%\WSHM* R,:B?P9$?G$=269FDD1IK$_S@I'3T7FO7^L?9*IC:"5S\K6
MT5ED/&=-S92://!H"FC9=Q?Y5$L\4PBXJ6[Y!8<QA?7KMP!MORFT"H),L:-A
MY_MM1P><]?D.[6^$TX*#9,1]+<0UWFQWNSC*!Q4]FJV,";7S+")#C*=72RT3
M\ $2( \F]E!J!96LT:F2)([,541I7U=799O;"8ZAYYVW+^/C,UI\ 5CLVGS^
MK)T>XKJ(=X;']P=F!Q<<^#8;_YU\^=MUO*$05]0GT$]/5\+HXGE8C0(?*ZJ
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M&BB:N9,*_4=8:0\8H0H57DC2U<S8-/^N3BR+91$CC9:GABD'Q\8D!?E!>RH
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M0GJYFF8[L]3?DF:[E:)^B6WZP.HP&$8N^R+"P0-=AJ))D"Y_5N,XPXO["^,
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M7)(A$@M:TUE >&QH"&@DCNY\5(?A:5!7@5*(8"=1 &(OI[P*H=B5,<V[2>/
M>CRD+"*N4"F<!8P#GV9!4]P#20XF.Y$?: \"60-M8M#KH4DAIO!4R^GI9;W<
MO+DG;LZX\I_J.K_7KNEQ%'@O0JO:)D0[4-R0Z%L%BFJBR=!V!H,?WRK;9#='
MO[O]O@V7_JK]<S6>C*QNA3<06&$B;L$(B640+*I>#[0DY!PYK/9QX"#DT[6$
M=K 8+V*LT!VH0J_J7R4UIE@"?)CY::I4OA@:A[R>@J[6C8V#HB6INEMP(JVZ
M^4I+D+5;R:VL=3Z6=^U#C#<E! WOAK0SF:71>W,3AFO!BS%8.CY^$L@%:+$P
M_'?EO==3.;V>W?LQ?P%P.Y#S1+U+U%RB%,UA0($H>NQ_+*?AW?F)/_8#/UV\
MR]]OR*_3TYWW[/[@]$=SU=?P@&-?#-?]O.ZWD7W>'VST\IILPO.UR81-1[QI
MAF%S"$UQ:9E?,,]!-\.K"I&SF.:[S/,6L+BJM%N%O;\#E3\6;[0U9/1Q] 8[
M@,U+QM8!G/&7__A'_Q_/19*&5;\B8)X77[ )VE"QO''\TW]6=1_\?/3#HVGN
M3T>G-D#QA1","X@^*4+R:BKC .:^)K4F4S&6$?UH6^)Z"O]P6/ >18K6L6#5
M/G_@^. 2&*>#OC48;E6EM&VGWL+2$NWF"L] EQL7YA ?;/$ACNY#2UQ=7R*[
MO&$^N4\4PWQR^RH!Y^?6!9>D9XUR[TO2'SE;50UKV;$PIV9._0BG/CVWG(N.
M<NK&C+>..,A;*"%>,S=BAZ%?EPE=P&>)"=6OQZW=9+,9ANS4;I*^(EH6L6[C
MZ$Y9HCG2A\)O5@3[Z)LG\Z".K \6#2$+.,8/_0O'&IZOCJIALCC,N_,-XJD9
M)7:]W[=+XO(\7^<>1?5;:6O]E31F%RE8OH^WKO!NK%R%#ZQ,6ZAF&%@"=N1.
M:1 O3Q36"4:P,/\.-D6S%_-2T)-TI[ZZPS<FYB)?IRY$\9S8H;B-9*#SEFA!
MF#RV/ PR3(R?OO,]?-<,25'.::2SS706%8UEB20;_T6I2I& ;:<2N+D.=:97
MW!C.)?8EAF'!/N#C&&,*5F<TW,;*9%=1J"0N[G>"\*<"PB8.,LES&HBEKT\&
M69>F$6,<1--!U<(C:H$/@)D:'N:4[E4!>ITD58<W!846P0]"):AB^<E4F77I
M-)1+G>ZEX'!,) 5^;U5>C-6=K^YUMGAEHT+> M235 ]6GYS.N@CM2!Y9O:>'
M,*$:2]M@,;CS_;X-S\-\!-2G+/$QSJ^T2"%JY&8BA3VHU- 9H$XVQ]]'O1_Q
M V:YEDQS 2I;;%R_6X\X7#$B8GA=<=MFU,%(CPI;K(U*A##/XB23FE:0<I",
M$D.=?ESE<S+G6V4$.#)"BM3.X\@U3%^3$?Y1L K*# 6BC2@^UL?QU[' (N:\
MPOGK&3$Y[X]Q&$H=S>(5\H5P)B;^&48"L,R?93,#=V!;*,#DK<+L4IV<4V&(
M9;+>:K$:>@1$B9'!69!:]+@>/4_VN4/M?A)',QT/!J='_Q8\O%PP(D]ESQ6N
M:E?%RNLF_]73#\=*A95H/$O $6AEXCNF[6@]8*RJ 7LFV7GBQR %_LYD#+\@
MFL+@PVK0-&&%SB_.J8+F?R@\#4#'RI494L54E2^/BV0F @+"78LNLK-6#-B@
MX]"FT/2RA#^!5Q:O2ASMX^9<P^2P:I@X7,-D_VN8M,PA$8_]--8.,.V#N(ZC
MVUC.]L=%\TI9XX>NA'\.Q2\2A"@H,EIOI!)AS:'U1:R^!.5&G9 8+O.;< @M
MS>EF3^L/)J\9]*>D&K=?33^4%=PC*?OYY#<Y%A_\:#Z5(-3%$;YE!/,#1#52
M]]B$^E<49_$0J0L%$'90:@AB'D6!4'^C)@%+=DA1AQ7JHC>YTK.\[(F\BV*S
M-]1320VDQ(+*M 8"N26,O^HQ29<)E 0]ZH=!S^Z!^AH$E"1&M5YTGC:H^*'X
M853YV1;7929X\QZIW$^H74FDA5)N.BK2*268HE*=6.)('FOM;)[FU5S,#FGW
MQ>*<ZN)HCP H/UU0M98$E>LR'1[&^24+E1CT+(-,.H=O)7@(&!6M#/9^-#ZN
MVCL _-LHPKLP^)',@4F>$N+/?;*(*CKA2HB@]F>O,S-1UQ9];:/I>CXU[%AG
M3]*KSMGJ5]<;COKU_JK7;?%[5-@;]\IHLF34H,LN4T9+IV]EDD2N3[17E&1Z
M  _VK[16AKVP5/]$E&JN%CX;CRY@!%G8C 6[WN_;"'CTU6B6;4QCOT $4]1M
MV?=/*VZ4>3Z:/2!$DYR]1$F1<)?7'0'9$D;A2?Y1: ,PTAZ5/(M: C>K2H=U
M%QPVN9LJ-P>ELQQ73IN@.P@8#Z0>"/$0@#*%:4UE.UQ@K8H=E2?3*86NRJ5I
MU<F&>8GF-@:&HU$TF-+%'&_)86KZLKCZ"!8V$%B3'P9W]\ 18XEJ!;1\6<3=
MJ>9>"!.@0X/6I<5M\4PQLRD?MQIL_YT77]."I6E*'_T@<T78KQU66$@OBT#X
MY!4HZ*0S?7ITMYV05RRL0@@40$0I&& &6D,6JS96C&7&=EB,[3((<MX396FA
M(#:A>85D*GS$E'8@#^HD0S^VZZI &5W)J/WJKJ)M3T$P5YS8KDK*#.@5I(.E
M6<BW:>5E''.E30+I270J4I$(J=-4K:8Z+O"$J?/H],$R"--I4BE>02QU-JNE
M8KM@.=PJ,U8:@WES1"[/2=6-V^\Y(ZKL!,;338:7P*4\()=^Y<JU  T6HC%\
M91E"^;6L']Y% >BK:!!JU['4OGWM$2YLPW4+?=PW>QT1S\$P"FT2)>*_D*]_
M+6=$P%T5$USI"0J#L7UTPVKPZSBWEKSX?ZSQXN\>2"PL7F/W'XB/&$T7>(LI
MX5O37>L7K)4KG]4J%EYARSS$L%*;(@&F:.KSR04Q?NU],;7XDMQHSPL3-3!]
M6>6=#Q74GVCFA^Q3LTKM:(GQQPWW8HDY>GP4U0-\44ZK>3BSVYWO]Y79KWX4
MIWJL;W/!D#5:EFZYG5:)_",4/ZMQ3*YPJG/G7%AH;]%=']$HZD&AN)SIZW6D
MZB^*RG2#)"F)<VEW#5G;2(?76&_,RZU-78+O@3@JHO/TE!:ZF_5\9(UAD':B
M#/] KH)D"K;8H@+20EEM#"*I[<VO  !V?V:+ZZ6X%+..QK%J43R^7DL:&(]"
M:9L_*+M#_N8?1J.^==%W=)S$BLB:<'7\P*/A0*14%G$,U5I#!I2%IKO.^2P?
MA,Z!J8]UB6)3JG4^![R79N$)ZM2T/ELL :>TG<'2KT(JUZ%+ 5*(C&J0$.ZO
M OE:S% MH/.%U6@8WC!W#G=HRW[;RM:+&Y-=<O4_*M>;Y^1\ZS4R]=7\>SF1
MO&RA5':G6&+7MQ$0;YC4R1))ML);C%NM@<>69%W>.:WFI\N,M#\:6L->;S-&
M:D(5U_#3E<&0+\)/39BS9VIBSNMWFQ5N:KAH#2#/Y:&R\L!R6.42@M3Q&9==
MN'2'N:; /)AY</MX<'[MO&,>7.J59T0O9R^A6=>RU]=TMEO/EE6\-5LN[O*W
M8,OGY];9V<5+L>55T>0[8LM5@+PY6RXFAV7?J'FJ^7*):.UAS!P;^^JQL7V.
MC>78V)>]/GC+]B'MVOE3';^[!QCKGZ^Q^R_J%C2)0"5%B"T\':)'*\P%ZZ.)
M7_G=>'ZYH7M4KFXEN*1B%<J2B8A<ZJ "3R]U4*E&&>7E&$ 3:NBI8H/.J>-A
MS>;F.=+C"X6NLJPWH"ZA[_YO31"-COA=!0#SB[[3D6&ERXJ):\(K<KJ)P2OU
M0/HSCMC<_7Y;8^"UY++D\^21.P9#B43B7CT2!F6&3@L :.M" &1_@%:68+@Z
M)K12AKG$J)D\;)V,JX9;T@=7H!8.OL0V3'".JG52(VXQ5>&)F\4Q?E<UVG!5
M1;2-57VMUG&M''BJ9)!.7<T.T("!16F;XNJ/#U\NZ>DI$+,*)L10IE4SL C"
M2\01U44HK"77CUV8+$5["%FE_$Z6%T6)%PP*G@M\E1';PTL'L\3B@6/=1XI,
MQ\JF<!D4^'171@IB D 6XA<(.< '$S5:"T.T7Q,!UL4ZO=9Q:UCH@\J!AP=1
M!?=Q12!4Q8"I$40(<U[ UJG<1!E[?M7MU3,/HHS$I$R*;4ZEDMZ<KY5BTBR-
MG>2!$?=1%GB4C%MU=1090)8 TW5^DI3H5DFE*8[PH0]91]DVA)69O:_:,B[:
M1]>'F$K=M#E0^D:T&I&:^-\K4S^,S=L>@Y=@50W9>^2H**$9?\T[154VK7M%
MO<R6VB<U64O8D9;0EKNWA]<D#]R^C>Z^I0M$I-7BTZ%J&Z$?J@/4-VK;>E6>
M7YEI'=-_'43:9ZVEU B=WIMH+>WCW"RI=B6IVG!#6;E$BO-$.)FLNU-<UQP7
M,W9K < F!!?3NZCA=ZT"Z.-]>ZL7;#F/H AB2L?" 62U.REP%Z6SABNZX\/E
M5-*'<;XR;KAV-5H9MQ)/W'4"YHN\5[_(&_!%WOY?Y.U \JQ.@RY3!'5>O,F#
MQZ#>GW7.[O]2,C[Y%'IO>'_U<MWJ7O.FL_UZRO,VCJ5C2G7=]"]5*2GY((_+
MQ$92@4E0QW07AH_7+96I"HK FY6U!2F:!11V24W"2\24)'<?I(MW7=SN:4/9
MOF,[3G]M0]G^Q<6ZWQW[?#1ZW@"G9VL'>.IO/<"VM;UR7V?2@?/D21\#U9K?
M+N 87FW>^AFWJ/OO?O>O7;NU ^JERIOES?)F]W"S18-M9\ =MI>--5V]I5ZH
M;/5DU)%N8)^-^FN;T#5;2R-[</H2;>G:(+E7M[ICL=U"%L!47X/6/[%*T[^/
MXY_^$S-/7AQJFMYZ@U; C='HU=#(E+TC1*H6^6/,>KJ.TF<590EROV?DHJ-
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M9PB?2$850 Y38VLF]?<MD<UQ1<,?'WEG-E=A0L;M0XB[61P#Y@0+X46 F6A
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M?V]T"5P+JA:P='S\!!3#* ,%S_^NO/>%@6*#B6)> *0(Y#Q1[Q(UE^@XRV%
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MITA\_7)Y]<?OXAH6.0-TSDA[ -!]#EW;$L/!J"=^E>(7[$<N_MN'_\*6/\8
M,4O<9$ %XKP'2M -G/%'7]U&EK@"(H(%A+X4%WVGW]>'X,,2[Q6L(_!!C=/R
M-3]#7&HU9<$<*&ER %--!J"C81L4)>XB<I9H?>H.5#OBF_/H'K@DX2B 8 Y'
MG.LX!OP%N!#$)3A 3T* >,N,=4_;PI^>VA?G:UNT.Z=/;9$^L =/?O=YTSZ]
M,_N;]+-<G4JT+WVGGA!^OB];>TKT^9J>2H[S0OO>B^[AA[+;CJ#P?F_S,+?&
M#9=?W%Q?V2)0XFTXWL<;/1ATRV7%E_LP/Y/'=+[S))D3I@%S:47H'J]H27#7
MQVXS?":G]>1T77&=,$F]B:+!536VP$]T56(8G<*0'\&E-#A]F[?+6'RHQWI0
MVVVA!WAO"(2)_]"HH6/$SUC<T6,]J.V^>K>OIY3-:8\5MS+\ZIN,?1CIR@0G
M_OKK%6?%'W2F=%>SXOO6V>G(&@TZEAC/E-OUH]Q[RCVUG;UN.;Q9W:$?7[8Z
MX/X;Z<^I.];KB:M8)8COXBK*XC0/NG1.'Z^,TAK$82.(C2 VY1F+.X;%?"'[
M)*'W40:!3"SQ]?\39Z-^SV$&T1F*Z1B#8"SNZ+$>U';YTI6)GXF_H\3/6-S1
M8SVH[;*E]C*ALQ]KN?6_4Q;WIR+#_@^38<]AM-VAK(XQ$L;BCA[K06V7+3HF
M?B;^CA(_8W%'C_6@MLMAM$^Z>[N:RCB N:]MK+.>J=@2O]D?;4M<3^&?-O6:
M=+C7Y#[%CG&4X,8Q7Q;6$W9Z>QTJR/&]3+F=H]R^W=]KHMU)?&^GU:T;%^80
M'VSQ(8[N0TM<75^BPG73*DV+NWKO%14SO]Y8T[IPK-/S4S[LPZ?;!I]/ES#]
M?QX<V;.;:)=ZRX<H#)6X].0L07WE@WW9*HUEP!H+"['6LJ[G:"RG(\L9[;61
MR1H+:RRLL;REQL*>%ACG3S\(?#D37VSQJ_R2J3:I*T-65UB"M99O/8/HAJ>6
M<\;:2@?(EK65 Z-Z]J_L4EOY3<(&0G%I4]M//[P-%I;NT->R*)P1JRXLSEK+
MQ)Y!@8,+"TB&S_KPR995EP.C>G:T[%)U^<467Z0?JEA\O<<VP)XE?FEG!/$I
MZRXLSUK+Q9Y!@J.A=3I@W:4#9,NZRX%1/;M==AJ.FZKY5(7BJRW^C.) AEX+
MU98S5EM8E+66@;'+A=465EM8;6&7RQNJ+1(@$DMQK8) I7[9X[X-ZLHYJRLL
MPEK+N)X3W')NG5V,^*P/GVQ973DPJF<ORR[5E5_]1(I?HFF81.')=2S35!>9
M:9/6<L%:"TNRUO*OYV@M9U9_Q*TC.T"VK+4<&-6SDV6GE?%D' 7B5SG3\2RB
M3=J*TV-UA458:QG7<TIJ75AGK*YT@6Q973DPJF<GRR[5E<L@$*KHO!*9SBO4
MEL4KF[3 _PD$WER #B'F\$04)L>M4FVXSB^+N_8RN6?5^3T]'UJCX1D?-U-N
M"[;+E+MQH)I]MM<FR0O4^85_Y3A0].<&RW?Z\/EM%:.EQ:R=?)5.+L07!0,F
M\#$18Q4JT*)\&8CH/@15:>K/0;$2@4H2D4YA<<Z/&]QAO=9BA:B<UX;'<KJ/
MIW+D' OQ.72#S(/G3_M4PU4D4PD'A>?A1K-9A&N*W&\BR<9_@;(KTDA$<U0Y
M$]2*8]=/$'U1 88W+N>Q'PAG9(E^KS_D,WR#,^Q7S] Y/;5&HW,^P_TZP\%Q
M]0BI,.%+'B$,+J3K@M$N0U>)>S^=BBB+X4=G)*X#&5KBM\3614C_K_]QWG?.
MWA>#XRK],%,XX9U*4N%EL1_>BJF*\;<D"["H!AJ\?N2)6[! P_PW>@_$N(KO
MP&3& =*I$E?1# "\L,LI84%@8H\W*"3V:IBVA&B>?U>@6J"^GV@['\UL6$\V
M"]][?C(/Y.(=_OI^+CT/8% @E3WR]53&N:*_^"M+4G^RR&>E5T]4Z+T?1]]Q
M^3 "*#*QIV(8Z/N&RLQSM(%28WQ[@#O]NJT& "? 3PO'U%S>*NUS.I$36.<[
M&=S+1?+^'S\MGU .?E+NFF'_'!"_OB'T O!LL"QRD!XJTXS5WQF0I8=\Q7!
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M77VMG&]B8%;9AS%>$@$ R!(%9HV$#4AQ99?P7 *67^++/+H'()$HAQ7-#9O
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MN$Q-^!\ ^S($U3 0ORF5ZK"^@)0H[8?1M%A99[$'4A*7CQ-^!'E,WIR89C:
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MLE(80 X7U :Y%,=G?7%CB]N:/'H(W_GJ4**,T=[ ^Y$A4*C%$F_#T!)QQCX
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MC.?)_>PC74^OZ2Z3R;IY_D>!>YHK578Y;>G"*9#O.IT!'C8O\ZX71\_$P,3
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MB!#.$,X0SMQ?N%:[81#4:  UK?:5L2^D.?4 9P GO#&@@R5F6"(-_E0((GR
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MXZWJCH3&Q\:TH0DSJU"N/39CZ+[R<5$K;;K9C-:GL>F0P2QZ\38_L?@E70I
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M&'\]E.> 7VM\ZF?S%* >Y4S6ZYUP?]OMLK\C[8/5Z\M5WNO28FUR&G%%\5L
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M5S;AAGY)'UYH^$P_Q5&Z3(:(R!?B]U^+7'*E"79')&=(D.,1R7D>D30FCY0
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MB5]T!'>Q>;4K=@U[8PR67#]JD 1O,EN0G#LIV//K']-CX0CO =GJPE<W1J6
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M_%=^1$5\3V")QS8 \GV:I;<LB-E#+'$I\%.#94OXI@0AVIPSW[!RU@( '(
MUL =CB1X<"7[@%\[*&UB?4CDRA5#(;@1C9T CN<,"7($C5#Q%%^YJX9B?2BV
MRZ3L/AY6AV'&UOSL/&?9TX/WY8SKE\&>N465]T#0)4 8(;'G2-KNZC8FBUS
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MF<X\B\[IBI^1Y;I%1F*>5?8VW^E\Y.&V!I8% 97+1PHVBXB@72U0Y2:XV8*
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MT=>2Q<&)$M;-G9Y/KIL5G (O;X,IXUZT&7H@]4!*)K\*5L3A.6)7]K(:*P9
MHDM:#^?5*EZ)<R61@$C\S..?L(SZ4CD7KOJ]A:QH0WJ1,$]R5GDY>/IY@CFA
MDKM=E[>S85">#;V\EQ)?LL3H',E4F642@FR=7)[<#DACT;/JJ'@UH^)*/2DK
M)I N"![@PDEC7ON2/'1/UP%*6ZN9E<)N/9OXT)65K)W$=Q(&X3)FEPB"H$Y5
MHYL<)Y:%'JM"B<D+ES"7MP$RN-KS[ ],S;97@C!1; GG2P3CXJ(SVM9G?UQJ
M=[\I8';4>(X&(R&5W47__/[M^_<?^)DO0W+_3?,<J9?CF/SA_='[]_A_/ "^
MU_Y,R3F=HV66?/?AB*"=7'@URI]^Q-#.M4#L"C?_AF/'>6!X9^$^+WA^__W1
MQS_\>/3C'_^ SWS\[NC#QQ^./OZP/\^ISU*MEQ(I'4E8'<NYLTD"]VH^"Q#_
M(L,<?F%!RE_"A<@Y'U1W"B+1Y@4#54.9O  +?A3Q.ZA5##9K4H::@!KM/ KF
MEUQ NR!SU@2LG*B]9](^\BKL%LLX]/DZ$SFD8"6LANH,MM#J;/Z%R&15M YN
MQSRYM:W:'H"MBG^54;"[E(,Y*!AYSB)D]@_:@02](H<5,8<F+T)8[GV1J/IP
M"+VO[AVU<V!]H[C,6!2DPHMP&7Q!M)%A96450=P'%$EGJ CFY"F!@HXKE#0L
M:&JOC#T;B%)<,F$=C!!AN?\EPX0D>3"RE-)B6P2R[,*':$G)Z3)(YEX(J!\7
MD7^^/PJQBHX4] C"B%R +L))'H(8==@]+F5I#\$>LL[ZE,C"C!BW\81F! WW
MD_$PA-NZ=!X_HH1Z-2Z[P6C,"Z(<(/8\8X/%4!3)&DD27](\ #'"B@2"&CD_
M' FJ!N&&N;!V"87]^B3S@S1F VJZ20K6*[D-Z&GIWN6@N^T^?Q%D_QF"*:[X
M!Q$6*-:U8WV/&H)\K=@?E<("%.9UYQY=E"@6Z41Y/H_UV/VQQJTY)D;'EA=V
M]UBD6#E+CB]R3P>G^I?R1@]  /WVA#8^G!*9&FQQ#G"KU]?B)X\KGD&Z@;48
M,S0[7&%%T+W<O,VK#<!-5Y(7KCC@)A =@X+?@8I=V9P(<""*!?C^D(D 'KTZ
M>&DK9WQYGK?FF%3GV+H!JJ'"R[YE*(KJ-9(>>2,I6M]H#$FB;S:82I]@V39^
M8W!1DJ:C'H_ O2DP 2R7*#I2.$ %QY$+$@T=@*WZW4> 0&$7J"Y@?+!G?,C9
M_O7-JBB#2)-O&Y*H93!!$Q+(I2=[GA-SD\5E1()2'>&*&*-F1@ZL_->>\^FP
M$*!Q$4=/ 3WCGR"R$ N\4(J"=F8O3 ;&!6_M"'H4F5>D@:Q%/#0<8'/9&Y)"
M=Y3G0033\@Y9QKJS-Q3*Y*W$0Q;Y^E5,B(P,=Q8J9E'B<H7%5K'M1L.E7 6C
M3\'\+ [YYS%3^5,EV7,_K9G#+V=*YCI7492AO,1S;Z[M"'$GXZ",Z[G\)6X8
M&5Y9# 5'-^>LFW$HAPV6AB"G;/NT@MH+E&)M&$/;EZ H@KO!N>T^D<6@3*7P
M%B1HNX+47;SQ0@#_CY+ EY8A(U%E4!Z,">(07%90MQU,9EXRN=*@$)8D2DI4
M7<0!&A6H4MZK?IXLAR)Q136,;CWVF\2V!W2(ZW ^?&N3I G0)@HX'ZCS/>+Z
M[)"D"OL(Y.:$,BS95A19FX36C7DG(=^K(9FFWB<R#!RHA[_(B2_?CI!;OGVR
M[=M7&I/5!7H7)+\!_/OG:$Y9Z@41!"*9U161!5Z7,YU)W97#[N%F0U9EUD 9
MX4I<(NY<";0A8KE,1:V<3@)J'KN1*1^KR)3XS\\T =L$YOHEMY2!,]=[,K$Q
M[0D$BC^([):H9I(<D:)GOXOAU)?53[)DNAR1-Q[?+R N!4A;\^2($NJ0U^Z%
M\O#$A/K@,8/AP&@ =(W%;*@?3G+)*S7.-3X2!4-QLEPQWHZXN3].B*FN(CI]
MX7C-.1RBE/J*W6%&'80GUR?%:Z'%@R[2K>GO&A.7$?*6)*Z$S'=#09 WE4JZ
M=K<KD6X$T49&%(B+ ES'[KXSM-]R)<K^ ATW^MO0?M=4=\3.2U3\0X)7OX(-
M+DJ"^9"L7FLHZGGO1*KP[V9<2QO6TQ-#= M^]JC1>!:)TS)\4,\Q=P&0?A4E
M*<,-Y]*;TT%61%$_+:=W1("BH^@04Z*4\\#Y15>K6;[F$S8/UN!%<B+3A<<@
M^ALN\+A2S>C!BBHH,^(E/LIU8/<>!L,RELR_-!5%GG)!1PI1.EO"EG,5;16H
MA.U$[$IA&+] 3+/U\"W1%[[[D+JJG7F'2-ZCD<.[+(Y=R6F8#\MS/@2>(FQ;
M],\1$_!M_T#Y9)ABPD>$H:/LCB99"%HW LJ)U#>19\*?OHT3A'W;5R'4F>-2
M4.SAP!8=('D')-">S+Z3^370*._%USE69;52C@JC(1B=H<S27([(!A(1U[;'
M0L22E/SIRLM=V'H CBA)3WF'^& ,+9Y9CJK($^+7.3<!0I3PBZ%@:#ERR*;L
M\KUH""/03( "E8K++!D=KLBEO(/&.;6>%P+1MS=Q%)?S0PRX;T3,LHS6?B/M
M M]:#?2U))06BBZ$TDGG:3P7N81.$H7-RACV%L]N0J?WY8S?-X)4+Q'*.0?B
M%3RE3T$$>>>#,?^^D#GR(7.-$1BO)"?^^G%6>+38W55M22PG%"05]$M55TG!
M@2 +S.8_2$%+%\J:.143R:\+.+G6KY5YGIV"/QV(R%ZD"^8HL^[0V8T)4U\,
M6-F*K5<2O66PGPE[97H2^6!QQ*CS@9.CZ!ZA\3)%0WA.V^$\&9>ODA.)Q,O2
M60^"C*,GL *!B>F!-SB/5UZP+S@!$#O&3,9SM"D!0?*K(&D_G-.()%43654<
M^Z:^-=<! Q5(?+*"8G__& Q\H9,5?B2-<)X:H2E]:WTU4E>KT:#TX;;@1WP>
MUR'-QT GCQ@M7&@_F]L,HK0QS:723'M)ZP#OZ0*K6/X<AQF_';+-91#2O=W\
M@A;)B1%!;?+=KZGJZ4J&W&^4/29863F]>(:\@8$'<T&."'H.#V/8D^_I'#+*
MH?#XLQ>$X"6_C-F]%YJ!Z$:?3\'CB.1<COFU]QCXD%\%(K=#KX)-P9LPN,N"
M)R!XT87\QL(7=/'I2 GP G0WX_?>68Z8T6!^'[CXV[+_CTA_KX5P03A\<\8;
MN7*&JDX1%AG-APPJU$%J%:ZL!874AI D4.\XC?E>J;YV 24>B,Q[2.K*H9;Y
MZC96>EOC@=*6N+BMR=WAK>)7!I_BC8'O W+IU,<A@+76NK.OU)T"/; S;G]4
MCY_=,=R.ZG>!U6<J)D4$X5Y%PJ.%)3<G$.4C0X.#2'H$'14#G<!@;@5(\U%Z
M$ZAB+0X ;G@':)+>>H%_0_<_I 45 F1TD#<9G(N>8?403+LRFLD(.2<7F4&"
MEMVW4MHUIV75S'P:1Q$]\;U5\NGT9!890*Q B@1)'I%/;T_?GMCU")B1(&SL
M/.$TW02)FI&DXKMQ.!WYGJ=5-I!5%(;=K001?N2G(C8>-;4TAGQ%MX9C<Y(U
M58+XW__TKQ\__/'?5+G2-SZ_T<^Y(F+=YG_I!0PC1V6)V:@<!._!W=6?17>@
M%X*CG3_ +T%,_<G/KR"Y#B)ZE=+5ON<]]$&5Z)'!7G"5UE,#5$\()(,KYOB4
MWAN"W2&_0H<(]LA^"8$QQZ^TFA!UL8I#>,0/2@"NYLOJF6O]2DLI1ER-K!,8
MBMOL,0SFGU,Y/-#/"#3"P9Z+G)(S=X5Y4<H7 4G.^LZ6%XC;WN-NXI3^XC&\
MB<Z8R-<S5C4/H'UK*N$08'I$%%L2,YG?.(*ASMG8-%GM)(PORJU7=WM1HP,P
M66LNP=)+MDOM!5:+G0W.!96*#F2#4E\I.OEN^F$"JJ/HFJXZ%MOF[V582^C[
MX&0B"Q@#3 N!%:<20Y[%6/D9'L. "+RQ'2ESLN"=NX6E?P\V&M_(M1F)DC6^
M4(*L72W&C!!R\8O.WVJ==Z/ F!&BE(JD2?+1KO+EA1!&?[^D-+T3_O/":+O_
MEE[5Q@07D@";W$]?U-*UG+9M24BE/$OAD#R1]#73MYM:?C8%+=DY2M*>T]0+
M[,$6=MTVAVI>@B[)"1\1[2;M4(LR+E\I,JLBY$@R-K@4(.!3]QD-B1_I[WW!
M@->B]JARJS@*RK8T%#O[H!I&X4#%U]=\#J^#SE8W63]Z60*(O7N0T7P0(,4>
M@U3XI"^#B.^?0Q-!2H4)0@CTRW-A17Q<P9 L%,=#ECYL$IQ\Y8*WEJ3H._/V
M;=_T"3IY1]<0I1<]%;>.V0*S1:XBKJRO9/0%5^9% %DB&H"&+RD,#ND29$C>
MDR-2!ML6N2M:=X@'_2&B0_^2D*)+1/7)I:E]]($L66/D:#+5'?LA*U@K2JQ?
M0$L3N1KPV]X!*AI% H2.5*J+^&.\_'J#PI9!EG6)^9+7Q'41Q0X;X*VTRA7A
M06B^'!R8K^B2@K"TC#H)T#<HVA:8Q=CR5=$>P#4S'W0;KP&S0**.;ME&! H[
M9#D((:K(&R$@;ZRY)(F0Y-&%)"W1B#9B#P](G/+F799I7HJG? -^%_*#H^I<
M]_S220WDOTDU-"?G.,I^6.5TD3OEJ%3Z@.[J.Z^3[57:%V\]EFX>F!<E'B;C
M)*<;_9N3+\&^K[>RI"(=E8T']!P4-[(E6CF"7)-OZ@&9PJ$&2:-?UG3.?WV(
MX2,-B V_RQVV1A)8+'@S,==#B@"Q5#^+N$G-NRR>*#S/(SC>#VJNFKSWNL?>
M:1%>K>#@0WSB^VCZ\T*(3[V*9-RLC%VXPAB!?=V-!1]8204G#-8%O[EDEL=S
MD"LG,0G6!Z 4JJ,5JR[%7^11&GP@YA"-B7LH>0G2I;!663?/=>-2"3/T+>6C
M@\EHD:]"D V P+2C=RG#?,X<-YX\ CI/"'%RECL<H=#<X'Q%HU(!,9.5:P&(
M5$@,@4[Y6*A\=PA_RO1QA":/LI<.])_B:(K\.YH&(HK26&I903)?' XU!XOR
MZ9/]_?L/;W[[%H%!['HI!'38;#%[B3C[9; >ZH@0! %H+2=I-XICN C*B533
M]8GWO 8%#N]8MKOO[DIZDPTILCB"HG!$1)=_KT-?,BHB!5B1(KONJ!H8B3 L
MVFC"Q[8&+F'IW^Y@< ;6[>3CG*18GE/+$; >8#^P]^4$FUH1;"_8&YI"TL4M
MBY\#G_JGF\\)A.+FN8E%:N*0VS78L>>0V[&6?.#]?I,E&+'\+2F0"3UGF9#V
M! \+F3&?Y5:7^;.2V67VIR@@&_"+YX*O+[[CY#6LT8_*.5_O&[M6+2!<,-FJ
ME!W8CARU(Z':8C3)"NI$D7<2G6=1RM)6- %1 0CI7*XMD1=P$?GG7KJO"JMH
M*:QM3HV<6X3U,-;_$K*:8R'RXVV 8Z#Q:+;J'!C4\PD<R[W08(9:[/O#P3B-
ML[$I>9OWUJE'NCY+;V@\75.2H@-3C"C)21/JL?F2S]PY?:9AC$B.:&;S@Q2L
M,!HPH-C$AA9<E1QQ!OV"I["[":9E ,HULK5<?=7^..1V-RD_U"G5>!&-60F.
M49X=ARY^V3>[WQIP'0YT'H19NH<#IR-,2Y(=*5!K3Z'"3GD.1)"N<"W?KC3B
M?8LW7IAN]"(6O"N T#A4GY.4*P5*(BXGX#):WD3-2:4V2RE-N?0(S!I2/11I
M2GN?%(EO:FI6K-]=MDI(Y;8,J!*FUP(89#2JJ:NE@V9A1;(2,T<[H$7QPSTE
M/V"1J_MG80O$G73N4LP&'[)IK_F!B+%69@LY.S*9^(CP.Q6< FXN44:%X=H\
M2ZOB8#41N K8%TI4H/*2)=^E$QG4Q0^"6T87&8!U*I26AUA/7(@C5.R&UAZ3
M;!52"Y[D:T:/!>LB! @0^55F@QXD9+D4F:-14;8/-1J*']P$<HX%IL]#7$[S
MX(.!;+^*L2A90X8N#[>%:6^\U3 4KJT:NT#1&2*7*6'*=3=J)'(&*:=#L^4?
M_B7@ASE?*YM!4Z4!P.4$!9S>R<_.9LRJH/HTMDEK==>YAKI^873KL=_4WI+7
M1QSNWY;4(8#^MV)+S1D<F&1A+Z'<(!J9EZYR<U!2KD'*?._/JY?:SU<?&%2C
M1<]/)G!)Z].AQ"8-'L9^04@:D*"S6GA;6NSUP&B!-F7=*9"/!1'+MT8'ZKE
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M#T.$L*'WCE[[D.N*LX5*WIRQN^!IF>ZM?U0W:* .3JD\1S-FA &'/)G3LNG
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MGII$=E!+45I!9@NP:%^&\4LRN)*B) D[*)K)D:K#% -XHQE=@OKX3(5]0+@
M3.6^:.2E363<%!@[XE;MCX7, (AL]6I\0U.N&LXI]0&H#U.L+UF\ F<]%)XY
M#[B"QY<LUR:#Z&F@'@65D]:269[031:<'0DD/^(C0[Z@!4>[^I!5X>4:!J$5
M$Z*X$&!#%!\B&!'%Z7!EKM;)RF<;)[FD(ZL9MRJLAMQ6A^UFQ-4SV\;YJT<%
MM+N6K8@JUW %?:X!I\Z)Z\>*F*5TQ#ZR.@-F.<G29<R"=%AM&LV;D!-T5I/&
ME"SZ)-4)9+U(@9:G6LJ%/8G\6V$?Q#]GB\L@XCM;X(7Y!6WH34_G#8B(&G>\
MX.K\X3*8]X 477!X+1QEJ$KP_%X2H%E6YV8_!ZC!Q&[F,MSJ3QCS5FQ+[G)"
ME^#AQHN")\V5#"SF$L$J#:5I8F!:6@OZXR%(4P5"QFAN>-%R84"R12 P3C=*
M.0T!_C,%8!\?X#_Y-\(TE7"^$- .Y?NX1H 0):L"$"@&;R2@)BLDT0#Q(_@=
MR^.,&.5-?$I7:(YYW!"1=T[X=XO@"W^,G^ ^!:Z\._ (&G,L8W@9&N?\X):C
M"L$H2$^9_"8M1$O4?N,RL>D\.)>KEE_C,B\4,.C[NGHE*2)H23CWJ7>^Y+1U
M*H%F.LG+EGALQO"\]Q&K2%4I,5"TY0B*W,%[+\C+"H76J]58%+)B&LKUYR,H
M=$>>4;YQ+-%JDQ!W<0D3>1-'>6WL_:%?\VU/WO/?2.K?(EYFSL )'*P-,<NJ
MC)25*NS/R+Y0*CM/YL'6NVBXD !]1WWTQB28/JE_?Q8GZ4V<_I6F=WF4EDC6
MN(R9_ B>^V# (98[N@JW$:X%T4'E_X(>\4]3LJ$I*3IU)--BT-6N=>SW/<KZ
M(BQ5@2\E5\XY^R-9<%S4^K ^? )8=!ZGZ>DIBU^BL[7WZ7ZX80<IDM.W!(GR
MQ7)[<D0^O;VWC.EJ1(ZP0P1E>_OU &2IJ!#C3(LR=R>SA79H\_NN@CS@N_IL
MH<S@\ XF5S)L:-!FKRS^U8@QN XK8 P\ ;"DFF2/+V'B L?.]=A4UD+.>:_Q
M$6/SU:R;L+QD$&.D5* 0=,(<H0.\+5"B4 T)LN;W)QE\YR3(X[$[R..Q(<CC
M9W$$1CY<L.;\UX<8/M**(U1B/^XHV)!QC",T%W)5!N!Z35PVAD;?"&&$J4J*
M YXA^+A4J:(F-"<7BVAR$1#L=0;WBN1A^8#.M0$%HU 1U?-<S!?5Y@L^QDUW
M0[EFY0 [-$='>Z;:N!N.NZ\ Y46 $S('Q:, 9+,/N6U/U'!+RF=:>H<+'DY2
M+!*6_NV3]P6*_PRZ^DD:UIVL@_NKKS5)R.J)+)+ 9B\1Y[L,UG(Q2P2D@?<1
MF6"6$\]?%4G^< 23J^CK$:@F#S#.I0JE5,R!5,VUZ_E!&(AM]I0^!=%?^2DR
M--0D1P#B.UA"YCHW.+HD._((_/#8LAQS8E-VN60UU".0N<2%%&P(\B' Z'!%
M+H5/S:Y+$RPGE=]+<*+M+NJKE?=X&L1K?N%;><//@:OC3][CU#NL]"W>59*3
M<A/49*#W54VZ)(6U76"K\/-5M.87_FN(O_[.6"%K0?2((%GRG?MRUL.E*J4?
M"3'LUS+]GTP6KGF(&PJ;UBM]=^"(3X)4&:Z%N5FS->.@#,%O/+F].CNJUZ5U
M W^.=+A .)\DU:WWC@ =IS:,H;D1_+T-7<D; ":T8V1<=GA(-YRSO446_HET
MB,Q/?,JX@NK/HKSB/7_@)@8OC?@3 ]P0"L+ _IHS07. SD;"3;C;:5V/AKXD
MBB')JT!%)115HGH"Y;B+03NI#IJ(/K0\='AQR"OOR9>?WTA3^A2SS3YYF94K
M1$Z[*,(WE]3M:A5&A5+FDUP8190HJI;39\V+5+*P-,LU0MV\.]X7%H#]5,+#
ME3_0@>)P0]^&#9Z'&9B*+[X(%!@HF2IJJ1HN-UATC(A'8.>K?%B!VA,N\!KP
M93QE1;^)ZK@H]BJZ_ON>B%+92S$V6/>^KASBD<1RSJ<!'K ]?#_1B*OT(1^D
M$Q_*M$/T.5B-9:C/("U&TD:QRM15J5]GRHP5,?6M2)?5*[&P+1H_?&&AB$J=
MXG8@\PJBIRNH.#PP^T+2)SD#E#%G09"'P_0*:_*6+LC9>AVB%@%8)AH^5R1'
M(RB-QB(?#2P@XP1U?BBRP&7,%C1(^8TNAQF>@/=8ZY7#ZHPC#F5MM+@DZ*9\
MHQYFS=^D^W257C 6L[.8038L%_ R]/9- ,[CK6N2L@BR(04?\BMPLH_E(M_G
MV>(D2@,_"#/8I^_S1(L+0"KR16:P ,24^5H7'@-G>J+"F0=#'FH;B]X54O2%
MJ,Z()&*M.]!(=:@(\AX#(G'TX6P"4URKHNKAAN1CJR741''*-QDYON!>6%)^
MZ0KG69B/,#;CWT+0%;J=\A!SFZ_C&90^Y'?1 2#H9UCGD-.PCG,^I+.EV PG
M/<ZO$30%9>"6Q<\!G_[3#8"A746YA^LD/\B'WI]H*A0JQ0J.PC<(!!=$WVIU
M30J.+F]3UH=A"]9\@3 MN)WE:00.[DTM$8S;88M[65A[QW/61W!B.LL8 9R&
MQ%<NQ,:0S?HH3>1UN%+W"7!NB-EU#H/*?U&?2<47@*/8,Y9(QNI27I@@"*Y)
M*%CX/?_B0N7Y*,[".B!Y<T4 N']% U,"U\"$7D^2L[KD^95J#CO1$RVM>2T>
M%2*1_),%[Q^@$.;1CX,2O'.F6SM>_/^S]^;-D>-6ONA78<R=>,^.4+>[JNVQ
M_>Z[?Z2VMCPJI4)+=\SX#P>51"HYS2337*3*_O07!PL)D  ))A<@E17CZ:I*
M8CL'V\%9?J?JF'@J!9X/77L9("#Z4^?"G9<ED8H;TD$H]$F\T? &(-P@>)"3
M9P:>EQNU2W'P&IG<FX/C0XFX4,OU;1*_@G_V)7H9I 2^ES"AQ L#>O@.NO"@
MCYGL^^,3&_6C\_@(K %S"%3*. ^3^Q>L\,8J2.)'$8D<_SU"#&UF(0"2CP:!
M3J,AKV*NJQ+&X8D#.?/*H= [7AA, Q_^K [H<D7/@7,_FA(FS0U>/N9^FD_*
M3>*3&9\ 0R4WJTE8.8_;E27V1=-Q[L.Q3 _SX@OL"VPDB3"T>@[97-VVW9FV
MRL@T&INNCXPNN[9JBKU*D@TLUPN\S0($4'C7!?R%1_$.Q=<ES8.$Z=,./+SS
MOEN3+LKHZ8D1=4>FD&N0*67+M<<:!F _CS9=QD ?%6%2J(?)O$V]VVK1N9Q>
M&CXN/(K!N7$UY-QLQ#Q7Y+-$,5*(-.EOII-T4AY$AY-_U'2WAF?S!$HBR2]3
MDDPC$3DP#T'JPJ4V?H9 #AHE]D9(%Q7&ZR3=4M$'A"T6B@Y!7&P(3/.S8X.@
MV4^W9!C3GM0C\X"M;MXJ4_/Q=FE6VUEBJ4:F2XHS?;R_M^2(,S!1A &2%O'I
M*IT29[.^CDNOY 9!B&Y&>,R&^@4+<,S--)>GZ @$U'?-3"@T&E-^Z1PYET=#
MY1KJDD?#B&QH\VBPX0GZP++_X+>BD/N'G684AGIHJJ1Z7J'RC6\/>'L"JHU2
M*EW,8;HO?22'1+E5CI8S!;(-&[4<H#CWT$LG1O6=3*VCU-V7G2![,K+!/J!=
MT@GM](P?IGNK'IYS,4?GT<DLQ3NJ3F5=32I10P8'?(]0;(N?PC<4W\0\+N@Z
M25G(YHJ MP]-M2OUY;U"9^"6BGA8%4FA2X,S?=;CM,^D28EG&T FFG0"R'UE
M+!EDR^41J:RGXZ59QB(3">>3'*AFV<8&%^,<Q T.7G+TF9)EQ9;^-LY)*.SS
MEE 1YD)3P@WRX7C">!PY(^=CH1R[M-U"JB;,QO>ZQLD7>$2R,I]'_NK7[_#@
M<2L9/U@A502(L-LDP%S)DS*1!*()OB!4_&U*MTTY)"6#Y,<,]'E5'*I%%R)1
M,I(!F8:TDB:/@@YE&H,9B>$K'6R<"%504! RRW$"]CP0^_)@_V':_)G@&$]Z
M."NQ"/9G+*TX0&D<*[&B38!H][V(!%9SM(%)K[@'Q+J1/:' UIB^A#F]D<H'
M\SW-5S/,,%YVJ4B(0^R05<?"&YJERCEB9M3?TYP+2^8(EW-'. *D(?0HJ%'N
M/PH7FJ:"P]?$Y'Z@ICL?H.Z>WI,AI_GG'S[_Z<C).>CP/B.(A1[N;@;OH+0
MPW6RQB,D0$S7"&4719H.<I."1CVQ50^:/?-8P\=%EK@D.6T1/L69I\AJ!>G.
M)LS0VU CW6*)DX3T#U> 05,4JF ^+=C!P]=HPF:@@=P%9,N2=Z[H,2? 4NUA
M=1"ON@/2_]0N =(9?>]*OG%DS46\0Q(U@Z@B+$;3!0',0']Y4@+=I!?)CU*"
MW=I[94]39GN:@6H9 O* *9^4]NEDG(45&69LHOB%9TT\'9$6Z9:S\>IH:HQ
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M_3?'O)K:VV >AK"=)D$R5+[:A!$ 4P.PPH01I%?Z[PIF;0YO[KD8(H6TRXS
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MGHMZ9+JD@$N82S5MDR:&3=Y0.@K()C3D[$@C89 S>FEPF [NL NOV#"'.;W
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MC4F2#(VJFRH[N;FH3Q$1SMA@8"S9H"P[';Z!-I+KS$"\#'()OGM-5[5)URP
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M(IK&(3+J3]]Q$/:&TI=$AITN]>:EW9NU[9&0G>EU29":M);X] $_L])PE:.
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M0;R[N4*.QR>52ZQ"/#'OA#SZRV[LQ0F/3[0R"%BDW!<IGP-P2GRA_2V) CS
MY7N,_[L)=_R"A8R1E;/>&O_(+?<CX8;MI.?<A@[#2_@X(&L\&0C-("FZ\,%@
M2@O^M)O!"L/8+N&,DA_SK'NO[+\4B6C^4='[DS"*C^+C\4D%>C;2JIJ46<L8
M/85;CA?*Q).!NPH"&7+<: D7RB(,I]T>HU#"ECM0 (V5X*VL.?<)D.S6FGF8
M'$X7_*M ZH;LOF%<BL(<ZF*H3R-QX=SA]DD*7[QY*AR4$C)E8EOVV!2R=4<H
M@W8]VK#PNBF1.:9U01B;L(;K;=>\S:+0(R%-0U2<-&K+W;%*<AX9,(LGQ%P/
M #0OK6*G)HLL+,DH!=H1DK0-<109(T';3)X6UEFF>REH>9B15U-]2!)7Q4'-
MQ4D9+?G"3],]/G &6;3JFMZ9LDF-1T=#;5TF\CDJ*NKII&:D8I>B%<VPCO\>
M(6(3B@-,1YJ'OQT&NB)0([9_YI4]T%-*Z&,F9?L4Y$;]*#U&$F64]:I]0IP_
M W$0&,==5SY]?GD*\X-O3E(77K&?/O_NY?>E0XS+(Y?\>^8=ONSS\N1_?4!8
MMEZ%$5T Q%D%+RYP58G*,@<'+UVMUVA%[EIFT )4<I*!7.[VC'K)D.5'NA;*
M0Y*]:=TQ9N*))+80<D-*9$Z)9%&V:Q3@IT?DO: 8K</IW35 K4/!V"X+B.Z]
M)PFJB %"[6$PY/J@L4L,_*W$@E.Z7%3"V1G3.ETGZ1J%>9&BF6Z7Z7D3C<J6
MX^>'63P?@;5'--G\#A,SK=Y!U-96ME,L5Q,9$7,??&JRQ9L?1L0 DBS7ZPSE
MUP5,"3XIX$=Z;(SJ?R<@[.*Q>"L8C+=FH_%\/AP"QDL&Y*W)B."X(1_HZ3.?
MT]Z\O&,[2[8*"!9YX!D9A,='X97#()"\E&=T)!X;"KN6/BC+))>,Y2U=4FQ%
MF2^H,\&X,"FC;L.<H0 ^HCRG.,%44"!>;C0@DFA+[OTTWQ/X#'@:AS&I-# ;
M7-5GF6^CO,+SJI?)%=KS<X&K&LJ./8$7M&N/]>U!YTQC1;KGZ"K""";//C<_
MAVKGML"IK.(42^CB,TZM@5,)X=2.<$J]EB9'DSK8JY29%J^VNRC9(P311JLT
M)-ZE=KUVN<V3C\P3A^:VI^[(/-6[B:,H? WA#%\) YS>S15?:@F)%T3Q:G_I
M;_%H,K8I!V,;/<D;AV^TXR.J5.V"Q%*U?.:QMOEA>S8#2-6D46ZW/)ZM&=0T
MK90Z2?":]3"UZ6+2+$:?D7OZ+HG+UP\5=5G^ID,36S=#ZIEJYG<LB=/O_[_C
M)"P2:1);+SW,60>_GS%G-Y:PB"T_32 T)#C?/^-K[R:^B=]0!F-;@,J0(I,,
M(QN$3>JWP+H"2>%WT!N>W]][98=>U>.'8D/#PX&X,5!1,RR)]\M^)CV.[@HX
M=K!HC:6>U69P\F?2&A&0:7O3WA #!\_7(QTTO']H.RZ/6=(&U+D]O:91T+G_
M'=\Q61 2X_R@*[EN9! ;GLV]?V32Y#T>A>LDC4-_<B+0*VS&![0#6R&#$]G3
M_PYV>Z=M>V7C9Q1-9._]@_TY@[O[I(3*>J0:M9.#B,E)TL&2O%JE!0IX)!"^
M",9 *6K);D]MZ+173^A6 \\TD[5G)L9$H_#D@S!#@I%CQ*]P[1".9YY.<.I$
MJCK4G2&X3W6L'4LP2(/=ZV:F@P@N L3= WHM\")(TCW1C362)S^#*? V7)$W
M4APLB6JL?(P.E#%%U#_8G6DY&&];II6N<G"3B$[B0TP-E!$=%DWD1I6-,^'S
M6&,@6_TBXZH!>%0[J\C(30;AL5$0Q0(=Q_1J!;OLDMVPM(N-I+V%'%C-56<'
M]_H!CR(- =Y!_9V*1^-#?U?]>BVE[ F+<W*KAMTI\F6N+"QT]6?CYUBAI^74
M<3(C$<*7K1A2R!J</2_.($*DEZ2"FDF)>"CB=W__4YJ\YYOK, :_GXLDW8VR
MMFC;'FW<8ZU[T/RT*VQ4FM@RT],RSV(;E2;I#-,2-BD]'%3]ZNLN3,EZ^7L1
MHVM<7D#Y>WK'BVD//PZG$YKW_DCR__[Q^"ECJ[+,,E!UYA%"H65/@C"D/=(/
MLZS86?A0.W%*?J"*'_\#_%@#V;F(YIE3?L"'R7T[+M$ZC,$)(:;@07A8][@M
MYEZ0PC,^)>$%?KH7"PT*26*=>F*#'G1[QCTR4D_J62XYC^OWO)R1Y7[*GI5(
M]+1(?0TW0SAM>4[?PQW"9(^2=2@F\)W:"VY$:EJ=;AM432M!-,^N+X#13T^K
M1_QBC.<]P[8D0P [LC+H?_[#;'[&M%QRI%=^IY%^G;OM)F2,C"P"G/C\YQDD
MFRH"^8N?LV0CHJ^T"&O&(>ZG@)W:EKW7_/%A %Y4C6 N)*H9V,'UVT+8==5K
MS<6>L$'HV1Y:U0R,40:E)Q)WDE;NS.*$^M+MA/I2=T)=<H18@OD#3/J%0M '
MBS=,S2MZ0)":@"2EC(F?2N%'X'UY:+;&$7Q^EQ4T;SGJ,X^/VV,#]\J1>\+0
MB7/ZM]F05C3OXSN?<2XM.;<2. ?.ZF=<?<=1HLBF!W2//?+3;')(#T$=1L/J
MED6>Y?BVPX/MRX(=B6^[B@.%6HS%Y^$U)G2 %QSYTSOW(U!@'!^QC[F?YN;D
MGJ/7,(Z/E&*%ZE9)YC'1I-#B9I0PFM?02^:C:U2$\H<P^_4Z18@#Y+D)!0^C
M]&"8%=Z@TQ$F4W%:4NWB]KY; T]*6,%T0I[4<[305\[3!@_@'A??8!9,F)V'
M/8%SZ,[;L?XL).89GVJV>53O6]*-Q_NQF(]G?*IKF-8_*JB<5K.5)BN$@@R"
M%'E$O'F&^*'*+]8Y<QDWR1:O3A8_<93YK#SBZD[.&Q+C6H(5U+,T@S=+J3EB
MT:^\>X_T_X%8(P482FLG\Z/V=7.F7CB3,F>1OH0YU9*1RY!?>"PF9ECRIVD3
M,$PQ?K:PA5:IM%.),JSA8R*J=J*)Q)&(T$HF86ZFDUOAGORO%RD*0HHQQ_ 5
M!B2J 4PEVJ GMCA3KIK1J)%B=]4D34V+C/NT7#_'*?[E-0Y_0P$>TCE%9&()
MMTMP0,BOG5-ER%-R]=7?@CV/H$CE18JEZ22*&&K'H3X?TK#@C!0'1C"U^-!
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M6'"M:1PY#A:$P# H4]5J[-N&_:7*K!;T/;Y<@SM,&J+<3_> >/R2!"'*B#>
M)I[CX$;LDWZ!3\$(9?=/&U2@],OE_>82WX:Z&[2EL!/+%XX*198YG9RI2TAG
MFXS'XB4C0*3YU9O22[6UH(LD/.'.=$]L35$GR"#A6"C(P%<,_("6:ZZ9*0,-
M_H:B8)VD8?R&LEP7Z75(.TXP0*.5 [T;!)VN-B OMRQ0\^I.D+M@:<C\Z-X/
M@YN8R8HMD<5M%>P?[]R;Z+S#V^C<E0%W.1#PEUM_UX.RIA,+K8GMUV:EUY=V
M@AA)T];M;> 2"1 4270U*-WY:;X'0"U5X*2JC!.\OT^9PITJ-OQTF1)K*4UF
MR349&JVI04W[1\)#$;_[^Y_2Y#W?7(<Q/,XODG1'G"2Y5ZXB]J5O7?N$LK"C
M]J D!P9;^32R8&)VRDK.!FW'@%%%-T@<:)0$QQ+\]HT##B3QE,!/ABG4IC"3
M#AN1$Y/2"=3=HBHSK>L$H=JX'(WMM:V\$P2)[GEZ;ZQF*?MGLY@9"%\G6<9?
M= ^() + VPAOMNLD%<VK^%A[VJ1)\;KI"$$9M74'F!45&2CX-#>9_-F)A3G]
MJ5J^2V[B'#_RLW UF2?,P8-Q8BI _[-<"]3J]$;*@O87/W]27W0\N2\<6/Z5
M.>("02!D=!,'Z.M_(LF]5%O(/J^)3^(CPG_%RST.L<"2^>D>_+S.BYQ 4#XE
M7_P<-&SDUS;7QM[-V"=_F>XV?GR9%J\E]K2&0FU))[:\$K6=&U(J#>F%'T4H
M.-]S'QA6L"T0X- FG6 +B'$5?KA2X)-*V%^0-]N='Z;T98?WS1O>*W"%^?&>
MONV6[S'>6YMPUWS=FM9T8F8JM),+/]NTH_KHRCI!B#;\1Z^]4Q1V@A19G67D
M[=11Q0FRFJI?,P6Q(W(%OFYN CR<<!W2.*:F9WUG82?F0?9J(+?$<OV<T8A5
M0:%%M8RA'W',ZZNO.1;APY<(W8:9@</$P4W;/_Z_A/@=FB<QXKYD%WCLKTFZ
M;]Y@)N6=F/<J1G=@!FZ#*. Q>G"":4V MW*-,P-IFWK8O+83Q!+P97R/D* [
M$L"/!RKLUDK=F,&3-5-_T@MY8[9O_XRX#M,L)]%C3^_)!?X*"*1/::@RLAM5
M<&(-#%795&X$BASW4^B(6CMT@J4J9^5VH+'V&DX0Q1]L.IV6^-VZ7?P1O=:A
M@ING5&M!)W@NP7U%N& "Z^,-"9NEA/SJ@ 93O^]&:]X)=NEA6UV!834QZ@_P
M!W#H6FE]&?1^2CA!$L]QRJ".U/?874*\(!%%L,Y(9EGQ.T"QWR7Y?Z'\H<Q-
M1-[P['93L6:6CAUY=3^@UQ"N\CB'RT3]V);+.+$V@-/X-0AZV'4CCKA-&C*J
MZ 2)++7O/?B1Z47^9BE'!I_CH:" /SP7JU6Q+<A0,=?QNT2C .VJ9?]*85C<
M!"80@3JB_EC7EW)B9AZ+W2XBMQ<^K_QL<QTE[S?Q.DFW]%W0]I(PJ^H$F?6E
MU(9'KBKI!!&E1D_T<]$&1^@*.T%*"88,MV&\"J.0K)GR9Q:1SW(&+O)K%&#Y
M) *B"@!/J^IKDCF-VH']8X8'E^*)%#QYGO'=!3LOPN]7[FT'5K :0&;#7V2D
M)IU82:WXF*7H)L5NXZ=R?ZA-?5/6G]M?PA@"&)IG6N.C_85\!\L+%XG@!I0?
M'7!)0KP%,4X$BD"-'G6=6)J:>/GNYU=9U/Y\*2+$B9]A8W)T!9V8B>YH,F7L
MZ@'5G2"7>CZ4;QO]<T%9T T2Q..6OI'U\Z,M;'__,+O3,KY$6S\.9(=;7;1T
M=QW[A#5>RY7.2'G2&5=R8OF)\!"E60P22F8$9)K[_*NUG89U[<\A"'IP!+SA
M%88')#L<R6A8'9X^(S3GQ+SK\UIKK? =5>S/,G=>/ ^3*'DE1E _?:VIZMM+
M.C$WB^!_"AK@GCTE_%F'[E!.WVK _J<$EAI!>PW .Q.?*X'@!+!8Y>$;A;EM
MBS6=H!\G&%ANNO,]@\8'(J]3@J&PVNLT"0;5G"!O1(#5MDBVAR2*V Z?PK[>
M?Q1.,%]&16G;7NJ2CM@_V,N%YHL%E W0!TF[HJNL$[/1@.I<%/DF2<'HI+&"
MZ(H[08XZJ353X:F5N"T5[-_(4D8;@,MKZ-=,4N&T5'1BUKBP7ZI2!5]C]<&@
M+^\$0<OTU8^98'^!C^HD@E1G<+K' 9Z(#"PADM!/]<F(NM%51QY^TH6O,?%5
MQF?_BKP&0-L(>0'##E>EN<?@!..[[;@.&FQ%Y":N:Y=4[4HWKJY*3I#6X8UD
MD RS7POV3VS!U9KNE8P9<?%&8AF:V>W2DKYJ6$M.S+R@P!%.9U!:P[.G$G);
M#_C.RB[-M[#WM)"OQE/>OS$G9ET8MC;VO%[&_AP2?4Q"KC5XI[*WUB]IF..9
M6#?S6QI7<F).B* NX]_$0>-EV2Y,]&W#@3FM958'BU-S#A6%G)BSZR*-PYR*
M7]?A5_A;BR>*OK03Q+#+RBS,4%O8^KN?C>,:B\9^!/CE5_C-6',J:2OGQ%RH
ME4[FZBG[&_LII:F4J<O%99&JH;W5Q:PO(I8S6.4S*WQR8JFH7QA4[4-0IO'S
M&R)IWY!T%XBK1>M ,U;;3C"JU.97:O]6\T]5S/YN$B>"XX_ 1"0IN0QO2JC@
MI@W(O*H3LZ1QZ%/-E*:H6V3([HK48EK9HUK):J]J?U%>ABE:Y5B*1JG:!5=?
MRHDY:E4JMSD4=U:S/S=2>"Q/AP4RFQ]E+>J<OG7M$_J8IP 5$*Z$D#NB/)6H
M*)\.NE5Z6#-.+&,:[$IC7 TT=2W%[<_F71(_)'L_ A^V. L#Q.9!_;9O+6V?
MF-L0G^11?.^G/-,0F'9NHY5F#7:4=V*Q+:((TE CC;378L(SJVE_UA["[%=P
MZWK&Q5(('8'';=>1:5+)B?DCS'_I]F9XJ7LSD/^P[-@4&:V"*M6^2\?NR/[J
MN(G#/(3P*+(_B:DC?"E('!B\D8@PG:1-*=RPGA-K1&O'$+0]+7DPC&O;GTVJ
M(X4GJN9(KA=P8GY&]$B:'H)6VYD3K)1!P*_]%6J*&EUEG2"DC@!E( AV5'&"
M+,U;^&(#J^\F;KB?P\JB"Q1+&^^Z%)##6W6".<]Q6D(/X+$R]4?&0;/ 7[N(
MX!HE5GFJ[J9Z5ER:(\<I51#CM&S_?)<?<_SQ)F*L@Q/_.7[.UW A^]=V8D40
M'1%^%26R#K-%*F^O87\&2Y!BT1&_2GE]CI_L,1AOFH8%PXINS!OG/O<4:7.-
MTA9V@A1MYHDVDCHK.4$:1$3F+"(2\/7T87CJDDX0<8EV^&P/N7I+EW?7H+AU
M(QWUVOXYB; 0YJ?[ZS!"J<:UNU;(B9FH9;ML!_G3E'6"$%CE%4CIXLT/(WCY
M72<I1#KJ?:D.J>\$P1K#$W4S*@"3<\=4D9E&U.P /1VI=2>8!7YD(359@3J]
M=,7"4VT67]*K 2=(UDP+%K,"%!2K''":V>2JG]<@5_9XN/1KV D6#54K_$2"
M(VYB^NIH(!A,V(T3[+N!%)0HRR'5K"8%6*V(?5'^/(ECM C\;?;E?*%/+:XN
MY@37^^8V=#JA81D%RD(M8EE!2^)"@V7\ !<S/'!Q 7S.I/R?>,>$V6T8HYL<
M;=O#3,?HP F6W1<O4;AZSAD-H+6/ 5NJ_3'07<L)XBJG]N;"O4MR5$^,T^Z(
M?&AC;K#B4-N5E':-WQKE/O@TJIVLHR_[YSW)I47@VFE"K;:46XUB]H=_[D>@
MZ7W<((!XI2"5%4"ZWA1L6,^)A:X[FEK/]<Y*3I"F$95!+2B^('I(V?6J]I>H
MZ-HIPG6!HB9]"7/Z2BP!:QI+M6=])^:5(<R70?K5WEJNB3);0BQ-BIPJ@#):
M 70)K(5V?<OHO3C!O(N$^&O3>06?%:HBA[^I7][:XDZ0P]<L1V^L- 5:<)^.
M*DZ053?,@B2\4A&C+.@$"2TZFYXJ'B?(H3="&7??K;UK%'6"# '*4:>'=2&*
MJW*TKK#/2>HCS$<0><_WXA<=RI%Y;2>(G2'5,WPCB$-$H]ZIEK<[(B<F14(.
MJQ(E@4KM)F:^?.PI2V&&E0YQ?1MQ@G2]"PB5C>\1IH'8:^* JQI;_ P&-.<$
M.Z0M$ </* \I;)JQ#<.TN@//"NKA@B5=;9+>9A$G9FGZ(ZN9M'3NOJVCDS\
M06IL<N&3$^OA#N6&N(ZJ&36O;7_/MH(_*=4Y/:I9]_2X3%;%MO0QU 3T*PNY
ML5OJ,JKTP8F=8F1D;Q47^[7@!-%JVT0_FYY8P_XQT!*;&E#H$<&!BVZ4QIEP
M0!M.S&9=&W()^9/5(KFFJ /S1\,911]C? L1P/CF/.G+.C$?#3=Z/;"V6AMA
M7-T)<C4OG!Z/(?O+3YDH:"WAD3XEHNI4@7PXJ"$G9E(.] &@%[UQ7U?6"4)*
M:[  \UTA]?\MQ/L)ST!+]L%>#=A?OK=5 #5?6UVI.;JK.#&30Q^7@IIMNA=L
MHQ,G6*>_-I3/HA[5["_X\S#;H14\X+K6N;:D?2*$X[],PP:(^,OU,D;W21CG
M!!G[$1!FN<"F2[1S<%/VV: 6N\LP)ET::Y-:3NQ#Y5U2.O^UH"8:U'."0)YL
MI>D#H%0N:4O;7XK$)>LZ3+-\$<?A&W[K^ND>M"GG1;Z,ERG>4TGZE%!_K5J1
M-B^O04TZ,<<:\TT'"'AW+2>(JYPV&4Y<"+E$1<<@ Z-ASS;<('P\C(.')(JN
M9TDF(_3D!!,;[W7!VUL3HM!1Q0FR>H3<Z-U!C*K;/_>)[NA+& $63:S0.-6^
M.S$_H&FHY:DC6*3MR)C]:]N?'2($_80OQO@I82$5*SSL5)%85U_4B3EKS<LL
MY/PLU4?JL[1W*TX0?R$F>3& :6DK[P1!PJ$->Z=7C)1I7>L62.K?BP4YO+:R
M^P1?PM%_A[N+)&B8(?4E[1\A:D03[6-:7]B1^2">0N#7]X;P0\%7^#9VE75B
M!^''SQM^Y]Q'_DHS(>TE'5A8D9]A.;\6UJ4\ODW*.S$K$)\'[W.2V(CDH<]
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M@:&UZ=,A?;8_7)*"CMCK+_"G<.5'3_@XB#26UM;23BS61JR35LNL+ND$$:(
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M*QIX<HTT%895G)BK&F;K$^ZL)1!65]C^# D8+D3*0R@&<;\'SD;O%IR8/^H
M5F&4,_6>[H1M*6Y_#J74?'CKXPUSC10HRYV%G9B9@UVWV]2-ER%D*HJ#!PT@
MX>2=.L%:L.'GS(8/AU";_UR]G!,$0%:$$.\^;30?^^K$8/ODJ[C&@I=R)GJV
MX03AY9X@:,C9+<A=G_4B6DMQ^V=KI<#GL:)BF*BQ]K^[LGU2F=%8O"#^ED0!
M0(*_Q_B_FW#'\63 C[U2+0 T"W^7Z4S1PUJUSYQEC)["+??(8#NO0:RRE/W!
MDV1]?AA R$%8):OF9JCF.[RK@A/'#+F0V^-)W8GTK(Z"$9Q0]0G^1N_%">;)
MWC@<?5@?:M16WA&"NE,IJPGKKF==C\N??9\^OSR%>:3%<^'?G9@134 0>?%!
M$@/\X(O*,FK7EIY-.$$VN6HI+LEE ?8 &NU*Q#'UFTAY[/1NQ?Z=* HDE7R-
MWP[DN+BFX8G9XLT/(R*G)<OU.D/Y=0$( W@"*0PSS&;K$WM8T_;9=!OFS+[^
MB/*<.K#0@Y0\?ZEVF:@A[WTLWQ+;4D="J^%-NK%U#E49,(FX!%0O7K)5&A+5
MP>CJB8Z^G& DV1D)T?.B>+6_]+=XYV1L+6A]<[IK.;!Y^FE2CT!M2K8EEA\3
M?JS1<XHY<[;%%9C5=()(37ISBIHW-$EZ2ROV%RR-!:1 G?@IT5BAM>].S)8D
M7_T=[YPL",D#1J]QZJCB!EGH%?;^ ]J!:-\CY-NHHA,D:I'%A)1AAH;0 YMR
M@@UUZZ#V<:\H9__($*SJ#^BUB/P\2?=$#FF$*SS' 4IOPQ4Y\&,&M5/><HW#
M9K26G9AEM6=/(ZRP]EV/T#ND/?NK1E#T,L2E;@]%J:!]$AZ*^-W?4\@M"LZ&
M+I)TIZ&CM;1]8IJ)7OY>Q.@Z*5(QR<L[7D)[^-$X78Q!*T[LSDNT!L1&,5(.
M,$'9NRF%&X/F]?;3O5BH30<YI$7[*T)48HB8V:H7?4M9^X0T%^477'5#E^$C
MOF/B84N\1VOVF5$9"%B:Q1!\+=7VY=;<K\-;<V+?CYB3K08V^H# P8MX6,?D
M=5?XT?@A=H</PPGVFV:,,RGO!$&C^A$]A-FOUUB&Y?;Q69R75)W:/[<:ARJ)
M2^$Q*SU<%+MKVR?V/DU6" 492=6@@A-L#>9HWLZ#FK//CD7Z$N8L+RNL6KXR
MF>JP06]'>2?."348IL8=3UO8"5)D:^=RK<E/5:'$;ZFF!J4YO9F>DJNO_A:$
M96([Q8($/H62*&*&,A5'IN[3"<9J?([U;N:M%9P@:3#(^T\,1M42QKQY]_:/
MS?)R)SX]^$3/SE'^#M[YH%?+-.[A1K6LNYCP='_@G%QW+Q&_.;'H>]J[E<;.
M?DTX0;:Y_6N8]<P)8N^+ERA</>?LI0O#C$%=K;O2V\K;/SH$">JQ6*U0EETC
M1;2FNIC5X6=ICH6#75VR)]FD4+HC_B3*/,B]*CJQY/0@Q[=M&*@&U>PO0-F,
MT6$#-*MAGZBG_R&:<'AZ_C=*DSO,[LZ':V<5^V311*PW=[K<PK7O3NP=S>W"
M<NP<>#<I:CM!K.P-_8 "1%4]5(C5/R=,ZME??@J;DQ\7?KIGRO?P#0TT8?5H
MSKI@?%7">J<<Z+XN'RN*.+),:^B.2K5':U:'GDW87[PUU10$9N"#I;$HU<6<
MF#41+KA;0Z$O;7\NA-"7A@)!6< )_HLY%72/C7H9)P;^N$G2' 11^J0CVA>U
MSJ99S@D"JO%0O1N6"L0PG.4:9$_R1(^#^Q1MPV*K5MKU;L8)\DL1^WQ/SEH"
MKJ5-7J@K[ 0I6J]DI?"G*^S "58%22S7Y3N!H"<E6Q8L!J /0CZ%YB'7OPW[
MA*M\;?"4T-@XJA9+L!R+!Y\2<DC6^NIIR/VO/S6X,5;#3BQS,EX&Q2YX9>C=
MI%LK.$$2,5]N:#@YS<6CO$(:I:S+Z5Q)G<$1DNX@$!<>D@\@P")<4^ESTZNB
M$_.#+S-Z1NH@.Z0"3@RYF0"[N7PZK),]F[!_?MZ&$! >W_OIKRQE "#KW=Y>
MZ *5VLO;)ZCN G!' 03[>@ZHJSFQ3'7Q_<(CI30$+]=TCRU3N,-3M($K[ UQ
MZ26'?^+GP56,3Y94&^0[;8_VUXP:JEU\L4X%!S^H#R=6HS#Q99YR+!D1W.[6
M/-X&]1PA4!GA3IT0!P?*MS7C!/DU3P<>!G@)D*$H,'+=[-F$_?. >0JR_R8-
MN%FMKZ%)-2=FM3J-KM9K2$K,3VCPB<(;LYX;5W>TC=&>&PPAJY#N3Z+BXPBY
M6F<B56'[2_<J?O/7211N_1?AUA8BXC1KU[">$W-5PF=@*1H27(*U2H NIBHT
M.$JSG"1!5DUAWS:<(%R6!G3N_N2C-MZ@;QM.$/X,J-]768Z79ZXVS,HE[._#
MOR<Q%M=2/R"Z0CRNO*"93!Y1^H9/C$S_Q#*OZL3<E.=\I?QJO2K:RMN?-_+N
MPT7(V2#OE<HN#!NC,6W&-9V8M3;<)OHS'(QLP?609]4-V)_7@P-EB":4JW4R
MKM<I'8&;[[R).G)CU1Q,''6B%J3\T1VXQ^G:"3:30P-TAC?;79J\4?]TO;*^
MI;@3Y)0G_J+(-PG!-VK%6J^7=(*(@8DV;ML<,\=JVPE&*1PP6\&2VLH[0=#!
M)X\$!E@=/^3F9.ALHYYT!OTYP5#!):#\Z]]"?!:GJ\V>!)L8.!.TU'2+R"_X
M="ZHC?@Z)2 ^J[W>3<J@FA/D<4RW55^C<DL=)PCCN$)/R6+UKR($(&F*WPX&
M_EP$<5>1:%[;"6)E/]_GV.=Z#^YY5,V6BMH>U9T@MU4'?X?>R:<^KYU:32>(
MY("?S(8D[+(+_4QV5G*"M,:K6N>II2SH! G*1)2ZZTY;V E2%(J<-CFOI;@3
MY"@=QM418X95K(?#W>'C>+/8XJ-JY3>O974)^ZJ:#BN;0]8T,AX- $%3D_.
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MYVX["4&C+S.-]^ZIR1@'A:LN@B"DK! $8181X(",DJ6Y<*#C?U6'.?['/R^
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M@J"3N<6D;S'<0B\Z9P7MR#QY4A6SO;DE7":"CV)6OS!&J&*AG7<4)#KJKJ8
M@TWH!\]>5%X;K>K?;8XHT<OT#5_W\LM<]=0>FN'.O+[%/\/G"-RG6!UKOA_4
MAERRI^;Y_H18<IR7E,1^?YBDF1KZ"J)W)%W$CX]+]IP5>IM7Y*H"GXP2UVIO
MEOWGF8UIA.NMDQ+B1,2+G\ '^8F]'JG.9F3?5_ . FVR+VTT<Z)<!-\1)2%Q
M;2/V)S(:#\R<B.\)(WT]MV(-9=>MP6$#[/;FV  YLME1)N1?D#KKY#/;FSGL
MF$YT'?7V6,:VA11$%V35U=N8I: ;;!S#VAA DF?F/+BX.&[.ES:YEX/,_;*
M8"NEU??R*<UT>PLCL$E6NQW ]R*'V]$;]LF=,8UW%1YY?>WBO\YFY%['"/%_
MZ&*$[;&,;?'#\XHKY%Q^MXL*G<AWU1'PEJ!))6!+:.IK )/XY?6K*,R-TT?W
MX<F>C%T%M^#H!5ML*HDE3!4RW33/] DD1;GH%[ !\#U[EZ@H&UV_+6AS5AN@
M'^];]56$?V96PM5'@/YY@*>B;/A#4.%"Y '1@KXYGKDK!]:]5_EEL#@2MWCK
M7J1NCZB/0:625J6\@B53OQ3UTPQ[[=7&RV<JE9PP36RS1VG1D2U/+&T_N@\V
ML./Z-?0[^:Q)/\US?0%89"Y+E2[>/>CCD(JOB)*C]0'4&25MUHHC]$A!I/+>
MA6/^GB(&N5V'2&NX#Z,*16 <D504ION#>'EZ/Z#[,JP)%W%#NJ 2F:B+]NLZ
M/B $XN(#JQWBD[L:GT0 5J*^Z!SJNK$TKZE@C7&-SWP]94_$M698OQ4R<PMM
M>3J&M2, 4"*XJQK\)PBBFD3,)#?ZJHPY50B)&C5J<Y&6ZZF,D;5Z33C2)#"D
MVS5+_-J11)-"A95_T$2M#U!\B_#@1C[5JA&TXXPF03!RP4HU,8$G54P$,XEH
M\RID#"J<!EBB +(:;4F$:DT#->F8M4L-?(G8L4E@)Q%R5H(F&P$V:N"NJZJE
M$I0V:ABO5;O;(6^3J'4D5+E5 ^LFA]IU*B0UJF\2&*I=LJ)0P4E IO-N908P
M3@))Q5N"$Q$YB6)O\K<$.^YR<D!==S%0(D G@2 U1+1%8MH#,PML_SA:8YPP
MN8/"\&ITW ]$UA%@!^6?$1P[B?/:62;AANU.%SK!B:3C/)6CJ:C;LXV?6E\Z
MM14N::E-U]L 6N&T\#U4?=(=):Q]$B393>FO1,M/ R4Y/B=\G$CK^\36H70=
M>Y.N=3]N$/M,<VO4M.2E5!18CUV 4=<MI%(]ID&J:M)?/1BGCW?(;=+NY4(G
M%;-Q)O%XNR)9->Q36I]I=Y:N-.5)]0&FZ_3&V(!>'KZW#2I)IB9,6YO!JKM0
MA8EQ.6#_F) ^SZ:O*_+S<AQ_F#;A*>0#%L[G<:L!<HBI9B46V(W;<Z]^9C5D
M1!;03L(?(8!6F&Y9@#5N&YTD6)TS/PL4QZW3RZ&H)=>T %2K-LL2:FQ].^&B
M?%3$EP(IQ X+4JP!G4=]SB\LV%6+QZV*?.9>5ICK<6D^4V.JL&UUA63*6]=>
MD'K1^?)@+O?1Z]K\=8QHUS8Y48Q,>FN_(*GID"%.D@*NWEF5 ?LG7)E'VJ7H
M56*@ ?9*X@UKN3T2#]3[:E[!*2&?PK.H3.0 (Y([H+(@R;'LT#ZT9P%,W&RE
M.YYLW'#.R?_]1AM?*SU- E"MWLB)6Y[UQ)M- L2.!UA)1I[Q%#-$&:E\SL60
M.N 3R\6X]B!+*%"3B/6^#D=9U6VX %%K/1\WR_GA:,O<&LX\X>FP\T(8X,^,
M[R]/RX\@ )'G7TY7+#+V]_I-8U#^#.($!GNN=Z#>QK9=)['+:!<0,U@%=$-E
MEQ&,,Q#CCR8_!#C<",DNWW_[W5]E7E!F=;"-8L1G=D7$A_AR= ?@$U+?=!;*
M'XF0]Q!D%;9^ 5@B!-O%.V*(>T!^O/42<._!B 11]@2NZBQF?W2/M-/I'-FZ
M&#$)YL'"=\>3'YX!P(G\FP@2NGQ!1*>;XD6?,RUQ<.3C:@NS^_PF!OZM"?Q%
MD<VX#&]CM8P_OWRI0W9D^82[C&!VF<0:SUM%UL#8)$N6E%5SI0/[% ;OB V
M+"4[7H>)YU=_7X9Q@FZW?X'D!6S"?0#_DV=AYS<]8_W#?-N<3G\)<,USK+-(
MX1<0HP6#[7T8W:<)DBB+Z&.6OJ\\CF5/HF73)5DEI5:R"+;T_<:J"M-6HVMX
MVUC?Z!_]M9=/9?<V.D/YGW [5F#?P).PETI9E%/-BJK$_V?O;F0RL&[16N:3
M9C5'5DWKZBW%>DSNBH'<HQ[RCUS?R-;'.HA:/^$>4(V]+FTHA-<\! DBD!AN
M^K3=2'W:_&5Q.1A<=8+=WCV-MTKA6>3/A4/JUGZYWW(/NIRV?R:W=T'8I?V1
MRXOZ^)QN/T*5R,O2@7Q/@J"+YAE>K.VYRD-N-YR[_S4F:L[K"6S@#FX(?+0)
M*XZ@>?[=F6IR(+I+!- O\2W(_^6!;K3J]UMV!*WH*,4UB? HR8KY_?GG)P$V
MU3$O 3+='3X)R*0>\&1ZM2<!T2 ><2VLH*O?>!+;:,.CK-:!,N<>:>,'?1QH
MH?][$H!3O-]5=!NW_B0@&22:LT7">ES[T]@@'=5D)Y&RU*-J)"> 30)L#:I1
M.XUDW)"9D?OS2)0I(\R!:* XF"FCWY\,T2'29AH;H28KU,3A*27E=I84FE?]
MN-$:_-[2%TXVB?T9U<NFUJ%KD4S!B%F;!)&;,5#T%@PWC3W360-HW-4:AM<-
M.X0HSCMA%:.AQDW.>V2C!U4N9',:K^T-]# D)QBTGT<A+7R'R!VO#C]\=3X8
MO3&U7@)FI_&^8\^,3"YZMX!ZFEJX?D[6*2)YIG>=_*GGH.KA'@.UMF1=>CQZ
MT3E7M;/M66P2^(Y^F\O6S;4<YL)U/#Y6L>FAD^:CVX"2EM+SQ\8 7B..N%;'
M&J]U-Q2PLA,9.^AFD9[K?-E&*]G#&OU31?X=>R%C*G(R^1%:CIC&&=@+L](:
MR>.[/=$F[4OVPC:7CNGI6+>,]B9.MMHDYHHG3E$8$N=W .((1:,TICH->P%7
M7VA/5PCM2\["YH3^\.M?YL(S=M#(L'H#?=_MCW:B9VB-VXLS6(86RT8W"93-
MV>AZVD+^I=/'GIXRH3/QHL2JG9VSZTV>!HJYOR>*+Z[0*='V_&"HS=>H]$TP
MB1UPY(K5:;B>]]6JRX)J#9_$'LWI;HZ< ).<3=%V/XUTK.&86_?D(CU;\$.V
M!0'8>TG>=GR;8/)\*7LNYKPDJ\0'JB=$ZQ[-1] *^]BO?^DG?2:S(MP%;NWL
MG%MFXRD:VJXV_)FP/A, (^L%Y]=FP8(,PCDI8$X*F),"YJ2 .2E@3@J8DP+F
MI( Y*4"XE"PY'FD3=Y\GL$'_N@[QG\R>NBLG->+-Z)6LI3_O[-MI; IZ 5B)
M1G]?A@'A@JGGKT%T_)Z']< SL9>NY]R.?AA"SM>P9F> #<M^?0SP]LI8V]]Q
MEH,J7\TL=M;O>Y5:)N@L75<6.\ASN^SO.4OG;-XW-$%WF<F<86*S$+_8[R/B
M;ASD<':?SQ@.;WU) YS1Y@<M\8+-23\V1BO/23^C#FJ8RI[.Z3Y3"DN8R@[-
MB3XV7YUSHL_XKM5KG5'S5EMU<\B[LR:Q<6I<<F@OUR122^:<+$<XD\%+2-KG
M-HD3X\YM0W'F36*'!KM6=+K^YC0KJ\X.QV$XB9T:[ QU<BO.SPK-.5$394Q7
M.%/G4Z-_)WORR0[W+I'U"6Z-6V$1Q^DQ3X4N'BY;[2@\+*NS,B? S0EP<P(<
ME>&5QZ=RI%Y@_-M]!#!# NB,)"_H&M$=A2/]W3F%R#KZ*(2.GT,?#>.C10Y%
M(8PONQ>1Q5M<+U&3X@_:2YMS&L6 A_H6OL,MDGR&/M*U[XXS4-?^:(TYP+&/
M* UY&6L2@,]Q<7/4U>C.,TLFGB'78BV3D)<GX=6<(S7LH>-^)>]).!@GY]VR
MWM"^\(EBA;Y;B!K-W<'D&L1@MJF;TU(? K37:!<1H\ 'XC'?,8Z%G==CMK=W
M\&IDQP1LZ1PL/R,L=X=<Y]GRW>-9X9H)^7V,+>4%\59TMQ[0E7<+WH$?GO#L
M<G+AFJED>AI;UH\@ )'GH[DMMD<80$PQ"7P',@N3ZVN)L*.FPW.9_"2,'M+B
MN"PWG@1JLWE-'3,)@4KB:#:TY4E"QM;!I&ZO24 W&W/[HS))86(X\*S7^-%-
M>0P#T@ ?T>@=;._#Z#[%KXO@1X"\8#,K^W, W<@5^LX6W<5V"S-^D;.>RZ&+
M12ISK]^T@@JX:C:EH;E)A\$[B!*(CGJ%(7)U3VX78PN1BH/2%,&4H*OHF^("
M(K/ ?_DUNV#0U8WH%5V]WW_[W5_Q!ZE@2G0P#B6'\=::F(M:(OAA)A(&"$+N
MUM/;&IOZ+QYF=PGWH-7;S&91/8O)1>H&/<0<8N?W,<BZ2^:[]$XP\7QR:\9,
M:9;)SU7',;][U2M49N=:[=T3N.9' >:PZO[Y/.OYVUHDP7,:;0YH27CF[*/7
M;33=,AGK2QRI3-#%#@O1'.%L05B3G!(\.;#99DJ^NCD)H-A16S)*Y*0@8OFA
M&&&:XP:%J^Q6T6FHEGV 8V,1B]G]VP$S"66X%D]*I\%I@#6$I;Q^5RKK]]/8
M"#7)EV,SF(0K>7"ZG>O$6D'N=)X^9POU9R.:2+:0T C+"N*9&DZ#,]ZN!KQ)
M, 5%/EK70:>1E:8S/F_BA?:N3."3LUWWD\-G53S?A?4M0]_WWL(H0SK8/L(-
MCFQ<[".0(7YAFP_!+D3CDHA)%R/XJG2$5OJ$UG3YRQK]6XQN "PJ<\,'5$?1
M[7D)WKU=Z,.C]U;?NF+#.!X8R:YZ765QE%0V!_W796/0?US$GA]!N(^\TP%N
M/)_B>^:W'7;*8-^<!-6?R6\[Z)2788HKPR .G)P9,4C,9H-.] 6<<HY<4F5S
M4DRLY?L:<P;C&VJUJ[ 03I0%O:UF=O(%^B!.D"J;7Z;Q$AVQ?1B=J2A+==$\
MPWL8Q<DSWM4E:HP/T#J"GL]F<_P.YK8>7PU(7L"7QBN(WN$&J1*KW3T,O& #
M\>V*5)"4 (IW/J;_Q V<T/H)S=NH>EG9<T,]A5%R6!R1TK?QJ/-E-!J6;V(F
MP9Q=]==!I_7%^X3'],B<6/WWX1%CW(.7WX9BMY2)2'3H\XS&%QV!$90JU\=<
MX%6I=U?F^ [:\ON&\7-5F)?+\]'V(6.@42X$CHC":FTP>/?J#7@491KI_(3V
M WP\X@< //_5:Y$KK87F[S\@U?(&AIG]@7VWTYIIGLD-C$]@ W=P(R%KL!OW
M)LNN/T)E<9;19]@+'7V?>Z'7?M<,WTMX]OSD_(P(&)N9]HCC/H$$$S+U[N0U
MUTWXP0&^19\<DJ\UT/SU5YR5#/9PTS3FU<CE8M)C3[/C2+H/+]B%$7AXNN4<
MV483W7):)I=F'O'5[CD*3Q$$B8?DKB"!;^$6@OAKL 51I?8 57SK,H[FM:S_
M?1^FT1JU ?\+HO )73X2/%&BE^9Y+G8)B-".9EM+.-X*?90]17X'[5=K$$.T
M4>1 _(CN]N AN/O<'/#]?A]&BS@&2 38_)[""&SI-Z_* /WPIZ9Q7\BO&!WZ
MV/ER_Q"WJ>SH*T MM@(BD.FK><ZD[";9QG4HWGQ.Z]ZPE$>N3YSH=ISJG;P,
MX^0&>-BS+F\(8@W0W^QKTGQ++7\.$QQ9CMV"W"7(CJ+[#@#1$>EJ62'.$L2O
MIS# CE8?9#_4+GGJI=!AF/Y6<@^H*DZC1:_?1QM',0QP&AJL]H>83PKNH_#(
M(D=T&_DI>:2NVC9[)_,7F!R6*2+6(Z<JH+XO6&= J*COI1=RM<OJ":TB3/T1
M.*"K$O7*_GB'O=TQSLBY"])C?NTKFA0T?=2PMRO?Z\O<'F',RF_G]=!\D)_"
M /V<!EM\+K^>=A&B0P9'8375/*.2^^?7P2I MQP)N0@V8/7FPSV-B)2ZZA8V
MRM@0]2E+]]7-P"^'*G]BGL*[FVWTSX&\0IQ%$MZF5.[ :ZEY/DTQ']]=M-E0
MVVF?2Y+O_"M($C_S?!^Q'Y_$>($MOC16R0')KL2K#Q!+% L%&D8UQD85Y\Y@
MK:JCF%MN&,=8*$!4#X+-^=8[(BD_SB>9/SM,7Z&XHV[^%[W!)#N2K^EF ^(8
M$0K5%LEHJ?OLU!'(&>LO$4S0K;K+=IMZ.F3ZZ;]_<P-MS3+"GB2_@VX39!K#
M &!4JMIG\\IB3U:I?S_&R^S*6.U>@0\V>&N7.,UGB^3(^#ZL&ARQ>;=T"\'_
M,.\B+>-J7NLJ &MX+(2R'%;:Y.D--<^FLO@7L$]]W/%,8I5;JCZQ^A;W:9 G
M:947*VT%^@;7[7[ 'I5R#E3VUVRBFY?D]O4;&/KAGM@>O&@/$NI<V(WM"(+O
M&*9\B6^7C1 >=5JK5&PQQDP0T3MZD'BAP04^"E&YH\9+*HRW5A](]2R/&CZ5
MB..2G0GB?T<-6)^QPR7 4[\D1-D<!1.DQ0&/'AU*7'&!1R.V=QI04&_'*D:C
MAD$^AKGD+D)V/W[ 9,.JZ564] 4OCQIIR0#F*L9Z;]5)H-M'?'5%$*E'+T\"
MT?ZR%$KEEJT%CQKA3NFD)3%20]E'C9<N^Q,G]'[4E:6NU&Y9&0&CQDRD8M2S
M#48-Q2!7+#>#8A+P]GO?"J7046-\Y8U;SZ$9-5*Z[MJNF3^C+DW6Z2)NY1R-
M&J)!+IMN2523P'V86XCAIIH$PM=R5IFLN5&7+^S$104Y?*,&;" ;F5(:XB0
M[]^$1H^1F 2XU_)10>;IJ,N:=F>A4LFPH\9N$&[*2^*=!+K]LDX9=_&H8;Z2
M 5"/^U]'B=1 PI-2+OHD .]?>*K$S4P"T:%(6+H@08[ZWT:-^C 6%;U[.XF-
MZ?4X=*IKD</^]QEV#;"3?-L<T7_,B.I!M"PKD@/[@TY@_0E@VDO5D\(C.>[P
MG[ZWI.\**\4N:74<3^G,<*NV%.AJ=1Y- 5U^S9D"UG';DGO%5KIZ3H'U.$U.
M@V M7_>G 'M6^;N+AI=6><&B E2MBN-DF#"K^%*!ZJP7=H:67D>J '96#Z\
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MX:462RMA#7 $$FZFL5Y,1G.5RQN#+I$P,L88FV$19F(K^K<+09 N+-J,!(=
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M&8S,.'3I;L86E.=G<V.WZVW&AKWY\/\K3THF?/9S"O.Q=0?K79R^*R*=T+/
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MRA_50R=Y4IG=C>:&(M)KQ$*5-^I%I&.L4+Z_]F3%:B".>,*2G<P5ML!^_4R
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M7D4O^-(N".:"Y1)+<]N;<R$OYPU9QI!K1[4+CKM/M',P!D@6W(#RQW*VWZF
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M&3A"E;$N?A]S2\$F-7S_I5%$F)_<+@F[V;DW%==]F43Z',;D3I5Z-T#7Z);
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M\/P5://'VORQ-N%J@\?D*^72:PNAYC+QR\(D'5AN%[9*)E3G#[8,O'NFBC=
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M.!C^!#/JJTGT+\2H?_YQ>'5Y]1/\8C \O[R[P$=@.:,K>K!W?GYWTSO_!4>
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M@Q'^2S\*(][V_^N."4/A&J(2__MB &L=.; M_4_7ESV, %& !;_%T>Z&@]$
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MMTH^7;EJ&NT9?C/NE<Y)I[-&5<3+.A&*XDPV< EVTSJ3)83&:EC X[" _N1
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M[ (QZ=-3F)B!/8-?!?/ U$^K.458*6-^X+L+,Z8&/_V:(;F@WC<K70VF:NB
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M -FMQY>M%RSN*YK'U'0&ITN+=76X]*F;S+C=&+?OQ,R(1PS#P\"Z 2@S7-4
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M!$:7) H*IH:N]_2707D"B![C-"-^1E(,VI*B< !W4;&^H!FDQ9C*I5]1ET1
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M8.XD],@B5E4"G<#T"K@:X(,T:LY@OR4V$<N46M*E1JJ],36,320I;I!$I2
MCF@ V4]GO3TQMQE+E9[:!8&,&$OK#+I.QNEDL!M6-E9X8!?&W++VD0J[MO#G
MOLQ<P<U/3V8'[<XO/5NCO:XW*;+J-)4X]) :,FZ$!R_ *",E"&1,@#&1DC8C
M<1++D54HL]!Q(FVLM*TPCN8W6@44ET;'(L%IR_8 VD2 !0&9@UF<\6(L6!^A
M_+*BLKASR)N=HSWQS _M'"7A*!Q*:DN*P![2SRC>KY J@)QLV7JB]+V)4DQ$
MZ[Q)-4A0P;:Q'G_H*-J*/K^TVB]^?F +YRWV2EC8 !SY$N7C(&]0]13SRFX_
MA,J82 "P]4RA,-*5@0*$](FT/E% 2A1>#S6'RQ2SFJ:,4-PSH*Z,EBANU"F,
M+DJD&]ABM9()=][0R,I$<B-I 3+4;SYQ%J2ILE13^8!A?0'FTXJV @8YI#$:
M5')0+ZX4IVR(97DCEK491H1*;[5 Q5^1($'<,XP7R58)ZB$";6<9%MUDV-9!
M_A;1MD\/6_,-')W(A&C$K2XXY4%N04%J8(A;W"0+G(-YDD=223>G:FW=M,1Z
M3PF/]D#8]T17&B"?;F?U@LK*E&";]=5E'&N3> -\*S06!8I&!=+ABBB)S22"
M-B\0"ZR7)3+>/:36QS!U\,WWEQXBH^(6&TRXJGQ@)[B)-$4'(B< BEW322PK
MPBTR53A<WUUX!F$@LHP-/4RD*[?9A&UR*;^6%M2@I1]O]UFT:/U\4!#!%;"G
M1\IW%10[FU\2Y)> L]MXI>VPNC'P5]:SXA/2"I5E.HXK0[!<J8'6J<VU=;A
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M2I=A@;84L3>0])8P32=8Y@3#$A;-EMWPS(YM6_C>>]@A6"H+X(^@O,!; ]2
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M:45; 8,<TA@-*CFH%U>*4S;$LKP1B]H,(T*EMUR@XELD2!#7#.-%LE&">HI
MVUJ&17<9MG&0OT>TS=/#QGP#1R<R(1IQJPM.>9!;4) :&.(6-\D<YV">Y)%4
MTLVH6ELU+;'>4\*C/1#VENA2 ^33[76]H+(R)=AF?749Q]HDW@#?"HU%@:)1
M@70X(TIB,XF@S0O$ NMEB8SW"*GU(4QUO_K^TE-D5-QBPPE7E0_L!#>1INA
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M> 0.H#)+#8)M X@4/D$ T_Y.8 W^1JAJ9#'1:B*HM"GXN+ZA:>J<(O)2Z9G
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MY)PMBZK.[K;=S9:31]UV=2?F7U!+ P04    "  0B&58V6@-.%L%   0(@
M#P   '1C;VXM97@S,E\R+FAT;>U:;6_;-A#^O/Z*6XL6"6#)LO.R5/("N*Z#
M!=OBP':![B,E4197BE0I*K;WZW<G68Z;Q-W:HD[;)!_D6'>\-SZ\W%W82VTF
M3Y] +^4LQD_H66$E/QV^=0ZZ;K?7KK\B0WO%T0MUO(3"+B7_]6G&S$PH'UAI
M]<\BR[6Q3-D@9W$LU,R'DWP1/*W$QN*J6;2B.E;GON<>"15D0CDI%[/4^AW\
M&NJ%4XA_2$*H3<R-@V]03B]O1"1:66+A?L?+;5";40L,*EK",B&7_E1DO( +
M/H>QSIAJ&$-MK<Z0U_*%=9@4,^4;4D]*:'VC)])2&_^95_T$\U18[A0YB[B?
M&^[,#<MK=?/:^%#+.+AAVT?-05OF(K:IGPCK1,C)%=DP7*0B%!;J+2 )I[UV
M_G7]ESRYY?YVA[_,OQ?/.L=>L.E9&_%1X63G6[PS'[^V=Q'JY>9S$?QES@Z&
MX^GYV?F@/ST?7<#EF_'D3?]B"M,1=$[@C3MQ!RY,AH.*VCDX\EH/)"[]"?1?
MCRZGP]>;07D@SC<;_M([AM$93'\;PJ0_?M6_&$Z<T=L_AG]!?S E2M?SNO<>
MDQ\F#]R5R'>SX><MF$1H$;QRX971<]6"P64?'ZG@"9P)Q50DF(11DHB(&] )
M3,?] 66,E)D,S2FMB)@L6G"N(A?V;,KAQ;-%U^M$P9C/1&$-EA?UFSC8;T&L
M(>6&ATM >58D2Q *6!1AU8"Z.,R%33=24)5Z@!7 8IU;'D->FJ)$D6 U3'AD
MA5857-$RTCUA)F2*%\YH(?D2^I$E"L&UA71F6[2.&$->5*1L">^4GDL>S[A_
MSWO^".@O=G6OL_^3344!?:5*!.Z84X4+")(S;3+H>,[O#52NX5F! BV*4JC6
MULA$7%?HPA?,6A:EB#X"H@*^*O9NH)TT;2 ]*:5$E.LLEP)MKX!-"PQ_7PK#
M,S2X(%L:%'<.]M@^: .=H[UX?PUH'I5&6)(P7$0I4S/>H+KS\N"P/ALH*^9Q
M@+;%CQ#^[B'<)0ASS(L)0K;&(%&94(A S)8U>"M<)TP8!!FJ+PA.K2J92@FX
MC!M*W$C($5]%JUJ5K!,Z"HQ%)1HQ0UREK-&H<VXJG<7M<^(V\=]]4.!A51N6
MA9(WFE<=-:FF!AMM):HCV5*7%J4M\.C7DCN>YWK/@]4"W!G)\H+[!<\9;BJO
M&WN4;AK15Z+ 3":%7?H-]XH)N>*UZY7PHQ/W^/@YA:5MXRT\AQWWX/ #'OS%
MW-2Z&AQX[B\8LSD:ZX2&LW=^]73HQ=TXNFW9%65JK#]6.X?;OFWHL.N<]PF-
M]!W1_)'\^@@"JD.S(P#<\Q^&;7%[C>?2AS^9P>+CJ(65:O?P,\"Q'KK5]KI'
M.=JFI8B_LVBTB_9=#<D#A=6])I9O%"&/Z'A$QW8WM\PM[G,B_[_K8V+WA45)
MT?;>X-((]"Q'UZZ=I J^'T6Z5!;KP\;G_8\="_RD&O*Q1?P^6\3I[2D%C="R
MG"D:%%#7=CWN6,\VA,5&3V*]07UB 4I;B#G/L*E,A,3G>D*Q,7,@;*WG#@.=
M9:(HFJYQ)0/EA]2M1MI@3\IH2!<N45/"#:>)GE#(P=22M! ^_VN&6"HL96[:
M<3WR.-@<>;1H7O*)8Q+8FZ<<UQCLDF,:!&*;S4D.2^Q*<8Q>-.WO.I#[&#6S
MZJ?%544GKV9<8<<L-P) \9%H0<G0B \Z]Z+$;:C#X'Y=H)[@TA_X'#ZZMU/W
M-JX"))(OG%B8>FA)4X,R4T$LBERRI4_4YB[!1C=R^\+ WV5!P_]&<;70P>-Y
M/S<)OI'_I*?K4C7'U%&7ITZ5E7PFYVQ95+5HKTWW.4Z?]-K539!_ 5!+ P04
M    "  0B&58@&E[%^P9  !\S0  #P   '1C;VXM97@Y-U\Q+FAT;>U=ZW/;
M.)+_O/M7\&9JMNPKV6,[;SN7JER2V4K=;I**<U7[[0HB(0L3DM  I&7M7W_]
M $"0HF0E\424H]W:C6V2>#0:C7[\NO%\6A7YB[\FSZ=29/!O\KQ252Y?O/G7
MT;,GQZ?/?^5?X85?W1O/QSI;)+9:Y/*_?BJ$N5+E>2+J2O^'*F;:5**L+F8B
MRU1Y=9X\G=U<_$3-9NK:?^2>'E5Z=GYR_$B5%X4JCZ9274VK\U/X=:QOCJSZ
M-[8PUB:3Y@C^ NT\G_DF)KJL\!5Y?GHRJRYX&-S@!3V;B$+EB_-/JI V>2?G
MR4==B-*_.-95I0MXMY(WU9'(U55Y;K![[ 2_]_VD.M?F_.<3^L_%?*HJ>61G
M(I7G,R./YD;,N+LY#WZL\^RB,[:UPX&QS%563<\GJCI*X4U9XAC>W$S56%4)
M+P&V\.+YKS/X'U"1J'G'A#@]A6\C6J0P#&GNF!BG7TF,3Q]?OGK_+ODP%::
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M-5\Q+FIP9U!+ 0(4 Q0    (  ^(95B/]\W*L7   !-V   2
M  "  2ZM  !I;6<Q.3@X-3 X-5\Q,"YJ<&=02P$"% ,4    "  0B&58(20E
M5N5>  !^9P  $@              @ $/'@$ :6UG,3DX.#4P.#5?,3$N:G!G
M4$L! A0#%     @ $(AE6" =5[6*U@  XN\  !$              ( !)'T!
M &EM9S$Y.#@U,#@U7S(N:G!G4$L! A0#%     @ $(AE6'6-)YE.;0  4WP
M !$              ( !W5," &EM9S$Y.#@U,#@U7S,N:G!G4$L! A0#%
M  @ $(AE6*%K=0206@  Q6D  !$              ( !6L$" &EM9S$Y.#@U
M,#@U7S0N:G!G4$L! A0#%     @ $(AE6#K'1=\<F   4Z,  !$
M     ( !&1P# &EM9S$Y.#@U,#@U7S4N:G!G4$L! A0#%     @ $(AE6.W6
MY=I480  GW8  !$              ( !9+0# &EM9S$Y.#@U,#@U7S8N:G!G
M4$L! A0#%     @ $(AE6#(^.GZ95@  6U\  !$              ( !YQ4$
M &EM9S$Y.#@U,#@U7S<N:G!G4$L! A0#%     @ $(AE6&H.#?%07@  A6L
M !$              ( !KVP$ &EM9S$Y.#@U,#@U7S@N:G!G4$L! A0#%
M  @ $(AE6##XTVF4@@  SH0  !$              ( !+LL$ &EM9S$Y.#@U
M,#@U7SDN:G!G4$L! A0#%     @ $(AE6$YAQ?R3+P0 E=$M !$
M     ( !\4T% '1C;VXM,C R,S$R,S$N:'1M4$L! A0#%     @ $(AE6,Q]
MVY]F8P$ E%P4 !$              ( !LWT) '1C;VXM,C R,S$R,S$N>'-D
M4$L! A0#%     @ $(AE6*FG3P+$/0  /]H! !               ( !2.$*
M '1C;VXM97@Q,%\Q.2YH=&U02P$"% ,4    "  0B&58[$9>.QP&  "$1@
M#P              @ $Z'PL =&-O;BUE>#(S7S$N:'1M4$L! A0#%     @
M$(AE6(U[:;XF"   C#@   \              ( !@R4+ '1C;VXM97@S,5\Q
M+FAT;5!+ 0(4 Q0    ( !"(95CO*JPZ&@@  &PX   /              "
M =8M"P!T8V]N+65X,S%?,BYH=&U02P$"% ,4    "  0B&58J0IAA60%   :
M(P  #P              @ $=-@L =&-O;BUE>#,R7S$N:'1M4$L! A0#%
M  @ $(AE6-EH#3A;!0  $"(   \              ( !KCL+ '1C;VXM97@S
M,E\R+FAT;5!+ 0(4 Q0    ( !"(95B :7L7[!D  'S-   /
M  "  39!"P!T8V]N+65X.3=?,2YH=&U02P4&     !4 %0 @!0  3UL+

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>tcon-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:tcon="http://www.traconpharma.com/20231231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tcon-20231231.xsd" xlink:type="simple"/>
    <context id="C_88b652d5-3be6-4a6b-aa98-270cb604d499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3d0aab07-6eea-4e52-afb9-65f4dc53f96e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cb79e9b9-01cb-43a2-8165-d3fd9d65c898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_46f8a63c-b29e-40ea-8d58-941155df4da0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ada76ad5-45b1-47ad-8d9b-60845220bcd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_49078ec3-8121-4069-a2aa-dbede8ef99ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9016afcd-3dde-4d11-9f4f-8fa39038db47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:WarrantsExpirationJuneFourTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74db5b1f-1c60-43e0-86e8-20cdd644d6d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_23ef9799-fd43-4275-9cd7-31fdf18c3424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f092d4a-d7e5-494a-a9df-840fef3b8d29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-02</endDate>
        </period>
    </context>
    <context id="C_b16315b6-4843-44d0-9eb8-3298bc62f493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-02</instant>
        </period>
    </context>
    <context id="C_0247f2f4-3917-4a82-af24-9a5bf778c6da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="C_ecaa62df-706a-45f3-889a-732b21b200f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ecdebc03-6503-4399-b16e-c105c0c28931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tcon:OrphanDrugTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_739f0e0d-35e3-4a1e-a0c0-95af5f5ab2ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_475df304-3dbb-4958-a84d-d4bcdf488834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_079f3f02-0a8c-4168-a44f-3fb63206aa35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f618c112-b46d-4d38-bbca-dce456ac7680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a70ce266-0b0f-498a-b880-2e0cec4cebe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9d44d79c-a241-471f-bb27-6c48118f0d44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e8c5c302-7618-485c-9ff6-32bd1855c0cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcon:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_55363737-381a-4453-8820-38a565d61aac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_076a27be-5a0e-4964-acbe-3687b701e0a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0c28515c-df0f-44e6-bbaa-f389e653f073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0094047e-e7f2-42e3-a4eb-0ed27b0d1e40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-04</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="C_bf3c9e40-b8ea-4aaf-989b-00a5b9696dd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aa5025a8-1fb4-4cdf-bae0-549dd0c077ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_40c3a24d-66cc-419c-a6ce-68d4a1b37552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_afe12a9f-a1ba-4eb0-8945-f294141cf382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0a421996-059e-47aa-914f-9c7cd5e3b7d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_753dbf14-c0c8-4d2d-b958-384acd243082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c22bb402-0325-47cc-ae07-b1647b8287b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_e41e9c0b-0129-486b-9356-bb65e6d7e6e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseTwoClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_fbc58ab3-c43d-4ba1-8648-0ac74912cc07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeOnePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_1ae2be0d-9dfa-467f-9bce-05b3c0ba56fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_a4750715-b498-4b30-8b83-398f57734854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="C_1e2ed30c-2d9e-4355-9b3f-cda6cfbdfac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_eafe3fa1-222e-4c1b-81f5-552231208588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2fe7dfff-ab8a-41ec-b669-52df31405891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e8c41e95-942f-4e44-ae98-385347e4f1c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_48cb3f8c-97ab-41bf-b369-556c94253861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c9cb59b-f528-4f05-be7c-a82ef8ff9fa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e9e0def7-4f33-4329-8019-2a7db36180ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_849890bd-5478-410b-adc7-afb456b7c75e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeOnePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_871edb40-17b4-426d-9503-2ecbf34f60e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_3bdfeab3-03b0-41d5-bcd4-2f2f5ac6bc5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3cdaff81-414c-42cf-8429-30f12793a1a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_f785d70c-45d9-4158-b4cc-5971017cd60b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0592da9d-0e35-4ada-8b6a-801b2b01bdcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="C_9ab8712e-6090-44da-8908-64f2c34aef15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyTwoPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_ce9c7c28-c3e5-426c-8989-80f05562dd11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61e3c61d-6eef-4e6d-be34-c3497437219f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_38834898-65ec-45e0-a908-a6b01f5f5240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d2b07739-4905-4cff-bd81-929c2939c81e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8341fd7b-20e9-4123-b191-98d68cf29a63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1f396fb6-a65f-482a-85ae-a6132f8551fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_19d1e4ec-58ad-4668-bed8-1390374bb8c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcon:MilestonePaymentsCategoryAxis">tcon:FirstPhaseClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_f6b50908-851a-401b-87d4-7d20d639276e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_cfb0c8e3-22a8-49de-b419-5303ff8938e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tcon:ResearchAndDevelopmentTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c4946e13-3da8-4743-9ee6-bc34ada03788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="C_b0dbc715-f6a8-4d77-87d7-e3f962470a0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_577ee070-e073-4976-81d8-6e2937b0617e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-02</instant>
        </period>
    </context>
    <context id="C_cd3ca734-457b-4506-8892-6849fbff690f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-02</endDate>
        </period>
    </context>
    <context id="C_3632bdcc-d356-4f7e-83a3-f74f7f3535fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7cad07f2-1244-4aba-b9a0-b522e10e9007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2122e3b2-efd5-46f7-9ea2-4421118c4fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8105d9cc-038e-40df-bb0a-861b99bb23f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8c775d2e-ff5c-46f6-b93f-e69459dc4932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9e8ae800-d235-4098-a3fa-dc1794018749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2872028b-ba94-482c-8437-c4832c35599a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6bcf6ae1-6f62-4022-a841-9cb5606b41f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_96edd94d-e38a-4eb9-8c60-62d39af94ba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:InhibrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:InhibrxLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_65bae7f1-a046-426a-b301-55274f90e5e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tcon:ResearchAndDevelopmentTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f5feec96-d065-4192-b005-a1dbce905bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c3f43995-11fa-4df2-a9ec-f4edd6b8a5b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9fba94f6-47dd-4e8a-9960-b690725bb795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9fa826a9-e422-4f13-8418-0d37f204106d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_639cfa51-d355-4e4e-883d-a0c36228443f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ae2450d-d4e4-40a6-b829-f38b64d59da3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a62feee6-1322-4bcf-9874-c9bc8fbcda7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3ff50e62-5e4c-4461-884d-ca0bbc261a94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_25f6f616-38af-477d-9616-f204a98ff0ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">tcon:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63121456-f0cf-46ef-b24c-282d6b4d3d1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbe644e9-34fa-49cf-aac0-7fe06affdd7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_64263ac1-80a3-46bd-b083-27c74a051284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a0cfd32a-d85b-4d8a-9619-e9e603c0063b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_7c23779b-d204-40a0-a57c-ba7a3fd5104a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_3707c748-2523-40f2-89ed-37a5e0f02667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0f40826a-5d90-43c5-8575-ad4a021189c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_36e936e9-4748-422c-af13-03094cd386a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_8336abd2-bdbf-4da8-8873-f9e6e654f71b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeTwoPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:DirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_e523f290-ecdf-4b86-9681-520bb864b996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9d6bf014-6462-420b-ba24-a41ec9fc6144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6cb97554-1115-4af1-8cfc-e45b449853ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeEightPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dadec75d-3635-4b34-97db-e4a9d80be690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:TwoThousandEighteenLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_948e03ad-dcda-4e45-bb27-1fb7cf42583e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_be1af667-5078-4781-80f6-a273e57ebc33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8c670a0a-691a-4b51-b9b6-9c1738acbd91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dee76b1c-3511-482e-af8c-baca4374550b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="C_2f47e236-54b6-4d53-9564-adba4ece78af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="C_aa5fbb77-e965-4baf-b389-6c9224794641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-05</instant>
        </period>
    </context>
    <context id="C_7ac1269c-37c7-4ba8-ad75-d74191163fc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0a40186b-dfa3-4450-9805-28d0eb65430b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9c65da7a-8508-4963-9ecf-2e2bffdab2b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18ad7425-f5b0-4ca5-b02f-4051b623fbc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_62d20795-8235-49dc-84d8-78968b279332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_70a6deb7-5ef8-433d-a7ac-fd7f122fe2e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0a381d93-758c-43f0-bafa-d1d2c3addbf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dbf3b97c-e0f0-4dfe-8eea-e3775ccab160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:TjFourThreeZeroNineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_2e8d066a-2058-4cb0-bb65-2e20e51ef896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_89504bb5-ef30-4956-bf15-4942d09489d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationMayThreeTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af8d7bab-03a5-4ea5-b757-607eeb29fa0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_318cdc34-f5fd-4dd9-b958-8376a005bba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcon:EquityIncentive2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fb97f606-1fe3-428b-be6a-b8b232235366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d67d2e6-6d0a-4e23-93d1-f44a73a8c83e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12cbadd1-c66c-4148-a655-212d5c0bb0a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:WarrantsExpirationMayThreeTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f964d2c-14b2-4bc3-b709-922d50a40833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:ImabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:BispecificAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_ce6896ec-3d61-4ba8-b0f3-65531cd77796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpLoanAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_901ce9d0-b622-4dc1-9cc3-0c5fd70773be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcon:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-01</instant>
        </period>
    </context>
    <context id="C_42ea9fad-5f3b-4079-b265-ececb47bd4b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0dde0b8e-4306-4c73-b564-93d2dc9f8a26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:EnvafolimabCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b0b548c4-d2f9-43e6-8243-8c33b7859be8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3383f0ff-32ac-4e6c-9cf5-2ccf590edc61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_3d853f01-db0c-4afc-ac37-748d6a24b52f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tcon:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5cd3a46f-aa21-4477-b98f-f737dfae502b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e0c31950-7a73-4c3c-b339-8d2b3ea2f977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="C_3b34aed6-5a9c-4e22-8703-226017dd6deb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:RunwayGrowthFinanceCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcon:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tcon:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_fa0eef6d-4f4f-4aa3-86c1-d8232518e2b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:TwentyTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeSevenPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_16e27699-d842-4a09-9bc5-311bdb55cc7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcon:WarrantsExpirationJuneFourTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2497856b-e351-4137-a3e8-c281dd005061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:InhibrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:InhibrxLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4da012b8-a385-42a2-9bf0-9a586e2e0ba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_ef2536be-eee0-447c-816b-aa4f24348c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tcon:CommonStockPurchasePriceOfOnePointThreeEightPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_8f06370c-a07e-49f3-9851-fcdb008745c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7eb1035b-caa0-4638-9b3d-88715a101c8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_050dae8e-e369-4b11-afe6-d1549da44936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_44f937fc-97bc-42b8-97d8-361c9c6f366c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_814ee833-9257-47ee-8583-cde42cd6e260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e6105ad8-44d1-4f33-bd31-6a2890669839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tcon:InhibrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcon:InhibrxLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_af96e684-e605-4756-a75e-d1a500792e14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b3b2c60e-9c95-477b-af58-492387fc1056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f632fdf6-d5bb-47f5-b665-011709762d71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac868d35-ee5d-4979-85bb-00dafa76357d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">tcon:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c703b19c-a29e-4412-99b9-5310a244f3a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_114c5392-d3f7-41e4-b75e-3aac9f0e4167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcon:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_fa2d3186-d82c-44fe-9ee7-07c5a15c9315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001394319</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcon:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>tcon:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Antibody">
        <measure>tcon:Antibody</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Tranche">
        <measure>tcon:Tranche</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_75a04f3f-e55a-48ac-a534-b51065901239">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_23731db1-5ab4-4335-832e-f836b7524b00">0001394319</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_aecfc7e0-50cc-46a2-b567-6219d44176a8">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      id="F_edd6578b-51b9-4d94-9c92-e08d58d290ce"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      id="F_af0f1790-87f7-4d5a-bc14-b2897ded686a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      id="F_f35279c3-d90a-4876-9a14-4f57ff1df69e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      id="F_3fcf7105-039a-49a1-b08a-a181e9c9b3ad"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_bed86c5b-265c-474e-b396-4938148d8b03">http://fasb.org/us-gaap/2023#CollaborativeArrangementMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      id="F_dea40108-736c-4212-9bb9-d449f9499fd0">http://fasb.org/us-gaap/2023#CollaborativeArrangementMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_7148ed3a-8abb-4a16-af47-75112a2b7341">http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      id="F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17">http://fasb.org/us-gaap/2023#OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      id="F_b539fbc4-b194-4f51-b5a6-68a58edce5fb">http://fasb.org/us-gaap/2023#OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      id="F_0423c714-cd31-4fc4-8227-88bbd1c67cbd">http://fasb.org/us-gaap/2023#RetirementPlanNameOtherMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      id="F_46bdfe8e-ae21-43ca-ba32-3a33adf3437b">http://fasb.org/us-gaap/2023#RetirementPlanNameOtherMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b40b095e-6fd8-4db7-9688-34b629bf1179">http://fasb.org/us-gaap/2023#RetirementPlanNameOtherMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <dei:DocumentType
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_35a31844-f312-4f4c-bf4f-8db536ecee34">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_1b75c1b3-31c2-449b-8bbc-55d81f32fd07">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_fc8184ef-9c4d-4e72-b4bf-5421e2e6098c">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_12aa6682-1487-48fd-a7e8-2086da8fd05c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b33970ce-6c5c-4904-a0e2-6be57f406adf">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_f6734b61-caee-4040-b9ee-96fc8aeb7eaf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_6da27319-e55e-4926-98d6-510f024ec9e6">001-36818</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_7635860d-fd5e-4a0a-b57a-5570ca1851fd">TRACON Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_0c718e5a-e9df-4e15-9e17-041fd5b6dee2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_958e2a48-2ac8-4563-9167-7a9ec9eca666">34-2037594</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_2e2cbf53-e7c8-4d85-b7cc-bc32caf84aec">4350 La Jolla Village Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_24ebe13f-8f66-466f-9190-834861a79e50">Suite 800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_73737e9a-2b78-4e9e-9ac7-ed0190b68e5a">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_4d8a0e7d-57d3-4a7c-942c-c21bcb6a6200">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b4086bf4-3863-4404-a4b9-414c6c29153a">92122</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_9f427da8-e6f1-4a76-a9cb-57b1c4aab3e9">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_f3509074-fe71-4ba0-886c-be4c04eb86f7">550-0780</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_c9d7a163-2460-4cd6-a09d-5a404ff17ebc">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_9c014604-f6dc-49f9-85cd-6bd0a34734fd">TCON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_f669e562-8146-46bd-9fbd-fa0a679a2d39">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_4bbfa8af-17c4-4d38-a60b-7dfc3782c566">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_eecfd880-c634-4f07-8a90-41da8b62311c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_54366c30-7996-4246-aacd-61c1fea003ef">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_30760647-6abf-4169-a843-7f0fe3505f9c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_54ad6f75-2e5c-4efa-a503-0e3df74e4f0d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_e54d0c3d-e9bd-4d81-a44c-6fa1c3301feb">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b675d5d5-f227-4b44-abf6-09cac0569a85">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_5bf70893-46dd-4f31-976a-d9131b4d7df1">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_710aaf73-d86c-400e-ad9d-d833cd7c029c">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b8276067-af37-46da-9fa6-885b78f75af4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_3383f0ff-32ac-4e6c-9cf5-2ccf590edc61"
      decimals="-5"
      id="F_2b7ca7e2-1b41-4356-80ff-b79bcf59e971"
      unitRef="U_USD">7600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_e0c31950-7a73-4c3c-b339-8d2b3ea2f977"
      decimals="INF"
      id="F_1acd673c-6d20-4ae8-8f07-3a86f9d66870"
      unitRef="U_shares">45504501</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_c5d11b77-f58a-448c-9493-6b5ae706bff1">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_487940d7-17ae-4c0b-a571-f3725d40a063">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_98bdf829-2a4b-41c1-bfaf-fb4857760740"
      unitRef="U_USD">8564000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_90184ef3-f597-4ef4-9c84-9dc8c2d67af7"
      unitRef="U_USD">17433000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_da61ebd9-0de3-43ee-b85e-5ec077f5dddd"
      unitRef="U_USD">526000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_935d8092-5816-4cde-9432-2eff2bff27fc"
      unitRef="U_USD">795000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_6b01632d-3a0f-43cb-9fcb-6a8153496b7a"
      unitRef="U_USD">9090000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_55c88196-aa11-416a-8d38-8ed2221391b0"
      unitRef="U_USD">18228000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_f27af587-759e-4d9b-8283-a1951b52541f"
      unitRef="U_USD">37000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_5c9ae591-a51c-474f-b3f7-30f8516fd1a6"
      unitRef="U_USD">51000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_19afcd54-61c2-440c-94fc-429d6e06b8f8"
      unitRef="U_USD">73000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_58adc410-4a91-4493-9aff-2809fe4defaa"
      unitRef="U_USD">67000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssets
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_fe95e0e3-b48a-44ec-8900-2ac5fcdaa706"
      unitRef="U_USD">905000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_b8b44f66-7a3e-4da3-8f87-1f02129f2ea5"
      unitRef="U_USD">1123000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_3626bec3-b712-4f95-94af-28bfa4035fa5"
      unitRef="U_USD">10105000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_5ea4d4b6-3496-4c1a-9d6e-77955e1662da"
      unitRef="U_USD">19469000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_bfc9cf45-103b-4dee-8d5c-52e86abf0747"
      unitRef="U_USD">2544000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_b058743e-7298-4176-891d-e5a15f74953a"
      unitRef="U_USD">3923000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_c882de5e-8439-4736-bdb4-13d9a1b8921f"
      unitRef="U_USD">7211000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_8d81376b-cfa6-4795-a8ec-7133d56f8496"
      unitRef="U_USD">7184000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_180c5af8-bc15-4223-bb5a-d68e172a1fa6"
      unitRef="U_USD">427000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_c26a30e5-7a5a-4c31-b1bd-ea5379e847f2"
      unitRef="U_USD">1457000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_4e50b30e-e886-419f-ac59-75fcb985cc47"
      unitRef="U_USD">9807000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_e122c03e-5d5a-482f-b615-eab3aee81f92"
      unitRef="U_USD">10182000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_d8ea527e-b6e5-4185-accc-b1ff1fac84af"
      unitRef="U_USD">22371000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_4374ee6d-e1cd-49f4-a6f3-6148e5445131"
      unitRef="U_USD">732000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_355a8cb7-16bc-4784-9c22-f35c750542d9"
      unitRef="U_USD">969000</us-gaap:OtherLiabilitiesNoncurrent>
    <tcon:ArbitrationFinancingPayable
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_1a4a8e62-acae-482f-9fc2-d7b6d59608e3"
      unitRef="U_USD">3280000</tcon:ArbitrationFinancingPayable>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_a3fe3fd4-652c-45f2-906f-3888eff68058"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_9ce93b42-1f90-44ef-af77-695e14a1b414"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_3c6ccf55-74bf-483a-be5a-f4e0e8f5b5cd"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_9a01ac39-bfc2-4d8d-afb8-cbe6dfbbfa51"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_f485436b-b3b3-4aef-ac32-7e27211d8cb0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_b52581be-4699-4138-9c6a-bacafcae5764"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_438f78a4-bfc9-4a1f-99bd-8b45d26d627f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_cb776419-0525-4980-a40e-05d121d50120"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_b61db3e4-9d07-4451-a451-41403970914e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_17779db0-1ae2-4c70-9259-bf8c502f6f62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_768186fb-e974-49c3-a8cb-090ae480a195"
      unitRef="U_shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_0b95f825-a114-45a3-84b6-97dc1a0b10dc"
      unitRef="U_shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_e5326080-1267-4be6-b1cc-14008dd8be7c"
      unitRef="U_shares">44269976</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_c4f66fcc-cc3b-4c1b-aab2-f47b7c73d092"
      unitRef="U_shares">44269976</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_e09adac0-faf8-4051-b8fb-00d907445b71"
      unitRef="U_shares">23125250</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="INF"
      id="F_4c792344-82bb-45b4-b559-03ff3dee32d9"
      unitRef="U_shares">23125250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_14bab557-736e-4edc-a635-be879fff0267"
      unitRef="U_USD">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_a6b1bd68-c52b-4c82-87a5-1e728a83cf91"
      unitRef="U_USD">23000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_2cb1312e-a900-4302-a026-c160ff926570"
      unitRef="U_USD">239646000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_759bb0ed-5c1f-4fb5-8823-468b88b542d6"
      unitRef="U_USD">229737000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_cc2bcb7c-2685-434f-9949-6efb30679e86"
      unitRef="U_USD">-240499000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_8ad7c9af-3ce6-497a-bbc8-d519cc5c8527"
      unitRef="U_USD">-236911000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_489465de-0503-4782-9d97-c22b1e4adc57"
      unitRef="U_USD">-809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_b001e6c7-cd2a-4b28-9453-8adaa6b98cb9"
      unitRef="U_USD">-7151000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_e6bfe39a-9130-49c0-9140-f5ccfddb8473"
      unitRef="U_USD">10105000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_4f60f443-1c8d-44f1-8a53-d25c5742036f"
      unitRef="U_USD">19469000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_651b4d42-19f0-4f8c-94ff-e9d3cb162937"
      unitRef="U_USD">12045000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_316399da-ba28-4be5-a8e1-f58cee827883"
      unitRef="U_USD">346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_a5da84af-45f0-4c4e-953c-cad85a1eed8c"
      unitRef="U_USD">12277000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_dd986e62-8284-4fa5-9573-acad0ddc14e6"
      unitRef="U_USD">13888000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_7f9dcd66-4a87-457c-bbe5-023a1cca8636"
      unitRef="U_USD">11146000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_4005ed30-6664-459b-a108-697890dfac8f"
      unitRef="U_USD">6666000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_0f2846d5-c240-4753-b701-c6bc04e71f42"
      unitRef="U_USD">14006000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_23e46a52-781a-42b1-adde-a675b1cfb5d0"
      unitRef="U_USD">17547000</us-gaap:GeneralAndAdministrativeExpense>
    <tcon:ArbitrationSuccessFees
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_3db47e11-ebbc-45e7-9f06-106c2de36918"
      unitRef="U_USD">2375000</tcon:ArbitrationSuccessFees>
    <us-gaap:OperatingExpenses
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_43a73e09-ff03-4e5a-9114-77555436f2c8"
      unitRef="U_USD">21318000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_9dfc8ecf-90a5-45e0-85f1-aa84e0271c86"
      unitRef="U_USD">27894000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_dea56bd9-8592-45c1-a626-f4aa4954d811"
      unitRef="U_USD">28693000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_0399574e-158d-437e-b179-bbac64faf0f4"
      unitRef="U_USD">-9273000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_c962dcac-8ae5-462a-b2d6-c80d71908a8f"
      unitRef="U_USD">-27894000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_e0cf1b89-5f36-45d5-93b5-6508f814dfa2"
      unitRef="U_USD">-28347000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_6ab6592a-e2df-4ff0-8f26-35f7e76a9201"
      unitRef="U_USD">-7304000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_dbfc5b15-fa99-42bd-abd2-3f5e236886ff"
      unitRef="U_USD">-994000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_37dbfb01-9728-4727-a5b2-d80a9ac46a21"
      unitRef="U_USD">-318000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_0b2e44b1-60eb-4b90-93f4-bd2b74a9bc60"
      unitRef="U_USD">12989000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_c5ddd61d-a9e7-4ed5-ae90-dff73712f9f4"
      unitRef="U_USD">-247000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_af377011-999e-44d8-9b99-810debc0f5b1"
      unitRef="U_USD">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_4d3d4490-bf59-47b5-9a6b-97efbf46fb30"
      unitRef="U_USD">5685000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_7313d02e-a36f-4b48-9e3c-32efbae8b109"
      unitRef="U_USD">-1241000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_f4c44370-51fd-4a84-8601-cd96dd85ece7"
      unitRef="U_USD">-320000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_43afa32d-9805-466a-adbf-9b0474155b6b"
      unitRef="U_USD">-3588000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_63375cd5-6f55-4389-bf48-69a06a11c3ac"
      unitRef="U_USD">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_20b14af3-4b38-4c0b-a23b-56b61946d62c"
      unitRef="U_USD">-28667000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="2"
      id="F_aea65718-bc00-49c3-b3f9-a447bdd4e3ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="2"
      id="F_f5284f79-c3a1-4080-bc29-edc74390aa64"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="2"
      id="F_47b038c3-2fbe-4ae7-b6ff-4fd34f55bcb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="2"
      id="F_63355943-ff38-4241-999a-794bb163344f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="2"
      id="F_4fe7f604-0405-4a99-8d0a-0ce208d78741"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="2"
      id="F_8c8c128b-8ade-4797-9949-1e42bd8c6041"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="0"
      id="F_516f522d-e9a8-4d50-a799-3d01a910c66a"
      unitRef="U_shares">32745708</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="0"
      id="F_411df331-7c61-4657-a0da-d62dba103e17"
      unitRef="U_shares">32745708</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="0"
      id="F_6ccd0023-10b6-4771-afc7-7d42a100e20b"
      unitRef="U_shares">20919118</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="0"
      id="F_7f3df95d-c199-4b68-93a2-2a956c1ad900"
      unitRef="U_shares">20919118</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="0"
      id="F_184dbb4b-f856-4312-88dc-4c8b5340049c"
      unitRef="U_shares">17252637</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="0"
      id="F_66199b1b-4575-4fc4-a1ae-bd0e6ba2b9cf"
      unitRef="U_shares">17252637</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_55363737-381a-4453-8820-38a565d61aac"
      decimals="0"
      id="F_4bf797ae-2b9b-47a8-ac54-590290659ed2"
      unitRef="U_shares">15478787</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_55363737-381a-4453-8820-38a565d61aac"
      decimals="-3"
      id="F_385058f2-2888-4097-8fd3-0a50133f75fa"
      unitRef="U_USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9fba94f6-47dd-4e8a-9960-b690725bb795"
      decimals="-3"
      id="F_ec67289e-2430-4429-bb4b-7528c808e2dc"
      unitRef="U_USD">204166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_70a6deb7-5ef8-433d-a7ac-fd7f122fe2e8"
      decimals="-3"
      id="F_a73d82cd-cb8b-47a7-8326-a1bb68e5c7ca"
      unitRef="U_USD">-179109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60"
      decimals="-3"
      id="F_33a89216-ac9a-4d94-92af-1d6b90625a1b"
      unitRef="U_USD">25072000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1"
      decimals="0"
      id="F_1078b15e-14e2-44b0-9dc8-4b581d400a60"
      unitRef="U_shares">40414</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_b3b2c60e-9c95-477b-af58-492387fc1056"
      decimals="-3"
      id="F_a1e3b2de-5556-434e-ae36-0c6d24a31b3f"
      unitRef="U_USD">149000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_9bdb8c73-2776-458b-8c87-2c0f899b13fb"
      unitRef="U_USD">149000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b3b2c60e-9c95-477b-af58-492387fc1056"
      decimals="-3"
      id="F_d3f11916-6ac8-4351-bbad-c6d1b60f4342"
      unitRef="U_USD">1775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_ade47460-4943-460f-a25f-c269c1da2d88"
      unitRef="U_USD">1775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tcon:IssuancesOfCommonStockNetOfOfferingCostsShares
      contextRef="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1"
      decimals="0"
      id="F_ee5605c4-60af-49cb-9300-bef6c93871bf"
      unitRef="U_shares">3926702</tcon:IssuancesOfCommonStockNetOfOfferingCostsShares>
    <tcon:IssuancesOfCommonStockNetOfOfferingCostsValue
      contextRef="C_3c31fefe-7e51-4d0b-8025-e89e95d006d1"
      decimals="-3"
      id="F_7a4c1a7d-3d36-4d53-8d5d-9228d7a2c5cd"
      unitRef="U_USD">4000</tcon:IssuancesOfCommonStockNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockNetOfOfferingCostsValue
      contextRef="C_b3b2c60e-9c95-477b-af58-492387fc1056"
      decimals="-3"
      id="F_c458734c-b021-46e7-95a9-bad59bb76011"
      unitRef="U_USD">13381000</tcon:IssuancesOfCommonStockNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockNetOfOfferingCostsValue
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_a55b348e-5b18-4116-89c5-27052e01810b"
      unitRef="U_USD">13385000</tcon:IssuancesOfCommonStockNetOfOfferingCostsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_f785d70c-45d9-4158-b4cc-5971017cd60b"
      decimals="-3"
      id="F_8522c302-d95e-4fb6-a910-7e5c94d22a12"
      unitRef="U_USD">-28667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_645735e2-93fd-4712-ad62-19ab967df636"
      unitRef="U_USD">-28667000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_475df304-3dbb-4958-a84d-d4bcdf488834"
      decimals="0"
      id="F_1c67a7a7-3f16-49c6-afb9-21a74da04d45"
      unitRef="U_shares">19445903</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_475df304-3dbb-4958-a84d-d4bcdf488834"
      decimals="-3"
      id="F_9595163e-da59-4a7c-bd01-8e62ab416d0f"
      unitRef="U_USD">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_74db5b1f-1c60-43e0-86e8-20cdd644d6d0"
      decimals="-3"
      id="F_d09faa4b-44ed-4a52-99e1-aa736f960c42"
      unitRef="U_USD">219471000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_050dae8e-e369-4b11-afe6-d1549da44936"
      decimals="-3"
      id="F_3a6519a2-e298-4a15-acfe-dee9076920d5"
      unitRef="U_USD">-207776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749"
      decimals="-3"
      id="F_6b7907af-9669-40a6-9648-da0a4c1a5d3a"
      unitRef="U_USD">11714000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="0"
      id="F_545e9483-87fa-461a-9af5-54dc6531d19f"
      unitRef="U_shares">56261</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af"
      decimals="-3"
      id="F_1f1cd178-f3a6-472a-8931-8eb63c8a8fcb"
      unitRef="U_USD">95000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_ba7588b5-4a78-4214-b7c6-286b22198b59"
      unitRef="U_USD">95000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af"
      decimals="-3"
      id="F_fe23c254-4daf-47c0-abfd-b896d307cf61"
      unitRef="U_USD">2041000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_ed6d856e-9729-4d0f-bdc8-78dcdceda621"
      unitRef="U_USD">2041000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="0"
      id="F_a912b4a8-1656-4c85-8ed3-6001f719dc2f"
      unitRef="U_shares">3232418</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="-3"
      id="F_ee10c2aa-99b6-45a7-b678-93f5111c8bb9"
      unitRef="U_USD">3000</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
      contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af"
      decimals="-3"
      id="F_59fa3880-ece0-469d-9ae8-3bad6604d041"
      unitRef="U_USD">7871000</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_62c5a3aa-14b8-4155-b150-2495aa2a5a70"
      unitRef="U_USD">7874000</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="0"
      id="F_a51492cc-828d-4574-b0ff-5e78be70d9c1"
      unitRef="U_shares">390668</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="-3"
      id="F_0d2473e8-0404-4803-b53d-99035326e265"
      unitRef="U_USD">1000</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_9b454bb3-ef73-473b-a73c-de708b6f6cf7"
      unitRef="U_USD">1000</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_9d6ff45e-ba09-4cf9-a53b-7c934ec2a5af"
      decimals="-3"
      id="F_a69c6573-a9fb-46eb-9b23-0f88dda370c5"
      unitRef="U_USD">259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_3175c419-1b77-4c89-b0d2-150c5b48c38d"
      unitRef="U_USD">259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_af96e684-e605-4756-a75e-d1a500792e14"
      decimals="-3"
      id="F_3f04fb4b-aefd-4bc8-b10a-57ae23511aad"
      unitRef="U_USD">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_90b0c5d1-6c22-4f16-baf9-de16738d1f0d"
      unitRef="U_USD">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0a421996-059e-47aa-914f-9c7cd5e3b7d5"
      decimals="0"
      id="F_9973d71e-0279-474e-829e-2fb117131637"
      unitRef="U_shares">23125250</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0a421996-059e-47aa-914f-9c7cd5e3b7d5"
      decimals="-3"
      id="F_9fd2f930-c16b-42c7-93d8-0dcf057aad09"
      unitRef="U_USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_38834898-65ec-45e0-a908-a6b01f5f5240"
      decimals="-3"
      id="F_d1ae1733-2695-47fd-8361-de143ca0604f"
      unitRef="U_USD">229737000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_42ea9fad-5f3b-4079-b265-ececb47bd4b6"
      decimals="-3"
      id="F_79768a71-6cf3-4e23-b649-e3e1b91917a2"
      unitRef="U_USD">-236911000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_80c763ad-26df-4bc0-a275-6d90d99fe7b2"
      unitRef="U_USD">-7151000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="0"
      id="F_1b2a8d24-0f20-4ed8-8fc9-49b3b99a1478"
      unitRef="U_shares">45569</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1"
      decimals="-3"
      id="F_3938729a-fda6-460a-adbc-42d23f9dc682"
      unitRef="U_USD">45000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_e700193b-0aa4-4fbb-b026-3c792d71f4f6"
      unitRef="U_USD">45000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1"
      decimals="-3"
      id="F_f65a4f39-c6fe-48e9-8dfe-34b3893f015b"
      unitRef="U_USD">1969000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_61275293-c071-4814-89dc-ac84e67418f7"
      unitRef="U_USD">1969000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="0"
      id="F_a137a5fd-f5ce-432b-b406-95c895b32d03"
      unitRef="U_shares">14231653</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsInShares>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="-3"
      id="F_7cfea3cc-af42-40cb-be33-8877df559a1f"
      unitRef="U_USD">14000</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
      contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1"
      decimals="-3"
      id="F_6570aebe-b2e6-4d3b-b6a6-db2a9ab09bf3"
      unitRef="U_USD">7902000</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_0d6fc045-bcaa-493f-80c6-3b19e9b86f31"
      unitRef="U_USD">7916000</tcon:IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="0"
      id="F_30dd7cfc-30a9-463e-815b-4ffdb4fb1038"
      unitRef="U_shares">6867504</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="-3"
      id="F_c5f6f452-daeb-46aa-81ba-11f717022cfb"
      unitRef="U_USD">7000</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue
      contextRef="C_78180068-1a5d-4eea-ac9b-4ecb6c9e47b1"
      decimals="-3"
      id="F_16619424-73b7-45d5-90a7-7039f848e7c2"
      unitRef="U_USD">-7000</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_40c3a24d-66cc-419c-a6ce-68d4a1b37552"
      decimals="-3"
      id="F_58dd05b8-6954-4cac-9ff0-03b11072a426"
      unitRef="U_USD">-3588000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_8d1651a0-3738-4ed9-a8e5-cd12770999ba"
      unitRef="U_USD">-3588000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0c28515c-df0f-44e6-bbaa-f389e653f073"
      decimals="0"
      id="F_fe073bf8-0a7d-4000-9fb1-9ed0ebbd1427"
      unitRef="U_shares">44269976</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0c28515c-df0f-44e6-bbaa-f389e653f073"
      decimals="-3"
      id="F_76b572c0-ede3-4ccf-8d33-906d69c02ad1"
      unitRef="U_USD">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_af8d7bab-03a5-4ea5-b757-607eeb29fa0c"
      decimals="-3"
      id="F_2b7fed4b-1fe3-43df-b28e-81afaeaea877"
      unitRef="U_USD">239646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_948e03ad-dcda-4e45-bb27-1fb7cf42583e"
      decimals="-3"
      id="F_6bc238aa-3462-423e-88a7-4e2ac192e7ef"
      unitRef="U_USD">-240499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_44a50f06-a1f3-4344-abf2-d966eaf0f9a8"
      unitRef="U_USD">-809000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_602f8af8-252b-4c63-b762-4eea019b00ba"
      unitRef="U_USD">-3588000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_95d02305-ae02-4fae-80d7-256de5497c67"
      unitRef="U_USD">-29135000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_125da621-a44d-443e-b77d-5a6c489465fb"
      unitRef="U_USD">-28667000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_f16c4011-420d-4abc-9f39-0432e7811921"
      unitRef="U_USD">1969000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_854a6634-60b9-4dc3-82ad-bb49976d24e0"
      unitRef="U_USD">2041000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_dfe69fae-b4b4-4d34-a627-b02560deedb7"
      unitRef="U_USD">1775000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_9ed3b137-4890-4db4-b206-17399f3538d3"
      unitRef="U_USD">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_384aad4a-6a32-43d4-bee8-2567b48e8d04"
      unitRef="U_USD">16000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_488f76cc-420e-41ba-8170-64e2c6bfba5d"
      unitRef="U_USD">14000</us-gaap:DepreciationDepletionAndAmortization>
    <tcon:InterestExpenseNoncash
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_50d09403-f958-4313-b5c0-9df0b24e2090"
      unitRef="U_USD">88000</tcon:InterestExpenseNoncash>
    <tcon:InterestExpenseNoncash
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_2e8ffe48-83fc-4c01-99a6-38e8b95df899"
      unitRef="U_USD">343000</tcon:InterestExpenseNoncash>
    <tcon:InterestExpenseNoncash
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_81e1dce6-0f52-4b0f-8146-7ca2856b1b73"
      unitRef="U_USD">61000</tcon:InterestExpenseNoncash>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_ec2155b1-00ba-4bd6-a6f1-5080a5044410"
      unitRef="U_USD">7325000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_5ca069cf-ff92-4de1-a2c4-10cc4a13c06d"
      unitRef="U_USD">435000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_41b65217-f23a-46ec-a3b3-59c0dc58abc2"
      unitRef="U_USD">21000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_a51238bf-1b0b-4feb-a52a-82bd7d44e195"
      unitRef="U_USD">1000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <tcon:LeaseAssetAmortizationAndLiabilityAccretionNet
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_95a9dfde-3027-4799-9a74-27410af87723"
      unitRef="U_USD">20000</tcon:LeaseAssetAmortizationAndLiabilityAccretionNet>
    <tcon:LeaseAssetAmortizationAndLiabilityAccretionNet
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_b726622d-c423-423e-a62b-6d23cb4efd8d"
      unitRef="U_USD">54000</tcon:LeaseAssetAmortizationAndLiabilityAccretionNet>
    <tcon:LeaseAssetAmortizationAndLiabilityAccretionNet
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_fb8e477b-b4a3-4bf9-8b2a-e10656373959"
      unitRef="U_USD">-73000</tcon:LeaseAssetAmortizationAndLiabilityAccretionNet>
    <tcon:EquityOwnershipLicenseRevenue
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_bb0234bd-6101-4ab8-82a7-d5b905d9f802"
      unitRef="U_USD">-246000</tcon:EquityOwnershipLicenseRevenue>
    <tcon:ImpairmentOfPrivateCompanyEquityOwnership
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_958a8f39-9c5f-42a8-a6bb-8fb3868d6ee7"
      unitRef="U_USD">246000</tcon:ImpairmentOfPrivateCompanyEquityOwnership>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_31adb16f-2dfb-4f84-b4dc-1cc5ea93c3b0"
      unitRef="U_USD">-269000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_f6debfd1-7567-4e51-9172-1d3f93a809c7"
      unitRef="U_USD">-69000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_94ce549c-8cf4-4499-9a34-1a961872e86d"
      unitRef="U_USD">80000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_a7b094a8-309b-41a4-875e-8f2f35d44045"
      unitRef="U_USD">-1391000</tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses>
    <tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_08027018-e9dd-49c4-b252-0a608cb927e4"
      unitRef="U_USD">-233000</tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses>
    <tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_4ae9ec37-cf94-450b-a947-cc06a2fe5b74"
      unitRef="U_USD">4683000</tcon:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_963ff0dd-46c7-4162-97fe-a8f9753404d3"
      unitRef="U_USD">-1030000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_c4a4efbe-bdbd-47a0-99a4-cd42190e67e5"
      unitRef="U_USD">-75000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_f85a76e7-9f73-4b7d-a976-d536e17f51a1"
      unitRef="U_USD">-58000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_518aa0a4-31e9-4422-9e9e-cd94a873224a"
      unitRef="U_USD">3676000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_abdaf322-91ea-42b4-b7e7-095589224dbc"
      unitRef="U_USD">-26239000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_f9fb6e6f-f3e7-4e77-b73a-857ab1866ce3"
      unitRef="U_USD">-22571000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_0e39de1a-540e-48b3-920a-b3278eebb90f"
      unitRef="U_USD">17000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_34f893d9-f694-4545-a5ee-9850bce2246b"
      unitRef="U_USD">48000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <tcon:ProceedsFromMaturityOfShortTermInvestments
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_402e4169-fcd7-4a85-942d-9172bdacafa5"
      unitRef="U_USD">4000000</tcon:ProceedsFromMaturityOfShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_190e73f1-c115-4788-be82-8f2a6424c9ed"
      unitRef="U_USD">-17000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_be73806a-d503-4026-bfd4-bb227cecf209"
      unitRef="U_USD">3952000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <tcon:ProceedsFromLongTermDebtAndArbitrationFinancing
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_4a069bd0-db5e-4a63-9935-cd8ffe74ff84"
      unitRef="U_USD">13390000</tcon:ProceedsFromLongTermDebtAndArbitrationFinancing>
    <tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_ca265712-a4b3-482a-b29a-bad7ba2dc358"
      unitRef="U_USD">20500000</tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable>
    <tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_5a936a05-3fb2-4900-b685-f16086eeccf2"
      unitRef="U_USD">1680000</tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable>
    <tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_543596be-8aa2-4e9d-b844-2cce22e9a930"
      unitRef="U_USD">2800000</tcon:RepaymentOfLongTermDebtAndArbitrationFinancingPayable>
    <tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_59e51efa-33c6-442c-a1c6-cf54b6aeed03"
      unitRef="U_USD">7916000</tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts>
    <tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_2b199c85-9396-47ad-a8ad-120403875ee0"
      unitRef="U_USD">7879000</tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts>
    <tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_4a84fe79-738e-419e-8f80-07a8b75d4416"
      unitRef="U_USD">13211000</tcon:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_3e4080ff-3a52-47ea-9689-d0d979417153"
      unitRef="U_USD">45000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_c92d0c96-6cd3-4f91-bb4d-0a1c3ff3ef3d"
      unitRef="U_USD">95000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_d3611cd2-558a-4840-8df5-c317d721686d"
      unitRef="U_USD">149000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_3d9cbb9f-e784-4d34-9417-36cd0cb9f9a7"
      unitRef="U_USD">-12539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_6e02356b-b567-4c66-9967-65a79c0b1de9"
      unitRef="U_USD">19684000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_682572c8-bb70-4d9a-b731-824d86f22c64"
      unitRef="U_USD">10560000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_332f250a-a340-4314-a026-3d6de931d78d"
      unitRef="U_USD">-8863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_52d50e0b-0026-47ff-8b98-4c9e8a9bce4f"
      unitRef="U_USD">-6572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_579c9ee3-14a2-41cd-a5d5-f73a6b5cfc86"
      unitRef="U_USD">-8059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_062f1301-1bf9-4716-8fe8-b98dfd35fa7d"
      unitRef="U_USD">17500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749"
      decimals="-3"
      id="F_4ff5c546-2e27-4ddd-a678-d50234406e79"
      unitRef="U_USD">24072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60"
      decimals="-3"
      id="F_18141452-b1b1-4c6d-8927-932274060fb5"
      unitRef="U_USD">32131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_69717792-f7ba-40d2-8866-99ad2e74ae0e"
      unitRef="U_USD">8637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_9540037c-32ff-46c1-bd79-230f0663783c"
      unitRef="U_USD">17500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749"
      decimals="-3"
      id="F_4d3a5fce-60b5-47d2-9e4d-508a7c66161a"
      unitRef="U_USD">24072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_06a4e669-b12a-4fd1-9847-277e5fd0f0a9"
      unitRef="U_USD">7491000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_64bd2c9b-8c5e-41a6-a3b6-f97ffcd83e91"
      unitRef="U_USD">359000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_ecb372b7-0323-4242-ab5e-1298c0f90ad6"
      unitRef="U_USD">266000</us-gaap:InterestPaidNet>
    <tcon:IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_4f448d33-e679-4999-b648-aa0cc12ef924"
      unitRef="U_USD">259000</tcon:IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_453d1100-6637-4d26-92fb-fb281bcccc92">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization and Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;TRACON Pharmaceuticals, Inc. (TRACON or the Company) was incorporated in the state of Delaware on October 28, 2004. TRACON is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and utilizes its cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, TRACON Pharma Limited and TRACON Pharma International Limited, which were formed in September 2015 and January 2019, respectively, and are currently inactive. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company has devoted substantially all its efforts to product development, raising capital, and building infrastructure and has not realized revenues from its planned principal operations. The Company has incurred operating losses since inception. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its product candidates and works to develop additional product candidates through research and development programs. At December 31, 2023, the Company had cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is classified as restricted cash as it is pledged as collateral for the Company&#x2019;s obligations under its corporate headquarters facility lease. The Company&#x2019;s ability to execute its operating plan through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financings, or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company&#x2019;s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, management believes that there is substantial doubt about its ability to continue as a going concern for a period of 12 months following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company plans to continue to fund its losses from operations through its existing cash and cash equivalents, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. In addition, the Company may fund its losses from operations through the Capital on Demand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Sales Agreement (the Sales Agreement) the Company entered into with JonesTrading in December 2020, as amended in March 2022, pursuant to which the Company may sell, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which remained available for sale as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the common stock purchase agreement (the LPC Purchase Agreement) the Company entered into with Lincoln Park Capital Fund, LLC (Lincoln Park) in May 2023, pursuant to which the Company may sell, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which remained available for sale as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Global economic and business activities continue to face widespread macroeconomic uncertainties, including labor shortages, inflation and monetary supply shifts, recession risks and potential disruptions from the Russia-Ukraine conflict. The Company continues to actively monitor the impact of these macroeconomic factors on its financial condition, liquidity, operations, and workforce. The extent of the impact of these factors on the Company&#x2019;s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company&#x2019;s business&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the date of this filing.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these investments. Cash and cash equivalents include cash in readily available checking and money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of money market funds held by the Company&#x2019;s financial institution as collateral for the Company&#x2019;s obligations under its facility lease for the Company&#x2019;s corporate headquarters in San Diego, California.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets, which is generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the lease term or estimated useful life of the related assets. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are recorded as other assets, accounts payable and accrued expenses, and other long-term liabilities within the consolidated balance sheet. The Company currently does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#x2019;s leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To date, the Company&#x2019;s revenue has been derived from license and collaboration agreements. The terms of these arrangements included payments to the Company for the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. In accordance with Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC 606), the Company performs the following five steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.  The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. Once a contract is determined to be within the scope of ASC 606, at contract inception the Company assesses the goods or services promised within the contract to determine those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Licenses of intellectual property:  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method.  Performance milestone payments represent a form of variable consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Achievement of milestones that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis and the Company recognizes revenue as or when the performance obligations under the contract are satisfied.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Manufacturing Supply Services: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its out-licensing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company receives payments from its collaborators based on billing schedules established in each contract. Up-front and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its collaboration arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Clinical Trial Expense Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the process of preparing the Company&#x2019;s consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s objective is to reflect the appropriate trial expenses in its consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with the clinical sites and applicable personnel and outside service providers as to the progress or state of consummation of trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#x2019;s clinical trial accruals are dependent upon accurate reporting by clinical sites and other third-party vendors. Although the Company does not expect its estimates to differ materially from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were no material adjustments to the Company&#x2019;s prior period estimates of accrued expenses for clinical trials.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs, including license fees, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense represents the grant date fair value of employee stock option grants, employee restricted stock unit grants (RSUs), and employee stock purchase plan (ESPP) rights recognized as expense over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and ESPP rights using the Black-Scholes option pricing model. The fair value of RSUs is based on the closing sales price for such stock on the date of grant. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than&#x2011;not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and comprehensive loss were the same for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted average number of shares of common stock outstanding that are subject to repurchase. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:5pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,766,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,664,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,015,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_3ebd5d09-c9e0-4fb5-bb52-7092146e5a38">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization and Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;TRACON Pharmaceuticals, Inc. (TRACON or the Company) was incorporated in the state of Delaware on October 28, 2004. TRACON is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and utilizes its cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, TRACON Pharma Limited and TRACON Pharma International Limited, which were formed in September 2015 and January 2019, respectively, and are currently inactive. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_9e7849d5-49ea-4ebe-bcad-97df0feb76e2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company has devoted substantially all its efforts to product development, raising capital, and building infrastructure and has not realized revenues from its planned principal operations. The Company has incurred operating losses since inception. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its product candidates and works to develop additional product candidates through research and development programs. At December 31, 2023, the Company had cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is classified as restricted cash as it is pledged as collateral for the Company&#x2019;s obligations under its corporate headquarters facility lease. The Company&#x2019;s ability to execute its operating plan through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financings, or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company&#x2019;s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, management believes that there is substantial doubt about its ability to continue as a going concern for a period of 12 months following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company plans to continue to fund its losses from operations through its existing cash and cash equivalents, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. In addition, the Company may fund its losses from operations through the Capital on Demand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Sales Agreement (the Sales Agreement) the Company entered into with JonesTrading in December 2020, as amended in March 2022, pursuant to which the Company may sell, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which remained available for sale as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the common stock purchase agreement (the LPC Purchase Agreement) the Company entered into with Lincoln Park Capital Fund, LLC (Lincoln Park) in May 2023, pursuant to which the Company may sell, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which remained available for sale as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-5"
      id="F_317a524e-8a7e-48ef-8527-6e6c92d722bb"
      unitRef="U_USD">-240500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-5"
      id="F_93503cee-2923-4a29-8c1f-60a0f47bda96"
      unitRef="U_USD">8600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-5"
      id="F_6d260d85-081e-426e-aa1d-c3285174c94a"
      unitRef="U_USD">100000</us-gaap:RestrictedCashNoncurrent>
    <tcon:MaximumAggregateValueOfStockToBeSold
      contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007"
      decimals="-5"
      id="F_ed27b498-e2c7-4e1f-bf3b-75d22a4f088f"
      unitRef="U_USD">50000000</tcon:MaximumAggregateValueOfStockToBeSold>
    <tcon:RemainingAmountAvailableUnderTheSalesAgreement
      contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007"
      decimals="-5"
      id="F_e07e4d29-ea55-4823-8022-a7aaf7fe9402"
      unitRef="U_USD">41500000</tcon:RemainingAmountAvailableUnderTheSalesAgreement>
    <tcon:MaximumAggregateValueOfStockToBeSold
      contextRef="C_8c775d2e-ff5c-46f6-b93f-e69459dc4932"
      decimals="-5"
      id="F_bc0ff916-84ce-4219-bc93-8792c9e935d0"
      unitRef="U_USD">26000000</tcon:MaximumAggregateValueOfStockToBeSold>
    <tcon:RemainingAmountAvailableUnderTheSalesAgreement
      contextRef="C_8c775d2e-ff5c-46f6-b93f-e69459dc4932"
      decimals="-5"
      id="F_037b4983-21a2-4c05-a5b6-bba5d4b49d1d"
      unitRef="U_USD">25000000</tcon:RemainingAmountAvailableUnderTheSalesAgreement>
    <tcon:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_9a88de92-2989-4ef0-9c63-0f06fa850658">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Global economic and business activities continue to face widespread macroeconomic uncertainties, including labor shortages, inflation and monetary supply shifts, recession risks and potential disruptions from the Russia-Ukraine conflict. The Company continues to actively monitor the impact of these macroeconomic factors on its financial condition, liquidity, operations, and workforce. The extent of the impact of these factors on the Company&#x2019;s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company&#x2019;s business&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</tcon:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_3b31ae96-86da-4da9-adff-d3d7c39e4c42">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the date of this filing.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_5aeafb44-b912-4f61-a9a6-5065975d58bb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these investments. Cash and cash equivalents include cash in readily available checking and money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_f77be179-151c-43ec-8f98-b5a50db7dbc2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of money market funds held by the Company&#x2019;s financial institution as collateral for the Company&#x2019;s obligations under its facility lease for the Company&#x2019;s corporate headquarters in San Diego, California.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_0f4e0964-09c7-4aac-8e1b-d2dcda519d92">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_c7470ac2-ad67-44cd-bef7-5e54ee0705a8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets, which is generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the lease term or estimated useful life of the related assets. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      id="F_1067d166-b835-46a1-aa90-bef94380caed">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_a19bda86-6496-4846-b64f-5e79dd7c7657">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are recorded as other assets, accounts payable and accrued expenses, and other long-term liabilities within the consolidated balance sheet. The Company currently does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#x2019;s leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_db03bc94-a9ea-4250-a128-7282210e3378">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To date, the Company&#x2019;s revenue has been derived from license and collaboration agreements. The terms of these arrangements included payments to the Company for the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. In accordance with Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC 606), the Company performs the following five steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.  The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. Once a contract is determined to be within the scope of ASC 606, at contract inception the Company assesses the goods or services promised within the contract to determine those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Licenses of intellectual property:  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method.  Performance milestone payments represent a form of variable consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Achievement of milestones that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis and the Company recognizes revenue as or when the performance obligations under the contract are satisfied.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Manufacturing Supply Services: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its out-licensing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company receives payments from its collaborators based on billing schedules established in each contract. Up-front and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its collaboration arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <tcon:ClinicalTrialExpenseAccrualsPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_eea23f10-dab4-4e99-b3db-9a7fdbc3573c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Clinical Trial Expense Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the process of preparing the Company&#x2019;s consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s objective is to reflect the appropriate trial expenses in its consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with the clinical sites and applicable personnel and outside service providers as to the progress or state of consummation of trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#x2019;s clinical trial accruals are dependent upon accurate reporting by clinical sites and other third-party vendors. Although the Company does not expect its estimates to differ materially from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were no material adjustments to the Company&#x2019;s prior period estimates of accrued expenses for clinical trials.&lt;/span&gt;&lt;/p&gt;</tcon:ClinicalTrialExpenseAccrualsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_ccf9b642-d4be-495b-bbc6-d40710d15086">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs, including license fees, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <tcon:PatentCostsPolicyPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_2f5f7599-cdb8-4989-8fe9-df5eef8ef874">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;</tcon:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_6b806a6c-d2a7-4dcf-86c6-68baa6e46844">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense represents the grant date fair value of employee stock option grants, employee restricted stock unit grants (RSUs), and employee stock purchase plan (ESPP) rights recognized as expense over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and ESPP rights using the Black-Scholes option pricing model. The fair value of RSUs is based on the closing sales price for such stock on the date of grant. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_7f54a350-86d5-455f-b4bb-f0bfe0c1c830">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than&#x2011;not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_165a1fa2-373e-4003-8229-03c8f2e7c495">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and comprehensive loss were the same for all periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_6c7cf2d8-dd85-462a-8c31-8cededb79d0d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted average number of shares of common stock outstanding that are subject to repurchase. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:5pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,766,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,664,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,015,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_f3618f84-2319-45fa-a0a5-aee55e071eaf">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:5pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,766,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,664,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,015,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c3f43995-11fa-4df2-a9ec-f4edd6b8a5b2"
      decimals="INF"
      id="F_a814dcd8-c6ba-4b5f-9066-5305ff8cf620"
      unitRef="U_shares">1533293</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a62feee6-1322-4bcf-9874-c9bc8fbcda7d"
      decimals="INF"
      id="F_ed3e3185-91d1-4e0d-a529-0afae35febbf"
      unitRef="U_shares">6766246</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e8c5c302-7618-485c-9ff6-32bd1855c0cd"
      decimals="INF"
      id="F_948949bc-e666-45de-8142-3108f3910bde"
      unitRef="U_shares">3121152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fa2d3186-d82c-44fe-9ee7-07c5a15c9315"
      decimals="INF"
      id="F_01d8425c-5211-414e-adcd-398b16d18dc5"
      unitRef="U_shares">2246310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3d0aab07-6eea-4e52-afb9-65f4dc53f96e"
      decimals="INF"
      id="F_3bee2a68-8c2f-453f-9751-d17fea3d63b9"
      unitRef="U_shares">10444</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5ae2450d-d4e4-40a6-b829-f38b64d59da3"
      decimals="INF"
      id="F_1086ceb6-44b3-4fb7-9cc1-b17b2427d257"
      unitRef="U_shares">3387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="INF"
      id="F_0d7d070b-6f20-49a7-90d3-9cee9d8835d7"
      unitRef="U_shares">4664889</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="INF"
      id="F_d5a611a0-5a8d-47e7-9c9a-20d2cbe00137"
      unitRef="U_shares">9015943</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_3b24b8b3-26ac-4e88-b974-0de74d07e0cf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="INF"
      id="F_b028cd23-0f0d-4668-b234-0c6ae352c73e"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_95c37d5a-4acd-4dd5-b9dc-f1ceef1a78fa">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Financial Instruments and Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents, which are classified as equity securities, and restricted cash consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.367%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.981%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.0009999999999994%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash and cash equivalents, prepaid and other assets, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1:	Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2:	Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of the Company&#x2019;s assets and liabilities, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.09%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Active Markets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;for Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_cc5f99e8-adfc-4430-9f08-d3f8447a2142">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents, which are classified as equity securities, and restricted cash consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.367%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.981%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.941000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.0009999999999994%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2872028b-ba94-482c-8437-c4832c35599a"
      decimals="-3"
      id="F_9fbf51c7-84b8-4cbf-8874-b1d777bc6f64"
      unitRef="U_USD">3689000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2872028b-ba94-482c-8437-c4832c35599a"
      decimals="-3"
      id="F_91154500-a32a-4b62-aa39-54fed72e833f"
      unitRef="U_USD">3689000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9d44d79c-a241-471f-bb27-6c48118f0d44"
      decimals="-3"
      id="F_3b620f6a-aa14-4bd9-bd11-b4631b39f3f8"
      unitRef="U_USD">10150000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9d44d79c-a241-471f-bb27-6c48118f0d44"
      decimals="-3"
      id="F_151637e6-131d-4c7e-bd89-75ecdeb90f8e"
      unitRef="U_USD">10150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_0be0b736-8c7d-4b4f-b7d7-41f49377bdc8"
      unitRef="U_USD">3616000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_4bbfb9bf-3787-479a-b264-4e4008857c9c"
      unitRef="U_USD">10083000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tcon:RestrictedCashFairValueDisclosure
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_f18d95ef-aacc-4f2e-a70d-cdf77e1f07a3"
      unitRef="U_USD">73000</tcon:RestrictedCashFairValueDisclosure>
    <tcon:RestrictedCashFairValueDisclosure
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_f7434d50-59a0-4fc8-9ed4-939e1b015df6"
      unitRef="U_USD">67000</tcon:RestrictedCashFairValueDisclosure>
    <tcon:CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_77fb99fd-1cbd-4ab8-b4ef-58eba35285df"
      unitRef="U_USD">3689000</tcon:CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure>
    <tcon:CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_c7441b99-8cd7-498f-81d8-7016cf6d0c39"
      unitRef="U_USD">10150000</tcon:CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_f87e7ebe-a985-47e3-8eae-dac7166f05d1"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <tcon:FairValueTransfersBetweenLevelsAmount
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_7d7ad7ee-07a6-4a2e-8d13-14cfd239f527"
      unitRef="U_USD">0</tcon:FairValueTransfersBetweenLevelsAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_1bb5d043-196e-467b-b380-ace7707983e1">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of the Company&#x2019;s assets and liabilities, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.09%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Active Markets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;for Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa5025a8-1fb4-4cdf-bae0-549dd0c077ec"
      decimals="-3"
      id="F_697e4c5e-3efa-46c6-8c71-4fd75d47efdc"
      unitRef="U_USD">3689000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f632fdf6-d5bb-47f5-b665-011709762d71"
      decimals="-3"
      id="F_cb48eb2f-eb16-4fa4-afbb-abeb07f0866c"
      unitRef="U_USD">3689000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7ac1269c-37c7-4ba8-ad75-d74191163fc4"
      decimals="-3"
      id="F_c3385f62-d85b-46e3-a245-2d0a5895e371"
      unitRef="U_USD">10150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4da012b8-a385-42a2-9bf0-9a586e2e0ba2"
      decimals="-3"
      id="F_adfa59ff-70ce-4eb7-9c43-d3a056f92975"
      unitRef="U_USD">10150000</us-gaap:AssetsFairValueDisclosure>
    <tcon:BalanceSheetRelatedDisclosuresTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_5da60362-22af-4f79-a4b0-314dd20546da">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Balance Sheet Details&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation and amortization expense related to property and equipment totaled approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued legal and accounting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued long-term debt terminal interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</tcon:BalanceSheetRelatedDisclosuresTextBlock>
    <tcon:ScheduleOfPropertyAndEquipmentTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b13a3fa2-3ed9-410c-8538-424764912891">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tcon:ScheduleOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_25f6f616-38af-477d-9616-f204a98ff0ba"
      decimals="-3"
      id="F_3b69b83b-8e82-4e91-9021-565d3c4bbfa0"
      unitRef="U_USD">203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ac868d35-ee5d-4979-85bb-00dafa76357d"
      decimals="-3"
      id="F_5cdbd4cb-f7a0-4ab7-9a93-9199b49ef5f6"
      unitRef="U_USD">203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_afe12a9f-a1ba-4eb0-8945-f294141cf382"
      decimals="-3"
      id="F_9722eca0-e1ef-415a-b040-1c4aac617bb8"
      unitRef="U_USD">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_18ad7425-f5b0-4ca5-b02f-4051b623fbc5"
      decimals="-3"
      id="F_6fb17be6-2851-4356-884b-88df6637b3d0"
      unitRef="U_USD">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e8c41e95-942f-4e44-ae98-385347e4f1c0"
      decimals="-3"
      id="F_fd07181d-69cc-4074-97cf-89a8f1ca4624"
      unitRef="U_USD">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_88b652d5-3be6-4a6b-aa98-270cb604d499"
      decimals="-3"
      id="F_be628cf5-5de0-4c22-87e5-73f7a2a69bb1"
      unitRef="U_USD">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_0f47a13e-45a5-4dc1-81e1-2ffcd1b48dc0"
      unitRef="U_USD">243000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_422a6ff3-2c17-416f-b590-e28486d529ac"
      unitRef="U_USD">243000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_f3bb68b0-bb2a-4a6a-b491-44608a9b4615"
      unitRef="U_USD">206000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_22924ae0-9210-44c3-9b4c-40c8b2ff5fa7"
      unitRef="U_USD">192000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_cd80bdd7-71cb-4060-be56-27aed5a7be56"
      unitRef="U_USD">37000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_6940a508-38e4-4d2c-b9e9-e2d42074a18d"
      unitRef="U_USD">51000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_64b3657f-659d-456b-b63b-68946759d4e7"
      unitRef="U_USD">14000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_c2f7b1f7-8782-4554-9c73-252f10c08a44"
      unitRef="U_USD">16000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_eba70183-52aa-4155-85dd-bf6af6d11b1d"
      unitRef="U_USD">14000000</us-gaap:DepreciationAndAmortization>
    <tcon:ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_d7bae144-282b-4e02-b52a-b71e372477b5">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued legal and accounting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued long-term debt terminal interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tcon:ScheduleOfAccountsPayableAndAccruedExpensesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_ff87433a-12b8-4a16-8558-a71bf72427bd"
      unitRef="U_USD">2544000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_bdeab0a3-67c9-45e4-a3b0-82e8c2ad04d1"
      unitRef="U_USD">3923000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_53f3e68c-020b-450f-add3-af9da523304f"
      unitRef="U_USD">6736000</us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_4f400bcb-d963-4b0a-b60e-8bc60e5fc230"
      unitRef="U_USD">6091000</us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_38ab88c7-14ff-4d96-8d9b-49df9547ebaa"
      unitRef="U_USD">199000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_118c3c09-aa0f-4f52-b325-77527541aea1"
      unitRef="U_USD">299000</us-gaap:AccruedProfessionalFeesCurrent>
    <tcon:AccruedLongTermDebtTerminalInterestCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_eba0693a-f736-42de-8c72-162219b0befd"
      unitRef="U_USD">425000</tcon:AccruedLongTermDebtTerminalInterestCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_2fe7dfff-ab8a-41ec-b669-52df31405891"
      decimals="-3"
      id="F_4313ae60-5a9e-4c2b-a0b2-5c716736f08a"
      unitRef="U_USD">236000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_753dbf14-c0c8-4d2d-b958-384acd243082"
      decimals="-3"
      id="F_5b9df6df-7ede-41ac-b04d-345ab586ec01"
      unitRef="U_USD">198000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_d8661689-cca7-41de-b27b-e7368873276a"
      unitRef="U_USD">40000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_e4f8a5e0-78fc-4273-9b04-e396d7a166d0"
      unitRef="U_USD">171000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DebtCurrent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_3e4eb5d3-8ebc-447a-a186-76b074133079"
      unitRef="U_USD">9755000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_c5fc3d7a-c113-43ed-b366-ec52d89ec6f2"
      unitRef="U_USD">11107000</us-gaap:DebtCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_74d0207f-b124-47a7-84a4-cbe75332170b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Long-Term Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Arbitration Financing Investment Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2022, the Company entered into a non-recourse financing agreement (the Investment Agreement) with certain investors (collectively, the Investors) pursuant to which the Investors agreed to pay the Company a maximum aggregate amount (Maximum Capital) equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million or a lesser amount based on the amount awarded (Arbitration Award), if any, to the Company in connection with its arbitration proceeding (the Arbitration) with I-Mab Biopharma (I-Mab). Of the Maximum Capital, (i) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (Initial Capital) was paid to the Company shortly after execution, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% was to be paid to the Company within 15 business days of issuance of an Arbitration Award, subject to the Arbitration Award size exceeding a prespecified threshold and satisfaction of other conditions set forth in the Investment Agreement, and (iii) the remainder was to be paid to the Company in tranches over a multi-year period, subject to the issuance of an Arbitration Award and the Arbitration Award size exceeding a prespecified threshold and satisfaction of other conditions set forth in the Investment Agreement. In connection with the execution of the Investment Agreement and funding of the Initial Capital amount, the Company paid a closing fee in the amount of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. In April 2023, the Company received notification of the Arbitration Award resulting from the Arbitration. As the Arbitration Award did not exceed the prespecified thresholds under the Investment Agreement, the Company will not receive any additional funds under the Investment Agreement such that, as of date of the Arbitration Award, the Maximum Capital is equal to the Initial Capital.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subject to and contingent on the Company&#x2019;s actual recovery of proceeds from an Arbitration Award or any contemporaneously resolved settlements with I-Mab and following the payment of applicable attorney&#x2019;s fees (the Proceeds), the Company was required to pay the Investors an amount (Repayment Amount) equal to the sum of (i) all amounts paid by the Investors to or on behalf of the Company pursuant to the Investment Agreement, plus (ii) a low sub-single digit to low single digit multiple calculated on each tranche of Maximum Capital actually paid by the Investors to or on behalf of the Company with the applicable multiple being based on the timing of payment from the Company and whether certain events relating to the Arbitration occurred, plus (iii) a mid-teen percentage annual rate of return on the amounts set forth in clauses (i) and (ii) that begins to accrue if the amounts are not paid by the Company to the Investors within a multi-month period specified in the Investment Agreement. If the amount of Proceeds are less than the Repayment Amount, then the Company was only required to pay to the Investors the Proceeds recovered (other than in circumstances in which the Company accepts a settlement offer that resolves the Arbitration for an amount less than the Repayment Amount without the prior written consent of the Investors), and in the circumstance in which there are no Proceeds then the Company was not required to pay the Investors any Repayment Amounts and the Investors have no right of recourse or right of action against the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2022, the Investors funded the Initial Capital amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which was recorded as arbitration financing payable on the consolidated balance sheets, net of debt discount, including the Initial Capital closing fee, and amortized over the estimated term of the agreement using the effective interest method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2023, the Company agreed to and collected a settlement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in full satisfaction of the Arbitration Award. The Company determined an effective interest rate and term over which the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related debt discount was amortized based on the known timing of collection of the proceeds from the Arbitration Award resulting in $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;f interest being recognized during the year ended December 31, 2023. At December 31, 2023, the arbitration financing investment agreement was paid in full and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; future amounts were owed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Runway Growth Finance Corp. Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2022, the Company entered into a loan and security agreement (the RGC Loan Agreement) with Runway Growth Finance Corp. (RGC). The RGC Loan Agreement was a long-term debt facility that provided a term loan commitment in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; tranches: (i) a Term A loan in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, with the full amount funded in a single disbursement on closing of the RGC Loan Agreement and repaid in January 2023 in connection with the Investment Agreement; (ii) a Term B loan in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to be funded in one or more disbursements at the request of the Company on or prior to June 30, 2024, subject to certain conditions being met; and (iii) a Term C loan in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that may be disbursed in a single disbursement in the lender&#x2019;s sole discretion upon the Company&#x2019;s request at any time from closing of the RGC Loan Agreement through and including December 31, 2024. In December 2022, the Company and RGC amended the RGC Loan Agreement (the RGC Loan Amendment) under which: (i) the Company repaid all amounts of principal and accrued but unpaid interest in respect of the Term A Loan (as defined in the RGC Loan Agreement) on January 3, 2023 without the obligation for the Company to pay the final payment fee or the prepayment fee described in the RGC Loan Agreement; (ii) on or before March 31, 2023, at the Company&#x2019;s request, if the Company has raised at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net cash proceeds from certain equity or debt transactions (including amounts raised in connection with the Investment Agreement) prior to making such request, RGC will loan to the Company an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, with the full amount funded in a single disbursement; (iii) the Company will not issue an additional warrant to RGC in connection with the loan, if any, described in clause (ii) above; and (iv) RGC&#x2019;s security interest in Specific Collateral was subordinated to the arbitration financing Investors&#x2019; security interest in the Specific Collateral. If the loan described in clause (ii) above is not made by March 31, 2023, the RGC Loan Agreement will terminate on that date, and the Company will not be obligated to pay the prepayment fee described in the RGC Loan Agreement but the final payment fee of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate principal amount of the funded term loans as described in the RCG Loan Agreement will become immediately due and payable. All other material terms and conditions of the RGC Loan Agreement remained unchanged and the transaction was accounted for as a debt modification. On April 5, 2023, the Company and RGC amended the RGC Loan Agreement effective March 31, 2023 such that the Company would have until April 15, 2023 to raise at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net cash proceeds from certain equity or debt transactions prior to making a request of RGC to redraw an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the RGC Loan Agreement, which RGC may, in its sole and absolute discretion, allow or deny. On April 20, 2023, the Company and RGC amended the RGC Loan Agreement effective April 15, 2023 to extend the time period described in the foregoing sentence from April 15, 2023 to April 28, 2023. The Company did not redraw the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the RGC Loan Agreement, as amended, by April 28, 2023, resulting in the RGC Loan Agreement terminating and the final payment fee becoming immediately due and payable on that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the funding of the Term A loan, the Company issued RGC warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,753&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock (the RGC Term A Warrants) at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per underlying share of the Company&#x2019;s common stock. The RGC Term A Warrants are fully exercisable in whole or in part at the option of the holder, payable in cash or on a cashless basis according to the formula set forth in the RGC Term A Warrants, and expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 2, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The fair value of the warrant at the grant date was determined utilizing a Black-Scholes pricing model, recorded as a component of the total debt discount and stockholders&#x2019; deficit within additional paid-in capital on the consolidated balance sheets, and was amortized to interest expense using the effective interest method over the term of the debt.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, long-term debt and unamortized debt discount balances associated with the RGC Loan Agreement were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less debt discount, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt, net of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less current portion of long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023, the RGC Loan Agreement was paid in full and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; future amounts were owed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Silicon Valley Bank Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2018, the Company entered into a third amendment to its Amended and Restated Loan and Security Agreement with Silicon Valley Bank (the 2018 Amended SVB Loan) under which the Company borrowed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, all of which was immediately used to repay the Company&#x2019;s then existing loan with SVB.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2018 Amended SVB Loan matured in June 2022 and in accordance with its terms, the Company paid a final payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million associated with the payoff of the 2018 Amended SVB Loan. In August 2022, the Company terminated the 2018 Amended SVB Loan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company&#x2019;s loan agreements with SVB:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expiration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 25, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;June 4, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;May 3, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <tcon:MaximumCapitalContribution
      contextRef="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9"
      decimals="INF"
      id="F_19a90205-1b72-4250-8325-ad596e1d5fa9"
      unitRef="U_USD">30000000</tcon:MaximumCapitalContribution>
    <tcon:InitialCapitalContributionFromInvestors
      contextRef="C_dee76b1c-3511-482e-af8c-baca4374550b"
      decimals="-5"
      id="F_529e66e9-157c-452c-a692-5fdf969d4257"
      unitRef="U_USD">3500000</tcon:InitialCapitalContributionFromInvestors>
    <tcon:PercentageOfInitialCapitalContributionFromInvestors
      contextRef="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9"
      decimals="2"
      id="F_02885daf-8205-45bd-81aa-37cee8043cc1"
      unitRef="U_pure">0.25</tcon:PercentageOfInitialCapitalContributionFromInvestors>
    <tcon:PercentageOfClosingFeeAmount
      contextRef="C_dee76b1c-3511-482e-af8c-baca4374550b"
      decimals="2"
      id="F_0839c8fa-6fcd-4b2f-9661-28d67cb4d596"
      unitRef="U_pure">0.02</tcon:PercentageOfClosingFeeAmount>
    <tcon:ArbitrationFinancingPayable
      contextRef="C_676e7f5e-a774-4005-88e2-f5d56efdc8e9"
      decimals="-5"
      id="F_03aaac48-7808-4b92-9df8-f19fee9c6592"
      unitRef="U_USD">3500000</tcon:ArbitrationFinancingPayable>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="C_f6b50908-851a-401b-87d4-7d20d639276e"
      decimals="-5"
      id="F_15c76efc-631b-40fe-94e7-c43583a63e8b"
      unitRef="U_USD">22000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <tcon:ArbitrationAwardInterestExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_c17ef000-8ed0-4bbf-915e-22cea87d6a62"
      unitRef="U_USD">7200000</tcon:ArbitrationAwardInterestExpense>
    <tcon:ArbitrationFinancingPayable
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_fa00f297-8a32-404b-85c2-aa98c844939c"
      unitRef="U_USD">0</tcon:ArbitrationFinancingPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6bcf6ae1-6f62-4022-a841-9cb5606b41f4"
      decimals="INF"
      id="F_32c0a6a3-e117-44c7-8661-1bb39d83ab11"
      unitRef="U_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <tcon:NumberOfTranche
      contextRef="C_a0cfd32a-d85b-4d8a-9619-e9e603c0063b"
      decimals="INF"
      id="F_080504ff-2ce9-466e-bcb8-b161ace2c5be"
      unitRef="U_Tranche">3</tcon:NumberOfTranche>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_b0b548c4-d2f9-43e6-8243-8c33b7859be8"
      decimals="-5"
      id="F_4bc09844-2715-47d6-a8c0-051a3d2309eb"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_7c23779b-d204-40a0-a57c-ba7a3fd5104a"
      decimals="INF"
      id="F_781bcfa5-c7f3-401e-aacd-e68bc520a355"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_871edb40-17b4-426d-9503-2ecbf34f60e9"
      decimals="INF"
      id="F_c70aa2b1-886a-4135-b74a-9639efc8fb19"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
      contextRef="C_c4946e13-3da8-4743-9ee6-bc34ada03788"
      decimals="-5"
      id="F_0c000889-67e2-45fd-86d4-1585e0a6e878"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_36e936e9-4748-422c-af13-03094cd386a4"
      decimals="-5"
      id="F_cc735f88-8afd-46bc-a1dd-780d6fcc6013"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <tcon:PercentageOfFinalPaymentFee
      contextRef="C_ce6896ec-3d61-4ba8-b0f3-65531cd77796"
      decimals="4"
      id="F_f82bd807-b127-415f-b90c-4f7bfddaf80f"
      unitRef="U_pure">0.0425</tcon:PercentageOfFinalPaymentFee>
    <us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
      contextRef="C_0094047e-e7f2-42e3-a4eb-0ed27b0d1e40"
      decimals="-5"
      id="F_fe55f2d8-c290-4813-92f5-4a1f88709236"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_aa5fbb77-e965-4baf-b389-6c9224794641"
      decimals="INF"
      id="F_d7af7516-d344-4d9b-8c67-427525c4df51"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_2f47e236-54b6-4d53-9564-adba4ece78af"
      decimals="INF"
      id="F_1a2a6db4-96d0-4282-8fbd-8f3e9281466b"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3b34aed6-5a9c-4e22-8703-226017dd6deb"
      decimals="INF"
      id="F_3ccd0705-ee3c-4342-aafd-fe129cb9bc3c"
      unitRef="U_shares">150753</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3b34aed6-5a9c-4e22-8703-226017dd6deb"
      decimals="INF"
      id="F_6a6aad33-9de1-46e7-9425-5327b6c74691"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_3b34aed6-5a9c-4e22-8703-226017dd6deb"
      id="F_676bc16b-3010-4365-adae-5ac7e34b8cd4">2032-09-02</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_6fa19861-1e14-4eb4-aa3d-5db0fbf3d45e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, long-term debt and unamortized debt discount balances associated with the RGC Loan Agreement were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less debt discount, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt, net of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less current portion of long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_c879cf24-918a-46ea-b197-48c7ea031e02"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <tcon:LongTermDebtNetOfUnamortizedLongTermAmortization
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_f918502e-7ae1-4797-b028-e4a496f29ebe"
      unitRef="U_USD">10000000</tcon:LongTermDebtNetOfUnamortizedLongTermAmortization>
    <tcon:LongTermDebtCurrentGross
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_69d2fe68-6214-45a0-9989-94a600f1581b"
      unitRef="U_USD">10000000</tcon:LongTermDebtCurrentGross>
    <tcon:LongTermDebtCurrentGross
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_085667db-92b2-46b5-a0dc-f4dd32f9903a"
      unitRef="U_USD">10000000</tcon:LongTermDebtCurrentGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_2b15a852-edd5-450a-b188-6f5b5ce7516a"
      unitRef="U_USD">193000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_e405e43d-1545-4682-82fd-306eba14f1a0"
      unitRef="U_USD">9807000</us-gaap:LongTermDebtCurrent>
    <tcon:InterestAndFinalPayment
      contextRef="C_e523f290-ecdf-4b86-9681-520bb864b996"
      decimals="INF"
      id="F_50308951-f3d4-4752-81c8-6e40e66501ed"
      unitRef="U_USD">0</tcon:InterestAndFinalPayment>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_dadec75d-3635-4b34-97db-e4a9d80be690"
      decimals="INF"
      id="F_2a15a65f-052b-4a61-979f-7585ab66e536"
      unitRef="U_USD">7000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <tcon:FinalPaymentOnPayoff
      contextRef="C_dadec75d-3635-4b34-97db-e4a9d80be690"
      decimals="-5"
      id="F_74df8b79-a200-49e0-a6d5-db50db5f2318"
      unitRef="U_USD">300000</tcon:FinalPaymentOnPayoff>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_bbfa3f1b-4a04-4d54-bd2d-0bbbba072286">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company&#x2019;s loan agreements with SVB:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expiration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 25, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;June 4, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;May 3, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had the following outstanding warrants for the purchase of common stock:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expiration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 25, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 27, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,369,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;June 4, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;May 3, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 2, 2032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e"
      decimals="INF"
      id="F_d73313f0-cca7-42ca-8e55-1188d18c615b"
      unitRef="U_shares">4669</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2399d0b9-3a5f-49b1-b6eb-50128ba4b62e"
      decimals="INF"
      id="F_8b3b708a-1578-4cbe-991c-251e31570595"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">51.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9016afcd-3dde-4d11-9f4f-8fa39038db47"
      decimals="INF"
      id="F_94a9807c-66ae-4eef-9501-ecb369d68c58"
      unitRef="U_shares">2906</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9016afcd-3dde-4d11-9f4f-8fa39038db47"
      decimals="INF"
      id="F_5110a429-ac66-4a27-bf88-f3cf6c2a47af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">77.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_12cbadd1-c66c-4148-a655-212d5c0bb0a1"
      decimals="INF"
      id="F_dab5ea98-26ae-4491-87de-1026a2688a65"
      unitRef="U_shares">5363</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_12cbadd1-c66c-4148-a655-212d5c0bb0a1"
      decimals="INF"
      id="F_3bb5bf1a-f927-4f81-bba1-a31b868055e6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9c65da7a-8508-4963-9ecf-2e2bffdab2b5"
      decimals="INF"
      id="F_4cdddef6-036a-4fd0-9b93-7936a678e709"
      unitRef="U_shares">12938</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_0ea94d46-5862-4372-a105-c50610d21531">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various license agreements pursuant to which the Company acquired licenses to certain intellectual property. The agreements generally required an upfront license fee and, in some cases, reimbursement of patent costs. Additionally, under each agreement, the Company may be required to pay annual maintenance fees, royalties, milestone payments and sublicensing fees. Each license agreement is generally cancelable by the Company, given appropriate prior written notice. At December 31, 2023, potential future milestone payments under these agreements totaled an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tcon:CollaborativeArrangementsMilestonePaymentsPotential
      contextRef="C_3bdfeab3-03b0-41d5-bcd4-2f2f5ac6bc5f"
      decimals="-5"
      id="F_03ffe534-ea5d-4cf5-80bf-70a09b991c6b"
      unitRef="U_USD">9600000</tcon:CollaborativeArrangementsMilestonePaymentsPotential>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_dadd8b55-ea52-4f76-9e5b-1fbdd5c6f7c4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lincoln Park Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company and Lincoln Park entered into the LPC Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Lincoln Park is committed to purchase up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company's shares of common stock from time to time and at the Company&#x2019;s sole discretion over the term of the LPC Purchase Agreement, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which remained available for sale as of December 31, 2023. In consideration for entering into the LPC Purchase Agreement, concurrently with the execution of the LPC Purchase Agreement, the Company issued to Lincoln Park &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;599,216&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock as a commitment fee, which was recorded as a component of stockholders&#x2019; deficit within additional paid-in capital on the consolidated balance sheets. Concurrently with entering into the LPC Purchase Agreement, the Company also entered into a Registration Rights Agreement in which the Company agreed to file one or more registration statements as permissible and necessary to register under the Securities Act for resale of the shares of its common stock that may be issued to Lincoln Park under the LPC Purchase Agreement, which occurred in May 2023. In May 2023, the Company also issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,735,207&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares (the Initial Purchase Shares) of the Company&#x2019;s common stock to Lincoln Park pursuant to the LPC Purchase Agreement at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5763&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Initial Purchase Share resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. At the Company's special meeting of stockholders held in September 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the potential future sale and issuance of shares of the Company&#x2019;s common stock to Lincoln Park in accordance with the pricing terms set forth in the LPC Purchase Agreement that could result in Lincoln Park owning in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such sale.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sale of Common Stock and Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2023, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;174,508&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,013,999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of underlying common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of underlying common stock (the 2023 Pre-Funded Warrants) for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in a private placement (the Private Placement) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2023 Pre-Funded Warrants may not be exercised if the holder&#x2019;s ownership of the Company&#x2019;s common stock would exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such exercise, unless approval by the Company's stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). The 2023 Pre-Funded Warrants were recorded as a component of stockholders&#x2019; deficit within additional paid-in capital on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;841,989&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,205,018&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of underlying common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of underlying common stock (the 2022 Pre-Funded Warrants) for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in a registered direct offering (the Offering) with an accredited institutional healthcare-focused fund. In accordance with their terms, the 2022 Pre-Funded Warrants may not be exercised if the holder&#x2019;s ownership of the Company&#x2019;s common stock would exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such exercise, unless approval by the Company's stockholders is obtained as required under the Nasdaq listing standards, including Nasdaq Listing Rules 5635(b) and (d). The 2022 Pre-Funded Warrants were recorded as a component of stockholders&#x2019; deficit within additional paid-in capital on the consolidated balance sheets. In connection with the Offering, the Company amended two existing pre-funded warrants to purchase shares of the Company&#x2019;s common stock held by the same institutional healthcare-focused fund to extend the exercise periods and to permit exercise in excess of a similar &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% limit following approval of the Company&#x2019;s stockholders of such exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the Company's 2023 Annual Meeting held in April 2023, stockholder approval, in accordance with applicable rules of the Nasdaq Stock Market, was obtained for the issuance of shares of common stock upon the potential future exercise of certain outstanding warrants held by this accredited institutional healthcare-focused fund, including the 2023 Pre-Funded Warrants and the 2022 Pre-Funded Warrants, that would result in it and its affiliates owning in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares of common stock outstanding immediately after giving effect to such exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;At-The-Market Issuance Sales Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2020, as amended in March 2022, the Company entered into a Capital on Demand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Sales Agreement (the Sales Agreement) with JonesTrading, pursuant to which it may sell from time to time, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock through JonesTrading, as sales agent or principal, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which remained available for sale as of December 31, 2023. Sales of the Company&#x2019;s common stock made pursuant to the Sales Agreement with JonesTrading, if any, will be made on the Nasdaq Capital Market under the Company&#x2019;s effective registration statement on Form S-3, subject to limitations on the amount of securities the Company may sell pursuant to its effective registration statement on Form S-3 within any 12-month period, by means of ordinary brokers&#x2019; transactions at market prices. Additionally, under the terms of the Sales Agreement, the Company may also sell shares of its common stock through JonesTrading, on the Nasdaq Capital Market or otherwise, at negotiated prices or at prices related to the prevailing market price. JonesTrading will use its commercially reasonable efforts to sell the Company&#x2019;s common stock from time to time, based upon the Company&#x2019;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay JonesTrading &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of gross proceeds for the common stock sold through the Sales Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had the following outstanding warrants for the purchase of common stock:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expiration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 25, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 27, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,369,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;June 4, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;May 3, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 2, 2032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,867,504&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock upon the cashless exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,245,984&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants. During the year ended December 31, 2022, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;390,668&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock upon the cashless exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398,093&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Compensation Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2015, the Company&#x2019;s Board adopted the 2015 Equity Incentive Plan (2015 Plan). Under the 2015 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. Initially, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,103&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were reserved for issuance under the 2015 Plan. In addition, pursuant to the June 10, 2021 amendment, the number of shares of common stock available for issuance under the 2015 Plan will be annually increased on the first day of each fiscal year during the term of the 2015 Plan, as amended, beginning with the 2022 fiscal year until (and including) January 1, 2031, by an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year or such lesser amount as the Company&#x2019;s Board may determine. The maximum term of the options granted under the 2015 Plan is no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Grants generally vest at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the vesting commencement date and ratably each month thereafter for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months, subject to continuous service. In addition, pursuant to a June 2021 amendment, the 2015 Plan was amended to allow an additional aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to be used exclusively for the grant of equity awards as a material inducement for individuals to commence employment at the Company in compliance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under all Plans is summarized as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,089,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Information about the Company&#x2019;s outstanding stock options as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested and expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,446,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.47&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of employee option grants during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The aggregate intrinsic value used in the above table of options at December 31, 2023 is based on the Company&#x2019;s closing market price per common share on December 29, 2023, the last business day of the 2023 fiscal year, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1751&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options were exercised during the years ended December 31, 2023 and 2022. The total grant-date fair value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Purchase&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Plan (ESPP)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2015, the Company&#x2019;s Board adopted the ESPP, which became effective upon the pricing of the Company&#x2019;s initial public offering on January 29, 2015. The ESPP permits participants to purchase common stock through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their eligible compensation. Initially, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,346&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock was reserved for issuance under the ESPP. In addition, pursuant to the June 10, 2021 amendment, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2022 fiscal year, by an amount equal to the lesser of: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (iii) such other amount as the Company&#x2019;s Board may determine. Stock compensation expense for the years ended December 31, 2023, 2022 and 2021 related to the ESPP was immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.265%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.564%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.325%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  The Company bases the risk&#x2011;free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  The Company considers its historical volatility when determining the expected volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The allocation of stock-based compensation expense was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.992%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the unrecognized compensation cost related to outstanding time-based options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and is expected to be recognized as expense over approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,766,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Awards available under the 2015 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;431,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;429,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,515,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,406,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <tcon:MaximumAggregateValueOfStockToBePurchased
      contextRef="C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702"
      decimals="-5"
      id="F_1557bc3b-ab21-4372-bd44-a05097508b83"
      unitRef="U_USD">26000000</tcon:MaximumAggregateValueOfStockToBePurchased>
    <tcon:RemainingAmountAvailableUnderTheSalesAgreement
      contextRef="C_c703b19c-a29e-4412-99b9-5310a244f3a2"
      decimals="-5"
      id="F_84d64a69-aaf2-4cc2-a3e5-5c369f94571e"
      unitRef="U_USD">25000000</tcon:RemainingAmountAvailableUnderTheSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0a40186b-dfa3-4450-9805-28d0eb65430b"
      decimals="INF"
      id="F_7e3a4233-f0f3-472f-967a-25d51ddbd8e3"
      unitRef="U_shares">599216</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1f396fb6-a65f-482a-85ae-a6132f8551fb"
      decimals="INF"
      id="F_eba909ff-d18b-475f-8613-26ea487d595a"
      unitRef="U_shares">1735207</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_114c5392-d3f7-41e4-b75e-3aac9f0e4167"
      decimals="4"
      id="F_4698f726-dcef-428d-8820-b485ecd35c83"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.5763</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_92a49bc8-c3ee-4412-8e51-cfd8a4ca0702"
      decimals="-5"
      id="F_86a97dac-53e9-432b-bf78-8f4b907ed4f1"
      unitRef="U_USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <tcon:PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement
      contextRef="C_3632bdcc-d356-4f7e-83a3-f74f7f3535fb"
      decimals="4"
      id="F_da4d330b-82eb-4d77-8025-fb38981f2240"
      unitRef="U_pure">0.1999</tcon:PercentageOfCommonStockOutstandingOwnedAfterSaleAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6cb97554-1115-4af1-8cfc-e45b449853ca"
      decimals="INF"
      id="F_55f381b3-c9b8-450f-b67c-5cca884f4ef0"
      unitRef="U_shares">174508</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ef2536be-eee0-447c-816b-aa4f24348c47"
      decimals="INF"
      id="F_320a3e2d-8e64-4b1d-acda-7175829dfce9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.38</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2e8d066a-2058-4cb0-bb65-2e20e51ef896"
      decimals="INF"
      id="F_b7b7a4ee-af33-4195-a7d4-ce13490783a5"
      unitRef="U_shares">2013999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_fa0eef6d-4f4f-4aa3-86c1-d8232518e2b4"
      decimals="INF"
      id="F_7251269c-5e6d-40be-9f04-fae4c65345da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.37</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3cdaff81-414c-42cf-8429-30f12793a1a2"
      decimals="INF"
      id="F_7e3d7e3c-f84f-46c3-b6a4-a76bbeb0bd4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcon:NetProceedsReceivedFromIssuanceDirectOffering
      contextRef="C_8c670a0a-691a-4b51-b9b6-9c1738acbd91"
      decimals="-5"
      id="F_aaf7f97d-edeb-4fad-adfa-8261b92f6e97"
      unitRef="U_USD">3000000</tcon:NetProceedsReceivedFromIssuanceDirectOffering>
    <tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise
      contextRef="C_63121456-f0cf-46ef-b24c-282d6b4d3d1d"
      decimals="INF"
      id="F_c86e9fa6-d689-4e00-900f-99f53cd68d19"
      unitRef="U_pure">0.1999</tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b0dbc715-f6a8-4d77-87d7-e3f962470a0c"
      decimals="INF"
      id="F_754c8b77-091c-4ac9-8474-3e09ceb43fdb"
      unitRef="U_shares">841989</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_8336abd2-bdbf-4da8-8873-f9e6e654f71b"
      decimals="INF"
      id="F_2787c2a6-b13d-42f6-be4c-2f843a9cac01"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fbc58ab3-c43d-4ba1-8648-0ac74912cc07"
      decimals="INF"
      id="F_807e879c-4d3b-46fb-b97c-a76a269c6aad"
      unitRef="U_shares">2205018</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_849890bd-5478-410b-adc7-afb456b7c75e"
      decimals="INF"
      id="F_c576cbf6-0077-4586-9b7c-7bb30cabc1b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.31</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1e2ed30c-2d9e-4355-9b3f-cda6cfbdfac8"
      decimals="INF"
      id="F_6bbc1870-4bc1-4a73-aa32-7c9519f9bd81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcon:NetProceedsReceivedFromIssuanceDirectOffering
      contextRef="C_ada76ad5-45b1-47ad-8d9b-60845220bcd2"
      decimals="-5"
      id="F_8ce15d2f-4631-4ca1-8326-5b1ba23febad"
      unitRef="U_USD">3900000</tcon:NetProceedsReceivedFromIssuanceDirectOffering>
    <tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise
      contextRef="C_9ab8712e-6090-44da-8908-64f2c34aef15"
      decimals="INF"
      id="F_c720945b-f672-4906-bd97-1a3dddec42d8"
      unitRef="U_pure">0.1999</tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise>
    <tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise
      contextRef="C_9ab8712e-6090-44da-8908-64f2c34aef15"
      decimals="INF"
      id="F_023abfbc-8866-4eba-bda7-d91bda6dd264"
      unitRef="U_pure">0.1999</tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise>
    <tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise
      contextRef="C_63121456-f0cf-46ef-b24c-282d6b4d3d1d"
      decimals="INF"
      id="F_2bf73041-4ac8-44ae-b7fc-59ef85187ac5"
      unitRef="U_pure">0.1999</tcon:MaximumPercentageOfHoldersOwnershipInterestInCommonStockAfterExercise>
    <tcon:MaximumAggregateValueOfStockToBeSold
      contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007"
      decimals="INF"
      id="F_8946c5cb-efaf-41e7-b152-0afad61adf34"
      unitRef="U_USD">50000000</tcon:MaximumAggregateValueOfStockToBeSold>
    <tcon:RemainingAmountAvailableUnderTheSalesAgreement
      contextRef="C_7cad07f2-1244-4aba-b9a0-b522e10e9007"
      decimals="-5"
      id="F_b436204d-cf1d-4305-b1f1-0cf5e27013f8"
      unitRef="U_USD">41500000</tcon:RemainingAmountAvailableUnderTheSalesAgreement>
    <tcon:PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement
      contextRef="C_bf3c9e40-b8ea-4aaf-989b-00a5b9696dd3"
      decimals="INF"
      id="F_2adde181-27af-4c68-af39-1993df1246df"
      unitRef="U_pure">0.025</tcon:PercentageOfGrossProceedsRequiredToPayForCommonStockSoldThroughSalesAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_076a27be-5a0e-4964-acbe-3687b701e0a6"
      decimals="INF"
      id="F_533a7a68-bd9a-4ab3-83fc-e84dcd6f416c"
      unitRef="U_shares">4669</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_076a27be-5a0e-4964-acbe-3687b701e0a6"
      decimals="INF"
      id="F_afc24f57-88b9-4a85-81a2-92eb97033adf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">51.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3707c748-2523-40f2-89ed-37a5e0f02667"
      decimals="INF"
      id="F_4f07f0aa-313b-4f02-b1fb-744899fab3e7"
      unitRef="U_shares">1369602</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3707c748-2523-40f2-89ed-37a5e0f02667"
      decimals="INF"
      id="F_7fdc4c2c-f73e-46c2-b201-9c8276395205"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_16e27699-d842-4a09-9bc5-311bdb55cc7f"
      decimals="INF"
      id="F_42aed9e4-512b-469d-a0d0-b5df85b1864b"
      unitRef="U_shares">2906</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_16e27699-d842-4a09-9bc5-311bdb55cc7f"
      decimals="INF"
      id="F_49713795-4f9d-4d11-9254-bf6034317e9c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">77.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_89504bb5-ef30-4956-bf15-4942d09489d7"
      decimals="INF"
      id="F_4af26c33-1402-4602-b6c4-dd34015f4cdd"
      unitRef="U_shares">5363</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_89504bb5-ef30-4956-bf15-4942d09489d7"
      decimals="INF"
      id="F_080e1054-4ab1-456a-aa93-4c2d3f3bb5db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2122e3b2-efd5-46f7-9ea2-4421118c4fa8"
      decimals="INF"
      id="F_6ac71f78-15c8-45df-ac01-4d6156242bec"
      unitRef="U_shares">150753</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2122e3b2-efd5-46f7-9ea2-4421118c4fa8"
      decimals="INF"
      id="F_6fc4b108-508e-4e8c-8dfc-6aae566a35b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_ada29e34-7695-4d74-967b-51e16c597e6b"
      unitRef="U_shares">1533293</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="INF"
      id="F_4453c47b-8f97-4bbd-82bd-f120159e65a6"
      unitRef="U_shares">6867504</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares>
    <tcon:CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock
      contextRef="C_9d6bf014-6462-420b-ba24-a41ec9fc6144"
      decimals="INF"
      id="F_37ca99de-22e2-4927-9110-48c4de58f707"
      unitRef="U_shares">7245984</tcon:CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock>
    <tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="INF"
      id="F_e24214c3-5944-4a47-8a98-067b98b7e24e"
      unitRef="U_shares">390668</tcon:IssuancesOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares>
    <tcon:CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock
      contextRef="C_5cd3a46f-aa21-4477-b98f-f737dfae502b"
      decimals="INF"
      id="F_419ac5e7-d869-4659-896a-69c3aa537966"
      unitRef="U_shares">398093</tcon:CashlessExerciseOfPrefundedWarrantsToPurchaseCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b16315b6-4843-44d0-9eb8-3298bc62f493"
      decimals="INF"
      id="F_21962738-e7ff-45c4-9413-2b7edfb950db"
      unitRef="U_shares">80103</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_6f092d4a-d7e5-494a-a9df-840fef3b8d29"
      decimals="INF"
      id="F_9d535c88-5aae-4df9-9e99-7cfecf574f43"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_318cdc34-f5fd-4dd9-b958-8376a005bba1"
      id="F_b41a2d45-7729-4da7-b71e-b5297cd41e53">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_814ee833-9257-47ee-8583-cde42cd6e260"
      decimals="2"
      id="F_bebf2c36-df59-49ff-8420-31183ab151fb"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_814ee833-9257-47ee-8583-cde42cd6e260"
      id="F_117c1059-a034-4797-917a-40f661bd3027">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0a381d93-758c-43f0-bafa-d1d2c3addbf9"
      id="F_a4f04151-d1a4-47c4-8a5d-69bb76153aa2">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <tcon:AdditionalCommonSharesToBeUsedForSpecificAward
      contextRef="C_6f092d4a-d7e5-494a-a9df-840fef3b8d29"
      decimals="INF"
      id="F_cbe1924d-9a7b-41f7-abcb-40775f8f9262"
      unitRef="U_shares">200000</tcon:AdditionalCommonSharesToBeUsedForSpecificAward>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_0def9fea-8f12-405b-967f-798ba5c38e83">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under all Plans is summarized as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,089,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157"
      decimals="INF"
      id="F_7f0f3407-d829-42ec-a64b-11459a67f3cd"
      unitRef="U_shares">2246310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157"
      decimals="2"
      id="F_5f737813-efa4-4a1a-9475-a1a03acfd1d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="INF"
      id="F_ba55af1a-8cdb-4641-873c-fcb8ac0d3792"
      unitRef="U_shares">1089400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="2"
      id="F_af54f67b-2624-4e75-90a9-32c1e5cdd0f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="INF"
      id="F_31f96f6d-dd78-40c5-93bb-75aa1dab695d"
      unitRef="U_shares">214558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="2"
      id="F_6751dcff-ade5-4fba-b3ae-1379516b2344"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="INF"
      id="F_7edf46e7-2c34-49d2-9b54-e64c0daa16f8"
      unitRef="U_shares">3121152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="2"
      id="F_3e815994-c74c-4290-8fef-40daf4b8be27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_2abdf6c9-db12-4b2f-b183-614ec8c51e67">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Information about the Company&#x2019;s outstanding stock options as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested and expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,446,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.47&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="0"
      id="F_3be1aa63-e0da-4a7e-a0b3-82d79386c8bd"
      unitRef="U_shares">3121152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="2"
      id="F_14e6d5fe-dec7-4792-97a1-f044031f6860"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      id="F_0bf2371f-2658-47bc-9096-3472e4bbf264">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="0"
      id="F_cad6c732-3621-450d-943e-d0fbee3812a6"
      unitRef="U_shares">3121152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="2"
      id="F_7fe702dd-5a1b-4dfb-a991-76f59176f21f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      id="F_074083c2-7fc6-49de-9568-e85eeaad0cf6">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="0"
      id="F_c0ffae82-5c43-4d2c-aff5-49b02b9d1dcb"
      unitRef="U_shares">1446873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="2"
      id="F_5f91778b-90de-4d37-b6c1-d621588a8c44"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      id="F_6f746c86-da9a-4f38-9770-c7491dfe43e9">P6Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="2"
      id="F_9000e9cb-17cb-486e-9f09-2d46e579a8a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      decimals="2"
      id="F_09afae0a-b2cd-4d4a-b511-1c14244dbd87"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284"
      decimals="2"
      id="F_5101e14e-7931-4e50-af5c-6bc668b5a3a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="4"
      id="F_44e1f714-0429-4b8b-927e-05fa7df50c7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.1751</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="INF"
      id="F_cd0e6043-db7a-4c44-93d8-2e5781110e5f"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      decimals="INF"
      id="F_87db1cc5-826b-4ced-8e69-d3c2e7a528c8"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="-5"
      id="F_28abab7b-2044-4c2d-92f7-e9183979e094"
      unitRef="U_USD">1900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      decimals="-5"
      id="F_fc7a3b80-1520-4b63-85f6-76e3fa9efa01"
      unitRef="U_USD">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284"
      decimals="-5"
      id="F_70c11f46-fe2c-4773-9cb6-3ac74c80af4a"
      unitRef="U_USD">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_901ce9d0-b622-4dc1-9cc3-0c5fd70773be"
      decimals="2"
      id="F_2a949e53-024c-4033-a7dc-aa1a903047ba"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_577ee070-e073-4976-81d8-6e2937b0617e"
      decimals="0"
      id="F_44e97544-733b-47a6-87aa-323603349dd2"
      unitRef="U_shares">18346</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tcon:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod
      contextRef="C_cd3ca734-457b-4506-8892-6849fbff690f"
      decimals="0"
      id="F_d005411d-30d8-4545-89e9-c3fb6576994b"
      unitRef="U_shares">250000</tcon:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_cd3ca734-457b-4506-8892-6849fbff690f"
      decimals="2"
      id="F_b1f40255-c210-4999-b0ea-dc01f17125e4"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_a2916e36-6cdf-408e-83f8-e6a1623ae333">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.265%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.564%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.325%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="3"
      id="F_84b75e7f-976d-420f-8909-69cce1dad1a4"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      decimals="3"
      id="F_faf2879d-208f-44cb-b6f6-099fffc7eae2"
      unitRef="U_pure">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284"
      decimals="3"
      id="F_3a0fd96e-4190-4d6a-a776-1ff04b973f5a"
      unitRef="U_pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="3"
      id="F_94d34471-1173-4de9-a553-deac8505bd14"
      unitRef="U_pure">0.901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      decimals="3"
      id="F_96d324b4-746e-4f11-9545-7883f078cbb7"
      unitRef="U_pure">0.898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284"
      decimals="3"
      id="F_a2a2be0d-8a44-42f3-b647-a571cd10f035"
      unitRef="U_pure">0.903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      id="F_31845c6e-a158-431c-b4f6-92557f1f0e32">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      id="F_20575880-788d-401e-8835-0f874afcdc72">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284"
      id="F_89d13d26-408f-42c7-a985-5e7d36b76f1f">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      decimals="2"
      id="F_64304e4c-d6fb-4105-b45f-295683b6e271"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      decimals="2"
      id="F_f16c6894-d6ad-413e-a9bf-52148d91beea"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_64263ac1-80a3-46bd-b083-27c74a051284"
      decimals="2"
      id="F_0b8c5b5f-5144-48f5-b7d4-bc2b440981f7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_1b0e4bdf-6b26-4e07-b772-501b12325608">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The allocation of stock-based compensation expense was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.992%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3ff50e62-5e4c-4461-884d-ca0bbc261a94"
      decimals="-3"
      id="F_854412ef-855b-486a-9dc8-0819754b9f54"
      unitRef="U_USD">935000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d2b07739-4905-4cff-bd81-929c2939c81e"
      decimals="-3"
      id="F_08213838-eccc-408b-82d0-7eec8796ac7e"
      unitRef="U_USD">830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6c9cb59b-f528-4f05-be7c-a82ef8ff9fa6"
      decimals="-3"
      id="F_dba361a8-7109-4d0f-8fe8-47faef45de70"
      unitRef="U_USD">628000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_44f937fc-97bc-42b8-97d8-361c9c6f366c"
      decimals="-3"
      id="F_6a8178f4-e0ce-46d0-817e-f8a20937142f"
      unitRef="U_USD">1034000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7eb1035b-caa0-4638-9b3d-88715a101c8a"
      decimals="-3"
      id="F_3e503db6-e37c-486d-813b-73c21a066872"
      unitRef="U_USD">1211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a70ce266-0b0f-498a-b880-2e0cec4cebe4"
      decimals="-3"
      id="F_bbba9155-3dd8-41e7-90f0-db5c82457924"
      unitRef="U_USD">1147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_ce10fa0b-f449-43d0-a174-64babc4ccd07"
      unitRef="U_USD">1969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_6ce449ec-b694-4498-9066-8053ceacf061"
      unitRef="U_USD">2041000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_94975c0b-4c15-4d4b-9cce-08f63a6fd85f"
      unitRef="U_USD">1775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_4b1ce3f1-2f58-4ec8-9f84-ec0c61ee03ca"
      decimals="-5"
      id="F_d754e9b7-14f4-4ad0-9694-edac2c51aedc"
      unitRef="U_USD">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_bb42dbdf-0db1-4ef1-acb0-0a7218e08157"
      decimals="-5"
      id="F_9b3d5c61-27b7-4e5f-a674-274375e7b668"
      unitRef="U_USD">3600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_5c0640ea-6b2e-4706-b104-cc1b0629bca4"
      id="F_8f4b184a-8caa-44aa-9cd5-4dbe4db503e6">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_8105d9cc-038e-40df-bb0a-861b99bb23f3"
      id="F_845f544f-c2e4-422d-8b4c-7c0f6f4afa7b">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_b7b978e6-3dbe-446c-bf97-a4c70a587996">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,766,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,121,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,246,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Awards available under the 2015 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;431,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;429,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,515,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,406,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</tcon:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_639cfa51-d355-4e4e-883d-a0c36228443f"
      decimals="0"
      id="F_d12b374f-009f-45f8-b2f1-4574f3a027c9"
      unitRef="U_shares">1533293</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_62d20795-8235-49dc-84d8-78968b279332"
      decimals="0"
      id="F_26e7b2d1-385c-467c-97b7-a988788fa1d7"
      unitRef="U_shares">6766246</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="0"
      id="F_251cb4e5-a3de-4da6-a4ce-58e5b9c4f697"
      unitRef="U_shares">3121152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="0"
      id="F_db0a1db6-8540-4f03-b0a4-0d7e8e3fddfa"
      unitRef="U_shares">2246310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_61e3c61d-6eef-4e6d-be34-c3497437219f"
      decimals="0"
      id="F_cfd11edc-3dd9-4086-bcec-c64e9ea58af3"
      unitRef="U_shares">431755</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_eafe3fa1-222e-4c1b-81f5-552231208588"
      decimals="0"
      id="F_7b5c4115-eee5-4d92-9e95-dc823ca99b62"
      unitRef="U_shares">150335</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a4750715-b498-4b30-8b83-398f57734854"
      decimals="0"
      id="F_5fd5bde8-8fd7-4aa5-a9d0-2528d814bffc"
      unitRef="U_shares">429500</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_49078ec3-8121-4069-a2aa-dbede8ef99ef"
      decimals="0"
      id="F_eb4f80dc-aaac-4333-adde-ae74bbbf7159"
      unitRef="U_shares">243817</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="0"
      id="F_b0ee9742-d028-4adc-808f-7c3cc17efabc"
      unitRef="U_shares">5515700</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="0"
      id="F_158a651a-65f0-4396-851e-54ae8528c412"
      unitRef="U_shares">9406708</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_005139f5-0d57-4ed6-85d7-9edfb694e87c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inhibrx, Inc.(Inhibrx) License Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the Company granted a non-exclusive, non-sublicensable, non-transferable (except in the event of the transfer or sale of all or substantially all of the business or assets of Inhibrx) worldwide perpetual license of its&#x2019; CRO-independent product development platform (PDP) to Inhibrx for a nonrefundable upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million plus an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the completion of certain training. The Company is obligated to be available over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period beginning on the date of license transfer to provide up to 500 hours of training to Inhibrx. The PDP license allows Inhibrx to use the Company&#x2019;s configuration documentation with a widely used software package in addition to use the Company&#x2019;s validation and qualification of the software package and the Company&#x2019;s standard operation procedure documents, policies, work instructions, and clinical operation templates in the administration of clinical trials and related research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the agreement, Inhibrx has sole responsibility for funding and conducting any such clinical trials and related research and development activities. The Company is not obligated to tailor any of the related documentation and is not involved in conducting any of the related clinical trials or research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed this agreement and identified multiple promised goods and services, which included at contract inception: (1) the PDP license and (2) up to 500 hours of training over a six-month period. Management evaluated these promised goods and services and determined each was a separate performance obligation. The transaction price at contract inception included fixed consideration of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront payment and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payment due upon the earlier of the completion of 500 hours of training or six months. The total $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million transaction price was allocated to each performance obligation based on relative standalone selling price. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million amount allocated to the PDP license performance obligation was recognized at the point in time Inhibrx could first use and benefit from the license, which occurred in the fourth quarter of 2023. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million amount allocated to the training performance obligation will be recognized over the six-month period in which the Company is obligated to be available to provide training.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Eucure and Biocytogen Collaborative Development and Commercialization Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, the Company, Eucure (Beijing) Biopharma Co., Ltd. (Eucure) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen), Eucure&#x2019;s controlling affiliate, entered into a collaborative development and commercialization agreement (the YH001 Collaboration Agreement) for the development of YH001, a monospecific investigational CTLA-4 antibody.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the YH001 Collaboration Agreement, the Company was granted an exclusive (including with respect to Eucure and its affiliates), nontransferable, license to develop and commercialize YH001 in North America for the treatment, through administration of YH001 by intravenous or subcutaneous means, of multiple human indications, including sarcoma, microsatellite stable colorectal cancer, renal cell carcinoma (RCC), and K-ras positive non-small cell lung cancer (collectively, the Initial Indications) or one or more of bladder cancer, endometrial cancer, and melanoma as substitute indications, which may be substituted for Initial Indications at the Company&#x2019;s discretion (each upon such substitution, a Substitute Indication).  The Company is responsible for, and will bear the costs of, preparing and filing all regulatory submissions and conducting any Phase 1, Phase 2, Phase 3, or post-approval clinical trials in North America for YH001 in the Initial Indications and potentially the Substitute Indications, while Eucure is responsible for conducting, and will bear the costs of, the preparation of chemistry, manufacturing and controls activities for YH001. Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to the Company for clinical trials pursuant to the terms of a clinical supply and quality agreement to be separately negotiated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During a specified period, the Company has the option, subject to Eucure&#x2019;s prior written approval, to expand the license to include the development and commercialization of YH001 for the treatment, through administration by intravenous or subcutaneous means, of all human and veterinary therapeutic indications in North America for a payment to Eucure in the low single digit millions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will be responsible for commercializing YH001 in North America, including booking of sales revenue in the Initial and Substitute Indications. The Company will owe Eucure escalating double digit royalties on net sales of YH001 in North America ranging from the mid-twenties to mid-double digits; provided that until the end of the first full calendar year following the first commercial sale of YH001, royalties will range from the lower double digits to the mid-double digits. If sales of YH001 exceed a pre-determined sales threshold in the first full year of sales following first commercial sale, the Company will owe a milestone to Eucure in the high single digit millions.  Payment obligations under the YH001 Collaboration Agreement continue on a country-by-country basis until the latest of (i) expiration of the last to expire licensed patent covering YH001, (ii) expiration of marketing or regulatory exclusivity covering YH001 and (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the first commercial sale of YH001 in such country in North America. Eucure has agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, YH001 to the Company at cost plus a low double digit markup for commercial sales pursuant to the terms of a commercial supply and quality agreement to be separately negotiated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;3D Medicines and Alphamab Collaboration and Clinical Trial Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, the Company, 3D Medicines Co., Ltd. (3D Medicines), and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) entered into a collaboration and clinical trial agreement (the Envafolimab Collaboration Agreement) for the development of envafolimab, also known as KN035, an investigational PD-L1 single-domain antibody (sdAb), or nanobody, administered by subcutaneous injection, for the treatment of sarcoma in North America. No consideration was exchanged in the Envafolimab Collaboration Agreement. Given no consideration was exchanged, no value was assigned to the Envafolimab Collaboration Agreement in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Envafolimab Collaboration Agreement, the Company was granted an exclusive license to develop and commercialize envafolimab for the treatment of sarcoma in North America.  The Company is responsible for conducting, and will bear the costs of Phase 1, Phase 2, and Phase 3 or post-approval clinical trials in North America for envafolimab in the indications of refractory and first line treatment of sarcoma. 3D Medicines and Alphamab are responsible for conducting, and will bear the costs of, investigational new drug (IND)-enabling studies (other than those specific to the sarcoma indication) and the preparation of chemistry, manufacturing and controls (CMC) activities sections of an IND application for envafolimab. 3D Medicines and Alphamab have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, envafolimab to the Company at pre-negotiated prices that vary based on clinical or commercial use. 3D Medicines and Alphamab retained the right to develop envafolimab in all territories outside of North America as well as within North America for all indications other than sarcoma.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue, unless (a) envafolimab is first approved in North America for an indication other than sarcoma and launched in North America, or (b) envafolimab is first approved in North America for sarcoma and subsequently approved in North America for an additional non-orphan indication and sold commercially by 3D Medicines and/or Alphamab, or a licensee, in which case 3D Medicines and Alphamab will be responsible for commercializing envafolimab for sarcoma in North America, including booking of sales revenue. If 3D Medicines and Alphamab become responsible for commercialization under the Envafolimab Collaboration Agreement, the Company has the option to co-market envafolimab for sarcoma in North America. In the event that envafolimab is first approved in North America for sarcoma and within three years of the commercial launch of envafolimab in North America for sarcoma 3D Medicines and Alphamab replace the Company as the party responsible for commercialization, and the Company elects and 3D Medicines and Alphamab agree for the Company to not co-market envafolimab for sarcoma in North America, then 3D Medicine and Alphamab will be required to compensate the Company for its costs associated with preparing for and conducting commercial activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the Company has the responsibility for commercialization under the Envafolimab Collaboration Agreement, the Company will owe 3D Medicines and Alphamab tiered double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits.  If 3D Medicines and Alphamab have responsibility for commercialization under the Envafolimab Collaboration Agreement, the Company will be entitled to (a) escalating double digit royalties on net sales of envafolimab for sarcoma in North America ranging from the teens to mid-double digits if the Company has chosen to not co-market envafolimab in sarcoma or (b) a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty on net sales of envafolimab for sarcoma in North America if the Company has chosen to co-market envafolimab in sarcoma.  Payment obligations under the Envafolimab Collaboration Agreement continue on a country-by-country basis until the last to expire licensed patent covering envafolimab expires.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3D Medicines and Alphamab retain the right to reacquire the rights to envafolimab for sarcoma in North America in connection with an arm&#x2019;s length sale to a third party, provided that the sale may not occur prior to completion of a pivotal trial of envafolimab in sarcoma without the Company&#x2019;s written consent and the parties must negotiate in good faith and agree to fair compensation to be paid to the Company for the value of and opportunity represented by the required rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each party agreed that during the term of the Envafolimab Collaboration Agreement, it would not develop or license from any third party a monospecific inhibitor to PD-L1 or PD-1 in sarcoma.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term of the Envafolimab Collaboration Agreement continues until the later of the date the parties cease further development and commercialization of envafolimab for sarcoma in North America or the expiration of all payment obligations.  The Envafolimab Collaboration Agreement may be terminated earlier by a party in the event of an uncured material breach by the other party or bankruptcy of the other party, or for safety reasons related to envafolimab.  In the event the Company elects, or a joint steering committee determines, to cease further development or commercialization of envafolimab, or if the Company fails to use commercially reasonable efforts to develop (including progress in clinical trials) and commercialize envafolimab and does not cure such failure within a specified time period, then the Company&#x2019;s rights and obligations under the Envafolimab Collaboration Agreement will revert to 3D Medicines and Alphamab.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;I-Mab Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2018, the Company and I-Mab entered into separate strategic collaboration and clinical trial agreements (the I-Mab Collaboration Agreements) for the development of programs for multiple immuno-oncology product candidates, including I-Mab&#x2019;s proprietary CD73 antibody TJ004309 (the TJ004309 Agreement) as well as up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; proprietary bispecific antibodies currently under development by I-Mab (the Bispecific Agreement).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the TJ004309 Agreement, the Company and I-Mab were collaborating on developing the TJ004309 antibody, with the Company bearing the costs of filing an IND and for Phase 1 clinical trials, with the parties sharing costs equally for Phase 2 clinical trials, and with the Company and I-Mab bearing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of the costs for pivotal clinical trials. I-Mab was responsible for the cost of certain non-clinical activities, the drug supply of TJ004309, and any reference drugs used in the clinical trials.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company would be entitled to receive escalating portions of royalty and non-royalty consideration and a royalty based on net sales if I-Mab licenses TJ004309 in certain territories or commercializes TJ004309, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The TJ004309 Agreement was terminatable by either party in the event of an uncured material breach by the other party or bankruptcy of the other party, for safety reasons related to TJ004309 or by I-Mab if the Company causes certain delays in completing a Phase 1 clinical trial. In addition, the TJ004309 Agreement was terminatable by I-Mab for any reason within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days following the completion of the first Phase 1 clinical trial, in which case the Company would be entitled to a minimum termination fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, or following the completion of the first Phase 2 clinical trial, in which case the Company would be entitled to a pre-specified termination fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and either a percentage of non-royalty consideration I-Mab may receive as part of a license to a third party or an additional payment if TJ004309 is approved for marketing outside Greater China before a third-party license is executed, in addition to a double digit percentage of royalty consideration.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As previously disclosed, in June 2020, I-Mab commenced an arbitration proceeding under the Rules of Arbitration of the International Chamber of Commerce before an arbitration tribunal seated in New York City (the Tribunal) after the Company invoked contractual dispute resolution provisions asserting that I-Mab had breached its contractual obligations under the TJ004309 Agreement and the Bispecific Agreement. In April 2023, the Company received notification from the Tribunal of the Arbitration Award. The Tribunal found in favor of the Company for certain claims and declared the Phase 1 clinical trial of TJ004309 Agreement &#x201c;Complete,&#x201d; as that term is defined in the TJ004309 Agreement as of January 2022. The Arbitration Award included the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million prespecified termination fee payable by I-Mab under the TJ004309 Agreement, which was collected in July 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company re-evaluated the transaction price as of the end of the reporting period and concluded the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million variable consideration associated with the prespecified termination fee was no longer fully constrained as it was determined to be probable that a significant reversal would not occur if the Company recognized the variable consideration as revenue in the current period. Accordingly, the Company recognized the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7148ed3a-8abb-4a16-af47-75112a2b7341;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;collaboration revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; within the accompanying consolidated statements of operations for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the resolution of the arbitration, the TJ004309 Agreement and the Bispecific Agreement have been terminated and no further revenue will be recognized associated with these agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million gain associated with the collection of the Arbitration Award in July 2023 consisted of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million collected amount less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million TJ004309 termination fee recognized as collaboration revenue. The gain has been included within other income, net within the accompanying consolidated statements of operations. Additionally, in connection with the Arbitration, the Company entered into a contingency fee arrangement with its legal counsels whereby counsels agreed to defer a portion of their legal fees (Success Fees) and would receive payment of the Success Fees in full or at a low single digit multiple depending on the amount awarded and contingent upon recovery of proceeds from an Arbitration Award. Success Fees in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were paid in 2023 and have been included within arbitration success fees within the accompanying consolidated statements of operations. In connection with the settlement, legal counsels also forgave approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in related legal invoices.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <tcon:NonrefundableUpfrontFee
      contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839"
      decimals="-5"
      id="F_d726d7d8-e894-478e-8e19-6376f696bbc5"
      unitRef="U_USD">3000000</tcon:NonrefundableUpfrontFee>
    <tcon:AdditionalPaymentOnPerformanceObligation
      contextRef="C_2497856b-e351-4137-a3e8-c281dd005061"
      decimals="-5"
      id="F_bde662a6-321d-48ac-b443-e3e4bf8fd564"
      unitRef="U_USD">200000</tcon:AdditionalPaymentOnPerformanceObligation>
    <tcon:TrainingPeriodDuration
      contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839"
      id="F_d280e4a4-430a-4b6a-98d9-0c72493b547d">P6M</tcon:TrainingPeriodDuration>
    <tcon:LicenseAgreementTerm
      contextRef="C_96edd94d-e38a-4eb9-8c60-62d39af94ba2"
      id="F_3970eb95-7193-4700-be0b-5d53383db2e8">The Company assessed this agreement and identified multiple promised goods and services, which included at contract inception: (1) the PDP license and (2) up to 500 hours of training over a six-month period. Management evaluated these promised goods and services and determined each was a separate performance obligation. The transaction price at contract inception included fixed consideration of the $3.0 million upfront payment and $0.2 million payment due upon the earlier of the completion of 500 hours of training or six months. The total $3.2 million transaction price was allocated to each performance obligation based on relative standalone selling price. </tcon:LicenseAgreementTerm>
    <tcon:NonrefundableUpfrontFee
      contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839"
      decimals="-5"
      id="F_42db2ae8-9df0-4f87-89c7-4ffc5506d67e"
      unitRef="U_USD">3000000</tcon:NonrefundableUpfrontFee>
    <tcon:AdditionalPaymentOnPerformanceObligation
      contextRef="C_2497856b-e351-4137-a3e8-c281dd005061"
      decimals="-5"
      id="F_250f1e95-33ca-4106-b223-5b18a599cc86"
      unitRef="U_USD">200000</tcon:AdditionalPaymentOnPerformanceObligation>
    <tcon:TransactionPrice
      contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839"
      decimals="-5"
      id="F_1f7bb44b-6851-4217-8cb0-ab52fbe2e250"
      unitRef="U_USD">3200000</tcon:TransactionPrice>
    <tcon:NonrefundableUpfrontFee
      contextRef="C_e6105ad8-44d1-4f33-bd31-6a2890669839"
      decimals="-5"
      id="F_4eb67852-70d3-4d0d-9986-3a0668c08a3f"
      unitRef="U_USD">3000000</tcon:NonrefundableUpfrontFee>
    <tcon:AdditionalPaymentOnPerformanceObligation
      contextRef="C_2497856b-e351-4137-a3e8-c281dd005061"
      decimals="-5"
      id="F_3ca6e20a-17aa-495a-8029-61de2036e5b9"
      unitRef="U_USD">200000</tcon:AdditionalPaymentOnPerformanceObligation>
    <tcon:CommercialSale
      contextRef="C_3d853f01-db0c-4afc-ac37-748d6a24b52f"
      id="F_52ca0786-18ad-4ea2-8446-deb6673037ff">P10Y</tcon:CommercialSale>
    <tcon:RoyaltyPercentageOfNetSales
      contextRef="C_0dde0b8e-4306-4c73-b564-93d2dc9f8a26"
      decimals="2"
      id="F_cefdca20-9289-40d3-a7b6-42292909e730"
      unitRef="U_pure">0.50</tcon:RoyaltyPercentageOfNetSales>
    <tcon:MaximumNumberOfProprietaryAntibodiesUnderDevelopment
      contextRef="C_8f964d2c-14b2-4bc3-b709-922d50a40833"
      decimals="INF"
      id="F_a23f8c0a-34bd-4a5e-a244-855436c5eeda"
      unitRef="U_Antibody">5</tcon:MaximumNumberOfProprietaryAntibodiesUnderDevelopment>
    <tcon:CollaborationAgreementPercentageOfCostBearing
      contextRef="C_0247f2f4-3917-4a82-af24-9a5bf778c6da"
      decimals="2"
      id="F_43b1d06d-bda2-4512-a76b-109e0a2bd55b"
      unitRef="U_pure">0.40</tcon:CollaborationAgreementPercentageOfCostBearing>
    <tcon:CollaborationAgreementPercentageOfCostBearing
      contextRef="C_0592da9d-0e35-4ada-8b6a-801b2b01bdcf"
      decimals="2"
      id="F_4312ab63-9bc7-4dd1-918a-f9cd2df55466"
      unitRef="U_pure">0.60</tcon:CollaborationAgreementPercentageOfCostBearing>
    <tcon:TerminationOfAgreementUponCompletionOfClinicalTrial
      contextRef="C_dbf3b97c-e0f0-4dfe-8eea-e3775ccab160"
      id="F_88fe0b68-9ec4-4d7e-84bf-6da4c1f05c4d">P90D</tcon:TerminationOfAgreementUponCompletionOfClinicalTrial>
    <tcon:TerminationFee
      contextRef="C_19d1e4ec-58ad-4668-bed8-1390374bb8c1"
      decimals="-5"
      id="F_1541b28c-b2db-4b35-94b1-338b9ffbe7cd"
      unitRef="U_USD">9000000</tcon:TerminationFee>
    <tcon:TerminationFee
      contextRef="C_e41e9c0b-0129-486b-9356-bb65e6d7e6e8"
      decimals="-5"
      id="F_689b524d-aa26-46fd-9a4e-119f153ed6a8"
      unitRef="U_USD">15000000</tcon:TerminationFee>
    <tcon:TerminationFeePayable
      contextRef="C_1ae2be0d-9dfa-467f-9bce-05b3c0ba56fb"
      decimals="-5"
      id="F_62f567a3-96e1-459a-a44d-f86e0826765f"
      unitRef="U_USD">9000000</tcon:TerminationFeePayable>
    <tcon:TerminationFee
      contextRef="C_8341fd7b-20e9-4123-b191-98d68cf29a63"
      decimals="-5"
      id="F_075f98e0-0ed1-4fb6-ba25-8514fa76346b"
      unitRef="U_USD">9000000</tcon:TerminationFee>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_63bca51e-dee9-43e9-9c2a-e2aeadd03140"
      unitRef="U_USD">9000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <tcon:LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee
      contextRef="C_f6b50908-851a-401b-87d4-7d20d639276e"
      decimals="-5"
      id="F_f8b3b212-e28d-401b-816f-1d18c03f547e"
      unitRef="U_USD">13000000</tcon:LitigationSettlementAmountAwardedFromOtherPartyNetOfTerminationFee>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="C_f6b50908-851a-401b-87d4-7d20d639276e"
      decimals="-5"
      id="F_a665f03e-3540-4349-913b-a559047a0287"
      unitRef="U_USD">22000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="C_c22bb402-0325-47cc-ae07-b1647b8287b1"
      decimals="-5"
      id="F_8f04935f-6460-4853-a0ed-ff87a99b72f3"
      unitRef="U_USD">9000000</us-gaap:LossContingencyDamagesAwardedValue>
    <tcon:ArbitrationSuccessFees
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_d9efbff4-56ce-4a72-a517-8ba192f36ff6"
      unitRef="U_USD">2400000</tcon:ArbitrationSuccessFees>
    <tcon:LossContingencyPaymentWriteOffAmount
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_ab833990-f43f-473d-9ac7-a08c73b37f40"
      unitRef="U_USD">300000</tcon:LossContingencyPaymentWriteOffAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_731bba8f-1aa0-4a26-8e1c-52a987692537">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operating lease obligations relate to its corporate headquarters as the Company leases its office space under a non-cancelable operating lease. The Company amended its lease in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; extending the lease term to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The lease is subject to base lease payments and additional charges for common area maintenance and other costs and includes certain lease incentives and tenant improvement allowances. Operating lease expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each of the three years ended December 31, 2023, 2022 and 2021. As of December 31, 2023, the Company did not have any finance leases, nor any other operating leases.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid within operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ROU assets recognized in exchange for new lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.187%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.621%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.786%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.621%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.786%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reported as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17;"&gt;&lt;span style="-sec-ix-hidden:F_b539fbc4-b194-4f51-b5a6-68a58edce5fb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(ROU asset)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Accounts payable and accrued expenses (lease liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Other long-term liabilities (lease liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the maturities of the Company&#x2019;s operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Und&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;er the terms of the lease agreement, the Company provided the lessor with an irrevocable letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e lessor is entitled to draw on the letter of credit in the event of any default by the Company under the terms of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <tcon:NonCancelableOperatingLeaseExpirationTerm
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_ccbce6e9-9636-474c-848d-1ff85fdbc783">2021-08</tcon:NonCancelableOperatingLeaseExpirationTerm>
    <tcon:NonCancelableOperatingLeaseTermToBeExtended
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_82ee6a93-c200-4608-b7a1-4bd7f8b94ffd">2027-04</tcon:NonCancelableOperatingLeaseTermToBeExtended>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_91dee6ff-9443-464f-9d49-0f9b667f3fe3"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-5"
      id="F_4ec2f867-3503-4820-857f-395c6ac5fdff"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-5"
      id="F_dec1b580-3d93-4203-a241-8406889e83cf"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_3822da41-601c-4a8c-a98f-0591f4274d73">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid within operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ROU assets recognized in exchange for new lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tcon:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock>
    <tcon:CashPaidWithinOperatingCashFlows
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_6274e52a-5836-4b9c-a602-7249a1bece68"
      unitRef="U_USD">320000</tcon:CashPaidWithinOperatingCashFlows>
    <tcon:CashPaidWithinOperatingCashFlows
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_ad11af25-f537-48c5-b06a-164792b8b7ea"
      unitRef="U_USD">285000</tcon:CashPaidWithinOperatingCashFlows>
    <tcon:CashPaidWithinOperatingCashFlows
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_747fa5e6-88aa-4126-a9d1-0d51df92f7dd"
      unitRef="U_USD">461000</tcon:CashPaidWithinOperatingCashFlows>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_ed9c20dc-9ea3-41a0-8654-f0f2c4570e55"
      unitRef="U_USD">1117000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <tcon:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_5d27fc73-e4cb-45cb-b82d-09a27621039c">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.187%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.621%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.786%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.621%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.786%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reported as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6e6d82a4-9da7-4514-ab70-9ec8ba062f17;"&gt;&lt;span style="-sec-ix-hidden:F_b539fbc4-b194-4f51-b5a6-68a58edce5fb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(ROU asset)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Accounts payable and accrued expenses (lease liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Other long-term liabilities (lease liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tcon:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_0e8620eb-0fcb-4d60-8cab-e5f288839fe4"
      unitRef="U_USD">905000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_a31a5b47-4143-47b1-9345-4e086907e0f3"
      unitRef="U_USD">1123000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_f5feec96-d065-4192-b005-a1dbce905bcf"
      decimals="-3"
      id="F_dc1bd56f-446b-48fb-bf7d-4999b19e1f66"
      unitRef="U_USD">236000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e9e0def7-4f33-4329-8019-2a7db36180ce"
      decimals="-3"
      id="F_55735a2a-ef04-44b1-b9e7-895d7f684461"
      unitRef="U_USD">198000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_46f8a63c-b29e-40ea-8d58-941155df4da0"
      decimals="-3"
      id="F_e95484e2-d7ab-49ca-93b2-963800225754"
      unitRef="U_USD">732000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_ce9c7c28-c3e5-426c-8989-80f05562dd11"
      decimals="-3"
      id="F_07bacb2c-7986-4b58-a70f-019345a9a43a"
      unitRef="U_USD">969000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_6adabc86-514d-41e7-9ecb-1d943241eae8"
      unitRef="U_USD">968000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_cdeaad83-aac8-430c-bc1b-e46165350a31"
      unitRef="U_USD">1167000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      id="F_14c76450-f8e1-442a-b4fa-9d00cf26eac1">P3Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      id="F_d09f7c39-902b-4766-b938-4ad8a979ff3a">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="3"
      id="F_bff6588c-8a85-4b5e-b10b-e5bf11d14224"
      unitRef="U_pure">0.113</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="3"
      id="F_820fe716-ca34-45fe-bf38-7da9a1f6a433"
      unitRef="U_pure">0.113</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <tcon:ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_254f4671-24c9-40de-84b2-dd78a1ad3a9c">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the maturities of the Company&#x2019;s operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tcon:ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_f36820a2-8e72-4eef-a278-d7dfa34be2b2"
      unitRef="U_USD">334000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_62ddbf51-844e-4df5-8411-6fdc9afc454f"
      unitRef="U_USD">349000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_a98dbec3-1ed5-4594-9f2b-8aacd7375878"
      unitRef="U_USD">365000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_301401e7-7530-43a8-898d-620938beb9d7"
      unitRef="U_USD">123000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_77d51688-2e3c-461b-8ef5-44eb5b197851"
      unitRef="U_USD">1171000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_3e218c22-9c09-4377-a015-d701473493f9"
      unitRef="U_USD">203000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_d824c9d0-b201-4bba-b5da-878e6cba4d26"
      unitRef="U_USD">968000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="0"
      id="F_6bb9e27a-0ba7-4c86-b53c-b28956b8e33e"
      unitRef="U_USD">73000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_59603721-fcf9-4cf7-869a-cb7ad852999d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets and deferred tax liabilities are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits and Orphan Drug Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 174 capitalized research expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has net deferred tax assets relating primarily to net operating loss (NOL) carryforwards and research and development and Orphan Drug credit carryforwards. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 requires taxpayers to capitalize and amortize research and development expenditures over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for domestic research and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years for foreign research pursuant to Section 174 of the Internal Revenue Code (Code). Subject to certain limitations, the Company may use these deferred tax assets to offset taxable income in future periods. Due to the Company&#x2019;s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company&#x2019;s deferred tax assets, as it is more likely than not that such assets will not be realized. The net change in the total valuation allowance for the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had federal and California NOL carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The federal and California NOL carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, if not utilized. The federal NOL generated after 2017 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will carryforward indefinitely, but the deductibility of such federal NOLs is limited to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of taxable income. As of December 31, 2023, the Company also had federal research and development and Orphan Drug tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and California research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The federal research and development and Orphan Drug tax credit carryforwards will begin expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, if not utilized. The California research credit will carry forward indefinitely under current law.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to Sections 382 and 383 of the Code, the annual use of the Company&#x2019;s NOL and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% occurs within a three-year period. The Company previously completed a Section 382/383 analysis regarding the limitation of NOL and research and development credit carryforwards as of December 31, 2018 and did not identify any change in ownership of more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% within the preceding three-year period since an ownership change was determined to have occurred at the time of the Company&#x2019;s initial public offering in January 2015. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since December 31, 2018. If the Company has experienced an ownership change at any time since December 31, 2018, utilization of the NOL or R&amp;amp;D credit carryforwards would be subject to an annual limitation under Section 382 of the Code. Any limitation may result in expiration of a portion of the NOL or R&amp;amp;D credit carryforwards before utilization. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Inflation Reduction Act of 2022, which incorporates a Corporate Alternative Minimum Tax (CAMT), was signed on August 16, 2022 and changes became effective for tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The act is not expected to have a significant impact on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The changes in the Company&#x2019;s unrecognized tax benefits are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accruals for interest or penalties in the accompanying consolidated balance sheets as of December 31, 2023 and 2022 and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized interest or penalties in the accompanying consolidated statements of operations for the three years in the period ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to the valuation allowance recorded against the Company&#x2019;s deferred tax assets, future changes in unrecognized tax benefits will not impact the Company&#x2019;s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to taxation in the United States and California. Due to the net operating loss carryforwards, the U.S. federal and California returns are open to examination for all years since inception. The Company has not been, nor is it currently, under examination by the federal or any state tax authority.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_c81546f6-2a10-4027-a19d-8799a6d4c9dd">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_750b7671-8a5d-458d-baad-1813ae5935b0"
      unitRef="U_USD">-754000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_0a0e3ece-05ca-4c37-9c83-969209a0fbe5"
      unitRef="U_USD">-6118000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_22c55c2b-0320-4cfe-bf90-af1a98c971d8"
      unitRef="U_USD">-6020000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_a68fd256-58de-4d03-b1e6-0552eb554723"
      unitRef="U_USD">-182000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_bb567db6-9add-4aea-8173-7e42096b7c2d"
      unitRef="U_USD">-1962000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_068f8974-d04c-4455-bbc1-f362f8fa93fe"
      unitRef="U_USD">-1889000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_7b9d9dfe-cdc3-42a1-96b3-e564af10970c"
      unitRef="U_USD">56000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_79a817ec-df3f-4313-9349-b41a7a91cfee"
      unitRef="U_USD">81000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_3986f461-af2e-4aa4-b652-d0fdcb40def0"
      unitRef="U_USD">93000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_05ae5f24-c991-497d-88fd-5f43697076fe"
      unitRef="U_USD">344000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_5fad3cea-d4b2-4cdd-a621-00c5709d01f6"
      unitRef="U_USD">2477000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_2e8bb53c-8ea2-4f9f-9ac5-868f5e6bf4b0"
      unitRef="U_USD">494000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_70d1cf8f-b002-40fd-8017-62d0303c9b51"
      unitRef="U_USD">1569000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_d4258bfe-571c-4670-816a-5d87709dffd9"
      unitRef="U_USD">2119000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_1302eb7f-662b-4ca9-9a6e-342991e59569"
      unitRef="U_USD">1661000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_05787da9-d9a9-4916-82ac-f20456f3497d"
      unitRef="U_USD">-40000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_fa4e77d0-4cbe-47b2-bc94-90c6ab4078cb"
      unitRef="U_USD">125000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_fc6fd198-d46a-4e24-bf54-33c996e47dec"
      unitRef="U_USD">28000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_6b30bccd-3b38-4793-bedf-edd0215d6d37"
      unitRef="U_USD">246000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_6f32295b-7c2b-4934-9936-1dfff3f04ded"
      unitRef="U_USD">78000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_bfae0153-759c-468f-9fff-6af0b575ac1e"
      unitRef="U_USD">203000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_004e2b8e-98a5-446d-8211-0fc806a46c69"
      unitRef="U_USD">1899000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_aa117f8e-ba06-46d4-bd84-9f6d20ffaa94"
      unitRef="U_USD">7438000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_a3c6a06d-df8c-494f-899a-bb11f3f96514"
      unitRef="U_USD">8752000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_2f1b891b-d7f6-459b-a302-baa5287c802a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_4c478aa8-ac62-493e-8aa5-8c7a340e29ce"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_60a00216-0fff-4ede-be4a-1631f3841759"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_aa4f20ea-b4fe-4c85-b078-ade8fec6015e">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets and deferred tax liabilities are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits and Orphan Drug Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 174 capitalized research expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_a72ddbf2-a72e-41b7-9952-4240d0d84397"
      unitRef="U_USD">50103000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_d7f28d34-3c0f-4b37-b687-72039c94c0ca"
      unitRef="U_USD">50779000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_5cc1e7f2-fbdc-4f75-bc12-ddb860ffad5b"
      unitRef="U_USD">12960000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_b3f7d921-bec8-43fb-88fe-1364e7041eb4"
      unitRef="U_USD">11928000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_21eb3473-db5b-4dc0-a5d6-06d1e77d383c"
      unitRef="U_USD">210000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_33583017-d994-4505-8388-6ad18e6f5ab3"
      unitRef="U_USD">236000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <tcon:DeferredTaxAssetsRightOfUseLiability
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_b363ded7-c3cc-4026-880c-f0ecb0b7ac24"
      unitRef="U_USD">204000</tcon:DeferredTaxAssetsRightOfUseLiability>
    <tcon:DeferredTaxAssetsRightOfUseLiability
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_06541643-728a-4ec6-bbae-717e8ba41bcf"
      unitRef="U_USD">245000</tcon:DeferredTaxAssetsRightOfUseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_3822d03b-226b-4c8a-aa10-95bf9f600c64"
      unitRef="U_USD">4253000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_b17a8513-14dc-46d1-8bfe-5de67ce927f3"
      unitRef="U_USD">2503000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_bc8fafb8-89aa-430e-9a81-b909bf106e7f"
      unitRef="U_USD">1720000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_c3113084-f48c-42a1-bdfd-f80cacf2559a"
      unitRef="U_USD">1906000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_94a86926-9857-4b9a-aa2f-0e94ac793640"
      unitRef="U_USD">69450000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_4ed2c482-7450-48bd-b922-3f06490a7d40"
      unitRef="U_USD">67597000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_80a1b34a-0a43-4628-89ec-e0147eceec2b"
      unitRef="U_USD">190000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_325d4da9-7c0d-41de-ad06-8619e427b532"
      unitRef="U_USD">236000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_b61cf8c2-c2c2-4b6b-a11f-88b91dc18e0c"
      unitRef="U_USD">190000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_fa031f2c-c173-4c78-ba4a-c24850437918"
      unitRef="U_USD">236000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_532f9cad-e734-4a4e-8c32-faea4fca32f6"
      unitRef="U_USD">69260000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_0992d496-b793-4b13-b2fb-d0653728b6f3"
      unitRef="U_USD">67361000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_23ca090e-91dc-43d8-a3ff-09e7d4e2d6aa"
      unitRef="U_USD">69260000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_ad8f5a96-f9e9-412d-b349-caafa589c044"
      unitRef="U_USD">67361000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_fbc331ee-57c7-4aa8-b341-77e91d13125d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_6ccc4417-4dbe-4276-81a3-f16352393435"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <tcon:ResearchAndDevelopmentExpenditureAmortizationPeriod
      contextRef="C_739f0e0d-35e3-4a1e-a0c0-95af5f5ab2ff"
      id="F_b41926ce-c331-4342-8802-97e8522dae82">P5Y</tcon:ResearchAndDevelopmentExpenditureAmortizationPeriod>
    <tcon:ResearchAndDevelopmentExpenditureAmortizationPeriod
      contextRef="C_0f40826a-5d90-43c5-8575-ad4a021189c6"
      id="F_225d70f5-bcab-4b37-a239-01535d92e947">P15Y</tcon:ResearchAndDevelopmentExpenditureAmortizationPeriod>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_f62c498d-0548-48c9-8ae9-117b92109bff"
      unitRef="U_USD">1900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-5"
      id="F_b8b475d2-8d65-41e7-9425-d2fd86d4bbcf"
      unitRef="U_USD">7400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-5"
      id="F_1a65d0f5-f44d-4328-9234-20e0d48c8911"
      unitRef="U_USD">8800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9fa826a9-e422-4f13-8418-0d37f204106d"
      decimals="-5"
      id="F_750dae08-377b-4b81-9288-38208a9ee153"
      unitRef="U_USD">190200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3d67d2e6-6d0a-4e23-93d1-f44a73a8c83e"
      decimals="-5"
      id="F_fa298b7f-fe3a-4db3-b13b-eb963b9315db"
      unitRef="U_USD">146900000</us-gaap:OperatingLossCarryforwards>
    <tcon:OperatingLossCarryforwardsExpirationBeginYear
      contextRef="C_23ef9799-fd43-4275-9cd7-31fdf18c3424"
      id="F_364fd51b-746a-4dd4-86dc-10acf4e3045f">2030</tcon:OperatingLossCarryforwardsExpirationBeginYear>
    <tcon:OperatingLossCarryforwardsExpirationBeginYear
      contextRef="C_dbe644e9-34fa-49cf-aac0-7fe06affdd7e"
      id="F_bda5449d-f639-48ba-8469-136d3f84852d">2033</tcon:OperatingLossCarryforwardsExpirationBeginYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-5"
      id="F_2624c9aa-2d08-4111-ae8b-d38404274bfe"
      unitRef="U_USD">106900000</us-gaap:OperatingLossCarryforwards>
    <tcon:PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="INF"
      id="F_2758cdc6-3193-462c-a4f5-0f3cf1fc45f9"
      unitRef="U_pure">0.80</tcon:PercentageOfOperatingLossCarryForwardsAvailableToOffsetFutureTaxableIncome>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_cb79e9b9-01cb-43a2-8165-d3fd9d65c898"
      decimals="-5"
      id="F_0541e288-9202-4b90-87fa-32f6f3ee8295"
      unitRef="U_USD">15100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_65bae7f1-a046-426a-b301-55274f90e5e5"
      decimals="-5"
      id="F_d2ec5b2d-4eee-4ba5-8795-d7d6e32aa683"
      unitRef="U_USD">3300000</us-gaap:TaxCreditCarryforwardAmount>
    <tcon:TaxCreditCarryforwardExpirationBeginYear
      contextRef="C_cfb0c8e3-22a8-49de-b419-5303ff8938e6"
      id="F_41adbd27-c5af-4427-ab9e-067b9ef94ee1">2031</tcon:TaxCreditCarryforwardExpirationBeginYear>
    <tcon:TaxCreditCarryforwardExpirationBeginYear
      contextRef="C_ecdebc03-6503-4399-b16e-c105c0c28931"
      id="F_16fe8f94-acb1-49b4-88a6-e4a7808fbd43">2036</tcon:TaxCreditCarryforwardExpirationBeginYear>
    <tcon:PercentOfOwnership
      contextRef="C_be1af667-5078-4781-80f6-a273e57ebc33"
      decimals="INF"
      id="F_aebd6677-5c77-4079-802b-8d7ceb57b5f6"
      unitRef="U_pure">0.50</tcon:PercentOfOwnership>
    <tcon:PercentOfOwnership
      contextRef="C_079f3f02-0a8c-4168-a44f-3fb63206aa35"
      decimals="INF"
      id="F_26247d9c-f12f-4656-97bf-cd26ff1d45d0"
      unitRef="U_pure">0.50</tcon:PercentOfOwnership>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_3d7e0ce2-9265-459c-9768-847ab80ef315">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The changes in the Company&#x2019;s unrecognized tax benefits are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f7ae2aa5-ce57-4044-8703-c2cff92a9c60"
      decimals="-3"
      id="F_73ca2ece-9f93-4789-816c-b832bb2e8812"
      unitRef="U_USD">6610000</us-gaap:UnrecognizedTaxBenefits>
    <tcon:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_ae3da179-0e64-4c68-9ad0-49c4f0516ab7"
      unitRef="U_USD">1000</tcon:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-3"
      id="F_0e89a993-e7a3-400a-95d8-1a8c84ea8141"
      unitRef="U_USD">506000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9e8ae800-d235-4098-a3fa-dc1794018749"
      decimals="-3"
      id="F_6afe1993-e07f-4ee0-b950-ca93c506c6dd"
      unitRef="U_USD">7117000</us-gaap:UnrecognizedTaxBenefits>
    <tcon:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_f9e308e2-d2ed-40de-baff-6ebba3c3439b"
      unitRef="U_USD">-5000</tcon:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-3"
      id="F_3c268336-20ea-438b-8b38-245291870d01"
      unitRef="U_USD">2984000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="-3"
      id="F_131f0e08-f8ef-404d-8566-663aef7971b6"
      unitRef="U_USD">10096000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-3"
      id="F_e1ce012e-e2af-4264-870d-5e292581e14c"
      unitRef="U_USD">532000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="-3"
      id="F_f02b10cc-9c0f-460d-863b-50be72cdb80f"
      unitRef="U_USD">10628000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_ecaa62df-706a-45f3-889a-732b21b200f2"
      decimals="0"
      id="F_b3fb0463-a040-4d1c-b7e5-43ccc0401f7b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_8f06370c-a07e-49f3-9851-fcdb008745c6"
      decimals="0"
      id="F_8f188335-a399-4617-ac38-5441c68cb030"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="INF"
      id="F_0e51e5b7-7980-4b08-aec4-9f3466a75d94"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_eb3c4b29-6783-4c12-90dc-8b8e4ff7d3cd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. 401(k) Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains a defined contribution &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0423c714-cd31-4fc4-8227-88bbd1c67cbd;"&gt;&lt;span style="-sec-ix-hidden:F_46bdfe8e-ae21-43ca-ba32-3a33adf3437b;"&gt;&lt;span style="-sec-ix-hidden:F_b40b095e-6fd8-4db7-9688-34b629bf1179;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;401(k) plan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain matching contributions to the 401(k) plan. Matching contributions for the years ended December 31, 2023, 2022 and 2021 totaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      decimals="-5"
      id="F_13de92e1-14b0-49a7-b190-f3197ac9cc21"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_48cb3f8c-97ab-41bf-b369-556c94253861"
      decimals="-5"
      id="F_be651047-daa9-40a8-a37a-b34c31b6dfc2"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_f618c112-b46d-4d38-bbca-dce456ac7680"
      decimals="-5"
      id="F_cd2b8154-78b7-4ce4-99f3-31617e8e2521"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <dei:AuditorFirmId
      contextRef="C_fb97f606-1fe3-428b-be6a-b8b232235366"
      id="F_63af7d8c-b6b8-487b-879f-c3bb840a58d7">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
